



SCIENTIFIC
REPORT
2016

IdiPAZ

INDEX

1	INTRODUCTION BY MANAGING DIRECTOR OF HULP AND SCIENTIFIC DIRECTOR OF IDIPAZ	2
2	EXECUTIVE SUMMARY	4
	2.1 Global Analysis	6
	2.2 Research Structure	10
	2.3 Training Report and Teaching	18
	2.4 Innovation and Transfer Activities	22
	2.5 Quality Committee	34
	2.6 Clinical Trials	36
	2.7 Platforms	54
	2.8 Scientific Production	74
	2.9 CIBERs and RETICs	84
	2.10 Institutional Projects	86
	2.11 Internationalization	88
3	INFORMATION GROUPS BY AREA	90
	3.1 Neuroscience Area	92
	3.2 Cardiovascular Area	116
	3.3 Infectious Diseases and Immunity Area	140
	3.4 Large System Pathologies Area	178
	3.5 Cancer and Human Molecular Genetics Area	226
	3.6 Surgery, Transplant and Health Technologies Area	268
4	ASSOCIATED CLINICIANS	288

INTERACTIVITY

- All menus are interactive
- In the bottom right of the pages there are hyperlinks to return to menus and sub-menus or to move to the next page

1 INTRODUCTION BY MANAGING DIRECTOR OF HULP AND SCIENTIFIC DIRECTOR OF IdiPAZ



Dr. Eduardo López-Collazo
Scientific Director of IdiPAZ



Dr. Rafael Pérez-Santamarina Feijóo
Managing Director of HULP
Chairman of the Board
of FIBHULP



Once again, the presentation of the Scientific Report of IdiPAZ provides an opportunity to recognize the achievements and improvements of our researchers. This report reflects the effort of the fifty-two research groups that constitute IdiPAZ, as well as the associated clinical groups. We congratulate all our members for the magnificent performed work and the achieved results.

The Hospital La Paz Institute for Health Research (Instituto de Investigación Sanitaria del Hospital Universitario La Paz, IdiPAZ) was created in 2009, as a result of the relationship that has been forged over the years between La Paz University Hospital (HULP), the Autonomous University of Madrid (UAM), and the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP). Since its establishment, IdiPAZ has promoted the configuration of multidisciplinary teams capable of addressing several facets of translational research, bearing in mind the need to generate innovation and transfer the results to the healthcare system. Over the years, we have maintained a progressive growth of our scientific activity, which is structured into six research areas: neurosciences, cardiovascular, infectious diseases and immunity, large system pathology, human cancer and molecular genetics and surgery, and transplants and health technology. The increasing scientific contributions performed by our research groups over the previous years have placed IdiPAZ among the top three health research institutes with the best scientific evaluation of Spain.


An evidence of our excellent position in clinical research is the fact that in 2016, IdiPAZ researchers have been improving in terms of scientific production; in particular, we published 1,097 articles, 848 of which were original. In addition, the overall impact factor reached 4,776.4 points, exceeding the 4,000 point threshold for the fourth consecutive year. There has also been a consolidation in the quality of the source journals, with a mean impact factor of 4.35 and with

more than 412 of the manuscripts published in journals in the first quartile of their subject area.

The 2016 Scientific Report also shows data reflecting the commitment of IdiPAZ to biomedical research training. The university involvement in most of the research groups has resulted in a high participation in graduate programmes, generating 41 Doctoral Theses this year; it is worth mentioning four of them with European mention. In parallel, our institution is making a great effort to open its activities, therefore we have organized several activities and workshops with the collaboration of our researchers and other institutions to increase our visibility and current potential while improving our plans for the future taking into account the internationalization aspects.

In addition, during the period 2012-2016, we are particularly proud for IdiPAZ innovative activity in terms of transferring of biomedical research. IdiPAZ filed 23 priority patents and 17 PCT; 5 national or regional phase entry applications were filed and 26 patents were granted, two of them European patents, which have placed us in a position of national leadership. Finally, we have done an effort to continue and improve our translational research with a direct application to the care of our patients, and in this strategic process 305 new contracts for clinical trials were signed in 2016

The excellence of our research institute is based on our human capital, our people, therefore we wish to express our admiration for them, who enable IdiPAZ to continue advancing to a promising future. There have been many achievements and we are confident that we will achieve many more. Our human potential and desire to continue progressing represent the best guarantee of continued success.





2 EXECUTIVE SUMMARY

-  **2.1 Global Analysis**
-  **2.2 Research Structure**
-  **2.3 Training Report and Teaching**
 - 2.3.1 Training Committee
 - 2.3.2 Training Courses
 - 2.3.3 Doctoral Theses
-  **2.4 Innovation and Transfer Activities**
 - 2.4.1 Innovation and Transfer Activities
 - 2.4.2 Patents and Trademarks
-  **2.5 Quality Committee**
-  **2.6 Clinical Trials**
-  **2.7 Platforms**
 - 2.7.1 Biobank
 - 2.7.2 UCICEC
 - 2.7.3 Experimental Surgery
 - 2.7.4 Simulation Platform
 - 2.7.5 Cell Culture Unit
 - 2.7.6 Automatic Sequencing Laboratory
 - 2.7.7 Image Laboratory
 - 2.7.8 Flow Cytometry Laboratory
 - 2.7.9 Radioisotope Laboratory
 - 2.7.10 Biostatistics Section
 - 2.7.11 Documentalist
 - 2.7.12 PAIN Platform
 - 2.7.13 Internationalization Platform
-  **2.8 Scientific Production**
-  **2.9 CIBERs and RETICs**
-  **2.10 Institutional Projects**
-  **2.11 Internationalization**





2.1 Global Analysis

In 2016, IdiPAZ research groups completed 1,097 publications, 848 of which were original articles. 51.7% are documents belong to IdiPAZ, the author was the first, the last or the corresponding author of the publication.


	Total	Impact factor	Mean impact factor
Publications	1,097	4,776.43	4.35
Owned Publications	567	1,626.57	2.87
Un-owned Publications	530	3,149.86	5.94
Originals	848	3,810.68	4.49
Owned Originals	391	962.45	2.46
Un-owned Originals	457	2,848.23	6.23

The total Impact Factor (IF) of the scientific production of IdiPAZ reached 4,776.43, therefore, for first year we exceeded the 4,500-point threshold.





The quality of the journals in which the articles were published has also experienced a significantly improvement. In 2008, 11.8% of the articles were published in high relevant journals (first decile) of their subject area, and increase until 15.68% in 2016, with a 37.56% of the articles published in journals in the first quartile. Likewise, since 2009, there was an increase in the quality of journals in which IdiPAZ originals, and currently 114 documents were published in first-quartile journals.

	1st Decile	1st Quartile	2nd Quartile	3rd Quartile	4th Quartile	Not Indexed
Publications	172	412	258	177	107	143
Originals	141	335	182	131	82	118



Considering originals published by IdiPAZ researchers, we keep the trend of the last years. For the fiftyth consecutive year, the IF of the originals exceeded the 3,000-point threshold, reaching 3,810.68 which represent the highest value for this entire series. Moreover, about 17% of the originals published in 2016 were in first-decile journals of their subject area, and almost 40% were in first quartile journals.






2.1 Global Analysis

The degree of integration of IdiPAZ researchers in national and international scientific networks is evidenced by the high number of articles published in collaboration, which accounts near of 82% of the total documents published, and 86.7% of the originals. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached 11% in 2016 for all manuscripts and 9.9% for originals.

Papers with international collaboration between 2008-2016



The upward trend in scientific activity conducted by our groups is also reinforced by the analysis of IdiPAZ originals. In 2016, 391 original IdiPAZ articles were published, with a mean impact factor of 2.46. The growth rates achieved in previous years have been increased in both indexes.

Owned originals between 2008-2016





2.2 Research Structure

Scientific Director

Eduardo López-Collazo

Scientific Assistant Director

Ignacio Zapardiel Gutiérrez

Executive Committee

Chairman

Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP; permanent delegation to Rodolfo Álvarez-Walther Sala.

Members

Juan Antonio Vargas Núñez. Dean of UAM Medical School

Eduardo López-Collazo. Scientific Director of IdiPAZ

Ana Coloma Zapatero. Director of FIBHULP

Francisco García Río. HULP Representative

Francisco Arnalich Fernández. UAM Representative

Secretary

Ana Coloma Zapatero. Director of FIBHULP

Governing Council

Chairman

Manuel Molina Muñoz. Health Care Vice Councillor CAM

Deputy Chairman

Rafael Garesse Alarcón. Chancellor of UAM

Members

Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP

Rodolfo Álvarez-Sala Walther. FIBHULP Patron

Miriam Rabaneda Gudiel. FIBHULP Patron

José María Muñoz y Ramón. FIBHULP Patron

Juan Antonio Vargas Núñez. FIBHULP Patron

Eduardo López-Collazo. Scientific Director of IdiPAZ

Almudena Castro Conde. FIBHULP Patron

Exuperio Díez Tejedor. FIBHULP Patron

Francisco Arnalich Fernández. FIBHULP Patron

Fernando Rodríguez Artalejo. UAM Representative

Amparo Cano García. UAM Representative

Pablo Lapunzina Badía. FIBHULP Patron

Juan José Pérez Blanco. FIBHULP Patron

Francisco Javier García-Samaniego Rey. FIBHULP Patron

Secretary

Ana Coloma Zapatero. Director of FIBHULP

External Scientific Committee

Juan Tamargo Menéndez

Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- Complutense University of Madrid. Madrid

Reiner Albert Veitia

Professor. Génomique fonctionnelle. Université Denis Diderot, Paris VII. Group leader of the Molecular Oncology and Ovarian Pathologies, l'Institut Jacques Monod. Paris

Joaquín Arribas López

Principal investigator. Vall d'Hebron Hospital. Barcelona
Chairman of the Technical Committee on Cancer Screening Health Research Fund (FIS).
Institute of Health Carlos III

Jacinta Cecilia Bustamante

Associate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris

Carlos Belmonte Martínez

Professor. Miguel Hernández University. Institute of Neurosciences. Alicante
President of the International Brain Research Organization (IBRO)

Juan Pedro Bolaños Hernández

Professor. Department of Biochemistry and Molecular Biology. University of Salamanca
Institute of Functional Biology and Genomics

Isabel Fabregat Romero.

Centre d'Oncologia Molecular. L'Hospitalet, Barcelona IDIBELL-Bellvitge Biomedical Research Institute. Barcelona

Carmen Maroto Vela

Professor. Chief of Microbiology. Clinical Hospital University of Granada

Santiago Rodríguez de Córdoba

Professor. Cellular and Molecular Medicine Department. Centro de Investigaciones Biológicas

Santiago Moreno Guillén

Chief of Infectious diseases Service. Ramón y Cajal Hospital. Madrid
Professor. Alcalá University. Madrid

Research Committee

Members

Eduardo López-Collazo

José Luis López-Sendón

Enrique Gómez Barrena

Francisco García Río

Jesús Frías Iniesta

Jaime Feliú Batlle

Jesús Mingorance Cruz

Rafael Selgas Gutiérrez

Nuria Vilboa Díaz

Inmaculada Ibáñez de Cáceres

Eduardo López Granados

Blanca Fuentes Gimeno

Javier de Castro Carpeño

Amparo Cano García

Francisco Arnalich Fernández

Guillermo Reglero Rada

Fernando Rodríguez Artalejo

Mercedes Salaces Sánchez

Nora Butta Coll

Rosario Perona Abellón

Antonio Pérez Martínez

Ignacio Zapardiel Gutiérrez

Alfonso Gil Martínez

Research Ethics Committee

Chairwoman

Almudena Castro Conde

Deputy Chairman

Jesús Frías Iniesta

Technical Secretary

Emma Fernández de Uzquiano

Members

María Concepción Prados Sánchez

José Ignacio Bernardino de la Serna

Antonio Buño Soto

Elena García Higuera

Jaime Fernández Bujarrabal

Nuria Rodríguez Salas

Filiberto Chulia Fernández

Ángel Robles Marhuenda

Fernando Cabañas Gómez

Elena Villamañán Bueno

Filomena Trocoli González

Carlos Lahoz Rallo

Miriam Romero Portales

Pedro Herranz Pinto

Nora Butta Coll

Rosa Villanueva Peña

Ramón Usandizaga Elio

Member from outside the institution

Mario Arancón Monge

Evangelina Garrido García

Technical Secretary

Emma Fernández de Uzquiano

Paz Lavilla Uriol

Sol de Gracia García

Maribel Arribas Álvarez

Animal Welfare Ethics Committee

Carmen Fernández Criado
Fernando Carceller Benito
Nuria Vilaboa Díaz
Carlota Largo Aramburu

Training Committee

Coordinator
Bárbara Martínez de Miguel

Members
Ana Isabel de Cos Blanco
Jesús Solera García
Julián Nevado Blanco

Quality Assurance Committee

Coordinator
José Jonay Ojeda Feo

Members
Blanca Fuentes Gimeno
Alberto Martín Vega
María Luisa Díaz Martínez
Margarita Rodrigo Angulo

Technical Secretary

Mercedes Ruiz Balibrea
Tamara Moruno García

Documentation Service

Raúl Román Cañizares

Coordinator of the Scientific Direction

Paloma Gómez Campelo

FIBHULP

Director
Ana Coloma Zapatero

Human Resources Manager
Head: Ana Gloria Herrera Puerta
María Quintanar Jaime

Private Projects Manager
Francisco Gil Gadea

Clinical Trial Manager
Head: Sara Moral Álamo
Desirée Hernández López

Public Projects Manager
Head: Silvia Arce Santamaría
Raquel Carmona del Mazo

Institutional Project Manager
José Luis Narro Villanueva
Marisa Tejedor Botello

Contracting Manager and Head of Legal Department
Sara Fernández Morata

Accountants
Head: Laura López Revuelta
Mónica García López

Researcher Reception and Attention
Carmen García Artiaga



Research Areas



Neuroscience Area

Coordinator:
Exuperio Díez Tejedor

GROUP	DIRECTOR
Psychiatry and Mental Health	Consuelo de Dios Perrino
Neurology and Cerebrovascular Diseases	Exuperio Díez Tejedor
Neuroprotective Strategies in Neurodegenerative Diseases	Antonio Cuadrado Pastor
Structure, Neurochemistry and Plasticity of Neural Circuits of the Cerebral Cortex and Thalamus	Francisco Clascá Cabré
Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies	Cecilio Giménez Martín



Cardiovascular Area

Coordinator:
José Luis López-Sendón Hentschel

GROUP	DIRECTOR
Research on Invasive Clinical Cardiology – ICCI-Paz	José Luis López-Sendón Hentschel
Cardiovascular Epidemiology and Nutrition	Fernando Rodríguez Artalejo
Coagulopathies and Alterations of Haemostasis	Victor Jiménez Yuste
Vascular Physiology and Pharmacology	Mercedes Salaices Sánchez
Vascular Pharmacology and Metabolism (FARMAVSM)	Carlos F. Sánchez Ferrer



Infectious Diseases and Immunity Area

Coordinator:
Eduardo López-Collazo

GROUP	DIRECTOR
AIDS and Infectious Diseases	José Ramón Arribas López
Molecular Microbiology	Jesús Mingorance Cruz
Immuno-Rheumatology	María Eugenia Miranda Carús
Innate Immune Response	Eduardo López-Collazo
Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System	Margarita López Trascasa Pilar Sánchez-Corral Gómez
Lymphocyte Pathophysiology in Immunodeficiencies	Eduardo López Granados
Drug Hypersensitivity and Innate Immune Response	Teresa Bellón Heredia
Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response	Cristina Calvo Rey
Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases	María José Mellado Peña
Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy	Antonio Pérez Martínez



Large System Pathology Area

Coordinator:
Francisco García Río

GROUP	DIRECTOR
Internal Medicine and Systemic Diseases	Francisco Arnalich Fernández
Organic Dysfunction and Failure in the Aggression	Abelardo García de Lorenzo y Mateos
Respiratory Diseases	Francisco García Río
Regulation of Gene Expression and by Hypoxia	Luis del Peso Ovalle
Nephrology	Rafael Selgas Gutiérrez
Neonatology	Adelina Pellicer Martínez
Aging and Fragility in the Elderly	Juan Ignacio González Montalvo
Molecular Hepatology	Paloma Jara Vega
Diagnosis and Treatment of Allergic Diseases	Santiago Quirce Gancedo
Gynecologic Oncology	Ignacio Zapardiel Gutiérrez
Patient Blood Management	Manuel Quintana Díaz
Endocrine Diseases	Lucrecia Herranz de la Morena
Urology	Luis Martínez-Piñeiro Lorenzo
Health Care Nurses Research	Jesús Castro Toro
Maternal and Fetal Medicine	José Luis Bartha Rasero
Emergency and Critical Pathology	Cesar Carballo Carmona



Cancer and Human Molecular Genetics Area

Coordinator:
Amparo Cano García

GROUP	DIRECTOR
INGEMM- Institute of Medical and Molecular Genetics	Pablo Lapunzina Badía
Translational Oncology	Jaime Feliú Battle
Experimental Therapies and Biomarkers in Cancer	Inmaculada Ibáñez de Cáceres Javier de Castro Carpeño
Oto-Neurosurgery Research	Luis Lassaletta Atienza
Cancer Molecular Pathology and Therapeutic Targets	David Hardisson Hernández
Mechanisms of Tumour Progression	Amparo Cano García
Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells	Carmela Calés Bourguet
Research and Diagnosis of Inherited Metabolic Diseases	María Belén Pérez González
Regulation of Ciliary Structure and Function by Phosphoinositides	Francesc García Gonzalo



Surgery, Transplant and Health Technologies Area

Coordinator:
Leopoldo Martínez Martínez

GROUP	DIRECTOR
Congenital Malformation Surgery	Leopoldo Martínez Martínez
Bone Pathophysiology and Biomaterials	Nuria Vilaboa Díaz
Cellular Engineering	María Paz de Miguel González
Clinical Pharmacology	Jesús Frías Iniesta
Osteoarticular Surgery Research – GICOA	Enrique Gómez Barrena
Reconstructive and Regenerative Research	Luis Landín Jarillo
Transplant	Francisco Hernández Oliveros





Public Research Contracts

Ramón y Cajal Stabilisation Contracts (13) - CAM

- Karen Elise Heath. INGEMM - Institute of Medical and Molecular Genetics Group
- Jesús Mingorance Cruz. Molecular Microbiology Group

Miguel Servet Stabilisation Contracts (12) - ISCIII/ CAM

- Teresa Bellón Heredia. Drug Hypersensitivity and Innate Immune Response Group
- Juan Ángel Fresno Vara. Translational Oncology Group
- Ángel Campos Barros. INGEMM - Institute of Medical and Molecular Genetics Group
- María Paz de Miguel González. Cellular Engineering Group
- Eduardo López-Collazo. Innate Immune Response Group
- Juan Antonio Rey Herranz. Oto-Neurosurgery research Group
- Berta Rodés Soldevila. AIDS and Infectious Diseases Group
- Pilar Sánchez-Corral Gómez. Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group
- María Rosa Torres Jiménez. Metabolic-Vascular Unit Group
- David Vicent López. Molecular Hepatology Group
- Nuria Vilboa Díaz. Bone Pathophysiology and Biomaterials Group

Miguel Servet Contracts Type I - ISCIII

- María Fernández Velasco (MSI1/00197). Innate Immune Response Group
- Laura Saldaña Quero (MSI1/00022). Bone Pathophysiology and Biomaterials Group

Miguel Servet Contracts Type II - ISCIII

- Nora Viviana Butta Coll (MSII14/00024). Coagulopathies and Alterations of Haemostasis Group
- María Inmaculada Ibáñez de Cáceres (MSII14/00008). Experimental Therapies and Biomarkers in Cancer Group
- Rosa María Rodríguez Pérez (MSII13/000022). Diagnosis and Treatment of Allergic Diseases Group

Intensification Contracts - ISCIII

- José Ramón Arribas López (INT15/00083). AIDS and Infectious Diseases Group
- Francisco José García Río (INT15/00076). Respiratory Diseases Group

Ramón y Cajal Contracts - MINECO

- Rebeca Pérez de Diego (RyC2011-07597). Innate Immune Response Group

Río Hortega Contracts - ISCIII

- Rocío Montejano Sánchez (CMI14/00034). AIDS and Infectious Diseases Group

Juan Rodés Contracts - ISCIII

- Emilio Cendejas Bueno (JR14/00027). Molecular Microbiology Group
- Ignacio Pérez Valero (JR13/00016). AIDS and Infectious Diseases Group

Sara Borrell Postdoctoral Contracts - ISCIII

- Raquel Rodríguez Díez (CD15/00003). Vascular Physiology and Pharmacology

Predoctoral Fellowship - ISCIII

- Clara Escudero Duch (FI14/00447). Bone Pathophysiology and Biomaterials Group
- Natalia Stella Ascariz (FI14/00391). Molecular Microbiology Group

Predoctoral Contract - MECD

- Irene Francisco Recuero (FPU13/00945). Associated Clinician
- Daniel Ruiz Pérez (FPU13/01638). Respiratory Diseases Group

Technical Support Stabilisation Contracts - CAM

- Francisco Gayá Moreno. AIDS and Infectious Diseases Group
- María Teresa Vallejo Cremades. Congenital Malformation Surgery Group
- Beatriz Sanz Minguela. Cell Culture Unit

PTA Contracts - MINECO

- Olga Pernía Arias (PTA2012-7141-I). Experimental Therapies and Biomarkers in Cancer Group
- Víctor Manuel Toledano Real (Pta2013-8265-I). Innate Immune Response Group

Technical Support in Management Contracts - ISCIII

- María Luisa Tejedor Botello (GIS14/00015). Associated Clinician

Youth Guarantee Contracts - CAM

- Verónica Aparicio Herranz (PEJ15/BIO/AI-045). Cellular Engineering
- Irene Dapia García (PEJ15/BIO/AI-0222). Institute of Medical and Molecular Genetics
- María Fernández Elvira (PEJ15/BIO/TL-0158). Institute of Medical and Molecular Genetics
- Nerea Lobato Vidal (PEJ15/BIO/AI-0286). Institute of Medical and Molecular Genetics
- Silvia Sánchez Casanova (PEJ15/BIO/AI-0250). Bone Pathophysiology and Biomaterials
- Cristina Vicente Capa (PEJ15/BIO/TL-0238). Molecular Hepatology

Youth Guarantee Contracts. MINECO

- Gonzalo Polo Paredes (PEJ-2014-A-18995). Experimental Surgery
- Alexander Otero García (PEJ-2014-A-23662). Cell Culture Laboratory

Human Resources

Programme	Organisation	Total
Ramón y Cajal Stabilisation Contracts (13)	CAM	2
Miguel Servet Stabilisation Contracts (12)	ISCIII/ CAM	11
Technical Support Stabilisation Contracts	CAM	3
TOTAL ESTABLISHED		16
Miguel Servet Contracts CP Type I	ISCIII	2
Miguel Servet Contracts CP Type II	ISCIII	3
Intensification Contracts	ISCIII	2
Ramón y Cajal Contracts	MINECO	1
Río Hortega Contracts	ISCIII	1
Juan Rodés Contracts	ISCIII	2
Sara Borrell Postdoctoral Contracts	ISCIII	1
Predoctoral Fellowship	ISCIII	2
Predoctoral Contract	MECD	2
PTA Contracts	MINECO	2
Technical Support in Management Contracts	ISCIII	1
Youth Guarantee Contracts	CAM	6
Youth Guarantee Contracts	MINECO	2
TOTAL PROGRAMMES		27
TOTAL ESTABLISHED + PROGRAMMES		43

CAIBER	CAIBER	6
FIS Projects	ISCIII	14
European Projects	EU	2
Research Network	ISCIII	14
Research Network	CAM	3
SAF/MAT	MINECO	3
Biobank	ISCIII	3
Commercial clinical trials	EECC Promoters	29
Private projects	Pharmaceutical Industry	71
In-house Projects	FIBHULP	7
ITEMAS Network	ISCIII	4
RETOS	MINECO	4
TOTAL EMPLOYEES DEPENDENT ON P.I.		160
Private projects	Pharmaceutical Industry	25
TOTAL FELLOWS DEPENDENT ON P.I.		25
TOTAL STAFF DEPENDENT ON P.I.		185

Technical Unit Staff	FIBHULP	13
TOTAL TECHNICAL UNIT		13
TOTAL		241



2.3 Training Report and Teaching



2.3.1. Training Committee

IdiPAZ's Training Committee is in charge of defining, elaborating and implementing the organization's training program. It must also ensure the proper development of the programs' objectives. This committee is designed in such a way that all members of the IdiPAZ are represented. It is composed of a coordinator and a representative from La Paz University Hospital (HULP) and a representative of the Autonomous University of Madrid (UAM).

IdiPAZ's training plan encompasses all studies la ongoing training (HULP) to postgraduate courses (UAM) which also includes IdiPAZ's own specialist courses.

In order to design its own courses' the committee annually consults via an online

needs analysis survey IdiPAZ members on their area of interests regarding the training needs observed by group leaders.

IdiPAZ's own courses are meant to complement HULP and UAM courses. These courses are coordinated by an IdiPAZ member who is not only the manager of these courses but also the person in charge of all the administrative documentation required by Spain's National Health System /Board, Thus IdiPAZ courses have the necessary state accreditation.

The committee also is in charge of our professionals' satisfaction follow up surveys.

Our specialist courses are taught by researchers and professionals of related disciplines.

COMPOSITION

Coordinator

Bárbara Martínez de Miguel

Members

Ana Isabel de Cos Blanco

Jesús Solera García

Julián Nevado Blanco

2.3.2. Training courses conducted by IdiPAZ in 2016

TITLE	HEAD	DATES	CREDITS	ASSISTANTS	HOURS	ASSESSMENT
Análisis de datos biomédicos con SPSS	Rosario Madero Jarabo	October 17 th -20 th	2	21	12	8.9
Lectura crítica de estudios de investigación. Recursos para la elaboración de una revisión sistemática	María Luisa Maquedano Martínez	April 5 th -7 th , 12 nd -13 rd	2.1	3	15	9
Normas de buena práctica clínica para investigadores y aspectos éticos de la investigación	Emma Fernández de Uzquiano	April 26 th -28 th	1	25	6	8.4
Técnicas ómicas en investigación biomédica	Valentini Konstantinidou	27 th -29 th	2.5	15	12	8.4

2.3.3. IdiPAZ Doctoral Theses

Áncer Arellano AG. Estudio de la asociación de genotipos del virus del papiloma humano con Chlamydia trachomatis y otros gérmenes en pacientes con fallo reproductivo [dissertation]. Madrid: UAM: 2016(7/10/2016).

Directors: Hardisson Hernández D, Gallegos Ávila G.

Arroyo Villa I. Estudio de las poblaciones celulares Th17 y Thf en la patogenia de la artritis reumatoide [dissertation]. Madrid: UAM: 2016(13/01/2016).

Directors: Miranda Carús ME, Martín Mola E.

Bautista Caro MB. Estudio sobre la biología de las células Th17 y Thf en espondiloartritis [dissertation]. Madrid: UAM: 2016(04/02/2016).

Directors: Miranda Carús ME, Martín Mola E.

Bernabéu Herrero ME. Defects in complement factor H-related proteins (FHRs) in renal pathology [dissertation]. Madrid: UAM: 2016(09/09/2016).

Director: Sánchez-Corral Gómez P.

Brogly N. Estudio comparativo de dos técnicas de localización del espacio epidural para la analgesia durante el trabajo de parto: pérdida de resistencia con aire o suero [dissertation]. Madrid: UAM: 2016(30/06/2016).

Directors: Gilsanz Rodríguez F, Guasch Arévalo E



Brose Piotrowicz IB. Avaliação das propriedades antioxidantes e anti-hipertensivas de peptídeos obtidos do concentrado proteico de farelo de arroz[dissertation]. Rio Grande: Universidade Federal do Rio Grande: 2016(27/05/2016).

Directors: Salas Mellado M, Miguel Castro M.

Cancelliere Fernández N. Evaluación de los modelos educativos, teórico y práctico, en residentes de primer año de especialidades médico-quirúrgicas[dissertation]. Madrid: UAM: 2016(19/9/2016).

Directors: Quintana Díaz M, Peña Sánchez JM.

Carrasco Ramírez P. Podoplanina es un componente de vesículas extracelulares que reprograma el contenido proteico de exosomas y modula la formación de vasos linfáticos [dissertation]. Madrid: UAM: 2016(1/04/2016).

Director: Quintanilla Ávila M.

de Velasco Oria de Rueda G. Análisis de un perfil de microARNs como factor pronóstico en cáncer de mama con afectación axilar [dissertation]. Madrid: UCM 2016(14/04/2016).

Directors: Fresno Vara JA, Ciruelos Gil E, Paz-Ares L.

Díaz Agero P. Desarrollo de una técnica de terapia celular e ingeniería tisular con células troncales somáticas mesenquimales para el tratamiento de las fistulas traqueo-bronquiales postquirúrgicas y las de origen yatrogénico[dissertation]. Madrid: UAM: 2016(12/02/2016).

Director: Álvarez-Sala Walther R.

Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España[dissertation]. Madrid: UAM: 2016(03/05/2016).

Director: Álvarez-Sala Walther R.

Fernández Fernández R. Resultados superiores del titanio frente al cromocobalto en cirugía primaria de cadera: resultados a largo plazo con el vástago Meridian[dissertation]. Madrid: UAM 2016(21/04/2016).

Director: Gil Garay E.

Ferrer Mayorga G. Efectos de la 1 α ,25-dihydroxyvitamin D3 en fibroblastos estromales de cáncer de colon[dissertation]. Madrid: UAM: 2016(25/11/2016).

Directors: Muñoz Terol A, Larriba Muñoz MJ.

Heredia Soto V. Identificación de biomarcadores relacionados con la transición epitelio mesénquima y caracterización de modelos celulares tridimensionales in vitro en cáncer de ovario avanzado[dissertation]. Madrid: UAM: 2016(15/11/2016).

Directors: Hardisson Hernández D, Mendiola Sabio M.

Hernández Esteban P. Técnica anatómica frente a técnica transtibial en la reconstrucción del LCA de la rodilla en pacientes futbolistas de alta demanda funcional.[dissertation]. Madrid: UAM: 2016(10/3/2016).

Director: Gómez Barrena E.

Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral[dissertation]. Madrid: UAM: 2016(23/06/2016).

Directors: López Collazo EM, García Río F.

Jurado Camino MT. Tolerancia a Endotoxinas: Una explicación a las infecciones recurrentes en la Leucemia Linfática Crónica[dissertation]. Madrid: UAM: 2016(11/03/2016).

Directors: López Collazo EM, Cubillos Zapata C.

Linares Espinós EE. Valor predictivo del volumen-centro de los resultados de la cirugía de cáncer renal con extensión venosa. Impacto en el modelo asistencial[dissertation]. Madrid: UAM: 2016(22/11/2016).

Director: Carballido Rodríguez J.

Martín Salces M. Alteraciones de la hemostasia en los síndromes mielodisplásicos[dissertation]. Madrid: UAM: 2016(08/11/2016).

Directors: Butta Coll NV, de Paz Arias R, Jiménez Yuste V.

Mateos Pañero B. Valoración del Euroscore y SAPS III como predictor de mortalidad hospitalaria en el postoperatorio de cirugía cardíaca [dissertation]. Madrid: UAM: 2016(1/12/2016).

Directors: Quintana Díaz M, Sánchez Casado M.

Montejano Sánchez R. Impacto del tratamiento antirretroviral con y sin nucleós(t)idos sobre la densidad mineral ósea y los biomarcadores de remodelado óseo[dissertation]. Madrid: UAM: 2016 (18/05/2016).

Directors: Arribas López JR, González García JJ, Arnalich Fernández F.

Moreno García AC. Terapia celular con células troncales derivadas de tejido adiposo (ADSC) para mejorar el proceso de reparación de defectos óseos en un modelo animal[dissertation]. Madrid: UAM: 2016(04/07/2016).

Director: Gil Garay E.

Moreno Pérez A. Teoría y práctica de la supervisión. Análisis del discurso de supervisores y psicoterapeutas [dissertation]. Madrid: UAH: 2016 (14/04/2016).

Director: Rodríguez Vega B, Fernández Liria A.

Navarro Vidal B. Logro de objetivos cardiometabólicos en sujetos hipertensos y diabéticos [dissertation]. Madrid: UAM: 2016 (13/03/2016).

Directors: Banegas Banegas JR, Graciani Pérez-Regadera MA.

Nozal Aranda P. Autoantibodies against proteins of the alternative complement pathway in renal diseases[dissertation]. Madrid: UAM: 2016(13/09/2016).

Director: López Trascasa M.

Ossorio González M. CCL18 y su implicación en esclerosis peritoneal: validación clínica de un nuevo marcador diagnóstico y pronóstico de alteración de la función peritoneal[dissertation]. Madrid: UAM: 2016(13/12/2016).

Directors: Selgas Gutiérrez R, Bajo Rubio MA.

Oyarzábal Sanz AL. Del gen a la patofisiología: nuevas enfermedades asociadas al catabolismo de los aminoácidos ramificados [dissertation]. Madrid: UAM: 2016(14/06/2016).

Director: Rodríguez Pombo P.

Palacios Ramírez R. Papel de ET-1 en la expresión de COX-2 y la contractilidad vascular en hipertensión. Modulación por PPAR γ [dissertation]. Madrid: URJC: 2016(03/05/2016).

Directors: Hernanz Martín R, Alonso Gordo MJ.

Pandiella Dominique A. Aproximación cuantitativa a la Apnea del sueño (2006-2010)[dissertation]. Madrid: UAM: 2016(28/01/2016).

Director: García Río F.

Paz Ramírez L. Utilidad del análisis molecular del ganglio centinela mediante técnica OSNA para la predicción intraoperatoria de afectación de ganglios no centinela en el cáncer de mama[dissertation]. Madrid: UAM: 2016(13/04/2016).

Directors: Hardisson Hernández D, Sánchez Méndez JL.

Pérez Valero I. Deterioro cognitivo asociado al virus de inmunodeficiencia humana (VIH) e inhibidores de proteasa potenciados con ritonavir en monoterapia [dissertation]. Madrid: UAM: 2016(01/02/2016).

Directors: Arribas López JR, Arnalich Fernández F.

Rodríguez Castellano E. Impacto del tratamiento del VHC sobre la infección VIH y la morbilidad no hepática en pacientes coinfectados VIH y VHC[dissertation]. Madrid: UAM: 2016(01/05/2016).

Directors: Berenguer Berenguer J, Arnalich Fernández F.

Rodríguez Fernández R. Evaluación de la eficacia de la funduplicatura Nissen laparoscópica mediante el uso de un cuestionario de calidad de vida y estudio esofagográfico baritado[dissertation]. Madrid: UAM: 2016(12/9/2016).

Directors: Quintana Díaz M, Martínez Cortijo S.

Rodríguez Sanz AI. Selección de posibles inhibidores de FABP4: Efectos en la actividad proinflamatoria de monocitos/macrófagos y en las interacciones macrófago/adipocito[dissertation]. Madrid: UAM: 2016(28/10/2016).

Directors: Bellón Heredia T, Selgas Gutiérrez R.

Romero Ribate D. Valoración del Síndrome de Apneas-Hipopneas del sueño como factor de riesgo de la Enfermedad Tromboembólica[dissertation]. Madrid: UAM: 2016(14/09/2016).

Director: García Río F.

Ruano Encinar M. Efecto de la prescripción electrónica asistida en pacientes pediátricos hospitalizados: evaluación de errores de medicación[dissertation]. Madrid: UAM: 2016(03/11/2016).

Director: Álvarez-Sala Walther R.

Ruiz Carrascoso G. Características microbiológicas y clínico-epidemiológicas de enterobacterias productoras de carbapenemasa OXA-48 en el contexto de un brote hospitalario[dissertation]. Madrid: UCM: 2016(10/02/2016).

Director: Mingorance Cruz J.

Sendagorta Cudós E. Prevalencia, diagnóstico y tratamiento de la displasia de alto grado anal asociada a la infección por el Virus del Papiloma Humano en pacientes infectados por el VIH[dissertation]. Madrid: UAM: 2016 (31/01/2016).

Directors: González García JJ, Herranz Pinto P.

Tiana Cerrolaza M. Mechanisms underlying gene repression in hypoxia[dissertation]. Madrid: UAM: 2016 (01/12/2016).


Director: del Peso Ovalle L. European Mention

Utrilla Contreras C. Valor de la Tomografía Computarizada Volumétrica en el estudio de la Enfermedad Pulmonar Obstructiva Crónica[dissertation]. Madrid: UAM: 2016(13/04/2016).

Director: García Río F.

Valbuena Gómez I. Eficacia de los recuperadores de sangre postoperatorios. Factores de riesgo transfusional y de hemorragia en la artroplastia total de rodilla [dissertation]. Madrid: UAM: 2016(20/12/2016).

Directors: Gilsanz Rodríguez F, Guasch Arévalo E.





2.4 Innovation and Transfer Activities

2.4.1. Innovation and Transfer Activities

The Innovation Support Unit (UAI) of FIBHULP was created in June 2010 within the framework of the ITEMAS Network – currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the UAI has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The UAI also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the UAI is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

ACTIVITIES

The main aim of the UAI is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the UAI has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.
- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.
- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.

- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Its impact in the Hospital has been strengthened by the creation of both the Innovation Platform and the Innovation Committee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital's Management Board in order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mission of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. It also forms part of the Innovation Committee, a decision-making body on the ideas to be supported by FIBHULP.

Among the greatest achievements of the Innovation Support Unit are the following:

1. The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.

At December 31 2016, the UAI had 164 innovation projects or ideas in active state, 28 of which were in the capture phase, 49 in the evaluation phase, 9 in development, 52 in transfer and 26 in the market. According to these data, it follows that 16% of the projects have been successfully exploited and positioned in the market, very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. Among the various types of projects handled by the UAI it is particularly noteworthy the volume of medical device-type projects, followed by projects such as "Bio", "Health ICT" and "eHealth". Although the UAI has more than six years of experience, most of the activity (134 projects) and its achievements have taken place in the last five years, period 2012-2016.

2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ's innovation community.

During the period 2012-2016, the UAI filed 23 priority patents (20 Spanish patents and 3 European patents) and 17 PCT; 5 national or regional phase entry applications were filed (2 before the EPO, 2 before USPTO and 1 before CIPO (Canadian Intellectual Property Office)) and 26 patents were granted (2 of them European patents). UAI's portfolio of patents in active state during period 2012-2016 reached the figure of 41 patent families and 1 utility model.

As for the software, during the period 2012-2016 the UAI registered 13 new computer applications.

Special mention should also be made to the UAI brand portfolio. During the period 2012-2016, 14 brands were requested and 14 were granted.

It is important to note that these brands, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.

3. The UAI has prepared a catalogue of technology offers -based on specification sheets- which includes the complete portfolio of exploitable IdiPAZ results. This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.

4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio. During the period 2012-2016 the UAI succeeded in signing 8 license agreements of intellectual property rights (copyright) and bringing 9 patents, 7 software, and 7 brands into commercial exploitation, which has meant a significant achievement in terms of economic return.

5. Thanks to UAI's support and management it has been possible to create and consolidate the first technology-based company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid. The spin-off concerned, Biomedica Molecular Medicine, exploits the research results in oncology – specifically, a genomic test to determine whether breast cancer patients should have chemotherapy – designed by some members of IdiPAZ.

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc.:

- "Oportunidades de financiación del programa ERC para investigadores de institutos de investigación biomédica" Workshop, April 6 2016
- "La compra pública innovadora en eHealth en el entorno sanitario" Workshop, June 3 2016
- "La innovación es posible: IdiPAZ te ayuda a lograrlo" Workshop, July 12 2016
- "Gestión de la Investigación FIBHULP-IdiPAZ" Workshop, December 13 2016

In addition, UAI has collaborated with important institutions and private entities to promote innovation, in particular it has participated in various forums and round tables organised by various stakeholders of the biomedical sector.

7. The UAI's has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results it is important to emphasize that several innovation projects managed by the Innovation Unit have been awarded with prestigious prizes over the last year:

- Award obtained in the first edition of the Healthstart Program by two of our innovation projects, in particular DILUBIO project, led by Dr Jesús Manuel Muñoz Caro, and PROTO:DEVICES project (High precision rectoscope) led by Dr Mario Álvarez Gallego (first prize and accessit respectively). Healthstart is the program of the Madrimasd Knowledge Foundation (Madri+d Foundation) and the Medical Technology Innovation Platform (ITEMAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the acceleration of technological start-ups of the Community of Madrid in the health-care sector;
- Prize won by the app Vivir con EPOC -developed by IdiPAZ's HEALTH CARE NURSES RESEARCH GROUP together with the company Navandu Technologies- in the first edition of the Andalusia Health Challenges initiative. This initiative was promoted by the Public Health Service of Andalusia (SSPA) in collaboration with the company

Vodafone and aims to promote the development of mobile applications (or apps) that improve user adherence to the treatment of chronic diseases. This first 'Challenge' was directed, in particular, to chronic obstructive pulmonary disease (COPD).

This same app has been awarded with other prizes such as the 2017 SaluDigital Award organized by Grupo Medforum, in the category of Best Health App.

ORGANISATION

Since its implementation, the UAI has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.

The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and a member of the Medical Oncology Department of the La Paz University Hospital/ Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The Innovation Unit also consists of a team of four experts in fostering innovation and protecting research results and technology transfer:

Estela Sánchez Simón, Law Graduate;

Marisa Tejedor Botello, Bachelor of Economic Sciences;

María Dolores Pérez Garre, Bachelor of Chemical Sciences.

and Adriana Varela Fernández, Bachelor of Economic Sciences;

CONTACT

Coordinator

Javier de Castro Carpeño
javier.decastro@salud.madrid.org
Phone: (+34) 91 207 12 34

Members

Estela Sánchez Simón
e_sanchez.innovacion@idipaz.es
Phone: (+34) 91 207 12 34

Marisa Tejedor Botello
marisa.tejedor@idipaz.es
Phone: (+34) 91 207 17 40

María Dolores Pérez Garre
maria.dolores.perez@idipaz.es
Phone: (+34) 91 207 12 34

Adriana Varela Fernández
adriana.varela@idipaz.es
Phone: (+34) 91 207 17 90



2.4.2. Patents and trademarks



Neuroscience Area

Neurology and Cerebrovascular Diseases Group

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Maíquez J, Lorrio González S, Negrodo Madriral P, inventors; Bioibérica S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors; CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS Neuroscience S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS Neuroscience S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.



Cardiovascular Area

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Figueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Vascular Physiology and Pharmacology Group

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaices Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; Nanoate, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A,



inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.



Infectious Diseases and Immunity Area

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: Bio-Drug Analysis BIDA. CM 13.808.531, 2015 March 10.



Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D'Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636; 2016 July 26.

Innate Immune Response Group

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.



Lymphocyte Pathophysiology in Immunodeficiencies Group

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vilko-va M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Drug Hypersensitivity and Innate Immune Response Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for screening compounds. P201430081, PCT/ES2015/070039; 2014 January 27.



Large System Pathologies Area

Organic Dysfunction and Failure in the Agression Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.



Nephrology Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J, Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8; 2015.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.



Diagnosis and Treatment of Allergic Diseases Group

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.



Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EPI6382413.9 (Publication Number pending); 2016 September 06.

Gynecologic Oncology Group

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.

Associated Clinician

de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EPI897578; 2005 May 16.



Cancer and Human Molecular Genetics Area

INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EPI332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM Instituto de Genética Médica y Molecular del Hospital Universitario La Paz; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.



Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.



INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentación, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723; 2015 September 23.

Experimental Therapies and Biomarkers in Cancer Group

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EPI947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.





Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M, inventors; FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradicio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediell Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediell Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Mechanisms of Tumour Progression Group

Matías-Guía Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EPI4155510.2, PCT/EP2015/053387; 2014 February 18.

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees. Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

Research and Diagnosis of Inherited Metabolic Diseases Group

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EPI6382373.5; 2016.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.



Surgery, Transplant and Health Technologies Area

Bone Pathophysiology and Biomaterials Group

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E, inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrastagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor 1 and uses thereof. US 62/495,501; 2016 September 16.

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.



Clinical Pharmacology Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX; CM 13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

Osteoarticular Surgery Research- GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Emergency and Critical Pathology Group

Carballo Cardona C; author; FIBHULP, assignee. Brand name: Diagether. CM15869911, 2016 September 29.

Associated Clinician

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM,

assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249; 2016 April 29.

Other Trademarks of IdiPAZ

FIBHULP, author; FIBHULP, assignee. Brand name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM 8.871.873; 2010 July 06, 2010 February 10.



FIBHULP, author; FIBHULP, assignee. Brand name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.



FIBHULP, author; FIBHULP, assignee. Brand name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.





2.5 Quality Committe

The vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical research at the national and European level. To achieve this objective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching.

IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management team of the IdiPAZ institutions. To support and facilitate quality, the institution maintains a Quality Committee.

During 2016, the Quality Committee fostered these principles but also achieved specific quality goals. The quality management system has been adapted to the requirements of the ISO 9001:2015, including in the scope both the Technical Secretariat and the Quality Committee. By the end of 2016 IdiPAZ will be ready to meet the requirements of the UNE 166002:2014 for innovation activities within the management system; and has also started to further expand the scope to the Innovation Support Unit and the Central Research and Clinical Trials Unit. Moreover, considering that IdiPAZ is a con-

tinuously evolving organisation, the Quality activities of our institution has been enriched by the different achievements made by the Hospital Universitario La Paz and Universidad Autónoma de Madrid.

The hospital, with its accumulative experience about quality of care improvement, has continued working intensively during this year. Protocols, clinical pathways and participation in clinical practice guidelines has been developed and reviewed. The attached tables show the clinical pathways reviewed in 2016 as well as the protocols developed or updated in the same period. In addition, the staff members continuously collaborate in the improvement of the institution by participating in clinical committees and creating improvement groups, as well as implementing satisfaction surveys for patients and professionals.

Also during 2016 19 departments maintained the standards ISO 9001:2008, ISO 14001:2004, ISO 22000:2005 and IQNet-SR10 of their individual quality management systems. The hospital has also 22 accredited units within the Spanish National Accreditation System.

Protocol/ Clinical pathway	Status
Abordaje quirúrgico en infarto con edema cerebral e hipertensión intracraneal	Revised
Acogida de pacientes obesos	Revised
Actuación del Fracaso Renal en la enfermedad de Ébola	Revised
Actuación en cirugía de mediastino	Revised
Actuación en Neonatología con el postoperatorio del paciente con cardiopatía congénita	Revised
Actuación en Reanimación Infantil con el postoperatorio del paciente con cardiopatía congénita	Revised

Protocol/ Clinical pathway	Status
Administración del hidroferol en ERCA	New
Alergia al dializador	New
Asepsia/antiseptia en los quirófanos de Cirugía Cardíaca de Adultos	Revised
Atención a ACV agudo	Revised
Atención a la TCA incluida en gestión de unidosos	Revised
Atención a los trastornos de conducta alimentaria	Revised
Atención a pacientes con bombas de infusión subcutánea continua de insulina (ISCI)	New
Atención al niño politraumatizado	Revised
Atención al paciente con riesgos suicida (ARSUIC)	Revised
Atención de pacientes con golpes de calor	Revised
Atención del paciente con agonía	Revised
Atención Nutricional en Fibrosis Quística	Revised
Atención Nutricional en Trastornos de la Conducta Alimentaria	Revised
Atención quirúrgica a los pacientes adultos con cardiopatías congénitas	Revised
Bronquiolitis aguda con criterio de ingreso en CIP	Revised
Cateterismo de venas pancreáticas y vena hepática derecha para detección preoperatorio de insulinomas	Revised
Cateterización de senos petrosos para determinación de ACTH	Revised
Cateterización de venas cervicales y torácicas para toma de muestras de PTH	Revised
Cateterización de venas suprarrenales en el hiperaldosteronismo	Revised
Cirugía plástica en enfermo intervenido de cirugía bariátrica	Revised
Comunicación de órdenes verbales en asa cerrada	Revised
Conservación de medicamentos en las unidades clínicas	Revised
Control metabólico de la diabetes gestacional	Revised
Cuidados de enfermería en hemodiálisis y diálisis peritoneal	Revised
Cuidados de enfermería en técnicas de recambio plasmático	New
Derivación de pacientes a ERCA	Revised
Derivación de pacientes con osteoporosis	New
Desensibilización a cotrimoxazol en niños	Revised
Diarrea en el niño viajero	Revised
Diagnóstico diferencial de eosinoflias	Revised
Educación nutricional y seguimiento grupal	Revised
Evaluación hipotálamo-hipofisaria en los traumatismos craneoencefálicos	Revised
Fiebre en el niño inmigrante	Revised
Inclusión en lista de espera de trasplante	Revised
Inmovilización terapéutica	Revised
Intervención intensiva en obesidad (Programa EGO)	Revised
Malnutrición Hospitalaria	Revised
Manejo ambulatorio del debut de diabetes tipo I	Revised
Manejo de Amebiasis	Revised
Manejo de Chikungunya	Revised
Manejo de Cólera	Revised
Manejo de Dengue	Revised
Manejo de Esquistosomiasis	Revised
Manejo de Strongyloidiasis	Revised
Manejo de Giardiasis	Revised
Manejo de la Anafilaxia	Revised

Protocol/ Clinical pathway	Status
Manejo de la anemia ferropénica en urgencias	Revised
Manejo de la Enfermedad de Chagas	Revised
Manejo de la Malaria	Revised
Manejo de Rabia	Revised
Manejo de Toxocariasis	Revised
Manejo de Triquinosis	Revised
Manejo de Trypanosomiasis	Revised
Manejo enfermedad tromboembólica venosa	Revised
Mantenimiento del carro de parada	Revised
Neumonía asociada a ventilación mecánica	Revised
Neumonía en Inmunodeprimido	Revised
Nutrición Artificial Domiciliaria	Revised
Nutrición en Hemodiálisis	Revised
Osteodistrofia en diálisis peritoneal	Revised
Preparación para colonoscopia en los pacientes en diálisis	New
Preparación para la colonoscopia en paciente ERCA	Revised
Prevención de Endocarditis Infecciosa en Pacientes Portadores de Prótesis Valvulares Cardíacas y Dispositivos Intravasculares	Revised
Prevención de lesiones de piel y tejidos blandos en pacientes sometidos a cirugía cardíaca.	Revised
Prevención de riesgo suicida en la unidad breve de hospitalización psiquiátrica	Revised
Prevención del cáncer de cuello de útero	Revised
Prevención y tratamiento de la intoxicación por metotrexato intravenoso	Revised
Protocolo de supresión salina para confirmación de hiperaldosteronismo primario	Revised
Provocación nasal específica e inespecífica	Revised
Prueba de estimulación del cortisol con comida	Revised
RCP avanzada	Revised
Recogida de lesiones detectadas en colonoscopia de cribado	New
Score de evaluación del donante del trasplante renal	New
Sepsis comunitaria sin foco en paciente con patología crónica	Revised
Sepsis comunitaria sin foco en paciente sano	Revised
Talleres de actividad física para el paciente con obesidad	Revised
Talleres de dietética para el paciente con obesidad	Revised
Talleres de psicología para el paciente con obesidad	Revised
Test de ayuno prolongado	Revised
Test de restricción hídrica	Revised
Transfusión segura en la unidad de quemados críticos	New
Trasplante de miembro superior	Revised
Tratamiento de la Hipertensión Pulmonar	Revised
Tratamiento de la Leucemia Mieloide Crónica	Revised
Tratamiento de las peritonitis en CAPD	Revised
Tratamiento endovascular del Infarto cerebral agudo	Revised
Uso racional de antibióticos en infección de orina	New
Utilización de medicamentos de alto riesgo	Revised
Validación farmacéutica en Pacientes Externos	Revised
Valoración de orificio del catéter peritoneal	Revised
Verificación planificación tratamientos radioterapia 3D	Revised
Vuelta a diálisis tras fallo de trasplante renal	Revised



2.6 Clinical Trials

Agrifoglio Rotaache A. Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con comparador, para evaluar la eficacia, la seguridad y la farmacocinética de Ulimorelina (LPI01) administrada por vía intravenosa en pacientes con intolerancia a la alimentación enteral. Type: clinical trial, phase II.

HULP code: 4624. Sponsored's protocol code: LPI01-CL-201. Sponsored by: Ipsen Innovation. Signed date: 17/05/2016

Alonso Dorrego JM. Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de uno o más tratamientos intradetrusor con 600 u 800 unidades de Dysport® para el tratamiento de la incontinencia urinaria en pacientes con hiperactividad neurógena del detrusor por lesión de la médula espinal o esclerosis múltiple. Type: clinical trial, phase III.

HULP code: 4713. Sponsored's protocol code: D-FR-52120-223. Sponsored by: Meditate Ltd. Signed date: 24/10/2016

Alonso Gregorio S. Estudio prospectivo, internacional, multicéntrico y de brazo único para evaluar la eficacia de Dispositivo Temporal Implantable de Nitinol (TIND) de medi-tate en sujetos con Hiperplasia Prostática Benigna (HPB). Type: Healthcare product.

HULP code: 4537. Sponsored's protocol code: MT-02. Sponsored by: Ipsen Pharma S.P.S. Signed date: 24/02/2016

Álvarez Escola C. Estudio observacional, multicéntrico internacional, para evaluar la efectividad en la práctica clínica cotidiana de la Lanreotida Autogel 120 mg, en intervalos posológicos prolongados (>4 semanas), para el tratamiento de la acromegalia: Estudio SOMACROL. Type: EPA-OD.

HULP code: PI-2285. Sponsored's protocol code: IPS-SOM-2015-01. Sponsored by: Csl Behring GmbH Clinical. Signed date: 18/05/2016

Álvarez Román MT. Estudio de extensión de fase IIIb, abierto, multicéntrico, sobre la seguridad y eficacia de una proteína de fusión del factor IX recombinante de la coagulación con la albumina (RIXFP) en pacientes con Hemofilia B. Type: clinical trial, phase IIIb.

HULP code: Anexo-II 401 I. Sponsored's protocol code: CSL654_3003. Sponsored by: Baxter Innovations GmbH. Signed date: 23/02/2016

Álvarez Román MT. Estudio de extensión de fase III, abierto, multicéntrico para evaluar la seguridad y eficacia del factor de la coagulación VIII recombinante (RVIII-cadena sencilla, csl627) en pacientes con Hemofilia A severa. Type: clinical trial, phase III.

HULP code: Anexo-I 4179. Sponsored's protocol code: CSL-3001. Sponsored by: Grifols S.A. Signed date: 18/05/2016

Álvarez Román MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNTP) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave (FVIII < 1 %. Type: clinical trial, phase III.

HULP code: 4487. Sponsored's protocol code: 261203. Sponsored by: Baxter Innovations GmbH. Signed date: 19/01/2016

Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC dirigida a dos concentraciones mínimas de FVIII distintas en sujetos con Hemofilia A grave. Type: clinical trial, phase III.

HULP code: 4547. Sponsored's protocol code: 261303. Sponsored by: CSL Behring GmbH Clinical. Signed date: 16/02/2016

Álvarez Román MT. Estudio multicéntrico, abierto y de administración repetida, para evaluar la seguridad y la eficacia de UCB7665 en sujetos con trombocitopenia inmune primaria" (TP0001. Type: clinical trial, phase II.

HULP code: 4562. Sponsored's protocol code: TP0001. Sponsored by: Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. Signed date: 31/03/2016

Álvarez Román MT. Estudio de fase I, prospectivo, abierto, de dos periodos, secuencia fija y aumento escalonado de la dosis sobre la FC y la seguridad de BAX 826 (APS-FVIII) en pacientes con Hemofilia A grave (FVIII < 1 %) previamente tratados. Type: clinical trial, phase I.

HULP code: 4563. Sponsored's protocol code: 291501. Sponsored by: Bio Products Laboratory Ltd. Signed date: 16/03/2016

Álvarez Román MT. Estudio multicéntrico de fase II, abierto, de un solo brazo, prospectivo, intervencional, del factor derivado del plasma VIII/VWF (Alphanate®) en la terapia de inducción de tolerancia inmune en sujetos con Hemofilia Congénita A. Type: clinical trial, phase II.

HULP code: 4655. Sponsored's protocol code: GB11406. Sponsored by: Baxter Innovations GmbH. Signed date: 27/07/2016

Álvarez Román MT. Estudio multicéntrico de recogida de datos retrospectivos sobre el uso del factor x de alta pureza de BPL en el tratamiento de pacientes con deficiencia del factor X hereditaria. Type: EPA-OD.

HULP code: PI-2192. Sponsored's protocol code: TEN 05. Sponsored by: Ucb Biosciencias GmbH. Signed date: 12/05/2016

Álvarez Román MT. Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune primaria en España. Type: EPA-OD.

HULP code: PI-2517. Sponsored's protocol code: VERTEX 2.0. Sponsored by: Melinta Therapeutics, Inc. Signed date: 18/10/2016

Álvarez-Sala Walther R. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de Delafloxacino intravenoso con cambio a vía oral en sujetos adultos con neumonía bacteriana adquirida en la comunidad. Type: clinical trial, phase IIIa.

HULP code: 4545. Sponsored's protocol code: ML-3341-306. Sponsored by: Hospital Universitario De Gran Canaria. Signed date: 14/06/2016

Añón Elizalde JM. Estudio comparativo, aleatorio, controlado, para evaluar la eficacia de la administración de Dexametasona en el tratamiento de pacientes con el síndrome de distrés respiratorio agudo. Type: clinical trial, phase IV.

HULP code: 4680. Sponsored's protocol code: P11 I-0143. Sponsored by: Medimmune. Signed date: 04/10/2016

Ares Segura S. Estudio de fase IIb aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en prematuros sanos. Type: clinical trial, phase II.

HULP code: 4660. Sponsored's protocol code: D5290C00003. Sponsored by: Janssen-Cilag España, S.A. Signed date: 03/10/2016

Arribas López JR. Estudio internacional, multicéntrico, observacional, prospectivo, sobre la seguridad de Maraviroc utilizado junto con la terapia de base optimizada en pacientes infectados por el VIH-I que han recibido tratamiento. Type: EPA-SP.

HULP code: Anexo-II 2754. Sponsored's protocol code: A4001067. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 31/05/2016

Arribas López JR. Estudio de fase III abierto para evaluar la seguridad del tratamiento en un solo comprimido de Elvitegravir/Cobicistat/Emtricitabina/Tenofovir alafenamida en pacientes infectados por el VIH-I con insuficiencia renal leve o moderada. Type: clinical trial, phase III.

HULP code: Anexo-I 3947. Sponsored's protocol code: GS-US-292-0112. Sponsored by: Gilead Sciences Inc. Signed date: 20/06/2016

Arribas López JR. Estudio de fase III, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento a un régimen en un solo comprimido administrado una vez al día de Darunavir/Cobicistat/Emtricitabina/Tenofovir alafenamida (D/C/F/TAF) frente a la continuación del régimen actual formado por un Inhibidor de la Proteasa Potenciado (IPP) combinado con Emtricitabina/Tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el Virus de la Inmunodeficiencia Humana de tipo I (VIH-I) con supresión virológica. Type: clinical trial, phase III.

HULP code: Anexo-I 4300. Sponsored's protocol code: TMC114IFD3013. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 27/05/2016

Arribas López JR. Estudio fase IIIb, aleatorizado, doble ciego, con cambio de tratamiento para evaluar la seguridad y eficacia de una combinación a dosis fija (CDF) de Emtricitabina/Rilpivirina/Tenofovir Alafenamida (FTC/RPV/TAF), en pacientes con VIH-I positivo que presentan supresión virológica en tratamiento con Emtricitabina/Rilpivirina/Tenofovir Disoproxil Fumarato (FTC/RPV/TDF). Type: clinical trial, phase IIIb.

HULP code: Anexo-I 4374. Sponsored's protocol code: GS-US-366-1260. Sponsored by: Gilead Sciences Inc. Signed date: 20/09/2016

Arribas López JR. Estudio fase IIIb, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinación a dosis fija (CDF) de Efavirenz/Emtricitabina/Tenofovir Disoproxil Fumarato (EFV/FTC/TDF) a una CDF de Emtricitabina/Rilpivirina/Tenofovir Alafenamida (FTC/RPV/TAF) en pacientes con infección por VIH I y supresión virológica. Type: clinical trial, phase IIIb.

HULP code: 4375. Sponsored's protocol code: GS-US-366-1160. Sponsored by: Sanofi Aventis S.A. Signed date: 20/09/2016

Arribas López JR. Ensayo clínico fase IIb, aleatorizado, controlado con principio activo, doble ciego, para investigar la seguridad, eficacia y dosis-respuesta de BMS-955176, administrado con Tenofovir/Emtricitabina en adultos infectados por VIH I Naive a tratamiento. Type: clinical trial, phase II.

HULP code: Anexo-I 4424. Sponsored's protocol code: AI468-038. Sponsored by: Gilead Sciences Inc. Signed date: 26/02/2016

Arribas López JR. Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de tres lotes de estabilidad y un lote de dosis alta de RSV-ZEBOV-GP (vacuna contra el virus del Ébola V920) en adultos sanos. Type: clinical trial, phase III.

HULP code: Anexo-I 4431. Sponsored's protocol code: V920-012. Sponsored by: Janssen-Cilag España, S.A. Signed date: 07/01/2016

Arribas López JR. Estudio fase III, multicéntrico, abierto, randomizado, para evaluar el cambio a MK 1439A en pacientes con supresión virológica infectados por el VIH-I en un régimen de un inhibidor de proteasa potenciado con Ritonavir y dos inhibidores de la transcriptasa inversa análogos de nucleósido (nrtis). Type: clinical trial, phase III.

HULP code: Anexo-I 4441. Sponsored's protocol code: 1439A-024. Sponsored by: Gilead Sciences Inc. Signed date: 27/09/2016

Arribas López JR. Estudio fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la farmacocinética, seguridad y actividad antiviral del JNJ-63623872 en combinación con Oseltamivir en pacientes adolescentes, adultos y ancianos hospitalizados por infección de gripe a. Type: clinical trial, phase II.

HULP code: Anexo-I 4501. Sponsored's protocol code: 63623872FLZ2002. Sponsored by: Gilead Sciences Inc. Signed date: 22/06/2016

García García S. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de medi3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Type: clinical trial, phase III.

HULP code: 4540. Sponsored's protocol code: HELIOS-AP. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 23/06/2016

García Martínez JR. Estudio exploratorio, aleatorizado, doble-enmascarado y controlado con placebo para evaluar la farmacodinámica, seguridad y tolerabilidad de BI 1026706 administrado de forma oral durante 12 semanas en pacientes con deficiencia visual leve debido a un edema macular diabético de predominio central. Type: clinical trial, phase II.

HULP code: 4629. Sponsored's protocol code: 1320.22. Sponsored by: Pfizer Inc. Signed date: 24/05/2016

García Puig J. Estudio de fase III multicéntrico, doble ciego, aleatorizado, controlado con placebo y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de PF-04950615 en la reducción del número de acontecimientos cardiovasculares graves en pacientes de alto riesgo. Type: clinical trial, phase III.

HULP code: Anexo-II 4044. Sponsored's protocol code: B1481022. Sponsored by: Pfizer Inc. Signed date: 30/06/2016

García Puig J. Ensayo clínico aleatorizado, controlado con placebo, para evaluar los resultados clínicos cardiovasculares tras el tratamiento con Exenatida una vez a la semana en pacientes con Diabetes Mellitus de Tipo 2. Type: clinical trial, phase III.

HULP code: Anexo-I 4103. Sponsored's protocol code: BCB109. Sponsored by: García Río, Francisco José. Signed date: 08/01/2016

García Puig J. Estudio de fase III multicéntrico, doble ciego, aleatorizado, controlado con placebo y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de PF-04950615 en la reducción del número de acontecimientos cardiovasculares mayores en pacientes de alto riesgo. Type: clinical trial, phase III.

HULP code: Anexo-II 4219. Sponsored's protocol code: B1481038. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 30/06/2016

García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstructiva del sueño. Type: Healthcare product.

HULP code: PI-2386. Sponsored's protocol code: PI-2386. Sponsored by: Abbvie Spain, S.L.U. Signed date: 04/11/2016

García-Samaniego Rey FJ. Estudio abierto y multicéntrico para evaluar los resultados a largo plazo con ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) y ABT 333 con o sin ribavirina (RBV) en adultos con infección crónica por el virus de la Hepatitis C (VHC) de genotipo 1 (topaz-i). Type: clinical trial, phase III.

HULP code: Anexo-II 4272. Sponsored's protocol code: M14-423. Sponsored by: Conatus Pharmaceuticals Inc. Signed date: 23/02/2016

García-Samaniego Rey FJ. Estudio abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de abt-493/abt-530 en adultos con infección crónica por el virus de la hepatitis c genotipo 1 (endurance-1). Type: clinical trial, phase III.

HULP code: 4505. Sponsored's protocol code: M13-590. Sponsored by: Abbvie Spain, S.L.U. Signed date: 18/01/2016

García-Samaniego Rey FJ. Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar Emricasán (IDN 6556), un inhibidor de la caspasa de administración oral, en sujetos con fibrosis por esteatohepatitis no alcohólica (EHNA). Type: clinical trial, phase II.

HULP code: 4609. Sponsored's protocol code: IDN-6556-12. Sponsored by: Gilead Sciences Inc. Signed date: 03/05/2016

García-Samaniego Rey FJ. Estudio de fase II, multicéntrico, aleatorizado, abierto, para evaluar la eficacia y seguridad de la combinación a dosis fija de Sofosbuvir/Velpatasvir (CDF) y Sofosbuvir/Velpatasvir en cdf y Ribavirina en pacientes con infección crónica por el genotipo 3 del VHC y cirrosis. Type: clinical trial, phase II.

HULP code: 4622. Sponsored's protocol code: GS-US-342-2097. Sponsored by: Amgen, S.A. Signed date: 15/07/2016

García-Samaniego Rey FJ. Eficacia y seguridad/tolerabilidad de Viekirax y Exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH 1, GT 1 o 4, y enfermedad renal crónica en estadios de IIIb a V, incluyendo aquellos en diálisis, en práctica clínica habitual en España Estudio viekind. Type: EPA-OD.

HULP code: PI-2303. Sponsored's protocol code: ABB-OMB-2015-01. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 09/05/2016

Gasior Kabat M. Seguridad de Romiplostim en el tratamiento de la trombocitopenia en pacientes con síndrome mielodisplásico de riesgo bajo o intermedio -I. Type: clinical trial, phase I.

HULP code: Anexo-II 2709. Sponsored's protocol code: 20060198. Sponsored by: Chu Saint Etienne. Signed date: 19/09/2016

Gómez Barrena E. Estudio en fase IIIb multicéntrico, aleatorizado, doble ciego y controlado, para evaluar la eficacia y seguridad de Rivaroxaban 10 mg frente a Enoxaparina 4000 UI para la profilaxis de TEV en cirugía ortopédica menor Estudio pronomos. Type: clinical trial, phase IIIb.

HULP code: 4550. Sponsored's protocol code: I408143. Sponsored by: Anthera Pharmaceuticals Inc. Signed date: 12/05/2016

Gómez Candela C. Estudio fase III, aleatorizado, abierto, con evaluador enmascarado y comparador activo para evaluar la inferioridad en la eficacia y seguridad de liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III.

HULP code: 4530. Sponsored's protocol code: AN-EPI3331. Sponsored by: Linical France Sarl. Signed date: 02/02/2016

Gómez Candela C. Estudio abierto para evaluar la eficacia y seguridad de Liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III.

HULP code: 4686. Sponsored's protocol code: AN-EPI3334. Sponsored by: Amgen, S.A. Signed date: 23/09/2016

Gómez Prieto P. Ensayo aleatorizado y doble ciego para evaluar la eficacia, la seguridad y la inmunogenicidad de abp 798 en comparación con Rituximab en sujetos con linfoma no Hodgkin (LNH) de células b cd20+. Type: clinical trial, phase III.

HULP code: Anexo-I 4216. Sponsored's protocol code: 20130109. Sponsored by: Abbott Laboratories, S.A. Signed date: 12/04/2016

Gómez Senent S. Estudio postcomercialización observacional de cohortes en pacientes con enfermedad inflamatoria intestinal (EII) tratados con Inflectra (Infliximab) en la práctica clínica habitual (connect-ibd). Type: EPA-SP.

HULP code: PI-2082. Sponsored's protocol code: ZOB INF 1402. Sponsored by: Merck KgaA. Signed date: 02/11/2016

Gómez Senent S. Estudio prospectivo observacional sobre una muestra de pacientes malnutridos con intolerancia gastrointestinal tras la administración de una fórmula peptídica alta en calorías y proteínas con MCT. Type: Non EPA.

HULP code: PI-2410. Sponsored's protocol code: DA13. Sponsored by: Hospira Productos Farmaceuticos Y Hospitalarios S.L. Signed date: 22/07/2016

González Casado I. Estudio observacional, prospectivo y multicéntrico a largo plazo en una cohorte de niños con talla baja nacidos pequeños para su edad gestacional (PEG) que han sido tratados con Saizen® / Prospective, single-cohort, multicentre observational long-term study in short children born small for Gestational Age (SGA) after treatment with Saizen® (Estudio salto). Type: EPA-LA.

HULP code: 3277. Sponsored's protocol code: EMR200098_008 2016. Sponsored by: Agencia Nacional de Investigación sobre el Sida y las Hepatitis Viricas. Signed date: 05/09/2016

González García JJ. Ensayo clínico en fase III para optimizar la inmuno-estimulación con maraviroc, un antagonista CCR5, combinado con tratamiento antorretroviral (TAR) en pacientes con infección por VIH-I avanzada, con diagnóstico tardío, criterio de definición de SIDA y/o recuentos de Cd4 por debajo de 200 células/mm3. Type: clinical trial, phase IV.

HULP code: Anexo-I 3680. Sponsored's protocol code: ANRS 146 OPTIMA. Sponsored by: Laboratorios VIIV Healthcare, S.L. Signed date: 02/02/2016

González García JJ. Estudio abierto de fase III para evaluar la eficacia y la seguridad del tratamiento con Boceprevir en pacientes coinfectados por el VIH y VHC (genotipo 1 (subtipo A o B)), que han fracasado al tratamiento previo con Peginterferón y Ribavirina. Type: clinical trial, phase III.

HULP code: Anexo-I 3788. Sponsored's protocol code: BOC-HIV. Sponsored by: Espin Basany, Eloy. Signed date: 13/07/2016

González García JJ. Estudio fase III, aleatorizado, multicéntrico, abierto, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento intramuscular de acción prolongada con Cabotegravir y Rilpivirina en el mantenimiento de la supresión virológica, tras una inducción con un tratamiento de comprimido único con un inhibidor de la integrasa en pacientes adultos infectados por el VIH-I que no han recibido un tratamiento antirretroviral previo. Type: clinical trial, phase III.

HULP code: 4679. Sponsored's protocol code: 201584. Sponsored by: Fundacio Clinic Per A La Reçerca Biomedica. Signed date: 10/08/2016

González Gómez C. Profilaxis antibiótica parenteral vs oral + parenteral en cirugía colónica: ensayo clínico prospectivo, randomizado, controlado y multicéntrico. Type: clinical trial, phase IV.

HULP code: 4693. Sponsored's protocol code: 2011/001/PROF-ATB. Sponsored by: Sociedad Española de Oncología y Hematología Pediátricas. Signed date: 31/10/2016

González Martínez B. Estudio intergrupo para niños o adolescentes con linfoma no-hodkin b o leucemia linfoblástica de células b; evaluación de eficacia y seguridad de Rituximab en pacientes de alto riesgo. Type: clinical trial, phase II.

HULP code: Anexo-I 3546. Sponsored's protocol code: IGR2009/1593. Sponsored by: Janssen Cilag International Nv. Signed date: 06/07/2016

Gutiérrez-Larraya Aguado F. Estudio prospectivo, abierto, con control-activo, para evaluar la farmacocinética, farmacodinamia, seguridad y eficacia de Rivaroxaban para la tromboprofilaxis en sujetos pediátricos de 2 a 8 años de edad después del procedimiento Fonta. Type: clinical trial, phase III.

HULP code: 4695. Sponsored's protocol code: 39039039CHD3001. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 23/09/2016

Herranz Pinto P. Estudio observacional para evaluar las recaídas en pacientes con psoriasis moderada - grave tratados con fármacos biológicos de acuerdo a la práctica clínica, en España Estudio biopres. Type: EPA-OD.

HULP code: Anexo-I 4173. Sponsored's protocol code: NOV-PSO-2013-01. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 18/01/2016

Herranz Pinto P. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de Secukinumab con jeringas precargadas de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave- allure. Type: clinical trial, phase III.

HULP code: 4665. Sponsored's protocol code: CAIN457A2323. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 22/09/2016

Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV), con o sin Dasabuvir (DSV) y con o sin Ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la Hepatitis C (VHC) genotipo 1 o 4 (zircon). Type: clinical trial, phase III.

HULP code: 4533. Sponsored's protocol code: M14-748. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 18/01/2016

Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV), con o sin Dasabuvir (DSV) y con o sin Ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la Hepatitis C (VHC) genotipo 1 o 4 (zircon). Type: clinical trial, phase III.

HULP code: Anexo-I 4533. Sponsored's protocol code: M14-748. Sponsored by: Glaxosmithkline, S.A. Signed date: 19/07/2016

Hillman Gadea N. Estudio de 24 semanas, multicéntrico, aleatorizado, abierto, de dos brazos y grupos paralelos, para evaluar la eficacia y seguridad del ajuste de dosis de insulina glargina u300 manejada por el paciente frente a la manejada por el médico en Diabetes Mellitus Tipo 2 (LPS14409). Type: clinical trial, phase IV.

HULP code: 4524. Sponsored's protocol code: LPS14409. Sponsored by: Glaxosmithkline, S.A. Signed date: 25/01/2016

Hillman Gadea N. Ensayo clínico 200977: albiglutida + insulina glargina frente a insulina lispro + insulina glargina en el tratamiento de sujetos con Diabetes Mellitus Tipo 2: Estudio SWITCH. Type: clinical trial, phase III.

HULP code: 4602. Sponsored's protocol code: 200977. Sponsored by: Sanofi Aventis S.A. Signed date: 01/03/2016

Hillman Gadea N. Ensayo clínico 200977: albiglutida + insulina glargina frente a insulina lispro + insulina glargina en el tratamiento de sujetos con Diabetes Mellitus Tipo 2: Estudio SWITCH. Type: clinical trial, phase III.

HULP code: Anexo-I 4602. Sponsored's protocol code: 200977. Sponsored by: Novo Nordisk A/S. Signed date: 30/03/2016

Hillman Gadea N. Estudio internacional de cohortes, prospectivo, sin intervención, para evaluar la seguridad del tratamiento con Levemir® (insulina detemir) en embarazadas con Diabetes Mellitus registro de embarazos de pacientes diabéticas. Type: EPA-LA.

HULP code: Anexo-I PI-2083. Sponsored's protocol code: NOV-INS-2013-0. Sponsored by: Population Health Research Institute. Signed date: 21/08/2016

Iannuccelli F. Ensayo clínico internacional, aleatorizado, controlado con placebo para evaluar el efecto del Dabigatran (un inhibidor directo de la trombina) y Omeprazol (un inhibidor de la bomba de protones) en pacientes con daño miocárdico después de la cirugía. Type: clinical trial, phase IIIa.

HULP code: 4481. Sponsored's protocol code: I160.143. Sponsored by: Astellas Pharma Europe B.V. Signed date: 07/07/2016

Jara Vega P. Estudio abierto, no comparativo, a largo plazo, para evaluar la eficacia y la seguridad de un régimen de inmunosupresor basado en Modigraf en pacientes pediátricos receptores de un aloinjerto de órgano sólido. Type: clinical trial, phase IV.

HULP code: Anexo-III 3252. Sponsored's protocol code: F506-CL-0404. Sponsored by: Novo Nordisk A/S. Signed date: 10/02/2016



Jiménez Yuste VM. Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129-0000-1003 administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia a. Type: clinical trial, phase III.
HULP code: Anexo-III 3526. Sponsored's protocol code: NN7088-3859. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/05/2016

Jiménez Yuste VM. Seguridad y eficacia de NNC0155-0000-0004 en la prevención y el tratamiento de las hemorragias en pacientes pediátricos con hemofilia a no tratados previamente. Type: clinical trial, phase III.
HULP code: Anexo-II 3602. Sponsored's protocol code: NN7008-3809. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 15/03/2016

Jiménez Yuste VM. Ensayo clínico aleatorizado, multicéntrico, abierto de fase III para evaluar la eficacia, seguridad y farmacocinética del ro5534262 profiláctico frente a la no profilaxis en pacientes con hemofilia a con inhibidores. Type: clinical trial, phase III.
HULP code: Anexo-I 4486. Sponsored's protocol code: BH29884. Sponsored by: Novo Nordisk A/S. Signed date: 10/02/2016

Jiménez Yuste VM. Ensayo clínico de fase III multicéntrico, abierto y de un solo brazo para evaluar la eficacia, la seguridad y la farmacocinética de la administración subcutánea de Emicizumab una vez a la semana en pacientes pediátricos con hemofilia a con inhibidores. Type: clinical trial, phase III.
HULP code: 4605. Sponsored's protocol code: BH29992. Sponsored by: Novo Nordisk A/S. Signed date: 10/05/2016

Jiménez Yuste VM. Ensayo clínico de fase III, aleatorizado, multicéntrico y abierto para evaluar la eficacia, la seguridad y la farmacocinética del Emicizumab profiláctico, en comparación con la ausencia de profilaxis, en pacientes con hemofilia a sin inhibidores. Type: clinical trial, phase III.
HULP code: 4606. Sponsored's protocol code: BH30071. Sponsored by: Roche Farma, S.A. Signed date: 28/04/2016

Jiménez Yuste VM. Guardian 9- Ensayo abierto y multicéntrico para evaluar la farmacocinética de Novoeight® (turoctocog alfa) en relación con el IMC en sujetos con hemofilia a. Type: clinical trial, phase I.
HULP code: 4618. Sponsored's protocol code: NN7008-4239. Sponsored by: Fundación Pública Andaluza Progreso Y Salud. Signed date: 23/09/2016

Jiménez Yuste VM. Ensayo multicéntrico, comparativo, doble ciego, aleatorizado y cruzado para investigar la farmacocinética y la seguridad de dosis única de Turoctocog alfa pegol a partir del proceso pivotal y de Turoctocog alfa pegol a partir del proceso comercial en pacientes con hemofilia a grave. Type: clinical trial, phase I.
HULP code: 4654. Sponsored's protocol code: NN7088-4033. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 02/09/2016

Jiménez Yuste VM. Ensayo clínico Estudio de fase III, multicéntrico y sin enmascaramiento para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica del Emicizumab administrado cada 4 semanas en pacientes con hemofilia a. Type: clinical trial, phase III.
HULP code: 4674. Sponsored's protocol code: BO39182. Sponsored by: Novo Nordisk A/S. Signed date: 29/08/2016

Loeches Yagüe B. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por enterobacteriaceae. Type: clinical trial, phase III.
HULP code: 4583. Sponsored's protocol code: SIMPLIFY. Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc. Signed date: 18/03/2016

López Arrieta JM. Un estudio de fase III, de 12 semanas de duración, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de 3 dosis fijas de Brexpiprazol (opc-34712) en el tratamiento de sujetos con agitación asociada con la demencia del tipo Alzheimer. Type: clinical trial, phase III.
HULP code: Anexo-II 4014. Sponsored's protocol code: 331-12-283. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 03/05/2016

López Arrieta JM. Estudio multicéntrico de fase III, aleatorizado, doble ciego, controlado con placebo, de 56 semanas de seguimiento, para evaluar la seguridad y la eficacia de bimagrumab IV sobre la masa corporal magra total y la actividad física en pacientes después de tratamiento quirúrgico de fractura de cadera. Type: clinical trial, phase II.
HULP code: Anexo-II 4206. Sponsored's protocol code: CBYM338D2201. Sponsored by: Glaxosmithkline Research And Development Limited. Signed date: 29/03/2016

López Arrieta JM. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación Umeclivir por inhalación o Umeclivir por inhalación en comparación con Tiotropio. Type: EPA-LA.
HULP code: PI-2186. Sponsored's protocol code: 201038. Sponsored by: Fundación De Investigación En Red En Enfermedades Cardiovasculares- Fircava. Signed date: 02/06/2016

López de Sá Areces E. Estudio prospectivo abierto del Andexanet alfa en pacientes tratados con un inhibidor de factor Xa que presentan una hemorragia mayor aguda. Type: clinical trial, phase III.
HULP code: 4523. Sponsored's protocol code: I4-505. Sponsored by: Dalcour Pharma Uk Ltd. Signed date: 02/02/2016

López de Sá Areces E. Estudio observacional sobre el tratamiento oral antiplaquetario tras síndrome coronario agudo en España (Spanish Observational Study of Oapt after ACS). Type: EPA-SP.
HULP code: PI-2206. Sponsored's protocol code: FIR-ACS-2015-01. Sponsored by: Portola Pharmaceuticals Inc. Signed date: 02/03/2016

López-Sendón Hentschel JL. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de Dalcetrapib sobre el riesgo cardiovascular (CV) en una población definida genéticamente con Síndrome Coronario Agudo reciente (SCA): el ensayo dal-gene. Type: clinical trial, phase III.
HULP code: 4627. Sponsored's protocol code: DAL-301. Sponsored by: Merck Sharp And Dohme De España, S.A. Signed date: 27/05/2016

López-Sendón Hentschel JL. Estudio de fase III fundamental, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y determinado por los episodios para evaluar la eficacia y la seguridad de Vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por vía oral, en sujetos con insuficiencia cardíaca con fracción de eyección disminuida (ICFED): Estudio victoria (vericiguat global study in subjects with heart failure with reduced ejection fraction). Type: clinical trial, phase III.
HULP code: 4685. Sponsored's protocol code: I242-001. Sponsored by: Iron Therapeutics UK. Limited. Signed date: 22/09/2016

Martín Arranz MD. Estudio doble ciego, aleatorizado, multicéntrico sobre una pauta posológica más alta de Adalimumab en comparación con una pauta estándar para el tratamiento de inducción y mantenimiento en pacientes con colitis ulcerosa moderada o muy activa. Type: clinical trial, phase III.
HULP code: Anexo-I 4185. Sponsored's protocol code: M14-033. Sponsored by: Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. Signed date: 03/02/2016

Martín Arranz MD. Estudio multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo sobre abt-494 para inducir la remisión sintomática y endoscópica en pacientes con enfermedad de Crohn activa de intensidad moderada a grave que han respondido de forma insuficiente al tratamiento anti-TNF o que no toleran el tratamiento. Type: clinical trial, phase II.
HULP code: Anexo-I 4417. Sponsored's protocol code: M13-740. Sponsored by: Geteccu (Grupo Español De Trabajo En Enfermedad De Crohn Y Colitis Ulcerosa). Signed date: 27/04/2016

Martín Arranz MD. Estudio multicéntrico de fase II, aleatorizado, doble ciego y controlado con placebo de grupos paralelos para investigar la seguridad y la eficacia de apd334 en pacientes con colitis ulcerativa activa de moderada a grave. Type: clinical trial, phase II.
HULP code: 4498. Sponsored's protocol code: APD334-003. Sponsored by: Abbvie Spain, S.L.U. Signed date: 28/04/2016

Martín Arranz MD. Estudio de extensión del Estudio apd334-003 en pacientes con colitis ulcerosa activa moderada o grave. Type: clinical trial, phase II.
HULP code: 4541. Sponsored's protocol code: APD334-005. Sponsored by: Pfizer, S.L.U. Signed date: 28/06/2016

Martín Arranz MD. Estudio de fase IIIb, aleatorizado, controlado y multicéntrico con Maltol férrico oral (feraccru) o hierro intravenoso (carboximaltosa férrica; cmf), para el tratamiento de la anemia ferropénica en sujetos con enfermedad inflamatoria intestinal. Type: clinical trial, phase IIIb.
HULP code: 4633. Sponsored's protocol code: ST10-01-304. Sponsored by: Abbvie Spain, S.L.U. Signed date: 20/04/2016

Martín Arranz MD. Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España. Type: Non EPA.
HULP code: PI-068A. Sponsored's protocol code: GIS-2015-INCIDENCIA. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 30/03/2016

Martín Arranz MD. Groupe d'étude thérapeutique des affections inflammatoires digestives); (Co-sponsor), GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) para la realización del Estudio observacional titulado: IBD cancer and serious infections in Europe: I-CARE EII cancer e infecciones graves en Europa: I-CARE. Type: EPA-SP.
HULP code: PI-2115. Sponsored's protocol code: GET-EII-2015-01. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 12/07/2016

Martín Mola E. Estudio de fase III, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de Taneczumab en adultos con lumbalgia crónica. Type: clinical trial, phase III.
HULP code: 4469. Sponsored's protocol code: A4091059. Sponsored by: Baxalta Innovations Gmhb. Signed date: 29/01/2016

Martín Salces M. Estudio de fase III, multicéntrico, abierto y no controlado para evaluar la seguridad y la eficacia de BAY 81-profiláctico. Type: clinical trial, phase III.
HULP code: Anexo-I 4099. Sponsored's protocol code: 81-8973/13400. Sponsored by: Grupo Español De Investigación En Sarcomas. Signed date: 24/10/2016

Martín Salces M. Estudio de fase III, multicéntrico, de un solo brazo y abierto sobre la eficacia y la seguridad del factor VIII recombinante porcino con dominio b suprimido (BAX 802) en sujetos con hemofilia A congénita con inhibidores del factor VIII sometidos a intervenciones quirúrgicas u otros procedimientos invasivos. Type: clinical trial, phase III.
HULP code: 4658. Sponsored's protocol code: 241502. Sponsored by: Bayer Hispania, S.L. Signed date: 15/07/2016

Martínez Marín V. Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de kit en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib. Type: EPA-OD.
HULP code: PI-2367. Sponsored's protocol code: DETERMINANTES CLÍNICOS Y MOLECULARES DE RESPUESTA Y PROGRESIÓN A LA INHIBICIÓN DE KIT EN PACIENTES CON TUMORES DEL ESTROMA GASTROINTESTINAL (GIST) CON RESPUESTA PROLONGADA A IMATINIB. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 01/06/2016

Martínez Marín V. Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (SSTR) en el tumor de estroma gastrointestinal (GIST) localizado (somagist). Type: Non EPA.
HULP code: PI-2453. Sponsored's protocol code: GEIS 46. Sponsored by: Chiltern International Spain, S.A. Signed date: 15/07/2016

Méndez Echevarría AM. Estudio multicéntrico, abierto, aleatorizado, de fase II/III para determinar la seguridad y eficacia de la Solitromicina en adolescentes (de 12 a 17 años de edad, ambos inclusive) y niños (2 meses a < 12 años de edad) con neumonía bacteriana adquirida en la comunidad sospechada o confirmada. Type: clinical trial, phase II.
HULP code: 4599. Sponsored's protocol code: CE01-203. Sponsored by: Biotronik Se&Co. Kg. Signed date: 13/06/2016

Merino Llorens JL. Estudio de la eficacia y la seguridad de f373280 para el mantenimiento del ritmo sinusal tras cardioversión eléctrica en pacientes con fibrilación auricular persistente e insuficiencia cardíaca crónica. Type: clinical trial, phase II.
HULP code: Anexo-IV 3814. Sponsored's protocol code: F373280CA201. Sponsored by: Biotronik Se&Co. Kg. Signed date: 28/03/2016


Merino Llorens JL. Triumph crt estimulación biventricular trifocal para la optimización de la terapia de desincronización cardíaca (TRC). Type: Healthcare product.
HULP code: 4519. Sponsored's protocol code: ICSY02. Sponsored by: Pierre Fabre Medicament S.A.S. Signed date: 18/02/2016

Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud y la respuesta a la TRC en mujeres y hombres. Type: Healthcare product.
HULP code: Anexo-I 4595. Sponsored's protocol code: CR017. Sponsored by: Sorin Group España, S.L. Signed date: 08/09/2016

Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRC en mujeres y hombres, código de protocolo cr017, versión 10 de 3 de diciembre de 2014. Type: Healthcare product.
HULP code: 4595. Sponsored's protocol code: CR017. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 14/06/2016

Merino Muñoz R. Estudio aleatorizado, doble ciego, controlado con placebo de Canakinumab en pacientes con fiebres periódicas hereditarias (TRAPS, HIDS o FMFRC) con retirada aleatorizada/reducción de la frecuencia de la dosis y posterior fase de tratamiento abierto a largo plazo. Type: clinical trial, phase III.
HULP code: Anexo-III 4138. Sponsored's protocol code: CACZ885N2301. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 29/03/2016

Montes Ramírez ML. Estudio fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con Cabotegravir y Rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica. Type: clinical trial, phase III.
HULP code: 4681. Sponsored's protocol code: 201585. Sponsored by: Sanofi Aventis S.A. Signed date: 10/08/2016



Montes Ramírez ML. Eficacia y seguridad/tolerabilidad de Viekirax y Exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH 1, GT 1 o 4, y enfermedad renal crónica en estadios de IIIb a V, incluyendo aquellos en diálisis, en práctica clínica habitual en España Estudio viekind. Type: EPA-OD.

HULP code: PI-2303. Sponsored's protocol code: ABB-OMB-2015-01. Sponsored by: Laboratorios VIIV Healthcare, S.L. Signed date: 09/05/2016

Montoya Lozano F. Cribado para la enfermedad de Gaucher en la población española con Esplenomegalia y/o Trombocitopenia de origen desconocido. Type: Non EPA.

HULP code: PI-2241. Sponsored's protocol code: GSS-GAU-20155-01. Sponsored by: Achaogen Inc. Signed date: 05/04/2016

Mora Rillo M. Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Plazomicina en comparación con Colistina en pacientes con infección causada por enterobacterias resistentes a los carbapenémicos (CRE). Type: clinical trial, phase III.

HULP code: Anexo-II 4039. Sponsored's protocol code: 4039 ACHN-490-007. Sponsored by: Genzyme Europe Bv. Signed date: 23/05/2016

Morado Arias M. Protocolo de registro de la enfermedad de Gaucher. Type: EPA-SP.

HULP code: 4122. Sponsored's protocol code: GEN-GAU-2013-01. Sponsored by: Bayer Ag. Signed date: 27/05/2016

Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de Rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórtica galileo. Type: clinical trial, phase III.

HULP code: Anexo-I 4525. Sponsored's protocol code: BAY17938. Sponsored by: Bayer Ag. Signed date: 30/09/2016

Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de Rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórtica galileo. Type: clinical trial, phase III.

HULP code: 4525. Sponsored's protocol code: BAY 17938. Sponsored by: Fundación Casa Del Corazón. Signed date: 29/03/2016

Moreno Gómez JR. Registro de pacientes con dispositivo biorreabsorbible en la práctica clínica habitual: medida de costes, efectividad, qalys, y eficiencia- Estudio repara-qaly. Type: Healthcare product.

HULP code: PI-2425. Sponsored's protocol code: COR-BVS-2016-01 ESTUDIO REPARA-QALY. Sponsored by: Spherium Biomed S.L. Signed date: 15/07/2016

Morera López RM. Ensayo clínico fase Ib-II de gel de melatonina oral para la prevención y tratamiento de la mucositis oral en pacientes con cáncer de cabeza y cuello tratados con quimiorradioterapia. Type: clinical trial, phase Ib.

HULP code: 4638. Sponsored's protocol code: JAN13004-30. Sponsored by: Angelini Farmaceutica S.A. Signed date: 22/06/2016

Morera López RM. Estudio de calidad de vida en pacientes con dolor irruptivo oncológico atendidos en los servicios de oncología radioterápica con intención paliativa. Type: EPA-SP.

HULP code: PI-2403. Sponsored's protocol code: CAVIDIOR ANG-MOR-2016-01. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 27/05/2016

Murias Loza SM. Registro observacional de Abatacept en pacientes con artritis idiopática juvenil. Type: EPA-LA.

HULP code: PI-2079. Sponsored's protocol code: IM101240. Sponsored by: Glaxosmithkline, S.A. Signed date: 11/07/2016

Núñez López MC. Estudio de vacunación cruzada con la formulación liofilizada de la vacuna de subunidades frente al herpes zóster (HZ/SU) de GSK biologicals (GSK 1437173a) en sujetos que previamente recibieron placebo en los Estudios zoster-006 y zoster-022. Type: clinical trial, phase III.

HULP code: 4597. Sponsored's protocol code: 204486. Sponsored by: Glaxosmithkline, S.A. Signed date: 27/04/2016

Núñez López MC. Eficacia, seguridad e inmunogenicidad de la vacuna HZ/SU de GSK biologicals GSK1437173a en un estudio fase IIIb, abierto, de seguimiento a largo plazo (ZOE-LTFU) de los Estudios 110390/113077 (zoster-006/022) y evaluación de dosis adicionales en adultos de edad avanzada. Type: clinical trial, phase IIIb.

HULP code: 4603. Sponsored's protocol code: 201190ZOSTER-049. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 13/05/2016

Olveira Martín A. Estudio observacional de carácter exploratorio, para describir el perfil de pacientes con hepatitis C con 18 años de edad o más tratados con regímenes sin Interferón según la adición de Ribavirina en España: evidencia de la práctica clínica real en 2015. Type: EPA-OD.

HULP code: PI-2407. Sponsored's protocol code: ID VEAP 6124. Sponsored by: Regeneron Pharmaceuticals, Inc. Signed date: 08/08/2016

Omeñaca Terés F. Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los Estudios de tratamiento con retosibán. Type: clinical trial, phase III.

HULP code: Anexo-I 4322. Sponsored's protocol code: 200722. Sponsored by: Glaxosmithkline, S.A. Signed date: 21/03/2016

Omeñaca Terés F. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de un anticuerpo monoclonal humano, regn2222, para la prevención de la infección por el VRS bajo atención médica en lactantes prematuros. Type: clinical trial, phase III.

HULP code: 4458. Sponsored's protocol code: R2222-RSV-1332. Sponsored by: Glaxosmithkline Research and Development Limited. Signed date: 21/07/2016

Omeñaca Terés F. Inmunogenicidad y seguridad de una dosis de recuerdo de Infanrix Hexa® (217744) de GSK biologicals en niños sanos nacidos de madres vacunadas con Boostrix® en el embarazo o en el posparto inmediato. Type: clinical trial, phase IV.

HULP code: 4613. Sponsored's protocol code: 201334 BOOSTRIX-049. Sponsored by: Novavax, Inc. Signed date: 13/05/2016

Omeñaca Terés F. Estudio en fase III, aleatorizado, enmascarado para el observador, controlado con placebo y con grupos secuenciales para determinar la inmunogenicidad y la seguridad de una vacuna. Type: clinical trial, phase III.

HULP code: 4663. Sponsored's protocol code: RSV-M-301. Sponsored by: Ionis Pharmaceuticals Inc. Signed date: 19/10/2016

Pascual Pascual SI. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico e internacional que evalúa en grupos paralelos la eficacia y seguridad de 2 dosis de pxt3003 en pacientes con síndrome de Charcot-Marie-Tooth de tipo 1A tratados durante 15 meses. Type: clinical trial, phase III.

HULP code: 4534. Sponsored's protocol code: CLN-PXT3003-02. Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc. Signed date: 10/08/2016

Pascual Pascual SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en Estudios experimentales de isis 396443. Type: clinical trial, phase III.

HULP code: 4577. Sponsored's protocol code: ISIS 396443-CS11. Sponsored by: Erydel S.P.A. Signed date: 07/04/2016

Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con ataxia telangiectasia. Type: clinical trial, phase III.

HULP code: 4598. Sponsored's protocol code: IEDAT-02-2015. Sponsored by: Pharnext, . Signed date: 02/06/2016

Peces Serrano R. Ensayo de fase IIIb, multicéntrico y abierto para evaluar la seguridad a largo plazo de Tolvaptán de liberación inmediata (opc-41061, de 30 mg a 120 mg/día, dosis dividida) en sujetos con poliquistosis renal autosómica dominante. Type: clinical trial, phase IIIb.

HULP code: 4473. Sponsored's protocol code: 156-13-211. Sponsored by: Medtronic Iberica S.A. Signed date: 25/02/2016

Peinado Peinado R. RECABA-Registro Español de Crioblación con Balón. Type: Healthcare product.

HULP code: PI-2454. Sponsored's protocol code: RECABA. Sponsored by: Janssen Cilag International N.V. Signed date: 02/11/2016

Pérez Martínez A. Infusión de células natural killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda. Type: Healthcare product.

HULP code: 4489. Sponsored's protocol code: NKCELL_LMA_2015. Sponsored by: Gilead Sciences Inc. Signed date: 20/04/2016

Pérez Martínez A. Estudio aleatorizado, abierto, de seguridad y eficacia de Ibrutinib en pacientes pediátricos y adultos jóvenes con linfoma no Hodgkin de células maduras b en recaída o refractario. Type: clinical trial, phase III.

HULP code: 4644. Sponsored's protocol code: 54179060LYM3003. Sponsored by: Pérez Martínez, Antonio. Signed date: 18/10/2016

Pérez Valero I. Estudio prospectivo, observacional de la utilización del medicamento Stribild® en adultos con infección por VIH. Type: EPA-LA.

HULP code: PI-1975. Sponsored's protocol code: GS-EU-236-0141. Sponsored by: Aveo Pharmaceuticals. Signed date: 20/05/2016

Pinto Marín Á. Estudio de fase III, aleatorizado, controlado, multicéntrico y abierto, para comparar el Tivozanib clorhidrato frente al Sorafenib en sujetos con carcinoma de células renales avanzado resistente al tratamiento. Type: clinical trial, phase III.

HULP code: 4570. Sponsored's protocol code: AV-951-15-303. Sponsored by: Pfizer, S.L.U. Signed date: 02/06/2016

Pinto Marín Á. Estudio exploratorio de fase II, abierto y con un solo grupo de tratamiento con Afatinib oral en monoterapia tras el fracaso a platino en pacientes con carcinoma urotelial avanzado/metastásico con desregulación de los receptores ERBB. Type: clinical trial, phase II.

HULP code: 4632. Sponsored's protocol code: I200.261. Sponsored by: Sociedad Española De Oncología Y Hematología Pediátricas. Signed date: 15/07/2016

Pinto Marín Á. Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre Avelumab* (MSB0010718c) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o metastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino. Type: clinical trial, phase III.

HULP code: 4659. Sponsored's protocol code: B9991001. Sponsored by: Grupo Grupo Sogug. Signed date: 04/07/2016

Pinto Marín Á. Estudio de fase III, Estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de Atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico. Type: clinical trial, phase III.

HULP code: 4699. Sponsored's protocol code: MO299833. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 05/10/2016

Pinto Marín Á. Validación del consorcio de la base de datos internacional de cáncer renal metastásico (IMDC) como clasificación pronóstica para terapias dirigidas (inhibidores de la ITC/MTOR) en segunda línea después del tratamiento con Pazopanib primera línea (spazo-2). Type: EPA-OD.

HULP code: PI-2523. Sponsored's protocol code: SOGUG-2016-A-IEC. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 26/10/2016

Plaza López de Sabando D. Estudio prospectivo internacional de meduloblastoma riesgo estándar clínico en niños mayores de 3 a 5 años con perfil bajo de riesgo biológico (pnet 5 MB - LR) o perfil-medio de riesgo biológico (PNET 5-SR MB). Type: clinical trial, phase II.

HULP code: 4556. Sponsored's protocol code: PNET5MB. Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 23/09/2016

Prados Sánchez C. Registro Observacional Europeo de pacientes con Fibrosis Quística (VOICE). Type: EPA-SP.

HULP code: PI-2397. Sponsored's protocol code: VX14-CFR-107. Sponsored by: Teva Pharma S.L.U. Signed date: 27/06/2016

Puertas Muñoz I. Registro Español de pacientes tratados con acetato de glatiramer (Copaxone®) 40 mg/ml. Type: EPA-SP.

HULP code: PI-2216. Sponsored's protocol code: TEV-ACE-2015-01. Sponsored by: Laboratoires Thea. Signed date: 05/04/2016

Ramos Castrillo A. ISY: Duokopt® satisfaction survey (Estudio de satisfacción de los pacientes de Duokopt®. Type: EPA-OD.

HULP code: PI-2466. Sponsored's protocol code: THE-DOR:2016-01. Sponsored by: Millennium Pharmaceuticals, Inc. Signed date: 13/09/2016

Redondo Sánchez A. Estudio de fase III, abierto, multicéntrico, randomizado para evaluar la eficacia y seguridad de Trastuzumab emtansine versus Trastuzumab como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo con presencia patológica de tumor residual en la mama o nódulo linfático axilar tras tratamiento preoperatorio. Type: clinical trial, phase III.

HULP code: Anexo-I 3783. Sponsored's protocol code: BO27938. Sponsored by: Lilly, S.A. Signed date: 12/01/2016

Redondo Sánchez A. Estudio aleatorizado de fase III de Lubinectedin (pm01183) frente a Doxorubicina liposomal pegilada o topotecán en pacientes con cáncer de ovario resistente a platino (Ensayo CORAIL). Type: clinical trial, phase III.

HULP code: Anexo-I 4400. Sponsored's protocol code: PM1183-C-004-14. Sponsored by: Tesaro Inc. Signed date: 13/07/2016

Redondo Sánchez A. Estudio fase II multicéntrico, abierto, de un solo brazo para evaluar la seguridad y eficacia de Bevacizumab en combinación con carboplatino y Paclitaxel en pacientes con cáncer de cérvix metastásico, recurrente o persistente. Type: clinical trial, phase II.

HULP code: Anexo-I 4422. Sponsored's protocol code: MO29594. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 15/04/2016



Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II (aleatorizado, doble ciego) en el que se evalúan Gemcitabina y Docetaxel, con o sin Olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Type: clinical trial, phase II.
HULP code: Anexo-I 4543. Sponsored's protocol code: ISB-MC-JGDL. Sponsored by: Lilly, S.A. Signed date: 29/02/2016

Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II (aleatorizado, doble ciego) en el que se evalúan Gemcitabina y Docetaxel, con o sin Olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Type: clinical trial, phase II.
HULP code: 4543. Sponsored's protocol code: ISB-MC-JGDL. Sponsored by: Pharmamar, S.A. Signed date: 27/01/2016

Redondo Sánchez A. Estudio en fase III, multicéntrico, aleatorizado y controlado con placebo de Atezolizumab (anticuerpo anti-pd-1) combinado con Nab-Paclitaxel en comparación con placebo con Nab-Paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tratado previamente. Type: clinical trial, phase III.
HULP code: 4581. Sponsored's protocol code: WO29522. Sponsored by: Pfizer Inc. Signed date: 20/04/2016

Redondo Sánchez A. Estudio de fase II aleatorizado de mIn0128 (inhibidor doble de torc1/2), mIn0128 + mIn117 (inhibidor de pi3k γ), Paclitaxel semanal, o la combinación de Paclitaxel semanal y mIn0128 en mujeres con cáncer de endometrio avanzado, recurrente o persistente. Type: clinical trial, phase II.
HULP code: 4614. Sponsored's protocol code: C31004. Sponsored by: Roche Farma, S.A. Signed date: 20/05/2016

Redondo Sánchez A. Estudio de fase III, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del tratamiento de mantenimiento con Niraparib en pacientes con cáncer de ovario avanzado portador de deficiencia de la recombinación homóloga (hrd) que han respondido a la quimioterapia de primera línea con platino. Type: clinical trial, phase III.
HULP code: 4642. Sponsored's protocol code: PR-30-5017-C. Sponsored by: Sanofi Aventis S.A. Signed date: 23/09/2016

Redondo Sánchez A. Estudio de fase III, multicéntrico, aleatorizado, abierto de Avelumab (msb0010718c) en monoterapia o en combinación con Doxorubicina liposomal pegilada frente a Doxorubicina liposomal pegilada en monoterapia en pacientes con cáncer de ovario refractario/resistente a platino. Type: clinical trial, phase III.
HULP code: 4652. Sponsored's protocol code: B9991009. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 23/06/2016

Remesal Camba A. Estudio para evaluar la disminución de la frecuencia de dosis en pacientes con artritis idiopática juvenil sistémica activa (AIJS) que experimentan anomalías de laboratorio durante el tratamiento con Tocilizumab. Type: clinical trial, phase IV.
HULP code: Anexo-II 3725. Sponsored's protocol code: VVA28029. Sponsored by: Sanofi-Aventis Recherche & Développement. Signed date: 06/09/2016

Remesal Camba A. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyección subcutánea (SC) a niños y adolescentes con edades comprendidas entre 2 y 17 años con artritis idiopática juvenil de curso poliarticular (AIJP), seguido de una fase de extensión. Type: clinical trial, phase III.
HULP code: 4604. Sponsored's protocol code: DRI13925. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 29/04/2016

Remesal Camba A. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyección subcutánea (SC) a niños y adolescentes con edades comprendidas entre 1 y 17 años con artritis idiopática juvenil sistémica (AIJS), seguido de una fase de extensión. Type: clinical trial, phase III.
HULP code: 4705. Sponsored's protocol code: DRI13926. Sponsored by: Boehringer Ingelheim International GmbH. Signed date: 17/10/2016

Rios Blanco JJ. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento oral con Nintedanib durante al menos 52 semanas en pacientes con enfermedad pulmonar intersticial asociada a esclerosis sistémica (SSC-ILD). Type: clinical trial, phase III.
HULP code: 4504. Sponsored's protocol code: I.199.214. Sponsored by: Ucb Celltech. Signed date: 17/02/2016

Robles Marhuenda AJ. Estudio prueba de concepto aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de ucb5857 durante 12 semanas en pacientes con síndrome de Sjögren primario. Type: clinical trial, phase II.
HULP code: Anexo-I 4429. Sponsored's protocol code: SS0004. Sponsored by: Glaxosmithkline, S.A. Signed date: 02/11/2016

Robles Marhuenda AJ. Estudio aleatorizado, doble ciego (abierto para el promotor), comparativo, multicéntrico para evaluar la seguridad y la eficacia de la coadministración de Belimumab (gsk1550188) subcutáneo y rituximab intravenoso en sujetos con síndrome de Sjögren primario. Type: clinical trial, phase II.
HULP code: 4488. Sponsored's protocol code: 201842. Sponsored by: Baxter Innovations GmbH. Signed date: 02/03/2016

Rodríguez de Rivera Garrido FJ. Estudio de fase III sobre la eficacia, la seguridad y la tolerabilidad de la infusión de inmunoglobulina (humana) al 10 % con hialuronidasa recombinante humana (HYQVIA/HYQVIA) y la infusión de inmunoglobulina (humana) al 10 % (gammagard liquid/kiovig) para el tratamiento de la polirradiculoneuropatía desmielinizante inflamatoria crónica (PDIC). Type: clinical trial, phase III.
HULP code: 4497. Sponsored's protocol code: I61403. Sponsored by: Sanofi Aventis S.A. Signed date: 17/02/2016

Rodríguez de Rivera Garrido FJ. Detención de enfermedad de Pompe en pacientes con miopatías de cinturas no definidas o hiperckemia asintomática. Type: Non EPA.
HULP code: Anexo-I PI-823. Sponsored's protocol code: L-GENZ-E-003. Sponsored by: Grupo Gemcad. Signed date: 27/07/2016

Rodríguez Salas N. Tratamiento de inducción con Folfox, con o sin aflibercept, seguido de quimio-radioterapia en carcinoma de recto localmente avanzado de alto riesgo un ensayo abierto, fase II randomizado. Type: clinical trial, phase II.
HULP code: Anexo-I 4230. Sponsored's protocol code: GEMCAD-I402. Sponsored by: Roche Farma, S.A. Signed date: 07/03/2016

Rodríguez Salas N. Estudio fase II, prospectivo, multicéntrico, abierto, randomizado, controlado con fármaco activo, de 3 grupos paralelos, para comparar la eficacia y seguridad de Masitinib en combinación con Folfiri (irinotecán, 5-fluorouracil y ácido folínico) frente al Masitinib solo, frente a mejores cuidados paliativos en pacientes con cáncer colorrectal metastásico en tercera o cuarta línea de tratamiento. Type: clinical trial, phase II.
HULP code: Anexo-I 4426. Sponsored's protocol code: ABI2010. Sponsored by: Laboratorios Servier, S.L. Signed date: 12/04/2016

Rodríguez Salas N. Ensayo clínico multicéntrico randomizado, de tratamiento de mantenimiento basado en biomarcadores para primera línea de cáncer colorrectal metastásico (modul). Type: clinical trial, phase II.
HULP code: 4532. Sponsored's protocol code: MO29112. Sponsored by: Laboratorios Servier, S.L. Signed date: 04/01/2016

Rodríguez Salas N. Estudio abierto, aleatorizado, fase II que compara s95005 con Bevacizumab frente a Capecitabina con Bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Type: clinical trial, phase II.
HULP code: 4580. Sponsored's protocol code: CL2-95005-002. Sponsored by: Abscience. Signed date: 18/04/2016

Rodríguez Salas N. Estudio abierto, aleatorizado, fase II que compara s95005 con Bevacizumab frente a Capecitabina con Bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Type: clinical trial, phase II.
HULP code: Anexo-I 4580. Sponsored's protocol code: CL2-95005-002. Sponsored by: Instituto Investigación Sanitaria Hospital La Fe. Signed date: 23/09/2016

Rubio Aparicio PM. Protocolo Europeo de tratamiento para el neuroblastoma de riesgo bajo e intermedio. Type: clinical trial, phase III.
HULP code: Anexo-I3353. Sponsored's protocol code: LINES. Sponsored by: Amgen, S.A. Signed date: 31/05/2016

San Román Pacheco S. Estudio abierto, de un solo brazo para evaluar la seguridad y eficacia a largo plazo de Romiplostim en sujetos pediátricos trombocitopenicos con purpura trombocitopenica inmune (PTI). Type: clinical trial, phase III.
HULP code: Anexo-I4211. Sponsored's protocol code: 20101221. Sponsored by: Glaxosmithkline Research And Development Limited. Signed date: 01/02/2016

Sánchez Hernández I. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación umecl/vi por inhalación o umecl por inhalación en comparación con tiotropio. Type: EPA-LA.
HULP code: pi-2186B. Sponsored's protocol code: 201038. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 23/06/2016

Tallón Barranco A. Estudio abierto para evaluar la eficacia y la seguridad de Ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad. Type: clinical trial, phase III.
HULP code: 4608. Sponsored's protocol code: MA30005. Sponsored by: Novo Nordisk Pharma, S.A. Signed date: 25/04/2016

Torres Jiménez R. Ensayo para comparar la seguridad cardiovascular de la insulina Degludec frente a la insulina Glargina en pacientes con diabetes de tipo 2 y alto riesgo de episodios cardiovasculares. Type: clinical trial, phase III.
HULP code: Anexo-II 4059. Sponsored's protocol code: EX1250-4080. Sponsored by: Laboratorios Inbisa S.A. Signed date: 13/01/2016

Usandizaga Elio R. Estudio sobre las condiciones de uso de Caribán® y de otros antieméticos en el tratamiento de las náuseas y vómitos en el embarazo: Estudio prospectivo observacional longitudinal. Type: EPA-SP.
HULP code: PI-2191. Sponsored's protocol code: LIN-DOX-2015-01. Sponsored by: Fundación Seimc-Gesida. Signed date: 04/04/2016

Valencia Ortega E. Estudio prospectivo para la detección precoz de carcinoma pulmonar en pacientes con infección por VIH. Type: Non EPA.
HULP code: PI-1820. Sponsored's protocol code: GESIDA 8815. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 08/06/2016

Valencia Ortega E. Estrategia de Switching con Raltegravir + abc/3tc en infección VIH-I controlada, Estudio retrospectivo observacional a 48 semanas Estudio kiral. Type: EPA-OD.
HULP code: PI-2424. Sponsored's protocol code: LEO-RAL-2015-01 GESIDA 8715. Sponsored by: Fundación Seimc-Gesida. Signed date: 16/06/2016

Villasante Fernández-Montes C. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo de 52 semanas de duración para evaluar la eficacia y la seguridad de qaw039 añadido al tratamiento existente para el asma en pacientes con asma grave no controlada. Type: clinical trial, phase III.
HULP code: 4507. Sponsored's protocol code: CQAW039A2314. Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 07/01/2016

Villasante Fernández-Montes C. Observacional, prospectivo, para evaluar la relación entre el grado de concordancia de las opiniones entre pacientes y médicos especialistas en el control sintomático y el riesgo futuro en pacientes con asma moderada. Type: Non EPA.
HULP code: PI-1886. Sponsored's protocol code: CONCORD-ASMA. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 29/01/2016

Zamora Auñón P. Estudio aleatorizado, doble ciego, controlado con placebo, de lee011 en combinación con Letrozol para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, her2-negativo que no han recibido terapia previa para la enfermedad avanzada. Type: clinical trial, phase III.
HULP code: Anexo-I 4070. Sponsored's protocol code: CLEE011A2301. Sponsored by: Medica Scientia Innovation Research. Signed date: 04/03/2016

Zamora Auñón P. Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de Palbociclib en combinación con Fulvestrant o Letrozol en pacientes con cáncer de mama metastasico Her2 negativo, er+ (parsifal I). Type: clinical trial, phase II.
HULP code: Anexo-II 4390. Sponsored's protocol code: MEDOPP067. Sponsored by: Medica Scientia Innovation Research. Signed date: 04/05/2016





2.7 Platforms

2.7.1. Biobank

IdiPAZ's Biobank main objective is to promote biomedical research, which will increase and enhance the quality of scientific production in Spain.

Biobank's work is specialized in the management of human biological samples for biomedical research (register, processing, storage and final assignment) in compliance with Spain's present legislation Law 14/2007 on Biomedical Research and the Royal Decree of Biobanks 1716/2011. Thus the confidentiality of the samples and associated data will be guaranteed.

The Biobank participates through the central node and peripheral nodes in various cooperative network structures (IDINET Platform). It is also part of the Hospitals Network (RetBioH), created in January 2010, through which we participate in the European platform called Biobanking and Biomolecular Resources Research Infrastructure (BBMRI).

IdiPAZ's Biobank also offers the scientific community the use of its equipment and the support of its professionals through an extensive offer of samples and services.

COMPOSITION

Science Coordinator

Eugenia García Fernández

Coordinator of Professionals/Experts

Marina Arranz Álvarez

Senior Experts in Pathology and Cytology

Cristina Salinas Sánchez



Contact

biobanco.hulp@salud.madrid.org

biobanco@idipaz.es

Phone: Biobank Laboratory (+34) 91 207 11 91

EQUIPMENT

- Eight -80°C deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes
- Combined refrigerator of 4° C y - 20° C
- Cryostat to cut frozen samples
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector
- Biological safety cabins IIA
- Centrifuge with capacity to process samples in tubes and Eppendorfs
- Automatic platform to manipulate and trace liquids
- Automatic nucleoids acid extractors. DNA and ARN from blood and frozen tissue or in paraffin
- Two mini coolers to freeze inclined biological samples below 1°C
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentame samples
- Two pairs of gloves to work in low temperatures
- Two pairs of cryogenic work gloves
- Vortex Mixer /agitator
- Spectrophotometer (Nanodrop)
- One set of automatic micropipettes
- One automatic electronic pipette
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, cells, DNA and ARN
- Printer/photocopier/scanner
- 3 computers and a management computer system
- Label printing system and a bar code reader connected to the management software

PORTFOLIO OF SERVICES

Technical and scientific assessment

- Collection and management of new collection
- Work Methodology/ Methods
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system
- Training and advice on the use of Biobank management software (Bio-e-Bank).
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank.
- Training of trainees (FCTs) of training cycles.

Sample/collection management

- Coordinating a collection of samples in multiple study/research centers
- Storage of pre-existing collections under LIB 14/2007.
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree
- Management and control of Informed Consent (CI) and/or clinic's regarding samples
- Aliquot of blood/salines/plasma/other liquids
- Sample reception and codification

Histology techniques

- Making paraffin block
- Making frozen tissue blocks
- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)
- Other kinds of stains
- Laser microdissection

Cell techniques

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques

- DNA and RNA blood extraction
- DNA and RNA extraction from frozen tissue and paraffin
- DNA and RNA quantification via spectrophotometer (NANODROP)

Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject.

On the other hand researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

BIOBANK'S SCIENTIFIC INDICATORS

In the year 2016, Biobank IdiPAZ has worked on 32 research projects funded by Spanish State aid, private foundations, industrial companies or cooperatives such as the National Network of Hospital Biobanks (RetBioH). The principal researchers of these projects belonged to IdiPAZ research groups and to external, national and international groups. Of these projects and together with the central node of the biobank, a total of 4,353 new samples have been stored, generating more than 15,400 aliquots.

During the same period 20 requests for samples were processed and a total of 1,873 samples were assigned, showing an exponential increase in demand compared to previous years.



2.7.2. UCICEC

La Paz Central Research and Clinical Trials Unit (Unidad Central de Investigación Clínica y Ensayos Clínicos de La Paz, HULP-UCICEC), is one of the IdiPAZ supported platforms of investigation. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UCICEC is integrated in the Spanish Clinical Research Network (SCReN).

Its wide portfolio of services provides support to researchers in design, set-up (including IRBs and Competent Authority approvals), management, data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the preparation of feasibility and financial reports, administrative tasks (i.e., investigators coordination, schedule of visits), as well as projects development and research, particularly in the recruitment and follow-up of patients and data collection, assistance in audit, inspections and adverse drug reactions management according to regulatory procedures, among other tasks. We also perform nursing activities and laboratory management, obtaining, processing and shipping the samples to central laboratories. All operations are GCP compliant as needed.

HULP-UCICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows harbour early phase clinical trials both in healthy volunteers and patients (children and adults).

COMPOSITION

Head

Jesús Frías Iniesta (MD, PhD)
jesus.frias@salud.madrid.org

UCICEC Manager

Alberto M. Borobia (MD, PhD)
alberto.borobia@salud.madrid.org
Phone: (+34) 91 207 14 66

Scientific Coordinator

Antonio J. Carcas (MD, PhD)
antonio.carcas@salud.madrid.org

Safety and Pharmacovigilance Coordinators

Antonio J. Carcas (MD, PhD)
antonio.carcas@salud.madrid.org

Elena Ramírez (MD, PhD)
elena.ramirez@salud.madrid.org

Responsible for Pharmacovigilance

Hoi Y. Tong (MD)
hoi.tong@idipaz.es

Project Manager / Senior Monitor

Maria Posada Novoa (MSc)
maria.posada@idipaz.es

Clinical Research Associate

Alicia Herranz Estellés (MD, MSc)
alicia.herranz@idipaz.es

Clinical Trials Nurses

Vega Mauleón Martínez
vega.mauleon@idipaz.es

Raquel de Madariaga Castell
raquel.madariaga@idipaz.es

Laura Vitón Vara (MSc)
laura.viton@idipaz.es

Nursing supervisor

Elena Martín de Castro
elena.martin@salud.madrid.org

Receptionist /Clinical Trials Assistant

Cristina Miragall Roig
cristina.miragall@salud.madrid.org
Phone: (+34) 91 207 14 66

FACILITIES

- 3 Work offices (9 work stations)
- 1 Meeting room (with audiovisual and teleconference systems)
- 1 Archive room
- Phase I/II Clinical Trial Unit:
 - A hospital ward with eight beds and four chairs (children and adults)
 - 1 Doctor's office
 - 1 Central point for sample collection
 - 1 Sitting room
- Carlos III Satellite Unit
 - 1 Work office and doctor's office
 - 1 Laboratory

EQUIPMENT

- 1 ECG
- 1 Centrifuge (Carlos III Satellite Unit)
- 2 Refrigerated centrifuge
- 1 Refrigerator
- 1 Room temperature chamber (Carlos III Satellite Unit)
- 3 -20°C freezers (1 in Carlos III Satellite Unit)
- 2 -80°C deep freezer
- 4 Vital signs monitors
- Defibrillator
- Temperature recording system
- Digital clocks synchronised by GPS
- 2 medical scales (1 in Carlos III Satellite Unit)
- Digital blood pressure monitors and pulse oximeters
- Digital timers
- Crash trolley
- 2 Cure trolleys
- Video surveillance system

- 11 patient calling devices
- 4 patient surveillance cameras

SERVICE PORTFOLIO

The portfolio of services includes more than 80 tasks grouped into:


- Methodologic support
- Clinical trial pre-study activities
- Study development
- Finalization and closure tasks
- Pharmacovigilance
- Statistics and data management
- Medical and nursing tasks

RESEARCH ACTIVITY OF UCICEC

During 2015, an important increase in UCICEC activity has taken place. The platform has provided assistance and support in start-up, coordination, data-management, laboratory management or nursing tasks in 74 commercial clinical trials of 21 IdiPAZ Research Groups and 19 independent clinical research projects of 11 IdiPAZ Research Groups. In this period, 4 audits and 1 inspection have been conducted and have been successfully overcome.

HULP-UCICEC has also provided methodological support in almost 100 clinical independent projects, including advice on study requirements and documentation, protocol development and design and preparation of application reports for competitive projects.

Finally, 6 early phase trials of the Neurology and Cerebrovascular Diseases, Oncology, Paediatrics Infectious Disease and Nutrition group have been conducted in our Phase I Unit.





2.7.3. Experimental Surgery

The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine-tunes procedures for new diagnostic and therapeutic techniques that use laboratory animals. In the teaching field, the Section organises and supports training courses in surgical, microsurgical, laparoscopic and anaesthetic techniques.

COMPOSITION

Section Head

Juan José Vázquez Estévez
jjose.vazquez@salud.madrid.org
Phone: (+34) 91 207 15 81

Veterinarian

Carlota Largo Aramburu
carlota.largo@salud.madrid.org
Phone: (+34) 91 207 15 81

Secretary

Irene Cuevas Gordo
irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54

Technicians and assistants

Ángela Mora; Isabel Rodríguez, M^a Teresa Arranz; Pablo Llorente; Pedro Gallego; Domingo Ortega; Gonzalo Polo and Daniel Ruiz

EQUIPMENT

The Section consists of one microsurgery room, an operating room and an animal facility. The microsurgery room has surgical microscopes, as well as inhalers anaesthesia systems for rodents. All experimental procedures with rodents are performed in this room. Its layout, with fixed and mobile posts, allows for the implementation of microsurgical and laparoscopic courses with simulators or live animals.

The operating room is equipped with double team surgical tables and anaesthesia stations with monitoring equipment, which allow for two surgeries to be performed simultaneously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray equipment. All procedures performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques.

Both microsurgery and operating room had an overhead camera, escreens and audio- video streaming between them and also with the auditorium.

There is also an experimental room for neurological studies using Rotarod or Plus Maze.

ANIMAL FACILITY

The research and teaching at IdiPAZ involving the use of laboratory animals is managed via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In this department we develop biomedical research projects, training courses specific to the va-




rious specialties as well as procedures for putting in place new diagnostic techniques or therapies that involve the use of experimental animals. In addition, the animal facility works with the Ethics Committee for Animal Wellbeing, whose authorisations is required for all procedures.

The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental phases, two rooms for animal handling and experimental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressurebased washing system, and several storage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Surgery where there is a double operating theatre, a microsurgery room and various additional rooms (dressing areas, offices, and store rooms).

The species typically used include: rodents (rats, mice and gerbils), rabbits, pigs, sheep and goats, and occasionally dogs, cats or guinea pigs. Recently, a fish housing unit has been established (zebra fish). To avoid contamination and permit a good workflow, the rooms for housing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the interior while avoiding the unnecessary entrance of unauthorised personnel.

The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage is includes stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to encourage the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects. For the cleanliness of the room and the animals, there are hot and cold water connections via a hose.



The rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position. The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room.

The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, gloves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish. There is a storeroom for feed and shavings and a room for handling and the performance of procedures.

In addition to two large areas of animals, the animal facility includes:

- A washroom equipped with a cage washer (Hobart), a stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it.
- A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray.
- Store room (clean material).
- Control room with computers for environmental control.


The animal facility complies with all current legislation and is registered with number ES-280790001941.

CONTACT

Carlota Largo Aramburu
carlota.largo@salud.madrid.org
Phone: (+34) 91 727 71 54

PORTAFOLIO OF SERVICE

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leaving space and anaesthesia, does not include surgery)






2.7.4. Simulation Platform

The IdiPAZ Simulation Centre offers professionals from various fields the following possibilities:

- Learning and training on the approach for patients in critical clinical conditions: cardiopulmonary resuscitation, shock of various origins, acute respiratory failure of various aetiologies, multiple trauma, arrhythmias, complicated births, difficult airways, safety, and leadership.
- Ongoing training of teams who treat patients in critical conditions: ICU, anaesthesia, emergency department, surgery.
- Learning and training on managing patients with technology-dependent conditions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, haemodialysis and haemofiltration and external ventricular assistance.
- Learning and training on managing technology for diagnostic and therapeutic use: echocardiography, abdominal ultrasonography, catheterisation, laparoscopic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy.
- Learning the use of invasive techniques: arterial and central venous cannulation, nasogastric and vesical catheterisation, suturing, thoracentesis, paracentesis, tracheostomy, nerve blocks.
- Learning to perform a correct medical history review and physical examination and communicating and contacting patients, using actors and advanced simulators.



COMPOSITION

Governing Council

- Dr. Javier Cobas Gamallo
D^a. Ana Coloma Zapatero
Dra. Carlota Largo Aramburu
D^a Elena Martín de Castro
Dr. Juan Vázquez Estévez
D. Juan José Pérez Blanco
Dr. Manuel Quintana Díaz
Dr. Pedro de la Oliva Senovilla
Dr. Ramón Cantero Cid
Dra. Ana M^a Sánchez Torres
Dra. Emilia Guash Arévalo
Dr. Esteban López de Sá y Areses
Dr. Ignacio Zapardiel Gutiérrez
D^a. Esther Rey Cuevas

Dr. Juan José Ríos Blanco
D^a. Estela Sánchez Simón

Chairman Governing Council

Dr. Juan Vázquez Estévez

Secretary Governing Council

D^a Ana Coloma Zapatero
D^a Estela Sánchez Simón

Audiovisual technician

D. Javier Rubio Bolívar


CONTACT

Juan Vázquez Estévez
jjose.vazquez@salud.madrid.org
Phone: (+34) 91 207 71 54

COURSES SIMULATION PLATFORM

Course	Director	Date	Assistants
Diplomado en Reanimación Cardiopulmonar Completa	AM Sánchez Torres	December, 19 th -20 th	18
Jornada temática: Hipertermia Maligna-De la Teoría a la Práctica	N Brogly	December, 14 th -15 th	10
Terapias de depuración extracorpórea en críticos	MÁ Alcalá	December, 12 nd	22
Actualización en el Manejo de niños con Patología Compleja	C Calvo Rey	December, 1 st	25
Máster UAM-UR	M Quintana Díaz	November, 29 th	8
Inmovilización Terapéutica	C Fernández Carretero	November, 29 th	40
Inmovilización Terapéutica	C Fernández Carretero	November, 22 th	40
Curso CRM (Crisis Resource Management) en Urología Pediátrica	JJ Vázquez, MJ Martínez Urrutia, S Riva Vila	November, 25 th	12

Course	Director	Date	Assistants
RCP Avanzada Pediátrica y Neonatal	MA Delgado	November, 23 th -25 th	20
Máster UAM-UR	M Quintana Díaz	November, 22 th	8
Curso de Asistencia Inicial al Trauma Pediátrico (AITP)	JA Ruiz Domínguez	November, 17 th -18 th	20
Taller de RCP Pediátrico Avanzada	JA Ruiz Domínguez	November, 10 th	20
Máster UAM-UR	M Quintana Díaz	November, 8 th	8
Proyecto de Innovación docente: Estrategias creativas para la simulación clínica en el grado de Enfermería: Simulación con marionetas y máscaras	MT González Gil	November, 7 th	10
VIII Curso de Ecografía en el Paciente Pediátrico Crítico	JJ Menéndez Suso	November, 2 th -4 th	16
Curso de Cirugía de Control de Daños	J Murcia, JJ Vázquez	October, 27 th	12
RCP Avanzada Pediátrica y Neonatal	MA Delgado	October, 19 th -21 st	20
Soporte Vital Básico Instrumentalizado	C Fernández Carretero	June, 27 th -28 th	20
PhyMEL-LS: Diseño e implementación de una sesión de simulación clínica utilizando Learning Space y la metodología PhyMEL	JJ Vázquez Estévez, M del Río	June, 27 th	9
Diplomado en Reanimación Cardiopulmonar Completa	AM Sánchez Torres	June, 14 th -15 th	18
Soporte Vital Básico Instrumentalizado	C Fernández Carretero	June, 13 th	25
Soporte Vital Básico	C Fernández Carretero	June, 3 th	25
RCP Avanzada Pediátrica y Neonatal	M Ángel Delgado	May, 25 th -27 th	20
Microcirugía Vasculo Nerviosa y sus Aplicaciones Clínicas	C Casado Pérez	May, 23 rd -27 th	20
Soporte Vital	C Fernández Carretero	May: 19 th , 23 rd and 24 th June: 24 th , 27 th and 28 th October: 11 st , 13 rd and 25 th	40
Curso de RCP Básica Instrumentalizada Pediátrica	JA Ruiz Domínguez	May, 18 th	20
Instructores en AITP	JJ Vázquez Estévez	May, 11 st	9
SYA para Enfermería	M Quintana Díaz	May, 09 th -13 rd	25
Inmovilización Terapéutica	C Fernández Carretero	May, 4 th	40
Inmovilización Terapéutica	C Fernández Carretero	May, 3 rd	40
RCPB para Enfermería	M Quintana Díaz	April, 28 th	25
Microcirugía experimental y colgajos microvasculares en la rata	J Arias Gallardo, MJ Morán Soto, J González Martín-Moro	April, 25 th -29 th	200
Multidisciplinar en Anestesiología	P Garrido	April, 21 st -23 rd	100
Formación de Formadores de Quirófano y Urgencias. Edición I	L Gallego Morales	April, 18 th -19 th	20
Ecografía en el Paciente Pediátrico Clínico	JJ Menéndez Suso	April, 12 nd -14 th	16
Curso de Simulación en Terapias Continuas de Depuración Extrarenal	Reinos-Barbero, P. Sanabria, L. Castro	April, 9 th	16
Suturas en Urgencias Pediátricas	L Martínez	April, 6 th	20
Curso Teórico Práctico de Cirugía Laparoscópica Avanzada en Urología: de la investigación a la práctica clínica	J Cisneros Ledo	March, 29 th - April, 1 st May 24 th -27 th October, 18 th -21 th	20
Formación Instructores en Simulación	P de la Oliva	March, 14 th -17 th	18
RCP Avanzada Pediátrica y Neonatal	MA Delgado	February, 24 th -26 th	15
Microcirugía Experimental y Colgajos Microvasculares en la Rata	J Arias, MJ Morán, J González	February, 22 nd -26 th	18
Asistencia Inicial al Trauma Pediátrico	JA Ruiz Domínguez	February, 18 th -19 th	20
Actualización RCP Adjuntos Urgencias	S García García	February, 10 th	12
Simulación en Vía Aérea	P Garrido	February, 5 th -6 th	100
Puesta a punto de modelo animal experimental de infarto cerebral para proyecto europeo RESSTORE	M Gutiérrez Fernández	January, 26 th -27 th	10
Actualización RCP	JA Ruiz Domínguez	January, 26 th	20
Actualización RCP Adjuntos Pediatría	S García García	January, 25 th	20



2.7.5. Cell Culture Unit

Cell culture techniques allow scientists to mimic maintenance and growth of cells under controlled and precise environmental conditions. This technology offers the employment and development of in vitro model systems aiming at elucidating the cellular and molecular mechanisms involved in certain disease processes, predicting cellular and tissue responses to a particular microenvironment and identifying and/or developing novel drugs and therapeutic targets. Therefore, cell culturing is considered as an essential tool in main aspects such as disease prevention and management, pre-clinical assessment of drug-based strategies and diagnosis of disorders and conditions that afflict human health.

The main objective of the Cell Culture Unit, integrated into the Hospital La Paz Institute for Health Research (IdiPAZ) as core support platform, is to provide users with basic instrumental and technical assistance in cell culture-related experimental approaches. This Unit facilitates the proposal and development of translational research initiatives, providing a convenient basis for creativity, innovation, as well as acquisition and dissemination of the scientific knowledge. The multidisciplinary and dynamic environment established in the Unit incites and promotes the creation of synergies, innovative perspectives and networking opportunities which can be a source of inspiration, exploration and stimulation for new interests, ideas and collaborative research activities. Furthermore, Cell Culture Unit is tightly vinculated to other joint platforms such as the Imaging Core and Flow Cytometry Laboratory, in which researchers can upgrade their objectives and improve and refine their hypotheses.

COMPOSITION

Head

Gema Vallés Pérez, PhD
gema.valles@salud.madrid.org
Phone: (+34) 91 207 15 76

Technical staff

Beatriz Sanz Minguela
Alexander Otero Guardia
Telephone: (+34) 91 727 70 00 (ext 2142).

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Telephone: (+34) 91 207 15 12




FACILITIES AND EQUIPMENT

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory is fitted with the following equipment:

Cabinets

- 3 Faster BIO 48 vertical laminar flow cabinets
- 1 Faster TWO 30 vertical laminar flow cabinet
- 3 Telstar Bio-II-A biological safety cabinets



- 1 Faster BH-EN 2004 biological safety cabinet
- 2 Nuair NU-437-400E biological safety cabinets
- 1 Heraeus HS-12 biological safety cabinets
- 1 Gelaire BSB 4A biological safety cabinet
- 1 Esco Class II BSC biological safety cabinet

Incubators

- 3 Thermo Forma Scientific incubators with temperature and CO₂ control and saturated humidity environment
- 2 HERAcell incubators with temperature and CO₂ control and saturated humidity environment
- 2 Biotech Galaxy S incubators with temperature and CO₂ control and saturated humidity environment
- 2 Nuair Autoflow incubators with temperature and CO₂ control and saturated humidity environment
- 1 Sanyo O₂/CO₂ incubator with temperature and gas control and saturated humidity environment
- This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO₂ and N₂.

Microscopes

- 1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.
- 1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.
- 1 Optika inverted light microscope
- 1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics
- 1 Lan Optics inverted light microscope

Centrifuges

- 2 Eppendorf 5810R refrigerated centrifuges
- 2 Eppendorf 5804 centrifuge
- 1 Hettich Universal 32R refrigerated centrifuge
- 1 Kubota 2010 centrifuge

Cell Separation System

- 1 Milteny Biotec autoMACS cell separation system

Freezing systems

- 1 Liebherr refrigerator (4 ° C and -20 ° C)
- 1 Balay refrigerator (4 ° C and -20 ° C)
- 1 Whirlpool refrigerator (4 ° C and -20 ° C)
- 1 Beko refrigerator (4 ° C and -20 ° C)

Other equipment

- 1 Presoclave 75 P-Selecta autoclave
- 1 Millipore water purification system

- 1 Heidolph Reax 2000 vortex
- 1 Raypa thermostatic waterbath
- 1 Memmert thermostatic waterbath
- 2 Precistern thermostatic waterbath
- 1 Grant JB Aqua 12 Plus thermostatic waterbath
- Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc

The cryopreservation room is equipped with

- 2 Statebourne Biorack 3000 liquid nitrogen tank
- 1 Thermo Locator 6 Plus liquid nitrogen tank
- 1 10 K Taylor Wharton liquid nitrogen tank
- 1 MVE cryosystem 4000 liquid nitrogen tank
- 1 Cryo Diffusion B2016 liquid nitrogen tank
- 1 Cryo diffusion B2048 liquid nitrogen tank
- 1 Cryo Diffusion B2011 liquid nitrogen tank
- 1 SEO GT40 liquid nitrogen tank
- 1 MVE XLC 511 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O₂ detector coupled to a mechanical ventilation system.

PORTFOLIO OF SERVICES

- Scientific and technical advice, personalized support and consultation: guidance in experimental setup and design, study planning, optimization of techniques and protocols, reagents and material acquisition, cells supply, troubleshooting, analysis and interpretation of results...
- Basic training and hands-on experiments (implementation of the self-service mode) according to biosafety, waste disposal and good laboratory practice guidelines.
- Access to specific facilities including instrumentation, equipment, materials and reagents.
- Preparation and supply of certain materials, reagents and sterile solutions.
- Management and general supervision including good laboratory practices and work habits, maintenance, cleaning and waste disposal and operation and maintenance of the equipment.
- Performance of experimental procedures: cell separation, cell isolation for cultivation, maintenance and propagation of cell lines and primary cultures, cryopreservation and resuscitation, viability and proliferation, etc...
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guidelines, operating procedures, reports and other required mandatory documentation.

- Detection, identification and treatment of contaminations in cell cultures.
- Access to technologies and common infrastructures as well as common standard equipment and other associated IdiPAZ facilities.


RESEARCH ACTIVITY INDICATORS

During 2016, our platform has provided assistance and support to more than 70 users belonging to multidisciplinary IdiPAZ groups such as Neurology and Cerebrovascular Diseases, Innate immune response, Immuno-rheumatology, Drug hypersensitivity, Experimental Therapies and Biomarkers in Cancer, Translational Oncology, Cancer Molecular Pathology and Therapeutic Targets, Molecular Hepatology, Diagnosis and Treatment of Allergic Diseases, Nephrology, Bone Pathophysiology and Biomaterials, Cellular Engineering and Experimental Surgery, Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, Respiratory Diseases and Urology.

The contribution and efforts of the Cell Culture Unit to the scientific productivity of these groups throughout this year is reflected by a relevant output of more than 70 research projects funded by competitive national calls (ISCIII, MINECO, CIBER...), private foundations, organizations, societies or pharmaceutical companies (Roche Farma, Baxter, HSF Pharmaceuticals, Pfizer, Novartis farmacéutica, Janssen Cilag, Fundación Marató TV3, Vissum corporación, Óptica general S.A.R.L., Proteomika ...) and international initiatives sponsored by the European Framework Programme for Research and Innovation (H2020) and the International Olympic Committee (IOC).

As additional indicators is relevant to mention the involvement of this platform in the development of 48 publications (mostly in top international journals), participation in 11 conferences and congresses, 2 book chapters, 13 doctoral theses, 10 patents and trademarks and its contribution to the basis or progress in numerous clinical trials.

Moreover, this division has also promoted and stimulated the establishment of collaborative alliances between IdiPAZ scientists and international groups and institutions such as the Chang Gung Memorial Hospital in Taiwan, the University of Liverpool or Glasgow in UK, the Pasteur Institute or the Centre Hospitalier Universitaire Grenoble Alpes in France, the University of Eastern Finland, the University Hospital Brno in Czech Republic, the University of California, Florida or Wisconsin-Madison in USA, the Utrecht University in The Netherlands, the Trinity College in Ireland, the Reviva Regenerative Medicine Center in Lebanon or companies such as HSF Pharmaceuticals in Switzerland or Optica General in Lebanon.



2.7.6. Automatic Sequencing Laboratory

The main role of the Automatic Sequencing Laboratory is to provide support for medical research and clinical routine. The goal is to increase the volume and quality of scientific results in a number of research and clinical groups inside our both Institute and elsewhere.

DESCRIPTION

Our laboratory is located inside a renowned hospital. This allows for frequent interactions with the hospital's various research groups, and thus allows for the laboratory members to stay up to date on state-of-the-art techniques in genetics. Nowadays, the Sanger sequencing method is regarded it as the gold standard for validation of Next-Generation Sequencing variants.

In order to achieve the goals stated above, our laboratory owns the necessary equipment and infrastructure for performing tasks such as conventional sequencing (Sanger method), marker DNA genotyping, and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates into the genetic analysers. Therefore, we are able to detect more than 30 polymorphic markers per sample. In addition, the laboratory equipment allows us to carry out extractions of DNA and RNA.

The laboratory is regularly involved in quality control audits on the Sanger sequencing and genotyping, as well as result homologation. Such audits are performed at both national and international levels (e.g., EMQN).

OFFERED TECHNIQUES

- Sanger sequencing.
- Marker DNA genotyping.
- Analysis of single nucleotide polymorphisms (SNPs) by primer extension (SNaPshot™).
- Aneuploidies by quantitative fluorescence PCR detection (QF-PCR).
- Short tandem repeats detection (TP-PCR).
- Multiplex ligation-dependent probe amplification (MLPAs).
- Microsatellite Instability (MSI).
- Support for sample preparation workflow to maximise the quality of results.
- On-demand training for the software analysing the result data.


COMPOSITION

Lab manager

M^a Rocío Mena de la Cruz
mariarocio.mena@salud.madrid.org

Technicians

Inmaculada Rueda Arenas
inmaculada.rueda@salud.madrid.org



María Victoria Gómez del Pozo
mgdelpozo@salud.madrid.org
Phone: (+34) 91 207 10 10 (ext. 226/230)

EQUIPMENT

Devices

- Eppendorf 5415D Centrifuge
- Veriti Thermocycler (Applied Biosystems)
- EpMOTION Eppendorf automated pipetting
- Genetic analysers 3130xl (x2) & 3730xl (Applied Biosystems - Life Technologies).

Software

- Sequencing Analysis 5.3.1
- Sequence Scanner 1.0
- GeneMapper 4.0
- Peak Scanner 1.0

RESEARCH ACTIVITIES



During 2016 our laboratory supported to research groups as well internal groups as outside researches. Our close interaction with these users enabled a number of contributions to these groups at different levels: from initial brainstorming as research staff, to sample processing useful in fields such as rare disease, Microbiology, Genotyping cellular, Immunology, Oncology, etc. Our laboratory's staff close collaboration with one of these groups has led to authorship of one original article, and contributing to about thirty more by offering sequencing services. In addition, our participation in several international and national congresses during last year, have allowed us to maintain training in new techniques.

2.7.7. Image Laboratory

The study, characterization and analysis of morphological and functional changes in cells and tissues is a very relevant discipline not only for the diagnosis in clinical pathology but also for a better understanding of the cause and mechanisms in various diseases studied by both basic and pre-clinical research. The mission of Image and Immunohistochemistry Laboratory Core is to provide a centralized service dedicated to assisting with the highest quality histology, immunohistochemistry and imaging equipment, as well as scientific and technical support to researchers. This core is open to all investigators, including; IdiPAZ and their affiliates, commercial and not-for-profit biotechnology companies, and other academic institutions.

Specialized staff will support the researchers' projects by evaluating the user's needs in histology or immunohistochemistry, help with planning large-scale projects, advice on using the most appropriate techniques for the processing and interpretation of experimental or preclinical research samples results. Trained and authorized users have free access to the platform; IdiPAZ staff in a Do-It-yourself manner and in a fee-for-service manner to all the rest. For service requests, users must refer to the head of the core. To fulfil its mission of enabling cutting-edge research, the facility houses two platforms, Immunohistochemistry and Microscopy Laboratory with state of the art Histology, Immunohistochemistry and Digital Microscopy technologies. The histology laboratory offers advice, protocols and automated high-throughput equipment allowing citospines, fixation techniques (paraffined or frozen), sectioning of tissues (microtomes and cryostats), and classical or advanced immuno-staining (Dako Autostainer). The image laboratory offers users equipment to develop the most demanding processing requirements including conventional microscopy as bright field, phase contrast and fluorescence in addition of confocal and advanced microscopy for in vivo imaging with high-speed camera and incubation system of cultures with temperature and gas control.

During 2016, Image unit maintained their quality standards in order to help users to get the excellence in their research by supporting projects (publics or privates, national or international grants), scientific dissemination (thesis) and high impact international publications. In addition core facility joins forces with other core facilities (Cell Culture, Biobank, Experimental Surgery..), to create a teamwork to combine technologies and applications for exchanging knowledge and expertise and working on common strategies for training and projects support. In the last year, we have extended the number of users inside Hospital La Paz (HULP, clinical and basic researchers), associated IdiPAZ groups (UAM), as well as other research groups (UCM, CSIC etc).



COMPOSITION

Scientific head

Maria Teresa Vallejo Cremades (PhD).
tvallejo.hulp@salud.madrid.org
Phone: (+34) 91 727 75 26


Technical

Paula Sánchez Guismera
Phone: (+34) 91 727 70 00 (ext. 42148-Immunohistochemistry Lab.)
(+34) 91 727 75 26- Microscopy Lab.

RESOURCES AND MANAGEMENT OF THE LABORATORY

IdiPAZ researchers can use all equipment in the Image Core by themselves, but only once they have been trained. In addition, the lab provides fee-for-service to external institutions and private companies. An introduction to the lab with some safety regulations and the basic training for the usage of the required instrument is provided on by the lab staff at any time of the year. Basic safety regulations for the proper work in the lab will be explained also to new users. Users must schedule the time of work in any equipment and booking reserve it's mandatory in all the facility.

Standard protocols both equipment and techniques and general rules for biosafety and lab safety are available in a separate document provided by the laboratory staff. Access to the Immunohistochemistry Lab is free, but the magnetic individual card is required to entry into the Microscopy lab.





The equipment is housed in two different laboratories belonging to the Image platform; the Immunohistochemistry and the Microscopy laboratories:

Immunohistochemistry Laboratory

- Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TP1020)
- Embedding unit for high quality paraffin blocking (Leica EG1160)
- Selecta Wax dispenser; paraffin wax dispenser with adjustable temperature from ambient to 100 °C
- 2 microtomes for specimen sectioning Leica RM2255
- 1 microtome for specimen sectioning Shandon AS325
- Leica EG 1150C Cold plate
- 2 thermostatic water Leica HI 1210 baths
- 1 thermostatic water Selecta Thermofn bath
- Automated Immunohistochemistry stainer (Autostainer Plus DAKO)
- 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)
- PTLINK DAKO
- Crison pH meter
- Liebherr upright freezer (-20°C and 4°C)
- Liebherr economy freezer (-20°C)
- Shandon Cytospin 2
- Memmert BE 500 oven
- Memmert UN 30 oven
- Selecta Agimatic-E magnetic stirrer with heating
- Pipettors
- Olympus CH microscope, for practical laboratory applications
- Gilson pipette sets
- NUAIRE laboratory fume hood.

Dissection equipped and staining area with manual options for Do-It-Yourself staining and cover-slipping.

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be solicited to the head of these laboratories.

The Image Analyses laboratory equipment includes:

- Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Illumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.
- NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
- Camera IMAGING SOURCE
- Camera Camera ANDOR Neo SCHOS refrigerated.
- Lauda Ecoline Star incubator edition 003
- Hotplate (OKO LAB)
- Doser gases (Okolab)
- Adapter culture plates microscope
- Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red)
- Olympus BX41 (Bright field) upright microscope with an attached Digital camera
- Zeiss Axioplan 2 upright microscope with five objectives

from 5x to 100x, phase contrast and fluorescent capabilities

- Zeiss Axio Lab.A1 microscope five objectives from 5x to 100x. ERC55 Axocan camera.
- Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles's size based on the scattering of light, includes a microscope, a LM10 viewing unit, a Marlin camera, an objective x20 and is connected to a image analysis software.
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LAS AF image analysis software
- Analysis station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.
- Nanosight NTA 3.1 analytical software

SERVICE PORTFOLIO

- Collection and processing for fixing and decalcification of samples.
- Sample processing in paraffin by hand or automatic.
 - Complete processing paraffin embedding.
 - Serial cut in microtome and tissue assembly.
- Antibodies' validation.
- Buffer preparation and distribution of consumables.
- Sample processing frozen.
 - Preparation of freeze blocks.
 - Serial sections of blocks freeze and cuts collected on slides or floating.
- Staining.
 - Hematoxylin - eosin.
 - Masson trichrome.
 - Nissl.
 - PAS.
 - Acetylcholinesterase.
 - Cytochemical and immunohistochemical techniques.
 - Decalcification of samples required.
 - Dewaxing cuts, performing staining.
 - Immunohistochemical staining automated system Autostainer.
 - Immunofluorescence in frozen tissue and paraffin. Protocols.
 - Dehydration and slide assembly.
- Image acquisition. Viewing and digital format acquisition.
 - Light microscopy.
 - Light microscopy with phase contrast.
 - Epifluorescence.
 - Confocal microscopy.
 - Advanced Microscopy in living cell.
- Fluorescence colocalization by confocal microscopy.
- 3D reconstruction.
- In vivo image acquisition of biological samples (incubation system for the temperature and CO₂).
- Morphometry in biological samples.
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence.
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.

2.7.8. Flow Cytometry Laboratory

Flow Cytometry Laboratory of IdiPAZ supports the scientific activity contributing to the advance in the research, at present benefit of different research groups of the Institute. The equipment allows for phenotypic analysis of subpopulations, quantification of soluble factors in biological samples and culture supernatants, cell cycle experiments.

COMPOSITION

Head

Victor M. Toledano Real
victor.toledano@idipaz.es
Phone: (+34) 91 207 15 12 (ext. 2484)

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

EQUIPMENT

The Flow Cytometry Laboratory of IdiPAZ has the following facilities:

- One Beckman Coulter Navios cytometer analyser is a clinical system that delivers analytical excellence by coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. With superior detection capabilities, the Navios provides accurate measurements, especially for rare events, which is critical to clinical diagnosis and monitoring. The fully-featured, easy-to-use Navios software provides tools to improve the quality of results as well as optimize workflow efficiencies in a clinical lab.
 - This analyser has three lasers; Blue solid state Diode: 488nm, 22mw laser output, Red solid state Diode: 638nm, 25mw laser output and Violet solid state Diode: 405nm, 40mw laser output. The Navios can analyse ten colours simultaneously in samples marked with the following fluorochromes: • FL1: FITC, GFP, Cy2, Alexa 488 • FL2: PE, Cy3 • FL3: PI, ECD, PE-TEXAS RED, RED RFD • FL4: PE-Cy5, PerCP, PerCP5.5, TC 7AAD, SPRD • FL5: PE-Cy7 • FL6: APC, Alexa 647 • FL7: APC-Alexa700, Alexa 700 • FL8: APC-Cy7, APC-Alexa750, APC-Alexa780 • FL9: Pacific Blue, eFluor 450 Cyan, Cyan, Violet RFD • FL10: Pacific Orange, AmCyan.
 - The Navios is connected to computer using the Navios acquisition and analysis programme.
- Two Becton Dickinson FACSCalibur™ cytometer analysers is a platform allows users to perform both cell analysis and cell sorting in a single benchtop system. The system supports a wide variety of research and clinical applications and is comple-




mented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.

- Each analyser has two lasers, a 488nm argon laser and a 635nm solid-state red diode laser. The FACSCalibur™ can analyse four colours simultaneously in samples marked with the following fluorochromes: • FL1: FITC, Alexa 488 • FL2: PE, PI • FL3: PE-Cy5, PerCP, Per-CP5.5 • FL4: APC, APCCy7, Alexa 647.

- The two cytometers are connected to Macintosh G4 OS.9.2.2 computers using the CellQuest™ acquisition and analysis programme, and Macintosh G5 OSX with CellQuestPro™ acquisition and analysis software.

• The laboratory also has an additional Mac G5 OSX analysis station with CellQuestPro™ acquisition and analysis software.



2.7.9. Radioisotope Laboratory

The radioactive facility of IdiPAZ laboratories is authorised by the Nuclear Safety Council (Consejo de Seguridad Nuclear, CSN) to operate with non-encapsulated sources radioisotopes: 3H, 33P, 32P, 125I and 51Cr.

Personnel of the Radiological Protection Department of HULP conduct radiological protection and periodically monitor laboratory contamination levels. They are also responsible for the removal and management of waste products and the management of users' personal dosimeters.

COMPOSITION

Head

Nuria Vilaboa Díaz
nuria.vilaboa@salud.madrid.org
Phone: (+34) 91 207 10 34

David Vicent López
david.vicent@salud.madrid.org
Phone: (+34) 91 207 10 30

Secretary


Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

EQUIPMENT

Contains exclusive areas for the use of β and γ isotopes; aliquot withdrawal and storage of radiolabeled compounds; and equipment for exclusive use with radioactive material.

The laboratory has the following equipment:

- CO2 incubator
- Cell harvester
- Beta counter
- Hybridisation oven
- Gel dryer
- SpeedVac® concentrator
- Screens and containers specifically for γ and β radiation emitters
- High-energy γ and β contamination detectors (Geiger counter)



2.7.10. Biostatistics Section

Section of Biostatistics mission is to provide methodological support to professionals of the University Hospital La Paz and generally IdiPAZ professionals and provide technical solutions to optimize clinical processes by incorporating necessary for this technology.

COMPOSITION

Clinical Biostatistics

Rosario Madero Jarabo
rosario.madero@salud.madrid.org
Phone: (+34) 91 207 71 12

Mariana Díaz Almirón
mariana.diaz@idipaz.es
Phone: (+34) 91 207 17 91

Bioengineer

Francisco Gayá Moreno
francisco.gaya@salud.madrid.org
Phone: (+34) 91 207 17 91

Clinical Epidemiologist

Jesús Díez Sebastián
jdiezs@salud.madrid.org
Phone: (+34) 91 207 17 91
(+34) 91 727 75 70




EQUIPMENT

The main programs used for data analysis:


- SAS 9.3 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA).
- SAS Enterprise Guide 5.1 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA).
- R version 3.2.5 R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- SPSS 9 (Copyright 1999 by SPSS Inc.).
- SYSTAT 11 (Copyright (c) 2004 by SYSTAT Software Inc., Richmon, CA, USA).
- nQuery Advisor 5.0 (Copyright (c) 1995-2002).
- PEST 4.0 Planning and Evaluation of Sequential Trials (Medical and pharmaceutical Statistics Research Unit. The University of Reading, UK).
- Review Manager (RevMan) Version 5.0. (Meta-analysis) Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.

SERVICE PORTFOLIO

- Study design.
- Creating systems to collect data (such as ms Access).
- Technical Support in the development of studies.
- Development of information processing systems (clinical imaging systems, reading of measurement systems, implementing statistics methods...).



- Results analysis: multivariate analysis (discriminant analysis, correspondence analysis, factor analysis, survival analysis, risk analysis, competing risks analysis...), generalized linear including models with mixed effects and generalized equations, risk models development for classification and prediction, building point system for risk evaluation, analysis of growth curves, clinical trial methodologies, sequential analysis of data, analysis of high dimensions (microarrays analysis), bicluster analysis. Resampling methods (Bootstrap, Jackknife, ...).
- Results dissemination.
- Training activities.



2.7.11. Documentalist

The documentalist from IdiPAZ aims to support and assist all members of the Institute with regard to the access and use of databases, literature searches, bibliometric indicators or any other related matter.

Another purpose of the documentalist is the development of control tools that are useful for making the registration of scientific production of the group belonging to the Institute. As a result of this register quarterly Bibliometric Reports are published showing the papers published by the researchers from IdiPAZ. These reports show provisional data that will later be submitted to the Directors of the Group for review and inclusion in the Annual Research Report.

The Research Report is the official document published on an annual basis which includes all the information regarding the research activities of each of the research groups.

COMPOSITION

Head

Raúl Román Cañizares
documentalista@idipaz.es
Phone: (+34) 91 207 15 12

SERVICE PORTFOLIO

- Perform the Annual Research Report of IdiPAZ
- Collaboration with researchers in the access and use of databases, literature searches, etc.
- Creating tools of scientific production control
- Development of Bibliometric Reports
- Evaluation of researchers
- Bibliometric assessment of Research Groups
- Advice on literature search tools
- Advice on the use of bibliometric techniques
- Poster printing for congress

2.7.12. PAIN Platform

The PAIN Platform-Early-Stage Researches Support Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a recently created service that aims to promote the design and development of research projects in several health areas, with high methodological quality, to enable our professionals in early-stage research. Additionally, the mission of the PAIN Platform is to promote the training and development of early career researchers of IdiPAZ.

COMPOSITION

Head

Paloma Gómez Campelo (PhD)
pgomez@salud.madrid.org
Phone: (+34) 91 207 15 12

SERVICE PORTFOLIO

- Methodological and epidemiological support to the study design of the professionals in early-stage research.
- Technical and methodological support in developing a research protocol for a study.
- Analysis of the grounds for refusal of rejected projects.
- Methodological support to write grant proposals to access all available funding programs.
- Technical support in writing other scientific documents.

2.7.13. Internationalization Platform

The IdiPAZ Internationalization Platform aims to become a fundamental tool to support IdiPAZ researchers to continue being a reference in the international arena. The main objective is to promote at international level the different research groups of IdiPAZ, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

SPECIFIC OBJECTIVES:

- Conduct an active monitoring international funding programs for R & D + i
- Identifying and disseminate interesting opportunities and calls for research groups
- Identifying and actively participate in international networks interesting for the center
- Introducing and disseminating the capabilities of the center and its research groups
- Identifying, defining, validating and developing project ideas that emerged in the center

- Supporting and encouraging participation in information events
- Organising information and training sessions on specific required areas
- Advising on the proposal preparation and the negotiation phase with the European Commission
- Managing the approved projects.


PROGRAMMES:

H2020

H2020 is the leading European program for funding research and innovation projects in various subject areas. For the period 2014-2020 it accounts with a budget of nearly € 80,000m.

Most activities are implemented through competitive calls managed by the European Commission with preset priorities in work programs.

The program structure can be seen reflected in the following figure:





EU HEALTH PROGRAMME

The Health Program of the EU is the main instrument available to the European Commission to carry out the Health Strategy of the EU. It is implemented through annual work plans, in which the criteria and funding priorities are established.

The total budget of the third program is 449.4 million euros for the period 2014-2020.

COST

COST is the first and widest European intergovernmental framework for transnational Cooperation in Science and Technology.

Its aim is to enable break-through scientific developments leading to new concepts and products and thereby contributes to strengthen Europe's research and innovation capacities. These networks, COST Actions, represent the main instrument available to the program for its implementation.

The calls are continuously open with two court dates per year.

Other programmes

- IMI
- INTERREG-SUDOE
- AAL
- ERA-NETs

Active projects

Project		Programme	Logo
SAPHeIN	Implementing SAPHetydoc for the wide adoption of eINvoicing	CEF TELECOM	
WEAKID	Clinical validation of miniature wearable dialysis machine	H2020	
ORTHOUNION	ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONS	H2020	
ERN TransplantChild (Coordinated by the HULP)	European Reference Network on transplantation in children	EU Health Programme	
ERN RARE-LIVER	European Reference Network on hepatological diseases	H2020	
VIRUSCAN	Optomechanics for Virology	H2020	
RESSTORE	REgenerative Stem cell therapy for STroke in Europe	H2020	
ENABLE	European Gram-negative Antibacterial Engine	IMI	
EPP eHealth	European Procurers Platform - eHealth - Transforming the market for eHealth Solutions	H2020	
NEO-CIRC	Dobutamine for NEOnatal CIRculatory failure defined by novel biomarkers	FP7	

COMPOSITION

Team

Adriana Varela Fernández
adriana.varela@idipaz.es
Phone: (+34) 91207 17 90

José Luis Narro Villanueva
jose.luis.narro@idipaz.es
Phone: (+34) 91727 75 76

Marisa Tejedor Botello
marisa.tejedor@idipaz.es
Phone: (+34) 91727 75 76

DOCUMENTATION

Webs

- **Participant portal:** it is the entry point for electronic administration of EU-funded research and innovation projects.
- **CORDIS:** it is the European Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense.
- **Eshorizonte2020:** it is the H2020 Spanish portal.
- **European IPR Helpdesk:** it offers free of charge, first-line support on IP and IPR matters to beneficiaries of EU funded research projects and EU SMEs involved in transnational partnership agreements, especially within the Enterprise Europe Network (EEN).
- **EURAXESS – Researchers in Motion:** it is a unique pan-European initiative providing access to a complete range of information and support services to researchers wishing to pursue their research careers in Europe or stay connected to it.
- **EATRIS:** European Infrastructure for Translational Medicine, it provides a new development pathway,

open to researchers and companies in need of support for advancing biomedical innovations.

- **ECRIN:** European Clinical Research Infrastructure Network, it is a public, non-profit organisation that links scientific partners and networks across Europe to facilitate multinational clinical research.

Documents and Forms

- Project Abstract
- Research Group Profile
- Annotated Model Grant Agreement - AMGA July 2016 version

Events organized by the Internationalization Platform

- Jornada de Formación Básica sobre el Programa HORIZON 2020
- FET Infoday 2017


SERVICE PORTFOLIO

- Participation in international networks of interest to the center
- Targeted dissemination of funding and project involvement opportunities
- Organization of information sessions and training courses
- Preparation and dissemination of scientific and technological profiles of the research groups
- Identification of project proposals under preparation in which the center can be involved.
- Advice on the definition of the project idea and the preparation of proposals
- Identification of partners for projects coordinated or participated by researchers at the center
- Support in the negotiation phase with the European Commission - EC before the signing of the grant agreement- GA.
- Management of funded projects.





2.8. Scientific Production



Journal	ISSN	Total of documents	Impact factor	Quartile
Accident Analysis and Prevention	0001-4575	1	2.685	D1
Acta Diabetológica	0940-5429	2	3.34	Q2
Acta Haematologica	0001-5792	1	1.205	Q4
Acta Orthopaedica et Traumatologica Turcica	1017-995X	1	0.599	Q4
Acta Oto-Laryngologica	0001-6489	1	1.116	Q3
Acta Paediatrica	0803-5253	4	2.043	Q2
Acta Tropica	0001-706X	1	2.218	Q2
Actas Dermo-Sifiliográficas	0001-7310	12	Not Indexed	
Actas Urológicas Españolas	0210-4806	3	1.181	Q4
Advances in Skin & Wound Care	1527-7941	1	1.088	Q3
Age and Ageing	0002-0729	1	4.282	Q1
AIDS	0269-9370	3	5.003	Q1
AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV	0954-0121	2	1.824	Q2
AIDS Research and Human Retroviruses	0889-2229	2	2.095	Q3
AIDS Reviews	1139-6121	3	3.195	Q2
Allergologia et Immunopathologia	0301-0546	3	1.439	Q4
Allergologie	0344-5062	1	0.311	Q4
Allergy International	1323-8930	1	3.194	Q2
Allergy	0105-4538	2	7.361	D1
Allergy & Rhinology	2152-6575	1	Not Indexed	
American Heart Journal	0002-8703	2	4.436	Q2
American Journal of Cardiology	0002-9149	3	3.398	Q2
American Journal of Case Reports	1941-5923	1	Not Indexed	
American Journal of Clinical Nutrition	0002-9165	1	6.926	D1
American Journal of Human Genetics	0002-9297	1	9.025	D1
American Journal of Medical Genetics Part A	1552-4825	6	2.259	Q3
American Journal of Medical Genetics Part C-Seminars in Medical Genetics	1552-4868	1	5.6	Q1
American Journal of Medical Quality	1062-8606	1	1.688	Q3
American Journal of Obstetrics and Gynecology	0002-9378	1	5.574	D1
American Journal of Physical Anthropology	0002-9483	1	2.552	Q2
American Journal of Physiology-Renal Physiology	1931-857X	1	3.611	Q1
American Journal of Respiratory and Critical Care Medicine	1073-449X	3	13.204	D1
American Journal of Transplantation	1600-6135	1	6.165	D1
Anales de Documentación	1575-2437	1	Not Indexed	
Anales de Pediatría	1695-4033	11	1.14	Q3
Anales del Sistema Sanitario de Navarra	1137-6627	2	0.625	Q4
Analytical Chemistry	0003-2700	1	6.32	D1
Andrology	2047-2919	1	2.427	Q2
Angiología	0003-3170	2	Not Indexed	
Annals of Allergy Asthma & Immunology	1081-1206	2	3.728	Q2
Annals of Burns and Fire Disasters	1592-9558	1	Not Indexed	
Annals of Hematology	0939-5555	2	3.083	Q2
Annals of Occupational Hygiene	0003-4878	1	1.71	Q3
Annals of Oncology	0923-7534	2	11.855	D1
Annals of Otolaryngology and Laryngology	0003-4894	2	1.384	Q2
Annals of Surgical Oncology	1068-9265	1	4.041	D1
Annals of the Rheumatic Diseases	0003-4967	8	12.811	D1
Annals of Translational Medicine	2305-5839	1	Not Indexed	
Anticancer Research	0250-7005	1	1.937	Q3
Antimicrobial Agents and Chemotherapy	0066-4804	2	4.302	Q1
Antioxidants & Redox Signaling	1523-0864	2	6.337	D1
Antiviral Therapy	1359-6535	4	2.594	Q2
Applied Physiology Nutrition and Metabolism	1715-5312	1	2.023	Q2
Applied Psychology-Health and Well Being	1758-0846	1	2.722	Q1
Archives of Bone and Joint Surgery-ABJS	2345-4644	1	Not Indexed	
Archives of Clinical Neuropsychology	0887-6177	2	2.044	Q3
Archives of Disease in Childhood-Fetal and Neonatal Edition	1359-2998	1	3.786	D1
Archives of Gynecology and Obstetrics	0932-0067	1	2.09	Q2
Archives of Orthopaedic and Trauma Surgery	0936-8051	1	1.942	Q2



2.8. Scientific Production

Archivos de Bronconeumología	0300-2896	9	2.979	Q2
Archivos de Cardiología de México	1405-9940	1		Not Indexed
Archivos de la Sociedad Española de Oftalmología	1989-7286	4		Not Indexed
Archivos Españoles de Urología	0004-0614	6	0.323	Q4
Arthritis & Rheumatology	2326-5191	2	6.918	D1
Arthritis Care & Research	2151-464X	2	3.319	Q2
Arthritis Research & Therapy	1478-6354	1	4.121	Q2
Asian Spine Journal	1976-1902	1		Not Indexed
Atención Primaria	0212-6567	2	1.042	Q3
Autoimmunity Reviews	1568-9972	1	8.961	D1
Autophagy	1554-8627	2	8.593	Q1
Behavioral and Brain Functions	1744-9081	1	2.207	Q3
Biochemical Pharmacology	0006-2952	1	4.581	Q1
Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids	1388-1981	1	5.547	Q1
Biochimica et Biophysica Acta-Molecular Basis of Disease	0925-4439	4	5.476	Q1
Biomaterials	0142-9612	1	8.402	D1
Biomedical Materials	1748-6041	2	2.469	Q2
Bioscience Reports	0144-8463	1	2.906	Q2
BJU International	1464-4096	1	4.338	Q1
Blood	0006-4971	1	13.164	D1
Blood Coagulation & Fibrinolysis	0957-5235	4	1.367	Q4
Blood Reviews	0268-960X	1	6.342	Q1
Blood Transfusion	1723-2007	2	1.607	Q4
BMC Cancer	1471-2407	2	3.288	Q2
BMC Medical Research Methodology	1471-2288	1	3.295	Q1
BMC Microbiology	1471-2180	1	2.644	Q2
BMC Neurology	1471-2377	1	2.006	Q3
BMC Palliative Care	1472-684X	1	1.602	Q3
BMC Pulmonary Medicine	1471-2466	1	2.435	Q3
BMJ Open	2044-6055	1	2.369	Q1
Bone Marrow Transplantation	0268-3369	1	3.874	Q2
Brain	0006-8950	2	10.292	D1
Brain & Development	0387-7604	1	1.52	Q4
Brain Research	0006-8993	1	2.746	Q3
Brain Structure & Function	1863-2653	1		Not Indexed
Brazilian Journal of Anesthesiology (Elsevier)	0104-0014	1		Not Indexed
Brazilian Journal of Physical Therapy	1413-3555	1	1.226	Q3
Breast Cancer Research and Treatment	0167-6806	1	3.626	Q2
Breast Care	1661-3791	1	1.553	Q3
Breastfeeding Medicine	1556-8253	1	1.551	Q3
British Journal of Anaesthesia	0007-0912	2	6.238	D1
British Journal of Cancer	0007-0920	3	6.176	Q1
British Journal of Dermatology	0007-0963	4	4.706	D1
British Journal of Haematology	0007-1048	3	5.67	Q1
British Journal of Nutrition	0007-1145	2	3.706	Q1
British Journal of Oral & Maxillofacial Surgery	0266-4356	1	1.218	Q3
British Journal of Pharmacology	0007-1188	3	5.491	D1
Cancer Cell	1535-6108	1	27.407	D1
Cancer Epidemiology	1877-7821	2	2.343	Q2
Cancer Epidemiology Biomarkers & Prevention	1055-9965	1	4.142	Q1
Cancer Letters	0304-3835	1	6.375	Q1
Cardiology	0008-6312	1	1.742	Q3
Cardiology and Therapy	2193-8261	1		Not Indexed
Cardiology in The Young	1047-9511	2	0.905	Q4
Cardiovascular & Hematological Disorders Drug Targets	2212-4063	1		Not Indexed
Cardiovascular Diabetology	1475-2840	1	4.752	Q1
Case Reports in Hematology	2090-6560	1		Not Indexed
Catheterization and Cardiovascular Interventions	1522-1946	1	2.602	Q2
Cell Death & Disease	2041-4889	2	5.965	Q1
Cell Death and Differentiation	1350-9047	1	8.339	D1
Cellular and Molecular Life Sciences	1420-682X	1	5.788	Q1
Central European Journal of Urology	2080-4806	5		Not Indexed
Cerebellum & Ataxias	2053-8871	1		Not Indexed

Cerebrovascular Diseases	1015-9770	1	2.974	Q2
Circulation	0009-7322	3	19.309	D1
Circulation Journal	1346-9843	3	3.544	Q2
Circulation-Cardiovascular Interventions	1941-7640	1	7.198	D1
Circulation-Cardiovascular Quality and Outcomes	1941-7705	1	4.524	Q2
Cirugía Cardiovascular	1134-0096	9		Not Indexed
Cirugía Pediátrica	0214-1221	3		Not Indexed
Cirugía y Cirujanos	0009-7411	1	0.276	Q4
Clinical & Translational Oncology	1699-048X	11	2.353	Q3
Clinical and Applied Thrombosis-Hemostasis	1076-0296	1	2.096	Q3
Clinical and Experimental Allergy	0954-7894	1	5.264	Q1
Clinical and Experimental Hypertension	1064-1963	1	1.162	Q4
Clinical and Experimental Immunology	0009-9104	1	3.41	Q2
Clinical and Experimental Obstetrics & Gynecology	0390-6663	1	0.429	Q4
Clinical and Experimental Pharmacology and Physiology	1440-1681	1	2.01	Q3
Clinical and Experimental Rheumatology	0392-856X	4	2.634	Q3
Clinical Cancer Research	1078-0432	2	9.619	D1
Clinical Cardiology	0160-9289	1	2.757	Q2
Clinical Endocrinology	0300-0664	2	3.327	Q2
Clinical Genetics	0009-9163	2	3.326	Q2
Clinical Immunology	1521-6616	3	3.99	Q2
Clinical Infectious Diseases	1058-4838	1	8.216	D1
Clinical Kidney Journal	1753-0784	1		Not Indexed
Clinical Microbiology and Infection	1198-743X	2	5.292	D1
Clinical Nutrition	0261-5614	2	4.548	Q1
Clinical Rheumatology	0770-3198	2	2.365	Q3
Clinical Sarcoma Research	2045-3329	1		Not Indexed
Clinical Science	0143-5221	1	4.936	Q1
Cochlear Implants International	1754-7628	2		Not Indexed
Contemporary Nurse	1037-6178	1	0.836	Q3
COPD-Journal of Chronic Obstructive Pulmonary Disease	1541-2555	1	2.576	Q3
Córnea	0277-3740	1	2.01	Q2
Critical Care	1466-609X	1	5.358	Q1
Critical Care Medicine	0090-3493	1	7.05	Q1
Critical Reviews in Oncology Hematology	1040-8428	3	4.971	Q1
Current Allergy and Asthma Reports	1529-7322	1	3.735	Q2
Current Cancer Drug Targets	1568-0096	1	2.992	Q3
Current Medical Research and Opinion	0300-7995	1	2.757	Q1
Current Opinion in Allergy and Clinical Immunology	1528-4050	1	3.463	Q2
Cytotherapy	1465-3249	2	3.203	Q2
Chest	0012-3692	3	6.044	Q1
Chinese Journal of Cancer Research	1000-9604	1	3	Q2
Chronic Respiratory Disease	1479-9723	1	1.818	Q3
Data in Brief	2352-3409	1		Not Indexed
Dermatologic Therapy	1396-0296	1	1.093	Q4
Diabetes	0012-1797	1	8.684	D1
Diabetes Care	0149-5992	1	11.857	D1
Diabetes-Metabolism Research and Reviews	1520-7560	1	3.263	Q2
Disease Models & Mechanisms	1754-8403	2	4.691	Q1
Drug and Alcohol Dependence	0376-8716	1	3.222	Q1
Drug Safety	0114-5916	1	3.435	Q1
Ebiomedicine	2352-3964	3		Not Indexed
Ecancermedicalscience	1754-6605	3		Not Indexed
Elife	2050-084X	1	7.725	D1
Embo Molecular Medicine	1757-4676	1	9.249	D1
E-Memoires de L'Academie Nationale de Chirurgie	1634-0647	1		Not Indexed
Emergencias	1137-6821	2	3.028	Q1
Emerging Infectious Diseases	1080-6040	1	8.222	D1
Endocrinología y Nutrición	1575-0922	2	1.106	Q4
Endocrinology Diabetes and Metabolism Case Reports	2052-0573	1		Not Indexed
Energies	1996-1073	1	2.262	Q2
Enfermedades Infecciosas y Microbiología Clínica	0213-005X	20	1.714	Q3
Enfermería Clínica	1130-8621	1		Not Indexed

Environmental Research	1096-0953	1	3.835	Q1
EuroIntervention	1774-024X	2	5.165	Q1
Europace	1099-5129	4	4.53	Q1
European Annals of Allergy and Clinical Immunology	1764-1489	1	Not Indexed	
European Archives of Oto-Rhino-Laryngology	0937-4477	3	1.66	Q2
European Food Research and Technology	1438-2377	1	1.664	Q2
European Geriatric Medicine	1878-7649	1	1.336	Q4
European Heart Journal	0195-668X	4	19.651	D1
European Heart Journal-Acute Cardiovascular Care	2048-8726	1	Not Indexed	
European Heart Journal-Cardiovascular Pharmacotherapy	2055-6837	2	Not Indexed	
European Journal of Anatomy	1136-4890	1	Not Indexed	
European Journal of Cancer Prevention	0959-8278	1	2.556	Q3
European Journal of Cardio-Thoracic Surgery	1010-7940	1	3.759	Q1
European Journal of Cardiovascular Nursing	1474-5151	1	2.763	D1
European Journal of Clinical Investigation	0014-2972	2	2.714	Q1
European Journal of Clinical Microbiology & Infectious Diseases	0934-9723	1	2.727	Q2
European Journal of Clinical Pharmacology	0031-6970	1	2.902	Q2
European Journal of Emergency Medicine	0969-9546	1	2.025	Q2
European Journal of Endocrinology	0804-4643	2	4.101	Q1
European Journal of Haematology	0902-4441	5	2.653	Q2
European Journal of Heart Failure	1388-9842	1	6.968	D1
European Journal of Human Genetics	1018-4813	2	4.287	Q1
European Journal of Internal Medicine	0953-6205	2	2.96	Q1
European Journal of Medical Genetics	1769-7212	1	2.137	Q3
European Journal of Neurology	1351-5101	1	3.988	Q1
European Journal of Nutrition	1436-6207	2	4.37	Q1
European Journal of Obstetrics & Gynecology and Reproductive Biology	0301-2115	1	1.666	Q3
European Journal of Orthopaedic Surgery & Traumatology	1633-8065	1	Not Indexed	
European Journal of Pediatric Surgery	0939-7248	6	1.313	Q3
European Journal of Pharmacology	0014-2999	1	2.896	Q2
European Journal of Preventive Cardiology	2047-4873	3	3.606	Q2
European Neuropsychopharmacology	0924-977X	1	4.239	Q1
European Spine Journal	0940-6719	2	2.563	Q1
European Surgery-Acta Chirurgica Austriaca	1682-8631	1	0.287	Q4
European Urology	0302-2838	1	16.265	D1
European Urology Supplements	1569-9056	1	3.462	Q1
Eurosurveillance	1560-7917	1	7.202	D1
Experimental Gerontology	0531-5565	1	3.34	Q1
Expert Opinion on Drug Metabolism & Toxicology	1742-5255	1	3.027	Q2
Expert Opinion on Investigational Drugs	1354-3784	1	4.716	Q1
Expert Opinion on Pharmacotherapy	1465-6566	3	3.894	Q1
Expert Opinion on Therapeutic Targets	1472-8222	1	4.873	Q1
Expert Review of Anticancer Therapy	1473-7140	1	2.212	Q3
Expert Review of Anti-Infective Therapy	1478-7210	1	3.139	Q2
Expert Review of Clinical Immunology	1744-666X	1	3.27	Q2
Expert Review of Hematology	1747-4086	5	2.246	Q3
Expert Review of Neurotherapeutics	1473-7175	1	3.149	Q2
Farmacia Hospitalaria	0214-753X	2	Not Indexed	
Febs Journal	1742-464X	1	3.902	Q2
Food & Function	2042-6496	1	3.247	Q1
Food & Nutrition Research	1654-6628	1	2.039	Q2
Free Radical Biology and Medicine	0891-5849	1	5.606	Q1
Frontiers in Aging Neuroscience	1663-4365	2	4.504	Q1
Frontiers in Immunology	1664-3224	1	6.429	Q1
Frontiers in Molecular Neuroscience	1662-5099	1	5.076	Q1
Frontiers in Neuroanatomy	1662-5129	2	3.267	D1
Frontiers in Pharmacology	1663-9812	2	4.4	Q1
Frontiers in Physiology	1664-042X	1	4.134	Q1
Frontiers in Psychology	1664-1078	1	2.323	Q2
Future Cardiology	1479-6678	3	Not Indexed	
Future Medicinal Chemistry	1756-8919	1	3.556	Q1
Future Oncology	1479-6694	1	2.131	Q3
Future Virology	1746-0794	1	0.958	Q4

Gastroenterología y Hepatología	0210-5705	1	0.917	Q4
General Hospital Psychiatry	0163-8343	1	2.279	Q3
Genetic Counseling	1015-8146	1	0.236	Q4
Genetic Epidemiology	0741-0395	1	1.884	Q2
Genetics and Molecular Biology	1415-4757	1	1.147	Q4
Genetics in Medicine	1098-3600	1	8.229	D1
Genome Medicine	1756-994X	1	7.071	D1
Geriatrics & Gerontology International	1444-1586	1	2.351	Q3
Gynecologic and Obstetric Investigation	1423-002X	1	1.415	Q4
Gynecologic Oncology	0090-8258	3	4.959	D1
Haematologica	0390-6078	1	7.702	D1
Haemophilia	1351-8216	7	3.569	Q2
Health & Place	1353-8292	1	2.541	Q2
Heart	1355-6037	4	6.059	Q1
Hepatology	0270-9139	3	13.246	D1
Hip International	1120-7000	1	1.055	Q3
Hipertensión y Riesgo Vascular	1989-4805	2	Not Indexed	
HIV Medicine	1464-2662	3	3.257	Q2
Human Genetics	0340-6717	2	4.637	Q1
Human Molecular Genetics	0964-6906	2	5.34	Q2
Human Reproduction Update	1355-4786	1	11.748	D1
Hypertension	0194-911X	1	6.857	D1
IEEE Systems Journal	1932-8184	1	3.882	D1
IEEE Transactions on Vehicular Technology	0018-9545	1	4.066	Q1
Immunotherapy	1750-743X	1	2.716	Q3
Indian Journal of Plastic Surgery	0970-0358	1	Not Indexed	
Inflammatory Bowel Diseases	1078-0998	2	4.525	Q1
Internal Medicine Journal	1444-0903	1	1.902	Q2
International Archives of Allergy and Immunology	1018-2438	1	2.72	Q3
International Journal of Antimicrobial Agents	0924-8579	1	4.307	Q1
International Journal of Cancer	0020-7136	1	6.513	Q1
International Journal of Cardiology	0167-5273	6	6.189	Q1
International Journal of Clinical Pharmacy	2210-7703	1	1.555	Q4
International Journal of Chronic Obstructive Pulmonary Disease	1178-2005	1	3.157	Q2
International Journal of Environmental Research and Public Health	1660-4601	1	2.101	Q2
International Journal of Gastronomy and Food Science	1878-450X	1	Not Indexed	
International Journal of Gynecological Cancer	1048-891X	4	2.369	Q2
International Journal of Gynecology & Obstetrics	0020-7292	2	2.174	Q2
International Journal of Immunogenetics	1744-3121	1	1.093	Q4
International Journal of Infectious Diseases	1201-9712	1	2.532	Q2
International Journal of Molecular Sciences	1422-0067	1	3.226	Q2
International Journal of Pediatric Otorhinolaryngology	0165-5876	1	1.159	Q3
International Journal of Stroke	1747-4930	1	3.314	Q2
International Journal of Systematic and Evolutionary Microbiology	1466-5026	1	2.134	Q3
International Journal of Tuberculosis and Lung Disease	1027-3719	1	2.468	Q3
Investigacion Clínica	0535-5133	1	0.493	Q4
JACC-Cardiovascular Interventions	1936-8798	1	8.841	D1
J AIDS-Journal of Acquired Immune Deficiency Syndromes	1525-4135	2	3.935	Q1
JAMA Cardiology	2380-6583	1	Not Indexed	
JAMA Dermatology	2168-6068	1	5.817	D1
JAMA-Journal of the American Medical Association	0098-7484	1	44.405	D1
JIMD Reports	2192-8312	1	Not Indexed	
Journal of Acute Disease	2221-6189	1	Not Indexed	
Journal of Aerosol Medicine and Pulmonary Drug Delivery	1941-2711	1	2.528	Q3
Journal of Agricultural and Food Chemistry	0021-8561	2	3.154	D1
Journal of Alzheimers Disease	1387-2877	2	3.731	Q2
Journal of Allergy and Clinical Immunology	0091-6749	2	13.081	D1
Journal of Allergy and Clinical Immunology-in Practice	2213-2198	3	5.317	Q1
Journal of Antibiotics	0021-8820	1	2.237	Q2
Journal of Antimicrobial Chemotherapy	0305-7453	3	5.071	D1
Journal of Applied Clinical Medical Physics	1526-9914	1	1.338	Q3
Journal of Arthroplasty	0883-5403	1	3.055	Q1
Journal of Back and Musculoskeletal Rehabilitation	1053-8127	1	0.912	Q3



2.8. Scientific Production

Journal of Biomedical Materials Research Part A	1549-3296	1	3.076	Q2
Journal of Bone and Mineral Metabolism	0914-8779	1	2.423	Q3
Journal of Cancer Research and Therapeutics	0973-1482	1	0.75	Q4
Journal of Cardiology	0914-5087	1	2.732	Q2
Journal of Cardiovascular Pharmacology and Therapeutics	1074-2484	1	3	Q2
Journal of Cardiovascular Surgery	0021-9509	1	2.179	Q2
Journal of Clinical and Experimental Dentistry	1989-5488	1	Not Indexed	
Journal of Clinical Anesthesia	0952-8180	1	1.667	Q3
Journal of Clinical Endocrinology & Metabolism	0021-972X	1	5.455	Q1
Journal of Clinical Gastroenterology	0192-0790	1	3.328	Q2
Journal of Clinical Hypertension	1524-6175	1	3.242	Q2
Journal of Clinical Immunology	0271-9142	3	3.253	Q2
Journal of Clinical Investigation	0021-9738	1	12.784	D1
Journal of Clinical Oncology	0732-183X	2	24.008	D1
Journal of Clinical Pathology	0021-9746	1	2.687	Q2
Journal of Clinical Pharmacy and Therapeutics	0269-4727	1	1.679	Q3
Journal of Clinical Sleep Medicine	1550-9389	1	3.429	Q2
Journal of Clinical Virology	1386-6532	3	3.051	Q2
Journal of Comparative Neurology	0021-9967	1	3.266	D1
Journal of Cystic Fibrosis	1569-1993	1	4.727	Q1
Journal of Chemotherapy	1120-009X	1	1.577	Q4
Journal of Diabetes and its Complications	1056-8727	1	2.734	Q3
Journal of Endourology	2152-4920	1	Not Indexed	
Journal of Epidemiology and Community Health	0143-005X	2	3.608	Q1
Journal of Exercise Rehabilitation	2288-176X	3	Not Indexed	
Journal of Functional Foods	1756-4646	1	3.144	Q1
Journal of Gastroenterology and Hepatology	0815-9319	1	3.452	Q2
Journal of General Virology	0022-1317	1	2.838	Q2
Journal of Gynecologic Oncology	2005-0380	1	3.14	Q1
Journal of Headache and Pain	1129-2369	1	2.141	Q1
Journal of High Energy Physics	1029-8479	1	6.063	Q1
Journal of Human Genetics	1434-5161	1	2.471	Q3
Journal of Hypertension	0263-6352	7	4.085	Q1
Journal of Immunotoxicology	1547-691X	1	2.021	Q3
Journal of Infection	0163-4453	3	4.201	Q1
Journal of Interventional Cardiology	0896-4327	1	1.88	Q3
Journal of Investigational Allergology and Clinical Immunology	1018-9068	13	3.094	Q2
Journal of Materials Science-Materials in Medicine	0957-4530	1	2.325	Q3
Journal of Maternal-Fetal & Neonatal Medicine	1476-7058	3	1.826	Q3
Journal of Medicinal Chemistry	0022-2623	2	6.259	D1
Journal of Minimal Access Surgery	0972-9941	1	1.282	Q3
Journal of Molecular Diagnostics	1525-1578	1	4.526	Q1
Journal of NeuroInterventional Surgery	1759-8486	1	3.551	Q1
Journal of Nuclear Medicine	0161-5505	1	6.646	D1
Journal of Nutrition Health & Aging	1279-7707	2	2.772	Q2
Journal of Obstetrics and Gynaecology	0144-3615	1	0.629	Q4
Journal of Occupational Health	1341-9145	1	1.848	Q2
Journal of Oncology	1687-8450	1	Not Indexed	
Journal of Paediatrics and Child Health	1034-4810	1	1.572	Q3
Journal of Parenteral and Enteral Nutrition	0148-6071	2	4.22	Q1
Journal of Pediatric Ophthalmology & Strabismus	0191-3913	2	0.902	Q4
Journal of Pediatrics	0022-3476	2	3.874	D1
Journal of Pediatrics Review	2322-4398	1	Not Indexed	
Journal of Physical Chemistry Letters	1948-7185	1	9.353	D1
Journal of Reproductive Medicine	0024-7758	1	0.848	Q4
Journal of Rheumatology	0315-162X	1	3.15	Q2
Journal of Sexual Medicine	1743-6095	1	2.978	Q2
Journal of Stroke & Cerebrovascular Diseases	1052-3057	2	1.517	Q4
Journal of Surgical Oncology	0022-4790	1	2.993	Q1
Journal of the American Association for Laboratory Animal Science	1559-6109	1	1.195	Q2
Journal of the American College of Cardiology	0735-1097	6	19.896	D1
Journal of the American Heart Association	2047-9980	1	4.863	Q1


Journal of the American Medical Directors Association	1525-8610	3	5.775	D1
Journal of the American Society of Hypertension	1933-1711	2	3.263	Q2
Journal of the American Society of Nephrology	1046-6673	1	8.966	D1
Journal of the European Academy of Dermatology and Venereology	0926-9959	1	3.528	Q1
Journal of the National Comprehensive Cancer Network	1540-1405	1	4.675	Q2
Journal of the Neurological Sciences	0022-510X	1	2.295	Q3
Journal of Thrombosis and Haemostasis	1538-7933	1	5.287	Q1
Journal of Thrombosis and Thrombolysis	0929-5305	3	2.142	Q3
Journal of Translational Medicine	1479-5876	2	3.786	Q1
Journal of Trauma and Acute Care Surgery	2163-0755	1	3.403	Q1
Journal of Ultrasound in Medicine	0278-4297	4	1.547	Q3
Journal of Viral Hepatitis	1352-0504	1	4.122	Q1
Journal of Virology	0022-538X	1	4.663	Q1
Journal of Virus Eradication	2055-6640	1	Not Indexed	
Journal of Womens Health	1540-9996	1	2.322	Q2
Journals of Gerontology Series A-Biological Sciences and Medical Sciences	1079-5006	2	5.957	D1
JOVE-Journal of Visualized Experiments	1940-087X	1	1.232	Q2
Kidney & Blood Pressure Research	1420-4096	1	3.104	Q2
Kidney International	0085-2538	2	8.395	D1
Lancet	0140-6736	12	47.831	D1
Lancet Infectious Diseases	1473-3099	3	19.864	D1
Lancet Neurology	1474-4422	1	26.284	D1
Leukemia & Lymphoma	1042-8194	1	2.755	Q2
Lipids in Health and Disease	1476-511X	1	2.073	Q3
Liver International	1478-3223	3	4.116	Q1
Lung Cancer	0169-5002	1	4.294	Q1
Lung India	0970-2113	1	Not Indexed	
Lymphatic Research and Biology	1539-6851	1	1.551	Q3
Maturitas	0378-5122	1	3.255	Q1
Mayo Clinic Proceedings	0025-6196	1	6.686	D1
Mechanisms of Ageing and Development	0047-6374	1	3.087	Q2
Medchemcomm	2040-2503	1	2.608	Q2
Medicina Clínica	0025-7753	15	1.125	Q3
Medicina Intensiva	0210-5691	5	1.231	Q4
Medicine	0025-7974	2	1.803	Q2
Melanoma Research	0960-8931	1	2.615	Q2
Methods in Molecular Biology	1940-6029	1	Not Indexed	
Microbial Biotechnology	1751-7907	1	3.513	Q2
Minerva Anestesiologica	0375-9393	2	2.623	Q2
Mitochondrion	1567-7249	1	3.704	Q2
Molecular and Cellular Biology	0270-7306	1	4.398	Q1
Molecular Cancer Therapeutics	1535-7163	1	5.764	Q1
Molecular Genetics & Genomic Medicine	2324-9269	3	Not Indexed	
Molecular Genetics and Metabolism	1096-7192	1	3.769	Q1
Molecular Immunology	0161-5890	1	3.326	Q2
Molecular Neurobiology	0893-7648	2	6.19	D1
Molecular Psychiatry	1359-4184	1	13.204	D1
Molecular Vision	1090-0535	1	2.057	Q2
Multiple Sclerosis Journal	1352-4585	1	4.84	Q1
Muscle & Nerve	0148-639X	1	2.605	Q2
Mycoses	0933-7407	1	2.252	Q2
Nature	0028-0836	1	40.137	D1
Nature Communications	2041-1723	2	12.124	D1
Nature Genetics	1061-4036	2	27.959	D1
Nature Medicine	1078-8956	1	29.886	D1
Nature Reviews Rheumatology	1759-4790	1	12.188	D1
Nefrología	0211-6995	3	1.183	Q4
Neonatology	1661-7800	1	2.598	Q1
Nephrology Dialysis Transplantation	1460-2385	3	4.47	Q1
Neurochemistry International	0197-0186	1	3.262	Q2
Neuroimage-Clinical	2213-1582	1	4.348	Q1
Neurologia	0213-4853	3	2.103	Q3



2.8. Scientific Production

Neurology-Neuroimmunology & NeuroInflammation	2332-7812	1		Not Indexed
Neuromuscular Disorders	0960-8966	1	2.969	Q2
Neuropharmacology	0028-3908	1	5.012	D1
Neuroradiology	0028-3940	1	2.093	Q2
Neurotoxicology	0161-813X	2	3.1	Q2
New England Journal of Medicine	0028-4793	5	72.406	D1
NPJ Primary Care Respiratory Medicine	2055-1010	1	2.793	D1
Nucleic Acids Research	0305-1048	1	10.162	D1
Nucleosides Nucleotides & Nucleic Acids	1525-7770	3	0.868	Q4
Nutrición Hospitalaria	0212-1611	4	0.747	Q4
Nutrients	2072-6643	1	3.55	Q2
Obesity	1930-7381	1	3.783	Q1
Obesity Surgery	0960-8923	1	3.947	D1
Ocular Immunology and Inflammation	0927-3948	1	2.453	Q2
Oncogene	0950-9232	3	7.519	D1
Oncogenesis	2157-9024	1	4.143	Q2
Oncoimmunology	2162-402X	3	7.719	D1
Oncotarget	1949-2553	10	5.168	Q1
Open Forum Infectious Diseases	2328-8957	4		Not Indexed
Open Orthopaedics Journal	1874-3250	1		Not Indexed
Ophthalmic Genetics	1381-6810	1	1.277	Q3
Organic Geochemistry	0146-6380	1	3.081	Q1
Orphanet Journal of Rare Diseases	1750-1172	2	3.507	Q2
Orthopedics	0147-7447	1	1.143	Q3
Osteoporosis International	0937-941X	2	3.591	Q2
PACE-Pacing and Clinical Electrophysiology	0147-8389	1	1.486	Q3
Pain Medicine	1526-2375	2	2.82	Q1
Pain Physician	1533-3159	1	2.84	Q2
Pain Practice	1530-7085	1	2.495	Q2
Pain Research & Management	1203-6765	1	2.027	Q3
Pain Research and Treatment	2090-1542	1		Not Indexed
Parasites & Vectors	1756-3305	1	3.08	Q1
Patient Preference and Adherence	1177-889X	2	1.798	Q2
Pediatric Allergy and Immunology	0905-6157	1	3.775	D1
Pediatric and Developmental Pathology	1093-5266	15	1.089	Q4
Pediatric Dermatology	0736-8046	2	0.99	Q4
Pediatric Hematology and Oncology	0888-0018	2	1.12	Q3
Pediatric Infectious Disease Journal	0891-3668	7	2.486	Q1
Pediatric Research	0031-3998	4	2.882	Q1
Pediatric Surgery International	0179-0358	1	1.181	Q3
Peritoneal Dialysis International	0896-8608	1	1.557	Q3
Pflugers Archiv-European Journal of Physiology	0031-6768	1	3.156	Q2
Pharmacoepidemiology and Drug Safety	1053-8569	6	2.552	Q2
Pharmacogenetics and Genomics	1744-6872	1	2.184	Q2
Pharmacogenomics	1462-2416	2	2.35	Q3
Pharmacogenomics Journal	1470-269X	1	3.815	Q1
Pharmacological Research	1043-6618	2	4.48	Q1
Pharmacology & Therapeutics	0163-7258	1	11.127	D1
Pituitary	1386-341X	1	2.481	Q3
Placenta	0143-4004	1	2.759	Q1
Plastic and Reconstructive Surgery	0032-1052	1	3.784	Q1
Plos Genetics	1553-7404	1	6.1	D1
Plos Neglected Tropical Diseases	1935-2735	1	3.834	D1
Plos One	1932-6203	24	2.806	Q1
Pm&R	1934-1482	1	1.785	Q2
Primary Care Diabetes	1751-9918	1	1.381	Q3
Proceedings of the National Academy of Sciences of the United States of America	0027-8424	2	9.661	D1
Quality of Life Research	0962-9343	1	2.344	Q2
Radiología	1578-178X	1		Not Indexed
Respiration	0025-7931	1	2.772	Q2
Respiratory Care	0020-1324	1	1.733	Q4

Resuscitation	0300-9572	1	5.23	D1
Reumatología Clínica	1699-258X	3		Not Indexed
Revista Brasileira de Anestesiología	0034-7094	3	0.903	Q4
Revista Clínica Española	0014-2565	5	0.971	Q3
Revista de Calidad Asistencial	1887-1364	1		Not Indexed
Revista de Neurología	0210-0010	9	0.743	Q4
Revista de Psiquiatría y Salud Mental	1888-9891	1	2.227	Q3
Revista Española de Anestesiología Y Reanimación	2340-3284	13		Not Indexed
Revista Española de Cardiología	0300-8932	32	4.485	Q2
Revista Española de Cirugía Ortopédica Y Traumatología	1988-8856	3		Not Indexed
Revista Española de Geriátria Y Gerontología	1578-1747	1		Not Indexed
Revista Española de Medicina Nuclear e Imagen Molecular	2253-654X	1	0.951	Q4
Revista Española de Nutrición Humana Y Dietética	2173-1292	4		Not Indexed
Revista Española de Quimioterapia	0214-3429	1	0.75	Q4
Revista Española de Salud Pública	1135-5727	4	0.69	Q4
Revista Iberoamericana de Micología	1130-1406	3	1.33	Q3
Revista Portuguesa de Cardiología	0870-2551	1	1.195	Q4
Rheumatology	1462-0324	1	4.818	Q1
Rheumatology International	0172-8172	1	1.824	Q3
RSC Advances	2046-2069	1	3.108	Q2
Scandinavian Journal of Rheumatology	0300-9742	1	2.667	Q2
Scientific Reports	2045-2322	10	4.259	Q1
Semergen	1578-8865	8		Not Indexed
Seminars in Arthritis and Rheumatism	0049-0172	3	4.498	Q1
Seminars in Nephrology	0270-9295	1	3.598	Q1
Sleep Medicine Reviews	1087-0792	1	8.958	D1
Spanish Journal of Psychology	1138-7416	1	0.502	Q4
Spine	0362-2436	1	2.499	Q2
Spine Deformity	2212-1358	1		Not Indexed
Stem Cells International	1687-966X	1	3.54	Q2
Stem Cells Translational Medicine	2157-6564	1	4	Q1
Stroke	0039-2499	1	6.032	D1
Supportive Care in Cancer	0941-4355	1	2.698	Q1
Taiwanese Journal of Obstetrics & Gynecology	1028-4559	1	0.925	Q4
Targeted Oncology	1776-2596	1	3.438	Q2
Techniques in Coloproctology	1123-6337	1	2.342	Q2
Therapeutic Hypothermia and Temperature Management	2153-7658	1	1.787	Q4
Thoracic and Cardiovascular Surgeon	0171-6425	1	1.424	Q3
Thorax	0040-6376	1	8.272	D1
Thrombosis and Haemostasis	0340-6245	5	5.627	D1
Thrombosis Research	0049-3848	3	2.65	Q2
Tobacco Control	0964-4563	1	5.469	Q1
Torture	1997-3322	6		Not Indexed
Toxicology and Applied Pharmacology	0041-008X	2	3.791	Q1
Translational Research	1931-5244	1	4.652	Q1
Translational Stroke Research	1868-4483	1	4.503	Q1
Transplant Immunology	0966-3274	1	1.78	Q3
Transplantation Reviews	0955-470X	1	3.113	Q2
Trends in Genetics	0168-9525	1	10.844	D1
Tumor Biology	1010-4283	1	3.65	Q2
Ultrasound in Obstetrics & Gynecology	1469-0705	1	4.71	D1
Ultrasound International Open	2509-596X	1		Not Indexed
Urologic Oncology-Seminars and Original Investigations	1078-1439	1	3.767	Q1
Urology	0090-4295	1	2.309	Q2
Virus Research	0168-1702	2	2.628	Q3
Viruses-Basel	1999-4915	1	3.465	Q2
World Journal of Gastroenterology	1007-9327	3	3.365	Q2
World Journal of Gastrointestinal Endoscopy	1948-5190	1		Not Indexed
World Journal of Orthopedics	2218-5836	1		Not Indexed
World Journal of Pediatrics	1708-8569	1	1.164	Q3





2.9 CIBERs and RETICs

2.9.1. CIBER- Network Biomedical Research Center

Acronym	CIBER	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
CIBER-bbn	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Instituto de Salud Carlos III	Vilaboa Díaz, Nuria Elda	Bone Pathophysiology and biomaterials	31/12/2017
CIBERehd	Networked Biomedical Research Center for Hepatic and Digestive Diseases	Instituto de Salud Carlos III	García-Samaniego Rey, Javier	Associated Clinician	31/12/2017
CIBERer	Networked Biomedical Research Center for Rare Diseases	Instituto de Salud Carlos III	López Trascasa, Margarita	Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System	31/12/2017
			Lapunzina Badía, Pablo	Cell Therapy and Gene Metastasis	31/12/2017
CIBEResp	Networked Biomedical Research Center for Public Health and Epidemiology	Instituto de Salud Carlos III	Rodríguez Artalejo, Fernando	Cardiovascular Epidemiology and Nutrition	31/12/2017
CIBERned	Networked Biomedical Research Center for Neurodegenerative Diseases	Instituto de Salud Carlos III	Cuadrado Pastor, Antonio	Neuroprotective strategies in neurodegenerative diseases	31/12/2017

2.9.2. RETICs- Networks for Cooperative Research in Health

Project	Acronym	Network	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
RD12/0018/0023	RICET	Tropical Disease Cooperative Research Network	Instituto de Salud Carlos III	Díaz Menéndez, Marta	AIDS and Infectious Diseases	31/12/2017
RD12/0026/0004	SAMID	Research Network for Maternal and Child Health and Development	Instituto de Salud Carlos III	Cabañas González, Fernando	Congenital Malformation Surgery	31/12/2017
RD12/0036/007	RTICC	Cooperative Cancer Research Network	Instituto de Salud Carlos III	Cano García, Amparo	Mechanisms of Tumour Progression	30/06/2017
PT13/0006/0012	ITEMAS	Medical Technology Innovation Platform	Instituto de Salud Carlos III	de Castro Carpeño, Javier	Translational Oncology	31/12/2017
PT13/0010/0003	ReTBioH	Biobanks Platform	Instituto de Salud Carlos III	García Fernández, María Eugenia	Cellular Engineering	31/12/2017
RD12/0014/0006	INVICTUS	Vascular and Cerebral Diseases Network	Instituto de Salud Carlos III	Díez Tejedor, Exuperio	Neurology and Cerebrovascular Diseases	31/12/2016
PT13/0002/0015	UCICEC	Research and Clinical Trials Units Platform	Instituto de Salud Carlos III	Frías Iniesta, Jesús	Clinical Pharmacology	31/12/2017
RD12/0017/0016	RIS	Research Network for AIDS	Instituto de Salud Carlos III	González García, Juan	AIDS and Infectious Diseases	31/12/2017
RD12/0042/0063	RIC	Cardiovascular Research Network	Instituto de Salud Carlos III	López-Sendón Hentschel, José Luis	Research on Invasive Clinical Cardiology - ICCI-Paz	31/12/2017
RD12/0026/0011	SAMID	Research Network for Maternal and Child Health and Development	Instituto de Salud Carlos III	Martínez Martínez, Leopoldo	Congenital Malformation Surgery	31/12/2017
RD12/0009/0012	RIER	Investigational Network in Inflammation and Rheumatic Diseases	Instituto de Salud Carlos III	Miranda Carús, María Eugenia	Immuno-Rheumatology	31/12/2017
RD12/0036/0021	RTICC	Cooperative Cancer Research Network	Instituto de Salud Carlos III	Muñoz Terol, Alberto	Mechanisms of Tumour Progression	30/06/2017
RD12/0043/0019	RETICEF	Cooperative Research Network in Aging and Fragility	Instituto de Salud Carlos III	Otero Puime, Ángel	Aging and Fragility in the Elderly	31/12/2017
RD12/0042/0024	RIC	Cardiovascular Research Network	Instituto de Salud Carlos III	Salaices Sánchez, Mercedes	Vascular Physiology and Pharmacology	30/06/2017
S2010-BMD2321	FIBROTEAM	Molecular mechanisms, experimental models and therapeutic approaches in the organic fibrosis: from the biological mediator to the clinical application	Comunidad de Madrid	Selgas Gutiérrez, Rafael	Nephrology	30/04/2016
RD12/0021/0004	REDINREN	Research Network for Renal Diseases	Instituto de Salud Carlos III	Selgas Gutiérrez, Rafael	Nephrology	31/12/2017
RD12/0026/0011	SAMID	Research Network for Maternal and Child Health and Development	Instituto de Salud Carlos III	Tovar Larrucea, Juan Antonio	Congenital Malformation Surgery	31/12/2016
MAT2014-52905-REDT	BIOIMPLANT	Research Network for the development of titanium implants functionalized	Ministerio de Economía y Competitividad	Vilaboa Díaz, Nuria Elda	Bone Pathophysiology and Biomaterials	31/05/2017
P2013/MIT-2862	FIObi	Research Network for multifunctional materials for the challenges of the Society	Comunidad de Madrid	Vilaboa Díaz, Nuria Elda	Bone Pathophysiology and Biomaterials	30/09/2018



2.10 Institutional Projects



TransplantChild (<http://www.transplantchild.com>) is an ERN for Paediatric transplantation (PT), both Solid Organ Transplantation (SOT) and Hematopoietic Stem Cell Transplantation (HSCT) which are low-prevalence and complex conditions that require highly specialized expertise and resources. It's the only ERN coordinated by Spanish Center (Hospital Universitario La Paz-FIBHULP), and the only focused in a therapeutic process.

The network scope is a cross-cutting approach to supports common areas in different types of transplants as immunosuppression, rejection, tolerance, risk of infection and psychosocial wellbeing.

Main lines of Action

Mission

TransplantChild aims to improve life expectancy and quality of life for EU paediatric patients requiring transplantation, by:

- Ensuring their access through the network to the best possible advice on diagnostic, care practices and support procedures, considering a cross-cutting approach.
- Developing and joining efforts within the Network & stakeholders for integrative, innovative and better procedures, information, training, knowledge and expertise.


Vision

To become a network of excellence for patients / families based on their health outcomes achieved throughout the life of the transplanted patient.

- Is based on innovative monitoring techniques and evidence-based treatments.
- Has highly specialized multidisciplinary teams committed to improving the quality of life of patients and their families, research, and dissemination of knowledge.


Members of the network

TransplantChild is integrated by 18 Healthcare Providers (HCP) institutions from 11 Members States. Together, ERN members advice on the patient's diagnosis, treatment and support during the transplant process (pre-transplant, transplant surgery and post-transplant phases).



Strategic areas

- To improve **patient healthcare** by facilitating the patient/family empowerment, access to information, experience and necessary knowledge to facilitate their decision-making and self-care.
- To harmonise clinical best practices by the development of **clinical practice guidelines**.
- Identifying, aligning and prioritising research and innovation focused on facilitating continuous improvement transplanted patient care.
- To harmonise and **spread knowledge** exchanging and disseminating knowledge and best practices within and outside the network.
- To Identify and fulfill **education and training** in PT, promoting the use of standardized continuous education training programmes.
- TO facilitate the development of effective organisational structures and to define the mechanisms needed for planning-monitoring and **organization, quality and safety**.






Added value of the Network

- The scarcity and fragmentation of specialist knowledge are the main reasons why patients may not find a satisfactory treatment and follow-up program.
- TransplantChild aims to consolidate knowledge and expertise scattered across countries. This will result in:
 - Better chances for patients to receive an accurate diagnosis and advice on the best treatment and support for their specific condition.
 - Giving healthcare providers access to a much larger pool of expertise.
 - Facilitating the patients' access to care, improving their health care outcomes and the sustainability of this complex procedure for national healthcare systems.



2.11 Internationalization



3 INFORMATION GROUPS BY AREA



3.1 Neuroscience Area

Documents: **106** IF: **384.544**
 Originals: **88** IF: **326.414**
 DI: **23** QI: **49**



3.2 Cardiovascular Area

Documents: **224** IF: **1,372.682**
 Originals: **169** IF: **1,118.856**
 DI: **41** QI: **98**



3.3 Infectious Diseases and Immunity Area

Documents: **212** IF: **956.421**
 Originals: **154** IF: **641.204**
 DI: **38** QI: **86**



3.4 Large System Pathologies Area

Documents: **291** IF: **1,309.496**
 Originals: **219** IF: **1,089.056**
 DI: **44** QI: **108**



3.5 Cancer and Human Molecular Genetics Area

Documents: **120** IF: **581.068**
 Originals: **102** IF: **522.905**
 DI: **20** QI: **58**



3.6 Surgery, Transplant and Health Technologies Area

Documents: **174** IF: **351.686**
 Originals: **141** IF: **281.096**
 DI: **11** QI: **35**



3.1 Neuroscience Area

Exuperio Díez Tejedor

Documents: **106** IF: **384.544**

Originals: **88** IF: **326.414**

DI: **23** QI: **49**

- Psychiatry and Mental Health Group
- Neurology and Cerebrovascular Diseases Group
- Neuroprotective Strategies in Neurodegenerative Diseases Group
- Structure, Neurochemistry and Plasticity of Neural Circuits of the Cerebral Cortex and Thalamus Group
- Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group

PSYCHIATRY AND MENTAL HEALTH GROUP



Publications: **9**

Impact Factor: **16.947**

QI: **2**

Consuelo de Dios Perrino

Facultativo Especialista de Área en Psiquiatría. HULP

Blanca Amador Sastre

Facultativo Especialista de Área en Psicología Clínica. HULP

Elena Barbero Val

Licenciada. HULP

Carmen Bayón Pérez

Facultativo Especialista de Área en Psiquiatría. HULP
Profesora Asociada. Facultad de Medicina. UAM

María Fe Bravo Ortiz

Jefe de Servicio de Psiquiatría. HULP
Profesora Asociada. Facultad de Medicina. UAM

Rosa Calvo Sagardoy

Psicóloga Clínica. Servicio de Psiquiatría. HULP

Susana Cebolla Lorenzo

Facultativo Especialista de Área en Psiquiatría. HULP

María Teresa González Salvador

Facultativo Especialista de Área en Psiquiatría. HULP

Nieves González Suárez

Facultativo Especialista de Área en Psiquiatría. HULP

Ana Hospital Moreno

Facultativo Especialista de Área en Psicología Clínica. HULP

Eduardo Jiménez Sola

Facultativo Especialista de Área en Psiquiatría. HULP

Ángela Palao Tarrero

Facultativo Especialista de Área en Psiquiatría. HULP

Pau Pérez Sales

Facultativo Especialista de Área en Psiquiatría. HULP

Beatriz Rodríguez Vega

Facultativo Especialista de Área en Psiquiatría. HULP
Profesora Asociada. Facultad de Medicina. UAM

Rosa Villanueva Peña

Facultativo Especialista de Área en Psiquiatría. HULP

Strategic Objective

The group is devoted to assess the efficacy of psychotherapeutic techniques as adjunctive to other therapeutic measures in mental disorders and other medical diseases.

Their main areas of investigation are: research in bipolar disorder, severe mental disorder, and other medical disorders such as multiple sclerosis, cancer and chronic pain. We participate in clinical trials on new treatments and specific therapies in order to improve and the prognosis of these disorders

We are specially focused in the assessment of the efficacy and effectiveness of techniques such as Mindfulness and we evaluate hypothetical mediators of response, such as neurotrophic factors or factors related to inflammatory response.

Moreover, the group is involved in the evaluation of new treatments or new indications in mental disorders through the participation in clinical trials.

Research Lines

Psychotherapeutic interventions in mental disorders.

Research Activity

DOCTORAL THESES

Moreno Pérez A. Teoría y práctica de la supervisión. Análisis del discurso de supervisores y psicoterapeutas [dissertation]. Madrid: UAH: 2016 (14/04/2016).

Directors: Rodríguez Vega B, Fernández Liria A.



BOOKS AND BOOK CHAPTERS

Roca M, García E, Bernardo M, Pérez V, Vieta E, de Dios C, Serrano M. Criterios de calidad en psiquiatría. Esquizofrenia. Depresión. Trastorno Bipolar. Madrid: Luzan 5, 2016.

Pérez Sales P. Tortura psicológica: definición, evaluación y medida. Madrid: Desclee de Brower, 2016.

PUBLICATIONS

- Bayón-Pérez C, Hernando A, Álvarez-Comino MJ, Cebolla S, Serrano L, Gutiérrez F, Montesinos F, Lagarde M, Bisbal O, Mataranz M, Rubio R, Pulido F. Toward a comprehensive care of HIV patients: Finding a strategy to detect depression in a Spanish HIV cohort. *AIDS Care*. 2016; 28(7):834-41. Article. IF: 1.824; Q2.
- Muñoz San José A, Oreja-Guevara C, Cebolla Lorenzo C, Carrillo Notario L, Rodríguez Vega B, Bayón Pérez C. Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions. *Neurología*. 2016; 31(2):113-20. Review. IF: 2.103; Q3
- Lubrini G, Lago MR, Periañez JA, Barranco AT, de Dios C, Fernández-Fourier M, Tejedor ED, García AF. The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis. *Mult Scler*. 2016; 22(12):1607-15. Article. IF: 4.84; Q1
- Medel-Herrero A, Gómez-Beneyto M, Saz-Parkinson Z, Bravo-Ortiz MF, Amate JM. Discordance between two national health statistics sources (EMH and EESCR) 1990-2009. Analysis of psychiatric morbidity. *Rev Psiquiatr Salud Ment*. 2016; 9(1):22-30. Article. IF: 2.227; Q3
- Navarro-Lashaya MA, Pérez-Sales P, López Neyr G, Martínez Maitane A, Morentín B. Incommunicado detention and torture in Spain part IV: Psychological and psychiatric consequences of ill-treatment and torture: trauma and human worldviews. *Torture*. 2016; 26(3):34-45. Article. Not Indexed
- Pacchiarotti I, León-Caballero J, Murru A, Verdolini N, Furio MA, Pancheri C, Valentí M, Samalin L, Roige ES, González-Pinto A, Montes J, Benabarre A, Crespo JM, Perrino CD, Goikolea JM, Gutiérrez-Rojas L, Carvalho AF, Vieta E. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. *Eur Neuropsychopharm*. 2016; 26(10):1562-78. Review. IF: 4.239; Q1
- Pérez-Sales P, Morentín B, Barrenetxea O, Navarro-Lashayas MA. Incommunicado detention and torture in Spain part II: Enhanced credibility assessment based on the Istanbul Protocol. *Torture*. 2016; 26(3):8-20. Article. Not Indexed
- Pérez-Sales P, Navarro-Lashayas MA, Plaza A, Morentín B, Barrios Salinas O. Incommunicado detention and torture in Spain Part III: 'Five days is enough': the concept of torturing environments. *Torture*. 2016; 26(3):21-33. Article. Not Indexed
- Polo R, Blanch J, Locutura J, Arazo P, Bachiller P, Bayón C, Estrada V, Fernández JL, Fumaz C, Galindo MJ, Tome MG, Iribarren JA, Lozano F, Marino A, Mellado MJ, Muñoz-Moreno JA, Navarro ML, Navines R, Prieto JFP, Rojo A, Rousaud A, Hernández JS, Santos J, Tuset M. Executive summary of the consensus document on psychiatric and psychological aspects in adults and children with HIV infection. *Enferm Infecc Micr Cl*. 2016; 34(1):54-60. Article. IF: 1.714; Q3

PUBLIC PROJECTS

Bravo Ortiz MF, Arango López C. AGES: Ambiente y genes en esquizofrenia-grupos de investigación de la Comunidad de Madrid (AGES-S2010/BMD-2422). Consejería de Educación de la CAM. 2016-2017.

Management centre: FIBHGM

Bravo Ortiz MF, Rodríguez Vega B. Desarrollo de habilidades y actitudes para el establecimiento de la relación médico paciente a través de un programa online de entrenamiento en mindfulness. UAM. 2016-2017.

Management centre: UAM

de Dios Perrino C. Terapia cognitiva basada en mindfulness frente a intervención psicoeducativa en pacientes con trastorno bipolar con síntomas subsindrómicos depresivos: ensayo piloto randomizado (PI13/00352). ISCIII. 2014-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

Alcobendas Rueda RM. Registro de enfermedades autoinflammatorias en la Comunidad de Madrid. Swedish Orphan Biovitrum S.L. 2014-Ongoing.

Management centre: FIBHULP

Bayón Pérez C. Curso de investigación mindfulness en la práctica clínica. Astrazeneca Farmacéutica Spain S.A. 2012-Ongoing.

Management centre: FIBHULP

Bravo Ortiz MF. Jornadas de investigación en el ámbito de intervenciones grupales en salud mental. Astrazeneca Farmacéutica Spain S.A. 2011-Ongoing.

Management centre: FIBHULP

Bravo Ortiz MF. Programa de ayuda a la formación en investigación en centros de investigación. Fundación Alicia Koplowitz. 2015-Ongoing.

Management centre: FIBHULP

Bravo Ortiz MF. XIV Jornadas de investigación en psiquiatría y salud mental: cognición, emoción y salud mental. Janssen-Cilag España S.A. 2014-Ongoing.

Management centre: FIBHULP

Bravo Ortiz MF. XVII Jornadas de investigación. Construyendo puentes entre la salud mental infarto-juvenil y de adultos. Janssen-Cilag España S.A. 2016-Ongoing.

Management centre: FIBHULP

Calvo Sagardoy R. Cambios biomagnéticos y cognitivo-emocionales en el tratamiento de las alteraciones de la imagen corporal en pacientes con trastornos en la conducta alimentaria. Colegio Oficial de Psicólogos de Madrid. 2005-Ongoing.

Management centre: FIBHULP

de Dios Perrino C. Regulación epigenética del sistema oxitocina-vasopresina y prosociabilidad en la manía bipolar. FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Rodríguez Vega B. Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos. Asociación Escuela Española de Psicoterapia. 2007-Ongoing.

Management centre: FIBHULP

Rodríguez Vega B. Evaluación cualitativa de dos estrategias de tratamiento para la depresión en un muestra de pacientes oncológicos. Asociación Escuela Española de Psicoterapia. 2007-Ongoing.

Management centre: FIBHULP

NEUROLOGY AND
CEREBROVASCULAR DISEASES GROUP

Publications: **57**

Impact Factor: **176.956**

QI: **19**

Exuperio Díez Tejedor

Jefe de Servicio de Neurología. HULP
Catedrático del Departamento de Neurología.
Facultad de Medicina. UAM

María José Aguilar-Amat Prior

Facultativo Especialista de Área en Neurología. HULP

María Alonso de Leciana Cases

Facultativo Especialista de Área en Neurología. HULP

Joaquín Arcas Martínez

Facultativo Especialista de Área en Neurología Pediátrica. HULP

Juan José Arévalo Manso

Enfermero. HULP

Francisco Javier Arpa Gutiérrez

Profesor Honorario. Facultad de Medicina. UAM

María Jesús Bullido Gómez-Heras

Profesor Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM "Severo Ochoa"

Fernando Carceller Benito

Jefe de Sección en Servicio de Neurocirugía. HULP

Sebastián Cerdán García-Esteller

Investigador Postdoctoral. Laboratorio de Imagen y Espectroscopia por Resonancia Magnética. IIB "Alberto Sols"

Delia Chaverri Rada

Facultativo Especialista de Área en Neurología. HULP

Jorge Eduardo Collazos Castro

Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Paraplégicos de Toledo

Josué Fernández Carnero

Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitarios La Salle

Andrés Francisco Fernández Prieto

Facultativo Especialista de Área en Radiología. HULP

Mireya Fernández-Fournier Fernández

Facultativo Especialista de Área en Neurología. HULP

Ana Frank García

Jefe de Sección en Servicio de Neurología. HULP
Profesora Titular de Neurología. Facultad de Medicina. UAM

Remedios Frutos Martínez

Facultativo Especialista de Área en Radiología. HULP

Blanca Fuentes Gimeno

Jefe de Sección en Servicio de Neurología. HULP
Profesor Asociado. UAM

Alfonso Gil Martínez

Fisioterapeuta. HULP

David Gómez Andrés

Investigador Predoctoral. Departamento de Anatomía, Histología y Neurociencia. UAM

Ana Cristina Guadaño Ferraz

Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. IIB "Alberto Sols"

María Dolores Gutiérrez Fernández

Investigadora Postdoctoral. Laboratorio de Neurociencias y Enfermedades Cerebrovasculares. HULP

María Hernández Barral

Facultativo Especialista de Área en Neurología. HULP

Rafael Herruzo Cabrera

Jefe de Sección de Medicina Preventiva y Salud Pública. HULP
Catedrático Facultad de Medicina. UAM

Vicente Iváñez Mora

Facultativo Especialista de Área en Neurología. HULP

Roy La Touche Arbizu

Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Manuel Lara Lara

Facultativo Especialista de Área en Neurología. HULP

Jesús María López Arrieta

Jefe de Sección de Geriátrica. Hospital de Cantoblanco — HULP
Profesor Asociado de Prácticas. Facultad de Psicología. UAM

María Pilar López Larrubia

Científica Titular. CSIC. IBB "Alberto Sols"



- Ibai López de Uralde Villanueva**
Investigador Predoctoral. Centro Superior de Estudios Universitarios La Salle
- Genny Lubrini**
Investigadora Postdoctoral. Servicio de Neurología. HULP
- Begoña Marín Aguilera**
Facultativo Especialista de Área en Radiología. HULP
- Juan Andrés Martín Gonzalo**
Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE
- Ángel Martín Montes**
Facultativo Especialista de Área en Neurología. HULP
- Antonio Martínez Bermejo**
Jefe de Servicio de Neurología Pediátrica. HULP
Profesor Asociado. Facultad de Medicina. UAM
- Mercedes Martínez Moreno**
Jefe de Sección en Servicio de Medicina Física y Rehabilitación. HULP
- Patricia Martínez Sánchez**
Facultativo Especialista de Área en Neurología. HULP
- Susana Moraleda Pérez**
Jefe de Sección de Medicina Física y Rehabilitación. HULP
- Pilar Negro Madrigal**
Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. UAM
- Susana Noval Martín**
Facultativo Especialista de Área en Oftalmología. HULP
- Jesús Oliván Palacios**
Facultativo Especialista de Área en Neurofisiología Clínica. HULP
- Laura Otero Ortega**
Investigadora Postdoctoral (Contrato Sara Borrell). HULP
- Joaquín Pardo Montero**
Profesor Titular. Centro Superior de Estudios Universitarios La Salle
- Alba París Alemany**
Profesora. Investigadora Predoctoral. Centro Superior de Estudios Universitarios La Salle
- Samuel Ignacio Pascual Pascual**
Jefe de Sección de Neurología Pediátrica. HULP
Profesor Asociado. Facultad de Medicina. UAM
- José Francisco Paz Solís**
Facultativo Especialista de Área en Neurocirugía. HULP
- Inmaculada Puertas Muñoz**
Facultativo Especialista de Área en Neurología. HULP
- Irene Pulido Valdeolivas**
Investigadora Predoctoral. Departamento de Anatomía, Histología y Neurociencia. HULP
- Estrella Rausell Tamayo**
Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. UAM
- José María Roda Frade**
Jefe de Servicio de Neurocirugía. HULP
- Irene Rodríguez Andonaegui**
Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE
- Berta Rodríguez Frutos**
Investigadora Postdoctoral. Laboratorio de Neurociencias y Enfermedades Cerebrovasculares. HULP
- Francisco Javier Rodríguez de Rivera Garrido**
Facultativo Especialista de Área en Neurología. HULP
- Aranzazu Royo Orejas**
Jefe de Sección de Radiología. HULP
- Gerardo Ruiz Ares**
Facultativo Especialista de Área en Neurología. HULP

- María Teresa Salas Campos**
Técnico Titulado Superior. Servicio de Neurología. HULP
- Patricia Sánchez García**
Técnico de Laboratorio. HULP
- Susana Santiago Pérez**
Facultativo Especialista de Área en Neurofisiología. HULP
- Borja Enrique Sanz Cuesta**
Facultativo Especialista de Área en Neurología (Contrato Río Hortega). HULP
- Antonio Tallón Barranco**
Facultativo Especialista de Área en Neurología. HULP
- Gema Torrijos Barbero**
Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-HULP
- Arturo Ugalde Canitrot**
Facultativo Especialista de Área en Neurofisiología Clínica. HULP
- Francisco Vivancos Matellano**
Facultativo Especialista de Área en Neurología. HULP

Strategic Objective

The research of this group is distributed in the following areas:

CEREBROVASCULAR

- Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic factors, extracellular vesicles and remyelinating drugs. Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).
- Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, exosomes) in the ischemic area.
- Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients. Comparative analysis of benefit and risk of primary mechanical thrombectomy versus intravenous thrombolysis in patients with acute ischemic stroke within the first 4.5 hours from onset.
- Study of the clinical (neurological and neuropsychological) and anthropological factors influencing functional recovery and reintegration of stroke patients as well as the compliance with the recommendations for secondary stroke prevention.

HEADACHES AND NEUROPATHIC PAIN

- Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.

NEURODEGENERATION

Amyotrophic Lateral Sclerosis

- ECAS scale (Edinburgh Cognitive Assessment Scale) validation and adaptation to Spanish language. Analysis of the different profiles of cognitive impairment in ALS patients by means of the ECAS scale (Edinburgh Cognitive Assessment Scale).
- SOPHIA Project: European Project on harmonization and optimization of the production and processing of samples for the study of biomarkers in ALS and other motor neuron diseases.
- Functional study of Autonomic Nervous System in Amyotrophic Lateral Sclerosis. Identification of differential patterns of the disease presentation and their impact on clinical outcome.

Alzheimer's disease

- Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer's disease.

Parkinson's disease

- Tremor as a negative predictive factor in developing dementia associated with Parkinson's disease.
- Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson's disease.

Hereditary ataxias

- Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.
- Participation in the Registry of the European Consortium EFACTS (European Friedreich's Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedreich's Ataxia.

COGNITION, BEHAVIOR AND NEUROLOGICAL ANTHROPOLOGY

- Analysis of the medium and long term results of workshops on post-stroke care attended by family and patients during the hospitalization time for an acute stroke on the degree of knowledge and acknowledgment of stroke and its risk factors.
- Evaluation of the perceived quality of physician-patient-family communication in cerebrovascular diseases and dementias.

NEUROIMMUNOLOGY

Multiple sclerosis

- Study of remyelinating substances as a biomarker white matter lesion in multiple sclerosis patients.
- Analysis of white matter biomarkers in Theiler's Murine Encephalomyelitis Virus (TMEV) animal model. Development of new reparative therapies based on the enhancement of remyelination in experimental animal model.
- Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.

AUTONOMIC NERVOUS SYSTEM

- Evaluation of the Autonomic Nervous System in movement disorders.
- Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.
- COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

NEUROMUSCULAR DISEASES

- Observational study of the clinical course of patients with Charcot-Marie-Tooth disease. Identification of prognostic factors.
- Efficacy of evaluation of Eslicarbazepine acetate in neuropathic pain in patients with peripheral neuropathies.

SLEEP


- Development and evaluation of intervention protocols in childhood insomnia treatment.
- Analysis of sleep microstructure in newborns with Prader Willi Syndrome.
- Study on the efficacy of child insomnia treatment with oral iron supplements against placebo.

EPILEPSY

- Evaluation of the benefit of the implementation of an outpatient clinic for first seizures.
- Analysis of factors influencing the recurrence of seizures, tolerance and adherence to drugs, during the first monotherapy in patients with epilepsy.
- Analysis of neuropsychological disorders in the primary generalized epilepsy.
- Evaluation of cognitive impact of antiepileptic treatment after the first seizure and at the start of the first monotherapy as well as in elderly patients with focal epilepsy.
- Influence of stress as a trigger of seizures in epilepsy.
- Depression and anxiety: impact on the therapeutic compliance of patients with epilepsy.
- Registry of patients treated with i.v. antiepileptic drugs. Analysis of indications, response and adverse events.

BRAIN DEVELOPMENT DISORDERS

- Study and functional classification of the gait of pediatric patients with cerebral palsy.
- Study and functional classification of the gait of patients with familial spastic paraparesis.
- Gait analysis as a tool for the differential diagnosis between child cerebral palsy and PEF in paediatric patients.





Research Lines

- Cerebrovascular diseases.
- Neurodegenerative diseases.
- Neuroimmunology. Multiple Sclerosis.
- Neuromuscular diseases and spinocerebellar ataxias. Motor neuron diseases Amyotrophic lateral sclerosis.
- Headache and neuropathic pain.
- Developmental disorders and neurological maturation (TRADESMA).

Research Activity

BOOKS AND BOOK CHAPTERS

Fuentes B, Martínez-Sánchez P, Ruiz-Ares G. Ictus por enfermedad carotídea. ¿De qué manera debo enfrentar esta situación? In: Agustín Godoy D. El libro de los interrogantes acerca del ACV. Colombia: Distribuna, 2016.

Fernández-Fournier Fernández M, Reverté Villarosa S. Traumatismo craneoencefálico. In: Lendínez Mesa A (Ed.). Enfermería en nerorehabilitación. Madrid: Elsevier, 2016. p.60-65

Fernández-Fournier Fernández M. Treating spasticity ameliorates quality of life and social functioning. In: 55 Relevant clinical cases of spasticity management in MS with THC:CBD oromucosal spray. vol.VII. Mayence: Editec, 2016. p.14-16

Palau F, Arpa J. Differential diagnosis of cerebellar ataxias. In: Gruol DL, Koibuchi N, Manto M, Molinari M, Schmahmann JD, Shen Y, (Eds.). Essentials of cerebellum and cerebellar disorders: a primer for graduate students. Switzerland: Springer International Publishing AG, 2016. p.523-529

Rodríguez de Rivera FJ. Patobiografía de Lou Gehrig. Esclerosis lateral amiotrófica. Madrid: You & Us S.A., 2016.

PUBLICATIONS

- Alcalde-Cabero E, Almazán-Isla J, López FJG, Callizo JRA, Avellanal F, Casasnovas C, Cemillán C, Cuadrado JI, Duarte J, Fernández-Pérez MD, Fernández O, Merino JAG, Montero RG, Montero D, Pardo J, Rodríguez-Rivera FJ, Ruiz-Tovar M, de Pedro-Cuesta J. Guillain-Barre syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. *BMC Neurol.* 2016;16:75. Article. IF: 2.006; Q3
- Anguita-Palacios MC, Talayero-San-Miguel M, Herrero-Cereceda S, Martín-Cadenas M, Pardo-Cuevas P, Gil-Martínez A. Fear and preoperative anxiety behaviour and pain intensity perceived after knee arthroscopy. *Enferm Clin.* 2016;26(4):227-33. Article. Not Indexed
- Arévalo-Manso JJ, Martínez-Sánchez P, Fuentes B, Ruiz-Ares G, Sanz-Cuesta BE, Prefasi D, Juárez-Martín B, Navarro-Parías A, Parrilla-Novo P, Díez-Tejedor E. Can we improve the early detection of atrial fibrillation in a stroke unit? Detection rate of a monitor with integrated detection software. *Eur J Cardiovasc Nur.* 2016;15(1):64-71. Article. IF: 2.763; D1

- Buendía I, Parada E, Navarro E, León R, Negro P, Egea J, López MG. Subthreshold concentrations of melatonin and galantamine improves pathological AD-Hallmarks in hippocampal organotypic cultures. *Mol Neurobiol.* 2016;53(5):3338-48. Article. IF: 6.19; D1
- Cea LA, Puebla C, Cisterna BA, Escamilla R, Vargas AA, Frank M, Martínez-Montero P, Prior C, Molano J, Esteban-Rodríguez I, Pascual I, Gallano P, Lorenzo G, Pian H, Barrio LC, Willecke K, Saez JC. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis. *Cell Mol Life Sci.* 2016;73(13):2583-99. Article. IF: 5.788; Q1
- de Lecinana MA, Egado JA, Casado I, Ribo M, Dávalos A, Masjuan J, Caniego JL, Martínez-Vila E, Tejedor ED. Reply to letter "Remarks on cerebral infarct from another point of view". *Neurología.* 2016;31(2):136. Letter. IF: 2.103; Q3
- de Lecinana MA, Fuentes B, Ximénez-Carrillo A, Vivancos J, Masjuan J, Gil-Núñez A, Martínez-Sánchez P, Zapata-Wainberg G, Cruz-Culebras A, García-Pastor A, Díaz-Otero F, Fandino E, Frutos R, Caniego JL, Méndez JC, Fernández-Prieto A, Barcena-Ruiz E, Díez-Tejedor E. A collaborative system for endovascular treatment of acute ischaemic stroke: the Madrid Stroke Network experience. *Eur J Neurol.* 2016;23(2):297-303. Article. IF: 3.988; Q1
- de Munain LL, Juan-García FJ, Duarte E, Martín-Mourelle R, Rodríguez S, Moraleda-Pérez S. Early pharmacologic treatment with botulinum toxin A in post-stroke spasticity: consensus evidence-based recommendations. *Rev Neurología.* 2016;63(8):363-9. Review. IF: 0.743; Q4
- de-la-Puerta-Ranea L, García-Calvo B, La Touche R, Fernández-Carnero J, Gil-Martínez A. Influence of the actions observed on cervical motion in patients with chronic neck pain: a pilot study. *J Exerc Rehabil.* 2016;12(4):346-54. Article. Not Indexed
- Elizagaray-García I, Muriente-González J, Gil-Martínez A. Education for patients with fibromyalgia. A systematic review of randomised clinical trials. *Rev Neurología.* 2016;62(2):49-60. Article. IF: 0.743; Q4
- Fernández-Alonso L, Muñoz-García D, La Touche R. The level of physical activity affects the health of older adults despite being active. *J Exerc Rehabil.* 2016;12(3):164-201. Article. Not Indexed
- Fernández-Montoya J, Buendía I, Martín YB, Egea J, Negro P, Avendaño C. Sensory input-dependent changes in glutamatergic neuro transmission-related genes and proteins in the adult rat trigeminal ganglion. *Front Mol Neurosci.* 2016;9:132. Article. IF: 5.076; Q1
- Ferrer-Peña R, Gil-Martínez A, Pardo-Montero J, Jiménez-Penick V, Gallego-Izquierdo T, La Touche R. Adaptation and validation of the Spanish version of the graded chronic pain scale. *Reumatol Clin.* 2016;12(3):130-8. Article. Not Indexed
- Fiz-Pérez L, Velázquez-Fragua R, García-Guixot S, García-Romero M, Martínez-Bermejo A. Dissection of vertebral arteries as the cause of acute cerebrovascular event in children. *Rev Neurología.* 2016;62(8):382-3. Letter. IF: 0.743; Q4
- Freitas AE, Egea J, Buendía I, Gómez-Rangel V, Parada E, Navarro E, Casas AI, Wojnicz A, Ortiz JA, Cuadrado A, Ruiz-Nuno A, Rodrigues ALS, López MG. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. *Mol Neurobiol.* 2016;53(5):3030-45. Article. IF: 6.19; D1
- Gil-Martínez A, Grande-Alonso M, La Touche R, Lara-Lara M, López-López A, Fernández-Carnero J. Psychosocial and somato-

- sensory factors in women with chronic migraine and painful temporomandibular disorders. *Pain Res Manag.* 2016;3945673. Article. IF: 2.027; Q3
- Gil-Martínez A, Grande-Alonso M, López-de-Uralde-Villanueva I, López-López A, Fernández-Carnero J, La Touche R. Chronic temporomandibular disorders: disability, pain intensity and fear of movement. *J Headache Pain.* 2016;17:103. Article. IF: 2.141; Q1
- González-Suárez I, Arpa J, Ríos-Blanco JJ. Brain microvasculature involvement in ANCA positive vasculitis. *Cerebrovasc Dis.* 2016;41(42891):313-21. Article. IF: 2.974; Q2
- Illán-Gala I, Martínez-Sánchez P, Fuentes B, Llamas-Osorio Y, de Terán JD, Báez M, Ruiz-Ares G, Sanz-Cuesta BE, Lara-Lara M, Díez-Tejedor E. Effect of anticoagulation on cardioembolic stroke severity, outcomes and response to intravenous thrombolysis. *J Thromb Thrombolys.* 2016;42(1):99-106. Article. IF: 2.142; Q3
- Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, del Tredici K, Field H, Fulop T, Grassi C, Griffin WST, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lovheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA. Microbes and Alzheimer's Disease. *J Alzheimers Dis.* 2016;51(4):979-84. Editorial Material. IF: 3.731; Q2
- Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj A, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramirez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Campion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, López OL, Deramecourt V, Fox NC, Cantwell LB, Tarraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RFAG, Tzourio C, Pastor P, Larson EB, Rotter JI, O'Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdottir J, Kauwe JSK, Wilhelmsen KC, Rujescu D, Nothen MM, Hofman A, Jones L, Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA, (Bullido MJ). A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol Psychiatr.* 2016;21(1):108-17. Article. IF: 13.204; D1
- Kawiorski MM, Martínez-Sánchez P, García-Pastor A, Calleja P, Fuentes B, Sanz-Cuesta BE, Lourido D, Marín B, Díaz-Otero F, Vicente A, Sierra-Hidalgo F, Ruiz-Ares G, Díez-Tejedor E, Fandino E, de Lecinana MA. Alberta Stroke Program Early CT Score applied to CT angiography source images is a strong predictor of futile recanalization in acute ischemic stroke. *Neuroradiology.* 2016;58(5):487-93. Article. IF: 2.093; Q2
- Kawiorski MM, Vicente A, Lourido D, Muriel A, Fandino E, Méndez JC, Sánchez-Gonzalez V, Aguado A, Álvarez-Velasco R, de Lecinana MA. Good clinical and radiological correlation from standard perfusion computed tomography accurately identifies salvageable tissue in ischemic stroke. *J Stroke Cerebrovasc.* 2016;25(5):1062-9. Article. IF: 1.517; Q4

- León-Hernández JV, Martín-Pintado-Zugasti A, Frutos LG, Alguacil-Diego IM, de la Llave-Rincón AI, Fernández-Carnero J. Immediate and short-term effects of the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronic myofascial neck pain. *Braz J Phys Ther.* 2016;20(5):422-31. Article. IF: 1.226; Q3
- López-de-Uralde-Villanueva I, Beltrán-Alacreu H, Fernández-Carnero J, Gil-Martínez A, La Touche R. Differences in neural mechanosensitivity between patients with chronic nonspecific neck pain with and without neuropathic features. A descriptive cross-sectional study. *Pain Med.* 2016;17(1):136-48. Article. IF: 2.82; Q1
- López-de-Uralde-Villanueva I, Beltrán-Alacreu H, Fernández-Carnero J, Kindelan-Calvo P, La Touche R. Widespread pressure pain hyperalgesia in chronic nonspecific neck pain with neuropathic features: A descriptive cross-sectional study. *Pain Physician.* 2016;19(2):77-87. Article. IF: 2.84; Q2
- López-de-Uralde-Villanueva I, Muñoz-García D, Gil-Martínez A, Pardo-Montero J, Muñoz-Plata R, Angulo-Díaz-Parreno S, Gómez-Martínez M, La Touche R. A systematic review and meta-analysis on the effectiveness of graded activity and graded exposure for chronic nonspecific low back pain. *Pain Med.* 2016;17(1):172-88. Review. IF: 2.82; Q1
- Lubrini G, Lago MR, Perrián JA, Barranco AT, de Dios C, Fernández-Fourier M, Tejedor ED, García AF. The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis. *Mult Scler.* 2016;22(12):1607-15. Article. IF: 4.84; Q1
- Lupo V, García-García F, Sancho P, Tello C, García-Romero M, Villarreal L, Alberti A, Sivera R, Dopazo J, Pascual-Pascual SI, Márquez-Infante C, Casasnovas C, Sevilla T, Espinos C. Assessment of targeted next-generation sequencing as a tool for the diagnosis of Charcot-Marie-Tooth disease and hereditary motor neuropathy. *J Mol Diagn.* 2016;18(2):225-34. Article. IF: 4.526; Q1
- Martí-Fabregas J, Prats-Sánchez L, Martínez-Domeno A, Camps-Renom P, Marín R, Jiménez-Xarrie E, Fuentes B, Dorado L, Purroy F, Arias-Rivas S, Delgado-Mederos R. The H-ATOMIC criteria for the etiologic classification of patients with intracerebral hemorrhage. *Plos One.* 2016;11(6):e0156992. Article. IF: 2.806; Q1
- Martín-Pintado-Zugasti A, Rodríguez-Fernández AL, Fernández-Carnero J. Postneedling soreness after deep dry needling of a latent myofascial trigger point in the upper trapezius muscle: Characteristics, sex differences and associated factors. *J Back Musculoskelet.* 2016;29(2):301-8. Article. IF: 0.912; Q3
- Masjuan J, Álvarez-Sabín J, Arias-Rivas S, Blanco M, de Felipe A, Escudero-Martínez I, Fuentes B, Gallego-Cullere J, Moniche-Álvarez F, Muñoz L, de la Ossa-Herrero NP, Sahuquillo P, Santamarina E, Sanz B, Tembl JJ, Zandío B. Urgent stroke care in hospitals with a stroke unit. Quick Project. *Rev Neurología.* 2016;62(7):303-10. Article. IF: 0.743; Q4
- Mayor-Ibarguren A, Roldán-Puchalt MC, Sancho-Bueso T, Pérez-López C, Álvarez-Linera J, Frutos R, Álvarez-Escola C, Regajo-Zapata R, Beato-Merino MJ, Herranz-Pinto P, Lecumberri B. Kaposi sarcoma secondary to endogenous adrenocorticotrophic hormone-dependent Cushing syndrome. *Brit J Dermatol.* 2016;174(6):1370-4. Article. IF: 4.706; D1
- Mínguez-Zuazo A, Grande-Alonso M, Saiz Moral B, La Touche R, Lara Lerma S. Therapeutic patient education and exercise therapy in patients with cervicogenic dizziness: a prospective case series clinical study. *J Exerc Rehabil.* 2016;12(3):216-25. Article. Not Indexed



- Muñoz-García D, Gil-Martínez A, López-López A, López-de-Uralde-Villanueva I, La Touche R, Fernández-Carnero J. Chronic neck pain and cervico-craniofacial pain patients express similar levels of neck pain-related disability, pain catastrophizing, and cervical range of motion. *Pain Res Treat*. 2016; 7296032. Article. Not Indexed
- Ntaios G, Vemmos K, Lip GYH, Koroboki E, Manios E, Vemmos A, Rodríguez-Campello A, Cuadrado-Godía E, Giralte-Steinhauer E, Arnao V, Caso V, Paciaroni M, Díez-Tejedor E, Fuentes B, Pérez Lucas J, Arauz A, Ameriso SF, Hawkes MA, Pertierra L, Gómez-Schneider M, Bandini F, Chavarria Cano B, Iglesias Mohedano AM, García Pastor A, Gil-Núñez A, Putaala J, Tatlisumak T, Barboza MA, Athanasakis G, Makaritsis K, Papavasileiou V. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. *Stroke*. 2016; 47(9):2278-85. Article. IF: 6.032; D1
- Pardo-Maza A, Lassaletta L, González-Otero T, Roda JM, Moraleda S, Arbizu A, Gavilán J. Evolution of patients with immediate complete facial paralysis secondary to acoustic neuroma surgery. *Ann Oto Rhinol Laryn*. 2016; 125(6):495-500. Article. IF: 1.384; Q2
- Pascual-Pascual SI, Nascimento A, Fernández-Llamazares CM, Medrano-López C, Villalobos-Pinto E, Martínez-Moreno M, Ley M, Manrique-Rodríguez S, Blasco-Alonso J. Clinical guidelines for infantile-onset Pompe disease. *Rev Neurología*. 2016; 63(6):269-79. Article. IF: 0.743; Q4
- Pastor P, Moreno F, Clarimón J, Ruiz A, Combarros O, Calero M, de Munain AL, Bullido MJ, de Pancorbo MM, Carro E, Antonell A, Coto E, Ortega-Cubero S, Hernández I, Tarraga L, Boada M, Lleo A, Dols-Icardo O, Kulisevsky J, Vázquez-Higuera JL, Infante J, Rabano A, Fernández-Blázquez MA, Valenti M, Indakoetxea B, Barandiaran M, Gorostidi A, Frank-García A, Sastre I, Lorenzo E, Pastor MA, Elcoroaristizabal X, Lennarz M, Maier W, Ramírez A, Serrano-Ríos M, Lee SE, Sánchez-Juan P. MPTP HI haplotype is associated with late-onset Alzheimer's disease risk in APOE epsilon 4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. *J Alzheimers Dis*. 2016; 49(2):343-52. Article. IF: 3.731; Q2
- Patino P, Parada E, Farre-Alins V, Molz S, Cacabelos R, Marco-Contelles J, López MG, Tascá CI, Ramos E, Romero A, Egea J. Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. *Neurotoxicology*. 2016; 57:61-8. Article. IF: 3.1; Q2
- Pérez-Villena A, Soto-Insuga V, Castano-de la Mota C, Martín-del Valle F, Pons-Rodríguez M, Losada-del Pozo R, Moreno-Acero N, Alarcón-Martínez H, Rodrigo-Moreno M, Miravet-Fuster E, Monfort-Belenguer L, Polo-Antúnez A, Martínez-Bermejo A, Merino-Andreu M. The importance of sleep problems in children with headache and other neurodevelopmental disorders in neuropaediatric services. *Rev Neurología*. 2016; 62(2):61-7. Article. IF: 0.743; Q4
- Pesántez-Ríos G, Martínez-Bermejo A, Pesántez-Cuesta G. Neuropsychological alterations are frequent in rolandic epilepsy and its atypical developments. *Rev Neurología*. 2016; 63(3):125-9. Review. IF: 0.743; Q4
- Prefasi D, Martínez-Sánchez P, Fuentes B, Díez-Tejedor E. Severity and outcomes according to stroke etiology in patients under 50 years of age with ischemic stroke. *J Thromb Thrombolysis*. 2016; 42(2):272-82. Article. IF: 2.142; Q3
- Prefasi D, Martínez-Sánchez P, Fuentes B, Díez-Tejedor E. The utility of the RoPE score in cryptogenic stroke patients <= 50 years in predicting a stroke-related patent foramen ovale. *Int J Stroke*. 2016; 11(1):NP7-NP8. Letter. IF: 3.314; Q2
- Pulido-Valdeolivas I, Gómez-Andrés D, Sanz-Gallego I, Rausell E, Arpa J. Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit. *Cerebellum Ataxias*. 2016; 3:4. Article. Not Indexed
- Reetz K, Dogan I, Hilgers RD, Giunti P, Mariotti C, Durr A, Boesch S, Klopstock T, de Rivera FJR, Schols L, Klockgether T, Burk K, Rai M, Pandolfo M, Schulz JB. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. *Lancet Neurol*. 2016; 15(13):1346-54. Article. IF: 26.284; D1
- Ríos A, López-Navas AI, López-López AI, Gómez FJ, Iriarte J, Herruzo R, Blanco G, Llorca FJ, Asunsolo A, Sánchez-Gallegos P, Gutiérrez PR, Fernández A, de Jesús MT, Martínez-Alarcón L, Lana A, Fuentes L, Hernández JR, Virseda J, Yelamos J, Bondía JA, Hernández AM, Ayala MA, Ramírez P, Parrilla P. Acceptance of living liver donation among medical students: A multicenter stratified study from Spain. *World J Gastroenterol*. 2016; 22(25):5800-13. Article. IF: 3.365; Q2
- Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M, Fuentes B, Ramos-Cejudo J, Díez-Tejedor E. Stem cell therapy and administration routes after stroke. *Transl Stroke Res*. 2016; 7(5):378-87. Article. IF: 4.503; Q1
- Rodríguez-Frutos B, Otero-Ortega L, Ramos-Cejudo J, Martínez-Sánchez P, Barahona-Sanz I, Navarro-Hernanz T, Gómez-de Frutos MD, Díez-Tejedor E, Gutiérrez-Fernández M. Enhanced brain-derived neurotrophic factor delivery by ultrasound and microbubbles promotes white matter repair after stroke. *Biomaterials*. 2016; 100:41-52. Article. IF: 8.402; D1
- Sánchez-Benavides G, Peña-Casanova J, Casals-Coll M, Gramunt N, Manero RM, Puig-Pijoan A, Aguilar M, Robles A, Antúnez C, Frank-García A, Fernández-Martínez M, Blesa R. One-year reference norms of cognitive change in Spanish old adults: data from the NEURONORMA Sample. *Arch Clin Neuropsychol*. 2016; 31(4):378-88. Article. IF: 2.044; Q3
- Sánchez-Herán A, Agudo-Carmona D, Ferrer-Pena R, López-de-Uralde-Villanueva I, Gil-Martínez A, Paris-Alemay A, La Touche R. Postural stability in osteoarthritis of the knee and hip: analysis of association with pain catastrophizing and fear-avoidance beliefs. *PM&R*. 2016; 8(7):618-28. Article. IF: 1.785; Q2
- Secades JJ, Álvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for acute ischemic stroke: A systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. *J Stroke Cerebrovasc*. 2016; 25(8):1984-96. Review. IF: 1.517; Q4
- Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, de Arcaya AA, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramio-Torrenta L, Cobo-Calvo A, Vinals M, de Andrés C, Meca-Lallana V, Cervello A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalbán X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders comparison according to the phenotype and serostatus. *Neurol Neuroimmunol Neuroinflamm*. 2016; 3(3):e225. Article. Not Indexed
- Sevilla T, Lupo V, Martínez-Rubio D, Sancho P, Sivera R, Chumillas MJ, García-Romero M, Pascual-Pascual SI, Muelas N, Dopazo J, Vilchez JJ, Palau F, Espinos C. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. *Brain*. 2016; 139:62-72. Article. IF: 10.292; D1
- Tapias G, García-Romero M, Crespo C, Cuesta M, Forne C, Pascual-Pascual SI. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin

type A: an observational, longitudinal, retrospective study. *Farm Hosp*. 2016; 40(5):412-26. Article. Not Indexed

- Ugalde-Canitrot A, García-Fernández M, García-Caballero J. Quality management in epileptology: can it really improve care for patients? *Am J Med Qual*. 2016; 31(1):94. Letter. IF: 1.688; Q3
- Vivancos-Matellano F, García-Ruiz AJ, Soler NGA. Pharmacoeconomic study of the treatment of advanced Parkinson's disease. *Rev Neurología*. 2016; 63(12):529-36. Article. IF: 0.743; Q4

PUBLIC PROJECTS

Bullido Gómez-Heras MJ. Identificación de alteraciones funcionales en modelos patogénicos de la enfermedad de Alzheimer: implicación de la vía lisosomal (SAF2014-53954-R). MINECO. 2015-2017.

Management centre: UAM

Cerdán García-Esteller S, López Larrubia P. Cerebral regulation of global energy balance in health and disease as detected by functional diffusion weighted MRI (SAF2014-53739-R). MINECO. 2015-2017.

Management centre: CSIC

de Leciana Cases MA. Identificación de proteínas implicadas en la neuroreparación tras la isquemia cerebral. Estudio clínico-experimental (PI14/00705). ISCIII. 2014-2016.

Management centre: FIBHRYC

Díez Tejedor E. Terapia reparadora con células madre mesenquimales alogénicas de tejido adiposo en el infarto cerebral agudo comparado con tratamiento convencional. Evaluación de seguridad. Estudio piloto (EC10-171). MSSSI. 2011-2017.

Management centre: FIBHULP

Díez Tejedor E. Red de Enfermedades Vasculares Cerebrales (ICTUS) (RD12/0014/0006). ISCIII. 2013-2016.

Management centre: FIBHULP

Díez Tejedor E. Identificación de marcadores de daño de fibras (axonal y mielina) en sustancia blanca cerebral y nuevas dianas terapéuticas para potenciar la reparación y recuperación en el infarto subcortical. Estudio trasnacional (PI12/01754). ISCIII. 2013-2017.

Management centre: FIBHULP

Fuentes Gimeno B. Terapia reparadora con exosomas de células troncales mesenquimales en el infarto cerebral con daño subcortical en un modelo animal experimental (PI15/01318). ISCIII. 2016-2018.

Management centre: FIBHULP

Gil Martínez A. Sistema de interacción natural para análisis y rehabilitación de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE) (RTC-2015-3870-I). MINECO. 2015-2017.

Management centre: FIBHULP

Gutiérrez Fernández MD. Exosomes as predictive biomarkers in acute ischemic stroke patients: a translational research approach (CP15/00069). ISCIII. 2016-2018.

Management centre: FIBHULP

Gutiérrez Fernández MD. Miguel Servet Tipo I (CP15/00069). ISCIII. 2016-2021.

Management centre: FIBHULP

Pascual Pascual SM. Translational research, experimental medicine and therapeutics on charcot-marie-tooth disease (TREAT-CMT). ISCIII. 2012-2016.

Management centre: FIBHULP

PRIVATE PROJECT

Díez Tejedor E. Analysis of the protective effect of olmesartan administered pre or post-cerebral infarction in an animal model. Pfizer; SLU. 2011-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Registro clínico para el seguimiento de tratamiento anticoagulante en prevención secundaria tras un ictus cardioembólico. Boehringer Ingelheim España, S.A. 2011-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta a tratamientos biológicos. Fundación Bio-gen Idec. 2013-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Informatización de la gestión de pacientes. Unidad de neuroinmunología y esclerosis múltiple en el Hospital Universitario La Paz. Novartis Farmaceutica, S.A. 2014-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Brain repair therapy with exosomes derived mesenchymal stem cells in experimental intracerebral hemorrhage model. Roche Farma, S.A. 2016-Ongoing.

Management centre: FIBHULP

Frank García A. Validación de los biomarcadores proteicos y metabólicos en muestras de pacientes. Neuron Biopharma S.A. 2010-Ongoing.

Management centre: FIBHULP

Gil Martínez A. Sistema de interacción natural para análisis y rehabilitación de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE). Fundación I+D del Software Libre. 2016-Ongoing.

Management centre: FIBHULP

Ivñez Mora V. Proyecto de creación de base de datos para la investigación clínica y epidemiológica en epilepsia. EISAI Farmacéutica S.A. 2009-Ongoing.

Management centre: FIBHULP

Jurado MJ. Traducción, adaptación cultural y validación del cuestionario de sueño sleep disturbance scale for children (SDSC) en población española infanto-juvenil de 6 a 16 años. 2014-Ongoing.

Management centre: FIBHULP

Moraleda Pérez S. Pacientes con parálisis facial periférica: registro de características clínicas antes y después del tratamiento con toxina botulínica tipo A y reeducación neuromuscular facial. Merz Pharma España. 2014-Ongoing.

Management centre: FIBHULP

Noval Martín S. Estudio multicéntrico de tres años de duración para evaluar la tomografía de coherencia óptica como medida de valoración en pacientes con esclerosis múltiple. Novartis Farmaceutica, S.A. 2012-Ongoing.

Management centre: FIBHULP



Pascual Pascual SI. Estudio de la eficacia de la toxina botulínica en el pie equino espástico de la parálisis cerebral y de los factores que influyen en la misma. Allergan, S.A. 2008-Ongoing.

Management centre: FIBHULP

Vivancos Matellano F. Análisis de la diferente evolución clínica de pacientes con enfermedad de parkinson con tratamiento adyuvante asociado de un inhibidor de la dopa decarboxilasa y un inhibidor de la COMT. Abbvie Spain, SLU. 2008-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Díez Tejedor E. Resstore Regenerative Stem Cell Therapy for stroke in Europe- RESSTORE. Therapeutic efficacy of allogenic adipose tissue derived mesenchymal stem cells for enhancing functional outcome in stroke patients (H2020 Topic PHC-15-2015). EU. 2016-2020.

Management centre: FIBHULP

Pascual Pascual SI. Traslational research, experimental medicine and therapeutic on Charcot-Marie-Tooth Disease (TREAT). EU. 2012-2016.

Management centre: FIBHULP

Rodríguez de Rivera Garrido FJ. European Friedreich's Ataxia Consortium Tor Translational Studies (EFACTS). EU. 2016-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

de Leciana Cases MA. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEV-COI. Amgen Europe GMBH.

HULP Code: PI-2382. Sponsored's Protocol Code: AMG-SIM-2016-01.

Signature Date: 04/08/2016

Díez Tejedor E. Ensayo de extensión, abierto, de fase III de ECU-MG-301 para evaluar la seguridad y la eficacia de eculizumab en sujetos con Miastenia Gravis Generalizada (MGG) resistente al tratamiento. Alexion Pharmaceutical Inc.

HULP Code: 4258. Sponsored's Protocol Code: ECU-MG-302.

Signature Date: 05/01/2016

Díez Tejedor E. Corporación internacional para la realización del ensayo clínico, estudio de fase 2, controlado con placebo, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y la seguridad de BMS-986141 en la prevención del infarto cerebral recurrente en sujetos que reciben Ácido Acetilsalicílico (AAS) después de un ictus isquémico agudo o de un accidente isquémico transitorio. Bristol Myers Squibb International Corporation.

HULP Code: 4612. Sponsored's Protocol Code: CV006-004.

Signature Date: 01/07/2016

Díez Tejedor E. Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y con grupos paralelos de la seguridad, la eficacia y la farmacodinámica de Basmi-

sanil (RO5186582) en adultos con deterioro motor grave tras un accidente isquémico. F Hoffmann-La Roche Ltd.

HULP Code: 4666. Sponsored's Protocol Code: BP29937.

Signature Date: 17/10/2016

Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo de fase II para investigar las posibles interacciones fármaco-fármaco entre clobazam y cannabidiol (GWP2003-P). GW Research Ltd.

HULP Code: 4508. Sponsored's Protocol Code: GWEP1428.

Signature Date: 18/01/2016

Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo, de dos partes para investigar las características farmacocinéticas, seguido de la eficacia y la seguridad de GWP42006 como terapia complementaria en pacientes con crisis epilépticas focales inadecuadamente controladas. GW Research Ltd.

HULP Code: 4509. Sponsored's Protocol Code: GWEP1330.

Signature Date: 24/05/2016

Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de tev-48125 frente a placebo respecto al tratamiento preventivo de la migraña crónica. Teva Branded Pharmaceutical Products R&D, Inc.

HULP Code: 4620. Sponsored's Protocol Code: TV48125-CNS-30049.

Signature Date: 12/07/2016

Díez Tejedor E. Estudio de fase Ib, abierto y multicéntrico, para evaluar la seguridad y la tolerabilidad y para determinar la dosis máxima tolerada de PF-05230907 en sujetos con hemorragia intracerebral. Pfizer Inc.

HULP Code: 4600. Sponsored's Protocol Code: B2341002.

Signature Date: 11/07/2016

Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de TEV-48125 frente a placebo respecto al tratamiento preventivo de la migraña episódica. Teva Branded Pharmaceutical Products R&D Inc.

HULP Code: 4619. Sponsored's Protocol Code: TV48125-CNS-30050.

Signature Date: 04/08/2016

Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento y con grupos paralelos que evalúa la seguridad, tolerabilidad y eficacia a largo plazo de la administración subcutánea de TEV-48125 para el tratamiento preventivo de la migraña. Teva Branded Pharmaceutical Products R&D Inc.

HULP Code: 4621. Sponsored's Protocol Code: TV48125-CNS-30051.

Signature Date: 04/08/2016

Díez Tejedor E. Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con lemrada® (alemtuzumab) en pacientes con formas reci-

divantes de esclerosis múltiple. Genzyme Europe BV.

HULP Code: PI-2054. Sponsored's Protocol Code: OBS13434.

Signature Date: 28/07/2016

Díez Tejedor E. Estudio multinacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo, seguido de un periodo de tratamiento activo, para evaluar la eficacia, la seguridad y la tolerabilidad de dos dosis de laquinimod administradas por vía oral (0,6 mg/día o 1,2 mg/día) en sujetos con Esclerosis múltiple Remitente-Recurrente (EMRR). Teva Pharmaceutical Industries Ltd.

HULP Code: Anexo-I 3764. Sponsored's Protocol Code: LAQ-MS-305.

Signature Date: 26/08/2016

Frank García A. Estudio de fase III, doble ciego y aleatorizado de RVT-101 frente a placebo cuando se añade al tratamiento estable con donepezilo ya existente, en pacientes con enfermedad de Alzheimer de leve a moderada. Axovant Sciences Ltd.

HULP Code: 4552. Sponsored's Protocol Code: RVT-101-3001.

Signature Date: 27/04/2016

Frank García A. Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcutánea sobre la capacidad cognitiva y funcional en enfermedad de Alzheimer en fase prodrómica. F Hoffmann-La Roche Ltd.

HULP Code: Anexo-III 3420. Sponsored's Protocol Code: WN25203.

Signature Date: 25/01/2016

Frank García A. Estudio de fase 2A aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico para estudiar la seguridad y tolerabilidad de JNJ-54861911 en pacientes con enfermedad de Alzheimer temprana (pre-demenia). Janssen-Cilag España S.A.

HULP Code: Anexo-I 4266. Sponsored's Protocol Code: 54861911ALZ2002.

Signature Date: 11/04/2016

Frank García A. Estudio de fase IIb/III, multicéntrico, aleatorizado, con doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de jnj-54861911 en sujetos asintomáticos con riesgo de desarrollar demencia de alzheimer. Janssen Cilag International Nv.

HULP Code: 4448. Sponsored's Protocol Code: 54861911ALZ2003.

Signature Date: 04/02/2016

López Arrieta JM. Un estudio de fase 3, de 12 semanas de duración, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de 3 dosis fijas de brexpiprazol (OPC-34712) en el tratamiento de sujetos con agitación asociada con la demencia del tipo Alzheimer. Otsuka Pharmaceutical Development & Commercialization Inc.

HULP Code: Anexo-II 4014. Sponsored's Protocol Code: 331-12-283.

Signature Date: 03/05/2016

López Arrieta JM. Estudio multicéntrico de fase IIA/IIB, aleatorizado, doble ciego, controlado con placebo, de 56

semanas de seguimiento, para evaluar la seguridad y la eficacia de bimagrumab i.v. sobre la masa corporal magra total y la actividad física en pacientes después de tratamiento quirúrgico de fractura de cadera. Novartis Farmaceutica S.A.

HULP Code: Anexo-II 4206. Sponsored's Protocol Code: CB-YM338D2201.

Signature Date: 29/03/2016

López Arrieta JM. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAs) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC/VI por inhalación o UMEC por inhalación en comparación con tiotropio. Glaxosmithkline Research and Development Limited.

HULP Code: PI-2186. Sponsored's Protocol Code: 201038.

Signature Date: 02/06/2016

Pascual Pascual SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en estudios experimentales de ISIS 396443. Ionis Pharmaceuticals Inc.

HULP Code: 4577. Sponsored's Protocol Code: ISIS 396443-CS11.

Signature Date: 07/04/2016

Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con ataxia telangiectasia. Erydel SPA.

HULP Code: 4598. Sponsored's Protocol Code: IEDAT-02-2015.

Signature Date: 02/06/2016

Pascual Pascual SI. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico e internacional que evalúa en grupos paralelos la eficacia y seguridad de 2 dosis de PXT3003 en pacientes con síndrome de Charcot-Marie-Tooth de tipo IA tratados durante 15 meses. Pharnext.

HULP Code: 4534. Sponsored's Protocol Code: CLN-PXT3003-02.

Signature Date: 10/08/2016

Rodríguez de Rivera Garrido FJ. Estudio de fase III sobre la eficacia, la seguridad y la tolerabilidad de la infusión de inmunoglobulina (humana) al 10 % con hialuronidasa recombinante humana (HYQVIA/HYQVIA) y la infusión de inmunoglobulina (humana) al 10 % (gammagard liquid/KIOVING) para el tratamiento de la polirradiculoneuropatía desmielinizante inflamatoria crónica (PDIC). Baxter Innovations GMBH.

HULP Code: 4497. Sponsored's Protocol Code: 161403.

Signature Date: 17/02/2016

Rodríguez de Rivera Garrido FJ. Detención de enfermedad de Pompe en pacientes con miopatías de cinturas no definidas o hiperckemia asintomática. Sanofi Aventis S.A.

HULP Code: Anexo-I PI-823. Sponsored's Protocol Code: L-GENZ-E-003.

Signature Date: 27/07/2016

Tallón Barranco A. Estudio abierto para evaluar la eficacia y la seguridad de ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una



respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad. F Hoffmann-La Roche Ltd.

HULP Code: 4608. Sponsored's Protocol Code: MA30005.

Signature Date: 25/04/2016

PATENTS AND TRADEMARKS


Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EPI769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EPI956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Valdivieso Ámate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Eçaich Ferrer J, Egea Máiquez J, Lorrio González S, Negro Madrigal P, inventors; BIOBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.



NEUROPROTECTIVE STRATEGIES IN NEURODEGENERATIVE DISEASES GROUP



Publications: **19**

Impact Factor: **114.192**

QI: **18**

Antonio Cuadrado Pastor

Catedrático. Facultad de Medicina. UAM

Ángel Juan García Yagüe

Investigador Postdoctoral. CIBERNED

Nadia Giselle Innamorato

Investigadora Predoctoral. UAM

Isabel Lastres Becker

Investigadora Senior (Contrato Ramón y Cajal). UAM

Ángela Martínez Valverde

Investigadora Postdoctoral. IIB "Alberto Sols"

Patricia Rada Llano

Investigadora Postdoctoral. IIB "Alberto Sols"

Research Lines

- Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases.
- The transcription factor Nrf2 as a new therapeutic target in Parkinson's and Alzheimer's disease.
- Molecular basis of type 2 diabetes and its complications (diabetic retinopathy and nephropathy).

Research Activity

PUBLICATIONS

- Arroba AI, Alcalde-Estévez E, García-Ramírez M, Cazzoni D, de la Villa P, Sánchez-Fernández EM, Mellet CO, Fernández JMG, Hernández C, Simo R, Valverde AM. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. *BBA-Mol Basis Dis*. 2016;1862(9):1663-74. Article. IF: 5.476; Q1
- Arroba AI, Rodríguez-de la Rosa L, Murillo-Cuesta S, Vaquero-Villanueva L, Hurlé JM, Varela-Nieto I, Valverde AM. Autophagy resolves early retinal inflammation in Igf1-deficient mice. *Dis Model Mech*. 2016;9(9):965-74. Article. IF: 4.691; Q1
- Baquedano E, Burgos-Ramos E, Canelles S, González-Rodríguez A, Chowen JA, Argente J, Barrios V, Valverde AM, Frago LM. Increased oxidative stress and apoptosis in the hypothalamus of diabetic male mice in the insulin receptor substrate-2 knockout model. *Dis Model Mech*. 2016;9(5):573-83. Article. IF: 4.691; Q1
- Beltramo E, Lopatina T, Mazzeo A, Arroba AI, Valverde AM, Hernández C, Simo R, Porta M. Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. *Acta Diabetol*. 2016;53(6):957-64. Article. IF: 3.34; Q2
- Calderón-Domínguez M, Sebastián D, Fucho R, Weber M, Mir JF, García-Casarrubios E, Obregón MJ, Zorzano A, Valverde AM,

Strategic Objective

Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response could be regulated pharmacologically to provide a therapeutic benefit in these diseases. To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor Nrf2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress. For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson's and Alzheimer's disease as well as co-morbid retinopathy and type II diabetes.



Cuadrado Pastor A. Red de investigación en NRF2 como nodo del "patogenosoma" (SAF2015-71304-REDT). MINECO. 2015-2017.

Management centre: UAM

Martínez Valverde A. Inflammation associated with chronic metabolic damage in diabetes mellitus and its complications (SAF2015-65267-R). MINECO. 2016-2018.

Management centre: CSIC

PRIVATE PROJECTS

Cuadrado Pastor A. Targeting NRF2 with SFX-01 to modify parkinson's disease progression in the AAV6- α -synuclein mouse model. Evgen. 2016-Ongoing.

Management centre: UAM

Martínez Valverde A. Desarrollo de mecanismo de acción del glicinato de metformina en un modelo de hepatocitos. Laboratorios Silanes. 2015-Ongoing.

Management centre: CSIC

INTERNATIONAL PROJECTS

Martínez Valverde A. Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicentric, prospective, phase II-III, double blind randomized controlled trial to assess the efficacy of neuroprotective administered topically to prevent or arrest diabetic retinopathy (EUROCONDOR) (FP7-HEALTH-2011-TWO-STAGE HEALTH.2011.2.4.3.1). EU. 2012-2016.

Management centre: CSIC

Cuadrado Pastor A. Aproximación terapéutica avanzada en cáncer combinando terapia fotodinámica y nanopartículas (PCIN-2016-071). MINECO-EU. 2016-2018.

Management centre: UAM

Cuadrado Pastor A. Knowledge transfer in redox biology for developing advanced molecular tools in neurodegenerative diseases - focus on the signature of NRF2 transcription factor in diagnosis and therapy (P_37_732). EU. 2016-2020.

Management centre: Victor Babes National Institute of Pathology (Bucharest)

PATENTS AND TRADEMARKS

Cuadrado Pastor A, Innamorato NG, inventors; CSIC, UAM, assignees. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS Neuroscience S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.

STRUCTURE, NEUROCHEMISTRY AND PLASTICITY OF NEURAL CIRCUITS OF THE CEREBRAL CORTEX AND THALAMUS GROUP



Publications: **3**

Impact Factor: **6.534**

QI: **2**

Francisco Clascá Cabré

Catedrático. Facultad de Medicina. UAM

Juan Álvarez-Linera Prado

Facultativo Especialista de Área en Radiodiagnóstico. HULP

Carlos Avendaño Trueba

Catedrático. Facultad de Medicina. UAM

Marina Cabrizo Alonso

Técnico de Laboratorio. UAM

Guadalupe Camarero Calderón

Investigadora Postdoctoral. IIB "Alberto Sols"

Carmen Cavada Martínez

Catedrática. Facultad de Medicina. UAM

Miguel Ángel García Cabezas

Profesor Asociado. Especialista en Anatomía Patológica. UAM

María García-Amado Sancho

Investigadora Predoctoral. UAM

María José García-Miguel Piedras

Ayudante de Universidad. Facultad de Medicina. UAM

Agnieszka Krzyzanowska

Investigadora Predoctoral. UAM

Raquel Márquez López

Técnico de Laboratorio. UAM

B. Yasmína Martín Martínez

Investigadora Predoctoral. UAM

Marta Miró Murillo

Técnico de Laboratorio. UAM

César Porrero Calzado

Investigador Predoctoral. UAM

Lucía Prensa Sepúlveda

Profesora Titular. Facultad de Medicina. UAM

Begoña Rodríguez Menéndez

Técnico de Laboratorio. UAM

Pablo Rubio Garrido

Profesor Contratado. Facultad de Medicina. Universidad San Pablo-CEU

Rosa Sánchez Lozano

Técnico de Laboratorio. UAM

Strategic Objective

Our project is aimed towards identifying and quantifying the cellular microcircuits, neurochemistry and plasticity of neural networks that connect the cerebral cortex and the thalamus, as well as a number of systems afferent to the thalamus and its modification through stimulation or injury.

These complex networks are the biological substrate of cognitive, perceptual and voluntary motor control capabilities. Although our objective is to advance understanding of the human brain, the implementation of the experimental techniques with the greatest problem-solving capacity must, in large part, be conducted in animal, primate and rodent models.

The information that our studies provide is necessary to understanding the cellular basis of higher brain functions as the foundation for understanding its normal and pathological function.

Research Lines

- Thalamocortical circuits: cellular and synaptic development and diversity in animal models.
- Structure of neural systems and models of human neurological diseases (Parkinson's and Alzheimer's) in the brains of primates and rodents.






- Plasticity of the somatosensory system.
- Inhibitory mechanisms involved in neuropathic pain in animal models.

Research Activity

PUBLICATIONS

- Cazemier JL, Clascá F, Tiesinga PHE. Connectomic analysis of brain networks: Novel techniques and future directions. *Front Neuroanat.* 2016;10:110. Review. IF: 3.267; D1
- de Manzo FP, Ingelmo I, Manzo A, Clascá F, Santamaría L. Quantitative changes in the V2 lateral visual cortex in developing rats with induced protein malnutrition. *Eur J Anat.* 2016;20(2):171-84. Article. Not Indexed
- Porrero C, Rodríguez-Moreno J, Quetglas JI, Smerdou C, Furuta T, Clascá F. A simple and efficient in vivo non-viral RNA transfection method for labeling the whole axonal tree of individual adult long-range projection neurons. *Front Neuroanat.* 2016;10:27. Article. IF: 3.267; D1



INVOLVEMENT OF GLYCINERGIC AND GLUTAMATERGIC SYSTEMS IN CENTRAL NERVOUS SYSTEM PATHOLOGIES GROUP



Publications: **3**

Impact Factor: **14.583**

Q1: **2**

Cecilio Giménez Martín

Catedrático. Facultad de Ciencias. UAM

María del Carmen Aragón Rueda

Catedrática. Facultad de Ciencias. UAM

Esther Arribas González

Investigadora Predoctoral. UAM

Ignacio Ibáñez Sainz-Pardo

Investigador Predoctoral. UAM

Beatriz Fuensanta López Corcuera

Profesora Titular. Facultad de Ciencias. UAM

Enrique Núñez Balbuena

Investigador Postdoctoral. UAM

Francisco Zafra Gómez

Catedrático. Facultad de Ciencias. UAM

Eva María Porlan Alonso

Investigador Postdoctoral. Ramón y Cajal. UAM

with GlyT2 (dockings on 3D models) for selecting regions that facilitate folding or activity of hyperekplexia mutants.

- Study of the interactome of GlyT2 with proteins already known or new mutants of human hyperekplexia.
- Development of alternative cellular models for the study of hyperekplexia mutants such as infection of primary neurons with lentiviral particles or the generation of induced pluripotent stem cells (iPSC) from patient samples.
- Regulation of GlyTs by receptors involved in pain signal processing in nociceptive pathways of the spinal cord.

Research Lines

- Regulatory mechanisms of neurotransmitters flow between neurons and glia in the nervous system under physiological conditions and in ischemia.
 - a) Regulation of intracellular trafficking of neurotransmitter transporter systems.
 - b) Regulation of the expression of transporters, channels and receptors in the CNS by micro RNAs.
- Molecular mechanisms of Dravet syndrome. Study of the intracellular trafficking and regulation of Nav1.1 sodium channel.
- Molecular mechanisms underlying neurogenesis and its regulation by diverse kinases

Strategic Objective

The group studies the physiological and pathological aspects of the glycine transporters (GlyTs) in the central nervous system as emerging drug targets in transmission mediated glycine dysfunctions as hyperekplexia or pain.

- Identification, analysis and classification of mutations in the gene of GlyT2 (SLC6A5) in human patients with hyperekplexia.
- Effects of mutations of hyperekplexia on the molecular structure, biogenesis and intracellular trafficking of GlyT2. Study of the interaction of inhibitors



Research Activity

PUBLICATIONS

- Ibáñez I, Díez-Guerra FJ, Giménez C, Zafra F. Activity dependent internalization of the glutamate transporter GLT-1 mediated by beta-arrestin 1 and ubiquitination. *Neuropharmacology*. 2016;107:376-86. Article. IF: 5.012; D1
- Quereda V, Porlán E, Canamero M, Dubus P, Malumbres M. An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stress. *Cell Death Differ*. 2016;23(3):430-41. Article. IF: 8.339; D1
- Porlán E, Martí-Prado B, Consiglio A, Farinas I. Stable and efficient genetic modification of cells in the adult mouse V-SVZ for the analysis of neural stem cell autonomous and non-autonomous effects. *J Vis Exp*. 2016;108:e53282. Article. IF: 1.232; Q2

PUBLIC PROJECTS

López Corcuera B, Rueda Aragón C. Estructura, función y regulación del transportador neuronal de glicina GLYT2 en mutaciones asociadas a hiperplexia humana: desarrollo de nuevos modelos de estudio. (SAF2014-58045-R). MINECO. 2015-2017.

Management centre: UAM

Porlan Alonso EM. Control de la división celular asimétrica por reguladores mitóticos: implicaciones para procesos patológicos y regenerativos del sistema nervioso (SAF2015-67756-R). MINECO. 2016-2018.

Management centre: UAM


Zafra Gómez F. Regulación por microRNAs de las sinapsis glutamatérgicas en isquemia. Desarrollo de técnicas no invasivas para el estudio de la neurotransmisión mediada por glutamato (SAF2014-55686-R). MINECO. 2015-2017.


Management centre: UAM

PRIVATE PROJECTS

Zafra Gómez F. Mecanismos moleculares del síndrome de Dravet. Fundación Ramón Areces. 2015-2016.

Management centre: UAM





3.2 Cardiovascular Area

José Luis López-Sendón Hentschel

Documents: **224** IF: **1,372.682**
 Originals: **169** IF: **1,118.856**
 DI: **41** QI: **98**

- Research on Invasive Clinical Cardiology – ICCI-Paz Group
- Cardiovascular Epidemiology and Nutrition Group
- Coagulopathies and Alterations of Haemostasis Group
- Vascular Physiology and Pharmacology Group
- Vascular Pharmacology and Metabolism Group (FARMAVSM)

RESEARCH ON INVASIVE CLINICAL CARDIOLOGY – ICCI-PAZ GROUP



Publications: **82**
 Impact Factor: **776.634**
 QI: **36**

José Luis López-Sendón Hentschel

Jefe de Servicio de Cardiología. HULP

Isabel Antorrena Miranda

Facultativo Especialista de Área en Cardiología. HULP

Eduardo Armada Romero

Facultativo Especialista de Área en Cardiología. HULP

Almudena Castro Conde

Facultativo Especialista de Área en Cardiología. HULP

Regina Dalmáu González-Gallarza

Facultativo Especialista de Área en Cardiología. HULP

Francisco Javier Domínguez Melcón

Facultativo Especialista de Área en Cardiología. HULP

Carlos Escobar Cervantes

Facultativo Especialista de Área en Cardiología. HULP

Jaime Fernández de Bobadilla Osorio

Facultativo Especialista de Área en Cardiología. HULP

Javier Fuertes Beneítez

Facultativo Especialista de Área en Cardiología. HULP

Guillermo Galeote García

Facultativo Especialista de Área en Cardiología. HULP

Elvira Ana González García

Facultativo Especialista de Área en Cardiología. HULP

Teresa González Gallego

Investigadora Senior (Contrato Ramón y Cajal). IIB "Alberto Sols"

Gabriela Guzmán Martínez

Facultativo Especialista de Área en Cardiología. HULP

Ángel Manuel Iniesta Manjavacas

Facultativo Especialista de Área en Cardiología. HULP

Santiago Jiménez Valero

Facultativo Especialista de Área en Cardiología. HULP

Teresa López Fernández

Facultativo Especialista de Área en Cardiología. HULP

Esteban López de Sá y Areses

Jefe de Sección de Cuidados Intensivos Cardiológicos. HULP

José Luis Merino Llorens

Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. HULP

María del Carmen Monedero Martín

Facultativo Especialista de Área en Cardiología. HULP

José Raúl Moreno Gómez

Jefe de Sección de Hemodinámica. HULP

María del Mar Moreno Yangüela

Jefe de Sección de Imagen Cardíaca. HULP

Rafael Peinado Peinado

Jefe de Sección de Arritmias y Electrofisiología. HULP

Elena María Refoyo Salicio

Facultativo Especialista de Área en Cardiología. HULP

Juan Ramón Rey Blas

Facultativo Especialista de Área en Cardiología. HULP

Luis Riera del Moral

Facultativo Especialista de Área en Angiología y Cirugía Vascular. HULP
 Profesor Asociado Departamento de Cirugía. UAM

Inmaculada Roldán Rabadán

Facultativo Especialista de Área en Cardiología. HULP

José Ruiz Cantador

Facultativo Especialista de Área en Cardiología. HULP

Ángel Sánchez Recalde

Facultativo Especialista de Área en Cardiología. HULP

Silvia Cayetana Valbuena López

Facultativo Especialista de Área en Cardiología. HULP

Strategic Objective

The group consists of various healthcare units of the Department of Cardiology at Hospital La Paz: Clinic/ Coronary Unit, interventional cardiology, cardiac imaging, electrophysiology, rehabilitation and adult congenital heart disease.



The main research lines focus on providing clinical responses, with direct participation in clinical trials and international multicentre registries. Moreover, clinical translational potential is reinforced through an institutional relationship with the CNIC.

Research Lines

- Myocardial ischaemia. Acute and chronic. Diagnosis, prognosis and treatment.
- Cardiac arrhythmias. Catheter navigation systems.
- Diagnosis and treatment. Post cardiac arrest hypothermia.
- Heart Failure. Diagnosis and treatment. Cardiotoxicity of antineoplastic agents.
- Cardiac diagnostic imaging.
- Aortic stenosis. Diagnosis and treatment.
- Adult congenital heart diseases.

Research Activity

DOCTORAL THESES

Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España [dissertation]. Madrid: UAM: 2016(03/05/2016).

Director: Álvarez-Sala Walther R.

BOOKS AND BOOK CHAPTERS

Castro Conde A. Organización en la insuficiencia cardiaca. In: Marzal Martín D, López-Sendón Henschel JL, Rodríguez Padial L. Proceso asistencial simplificado de la insuficiencia cardiaca. Madrid: Sociedad Española de Cardiología, 2016. p.135-160

Kerkhove DG, Rigo F, Arpino G, Jerusalem G, López-Sendón J, Juanatey JR, Plana JC, Moonen M, Scherrer-Crosbie M, Monaghan M, Maurea N, Cécile O, Erba PA, Coucke P, Frères P, Dulgheru R, Hinojar R, Sicari R, López-Fernández T, Marwick TH, Suter TM, Edvardsen T, Bours V, Sánchez V, González A, Cosyns D, Bucciarelli-Ducci C, Cardinale D, Rodríguez Muñoz D. Cardiotoxicity: future research directions. In: Lancellotti P, Zamorano J, Galderisi M. Anticancer treatments and cardiotoxicity. San Diego: Elsevier, 2016. p.409-411

PUBLICATIONS

- Ageno W, Buller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ. Managing reversal of direct oral anticoagulants in emergency situations Anticoagulation Education Task Force White Paper. *Thromb Haemostasis*. 2016;116(6):1003-10. Article. IF: 5.627; D1
- Akerstrom F, Pachon M, García-Fernández FJ, Salvador-Montañés O, Jensen-Urstad M, Puchol A, Peinado R, Salgado R, Insulander P, Rodríguez-Padial L, Arias MA. Number of beats in the transition zone with fixed SA interval during right ventricular overdrive pacing determines accessory pathway location in orthodromic reentrant tachycardia. *Pace*. 2016;39(1):21-7. Article. IF: 1.486; Q3
- Alfonso F, Pérez-Vizcaino MJ, del Blanco BG, García-Touchard A, López-Minguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchis J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P,

Cárdenas A, Fernández C. Everolimus-eluting stents in patients with bare-metal and drug-eluting in-stent restenosis results from a patient-level pooled analysis of the RIBS IV and V Trials. *Circ Cardiovasc Int*. 2016;9(7):e003479. Article. IF: 7.198; D1

- Ambrosio G, Komajda M, Mugelli A, López-Sendón J, Tamargo J, Camm J. Management of stable angina: A commentary on the European Society of Cardiology guidelines. *Eur J Prev Cardiol*. 2016;23(13):1401-12. Editorial Material. IF: 3.606; Q2
- Anguera I, García-Alberola A, Dallaglio P, Toquero J, Pérez L, Martínez JG, Peinado R, Rubín JM, Brugada J, Cequier A. Shock reduction with long-term quinidine in patients with brugada syndrome and malignant ventricular arrhythmia episodes. *J Am Coll Cardiol*. 2016;67(13):1653-4. Letter. IF: 19.896; D1
- Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, López-Sendón J, Avezum A, Granger CB, Goodman SG. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. *Int J Cardiol*. 2016;218:291-7. Article. IF: 6.189; Q1
- Aroca A, Polo L, Sánchez R, Bret M, González A, Rey J, Ruiz J, Peña N, Pérez N, González A, Sánchez-Recalde A, Villagrà F. Single ventricle surgery in adulthood. A considered decision. *Cir Cardiovasc*. 2016;23(2):80-6. Article. Not Indexed
- Arroyo-Ucar E, Moreno R, del Prado S, López T, Sánchez-Recalde A, Orbe LC, Jiménez-Valero S, Galeote G, Ramírez MU, Davia RG, Plaza I, Mesa JM, López-Sendón JL. Echogenic mobile images in intraprocedural three-dimensional transesophageal echocardiographic monitoring during percutaneous aortic valve implantation: Incidence, characteristics and clinical implications. *Rev Port Cardiol*. 2016;35(3):133-8. Article. IF: 1.195; Q4
- Barrios V, Escobar C. Blood pressure goals revisited. *J Hypertens*. 2016;34(7):1444-5. Letter. IF: 4.085; Q1
- Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. *Future Cardiol*. 2016;12(4):449-66. Article. Not Indexed
- Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. *Future Cardiol*. 2016;12(4):419-33. Article. Not Indexed
- Barrios V, Escobar C. Improving cardiovascular protection: focus on a cardiovascular polypill. *Future Cardiol*. 2016;12(2):181-96. Review. Not Indexed
- Bohm M, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, Mahfoud F, López-Sendón J, Ponikowski P, Tavazzi L, Swedberg K, Komajda M. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. *Eur J Heart Fail*. 2016;18(6):672-83. Article. IF: 6.968; D1
- Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Ophuis TO, Budaj A, Goto S, López-Sendón J, Díaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. *Eur Heart J*. 2016;37(14):1133-42. Article. IF: 19.651; D1
- Bonaca MP, Bhatt DL, Storey RF, Steg G, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Spinar J, Aylward P, Corbaláá R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. *J Am Coll Cardiol*. 2016;67(23):2719-28. Article. IF: 19.896; D1
- Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GYH, Steg PG, ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ripoll EF, Oldgren J, Hohnloser SH, (López Sendón JL). Design and rationale of the RE-DUAL PCI Trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonval-

ular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. *Clin Cardiol*. 2016;39(10):555-64. Article. IF: 2.757; Q2

- Caro-Codón J, Galeote G, Álvarez-Ortega C, Moreno R, López-Sendón JL. A marble in the heart. *JACC-Cardiovasc Int*. 2016;9(24):2573-4. Editorial Material. IF: 8.841; D1
- Caro-Codón J, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, Moreno R. Radiation-induced coronary artery disease: Useful insights from OCT. *Int J Cardiol*. 2016;202:535-6. Letter. IF: 6.189; Q1
- Caro-Codón J, Valbuena-López S, Álvarez-Ortega C, Moreno-Yanguela M, Moreno R. Rapid pacing-induced massive mitral regurgitation during transcatheter aortic valve implantation. *Circ J*. 2016;80(3):748-9. Editorial Material. IF: 3.544; Q2
- Conde AC, Martín DM, González-Gallarza RD, Esteban VA, Bueno MM, Marimón XGM, Senén AB, Murga N, Abeyta M. Vascular risk and cardiac rehabilitation 2015: A selection of topical issues. *Rev Esp Cardiol*. 2016;69(3):294-9. Article. IF: 4.485; Q2
- Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu GM, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, López-Sendón J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet alfa for acute major bleeding associated with factor XA inhibitors. *New Engl J Med*. 2016;375(12):1131-41. Article. IF: 72.406; D1
- Chan WK, Goodman SG, Brieger D, Fox KAA, Gale CP, Chew DP, Udell JA, López-Sendón J, Huynh T, Yan RT, Singh SM, Yan AT. Clinical characteristics, management, and outcomes of acute coronary syndrome in patients with right bundle branch block on presentation. *Am J Cardiol*. 2016;117(5):754-9. Article. IF: 3.398; Q2
- Dallaglio PD, Anguera I, Jiménez-Candil J, Peinado R, García-Seara J, Arcocha MF, Macías R, Herreros B, Quesada A, Hernández-Madrid A, Álvarez M, di Marco A, Filgueiras D, Matía R, Cequier A, Sabate X. Impact of previous cardiac surgery on long-term outcome of cavotricuspid isthmus-dependent atrial flutter ablation. *Europace*. 2016;18(6):873-80. Article. IF: 4.53; Q1
- Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barra-bes JA, Cequier A, Claeys MJ, de Luca L, Dorler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Luscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. Use, patient selection and outcomes of P2Y₁₂ receptor inhibitor treatment in patients with STEMI based on contemporary European registries. *Eur Heart J Cardiovasc Pharmacother*. 2016;2(3):152-67. Article. Not Indexed
- de Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanan F, Lopes RD, López-Sendón J, Renda G, Horowitz J, Granger CB, Wallentin L. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban versus warfarin in stroke and other thromboembolic events in atrial fibrillation trial. *Am Heart J*. 2016;175:175-83. Article. IF: 4.436; Q2
- Díaz SD, Salicio ER, Valbuena-López SC, Peña MFV, Ramírez-Valdiris U, Guzmán-Martínez G. Multidetector computed tomography usefulness in infective endocarditis. *Rev Esp Cardiol*. 2016;69(4):442-5. Letter. IF: 4.485; Q2
- Escobar C, Barrios V, Prieto L. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. *Eur J Intern Med*. 2016;30:E17-8. Letter. IF: 2.96; Q1
- Esteve-Pastor MA, García-Fernández A, Macías M, Sogorb F, Valdés M, Roldán V, Muñoz J, Badimón L, Roldán I, Bertomeu-Martínez V, Cequier A, Lip GYH, Anguita M, Marín F. Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients? *Circ J*. 2016;80(10):2102-8. Article. IF: 3.544; Q2
- Esteve-Pastor MA, Marín F, Bertomeu-Martínez V, Roldán-Rabadán I, Cequier-Fillat A, Badimón L, Muñoz-García J, Valdés M,

Anguita-Sánchez M. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS₂ and CHA₂DS₂-VASc scores. *Intern Med J*. 2016;46(5):583-9. Article. IF: 1.902; Q2

- Estrada A, Doiño D, Merino JL. Perimitral atrial flutter ablation by transaortic radiofrequency application. *Europace*. 2016;18(7):1037. Article. IF: 4.53; Q1
- Fernández-Lozano I, Brugada J, Alzueta J, Arbelo E, Arribas F, García-Bolao I, Merino JL, Olalla JJ, Osa J, Quesada A, Anguita M, Cequier A, Alfonso F, Badimón L, Barrabés JA, Lozano IF, de Diego JGG, Padial LR, San Román JA, Sánchez PL, Sanchis J, Sionis A. Comments on the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Rev Esp Cardiol*. 2016;69(2):94-101. Editorial Material. IF: 4.485; Q2
- Ferreira-González I, Abu-Asi E, Arias MA, Gallego P, Sánchez-Recalde A, Avanzas P, Bayes-Genis A, de Isla LP, Sanchis J. *Revista Española de Cardiología*: Current position and future directions. *Rev Esp Cardiol*. 2016;69(3):327-36. Editorial Material. IF: 4.485; Q2
- Fontenla A, Martínez-Ferrer JB, Alzueta J, Vinolas X, García-Alberola A, Brugada J, Peinado R, Sancho-Tello MJ, Cano A, Fernández-Lozano I. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. *Europace*. 2016;18(11):1726-34. Article. IF: 4.53; Q1
- García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting. *Med Clin-Barcelona*. 2016;146(12):561.e1-8. Article. IF: 1.125; Q3
- Gemma D, Gómez RM, de Bobadilla JF, García GG, Fernández TL, López-Minguez JR, López-Sendón JL. Percutaneous balloon mitral valvuloplasty and closure of the left atrial appendage: Synergy of two procedures in one percutaneous intervention. *Rev Port Cardiol*. 2016;35(11):617. Article. IF: 1.195; Q4
- Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernández V, Al-Saady N, Pelek N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet*. 2016;388(10055):1995-2003. Article. IF: 47.831; D1
- Gómez-Lara J, Salvatella N, Gonzalo N, Hernández-Hernández F, Fernández-Nofrerías E, Sánchez-Recalde A, Bastante T, Marciano A, Romaguera R, Ferreiro JL, Roura G, Teruel L, Ariza-Sole A, Miranda-Guardiola F, García-Abad VR, Gómez-Hospital JA, Alfonso F, Cequier A. IVUS-guided treatment strategies for definite late and very late stent thrombosis. *Eurointervention*. 2016;12(11):E1355-65. Article. IF: 5.165; Q1
- Green AS, Lorite NM, Bueno H, Payeras AC, Molina BD, Juanatey JRG, Urioste LMR, Gómez JLZ, Bonet LA, Sole AA, Freire RB, Rodríguez JLL, de Sa EL, Fernández SL, Asenjo RM, Pérez SM, Figal DP, Cubero JS, Román AV, Calvar JAS, Manterola FA, Ynsaurriaga FA, Masip AE, Gonzalez IF, Navarro MJ, Ortuno FM, de Isla LP, Padial LR, Fernández PLS, Green AS, García RV. Comments on the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Rev Esp Cardiol*. 2016;69(12):1119-25. Editorial Material. IF: 4.485; Q2
- Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L, (López Sendón JL). Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. *Eur Heart J*. 2016;37(16):1325-33. Article. IF: 19.651; D1
- Hernández JMD, Moreno R, Lee DH, García del Blanco B, San Martín JC, García Blas S, Serra García V, Gaviria K, García I, Zue-



López-Sendón Hentschel JL. Red de Enfermedades Cardiovasculares (RECAVA) (RD12/0042/0063). ISCIII. 2013-2017.
Management centre: FIBHULP

López-Sendón Hentschel JL. Toxicidad cardiovascular por fármacos antitumorales. Valoración del riesgo y diagnóstico precoz (P113/00559). ISCIII. 2014-2017.
Management centre: FIBHULP

PRIVATE PROJECTS

Castro Conde A. Tecnologías disruptivas para la rehabilitación del futuro paquete de trabajo I: modelado de sistemas biónicos híbridos para escenarios de rehabilitación virtuales y ubicuos basados en la evidencia. Paquete de trabajo 6: adaptación inteligente de terapia. Laboratorios Servier S.L. 2011-Ongoing.
Management centre: FIBHULP

Castro Conde A. Curso de rehabilitación cardiaca. 2012-Ongoing.
Management centre: FIBHULP

Castro Conde A. Jornadas de formación en investigación en la prevención secundaria y rehabilitación. Astrazeneca Farmacéutica Spain S.A. 2013-Ongoing.
Management centre: FIBHULP

Castro Conde A. II Encuentro nacional de investigación en Rehabilitación Cardiaca. Laboratorio Menarini S.A. 2015-Ongoing.
Management centre: FIBHULP

Dalmáu González-Gallerza R. Estudio de los beneficios de la marcha nórdica dentro de un programa de rehabilitación cardíaca en pacientes con Síndrome Coronario Agudo Reciente. Laboratorio Menarini S.A. 2011-Ongoing.
Management centre: FIBHULP

Jiménez Valero S. Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S.L. 2015-Ongoing.
Management centre: FIBHULP

Jiménez Valero S. Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: estudio IVI. Abbott Laboratories S.A. 2009-Ongoing.
Management centre: FIBHULP

López-Sendón Hentschel JL. Sesiones clínicas de Cardiología. Astrazeneca Farmacéutica Spain S.A. 2006-Ongoing.
Management centre: FIBHULP

López-Sendón Hentschel JL. International study of comparative health effectiveness with medical and invasive approaches - estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. 2013-Ongoing.
Management centre: FIBHULP

López-Sendón Hentschel JL. Biomarcadores en la cardiotoxicidad por agentes antineoplásicos: rendimiento diagnóstico. Bayer Hispania S.L. 2015-Ongoing.
Management centre: FIBHULP

López-Sendón Hentschel JL. Sesiones interhospitalarias de formación en investigación en Cardiología. Astrazeneca Farmacéutica Spain S.A. 2016-Ongoing.
Management centre: FIBHULP

Merino Llorens JL. Actividades formativas de investigación en Cirugía Cardíaca Pediátrica. Bayer Hispania S.L. 2006-Ongoing.
Management centre: FIBHULP

Merino Llorens JL. Innovación tecnológica en cardiología: mapas tridimensionales de ciclo de retorno para la ablación de taquicardias macroreentrantes. Bayer Hispania S.L. 2007-Ongoing.
Management centre: FIBHULP

Merino Llorens JL. Formación en investigación en Electrofisiología Cardíaca. European Society of Cardiology. 2015-Ongoing.
Management centre: FIBHULP

Moreno Gómez JR. Evaluación clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Subproyecto: análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Abbott Laboratories S.A. 2011-Ongoing.
Management centre: FIBHULP

Peinado Peinado R. Síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Boston Scientific Ibérica S.A. 2008-Ongoing.
Management centre: FIBHULP

Peinado Peinado R. Utilidad de la estimulación programada ventricular izquierda para la inducción de la taquicardia ventricular monomórfica clínica en pacientes con infarto previo-Boston. Boston Scientific Ibérica S.A. 2009-Ongoing.
Management centre: FIBHULP

Peinado Peinado R. Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Medtronic Iberica S.A. 2009-Ongoing.
Management centre: FIBHULP

CLINICAL TRIALS

Castro Conde A. Registro de hipercolesterolemia familiar en el síndrome coronario agudo. Sociedad Española de Cardiología.
HULP Code: PI-067. Sponsored's Protocol Code: HF-SCA.
Signature Date: 11/04/2016

Dalmáu González-Gallerza R. Evaluación del control glucémico en pacientes con alto riesgo cardiovascular y diabetes mellitus tipo 2 en consultas de atención primaria y cardiología. Sociedad Española de Cardiología.
HULP Code: PI-2409. Sponsored's Protocol Code: RICARD2.
Signature Date: 27/09/2016

Escobar Cervantes C. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEV-COI. Amgen Europe GMBH.

HULP Code: PI-2382B. Sponsored's Protocol Code: AMG-SIM-2016-01.
Signature Date: 04/08/2016

López de Sá Areces E. Estudio prospectivo abierto del andexanet alfa en pacientes tratados con un inhibidor de factor Xa que presentan una hemorragia mayor aguda. Portola Pharmaceuticals Inc.
HULP Code: 4523. Sponsored's Protocol Code: 14-505.
Signature Date: 02/02/2016

López de Sa Areces E. Estudio observacional sobre el tratamiento oral antiplaquetario tras síndrome coronario agudo en España (spanish observational study of oapt after ACS). Fundación de Investigación en Red en Enfermedades Cardiovasculares-FIRCAVA.
HULP Code: PI-2206. Sponsored's Protocol Code: FIR-ACS-2015-01.
Signature Date: 02/03/2016

López-Sendón Hentschel JL. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de dalcetrapib sobre el riesgo cardiovascular (CV) en una población definida genéticamente con síndrome coronario agudo reciente (SCA): el ensayo DAL-GENE. Dalcor Pharma UK Ltd.
HULP Code: 4627. Sponsored's Protocol Code: DAL-301.
Signature Date: 27/05/2016

López-Sendón Hentschel JL. Estudio de fase III fundamental, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y determinado por los episodios para evaluar la eficacia y la seguridad de vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por vía oral, en sujetos con insuficiencia cardíaca con fracción de eyección disminuida (ICFED): estudio victoria (vericiguat global study in subjects with heart failure with reduced ejection fraction). Merck Sharp and Dohme de España S.A.
HULP Code: 4685. Sponsored's Protocol Code: 1242-001.
Signature Date: 22/09/2016

Merino Llorens JL. Estudio de la eficacia y la seguridad de F373280 para el mantenimiento del ritmo sinusal tras cardioversión eléctrica en pacientes con fibrilación auricular persistente e insuficiencia cardíaca crónica. Pierre Fabre Medicament S.A.S.
HULP Code: Anexo-4 3814. Sponsored's Protocol Code: F373280CA201.
Signature Date: 28/03/2016

Merino Llorens JL. Triumph CRT. Estimulación biventricular trifocal para la optimización de la terapia de resincronización cardíaca (TRC). Sorin Group España S.L.
HULP Code: 4519. Sponsored's Protocol Code: ICSY02.
Signature Date: 18/02/2016

Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRV en mujeres y hombres. Biotronik Se&Co KG.

HULP Code: Anexo-I 4595. Sponsored's Protocol Code: CR017.
Signature Date: 08/09/2016

Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRC en mujeres y hombres, código de protocolo CR017, versión 1.0 de 3 de diciembre de 2014. Biotronik Se&Co KG.
HULP Code: 4595. Sponsored's Protocol Code: CR017.
Signature Date: 14/06/2016

Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatheter de una válvula aórtica-Galileo. Bayer AG.
HULP Code: Anexo-I 4525. Sponsored's Protocol Code: BAY17938.
Signature Date: 30/09/2016

Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatheter de una válvula aórtica-Galileo. Bayer AG.
HULP Code: 4525. Sponsored's Protocol Code: BAY 17938.
Signature Date: 29/03/2016

Moreno Gómez JR. Registro de pacientes con dispositivo biorreabsorbible en la práctica clínica habitual: medida de costes, efectividad, QALYS, y eficiencia. Fundación Casa del Corazón.
HULP Code: PI-2425. Sponsored's Protocol Code: COR-BVS-2016-01 ESTUDIO REPARA-QALY.
Signature Date: 15/07/2016

Peinado Peinado R. RECABA, Registro Español de Crioblación con Balón. Medtronic Ibérica S.A.
HULP Code: PI-2454. Sponsored's Protocol Code: RECABA.
Signature Date: 02/11/2016

PATENTS AND TRADEMARKS

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.



- Sitting time and mortality in older adults with disability: A national cohort study. *J Am Med Dir Assoc*. 2016;17(10):960.e15. Article. IF: 5.775; D1
- Martínez-Vizcaino V, Cervero-Redondo I, Álvarez-Buena C, Rodríguez-Artalejo F. The accuracy of diagnostic methods for diabetic retinopathy: A systematic review and meta-analysis. *Plos One*. 2016;11(4):e0154411. Review. IF: 2.806; Q1
 - Martín-María N, Caballero FF, Olaya B, Rodríguez-Artalejo F, Haro JM, Miret M, Ayuso-Mateos JL. Positive affect is inversely associated with mortality in individuals without depression. *Front Psychol*. 2016;7:1040. Article. IF: 2.323; Q2
 - Monroy-Parada DX, Moya MA, Bosqued MJ, López L, Rodríguez-Artalejo F, Royo-Bordonada MA. Vending machines of food and beverages and nutritional profile of their products at schools in Madrid, Spain, 2014-2015. *Rev Esp Salud Pública*. 2016;90:E1-9. Article. IF: 0.69; Q4
 - Ortola R, García-Esquinas E, Galán I, Rodríguez-Artalejo F. Patterns of alcohol consumption and health-related quality of life in older adults. *Drug Alcohol Depend*. 2016;159:166-73. Article. IF: 3.222; Q1
 - Ortola R, García-Esquinas E, León-Muñoz LM, Guallar-Castillón P, Valencia-Martín JL, Galán I, Rodríguez-Artalejo F. Patterns of alcohol consumption and risk of frailty in community-dwelling older adults. *J Gerontol A-Biol*. 2016;71(2):251-258. Article. IF: 5.957; D1
 - Padrón A, Galán I, García-Esquinas E, Fernández E, Ballbe M, Rodríguez-Artalejo F. Exposure to secondhand smoke in the home and mental health in children: a population-based study. *Tob Control*. 2016;25(3):307-12. Article. IF: 5.469; Q1
 - Pérez-Tasigchana RF, León-Muñoz LM, López-García E, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Mediterranean diet and health-related quality of life in two cohorts of community-dwelling older adults. *Plos One*. 2016;11(3):e0151596. Article. IF: 2.806; Q1
 - Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, Baz-Alonso JA, Durán-Muñoz D, González-Babarro E, SanMartín M, Parajes T, Torres-Torres I, Piñón-Esteban M, Calvo-Iglesias F, Olcoz-Chiva MT, Rodríguez-Artalejo F. The frailty syndrome and mortality among very old patients with symptomatic severe aortic stenosis under different treatments. *Int J Cardiol*. 2016;224:125-31. Article. IF: 6.189; Q1
 - Ruiz-Hurtado G, Ruilope LM, de la Sierra A, Sarafidis P, de la Cruz JJ, Gorostidi M, Segura J, Vinyoles E, Banegas JR. Association between high and very high albuminuria and nighttime blood pressure: Influence of diabetes and chronic kidney disease. *Diabetes Care*. 2016;39(10):1729-37. Article. IF: 11.857; D1
 - Sánchez-Martínez M, Castell MV, González-Montalvo JI, de la Cruz JJ, Banegas JR, Otero A. Transitions in functional status of community dwelling older adults: Impact of physical performance, depression and cognition. *Eur Geriatr Med*. 2016;7(2):111-6. Article. IF: 1.336; Q4
 - Sánchez-Martínez M, López-García E, Guallar-Castillón P, Cruz JJ, Orozco E, García-Esquinas E, Rodríguez-Artalejo F, Banegas JR. Social support and ambulatory blood pressure in older people. *J Hypertens*. 2016;34(10):2045-52. Article. IF: 4.085; Q1
 - Sandoval-Insausti H, Pérez-Tasigchana RF, López-García E, García-Esquinas E, Rodríguez-Artalejo F, Guallar-Castillón P. Macro-nutrients intake and incident frailty in older adults: A prospective cohort study. *J Gerontol A-Biol*. 2016;71(10):1329-34. Article. IF: 5.957; D1
 - Soler-Vila H, García-Esquinas E, León-Muñoz LM, López-García E, Banegas JR, Rodríguez-Artalejo F. Contribution of health behaviours and clinical factors to socioeconomic differences in frailty among older adults. *J Epidemiol Commun H*. 2016;70(4):354-60. Article. IF: 3.608; Q1
 - Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, Bixby H, Cowan MJ, Ali MK, Taddei C, Lo VWC, Reis-Santos B, Stevens GA, Riley LM, Miranda JJ, Bjerregaard P, Rivera JA, Fouad HM, Ma GS, Mbanya JCN, McGarvey ST, Mohan V, Onat A, Ramachandran A, Ben Romdhane H, Paciorek CJ, Bennett JE, Ezzati M, Abdeen ZA, Kadir KA, Abu-Rmeileh NM, Acosta-Cazares B, Adams R, Aekplakorn W, Aguilar-Salinas CA, Agyemang C, Ahmadvand A, Al-Othman AR, Alkerwi A, Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Anjana RM, Aounallah-Skhiri H, Aris T, Arlappa N, Arveiler D, Assah FK, Avdicova M, Azizi F, Balakrishna N, Bandosz P, Barbagallo CM, Barcelo A, Batieha AM, Baur LA, Ben Romdhane H, Benet M, Bernabe-Ortiz A, Bharadwaj S, Bhargava SK, Bi YF, Bjerregaard P, Bjertness E, Bjertness MB, Bjorklund C, Blokstra A, Bo S, Boehm BO, Boissonnet CP, Bovet P, Brajkovich I, Breckenkamp J, Brenner H, Brewster LM, Brian GR, Bruno G, Bugge A, de León AC, Can G, Candido APC, Capuano V, Carlsson AC, Carvalho MJ, Casanueva FF, Casas JP, Caserta CA, Castetbon K, Chamukuttan S, Chaturvedi N, Chen CJ, Chen FF, Chen SH, Cheng CY, Chetrit A, Chiou ST, Cho Y, Chudek J, Cifkova R, Claessens F, Concin H, Cooper C, Cooper R, Costanzo S, Cottle D, Cowell C, Crujeiras AB, D'Arrigo G, Dallongeville J, Dankner R, Dauchet L, de Gaetano G, De Henauw S, Deepa M, Dehghan A, Deschamps V, Dhana K, Di Castelnuovo AF, Djalalinia S, Doua K, Drygas W, Du Y, Dzerve V, Egbagbe EE, Eggertsen R, El Ati J, Elosua R, Erasmus RT, Erem C, Ergor G, Eriksen L, Escobedo-de la Pena J, Fall CH, Farzadfar F, Felix-Redondo FJ, Ferguson TS, Fernández-Berges D, Ferrari M, Ferreccio C, Feskens EJM, Finn JD, Fogar B, Foo LH, Forslund AS, Fouad HM, Francis DK, Franco MD, Franco OH, Frontera G, Furusawa T, Gaciong Z, Garnett SP, Gaspoz JM, Gasull M, Gates L, Geleijnse JM, Ghasemian A, Ghimire A, Giampaoli S, Gianfagna F, Giovannelli J, Giwerzman A, Gross MG, Rivas JPG, Gorbea MB, Gottrand F, Grafnetter D, Grodzicki T, Gronstedt A, Gruden G, Gu DF, Guan OP, Guerrero R, Guessous I, Guimaraes AL, Gutierrez L, Hambleton IR, Hardy R, Kumar RH, Hata J, Heidemann C, Herrala S, Hihtaniemi IT, Ho SY, Ho SC, Hofman A, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Htike MMT, Htike MMT, Hu Y, Hussieni AS, Huybrechts I, Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Ikeda N, Ikram MA, Irazola VE, Islam M, Iwasaki M, Jacobs JM, Jafar T, Jamil KM, Jasienska G, Jiang CQ, Jonas JB, Joshi P, Kafatos A, Kalter-Leibovici O, Kasaeian A, Katz J, Kaur P, Kavousi M, Kelishadi R, Kengne AP, Kersting M, Khader YS, Khalili D, Khang YH, Kiechl S, Kim J, Kolsteren P, Kratzer W, Kromhout D, Kujala UM, Kula K, Kyobutungi C, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O, Lanska V, Lappas G, Laxmaiah A, Leclercq C, Lee J, Lee J, Lehtimäki T, Lekhraj R, León-Muñoz LM, Li YP, Lim WY, Lima-Costa MF, Lin HH, Lin X, Lissner L, Lorbeer R, Lozano JE, Luksiene D, Lundqvist A, Lytsy P, Ma GS, Machado-Coelho GLL, Machi S, Maggi S, Magliano DJ, Makdisse M, Rao KM, Manios Y, Manzato E, Margozzini P, Marques-Vidal P, Martorell R, Masoodi SR, Mathiesen EB, Matsha TE, Mbanya JCN, McFarlane SR, McGarvey ST, McLachlan S, McNulty BA, Mediene-Bencheokor S, Meirhaeghe A, Menezes AMB, Merat S, Meshram II, Mi J, Miquel JF, Miranda JJ, Mohamed MK, Mohammad K, Mohammadifard N, Mohan V, Yusuf MFM, Moller NC, Molnar D, Mondo CK, Morejon A, Moreno LA, Morgan K, Moschonis G, Mossakowska M, Mostafa A, Motta J, Motta J, Mu TT, Muiesan ML, Muller-Nurasyid M, Mursu J, Nagel G, Namesna J, Nang EEK, Nangia VB, Navarrete-Muñoz EM, Ndiaye NC, Nenko I, Nervi F, Nguyen ND, Nguyen QN, Nieto-Martínez RSE, Ning G, Ninomiya T, Noale M, Noto D, Al Nsour M, Ochoa-Aviles AM, Oh K, Onat A, Ordunez P, Osmond C, Otero JA, Owusu-Dabo E, Pahomova E, Palmieri L, Panda-Jonas S, Panza F, Parsaeian M, Peixoto SV, Peltonen M, Peters A, Peykari N, Pham ST, Pilav A, Pitakaka F, Piwonska A, Piwonski J, Plans-Rubio P, Porta M, Portegies MLP, Poustchi H, Pradeepa R, Price JF, Punab M, Qasrawi RF, Qorbani M, Radisauskas R, Rahman M, Raitakari O, Rao SR,

Ramachandran A, Ramke J, Ramos R, Rampal S, Rathmann W, Redon J, Regan PFM, Rigo F, Robinson SM, Robitaille C, Rodríguez-Artalejo F, Rodríguez-Pérez MD, Rodríguez-Villamizar LA, Rojas-Martínez R, Ronkainen K, Rosengren A, Rubenstein A, Rui O, Ruiz-Betancourt BS, Horimoto ARVR, Rutkowski M, Sabana-yagam C, Sachdev HS, Saidi O, Sakarya S, Salanave B, Salonen JT, Salvetti M, Sánchez-Abanto J, Santos D, dos Santos RN, Santos R, Saramies JL, Sardinha LB, Sarrafzadegan N, Saum KU, Scazufca M, Scharngrotsky H, Scheidt-Nave C, Sein AA, Sharma SK, Shaw JE, Shibuya K, Shin Y, Shirir, Siantar R, Sibai AM, Simon M, Simons J, Simons LA, Sjostrom M, Slowikowska-Hilczler J, Slusarczyk P, Smeeth L, Snijder MB, So HK, Sobngwi E, Soderberg S, Solfrizzi V, Sonestedt E, Soumare A, Staessen JA, Stathopoulou MG, Steene-Johannessen J, Stehle P, Stein AD, Stessman J, Stockl D, Stokwiszewski J, Stronks K, Strufaldi MW, Sun CA, Sundstrom J, Sung YT, Suriyawongpaisal P, Sy RG, Tai ES, Tamosiunas A, Tang L, Tarawneh M, Tarqui-Mamani CB, Taylor A, Theobald H, Thijs L, Thuesen BH, Tolonen HK, Tolstrup JS, Topbas M, Torrent M, Traissac P, Trinh OTH, Tulloch-Reid MK, Tuomainen TP, Turley ML, Tzourio C, Ueda P, Ukoli FAM, Ulmer H, Uusitalo HMT, Valdivia G, Valvi D, van Rossem L, van Valkengoed IGM, Vanderschueren D, Vanuzo D, Vega T, Velasquez-Melendez G, Veronesi G, Verschuren WMM, Verstraeten R, Viet L, Vioque J, Virtanen JK, Viswanathan B, Vollenweider P, Voutilainen S, Vrijheid M, Wade AN, Wagner A, Walton J, Mohamad WNW, Wang F, Wang MD, Wang Q, Wang YX, Wannamethee SG, Weerasekera D, Whincup PH, Widhalm K, Wijga AH, Wilks RJ, Willeit J, Wilsongaard T, Wojtyniak B, Wong TY, Woo J, Woodward M, Wu FC, Wu SL, Xu HQ, Yan WL, Yang XG, Ye XW, Yoshihara A, Younger-Coleman NO, Zamboni S, Zargar AH, Zdrojewski T, Zhao WH, Zheng YF, Cisneros JZ. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387(10027):1513-30. Article. IF: 47.831; D1

PUBLIC PROJECTS

Banegas Banegas JR. Estimación de la presión arterial central de 24 horas y determinación de umbrales diagnósticos de la presión arterial central en hipertensos atendidos en Atención Primaria (PI13/02321). ISCIII. 2014-2016.

Management centre: UAM

López García E. Impacto de la dieta en indicadores globales de bienestar en la población mayor española (PI13/00288). ISCIII. 2014-2016.

Management centre: UAM

Rodríguez Artalejo F. Conductas alimentarias, dieta mediterránea, obesidad sarcopénica y precursores modificables de la discapacidad en los ancianos (PI12/01166). ISCIII. 2013-2016.

Management centre: UAM

Rodríguez Artalejo F. El Síndrome de Fragilidad y los factores psicosociales en las trayectorias de envejecimiento saludable: una cohorte comunitaria de adultos mayores en España. Proyectos de cohortes CIBER, en el marco de las Estrategias en Salud del Sistema Nacional de Salud (SBS). ISCIII. 2016-Ongoing.

Management centre: UAM

Rodríguez Artalejo F. Centro de investigación biomédica en red de epidemiología y salud pública (CIBEResp). ISCIII. 2006-2017.

Management centre: UAM

Rodríguez Artalejo F. Impacto de los principales patrones de consumo de bebidas alcohólicas sobre la salud de los adultos mayores en España (2014/002). Plan Nacional sobre Drogas. 2015-2017.

Management centre: UAM


INTERNATIONAL PROJECTS

Rodríguez Artalejo F. Utility ofOMIC-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - the frailomic initiative (FP7-HEALTH-2012-No 305483-2). EU. 2013-2017.

Management centre: UAM

Rodríguez Artalejo F. Ageing trajectories of health: longitudinal opportunities and synergies (ATHLOS) (H2020-PHC-2014. 635316-2.). EU. 2015-2019.

Management centre: UAM





COAGULOPATHIES AND ALTERATIONS OF HAEMOSTASIS GROUP



Publications: **17**
Impact Factor: **70.37**
Q1: **7**

Víctor Manuel Jiménez Yuste

Jefe de Servicio de Hematología. HULP

María Teresa Álvarez Román

Facultativo Especialista de Área en Hematología y Hemoterapia. HULP

Nora Viviana Butta Coll

Investigadora Senior (Contrato Miguel Servet- Tipo 2). Jefe de Laboratorio. HULP

Ihosvany Fernández Bello

Investigador Postdoctoral. HULP

Raquel Fernández Morata

Técnico de Laboratorio. HULP

Elena García Arias-Salgado

Investigadora asociada. Advanced Medical Projects Madrid

Sara García Barcenilla

Coordinadora de Estudios. HULP

Mónica Martín Salces

Facultativo Especialista de Área en Hematología y Hemoterapia. HULP

Isabel Rivas Pollmar

Médico Adjunto en Hematología. HULP

In addition, we perform epidemiological studies to facilitate patient data analysis and therapeutic treatment.

Research Lines

1- Haemophilia A and B:

- Genetic and molecular studies in patients with haemophilia A and B.
- Risk factors for the development of factor FVIII/ FIX inhibitors in patients with haemophilia A and B. Individualised treatment adaptation based on the nature of antigenic epitopes.
- Epidemiological studies of congenital haemophilia A and B, acquired haemophilia A and von Willebrand's disease.

2- Haemostasis disorders:

- Haemostasis in thrombocytopenic diseases (immune thrombocytopenia and myelodysplastic syndromes).
- Haemostasis in inflammatory diseases.

Research Activity

DOCTORAL THESES

Martín Salces M. Alteraciones de la hemostasia en los síndromes mielodisplásicos [dissertation]. Madrid: UAM: 2016(08/11/2016).

Directors: Butta Coll NV, de Paz Arias R, Jiménez Yuste V.

PUBLICATIONS

- Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, Martín-Salces M, Arias-Salgado EG, Pollmar MIR, Sanz RJ, Butta NV. Procoagulant profile in patients with immune thrombocytopenia. *Brit J Haematol.* 2016;175(5):925-34. Article. IF: 5.67; Q1
- Álvarez-Román MT, Pollmar MIR, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. *AIDS.* 2016;30(7):1141-2. Letter. IF: 5.003; Q1
- Auerswald G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Salek SZ. Pain and pain management in haemophilia. *Blood Coagul Fibrin.* 2016;27(8):845-54. Review. IF: 1.367; Q4
- Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo A, Loures E, Cid AR, Bonnad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruin G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilarino D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzagala K, Marco P, Palomo A, Sarmiento L, Inigo B, Nieto MD, Vidal R, Martínez MP, Aguinaco R, Cesar JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borrás N, Vidal F. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. *Thromb Haemostasis.* 2016;115(1):40-50. Article. IF: 5.627; D1
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Hernández-Moreno AL. Coexistence of factor VII deficiency and hereditary spastic paraplegia in two siblings. *Case Rep Hematol.* 2016; 1351873. Article. Not Indexed
- González-López TJ, Álvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Núñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Minano C, de Cabo E, Fisac R, Aguilar C, Báñez A, Penarrubia MJ, García-Frade LJ, González-Porras JR. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. *Eur J Haematol.* 2016;97(3):297-302. Article. IF: 2.653; Q2
- Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J. Current view and outcome of ITI therapy - A change over time? *Thromb Res.* 2016;148:38-44. Article. IF: 2.65; Q2
- Jiménez-Yuste V, Kruse-Jarres R, Rangarajan S, Altisent C. The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders. *Thromb Haemostasis.* 2016;116:S1. Editorial Material. IF: 5.627; D1.
- Jiménez-Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E. Clinical overview of Fandhi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. *Haemophilia.* 2016;22(1):E71-4. Letter. IF: 3.569; Q2
- Jiménez-Yuste V, Oldenburg J, Rangarajan S, Peiró-Jordán R, Santagostino E. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. *Haemophilia.* 2016;22(6):859-65. Article. IF: 3.569; Q2
- Kreuz W, Ettingshausen CE, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanska E, Campos M, Benedik-Dolnicar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Salek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O. First prospective report on immune tolerance in poor risk haemophilia A inhibi-

tor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. *Haemophilia.* 2016;22(1):87-95. Article. IF: 3.569; Q2

• López-Fernández MF, Roca CA, Álvarez-Román MT, Hirnyk MIC, Mingot-Castellanos ME, Jiménez-Yuste V, Haro ARC, Pérez-Garrido R, Balbas CS. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. *Thromb Haemostasis.* 2016;115(5):872-95. Article. IF: 5.627; D1

• Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. *Virus Res.* 2016;213:224-9. Article. IF: 2.628; Q3

• Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, Cid-Haro AR, Pérez-Garrido R, Sedano-Balbás C. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. *Eur J Haematol.* 2016;96(5):461-74. Review. IF: 2.653; Q2

• Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petes B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, Pronczinski MV, Altisent C, Castaman G, Yamamoto K, Álvarez-Román MT, Voigt C, Blackman N, Jacobs I. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. *Blood.* 2016;127(14):1761-9. Article. IF: 13.164; D1

• Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. *Thromb Haemostasis.* 2016;116:S10-S17. Article. IF: 5.627; D1

• Wang M, Álvarez-Román MT, Chowdhary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX FC fusion protein for the treatment of active patients: a literature review and case reports. *Blood Coagul Fibrin.* 2016;27(7):737-44. Review. IF: 1.367; Q4

PUBLIC PROJECTS

Butta Coll NV. Diferencias en la hemostasia de pacientes con trombocitopenia: identificación de mecanismos procoagulantes compensatorios del efecto de la disminución del número de plaquetas (PI12/01831). ISCIII. 2013-2016.

Management centre: FIBHULP

Butta Coll NV. Estudio prospectivo de pacientes con trombocitopenia inmune: identificación de mecanismos fisiopatológicos que condicionan el fenotipo clínico y la respuesta a la terapia (PI15/01457). ISCIII. 2016-2018.

Management centre: FIBHULP

Butta Coll NV. Contrato Miguel Servet Tipo II (MSIII I/000024). ISCIII. 2015-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

Álvarez Román MT. Manejo de la patología urgente en pacientes con hemofilia en el ámbito extrahospitalario. Desarrollo de un protocolo de actuación extrahospitalario. Desarrollo de un protocolo de actuación coordinado entre el summa I12 y el Servicio de Trombosis y Hemosta. Antares Consulting S.A. 2014-Ongoing.

Management centre: FIBHULP

Strategic Objective

This group's research activities address various relevant questions in the area of haematology and focus on the characterisation of the genetic and molecular basis of coagulation and haemostatic function. Our group investigates physiological processes such as coagulation, haemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signalling, with special emphasis on their relevance to pathological processes.



Butta Coll NV. Estudio de la hemostasia en la enfermedad de Behçet. Antares Consulting S.A. 2011-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Alteraciones citogenéticas en donantes de sangre sanos. FIBHULP. 2004-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Monitorización del tratamiento con agentes bypass, en pacientes con hemofilia e inhibidor mediante tres métodos de evaluación global de la hemostasia. Antares Consulting S.A. 2007-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Estudio retrospectivo de utilización de Fanhdi en enfermedad de Von Willebrand y hemofilia A. Baxter S.L. 2008-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Desarrollo de un nuevo método de laboratorio de alta sensibilidad para la detección cuantitativa de anticuerpos contra el factor VIII. Pfizer S.L.U. 2012-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Sinovitis post-hemartros. Estudio clínico, biológico y ecográfico. Post-hemarthrosis sinovitis markers on patients with haemophilia on prophylaxis. Clinical, biological and ultrasonographic study. CAM. 2012.

Management centre: FIBHULP

Jiménez Yuste VM. Estudio in vitro del efecto procoagulante de factor VII recombinante activado y vatreptacog alfa en sangre de pacientes con hemofilia grave mediante tromboelastografía y test de generación de tromina. Novo Nordisk A.S. 2012-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Case-control pilot study of the immune modulating effect of feiba on patients with haemophilia A and inhibitors. Baxter Healthcare Corporation. 2013-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Evaluación de la disfunción endotelial e identificación de factores de riesgo asociados a la enfermedad cardiovascular en el paciente con hemofilia. Antares Consulting S.A. 2013-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Curso de Hematología: investigación y clínica. Glaxosmithkline S.A. 2014-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Field study to evaluate the assay variability of bay 81-8973 measurements with methodologies, reference standards and reagents routinely used in clinical laboratories. Bayer Hispania S.L. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Field study to evaluate the activity a site specific of B-domain deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9024) in plasma samples measured with both chromogenic and one stage assays used in clinical laboratories. Bayer Hispania S.L. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Estudio del papel de los biomarcado-

res de daño endotelial, hepatocelular y fibrosis hepática y la elastografía de transición en el diagnóstico del síndrome de obstrucción sinusoidal. Eusa Pharma Iberia S.L.U. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. One-year training and research scholarship programme in haemophilia and other haemostatic disorders. Novo Nordisks Health Care AG. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Individualización del régimen profiláctico con agentes biapás en pacientes con hemofilia e inhibidor de alta respuesta mediante tromboelastometría y trominografía. Antares Consulting S.A. 2014-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Tailoring prophylaxis in children with severe haemophilia: impact of the trough procoagulant state on the incidence of breakthrough bleeding. Novo Nordisks Health Care AG. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Curso en investigación y tratamiento de la hemofilia. Laboratorios Pfizer Ltda. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Individualización de la profilaxis: estudio de los niveles valles mediante técnicas globales e impacto de la actividad física. Baxalta GMBH. 2015-Ongoing.

Management centre: FIBHULP

Jiménez Yuste VM. Formación orientada a la investigación en el área de hematología. Profármaco-2 S.L. 2015-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Álvarez Román MT. Estudio de extensión de fase III, abierto, multicéntrico para evaluar la seguridad y eficacia del factor de la coagulación VIII recombinante (RVIII-cadena sencilla, CSL627) en pacientes con hemofilia a severa. CSL Behring GMBH Clinical.

HULP Code: Anexo-I 4179. Sponsored's Protocol Code: CSL-3001.

Signature Date: 18/05/2016

Álvarez Román MT. Estudio multicéntrico de fase II, abierto, de un solo brazo, prospectivo, intervencional, del factor derivado del plasma VIII/VWF (Alphanate®) en la terapia de inducción de tolerancia inmune en sujetos con hemofilia congénita A. Grifols S.A.

HULP Code: 4655. Sponsored's Protocol Code: GB11406.

Signature Date: 27/07/2016

Álvarez Román MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNT) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave (FVIII < 1 %). Baxter Innovations GMBH.

HULP Code: 4487. Sponsored's Protocol Code: 261203.

Signature Date: 19/01/2016

Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC di-

rigida a dos concentraciones mínimas de FVIII distintas en sujetos con hemofilia A grave. Baxter Innovations GMBH.

HULP Code: 4547. Sponsored's Protocol Code: 261303.

Signature Date: 16/02/2016

Álvarez Román MT. Estudio de extensión de fase IIIB, abierto, multicéntrico, sobre la seguridad y eficacia de una proteína de fusión del factor IX recombinante de la coagulación con la albumina (RIXFP) en pacientes con hemofilia B. CSL Behring GMBH Clinical.

HULP Code: Anexo-II 4011. Sponsored's Protocol Code:

CSL654_3003.

Signature Date: 23/02/2016

Álvarez Román MT. Estudio de fase I, prospectivo, abierto, de dos periodos, secuencia fija y aumento escalonado de la dosis sobre la FC y la seguridad de BAX 826 (APSFVIIIIR) en pacientes con hemofilia a grave (FVIII < 1 %) previamente tratados. Baxter Innovations GMBH.

HULP Code: 4563. Sponsored's Protocol Code: 291501.

Signature Date: 16/03/2016

Álvarez Román MT. Estudio multicéntrico de recogida de datos retrospectivos sobre el uso del factor X de alta pureza de BPL en el tratamiento de pacientes con deficiencia del factor X hereditaria. Bio Products Laboratory Ltd.

HULP Code: PI-2192. Sponsored's Protocol Code: TEN 05.

Signature Date: 12/05/2016

Álvarez Román MT. Estudio multicéntrico, abierto y de administración repetida, para evaluar la seguridad y la eficacia de UCB7665 en sujetos con trombocitopenia inmune primaria (tp0001). UCB Biosciences GMBH.

HULP Code: 4562. Sponsored's Protocol Code: TP0001.

Signature Date: 31/03/2016

Álvarez Román MT. Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune primaria en España. Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia.

HULP Code: PI-2517. Sponsored's Protocol Code: VERTEX 2.0.

Signature Date: 18/10/2016

Jiménez Yuste VM. Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129-0000-1003 administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia A. Novo Nordisk AS.

HULP Code: Anexo-III 3526. Sponsored's Protocol Code:

NN7088-3859.

Signature Date: 09/05/2016

Jiménez Yuste VM. Ensayo clínico de fase III, aleatorizado, multicéntrico y abierto para evaluar la eficacia, la seguridad y la farmacocinética del emicizumab profiláctico, en comparación con la ausencia de profilaxis, en pacientes con hemofilia A sin inhibidores. F Hoffmann-La Roche Ltd.

HULP Code: 4606. Sponsored's Protocol Code: BH30071.

Signature Date: 28/04/2016

Jiménez Yuste VM. Ensayo clínico aleatorizado, multicéntrico, abierto de fase III para evaluar la eficacia, seguridad y farmacocinética del RO5534262 profiláctico frente a la no profilaxis en pacientes con hemofilia A con inhibidores. Roche Farma S.A.

HULP Code: Anexo-I 4486. Sponsored's Protocol Code: BH29884.

Signature Date: 10/02/2016

Jiménez Yuste VM. Seguridad y eficacia de NNC0155-0000-0004 en la prevención y el tratamiento de las hemorragias en pacientes pediátricos con hemofilia A no tratados previamente. Novo Nordisk AS.

HULP Code: Anexo-II 3602. Sponsored's Protocol Code: NN7008-3809.

Signature Date: 15/03/2016

Jiménez Yuste VM. Ensayo clínico de fase III multicéntrico, abierto y de un solo brazo para evaluar la eficacia, la seguridad y la farmacocinética de la administración subcutánea de emicizumab una vez a la semana en pacientes pediátricos con hemofilia A con inhibidores. F Hoffmann-La Roche Ltd.

HULP Code: 4605. Sponsored's Protocol Code: BH29992.

Signature Date: 10/05/2016

Jiménez Yuste VM. Ensayo multicéntrico, comparativo, doble ciego, aleatorizado y cruzado para investigar la farmacocinética y la seguridad de dosis única de turoctocog alfa pegol a partir del proceso pivotal y de turoctocog alfa pegol a partir del proceso comercial en pacientes con hemofilia A grave. Novo Nordisk AS.

HULP Code: 4654. Sponsored's Protocol Code: NN7088-4033.

Signature Date: 02/09/2016

Jiménez Yuste VM. Ensayo clínico estudio de fase III, multicéntrico y sin enmascaramiento para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica del emicizumab administrado cada 4 semanas en pacientes con hemofilia A. F Hoffmann-La Roche Ltd.

HULP Code: 4674. Sponsored's Protocol Code: BO39182.

Signature Date: 29/08/2016

Jiménez Yuste VM. Guardian 9. Ensayo abierto y multicéntrico para evaluar la farmacocinética de Novoeight® (turoctocog alfa) en relación con el IMC en sujetos con hemofilia A. Novo Nordisk AS.

HULP Code: 4618. Sponsored's Protocol Code: NN7008-4239.

Signature Date: 23/09/2016

Martín Salces M. Estudio de fase III, multicéntrico, de un solo brazo y abierto sobre la eficacia y la seguridad del factor VIII recombinante porcino con dominio B suprimido (BAX 802) en sujetos con hemofilia A congénita con inhibidores del factor VIII sometidos a intervenciones quirúrgicas u otros procedimientos invasivos. Baxalta Innovations GMBH.

HULP Code: 4658. Sponsored's Protocol Code: 241502.

Signature Date: 15/07/2016

Martín Salces M. Estudio de fase III, multicéntrico, abierto y no controlado para evaluar la seguridad y la eficacia de BAY81-profiláctico. Bayer Hispania SL.

HULP Code: Anexo-I 4099.

Sponsored's Protocol Code: 81-8973/13400.

Signature Date: 24/10/2016





VASCULAR PHYSIOLOGY AND PHARMACOLOGY GROUP



Publications: **21**
 Impact Factor: **73.617**
 Q1: **13**

Mercedes Salaiques Sánchez

Catedrática. Departamento de Farmacología. Facultad de Medicina. UAM

Andrea Aguado Martínez

Investigadora Postdoctoral. UAM

María Jesús Alonso Gordo

Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

María Soledad Avendaño Herrador

Investigador Postdoctoral. UAM

Gloria Balfagón Calvo

Catedrática. Departamento de Fisiología. Facultad de Medicina. UAM

Javier Blanco Rivero

Profesor Contratado. Departamento de Fisiología. Facultad de Medicina. UAM

Ana María Briones Alonso

Investigadora Senior (Contrato Ramón y Cajal). UAM

Laura Caracuel Cano

Investigadora Postdoctoral. UAM

Ana Belén García Redondo

Investigadora Postdoctoral. UAM

María González Amor

Investigadora Predoctoral. UAM

Raquel Hernanz Martín

Profesora Contratada. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Ángela Martín Cortes

Profesora Contratada. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Marta Miguel Castro

Científico Titular. Instituto de Investigación en Ciencias de la Alimentación. Consejo Superior de Investigaciones Científicas (CIAL, CSIC-UAM)

Roberto Palacios Ramírez

Investigador Predoctoral. Universidad Rey Juan Carlos

Raquel Rodríguez Díez

Investigadora Postdoctoral. UAM

Strategic Objective

Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension.

The group is located at the Faculty of Medicine (UAM) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cell based studies combined with physiological, pharmacological and molecular biology techniques. In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in the role of prostanoids derived from the inducible isoform of cyclooxygenase (COX-2) and reactive oxygen spe-

cies (and their interaction among each other or with other mediators such as nitric oxide) in inflammatory conditions that resemble those found in cardiovascular pathologies. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

Research Lines

- Oxidative stress, COX-derived products and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies.
- Adipose tissue and vascular alterations in cardiovascular pathologies.
- Neural control of vascular tone.
- Cardiovascular effects of heavy metals.
- Antioxidant and antihypertensive properties of bioactive peptides.

Research Activity

DOCTORAL THESES

Brose Piotrowicz IB. Avaliação das propriedades antioxidantes e anti-hipertensivas de peptídeos obtidos do concentrado proteico de farelo de arroz[dissertation]. Rio Grande: Universidade Federal do Rio Grande: 2016(27/05/2016).

Directors: Salas Mellado M, Miguel Castro M.

Palacios Ramírez R. Papel de ET-1 en la expresión de COX-2 y la contractilidad vascular en hipertensión. Modulación por PPARγ[dissertation]. Madrid: URJC: 2016(03/05/2016).

Directors: Hernanz Martín R, Alonso Gordo MJ.



PUBLICATIONS

- Aguado A, Fischer T, Rodríguez C, Manea A, Martínez-González J, Touyz RM, Hernanz R, Alonso MJ, Dixon DA, Briones AM, Salaiques M. Hu antigen R is required for NOX-1 but not NOX-4 regulation by inflammatory stimuli in vascular smooth muscle cells. *J Hypertens*. 2016;34(2):253-65. Article. IF: 4.085; Q1
- Aleixandre A, Miguel M. Dietary fiber and blood pressure control. *Food Funct*. 2016;7(4):1864-71. Review. IF: 3.247; Q1
- Avendaño MS, Martínez-Revelles S, Aguado A, Simoes MR, González-Amor M, Palacios R, Guillem-Llobat P, Vassallo DV, Vila L, García-Puig J, Beltrán LM, Alonso MJ, Cachofeiro MV, Salaiques M, Briones AM. J Role of COX-2-derived PGE(2) on vascular stiffness and function in hypertension. *Brit J Pharmacol*. 2016;173(9):1541-55. Article. IF: 5.491; D1
- Azevedo BF, Simoes MR, Fiorim J, Botelho T, Angeli JK, Vieira JVA, Alonso MJ, Salaiques M, dos Santos L, Vassallo DV. Chronic mercury exposure at different concentrations produces opposed vascular responses in rat aorta. *Clin Exp Pharmacol P*. 2016;43(7):712-9. Article. IF: 2.01; Q3
- Callera GE, Antunes TT, Correa JW, Moorman D, Gutsol A, He Y, Cat AND, Briones AM, Montezano AC, Burns KD, Touyz RM. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis. *Bioscience Rep*. 2016;36:e00398. Article. IF: 2.906; Q2

- Criado M, Balsera B, Mulet J, Sala S, Sala F, de la Torre-Martínez R, Fernández-Carvajal A, Ferrer-Montiel A, Moreno-Fernández S, Miguel M, de Vega MJ, González-Muñiz R. 1,3-diphenylpropan-1-ones as allosteric modulators of alpha 7 nACh receptors with analgesic and antioxidant properties. *Future Med Chem*. 2016;8(7):731-49. Article. IF: 3.556; Q1
- Fernández-Vallinas S, Miguel M, Aleixandre A. Long-term antihypertensive effect of a soluble cocoa fiber product in spontaneously hypertensive rats. *Food Nutr Res*. 2016;60:29418. Article. IF: 2.039; Q2
- Galán M, Salaiques M. T-regulatory cells and vascular function: the importance of their immunosuppressive action in hypertensive disease. *J Hypertens*. 2016;34(1):36-8. Editorial Material. IF: 4.085; Q1
- Garcés-Rimón M, González C, Uranga JA, López-Miranda V, López-Fandino R, Miguel M. Pepsin egg white hydrolysate ameliorates obesity-related oxidative stress, inflammation and steatosis in Zucker fatty rats. *Plos One*. 2016;11(3):e0151193. Article. IF: 2.806; Q1
- Garcés-Rimón M, López-Exposito I, López-Fandino R, Miguel M. Egg white hydrolysates with in vitro biological multiactivities to control complications associated with the metabolic syndrome. *Eur Food Res Technol*. 2016;242(1):61-9. Article. IF: 1.664; Q2
- Garcés-Rimón M, Sandoval M, Molina E, López-Fandino R, Miguéla M. Egg protein hydrolysates: New culinary textures. *Int J Gastronomy Food Sci*. 2016;3:17-22. Article. Not Indexed
- García-Redondo AB, Aguado A, Briones AM, Salaiques M. NADPH oxidases and vascular remodeling in cardiovascular diseases. *Pharmacol Res*. 2016;114:110-20. Review. IF: 4.48; Q1
- Morales-Cano D, Moreno L, Barreira B, Briones AM, Pandolfi R, Moral-Sanz J, Callejo M, Mondéjar-Parreno G, Cortijo J, Salaiques M, Duarte J, Pérez-Vizcaino F, Cogolludo A. Activation of PPAR beta/delta prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries. *Clin Sci*. 2016;130(20):1823-36. Article. IF: 4.936; Q1
- Rizzetti DA, Altermann CD, Martínez CS, Pecanha FM, Vassallo DV, Uranga-Ocio JA, Castro MM, Wiggers GA, Mello-Carpes PB. Ameliorative effects of egg white hydrolysate on recognition memory impairments associated with chronic exposure to low mercury concentration. *Neurochem Int*. 2016;101:30-7. Article. IF: 3.262; Q2
- Rizzetti DA, Fernández F, Moreno S, Ocio JAU, Pecanha FM, Vera G, Vassallo DV, Castro MM, Wiggers GA. Egg white hydrolysate promotes neuroprotection for neuropathic disorders induced by chronic exposure to low concentrations of mercury. *Brain Res*. 2016;1646:482-9. Article. IF: 2.746; Q3
- Santiago E, Martínez MP, Climent B, Muñoz M, Briones AM, Salaiques M, García-Sacristán A, Rivera L, Prieto D. Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2. *Brit J Pharmacol*. 2016;173(22):3176-95. Article. IF: 5.491; D1
- Sastre E, Caracuel L, Blanco-Rivero J, Callejo M, Xavier FE, Balfagón G. Biphasic effect of diabetes on neuronal nitric oxide release in rat mesenteric arteries. *Plos One*. 2016;11(6):e0156793. Article. IF: 2.806; Q1
- Sastre E, Caracuel L, Prieto I, Llevenen P, Aller MA, Arias J, Balfagón G, Blanco-Rivero J. Decompensated liver cirrhosis and neural regulation of mesenteric vascular tone in rats: role of sympathetic, nitrergic and sensory innervations. *Sci Rep-Uk*. 2016;6:31076. Article. IF: 4.259; Q1
- Schmidt PM, Escobar AG, Torres JGD, Martínez CS, Rizzetti DA, Kunz SN, Vassallo DV, Alonso MJ, Pecanha FM, Wiggers GA. Aluminum exposure for one hour decreases vascular reactivity in conductance and resistance arteries in rats. *Toxicol Appl Pharm*. 2016;313:109-18. Article. IF: 3.791; Q1



- Victorio JA, Clerici SP, Palacios R, Alonso MJ, Vassallo DV, Jaffe IZ, Rossoni LV, Davel AP. Spironolactone prevents endothelial nitric oxide synthase uncoupling and vascular dysfunction induced by beta-adrenergic overstimulation role of perivascular adipose tissue. *Hypertension*. 2016;68(3):726. Article. IF: 6.857; D1
- Wiggers GA, Furiere LB, Briones AM, Avendaño MS, Pecanha FM, Vassallo DV, Salaices M, Alonso MJ. Cerebrovascular endothelial dysfunction induced by mercury exposure at low concentrations. *Neurotoxicology*. 2016;53:282-9. Article. IF: 3.1; Q2

PUBLIC PROJECTS

Alonso Gordo MJ. Effect of exposure to lead and cadmium on cardiovascular system in animal models (PHBP14-00001). MECD. 2015-2016.

Management centre: URJC

Alonso Gordo MJ. Modulation by NRF2 of hypertension-associated vascular damage. Relationship with TLR4 (SAF2015-69294-R). MINECO. 2016.

Management centre: UAM

Balfagón Calvo G. Sexual dimorphism in vascular nitric neuropathy in diabetes: analysis of the pathway involved and effects of its modulation. (SAF2012-38530). MINECO. 2013-2016.

Management centre: UAM

Briones Alonso AM. Relación entre postanoídes, especies reactivas de oxígeno y aldosterona del tejido adiposo y su papel en las alteraciones cardiovasculares asociadas a hipertensión y obesidad (PI13/01488). ISCIII. 2014-2016.

Management centre: FIBHULP

Miguel Castro M. Efecto de un hidrolizado de proteínas de huevo con pepsina en un modelo experimental de síndrome metabólico inducido por dieta (INTRAMURAL 2015701028). CSIC. 2015-2016.

Management centre: CSIC

Miguel Castro M. Obtención de hidrolizados de proteínas de huevo para controlar las distintas alteraciones asociadas al Síndrome Metabólico. Evaluación de su eficacia y seguridad en humanos (AGL-2012-32387). MINECO. 2015-2016.

Management centre: CSIC

Salaices Sánchez M. CIBER Enfermedades Cardiovasculares (CB16/11/00286). ISCIII. 2016-2017.

Management centre: UAM

Salaices Sánchez M. Hypertension and reciprocal regulation of reactive oxygen species and prostanoids in vascular cells. Role of angiotensin II/TLR4 pathway on the production of both mediators. (SAF2012-36400). MINECO. 2013-2016.

Management centre: UAM

Salaices Sánchez M. Red de Investigación Cardiovascular (RIC) (RD12/0042/0024). ISCIII. 2013-2017.

Management centre: UAM

PRIVATE PROJECTS

Briones Alonso AM. Relación entre postanoídes, especies reactivas de oxígeno y aldosterona del tejido adiposo

y su papel en las alteraciones cardiovasculares asociadas a hipertensión y obesidad. Roche Farma, S.A. 2014-Ongoing.

Management centre: FIBHULP

Miguel Castro M. Estudio de los procesos de proteólisis en el desarrollo de aromas y sabores en el jamón puro ibérico de bellota y caracterización de péptidos bioactivos. Arturo Sanchez e Hijos. 2016-Ongoing.

Management centre: CSIC

Miguel Castro M. Participación en comité de expertos y asesoramiento científico en materia de alimentación y bebidas: cerveza 0,0% isotónica. Farfara Lab. 2016-Ongoing.

Management centre: CSIC

INTERNATIONAL PROJECTS

Alonso Gordo MJ. Efecto de la exposición a los metales tóxicos plomo y cadmio sobre el sistema cardiovascular en modelos animales (PHBP14-00001). MECyD. 2015-2016.

Management centre: UAM

Briones Alonso AM. ADMIRE - Aldosterone and mineralocorticoid receptor: pathophysiology, clinical implication and therapeutic innovations (COST BM1301). EU. 2014-2017.

Management centre: UAM

Miguel Castro M. Egg white hydrolysates as functional food ingredients to control the cardiometabolic complications associated to oxidative stress induced by heavy metals exposure (406715/2013-0). Conselho Nacional de Desenvolvimento Científico e Tecnológico del Gobierno de Brasil. 2014-2017.

Management centre: Universidad Federal do Espirito Santo

PATENTS AND TRADEMARKS

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaices Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; Nanoate, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779,

EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.




González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.





VASCULAR PHARMACOLOGY AND METABOLISM GROUP (FARMAVSM)

 Publications: **3**
 Impact Factor: **13.237**
 QI: **3**

Carlos Félix Sánchez Ferrer

Catedrático de Farmacología. UAM

Elena Cercas Alonso

Técnico Especialista en Análisis Clínico.
UAM

Jorge Francisco Gómez Cerezo

Jefe de Servicio de Medicina Interna.
Hospital Universitario Infanta Sofía

Concepción Peiró Vallejo

Profesora Titular de Farmacología. UAM

Mariella Ramos González


Investigador Predoctoral. UAM

Susana Vallejo Fernán

Investigador Postdoctoral. UAM

Strategic Objective

Our research deals with the challenge I of the Spanish Strategy for Science and Technology and for Innovation: "Health, demographic change and wellbeing". The main goal is to improve our understanding of vascular ageing, both in healthy and pathological conditions, like obesity and type 2 diabetes mellitus. Vascular ageing is associated with complex vascular structural and functional changes. It represents a crucial process for the health status of elderly people and the main risk factor for the development of cardiovascular diseases. Obesity and type 2 diabetes mellitus are extremely prevalent and closely related diseases, so that the term "diabesity" has



been coined. Diabesity is among the highest health and socioeconomic challenge in Western countries, especially due to cardiovascular complications. Epidemiological studies indicate that these patients have reduced life expectancy, in close relation to the development of diseases, such as hypertension and atherosclerosis. Diabesity is also considered an age-related disease, as well as a progeric entity, sharing similar cellular and molecular mechanisms than the age-induced vascular dysfunction. Unders-

tanding the pathways involved in vascular damage and premature ageing associated to diabesity should help to delay vascular complications. Furthermore, preservation of vascular function in ageing should not only reduce deaths and disabilities secondary to cardiovascular events but should attenuate other negative aspects of the ageing process that lead to loss of function and/or disability, such as motor capacity and cognitive frailty. Indeed, it seems now quite evident that robustness in advanced age cannot be achieved without preservation of vascular function.

Research Lines

The main objective of FARMAVSM for the next 5 years is to determine how those called progeric cardiometabolic diseases, particularly obesity, diabetes mellitus and/or metabolic syndrome, can favour the vascular ageing process. In particular, we will analyse the role for selected adipokines over-produced and released by the inflamed adipose tissue in the development of premature vascular ageing. We aim to characterize the cellular and molecular mechanisms of action of selected adipokines that may lead to alterations in the vascular function and/or structure, as well as their interaction with other key factors influencing cardiometabolic diseases such is high glucose. Moreover, as pharmacologists, we aspire to characterize new pharmacological targets that could be relevant to prevent or delay accelerated vascular ageing and the associated cardiovascular risk. To achieve this global objective, we have now an active grant by the Plan Nacional de I+D covering 2015 to 2017, and we expect to obtain further financial support for the period 2018 to 2020. Furthermore, we have active projects with pharmaceutical companies (Boehringer Ingelheim). Our strategy will also include our incorporation to national networks (CIBER or RETICS), and international programmes (Horizon 2020). Indeed, this is in fact one of the reasons for asking our inclusion in IdiPAZ. Additionally, we aimed

to include new researchers into FARMAVSM, both at pre- and postdoctoral level (FPU-MEC, FPU-UAM, Marie Skłodowska-Curie Actions, Juan de La Cierva, Ramón y Cajal).

Research Activity

PUBLICATIONS

- Peiró C, Romacho T, Azcutia V, Villalobos L, Fernández E, Bolaños JP, Moncada S, Sánchez-Ferrer CF. Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. *Cardiovasc Diabetol*. 2016;15:82. Article. IF: 4.752; Q1
- Romacho T, Vallejo S, Villalobos LA, Wronkowitz N, Indrakusuma I, Sell H, Eckel J, Sánchez-Ferrer CF, Peiró C. Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A(2) release. *J Hypertens*. 2016;34(5):869-76. Article. IF: 4.085; Q1
- Villalobos LA, Hipólito- Luengo AS, Ramos-González M, Cercas E, Vallejo S, Romero A, Romacho T, Carraro R, Sánchez-Ferrer CF, Peiró C. The angiotensin-(1-7)/mas axis counteracts angiotensin II-dependent and -independent pro-inflammatory signaling in human vascular smooth muscle cells. *Front Pharmacol*. 2016;7:482. Article. IF: 4.4; Q1

PUBLIC PROJECTS

Peiró Vallejo CM, Sánchez Ferrer CF. Adipoquinas y envejecimiento vascular: mecanismos implicados y modulación farmacológica (SAF2014-52762-R). MINECO. 2015-2017.

Management centre: UAM

PRIVATE PROJECTS

Sánchez-Ferrer CF. Endothelial dysfunction induced by the adipokine dipeptidyl peptidase 4 (DPP-4) in human mesenteric microvessels and its prevention by linagliptin. *Boehringer Ingelheim España*. 2015-2016.

Management centre: UAM



3.3 Infectious Diseases and Immunity Area

Eduardo López-Collazo

Documents: **212** IF: **956.421**
 Originals: **154** IF: **641.204**
 DI: **38** QI: **86**

- AIDS and Infectious Diseases Group
- Molecular Microbiology Group
- Immuno-Rheumatology Group
- Innate Immune Response Group
- Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System Group
- Lymphocyte Pathophysiology in Immunodeficiencies Group
- Drug Hypersensitivity and Innate Immune Response Group
- Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases Group
- Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group

AIDS AND INFECTIOUS DISEASES GROUP



Publications: **43**
 Impact Factor: **292.427**
 QI: **19**

José Ramón Arribas López

Jefe de Sección de Enfermedades Infecciosas. HULP
 Profesor Asociado. UAM

Marta Arsuaga Vicente

Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP

José Ignacio Bernardino de la Serna

Facultativo Especialista de Área en Medicina Interna. Unidad VIH. HULP

Lara Crespillo Andújar

Médico Ajunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP

Fernando de la Calle Prieto

Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP
 Profesor Colaborador. UAM

Alicia de Pablo Olaiz

Técnico de Laboratorio (Contrato de Técnico de Apoyo). HULP

Marta Díaz Menéndez

Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. HULP

Marta Gálvez Charro

Enfermera. Unidad de VIH. HULP

Francisco Gayá Moreno

Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). HULP

Alicia González Baeza

Investigadora colaboradora. HULP

Juan Julián González García

Jefe de Sección. Unidad de VIH. HULP

Pedro Herranz Pinto

Facultativo Especialista de Área en Dermatología. Jefe de Sección. HULP

Víctor Hontañón Antoñana

Investigador contratado. RIS

María Concepción Ladrón de Guevara García

Facultativo Especialista de Área en Microbiología y Parasitología. Hospital Carlos III- HULP

María del Mar Lago Núñez

Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP

Raquel Martín Jara

Enfermera. Unidad de VIH. HULP

Mario Mayoral Muñoz

Enfermero. HULP

Juan José Miguel Castro

Enfermero. HULP

Rocío Montejano Sánchez

Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP

María Luisa Montes Ramírez

Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. HULP

Marta Mora Rillo

Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP

Francisco Moreno Ramos

Farmacéutico. HULP

José Francisco Pascual Pareja

Facultativo Especialista de Área de Medicina Interna. Hospital de Cantoblanco — HULP

José María Peña Sánchez de Rivera

Jefe de Sección de Medicina Interna. HULP
 Catedrático. UAM

Ignacio Pérez Valero

Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. HULP



de Pablo Olaiz A. Contrato de técnico de apoyo (CA12/00333). ISCIII. 2013-2016.

Management centre: FIBHULP

Gayá Moreno F. Contrato de técnico de apoyo. ISCIII, CAM. 2008-Ongoing.

Management centre: FIBHULP

González García JJ. Erradicación del VHC en pacientes coinfectados por VIH/VHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica (EC11-241). MSSSI. 2012-2017.

Management centre: FIBHULP

González García JJ. Red de SIDA (RIS) (RD12/0017/0016). ISCIII. 2013-2017.

Management centre: FIBHULP

González García JJ. Efectos de la erradicación del VHC en pacientes con cirrosis avanzada por VHC. Una aproximación translacional (PI14/01581). ISCIII. 2015-2017.

Management centre: FIBHULP

Montejano Sanchez R. Contrato Río Hortega. (CM14/00034). ISCIII. 2015-2017.

Management centre: FIBHULP

Mora Rillo M. Red de Investigación Cooperativa en Enfermedades Tropicales (RICET) (RD12/0018/0023). ISCIII. 2013-2017.

Management centre: FIBHULP

Paño Pardo JR. Cohorte ambispectiva de pacientes con infecciones por enterobacterias productoras de carbapenemasa (PI14/01832). ISCIII. 2015-2016.

Management centre: FIBHULP

Pérez Valero I. Contrato Juan Rodés (JR13/00016). ISCIII. 2014-2016.

Management centre: FIBHULP

Pérez Valero I. Seguridad neurocognitiva de terapias antirretrovirales no convencionales con inhibidores de proteasa (IPS) (PI14/01876). ISCIII. 2015-2017.

Management centre: FIBHULP

Rodés Soldevila B. Contrato de estabilización I2 (CESI1/021). ISCIII, CAM. 2012-Ongoing.

Management centre: FIBHULP

Rodés Soldevila B. Análisis de la expresión de los niveles de proteínas modificadoras y otros mecanismos epigenéticos asociados a la regulación de la transcripción del VIH en pacientes LTNP/EC (PI12/00850). ISCIII. 2013-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

Arribas López JR. Aplicación de la secuenciación de genomas individuales (SGI) al estudio de la resistencia a antirretrovirales en poblaciones minoritarias celulares y plasmáticas en pacientes infectados por VIH. Fundación para la Investigación y la Prevención del SIDA. 2009-Ongoing.

Management centre: FIBHULP

Arribas López JR. Registro descriptivo longitudinal retrospectivo de los pacientes Naïve incluidos en la cohorte de pacientes con infección por VIH del Hospital La Paz de

Madrid (Cohorte VIH-La Paz) PI-890. Janssen-Cilag España S.A. 2010-Ongoing.

Management centre: FIBHULP

Arribas López JR. Reparación y asesoramiento para el desarrollo del curso de investigación sobre VIH y deterioro neurocognitivo, a través del grupo "SIDA y enfermedades infecciosas". Bristol Myers Squibb S.A.U. 2012-Ongoing.

Management centre: FIBHULP

Arribas López JR. VIII Jornadas de actualización científica en enfermedades infecciosas. 27 y 28 de septiembre de 2012. Novartis Farmacéutica S.A. 2012-Ongoing.

Management centre: FIBHULP

Arribas López JR. Research in boosted PI monotherapy. 2012-Ongoing.

Management centre: FIBHULP

Arribas López JR. Curso de actualización de la investigación en simplificación con inhibidores de proteasa. Janssen Cilag S.A. Colombia. 2014-Ongoing.

Management centre: FIBHULP

Arribas López JR. Curso de actualización en investigación en VIH: aprendizajes pasados y nuevos conceptos. Janssen Cilag S.A. Colombia. 2014-Ongoing.

Management centre: FIBHULP

Arribas López JR. Curso de avances en la investigación en el tratamiento con inhibidores de proteasa. Janssen Cilag S.A. Colombia. 2015-Ongoing.

Management centre: FIBHULP

Arribas López JR. XI Jornadas de actualización en enfermedades infecciosas: de la investigación a la práctica clínica. Gilead Sciences S.L. 2015-Ongoing.

Management centre: FIBHULP

Arribas López JR. Estudio de longitud telomérica en pacientes infectados por el VIH expuestos a dos estrategias de tratamiento antirretroviral diferente (Telomere Length Substudy). The European Treatment Network For HIV, Hepatitis and Global Infectious Diseases. 2016-Ongoing.

Management centre: FIBHULP

Arribas López JR. XI Jornadas de actualización en enfermedades infecciosas: de la investigación a la práctica clínica. 2016-Ongoing.

Management centre: FIBHULP

Bernardino de la Serna JI. Cohorte observacional internacional coordinada por la cohorte Suiza de VIH (SHCS) sobre la contribución de las variables genéticas asociadas a la aparición de la enfermedad coronaria en pacientes infectados por el virus de la inmunodeficiencia humana. VIH Kantonsspital Bruderholz. 2011-Ongoing.

Management centre: FIBHULP

de la Calle Prieto F. Curso de consejo integral al viajero: de la investigación a la práctica clínica. Clientes Varios. 2016-Ongoing.

Management centre: FIBHULP

González García JJ. Estudio de cohorte de pacientes con infección por VIH del Hospital La Paz de Madrid (cohorte VIH-La Paz). Gilead Sciences S.L. 2008-Ongoing.

Management centre: FIBHULP

González García JJ. Características clínicas y epidemiológicas de la coinfección VHC-VIH en la población española en 2008. 2008-Ongoing.

Management centre: FIBHULP

González García JJ. Erradicación del virus de la hepatitis C en pacientes infectados por el VIH: efectos a largo plazo sobre la morbilidad y mortalidad no relacionada con la hepatopatía, sobre la activación inmune y sobre marcadores metabólicos, de inflamación y de baño Enot. Fundación para la Investigación y la Prevención del SIDA. 2011-Ongoing.

Management centre: FIBHULP

Herranz Pinto P. Terapia biológica con artritis psoriásica y psoriasis y su investigación asociada. Merck Sharp and Dohme de España S.A. 2005-Ongoing.

Management centre: FIBHULP

Herranz Pinto P. Curso manejo global de la toxicidad mucocutánea de las terapias antineoplásicas. De la investigación a la práctica clínica. Merck S.L. 2016-Ongoing.

Management centre: FIBHULP

Herranz Pinto P. Jornada científica: lucha antiviral en el siglo XXI. Gilead Sciences S.L. 2016-Ongoing.

Management centre: FIBHULP

Montes Ramírez ML. Estudio de hepatopatías en pacientes infectados por VIH sin hepatitis víricas que reciben tratamiento antirretroviral. Abbvie Spain S.L.U. 2016-Ongoing.

Management centre: FIBHULP

Paño Pardo JR. Evaluación de la utilización de antifúngicos a través de datos agregados de consumo: elaboración de un modelo. Gilead Sciences S.L. 2010-Ongoing.

Management centre: FIBHULP

Peña Sánchez de Rivera JM. Estudio de cohorte de pacientes con infección por VIH del Hospital La Paz de Madrid (cohorte VIH-La Paz). Glaxosmithkline S.A. 2008-Ongoing.

Management centre: FIBHULP

Pérez Valero I. Jornada de actualización en infecciones de transmisión sexual para Atención Primaria: de la investigación a la práctica clínica. Gilead Sciences S.L. 2015-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Pérez Valero I. CNS HIV anti-retroviral therapy effects research (HHS-N-271-2010-00036C). National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS). 2002-2016.

Management centre: National Institute of Mental Health

(NIMH), National Institute of Neurological Disorders and Stroke (NINDS)

CLINICAL TRIALS

Arribas López JR. Estudio internacional, multicéntrico, observacional, prospectivo, sobre la seguridad de mara-

viroc utilizado junto con la terapia de base optimizada en pacientes infectados por el VIH-I que han recibido tratamiento. Pfizer S.L.U.

HULP Code: Anexo-2 2754. Sponsored's Protocol Code: A4001067.

Signature Date: 31/05/2016

Arribas López JR. Estudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/tenofovir alafenamida en pacientes infectados por el VIH-I con insuficiencia renal leve o moderada. Gilead Sciences Inc.

HULP Code: Anexo-I 3947. Sponsored's Protocol Code: GS-US-292-0112.

Signature Date: 20/06/2016

Arribas López JR. Estudio de fase 3, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento a un régimen en un solo comprimido administrado una vez al día de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/TAF) frente a la continuación del régimen actual formado por un inhibidor de la proteasa potenciado (IPP) combinado con emtricitabina/tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el virus de la inmunodeficiencia humana de tipo I (VIH-I) con supresión virológica. Janssen-Cilag España S.A.

HULP Code: Anexo-I 4300. Sponsored's Protocol Code: TM-C114FD3013.

Signature Date: 27/05/2016

Arribas López JR. Estudio fase 3b, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinación a dosis fija (CDF) de efavirenz/emtricitabina/tenofovir disoproxil fumarato (EFV/FTC/FDF) a una CDF de emtricitabina/rilpivirina/tenofovir alafenamida (FTC/ RPV/TAF) en pacientes con infección por VIH I y supresión virológica. Gilead Sciences Inc.

HULP Code: 4375. Sponsored's Protocol Code: GS-US-366-1160.

Signature Date: 20/09/2016

Arribas López JR. Ensayo clínico fase 2b, aleatorizado, controlado con principio activo, doble ciego, para investigar la seguridad, eficacia y dosis-respuesta de BMS-955176, administrado con tenofovir/emtricitabina en adultos infectados por VIH I naïve a tratamiento. Bristol Myers Squibb International Corporation.

HULP Code: Anexo-I 4424. Sponsored's Protocol Code: AI468-038.

Signature Date: 27/05/2016

Arribas López JR. Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de tres lotes de estabilidad y un lote de dosis alta de RSV-ZEBOV-GP (vacuna contra el virus del ébola V920) en adultos sanos. Merck Sharp And Dohme de España S.A.

HULP Code: Anexo-I 4431. Sponsored's Protocol Code: V920-012.

Signature Date: 07/01/2016

Arribas López JR. Estudio fase III, multicéntrico, abierto, randomizado, para evaluar el cambio a MK 1439A en pacientes con supresión virológica infectados por el VIH-I en un régimen de un inhibidor de proteasa potenciado con ritonavir y dos inhibidores de la transcriptasa inversa



análogos de nucleósido. Merck Sharp & Dhome Corp.
HULP Code: Anexo-I 4441. Sponsored's Protocol Code: 1439A-024.

Signature Date: 27/09/2016

Arribas López JR. Estudio fase 2, aleatorizado, doble ciego, controlado con placebo para evaluar la farmacocinética, seguridad y actividad antiviral del JNJ-63623872 en combinación con oseltamivir en pacientes adolescentes, adultos y ancianos hospitalizados por infección de gripe A. Janssen-Cilag España S.A.

HULP Code: Anexo-I 4501. Sponsored's Protocol Code: 63623872FLZ2002.

Signature Date: 22/06/2016

Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/emtricitabina/tenofovir alafenamida en comparación con dolutegravir + emtricitabina/tenofovir alafenamida en adultos infectados por el VIH-I sin tratamiento antirretroviral previo. Gilead Sciences Inc.

HULP Code: Anexo-I 4573. Sponsored's Protocol Code: GS-US-380-1490.

Signature Date: 01/07/2016

Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/emtricitabina/tenofovir alafenamida en comparación con dolutegravir + emtricitabina/tenofovir alafenamida en adultos infectados por el VIH-I sin tratamiento antirretroviral previo. Gilead Sciences Inc.

HULP Code: 4573. Sponsored's Protocol Code: GS-US-380-1490.

Signature Date: 01/03/2016

Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/emtricitabina/tenofovir alafenamida en comparación con abacavir/dolutegravir/lamivudina en adultos infectados por el VIH-I sin tratamiento antirretroviral previo. Gilead Sciences Inc.

HULP Code: 4574. Sponsored's Protocol Code: GS-US-380-1489.

Signature Date: 01/04/2016

Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/emtricitabina/tenofovir alafenamida en comparación con abacavir/dolutegravir/lamivudina en adultos infectados por el VIH-I sin tratamiento antirretroviral previo. Gilead Sciences Inc.

HULP Code: Anexo-I 4574. Sponsored's Protocol Code: GS-US-380-1489.

Signature Date: 01/07/2016

Arribas López JR. Estudio piloto de fase III abierto para evaluar el cambio a la combinación de dosis fijas (CDF) elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (E/C/F/TAF) en sujetos adultos infectados por el VIH-I con supresión virológica que tienen la mutación de resistencia a itian archivada aislada M184V/M184I. Gilead Sciences Inc.

HULP Code: 4575. Sponsored's Protocol Code: GS-US-292-1824.

Signature Date: 04/02/2016

Arribas López JR. Estudio de fase III, aleatorizado, doble ciego, multicéntrico, con grupos paralelos, de ausencia de inferioridad, para evaluar la eficacia, seguridad y tolera-

bilidad de dolutegravir más lamivudina en comparación con dolutegravir más tenofovir/emtricitabina en adultos infectados por el VIH-I no tratados previamente. GlaxoSmithkline Research and Development Limited.

HULP Code: 4645. Sponsored's Protocol Code: 205543.

Signature Date: 08/09/2016

Arribas López JR. Reconstitución inmune en pacientes con infección por el VIH-I no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 cels/mm³ que reciben un régimen de fármacos. Fundacio Clinic per a la Recerca Biomedica.

HULP Code: 4641. Sponsored's Protocol Code: ADVANZ 4.

Signature Date: 27/07/2016

Arribas López JR. Estudio fase 3b, aleatorizado, doble ciego, con cambio de tratamiento para evaluar la seguridad y eficacia de una combinación a dosis fija (CDF) de emtricitabina/rilpivirina/tenofovir alafenamida (FTC/RPV/TAF), en pacientes con VIH-I positivo que presentan supresión virológica en tratamiento con emtricitabina/rilpivirina/tenofovir disoproxil fumarato (FTC/RPV/TDF). Gilead Sciences Inc.

HULP Code: Anexo-I 4374. Sponsored's Protocol Code: GS-US-366-1260.

Signature Date: 20/09/2016

González García JJ. Ensayo clínico en fase III para optimizar la inmuno-estimulación con maraviroc, un antagonista CCR5, combinado con tratamiento antirretroviral (TAR) en pacientes con infección por VIH-I avanzada, con diagnóstico tardío, criterio de definición de SIDA y/o recuentos de CD4 por debajo de 200 células/mm³. Agencia Nacional de Investigación sobre El SIDA y las Hepatitis Viricas (Inserm-Anrs).

HULP Code: Anexo-I 3680. Sponsored's Protocol Code: ANRS 146 OPTIMA.

Signature Date: 02/02/2016

González García JJ. Estudio fase III, aleatorizado, multicéntrico, abierto, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en el mantenimiento de la supresión virológica, tras una inducción con un tratamiento de comprimido único con un inhibidor de la integrasa en pacientes adultos infectados por el VIH-I que no han recibido un tratamiento antirretroviral previo. Laboratorios VIIV Healthcare S.L.

HULP Code: 4679. Sponsored's Protocol Code: 201584.

Signature Date: 10/08/2016

González García JJ. Estudio abierto de fase III para evaluar la eficacia y la seguridad del tratamiento con boceprevir en pacientes coinfectados por el VIH y VHC (genotipo I (subtipo A o B)), que han fracasado al tratamiento previo con peginterferón y ribavirina. Fundacio Clinic per a la Recerca Biomédica.

HULP Code: Anexo-I 3788. Sponsored's Protocol Code: BOC-HIV.

Signature Date: 13/07/2016

Herranz Pinto P. Estudio observacional para evaluar las recaídas en pacientes con psoriasis moderada - grave tratados con fármacos biológicos de acuerdo a la práctica clínica en España. Estudio Biopres. Novartis Farmacéutica S.A.

HULP Code: Anexo-I 4173. Sponsored's Protocol Code: NOV-PSO-2013-01.

Signature Date: 18/01/2016

Herranz Pinto P. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de secukinumab con jeringas precargadas de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave - allure. Novartis Farmacéutica S.A.

HULP Code: 4665. Sponsored's Protocol Code: CAIN457A2323.

Signature Date: 22/09/2016

Montes Ramírez ML. Eficacia y seguridad/tolerabilidad de viekirax y exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH I, GT I o 4, y enfermedad renal crónica en estadios de IIIb A V, incluyendo aquellos en diálisis, en práctica clínica habitual en España. Estudio Viekind. Abbvie Spain S.L.U.

HULP Code: PI-2303. Sponsored's Protocol Code: ABB-OMB-2015-01.

Signature Date: 09/05/2016

Montes Ramírez ML. Estudio fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-I con supresión virológica. Laboratorios VIIV Healthcare S.L.

HULP Code: 4681. Sponsored's Protocol Code: 201585.

Signature Date: 10/08/2016

Mora Rillo M. Estudio de fase 3, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de plazomicina en comparación con colistina en pacientes con infección

causada por enterobacterias resistentes a los carbapenémicos (CRE). Achaogen Inc.

HULP Code: Anexo-2 4039. Sponsored's Protocol Code: 4039 ACHN-490-007.

Signature Date: 23/05/2016

Pérez Valero I. Estudio prospectivo, observacional de la utilización del medicamento stribild® en adultos con infección por VIH. Gilead Sciences Inc.

HULP Code: PI-1975. Sponsored's Protocol Code: GS-EU-236-0141.

Signature Date: 20/05/2016

Ríos Blanco JJ. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento oral con nintedanib durante al menos 52 semanas en pacientes con «enfermedad pulmonar intersticial asociada a esclerosis sistémica» (SSC-ILD). Boehringer Ingelheim International GMBH.

HULP Code: 4504. Sponsored's Protocol Code: I.199.214.

Signature Date: 17/02/2016

PATENTS AND TRADEMARKS

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FI-BHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.



MOLECULAR
MICROBIOLOGY
GROUP

Publications: **32**
 Impact Factor: **113.016**
 Q1: **9**

Jesús Mingorance Cruz

Investigador Senior (Contrato Ramón y Cajal - I3). HULP

Emilio Cendejas Bueno

Investigador Postdoctoral (Contrato Juan Rodés). HULP

María Teresa Corcuera Pindado

Técnico Grado Superior. HULP

Manuela de Pablos Gómez

Facultativo Especialista de Área en Microbiología. HULP

Francisca Natalia Fernández Romero

Investigadora Predoctoral. HULP

Silvia García Bujalance

Facultativo Especialista de Área en Microbiología. HULP

María Jesús García García

Profesor Titular del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. UAM

Adelaida García Perea

Facultativo Especialista de Área en Microbiología. HULP

Julio García Rodríguez

Jefe de Servicio de Microbiología. HULP

Paulino Gómez Puertas

Científico Titular CSIC. CBM "Severo Ochoa"

Profesor Honorario. UAM

María Rosa Gómez-Gil Mira

Facultativo Especialista de Área en Microbiología. HULP

María Belén Loeches Yagüe

Médico Adjunto. Unidad de Enfermedades Infecciosas. HULP

Elena López Camacho

Investigadora Postdoctoral. HULP

Carmen Menéndez Gómez

Profesora Honoraria del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. UAM

Dolores Montero Vega

Facultativo Especialista de Área en Microbiología. HULP

Arturo Noguero Asensio

Jefe de Servicio de Medicina Interna. Hospital Universitario del Sureste

Verónica Pérez Blanco

Facultativo Especialista de Área en Medicina Preventiva. HULP

María Inmaculada Quiles Melero

Facultativo Especialista de Área en Microbiología. HULP

Alicia Rico Nieto

Facultativo Especialista de Área en Microbiología. HULP

María Pilar Romero Gómez

Facultativo Especialista de Área en Microbiología. HULP

Guillermo Ruiz Carrascoso

Facultativo Especialista de Área en Microbiología. HULP

Alma María Sotillo Torquemada

Investigadora Predoctoral. HULP

Natalia Stella Ascariz

Investigadora Predoctoral. HULP

Carlos Toro Rueda

Facultativo Especialista de Área en Microbiología. Hospital Carlos III-HULP

Strategic Objective

The Molecular Microbiology research group is integrated into the Department of Microbiology at Hospital La Paz, and a significant number of its members are physicians in the department devoted to microbiological diagnostic work. This integration determines the group's strategic approach and therefore, the different lines of research revolve around several aspects of clinical microbiology and infectious diseases.

An important line of activity (Clinical Microbiology) is the result of the routine activities provided

by the department, but goes further and deeper into the methodological, epidemiological and pathological challenges encountered in the daily routine.

One research line derived from the former is the development of methods for the molecular characterisation of pathogenic microorganisms, including microbiological diagnosis and epidemiological analysis, and more recently, microbial genomics.

Another line focuses on the study of the evolution of pathogenic microorganisms. As a model of opportunistic pathogens, we study *Escherichia coli*, a microorganism that is well characterised at the genetic level and that is clinically relevant as the primary cause of urinary tract infections and one of the most frequently involved in bacteraemia.

As a model of viral pathogens, we study the dynamics of HIV viral populations over time and in terms of the response to antiretroviral treatment.

Another important focus, given the scarcity of new antibiotics, is the search for new therapeutic targets. In this line, we study bacterial division as a promising target for the development of new antibiotics.

Research Lines

- Molecular epidemiology and evolution of pathogens.
- Molecular methods for diagnostics of infectious diseases.
- Microbial genomics.
- Biochemistry and molecular biology of bacterial cell division.
- Clinical Microbiology.

Research Activity**DOCTORAL THESES**

Ruiz Carrascoso G. Características microbiológicas y clínico-epidemiológicas de enterobacterias productoras de carbapenemasa OXA-48 en el contexto de un brote hospitalario [dissertation]. Madrid: UCM: 2016 (10/02/2016).

Director: Mingorance Cruz J.

BOOKS AND BOOK CHAPTERS

de la Vega E, Corcuera MT, Gómez F. Técnicas de análisis hematológico: Altamar Editorial, 2016.

Hernández B, Corcuera MT, Gómez F, Domínguez P, Simón F, Lorenzo MI. Microbiología Clínica: Altamar Editorial, 2016.

PUBLICATIONS

- Arroyo-Fajardo A, Troyano-Hernández P, Sotillo A, Romero-Gómez MP. Nocardia veterana bacteraemia after a lung infection in a patient with acute myeloid leukaemia. *Enferm Infecc Microb Cl.* 2016;34(7):463-4. Letter. IF: 1.714; Q3
- Arsuaga M, Bujalance SG, Díaz-Menéndez M, Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man. *Lancet Infect Dis.* 2016;16(10):1107. Letter. IF: 19.864; D1

• Cendejas-Bueno E, Borobia AM, Gómez-López A, Escosa-García L, Río-García M, Plaza D, García-Rodríguez J, Carcas-Sansuán A. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible *Aspergillus fumigatus*: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. *Int J Antimicrob Ag.* 2016;47(5):410-1. Letter. IF: 4.307; Q1

• Dahdouh E, Orgaz B, Gómez-Gil R, Mingorance J, Daoud Z, Suárez M, San José C. Patterns of biofilm structure and formation kinetics among *Acinetobacter baumannii* clinical isolates with different antibiotic resistance profiles. *Medchemcomm.* 2016;7(1):157-63. Article. IF: 2.608; Q2

• de Pablo A, Bogoi R, Bejarano I, Toro C, Valencia E, Moreno V, Martín-Carbonero L, Gómez-Hernando C, Rodes B. Short communication: p21/CDKN1A expression shows broad interindividual diversity in a subset of HIV-1 elite controllers. *AIDS Res Hum Retrov.* 2016;32(3):232-6. Article. IF: 2.095; Q3

• Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masia M, Berenguer J, Portilla J, Vilades C, Martínez E, Blanco JR, (Mingorance J). Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy. *HIV Med.* 2016;17(9):653-61. Article. IF: 3.257; Q2

• Falcés-Romero I, Gutiérrez-Arroyo A, Romero-Gómez MP. Catheter-associated bacteremia by *Pandoraea pnomenusa* in an infant with acute lymphoblastic leukemia. *Med Clin-Barcelona.* 2016;147(3):132. Letter. IF: 1.125; Q3

• Fortún J, Martín-Dávila P, de la Pedrosa EGG, Silva JT, García-Rodríguez J, Benito D, Venanzi E, Castaño F, Fernández-Ruiz M, Lázaro F, García-Luján R, Quiles I, Cabanillas JJ, Moreno S, Aguado JM. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. *J Infection.* 2016;72(6):738-44. Article. IF: 4.201; Q1

• Fragoso PL, de los Bués AB, Ljubic LB, Zarzuelo AD, Gómez MPR, Rillo MM. Herpes simplex keratitis in rheumatoid arthritis patients. *Ocul Immunol Inflamm.* 2016;24(3):282-7. Article. IF: 2.453; Q2

• García JL, Salgado T, Nieto AR. Subacute back pain. *Rev Clin Esp.* 2016;216(3):165-6. Editorial Material. IF: 0.971; Q3

• García MJ, Gola S. Gene and whole genome analyses reveal that the mycobacterial strain JS623 is not a member of the species *Mycobacterium smegmatis*. *Microb Biotechnol.* 2016;9(2):269-74. Article. IF: 3.513; Q2

• García MJ, López MR. Do we have strategies to improve the preventive treatment of latent tuberculosis infection? *Clin Infect Dis.* 2016;62(11):1401-2. Editorial Material. IF: 8.216; D1

• García V, Escosa L, Cabrero M, Romero-Gómez MP. Sepsis-like syndrome and acute meningoencephalitis due to parechovirus type 3. *Enferm Infecc Microb Cl.* 2016;34(1):73-4. Letter. IF: 1.714; Q3

• García-Rodríguez J, Quiles-Melero MI. Primary fungal peritonitis: A pending subject. *Enferm Infecc Microb Cl.* 2016;34(8):469-70. Editorial Material. IF: 1.714; Q3

• Kartashev V, Doring M, Nieto L, Coletta E, Kaiser R, Sierra S, (García Bujalance S). New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. *J Clin Virol.* 2016;81:82-9. Article. IF: 3.051; Q2

• Mendieta-Moreno JI, Trabada DG, Mendieta J, Lewis JP, Gómez-Puertas P, Ortega J. Quantum mechanics/molecular mechanics free energy maps and nonadiabatic simulations for a photochemical reaction in DNA: Cyclobutane thymine dimer. *J Phys Chem Lett.* 2016;7(21):4391-7. Article. IF: 9.353; D1

• Mingorance J, Regueiro B, Muñoz-Bellido JL. Historical perspective of mass spectrometry in microbiology. *Enferm Infecc Microb Cl.* 2016;34 Suppl 2:3-7. Article. IF: 1.714; Q3



- Monteserin J, Paul R, López B, Cnockaert M, Tortoli E, Menéndez C, García MJ, Palomino JC, Vandamme P, Ritacco V, Martín A. Combined approach to the identification of clinically infrequent non-tuberculous mycobacteria in Argentina. *Int J Tuberc Lung Dis*. 2016;20(9):1257-62. Article. IF: 2.468; Q3
- Muñiz FDM, Redondo MM, Sánchez CP, Rodríguez JG. Chronic lung infection caused by *Trichosporon mycotoxinivorans* and *trichosporin mucoides* in an immunocompetent cystic fibrosis patient. *Arch Bronconeumol*. 2016;52(7):400. Letter. IF: 2.979; Q2
- Paño-Pardo JR, Quintana BL, Perona FL, Carrascoso GR, Romero-Gómez MP, Yagüe BL, Díaz-Pollán B, Martínez-Virto A, Mingorance J, Rodríguez JG, Arribas JR, Gómez-Gil R. Community-onset bloodstream and other infections, caused by carbapenemase-producing enterobacteriaceae: Epidemiological, microbiological, and clinical features. *Open Forum Infect Dis*. 2016;3(3):ofw136. Article. IF: Not Indexed
- Paño-Pardo JR, Schuffelmann-Gutiérrez C, Escosa-García L, Laplaza-González M, Moreno-Ramos F, Gómez-Gil R, López JD, Jordán I, Téllez C, de la Oliva P. Opportunities to improve antimicrobial use in paediatric intensive care units: a nationwide survey in Spain. *Clin Microbiol Infect*. 2016;22(2):171-7. Article. IF: 5.292; D1
- Pescador P, Romero-Gómez MP, Gil RG, Mingorance J. Evaluation of combined use of the MALDI-TOF and GenomEra MRSA/SA assay for the direct detection of methicillin resistance in *Staphylococcus aureus* from positive blood culture bottles. *Enferm Infec Micr Cl*. 2016;34(10):687-8. Letter. IF: 1.714; Q3
- Pie J, Puisac B, Hernández-Marcos M, Teresa-Rodrigo ME, Gil-Rodríguez M, Baquero-Montoya C, Ramos-Cáceres M, Bernal M, Ayerza-Casas A, Bueno I, Gómez-Puertas P, Ramos FJ. Special cases in cornelia de lange syndrome: the Spanish experience. *Am J Med Genet C*. 2016;172(2):198-205. Review. IF: 5.6; Q1
- Quiles Melero I, Peláez T, Rezusta López A, García-Rodríguez J. Application of mass spectrometry in mycology. *Enferm Infec Micr Cl*. 2016;34 Suppl 2:26-30. Article. IF: 1.714; Q3
- Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by *Kocuria kristinae*. *Enferm Infec Micr Cl*. 2016;34(7):464-5. Letter. IF: 1.714; Q3
- Rossi CGA, Gómez-Puertas P, Serrano JAA. In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of *Pseudomonas aeruginosa*. *BMC Microbiol*. 2016;16:234. Article. IF: 2.644; Q2
- San-Juan R, Viedma E, Chaves F, Lalueza A, Fortún J, Loza E, Pujol M, Ardanuy C, Morales I, de Cueto M, Resino-Foz E, Morales-Cartagena A, Rico A, Romero MP, Orelana MA, López-Medrano F, Fernández-Ruiz M, Aguado JM. High MICs for vancomycin and daptomycin and complicated catheter-related bloodstream infections with methicillin-sensitive *Staphylococcus aureus*. *Emerg Infect Dis*. 2016;22(6):1057-66. Article. IF: 8.222; D1
- Sobrino-Vegas P, Moreno S, Rubio R, Viciano P, Bernardino JJ, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V, (Alcáriz NS, Mingorance J). Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. *J Infection*. 2016;72(5):587-96. Article. IF: 4.201; Q1
- Sotillo A, Paño-Pardo JR, López-Quintana B, Gómez-Gil R. Development of daptomycin resistance during therapy in a patient with methicillin-resistant *Staphylococcus aureus* endocarditis: A case report. *Enferm Infec Micr Cl*. 2016;34(8):534-5. Letter. IF: 1.714; Q3
- Stella-Ascariz N, Montejano R, Martín-Vicente M, Mingorance J, Pérez-Valero I, Bernardino JJ, Arribas JR. Long-Term control of human immunodeficiency virus-1 replication despite extensive resistance to current antiretroviral regimens: Clonal analysis of

resistance mutations in proviral deoxyribonucleic acid. *Open Forum Infect Dis*. 2016;3(1):ofw041. Article. IF: Not Indexed

- Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leao SC, García MJ, Vasireddy S, Turenne CY, Griffith DE, Phillely JV, Baldan R, Campana S, Cariani L, Colombo C, Taccetti G, Teri A, Niemann S, Wallace RJ, Cirillo DM. Emended description of *Mycobacterium abscessus*, *Mycobacterium abscessus* subsp. *abscessus* and *Mycobacterium abscessus* subsp. *bolletii* and designation of *Mycobacterium abscessus* subsp. *massiliense* comb. nov. *Int J Syst Evol Micr*. 2016;66:4471-9. Article. IF: 2.134; Q3
- Valencia ME, Quiles MI. Urinary infection through *Mycobacterium fortuitum* in patient with infection by HIV. *Rev Esp Quim*. 2016;29(4):226-7. Letter. IF: 0.75; Q4

PUBLIC PROJECTS

Menéndez Gómez MC. Micobacterias: carácter patógeno y relación con el entorno. Centro de estudios de América Latina (UAM-BSCH). 2015-2016.

Management centre: UAM

Mingorance Cruz J. Contrato de estabilización Ramón y Cajal (I3). ISCIII, CAM. 2011-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Trazabilidad de microorganismos patógenos: tipificación de alta resolución mediante identificación de sitios de inserción de elementos móviles por secuenciación masiva dirigida (PI13/01218). ISCIII. 2014-2016.

Management centre: FIBHULP

Stella Ascariz N. Contrato predoctoral (FI14/00391). ISCIII. 2015-2018.

Management centre: FIBHULP

PRIVATE PROJECTS

García Bujalance S. Detección de variantes minoritarias de mutaciones de resistencia del VIH-1 mediante pirosecuenciación y evaluación de su impacto sobre la eficacia de los tratamientos antirretrovirales PI-686. Laboratorios VIIV Healthcare S.L. 2010-Ongoing.

Management centre: FIBHULP

García Bujalance S. Evaluación del rendimiento del ensayo aptima HIV-1 Quant para la detección y cuantificación del HIV-1 en muestras de plasma. Hologic Deutschland GMBH. 2016-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Estudio poblacional de las especies de candida invasoras. Astellas Pharma S.A. 2010-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Estudio de la sensibilidad in vitro y sinergia de anidulafungina y voriconazol frente a aislamientos clínicos de especies de *Aspergillus* del Hospital Universitario La Paz. 2010-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Diagnóstico de aspergilosis invasora mediante detección de ácidos nucleicos de *Aspergillus* SPP en sangre. Gilead Sciences S.L. 2011-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Identificación de *Aspergillus* a través del sistema Malditof. Maldifumi. 2012-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Colaboración para el desarrollo de proyectos específicos entre el grupo de investigación de microbiología molecular del IdiPAZ en concreto: el desarrollo de soluciones en el ámbito de la microbiología molecular para atención en el punto de necesidad (POC). Epistem Ltd. 2016-Ongoing.

Management centre: FIBHULP

Gómez-Gil Mira MR. In vitro activities of ceftaroline, daptomycin, linezolid, and vancomycin against bacteremic methicillin-resistant *Staphylococcus aureus* isolates. AstraZeneca Farmaceutica Spain S.A. 2013-Ongoing.

Management centre: FIBHULP

Gómez-Gil Mira MR. Aislamiento, identificación, estudio de sensibilidad, control de calidad y envío al laboratorio central de enterobacterias productoras de carbapenemas. AstraZeneca Farmaceutica Spain S.A. 2016-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Identificación y caracterización de patógenos con interés intrahospitalario bajos sistemas automatizables con potencial implantación hospitalaria. Bio-tools-Biotechnological Medical Laboratori. 2009-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Molecular epidemiology of resistance to linezolid in gram positive cocci in a tertiary hospital. 2009-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. La utilidad clínica de sepsifast para el diagnóstico de sepsis en pacientes nefrológicos. Roche Diagnostics S.L. 2010-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Idi-20101176-kits de diagnóstico basados en pirosecuenciación. Laboratorios VIIV Healthcare S.L. 2011-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Aplicación de los métodos de tipado genómico y molecular a la elaboración del mapa microbiológico del Hospital Universitario La Paz. Epistem Ltd. 2012-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Septidrive. Development and evaluation of a new sepsis test. 2012-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Validación clínica de un biosensor para la identificación de *Streptococcus pneumoniae*. CISC. 2013-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Desarrollo de un dispositivo lab on a chip para la detección en POCT (Points of Care Testing) de la resistencia a antibióticos de muestras de orina. Diagnochip Spa. 2014-Ongoing.

Management centre: FIBHULP

Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención (POCT) de QPCR para el diagnóstico microbiológico. Epistem Ltd. 2012-Ongoing.

Management centre: FIBHULP

Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención (POCT) de QPCR para diagnóstico biológico. Arcis Biotechnology Holdings Ltd. 2012-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Mingorance Cruz J. Optomechanics for virology - Viriscan (VIRUSCAN). EU. 2016-2021.

Management centre: FIBHULP

CLINICAL TRIALS

Loeches Yagüe B. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por enterobacteriaceae. Fundación Pública Andaluza Progreso y Salud.

HULP Code: 4583. Sponsored's Protocol Code: SIMPLIFY.

Signature Date: 18/03/2016

PATENTS AND TRADEMARKS

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Bioteools Biotechnological & Medical Laboratories S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.



IMMUNO- RHEUMATOLOGY GROUP



Publications: **24**
Impact Factor: **132.042**
QI: **11**

María Eugenia Miranda Carús

Facultativo Especialista de Área en Reumatología. HULP

Pilar Aguado Acín

Facultativo Especialista de Área en Reumatología. HULP

Alejandro Balsa Criado

Jefe de Sección en Reumatología. HULP

Profesor Asociado. Facultad de Medicina. UAM

Paula Fortea Gordo

Investigadora predoctoral

María Gema Bonilla Hernán

Facultativo Especialista de Área en Reumatología. HULP

Ana Castilla Plaza

Facultativo Especialista de Área en Reumatología. HULP

Eugenio de Miguel Mendieta

Facultativo Especialista de Área en Reumatología. HULP

Sara García Carazo

Facultativo Especialista de Área en Reumatología. HULP

María Teresa Jurado Camino

Investigadora Postdoctoral. HULP

Emilio Martín Mola

Jefe de Servicio de Reumatología. HULP

Profesor Asociado. Facultad de Medicina. UAM

Ana Martínez Feito

Investigadora Predoctoral. HULP

Irene Monjo Henry

Facultativo Especialista de Área en Reumatología. HULP

Francisco de Borja Hernández Breijo

Investigador post doctoral

María Victoria Navarro Compán

Facultativo Especialista de Área en Reumatología. HULP

Laura Nuño Nuño

Médico Adjunto Interino en Reumatología. HULP

Eva Olariaga Mérida

Investigador en Inmunología. HULP

María Dora Pascual-Salcedo Pascual

Químico Adjunto en Inmunología. HULP

Chamaida Plasencia Rodríguez

Facultativo Especialista de Área en Reumatología. HULP

Diana Peiteado López

Facultativo Especialista de Área en Reumatología. HULP

Lorena Valdeolivas de Opazo

Investigadora predoctoral

Alejandro Villalba Yllán

Facultativo Especialista de Área en Reumatología. HULP

Strategic Objective

Our objective is to investigate the pathogenesis of rheumatic diseases, specifically focusing on genetics, metabolic pathways and immunopathogenesis.

Research Lines

- Immunopathogenesis and genetics of inflammatory and autoimmune arthritis.
- Imaging of inflammatory and autoimmune arthritis.
- Immunopathogenesis and genetics of osteoporosis.
- Immunogenicity of biological therapies with monoclonal antibodies.

Research Activity

DOCTORAL THESES

Arroyo Villa I. Estudio de las poblaciones celulares Th17 y Thf en la patogenia de la artritis reumatoide[dissertation]. Madrid: UAM: 2016(13/01/2016).

Directors: Miranda Carús ME, Martín Mola E.

Bautista Caro MB. Estudio sobre la biología de las células Th17 y Thf en espondiloartritis[dissertation]. Madrid: UAM: 2016(04/02/2016).

Directors: Miranda Carús ME, Martín Mola E.

PUBLICATIONS

- Alcobendas R, Rodríguez-Vidal A, Pascual-Salcedo D, Murias S, Remesal A, Diego C, Merino R. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study. *Clin Exp Rheumatol.* 2016;34(5):955-6. Letter. IF: 2.634; Q3
- Almodóvar R, Navarro-Compán V, Fernández-Carballido C, Hernández A, de Miguel E, Zarco P. Differences between familial and sporadic early spondyloarthritis: results from the ESPERANZA cohort. *Clin Exp Rheumatol.* 2016;34(4):575-80. Article. IF: 2.634; Q3
- Baron R, Likar R, Martín-Mola E, Blanco FJ, Kennes L, Mueller M, Falke D, Steigerwald I. Effectiveness of tapentadol prolonged release (PR) compared with Oxycodone/Naloxone PR for the management of severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b/4 study. *Pain Pract.* 2016;16(5):580-99. Article. IF: 2.495; Q2
- de Hooge M, van den Berg R, Navarro-Compán V, Reijnen M, van Gaalen F, Fagerli K, Landewe R, van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? *Ann Rheum Dis.* 2016;75(7):1308-14. Article. IF: 12.811; D1
- del Río-Martínez P, Navarro-Compán V, Díaz-Miguel C, Almodovar R, Mulero J, de Miguel E. Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: Results from the Esperanza Cohort. *Semin Arthritis Rheu.* 2016;45(4):400-3. Review. IF: 4.498; Q1
- Ferreiro-Iglesias A, Montes A, Pérez-Pampín E, Canete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Cáliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Márquez A, Martín J, Gómez-Reino JJ, González A. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. *Pharmacogenomics J.* 2016;16(2):137-40. Article. IF: 3.815; Q1
- Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compán V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. *Ann Rheum Dis.* 2016;75(6):991-6. Article. IF: 12.811; D1
- Koski JM, Kamel A, Waris P, Waris V, Tarkainen I, Karvanen E, Szklarek M, Aydin SZ, Alasaarela E, Schmidt W, de Miguel E, Mandl P, Filippucci E, Ziswiler H, Terslev L, Ats K, Kurucz R, Naredo E, Balint P, Iagnocco A, Lepojarvi S, Elseoud A, Fouda M, Saarakkala S. Atlas-based knee osteophyte assessment with ultrasonography and radiography: relationship to arthroscopic degeneration of articular cartilage. *Scand J Rheumatol.* 2016;45(2):158-64. Article. IF: 2.667; Q2
- Kviatkovsky MJ, Ramiro S, Landewe R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martín-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. *J Rheumatol.* 2016;43(9):1680-6. Article. IF: 3.15; Q2
- López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santanello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JHW, Riekemasten G, van der Helm-Van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg O, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BPC, Denton CP, Fonseca C, Radstake TRDJ, Worthington J, Mayes MD, Martín J. IRF4 Newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. *Arthritis Rheumatol.* 2016;68(9):2338-44. Article. IF: 6.918; D1
- López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Fillo J, Magro C, Tejera-Segura B, Huaranga MAR, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Sánchez MDM, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. *Sci Rep-Uk.* 2016;6:31979. Article. IF: 4.259; Q1
- Martín-Mola E, Balsa A, García-Vicuña R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. *Rheumatol Int.* 2016;36(8):1043-63. Article. IF: 1.824; Q3
- Moots RJ, Balsa A, Wolbink G. Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. *Ann Rheum Dis.* 2016;75(5):E24. Letter. IF: 12.811; D1
- Navarro-Compán V, Machado PM. Sacroiliac joint radiographic progression - speed and determinants. *Nat Rev Rheumatol.* 2016;12(7):380-1. Editorial Material. IF: 12.188; D1
- Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D, Canete JD. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. *Rheumatology.* 2016;55(7):1188-94. Article. IF: 4.818; Q1
- Navarro-Compán V, Ramiro S, Landewe R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. *Ann Rheum Dis.* 2016;75(5):874-8. Article. IF: 12.811; D1
- Nolla JM, Rodríguez M, Martín-Mola E, Raya E, Ibero I, Nocea G, Aragón B, Lizan L, Prades M. Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. *Patient Prefer Adher.* 2016;10:1101-13. Article. IF: 1.798; Q2
- Plasencia C, Wolbink G, Kriekkaert CLM, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuno L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A. Comparing a tapering strategy to the standard dosing regimen of TNF inhibi-



Balsa Criado A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de secukinumab en pacientes con espondiloartritis axial no radiográfica activa durante un periodo de 2 años. Novartis Farmaceutica S.A.

HULP Code: 4596. Sponsored's Protocol Code: CAIN457H2315.

Signature Date: 09/05/2016

Balsa Criado A. Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, de prueba de concepto y búsqueda de dosis de BI 655066 en pacientes con artritis psoriásica activa. Boehringer Ingelheim España S.A.

HULP Code: 4628. Sponsored's Protocol Code: 1311.5.

Signature Date: 23/05/2016

Balsa Criado A. Comparación de las prestaciones de un test rápido de detección de anticuerpos anti-infliximab (promonitor quick) en pacientes de reumatología en tratamiento activo con infliximab con la prueba estándar de laboratorio (elisa promonitor). Progenika Biopharma S.A.

HULP Code: PI-2254. Sponsored's Protocol Code: PQ-EF2.

Signature Date: 42565

de Miguel Mendieta E. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia de secukinumab subcutáneo hasta 1 año en el tratamiento de la entesitis del tendón de aquiles en pacientes adultos con artritis psoriásica (APS) activa y espondiloartritis axial (Espa Axial). Novartis Farmacéutica S.A.

HULP Code: 4673. Sponsored's Protocol Code: CAIN457F3301.

Signature Date: 27/09/2016

de Miguel Mendieta E. Estudio multicéntrico, observacional, no intervencionista, transversal y retrospectivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con espondilitis anquilosante y artritis psoriásica trata-

dos en consultas de reumatología en España (estudio Midas). Novartis Farmaceutica S.A.

HULP Code: Contrato PI-2457. Sponsored's Protocol Code:

CAIN457FES02.

Signature Date: 11/10/2016

Martín Mola E. Estudio de fase 3, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de tanezumab en adultos con lumbalgia crónica. Pfizer S.L.U.

HULP Code: 4469. Sponsored's Protocol Code: A4091059.

Signature Date: 29/01/2016

PATENTS AND TRADEMARKS

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531; 2015 March 10.



Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D'Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636; 2016 July 26.

INNATE IMMUNE RESPONSE GROUP



Publications: **20**

Impact Factor: **108.78**

Q1: **14**

Eduardo López-Collazo

Director Científico. IdiPAZ

Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP

Luis Augusto Aguirre Perez

Investigador Senior. HULP

Susana Alemany de la Peña

Investigadora Senior. Jefe de Laboratorio IIB "Alberto Sols"

José Avendaño Ortiz

Ayudante de Investigación. HULP

Lisardo Boscá Gomar

Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"

Ramón Cantero Cid

Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. HULP

José Germán Casas Martín

Investigador Predoctoral. HULP

Antonio Castrillo Viguera

Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"

María Fernández Velasco

Investigadora Senior (Contrato Miguel Servet- Tipo I). IIB "Alberto Sols"

Santiago Gómez Ruiz

Profesor Titular. Universidad Rey Juan Carlos

María Susana Guerra García

Investigadora Postdoctoral. UAM

Enrique Hernández Jiménez

Investigador Predoctoral (Contrato Predoctoral). HULP

Charbel Antonio Maroun Eid

Facultativo especialista de área en urgencias. HULP

Paloma Martín Sanz

Investigadora Senior. Jefe de Laboratorio. IIB "Alberto Sols"

Aurora Muñoz Jiménez

Técnico de Laboratorio. HULP

Rebeca Pérez de Diego

Investigadora Senior (Contrato Ramón y Cajal). HULP

Sanjiv Prashar

Profesor Titular. Universidad Rey Juan Carlos

Víctor Manuel Toledano Real

Técnico de Laboratorio (Contrato de Técnico de Apoyo). HULP

Aníbal Ramón Varela Serrano

Técnico de Laboratorio. HULP

Strategic Objective

This group focuses on the study of the reprogramming of the innate immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, acute coronary syndrome, lung cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages during refractory states.

The innate immune response is activated in various clinical contexts that can be modelled in vitro. The initial reaction of the Innate Immune System is marked by an inflammatory response that is similar in different contexts.

However, after the initial response, a "deviation" is produced towards an "alternative" response that may, in many cases, lead to refractory states such as endotoxin and tumour tolerance. These refractory states may have undesirable clinical consequences and their study is the objective of our research.



Research Lines

- Molecular mechanisms of endotoxin tolerance in several clinical contexts: respiratory diseases (OSA and cystic fibrosis), acute coronary syndrome, sepsis, septic shock and leukaemias.
- Molecular mechanisms of the innate immune system tolerance to tumours in several clinical contexts.
- Role of the innate immune system in metastasis.

Research Activity

DOCTORAL THESES

Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral [dissertation]. Madrid: UAM: 2016(23/06/2016).

Directors: López Collazo EM, García Río F.

Jurado Camino MT. Tolerancia a Endotoxinas: Una explicación a las infecciones recurrentes en la Leucemia Linfática Crónica [dissertation]. Madrid: UAM: 2016(11/03/2016).

Directors: López Collazo EM, Cubillos Zapata C.

PUBLICATIONS

- Al Ali S, Baldanta S, Fernández-Escobar M, Guerra S. Use of reporter genes in the generation of vaccinia virus-derived vectors. *Viruses*. 2016;8(5):134. Review. IF: 3.465; Q2
- Bonastre J, Landín L, Bolado P, Casado-Sánchez C, López-Collazo E, Díez J. Effect of cold preservation on chronic rejection in a rat hindlimb transplantation model. *Plast Reconstr Surg*. 2016;138(3):628-37. Article. IF: 3.784; Q1
- Contreras-Jurado C, Alonso-Merino E, Saiz-Ladera C, Valino AJ, Regadera J, Alemany S, Aranda A. The thyroid hormone receptors inhibit hepatic interleukin-6 signaling during endotoxemia. *SCI Rep-Uk*. 2016;6:30990. Article. IF: 4.259; Q1
- Cubillos-Zapata C, Avendaño-Ortiz J, Córdoba R, Hernández-Jiménez E, Toledano V, de Diego RP, López-Collazo E. Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia. *Oncoimmunology*. 2016;5(12):e1242544. Article. IF: 7.719; D1
- Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, Arribas-Jiménez C, Hernández-Jiménez E, Toledano V, Villaescusa T, Moreno V, López-Collazo E. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma. *Oncoimmunology*. 2016;5(12):e1231290. Article. IF: 7.719; D1
- Fernández-Escobar M, Baldanta S, Reyburn H, Guerra S. Use of functional genomics to understand replication deficient poxvirus-host interactions. *Virus Res*. 2016;216:1-15. Article. IF: 2.628; Q3
- Fernández-Escobar M, Nájera JL, Baldanta S, Rodríguez D, Way M, Esteban M, Guerra S. Suppression of NYVAC infection in HeLa cells requires Rnase I but is independent of protein kinase R activity. *J Virol*. 2016;90(4):2135-41. Article. IF: 4.663; Q1
- García-Gómez S, Doorno RA, Martínez-Barricarte R, Torres JM, Cerdán AF, Dávila M, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Vallejo-Cremades MT, López-Collazo E, Arquer MF, Sánchez-Ramón S, Casanova JL, de Diego RP. Actin polymerisation after FC gamma R stimulation of human fibro-

blasts is BCL10 independent. *Clin Immunol*. 2016;163:120-2. Letter. IF: 3.99; Q2

- Leivas A, Pérez-Martínez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martínez-López J. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. *Oncoimmunology*. 2016;5(12):e1250051. Article. IF: 7.719; D1
- Moreno-Cáceres J, Máinez J, Mayoral R, Martín-Sanz P, Egea G, Fabregat I. Caveolin-1-dependent activation of the metalloprotease TACE/ADAM17 by TGF-beta in hepatocytes requires activation of SRC and the NADPH oxidase NOX1. *Febs J*. 2016;283(7):1300-10. Article. IF: 3.902; Q2
- Motino O, Agra N, Contreras RB, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde AM, Francés DE, Martín-Sanz P. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. *BBA-Mol Basis Dis*. 2016;1862(9):1710-23. Article. IF: 5.476; Q1
- Pintor-Tortolero J, García JC, Cantero R. Transanal minimally invasive surgery approach for rectal GIST. *Tech Coloproctol*. 2016;20(5):321-2. Editorial Material. IF: 2.342; Q2
- Pourcet B, Gage MC, León TE, Waddington KE, Pello OM, Steffensen KR, Castrillo A, Villedor AF, Pineda-Torra I. The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms. *SCI Rep-Uk*. 2016;6:25481. Article. IF: 4.259; Q1
- Prieto P, Fernández-Velasco M, Fernández-Santos ME, Sánchez PL, Terrón V, Martín-Sanz P, Fernández-Avilés F, Boscá L. Cell expansion-dependent inflammatory and metabolic profile of human bone marrow mesenchymal stem cells. *Front Physiol*. 2016;7:548. Article. IF: 4.134; Q1
- Rackov G, Hernández-Jiménez E, Shokri R, Carmona-Rodríguez L, Manes S, Álvarez-Mon M, López-Collazo E, Martínez C, Balomenos D. p21 mediates macrophage reprogramming through regulation of p50-p50 NF-kappa B and IFN-beta. *J Clin Invest*. 2016;126(8):3089-103. Article. IF: 12.784; D1
- Rudnicki M, Tripodi GL, Ferrer R, Boscá L, Pitta MGR, Pitta IR, Abdalla DSP. New thiazolidinediones affect endothelial cell activation and angiogenesis. *Eur J Pharmacol*. 2016;782:98-106. Article. IF: 2.896; Q2
- Silva JC, César FA, de Oliveira EM, Turato WM, Tripodi GL, Castilho G, Machado-Lima A, de las Heras B, Boscá L, Rabello MM, Hernández MZ, Pitta MGR, Pitta IR, Passarelli M, Rudnicki M, Abdalla DSP. New PPAR gamma partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLR-/- mice. *Pharmacol Res*. 2016;104:49-60. Article. IF: 4.48; Q1
- Singh P, González-Ramos S, Mojena M, Rosales-Mendoza CE, Emami H, Swanson J, Morss A, Fayad ZA, Rudd JHF, Gelfand J, Paz-García M, Martín-Sanz P, Boscá L, Tawakol A. GM-CSF enhances macrophage glycolytic activity in vitro and improves detection of inflammation in vivo. *J Nucl Med*. 2016;57(9):1428-35. Article. IF: 6.646; D1
- Villar-Lorenzo A, Ardiles AE, Arroba AI, Hernández-Jiménez E, Pardo V, López-Collazo E, Jiménez IA, Bazzocchi IL, González-Rodríguez A, Valverde AM. Friedelane-type triterpenoids as selective anti-inflammatory agents by regulation of differential signaling pathways in LPS-stimulated macrophages. *Toxicol Appl Pharm*. 2016;313:57-67. Article. IF: 3.791; Q1
- Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S, Sánchez-Madrid F. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. *Nat Commun*. 2016;7:13588. Article. IF: 12.124; D1

PUBLIC PROJECTS

Fernández Velasco M. Contratos Sara Borrell (CD12/00542). ISCIII. 2013-2016.

Management centre: FIBHULP

Fernández Velasco M. NLR-NOD1 contribution to diabetic cardiomyopathy (CPI1/00197). ISCIII. 2012-2016.

Management centre: FIBHULP

Fernández Velasco M. Implicación de los receptores NOD1 en el desarrollo de la insuficiencia cardíaca (PI14/01078). ISCIII. 2015-2017.

Management centre: FIBHULP

Fernández Velasco M. Contrato Miguel Servet tipo I (MS11/00197). ISCIII. 2012-2016.

Management centre: FIBHULP

Hernández Jiménez E. Contrato predoctoral (FI12/00284). ISCIII. 2012-2016.

Management centre: FIBHULP

López Collazo EM. Tolerancia a endotoxinas: ¿Una puerta hacia el tratamiento eficaz de la sepsis? (PI14/01234). ISCIII. 2015-2017.

Management centre: FIBHULP

López Collazo EM. The risk of infections in several pathologies: a thorough study with clinical tools development for personalised medicine (PIE15/00065). ISCIII. 2016-2018.

Management centre: FIBHULP

López Collazo EM. Contrato de estabilización Miguel Servet (I2). ISCIII, CAM. 2009-Ongoing.

Management centre: FIBHULP

Pérez de Diego R. Respuesta inmune celular y humoral de la enfermedad inflamatoria intestinal. Papel de los patrones moleculares asociados a patógenos en la etiología y evolución clínica (PI14/00616). ISCIII. 2015-2017.

Management centre: FIBHULP

Pérez de Diego R. Contrato Ramón y Cajal (RyC 2011-07597). MINECO. 2011-2017.

Management centre: FIBHULP

Pérez Martínez A. Infusión de células natural killer activadas y expandidas en combinación con quimioterapia en pacientes pediátricos con leucemia/linfoma T refractaria (EC11-057). MSSSI. 2013-2016.

Management centre: FIBHULP

Pérez Martínez A. Diseño del receptor antigénico quimérico NKG2D (CAR-NKG2D) como terapia celular en los sarcomas infantiles (PI15/00973). ISCIII. 2016-2018.

Management centre: FIBHULP

Toledano Real VM. Contrato PTA (PTA2013-8265-I). MINECO. 2015-2018.

Management centre: FIBHULP

PRIVATE PROJECTS

Cantero Cid R. Cultivo y estudio de células troncales (STEM) de adenocarcinoma de recto humano pre y post-

tratamiento con radiobiocimioterapia. Usos potenciales en terapia oncológica. Fundación Mutua Madrileña. 2014-Ongoing.

Management centre: FIBHULP

Cantero Cid R. Premio por la publicación del artículo: Negative pressure therapy to reduce risk of wound infection following diverting loop ileostomy reversal. An initial study. KCI UK Holdings Limited. 2016-Ongoing.

Management centre: FIBHULP

Gómez Ruiz S. Phosphorus-rich early transition metal and rare earth metal complexes as precursors for metal phosphides. DAAD-Fundación Universidad. 2014-Ongoing.

Management centre: URJC

López Collazo EM. Estudio del sistema inmune infiltrado en el cáncer de pulmón y búsqueda de marcadores pronósticos en células circulantes de pacientes que sufren esta enfermedad. Encinar. 2014-Ongoing.

Management centre: FIBHULP

López Collazo EM. Programa específico de investigación para la obtención y validación de un método de muestreo (Screening) masivo para descartar el dopaje en el deporte. Fundación Hospital de Madrid. 2013-Ongoing.

Management centre: FIBHULP

López Collazo EM. Transplantation (SOT & HSCT) in children transchild. FIBHULP. 2016-Ongoing.

Management centre: FIBHULP

Pérez de Diego R. Medicina de precisión en inmunodeficiencias primarias: desentrañando nuevas etiologías genéticas mediante aproximaciones "ómicas". Fundación Mutua Madrileña. 2015-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Infusión de células natural killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda. Fundación Mutua Madrileña. 2015-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Inmunoterapia con células natural killer en el cáncer infantil. Fundación Cris contra el Cáncer. 2015-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Inmunoterapia en sarcomas: combinación del anticuerpo antiCXCR4 y la terapia celular NK. Fundación la Sonrisa de Alex. 2016-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. NK cell team-2: inmunoterapia con células natural killer en el niño. Fundación Cris contra el Cáncer. 2014-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Optimización de la terapia celular NK en sarcomas pediátricos mediante el uso nanopartículas multifuncionalizadas. PI-1567. Fundación Cris contra el Cáncer. 2013-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Terapia celular basada en el receptor



quimérico NKG2D (CAR-NKG2D) para la leucemia infantil. Fundación Uno entre Cien Mil. 2015-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Terapia celular con el receptor antigénico quimérico NKG2D(CAR-NKG2D) para los tumores sólidos infantiles. Fundación Asociación Española contra el Cáncer. 2016-Ongoing.

Management centre: FIBHULP

Pérez Martínez A. Unidad de Investigación y de terapias avanzadas en Hematooncología infantil. Fundación Cris contra el Cáncer. 2016-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

López Collazo EM, Belda Iniesta C. Massive screening methodology to discard doping. COI. 2015-Ongoing.

Management centre: COE.

CLINICAL TRIALS

Pérez Martínez A. Infusión de células natural killer como tratamiento de consolidación en niños

y adolescentes con leucemia mieloblástica aguda. Pérez Martínez A.

HULP Code: 4489. Sponsored's Protocol Code: NKCELL_LMA_2015.

Signature Date: 20/04/2016


Pérez Martínez A. Estudio aleatorizado, abierto, de seguridad y eficacia de ibrutinib en pacientes pediátricos y adultos jóvenes con linfoma No Hodgkin de células maduras B en recaída o refractario. Janssen Cilag International NV.

HULP Code: 4644. Sponsored's Protocol Code: 54179060LYM3003.


Signature Date: 18/10/2016

PATENTS AND TRADEMARKS

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.



DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH ABNORMALITIES GROUP



Publications: **7**

Impact Factor: **17.655**

QI: **0**

Margarita López Trascasa

Jefa de Sección en Inmunología. HULP

Profesor Asociado de la Facultad de Medicina. UAM

Pilar Sánchez-Corral Gómez

Investigadora Senior (Contrato Miguel Servet - I3SNS). Jefa de Laboratorio. HULP

Fernando Corvillo Rodríguez

Investigador Predoctoral. HULP

Sofía Garrido Herrero

Técnico de Laboratorio. HULP

Alberto López Lera

Investigador Postdoctoral. Contratado CIBERER. HULP

Marta Melgosa Hijosa

Facultativo Especialista de Área en Nefrología Infantil. HULP

Rocío Mena de la Cruz

Responsable de Laboratorio de Secuenciación. HULP

Pilar Nozal Aranda

Investigadora Predoctoral. HULP

Antonia Peña Carrión

Facultativo Especialista de Área en Nefrología Infantil. HULP

components. By following a clearly translational approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up.

The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III).

Research Lines

- Screening and characterization of genetic and acquired Complement defects in renal disease.
- Biochemical and molecular diagnosis of isolated Complement deficiencies.
- Screening and molecular characterization of disease-modifying genes in Hereditary Angioedema.
- Genetic and immunological mechanisms associated with Complement dysregulation in partial lipodystrophy.

Strategic Objective

This is a national reference group for the study of primary or acquired defects in the complement system.

The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in several human diseases, the majority of which are classified as rare diseases. In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement

Research Activity

DOCTORAL THESES

Bernabéu Herrero ME. Defects in complement factor H-related proteins (FHRs) in renal pathology[dissertation]. Madrid: UAM: 2016 (09/09/2016).

Director: Sánchez-Corral Gómez P. European Mention





Nozal Aranda P. Autoantibodies against proteins of the alternative complement pathway in renal diseases [dissertation]. Madrid: UAM: 2016(13/09/2016).

Director: López Trascasa M.

PUBLICATIONS

- Blom AM, Corvillo F, Magda M, Stasilojc G, Nozal P, Pérez-Valdivia MA, Cabello-Chaves V, de Córdoba SR, López-Trascasa M, Okroj M. Testing the activity of complement convertases in serum/plasma for diagnosis of C4NeF-Mediated C3 glomerulonephritis. *J Clin Immunol*. 2016;36(5):517-27. Article. IF: 3.253; Q2
- Corvillo F, García-Morato MB, Nozal P, Garrido S, Tortajada A, de Córdoba SR, López-Trascasa M. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. *Clin Exp Immunol*. 2016;184(1):118-25. Article. IF: 3.41; Q2
- García-Morato MB, Padilla-Merlano B, Nozal P, Espino M, Juárez C, Villar LM, López-Trascasa M. Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. *Rev Clin Esp*. 2016;216(3):128-34. Article. IF: 0.971; Q3
- Nozal P, Bernabéu-Herrero ME, Uzonyi B, Szilagy A, Hyvarinen S, Prohaszka Z, Jokiranta TS, Sánchez-Corral P, López-Trascasa M, Jozsi M. Heterogeneity but individual constancy of epitopes isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. *Mol Immunol*. 2016;70:47-55. Article. IF: 3.326; Q2
- Nozal P, López-Trascasa M. Autoantibodies against alternative complement pathway proteins in renal pathologies. *Nefrología*. 2016;36(5):489-95. Review. IF: 1.183; Q4
- Pedrosa M, Phillips-Angles E, López-Lera A, López-Trascasa M, Caballero T. Complement study versus C1NH gene testing for the diagnosis of type I hereditary angioedema in children. *J Clin Immunol*. 2016;36(1):16-8. Letter. IF: 3.253; Q2
- Tenorio J, Romanelli V, Martín-Trujillo A, Fernández GM, Segovia M, Perandones C, Jurado LAP, Esteller M, Fraga M, Arias P, Gordo G, Dapia I, Mena R, Palomares M, de Nancrales GP, Nevado J, García-Miñaur S, Santos-Simarro F, Martínez-Glez V, Vallespín E, Monk D, Lapunzina P. Clinical and molecular analyses of Beckwith-Wiedemann syndrome: Comparison between spontaneous conception and assisted reproduction techniques. *Am J Med Genet A*. 2016;170(10):2740-9. Article. IF: 2.259; Q3

PUBLIC PROJECTS

López Trascasa M. Networked Biomedical Research Center for Rare Diseases (CIBERer). ISCIII. 2010-2016.

Management centre: FIBHULP

López Trascasa M. Implicaciones del Sistema del Complemento en la patología humana (SAF2012-38636). MINECO. 2013-2016.

Management centre: FIBHULP

López Trascasa M. Nuevos biomarcadores en enfermedades mediadas por el sistema del complemento (PI15/00255). MINECO. 2016-2018.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Línea de incorporación estable de investigadores (I3). ISCIII, CAM. 2008-Ongoing.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Diagnóstico, caracterización y relevancia clínica de defectos en la familia factor H/CFHRS del complemento en patología renal (PI12/00597). ISCIII. 2013-2017.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Mecanismos patogénicos en enfermedades raras y comunes asociadas con desregulación del complemento (CIBERer-ER16PIAC754). ISCIII. 2016-2016.

Management centre: CIB-CSIC

Sánchez-Corral Gómez P. Nefropatías asociadas con desregulación del complemento: estudio de factores de riesgo y evolución mediante proteómica traslacional (PI16/00723). ISCIII. 2017-2019.

Management centre: FIBHULP

PRIVATE PROJECTS

López Trascasa M. Complementest. Déficit y alteraciones del sistema del complemento en patología humana. Secugen S.L. 2011-Ongoing.

Management centre: FIBHULP

López Trascasa M. Estudio de las bases moleculares del síndrome hemolítico urémico atípico y creación de un Registro Español de SHU-atípico. Secugen S.L. 2011-Ongoing.


Management centre: FIBHULP

PATENTS AND TRADEMARKS

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest. CM 009.658.791; 2011, January 14.



LYMPHOCYTE PATHOPHYSIOLOGY IN IMMUNODEFICIENCIES GROUP



Publications: 11

Impact Factor: 41.919

Q1: 3

Eduardo López Granados

Coordinador de Inmunología. HULP

Rita Francisca Álvarez Doorno

Facultativo Especialista de Área en Inmunología. HULP

Francisco Javier Alves Ferreira

Facultativo Especialista de Área en Anatomía Patológica. HULP

Lucía del Pino Molina

Investigadora Predoctoral. HULP

Antonio Ferreira Cerdán

Facultativo Especialista de Área en Inmunología. HULP

María Cruz García Rodríguez

Facultativo Especialista de Área en Inmunología. HULP

Julia Leal de la Rosa

Facultativo Especialista de Área en Pediatría General. HULP

Montserrat Lozano Doncel

Técnico de Laboratorio. HULP

Diego Plaza López de Sabando

Facultativo Especialista de Área en Hemato-Oncología Pediátrica. HULP

Ángel Julián Robles Marhuenda

Facultativo Especialista de Área en Medicina Interna. HULP

Rebeca Rodríguez Pena

Facultativo Especialista de Área en Inmunología. HULP

María Carmen Salcedo Moreno

Técnico de Laboratorio. HULP

Ana Sastre Urguelles

Facultativo Especialista de Área en Hemato-Oncología Pediátrica. HULP

Esther Tato Gutiérrez

Técnico de Laboratorio. HULP

Juan Manuel Torres Canizales

Médico Interno Residente en Inmunología. HULP

Strategic Objective

Defective molecular events driving the differentiation, activation and homeostasis of lymphocytes underline the pathophysiology of numerous immunological and haematological diseases. In primary immunodeficiencies (PIDs), intrinsic impairments of immune cells lead to infection and, in some cases, autoimmunity and cancer.

Common variable immunodeficiency disorders (CVIDs) are the most frequent but least understood types of PID and are a major focus of our research.

Our group attempts to unravel the molecular basis for functional defects of lymphocytes in several PIDs as well as the basis for autoimmune and lymphoproliferative complications. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of the syndromes and lay the groundwork for new, more effective treatments.

We have recently been concentrating our efforts on understanding differentiation and survival cell signalling pathways and the control of gene transcription in B cells from affected individuals. The B cell receptor (BCR), the TNF-R family members and the Toll-like receptors (TLRs) are fundamental to the synergistic action of B cell function. It is increasingly evident that innate and adaptive pathways intersect and reinforce each other and that TLRs play a fundamental role in this relationship.

Methodological and conceptual approaches applied to the study of PIDs can be applied to monitoring



more prevalent secondary immunodeficiency states such as immunological reconstitution in haematopoietic stem cell transplantation (HSCT), acute viral infection, and use of immunosuppressive treatments in transplantation and autoimmunity. We validate new biological markers and assays for a patient-based rather than a disease-based therapeutic approach in the latest clinical scenarios, to facilitate clinical decisions and to maximise the clinical efficiency and safety of treatments.

Research Lines

- The study of the anatomical, genetic, epigenetic and biochemical bases for lymphoid function deficiency in immunodeficiencies of antibody formation and their autoimmune and lymphoproliferative complications.
- Role of Toll Like Receptors (TLRs) and signalling pathways in lymphoid maturation and immune response to infection in primary immunodeficiencies.
- Identification of new biomarkers for lymphoid function for monitoring in states of immunodeficiency secondary to: acute viral infection, immune reconstitution after transplantation of haematopoietic progenitors and use of immunosuppressive therapies in transplantation, autoimmunity and chronic inflammation.

Research Activity

PUBLICATIONS

- Bautista F, Gallego S, Cañete A, Mora J, Heredia CD, Cruz O, Fernández JM, Rives S, Madero L, Castel V, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L. Landscape of early clinical trials for childhood and adolescence cancer in Spain. *Clin Transl Oncol*. 2016;18(7):708-13. Article. IF: 2.353; Q3
- Calvo C, Gallardo P, Torija P, Bellón S, Méndez-Echeverría A, del Rosal T, Baquero-Artigao F, Sainz T, Romero M, Cabrerizo M. Enterovirus neurological disease and bacterial coinfection in very young infants with fever. *J Clin Virol*. 2016;85:37-9. Article. IF: 3.051; Q2
- Gallego-Bustos F, Gotea V, Ramos-Amador JT, Rodríguez-Peña R, Gil-Herrera J, Sastre A, Delmiro A, Rai G, Elnitski L, González-Granado LI, Allende LM. A Case of IL-7R deficiency caused by a novel synonymous mutation and implications for mutation screening in SCID diagnosis. *Front Immunol*. 2016;7:443. Article. IF: 6.429; Q1
- García-Gómez S, Doformo RA, Martínez-Barricarte R, Torres JM, Cerdán AF, Dávila M, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Vallejo-Cremades MT, López-Collazo E, Arquero MF, Sánchez-Ramón S, Casanova JL, de Diego RP. Actin polymerisation after FC gamma R stimulation of human fibroblasts is BCL10 independent. *Clin Immunol*. 2016;163:120-2. Letter. IF: 3.99; Q2
- González B, Bueno D, Rubio PM, Román SS, Plaza D, Sastre A, García-Miguel P, Fernández L, Valentín J, Martínez I, Pérez-Martínez A. An immunological approach to acute myeloid leukaemia. *An Pediatr*. 2016;84(4):195-202. Article. IF: 1.14; Q3
- Iparraguirre L, Gutiérrez-Camino A, Umérez M, Martín-Guerre-

ro I, Astigarraga I, Navajas A, Sastre A, de Andoin NG, García-Orad A. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. *Pharmacogenet Genom*. 2016;26(11):517-25. Article. IF: 2.184; Q2

- López-Rodríguez M, Herrera-Ramos E, Sole-Violán J, Ruiz-Hernández JJ, Borderías L, Horcajada JP, Lerma-Chippirraz E, Rajas O, Briones M, Pérez-González MC, García-Bello MA, López-Granados E, de Castro FR, Rodríguez-Gallego C. IFITM3 and severe influenza virus infection. No evidence of genetic association. *Eur J Clin Microbiol*. 2016;35(11):1811-7. Article. IF: 2.727; Q2
- Méndez-Echeverría A, del Rosal T, Pérez-Costa E, Rodríguez-Peña R, Zaruza A, Ferreira-Cerdán A, Bravo M, Mellado MJ, López-Granados E. Clinical features before hematopoietic stem cell transplantation or enzyme replacement therapy of children with combined immunodeficiency. *Pediatr Infect Dis J*. 2016;35(7):794-8. Article. IF: 2.486; Q1
- Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by *Kocuria kristinae*. *Enferm Infecc Microbiol Clin*. 2016;34(7):464-5. Letter. IF: 1.714; Q3
- Ruiz-Pinto S, Pita G, Patino-García A, García-Miguel P, Alonso J, Pérez-Martínez A, Sastre A, Gómez-Mariano G, Lissat A, Scotlandi K, Serra M, Ladenstein R, Lapouble E, Pierron G, Kontny U, Picci P, Kovar H, Delattre O, González-Neira A. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. *Ann Oncol*. 2016;27(9):1788-93. Article. IF: 11.855; D1
- Sánchez-Ramón S, de Gracia J, García-Alonso AM, Molina JJR, Melero J, de Andrés A, de Morales JMGR, Ferreira A, Oejo-Vinyals JG, Cid JJ, Martínez JMG, Lasheras T, Vargas ML, Gil-Herrera J, Rodríguez MCG, Castaner JL, Granada LIG, Allende LM, Soler-Palacín P, Herraiz L, Hoyos ML, Bellón JM, Silva G, Gurbindo DM, Carbone J, Rodríguez-Sainz C, Matamoros N, Parker AR, Fernández-Cruz E. Multicenter study for the evaluation of the antibody response against salmonella typhi VI vaccination (EM-PATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency. *Clin Immunol*. 2016;169:80-4. Article. IF: 3.99; Q2

PUBLIC PROJECTS

López Granados E. Evaluación de protocolos avanzados de monitorización inmunológica para un mejor manejo terapéutico en trasplante de progenitores hematopoyéticos e intestinal (PII3/02296). ISCIII. 2014-2017

Management centre: FIBHULP

PRIVATE PROJECTS

López Granados E. Actualización y renovación de la actividad en el Servicio de Inmunología del Hospital Universitario La Paz. CSL Behring S.A. 2012-Ongoing.

Management centre: FIBHULP

López Granados E. Aplicaciones clínicas de la monitorización inmunológica avanzada en el trasplante de órgano sólido infantil. Fundación Mutua Madrileña. 2014-Ongoing.

Management centre: FIBHULP

López Granados E. Cáncer, fallo medular e inmunodeficiencia en niños, un esfuerzo integrado para comprender sus bases moleculares y mejorar su diagnóstico y pronóstico clínico. Fundación Asociación Española contra el Cáncer. 2014-Ongoing.

Management centre: FIBHULP

López Granados E. Estudio de la respuesta antiviral T mediante ensayo de OX40 y su correlación con la terapia inmunosupresora para una monitorización individualizada del niño trasplantado. Cytognos. 2015-Ongoing.

Management centre: FIBHULP

López Granados E. XII Reunión del Registro Español Inmunodeficiencias Primaria. CAM. 2015-Ongoing.

Management centre: FIBHULP

Robles Marhuenda AJ. Relevancia clínica y problemática terapéutica del síndrome de los anticuerpos antifosfolípidos. Sanofi Aventis S.A. 2006-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Méndez Echeverría AM. Estudio multicéntrico, abierto, aleatorizado, de fase II/III para determinar la seguridad y eficacia de la solitromicina en adolescentes (de 12 a 17 años de edad, ambos inclusive) y niños (> 2 meses a < 12 años de edad) con neumonía bacteriana adquirida en la comunidad sospechada o confirmada. Chiltern International Spain S.A.

HULP Code: 4599. Sponsored's Protocol Code: CE01-203.

Signature Date: 13/06/2016


Robles Marhuenda AJ. Estudio aleatorizado, doble ciego (abierto para el promotor), comparativo, multicéntrico para evaluar la seguridad y la eficacia de la coadministración de belimumab (GSK1550188) subcutáneo y rituximab intravenoso en sujetos con Síndrome de Sjögren primario. Glaxosmithkline S.A.

HULP Code: 4488. Sponsored's Protocol Code: 201842.

Signature Date: 02/03/2016

PATENTS AND TRADEMARKS

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vikova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 October 30.





DRUG HYPERSENSIBILITY AND INNATE IMMUNE RESPONSE GROUP



Publications: **24**

Impact Factor: **59.765**

QI: **4**

Teresa Bellón Heredia

Investigadora Senior (Contrato Miguel Servet -12). Jefe de laboratorio. HULP

María del Rosario Cabañas Moreno

Facultativo Especialista de Área en Alergología. HULP

Francisco José de Abajo Iglesias

Facultativo Especialista de Área en Farmacología. Hospital Universitario Príncipe de Asturias

Profesor Titular. Facultad de Medicina. Universidad de Alcalá

Jessica González Ramos

Médico Interno Residente en Dermatología. HULP

Victoria Lerma Hambleton

Coordinadora de casos del estudio PIELenRed. Hospital Universitario Príncipe de Asturias

Aranzazu Isabel Rodríguez Sanz

Investigador Postdoctoral. HULP

Gastón Roustán Gullón

Facultativo Especialista de Área en Dermatología. Hospital Universitario Puerta de Hierro
Profesor Asociado. Facultad de Medicina. UAM

mal necrolysis (TEN). Among them, SJS and TEN are the most severe clinical entities and are nowadays considered as variants of the same disease characterized by keratinocyte necrosis and epidermal detachment with the formation of subepidermal bullae. From the immunopathogenic point of view, SCARs are T-cell mediated type IV hypersensitivity reactions. However, T cells can orchestrate different types of immune responses and this functional heterogeneity has led to a further sub-classification into type IVa-IVd hypersensitivity that considers the distinct cytokine production pattern by T cell subpopulations, and emphasizes the participation of different effector cells causing inflammation and tissue damage. Current knowledge supports the active participation of cytotoxic lymphocytes in different clinical entities. Our project aims to a better understanding of the immune mechanisms underlying the etiopathogenesis of these diseases. The study is performed in the framework of the consortium PIELenRed (Plataforma interdisciplinar para el estudio de reacciones cutáneas graves en Red) integrated by researchers belonging to different hospitals in Madrid.

Reactivation of latent herpesvirus has been described during the development of some of the previously mentioned clinical entities. In order to improve our understanding of the behaviour of the immune system during viral replication, collaboration has been established with the Kidney Transplant Unit (Nephrology Service, HULP). Kidney transplant recipients are being followed immediately before and after transplant in order to identify patients with active cytomegalovirus (CMV/HHV-5) replication.

General objectives for the next 5 years

The main objectives are:

- Biobanking of samples of severe cutaneous adver-

se reactions to medications (DRESS, AGEP and SJS/TEN) associated to the registry PIELenRed, and integrated in the international registry RegiSCAR.

- To investigate in vitro test for drug causality assessment.
- To explore the involvement of the innate immune response (in particular natural cytotoxic activity) during the development of SCARs.
- Identification of biomarkers of susceptibility.
- To find biomarkers for disease and response to treatments.
- To explore the potential of microRNAs in SJS/TEN as biomarkers of disease and of response to treatments, as well as their relationship with pathogenic mechanisms.
- To analyze the evolution of the cytotoxic response in patients with CMV replication.
- Compare the innate immune response in patients with CMV replication after kidney transplant and in patients with SCARs.

Research Lines

- Biobanking of biological samples from patients with severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN).
- Development and evaluation of in vitro tests for drug causality assessment.
- Identification of biomarkers of susceptibility.
- Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome /Toxic epidermal necrolysis (SJS/TEN).
- Differential analysis of the cytokine pattern involved in different SCARs (AGEP, DRESS and SJS/TEN)
- Analysis of miRNAs as biomarkers of disease and response to treatments.

Research Activity

DOCTORAL THESES

Rodríguez Sanz AI. Selección de posibles inhibidores de FABP4: efectos en la actividad proinflamatoria de monocitos/macrófagos y en las interacciones macrófago-adipocito [dissertation]. Madrid: UAM; 2016(28/10/2016).

Directors: Bellón Heredia T, Selgas Gutiérrez R

BOOKS AND BOOK CHAPTERS

Cabañas Moreno R. Fisiopatología y genética del angioedema. In: Caballero Molina T, Cabañas Moreno R. Angioedema. Madrid: Comunicación y Ediciones Sanitarias S.L., 2016. p.27-52

Cabañas Moreno R. Angioedema histaminérgico. In: Caballero Molina T, Cabañas Moreno R. Angioedema. Madrid: Comunicación y Ediciones Sanitarias S.L., 2016. p.53-72

Cabañas Moreno R. Manifestaciones clínicas por órganos y sistemas de las reacciones de hipersensibilidad inducidas por fármacos. Reacciones cutáneas graves. In: Dávila Gon-

zález IJ, Jáuregui Presa I, Olaguibel Rivera JM, Zubeldia Ortuño JM. Tratado de Alergología. Madrid: Ergón, 2016. p.1415-50

PUBLICATIONS

- Alfageme F, Cerezo E, Fernández I S, Aguilo R, Vilas-Sueiro A, Roustán G. Introduction of basic dermatologic ultrasound in undergraduate medical education. *Ultrasound Int Open*. 2016;2(4):E136-9. Article. Not Indexed
- Arruti N, Villarreal O, Bernedo N, Audicana MT, Velasco M, Uriel O, Martínez A, Bellón T. Positive allergy study (Intradermal, Patch, and Lymphocyte Transformation Tests) in a case of isoniazid-induced DRESS. *J Invest Allerg Clin*. 2016;26(2):119-20. Editorial Material. IF: 3.094; Q2
- Bellón T, Lerma V, González-Valle O, Herrada CG, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. *Brit J Dermatol*. 2016;174(3):621-4. Article. IF: 4.706; D1
- Bellón T, Ramírez E, Borobia AM, Lerma V, Moreno-Hidalgo MA, Laosa O, Aramburu JA, González-Herrada C, de Abajo FJ. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome. *Pharmacogenomics*. 2016;17(6):541-5. Article. IF: 2.35; Q3
- Brauer R, Douglas I, Rodríguez LAG, Downey G, Huerta C, de Abajo F, Bate A, Tepie MF, de Groot MCH, Schlienger R, Reynolds R, Smeeth L, Klungel O, Ruigómez A. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. *Pharmacoepidem Dr S*. 2016;25:29-38. Article. IF: 2.552; Q2
- Brauer R, Ruigómez A, Downey G, Bate A, Rodríguez LAG, Huerta C, Gil M, de Abajo F, Requena G, Álvarez Y, Slattery J, de Groot M, Souverein P, Hesse U, Rottenkolber M, Schmiedl S, de Vries F, Tepie MF, Schlienger R, Smeeth L, Douglas I, Reynolds R, Klungel O. Prevalence of antibiotic use: a comparison across various European health care data sources. *Pharmacoepidem Dr S*. 2016;25:11-20. Article. IF: 2.552; Q2
- Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V, (Cabañas R). Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. *J Invest Allerg Clin*. 2016;26(6):383-6. Article. IF: 3.094; Q2
- Canabal J, Caballero T, Caminoa M, Fiandor A, Quirce S, Cabañas R. Anaphylactic shock caused by a hidden allergen in blood sausage. *J Invest Allerg Clin*. 2016;26(3):200-1. Editorial Material. IF: 3.094; Q2
- Carrascosa R, Alfageme F, Roustán G, Suárez MD. Skin ultrasound in Kaposi sarcoma. *Actas Dermosifiliogr*. 2016;107(4):E19-E22. Article. Not Indexed
- González-Ramos J, Noguera-Morel L, Tong HY, Ramírez E, Ruiz-Bravo E, Bellón T, Cabanas R, Cachafeiro L, Herranz-Pinto P. Two cases of overlap severe cutaneous adverse reactions to benzimidazole treatment for asymptomatic Chagas disease in a non-endemic country. *Brit J Dermatol*. 2016;175(3):604-7. Article. IF: 4.706; D1
- Huerta C, Abbing-Karahogopian V, Requena G, Oliva B, Álvarez Y, Gardarsdottir H, Miret M, Schneider C, Gil M, Souverein PC, de Bruin ML, Slattery J, de Groot MCH, Hesse U, Rottenkolber M, Schmiedl S, Montero D, Bate A, Ruigómez A, García-Rodríguez LA, Johansson S, de Vries F, Schlienger RG, Reynolds RF, Klungel OH, de Abajo FJ. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic health-care databases: a cross-national descriptive study from the PROTECT-EU Project. *Pharmacoepidem Dr S*. 2016;25:56-65. Article. IF: 2.552; Q2
- Ingelmo AR, Díaz ID, Moreno RC, Quesada MCM, García-Avilés C, Núñez IG, Tadeo JIM, Ballesteros RM, Ortega-Rodríguez N, Vilchez MAP, Sánchez-Morillas L, Albelda CV, Rodilla EM, Jaén

Strategic Objective

Cutaneous adverse drug reactions are unpredictable and represent a plethora of skin diseases with various degrees of severity. The spectrum ranges from mild to potentially fatal multisystem maladies. Those of most concern are usually referred to as severe cutaneous adverse reactions (SCARs), and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug induced hypersensitivity syndrome or hypersensitivity syndrome (DIHS/HSS), Stevens-Johnson's syndrome (SJS), and toxic epider-



- MJT. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. *J Invest Allerg Clin*. 2016;26(3):144-55. Review. IF: 3.094; Q2
- Macía-Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AFZ. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. *Drug Safety*. 2016;39(1):29-43. Article. IF: 3.435; Q1
 - Phillips-Angles E, González-Muñoz M, Domínguez-Ortega J, Cabañas R, Quirce S. Usefulness of basophil activation test in diagnosis of hypersensitivity to etoricoxib. *J Allergy Clin Immunol Pract*. 2016;4(2):350-1. Letter. IF: 5.317; Q1
 - Porrino-Bustamante ML, Alfageme F, Suárez L, de Domingo MAG, Hospital M, Roustán G. High-frequency color doppler sonography of bullous pemphigoid correlation with histologic findings. *J Ultras Med*. 2016;35(8):1821-25. Article. IF: 1.547; Q3
 - Prieto-García A, Marcos C, Caballero T. Classification of angioedema without wheals. *Ann Allerg Asthma Im*. 2016;116(2):177-177. Letter. IF: 3.728; Q2
 - Requena G, Huerta C, Gardarsdottir H, Logie J, González-González R, Abbing-Karahagopian V, Miret M, Schneider C, Souverein PC, Webb D, Afonso A, Boudiaf N, Martín E, Oliva B, Álvarez A, de Groot MCH, Bate A, Johansson S, Schlienger R, Reynolds R, Klungel OH, de Abajo FJ. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. *Pharmacoepidem Dr S*. 2016;25:66-78. Article. IF: 2.552; Q2
 - Requena G, Logie J, Martín E, Boudiaf N, González RG, Huerta C, Álvarez A, Webb D, Bate A, Rodríguez LAG, Reynolds R, Schlienger R, Gardarsdottir H, de Groot M, Klungel OH, de Abajo F, Douglas IJ. Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. *Pharmacoepidem Dr S*. 2016;25:79-87. Article. IF: 2.552; Q2
 - Roldán FA, Fernández IS, Garza FZM, Gullón GR. Update on the use of ultrasound in vascular anomalies. *Actas Dermosifiliogr*. 2016;107(4):284-93. Review. Not Indexed
 - Sánchez-González MJ, Barbarroja-Escudero J, Antolín-Amerigo D, Rodríguez-Rodríguez M, Pericet-Fernández L, Vélez D, Bellón-Heredia T, Álvarez-Mon M. Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described. *Allergol Int*. 2016;65(4):469-71. Letter. IF: 3.194; Q2
 - Souvein PC, Abbing-Karahagopian V, Martín E, Huerta C, de Abajo F, Leufkens HGM, Candore G, Álvarez Y, Slattery J, Miret M, Requena G, Gil MJ, Groenwold RHH, Reynolds R, Schlienger RG, Logie JW, de Groot MCH, Klungel OH, van Staa TP, Egberts TCG, de Bruin ML, Gardarsdottir H. Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. *Pharmacoepidem Dr S*. 2016;25:88-102. Article. IF: 2.552; Q2
 - Urrutia S, Roustán G, Plazas MJ, Armengol S, Paz S, Lizan L. Oral alitretinoin in the treatment of severe refractory chronic hand eczema in the Spanish National Health System: Description and analysis of current clinical practice. *Actas Dermosifiliogr*. 2016;107(2):142-8. Article. Not Indexed
 - Wortsmán X, Alfageme F, Roustán G, Arias-Santiago S, Martorell A, Catalano O, di Santolo MS, Zarchi K, Bouer M, González C, Bard R, Mandava A, Crisan M, Crisan D, Gaitini D. Proposal for an assessment training program in dermatologic ultrasound by the DERMUS Group. *J Ultras Med*. 2016;35(11):2305-9. Editorial Material. IF: 1.547; Q3
 - Wortsmán X, Alfageme F, Roustán G, Arias-Santiago S, Martorell A, Catalano O, di Santolo MS, Zarchi K, Bouer M, González C, Bard R, Mandava A, Gaitini D. Guidelines for performing derma-

tologic ultrasound examinations by the DERMUS Group. *J Ultras Med*. 2016;35(3):577-80. Article. IF: 1.547; Q3

PUBLIC PROJECTS

Bellón Heredia T. Lesiones cutáneas graves asociadas a medicamentos. Mantenimiento de un biobanco de muestras e identificación de posibles marcadores biológicos: análisis de microRNAs como biomarcadores de enfermedad (PI13/01768). ISCIII. 2014-2017.

Management centre: FIBHULP

Bellón Heredia T. Contrato de Estabilización Miguel Serret (I2). ISCIII. 2007-Ongoing.

Management centre: FIBHULP

PRIVATE PROJECTS

Bellón Heredia T. Enfermedad por CMV después del trasplante renal. Importancia de la monitorización inmunológica: respuesta específica t CD8 y expresión de CD94/NKG2C en relación con el rechazo. Roche Farma. 2010-Ongoing.

Management centre: FIBHULP

Bellón Heredia T. Reacciones de hipersensibilidad cutánea graves asociadas a medicamentos: biobanco de muestras biológicas asociadas a un registro de casos para el estudio de los determinantes y mecanismos biológicos y realización del test de transformación linfocitaria. Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias. 2014-Ongoing.

Management centre: FIBHULP

Bellón Heredia T. Formación en la investigación. SYF Galenus Center S.L. 2015-Ongoing.

Management centre: FIBHULP

de Abajo Iglesias FJ. Cáncer colorrectal y medicamentos: estudio de casos y controles en la base de datos BiFAP. Instituto Teófilo Hernando. 2014-2017.

Management centre: FIB-HUPA

de Abajo Iglesias FJ. Convenios de colaboración Registro poblacional de trastornos cutáneos graves asociados a medicamentos. Agencia Española de Medicamentos y Productos Sanitarios. 2015-2016.

Management centre: FIB-HUPA

PATENTS AND TRADEMARKS

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

PEDIATRIC RESPIRATORY, SYSTEMIC AND NEUROLOGICAL INFECTIONS & HOST GROUP*

María Cabrerizo



Cristina Calvo



Rosa Albañil



María Luz García García



Teresa del Rosal



Ana Méndez Echeverría



Inmaculada Casas

Cristina Calvo Rey

Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. HULP

María Rosa Albañil Ballesteros

Pediatra Titular. Centro de Salud de Cuzco. Atención Primaria

María Mercedes Bueno Campaña

Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorcón

María Cabrerizo Sanz

Investigador titular. ISCIII

Ana María Calderón Reyón

Ayudante de Investigación. ISCIII

Inmaculada Casas Flechas

Científico Titular de OPIs. ISCIII

Teresa del Rosal Rabes

Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. HULP

María Luz García García

Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa

Mónica González Esguevillas

Ayudante de Investigación. Centro Nacional de Microbiología. ISCIII

María de la Montaña Iglesias Caballero

Titulado Superior ATP. Centro Nacional de Microbiología. ISCIII

Ana María Méndez Echeverría

Facultativo Especialista de Área en Pediatría General. HULP

Mar Molinero Calamita

Colaboradora I+D+I. Centro Nacional de Microbiología. ISCIII

Almudena Otero Sánchez

Centro Nacional de Microbiología. ISCIII

Juan Francisco Pozo Sánchez

Investigador Titular de OPIs. Unidad de Virus Respiratorios y Gripe. ISCIII

* Group recently created: February 2017

Strategic Objective

Infectious diseases are the most frequent pathology in childhood. Our group is focused in the study of paediatric infections with special attention to those associated to viruses.

The acute respiratory infections (ARIs) of lower respiratory tract are the most frequent infectious diseases in humans and these suppose at least 4 million of deaths yearly in the world. A high proportion of these infections are related with viral aetiology and particularly in children. In our country, the viral ARIs are one of the most frequent causes of hospitalization in children less than 2 years old. Using the metagenomics and applying an adapted method designed and developed for ARIs study, we will have achieved an increased knowledge of viral infections in hospitalized children of all ages, as well as in outpatients. Metagenomics could allow recognizing new viruses and also permits a deeper knowledge of traditional respiratory virus groups. Any new technological tool and its application to respiratory infection will mean an improvement in the diagnosis and monitoring of these types of infections and their immediate use is specified for resolving alerts in public health associated with respiratory viral infections like the case of MERS-CoV, avian flu, or other influenza pandemics. We are also interested in the study of the immunological response of the infants to the viral infections, and the mechanisms that allow develop recurrent wheezing, or asthma (the most frequent chronic disease in children).

Emerging viral infections have also an important role




in the pathology in childhood. Recently picornaviruses, mainly human parechovirus and enterovirus are causing outbreaks and several neurological infections, morbidity and mortality. They were associated with a wide range of pathologies, from febrile syndrome to respiratory, neurological or systemic diseases. In newborns, these infections can be severe, even fatal. Surveillance of these polio-like diseases is a public health concern and it is one of our group objectives.

Finally, to study viral infections in high risk group of children (newborn, chronic lung diseases, immunodeficiencies, oncologic patients...) is also a priority in our group.

Research Lines

- Respiratory viral infections in hospitalized children. Viral metagenomic methods applied to the severe infections of the lower respiratory tract.

- Respiratory viral infections in children in Primary Care.
- Respiratory viral infections in high risk group of children (newborn, chronic lung diseases, immunodeficiencies, oncologic patients...).
- Applying of new technologies as echography to value risk conditions in viral infections.
- Immune response of the children and interleukins profile in infants with respiratory viral infections and correlation with the development of recurrent wheezing in the first years of life.
- Detection and characterization of enterovirus (EV) and parechovirus (PeV) systemic and neurological infections in children.
- Neurological development in children with EV and PeV infections.
- Kawasaki disease.



PEDIATRIC SYSTEMIC INFECTIONS; HIV, TUBERCULOSIS, IMPORTED AND EMERGENT GROUP*



María José Mellado Peña

Jefe de Servicio. HULP

Fernando Baquero Artigao

Facultativo Especialista de Área de Pediatría. HULP
Profesor asociado. UAM

Francisco José Climent Alcalá

Facultativo Especialista de Área en Pediatría. Unidad de Patología Compleja. HULP
Colaborador docente. UAM

Luis Escosa García

Facultativo Especialista de Área de Pediatría. HULP

Marta García Fernández de Villalta

Facultativo Especialista de Área en Pediatría. HULP
Colaborador Clínico Docente. UAM

María Milagros García López de Hortelano

Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. HULP

Roi Piñeiro Pérez

Jefe Asociado del Servicio de Pediatría. Hospital General de Villalba

Talía Sainz Acosta

Facultativo Especialista de Área en Pediatría. HULP
Profesor colaborador. UCM

- Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response.
- Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management.
- Immunization strategies in children: immune response in high risk patient's vaccine effectiveness and barriers.

Research Lines

- **Vertically acquired HIV infection in children**
 - Immuno-pathogenesis: Immune-activation, inflammation and biomarkers.
 - Epidemiology, immuno-virological factors.
 - Comorbidities, long term follow-up, cardiovascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction.
 - Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies.
 - HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control.
 - Gut Microbiota and bacterial traslocation intestinal as modulating factors for inflammation and immune-activation in HIV-infected children.
 - Transition to adult care: barriers, strategies to maintain adherence to care.

Strategic Objective

- Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches.
- Epidemiology of Paediatric Tuberculosis in Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.

* Group recently created: february 2017

- **Epidemiology of paediatric Tuberculosis (TB).**
 - Epidemiology of paediatric TB. Paediatric cases as a sentinel for burden of diseases.
 - Molecular epidemiology of paediatric TB: resistant strains.
 - Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients, migrants and Internationally adopted childre
 - Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.
 - New fixed-dosed combinations. Off label drugs in children. Pharmacodynamic and pharmacokinetic.
- **Congenital infectious diseases**
 - Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.
 - CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.
- **Epidemiology of imported and emergent diseases in children**
 - Paediatric International Outbreaks: Epidemiology and public health impact: Zika. Rabies. Dengue. Chikungunya. Haemorrhagic fevers, Mers-co.
 - Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children.
- **Immunization strategies in children, including high risk patients**
 - Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.
 - Vaccine immunogenicity: barriers in paediatric populations.



TRANSLATIONAL RESEARCH IN PEDIATRIC ONCOLOGY, HEMATOPOIETIC GROUP*



Antonio Pérez Martínez

Facultativo Especialista de Área en Pediatría, Oncología y Hematología. HULP

David Bueno Sánchez

Facultativo Especialista de Área en Pediatría, Oncología y Hematología. HULP

Pilar Carrasco Salas

Diagnóstico Molecular. HULP

Adela Escudero López

Investigadora Postdoctoral. HULP

Berta González Martínez

Facultativo Especialista de Área en Pediatría. HULP

Pablo González Navarro

Técnico en Laboratorio. HULP

Irene González Magro

Investigador Predoctoral. HULP

Pedro María Rubio Aparicio

Facultativo Especialista de Área en Pediatría, Oncología y Hematología. HULP

Sonsoles San Román Pacheco

Facultativo Especialista de Área en Pediatría, Oncología y Hematología. HULP

Jaime Valentín Quiroga

Investigador Predoctoral. HULP

María Vela Cuenca

Investigador Postdoctoral. HULP

through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells transplantation.

Research Lines

- Analysis of solid / hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level.
- Cell therapy with activated NK cells in childhood cancer.
- Hematopoietic progenitor transplantation as a platform for cell therapy.
- Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.
- Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2D-CAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
- Optimization of NK cell therapy using nanotechnology and antigenic chimeric receptors (CAR).
- Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy
- Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.

Strategic Objective

Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily

* Group recently created: february 2017



3.4 Large System Pathology Area

Francisco García Ríó

Documents: **291** IF: **1,309.496**

Originals: **219** IF: **1,089.056**

DI: **44** QI: **108**

- Internal Medicine and Systemic Diseases Group
- Organic Dysfunction and Failure in the Aggression Group
- Respiratory Diseases Group
- Regulation of Gene Expression and by Hypoxia Group
- Nephrology Group
- Neonatology Group
- Aging and Fragility in the Elderly Group
- Molecular Hepatology Group
- Diagnosis and Treatment of Allergic Diseases Group
- Gynecologic Oncology Group
- Patient Blood Management Group
- Endocrine Diseases Group
- Urology Group
- Health Care Nurses Research Group
- Maternal and Fetal Medicine Group
- Emergency and Critical Pathology Group

INTERNAL MEDICINE AND SYSTEMIC DISEASES GROUP



Publications: **18**

Impact Factor: **150.429**

QI: **9**

Francisco Arnalich Fernández

Jefe de Servicio de Medicina Interna. HULP
Catedrático. Facultad de Medicina. UAM

Gema Atienza Toledo

Técnico de Laboratorio. UAM

Anna Bordas Sánchez

Investigadora Predoctoral. UAM

José Luis Cedillo Mireles

Becario Predoctoral (Contrato FPU). UAM

María del Carmen Fernández Capitán

Jefe de Sección de Medicina Interna. HULP
Profesora asociada de Medicina. UAM

Carolina Martín Sánchez

Becaria Predoctoral (Contrato FPI). UAM

Carmen Montiel López

Catedrática de Universidad. Facultad de Medicina. UAM

María Angustias Quesada Simón

Facultativo Especialista de Área en Medicina Interna. HULP
Profesora Honoraria de Medicina. UAM

Jaime Renart Pita

Investigador Científico. IIB "Alberto Sols"

Juan José Ríos Blanco

Facultativo Especialista de Área en Medicina Interna. HULP
Profesor Asociado de Medicina. UAM

Strategic Objective

In the setting of the systemic response frequently found in patients attended in Internal Medicine wards, our group has studied some **regulatory mechanisms of the innate immune response** in patients with sepsis and other inflammatory states such as acute coronary syndromes (ACS), cystic fibrosis and cancer.

The first line of our research is the **link between the parasympathetic and innate immune systems**, that is the molecular mechanisms by which acetylcholine can influence the immune system via the **'cholinergic anti-inflammatory pathway'**. This pathway is mediated by the vagus nerve which releases acetylcholine to interact with the $\alpha 7$ subunit of the nicotinic acetylcholine receptor ($\alpha 7nAChR$). We firstly reported that the neuronal $\alpha 7$ nicotinic receptor subunit gene (CHRNA7) is partially duplicated in the human genome forming a hybrid gene (CHR-FAM7A) with the novel FAM7A gene, and provided experimental data showing that $\text{dup}\alpha 7$ could modulate $\alpha 7$ receptor-mediated synaptic transmission and cholinergic anti-inflammatory response (J Biol Chem 2011). The Toll-like receptor (TLR) plays an important role in the induction of the hyperinflammatory response and tissue injury in sepsis. We found that the $\alpha 7$ gene expression level in septic patients' peripheral blood mononuclear cells (PBMC) is a clinically relevant marker to assess the magnitude of the patient's inflammatory state, disease severity, and clinical outcome (J Infect Dis 2015).

Another exciting line of our research is **the involvement of the $\alpha 7$ -nicotinic receptor** and its endogenous modulator $\text{dup}\alpha 7$ in **human smoking-related tumors**, and particularly their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistance. This topic has attracted a grant from the Ministerio de Economía y Competitividad from 2014-2017. Besides, professor Jaime Renart who works in our team group, is doing new research on the **molecular mechanisms of podoplanin**, a type I transmembrane mucin widely known as a marker for lymphatic endothelial cells that



has a critical role during development of the heart, lungs and lymphatic endothelial system. The expression of podoplanin is significantly enhanced during tissue-remodelling processes and in several types of human cancer, including squamous cell carcinomas.

Research Lines

Applied research lines:

- Molecular mechanisms involved in the innate immune response.
- Link between the parasympathetic and innate immune systems.

Collaborative research line:

- Adaptative immune response in human immunodeficiency virus (HIV) infection.
- Multicentric group: RIETE group (Registro Español de Enfermedad Trombo-Embólica).
- Molecular mechanisms of podoplanin during tissue-remodelling processes and in several types of human cancer.
- Mechanisms and clinical features of systemic autoimmune diseases.

Lines of study framed in basic research projects:

- Study of the pathophysiological role of nicotinic $\alpha 7$ and dup-a7 receptors expressed in human macrophages, neurons and lung carcinoma cells.
- Identification of signalling pathways connecting nicotinic $\alpha 7$ receptors and negative regulators of TLR-mediated inflammation in human macrophages.

Research Activity

DOCTORAL THESES

Montejano Sánchez R. Impacto del tratamiento del tratamiento antiretroviral con y sin nucleosidos sobre la densidad mineral ósea y los biomarcadores de remodelado óseo [dissertation]. Madrid: UAM: 2016(01/04/2016).

Directors: Arribas López JR, Arnalich Fernández F.

Pérez Valero I. Deterioro cognitivo asociado al virus de inmunodeficiencia humana (VIH) e inhibidores de proteasa potenciados con ritonavir en monoterapia [dissertation]. Madrid: UAM: 2016(01/02/2016).

Directors: Arribas López JR, Arnalich Fernández F.

Rodríguez Castellano E. Impacto del tratamiento del VHC sobre la infección VIH y la morbimortalidad no hepática en pacientes coinfectados VIH y VHC [dissertation]. Madrid: UAM: 2016(01/05/2016).

Directors: Berenguer Berenguer J, Arnalich Fernández F.

PUBLICATIONS

• Alonso-Fernández A, Suquía AG, de la Peña M, Casitas R, Pierola J, Barcelo A, Soriano JB, Fernández-Capitan C, Martínez-Cerón E, Carrera M, García-Río F. OSA is a risk factor for recurrent VTE. *Chest*. 2016;150(6):1291-301. Article. IF: 6.044; Q1

• Brito-Zerón P, Bosch X, Pérez-de-Lis M, Pérez-Álvarez R, Fraile G, Gheitas H, Retamozo S, Bove A, Monclus E, Escoda O, Moreno A, López-Guillermo A, Khamashta MA, Ramos-Casals M, (Ríos-Blanco JJ). Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. *Semin Arthritis Rheu*. 2016;45(4):391-9. Review. IF: 4.498; Q1

• Carrasco-Ramírez P, Greening DW, Andrés G, Gopal SK, Martín-Villar E, Renart J, Simpson RJ, Quintanilla M. Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. *Oncotarget*. 2016;7(13):16070-89. Article. IF: 5.168; Q1

• Comín-Colet J, Anguita M, Formiga F, Almenar L, Crespo-Leiro MG, Manzano L, Muñoz J, Chaves J, de Frutos T, Enjuanes C, (Quesada Simón MA). Health-related quality of life of patients with chronic systolic heart failure in Spain: Results of the VIDA-IC Study. *Rev Esp Cardiol*. 2016;69(3):256-71. Article. IF: 4.485; Q2

• Chew CRM, Batres SA, Blanco JJR. Update in pulmonary arterial hypertension. *Rev Clin Esp*. 2016;216(8):436-44. Review. IF: 0.971; Q3

• de la Calle-Prieto F, Arsuaga-Vicente M, Mora-Rillo M, Arnalich-Fernández F, Arribas JR. Ebola virus disease: Update. *Enferm Infecc Microb Cl*. 2016;34(7):452-60. Review. IF: 1.714; Q3

• Frasson S, Gussoni G, Di Micco P, Barba R, Bertolotti L, Núñez MJ, Valero B, Sampérez AL, Rivas A, Monreal M, (Fernández-Capitán C). Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. *J Thromb Thrombolys*. 2016;41(3):404-12. Article. IF: 2.142; Q3

• González-Suárez I, Arpa J, Ríos-Blanco JJ. Brain microvasculature involvement in ANCA positive vasculitis. *Cerebrovasc Dis*. 2016;41(42891):313-21. Article. IF: 2.974; Q2

• Jiménez D, de Miguel-Díez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M, (Fernández-Capitán C). Trends in the management and outcomes of acute pulmonary embolism analysis from the RIETE Registry. *J Am Coll Cardiol*. 2016;67(2):162-70. Article. IF: 19.896; D1

• Montes R, Guruceaga E, González-Porrás JR, Reverter JC, Marco P, Pina E, Páramo JA, Hermida J, Lecumberri R, (Fernández-Capitán C). Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. *Eur J Haematol*. 2016;97(2):128-36. Article. IF: 2.653; Q2

• Morillo R, Jiménez D, Aibar MA, Mastroiacovo D, Wells PS, Sampérez A, de Sousa MS, Muriel A, Yusen RD, Monreal M, (Fernández-Capitán C). DVT management and outcome trends, 2001 to 2014. *Chest*. 2016;150(2):374-83. Article. IF: 6.044; Q1

• Rabadán IR, Sánchez MA, Marín F, Quesada MA, Siles JC, Peinado R, Bertoméu V, Fillat AC, Badimón L, Muñoz J. Current antiarrhythmic therapy for nonvalvular atrial fibrillation in Spain. Data From the FANTASIA Registry. *Rev Esp Cardiol*. 2016;69(1):54-60. Article. IF: 4.485; Q2

• Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by *Kocuria kristinae*. *Enferm Infecc Microb Cl*. 2016;34(7):464-5. Letter. IF: 1.714; Q3

• Salamanca-Bautista P, Conde-Martel A, Aramburu-Bodas O, Formiga F, Trullas JC, Quesada-Simón MA, Casado-Cerrada J, Ruiz-Laiglesia F, Manzano L, Montero-Pérez-Barquero M. Precipitating factors of heart failure admission: Differences related to age and left ventricular ejection fraction. *Int J Cardiol*. 2016;219:150-5. Article. IF: 6.189; Q1

• Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, Mari-Alfonso B, Colunga-Argüelles D, Rubio JLC, Rubio-Rivas M,

Freire-Dapena M, Guillén-del Castillo A, Iniesta-Arandia N, Castillo-Palma MJ, Egurbide-Arberas M, Trapiella-Martínez L, Vargas-Hitos JA, Todoli-Parra JA, Rodríguez-Carballeira M, Marín-Ballve A, Pla-Salas X, Ríos-Blanco JJ, Fonollosa-Pla V. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. *Semin Arthritis Rheu*. 2016;46(2):200-8. Review. IF: 4.498; Q1

• Tong HY, Dávila-Fajardo CL, Borobia AM, Martínez-González LJ, Lubomirov R, León LMP, Banares MJB, Díaz-Villamarín X, Fernández-Capitan C, Barrera JC, Carcas AJ. A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed Spanish population. *Plos One*. 2016;11(3):e0150456. Article. IF: 2.806; Q1

• Trullas JC, Manzano L, Formiga F, Aramburu-Bodas O, Quesada-Simón MA, Arias-Jiménez JL, García-Escriva D, Romero-Requena JM, Jordana-Comajuncosa R, Montero-Pérez-Barquero M. Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure. *Cardiology*. 2016;135(3):196-201. Article. IF: 1.742; Q3

• Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AIM, Rapp C, Hoepelman AIM, Gutman J, (Arnalich Fernández F). Clinical Management of ebola virus disease in the United States and Europe. *New Engl J Med*. 2016;374(7):636-46. Article. IF: 72.406; D1

PUBLIC PROJECTS

Montiel López C, Arnalich Montiel F. The $\alpha 7$ -nicotinic receptor and its endogenous modulator dupa7 in human smoking-related tumors: their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistance (SAF2014-56623-R). MINECO. 2014-2017.

Management centre: UAM

PRIVATE PROJECTS

Arnalich Fernández F. Gestión multidisciplinar de la asistencia al paciente con insuficiencia cardíaca. Academia de Estudios MIR S.L. 2008-Ongoing.

Management centre: FIBHULP

Arnalich Fernández F. Papel del DUP-ALFA7, un duplicado parcial de la subunidad ALFA7 del receptor nicotínico humano, en el desarrollo tumoral asociado al consumo de tabaco. Fundación Mutua Madrileña. 2011-Ongoing.

Management centre: FIBHULP

Arnalich Fernández F. Plan de difusión de la enfermedad de Fabry. Almirall S.A. 2015-Ongoing.

Management centre: FIBHULP

Arnalich Fernández F. Servicio de Urgencias. 2016-Ongoing.

Management centre: FIBHULP

Fernández Capitán MC. Estudio longitudinal predictivo de hipertensión pulmonar posttrombótica basado en la creación de una red de biobancos vinculados a datos clínicos de Embolismo Pulmonar (Estudio Osiris). Laboratorios Farmacéuticos Rovi S.A. 2015-Ongoing.

Management centre: FIBHULP

Ríos Blanco JJ. Estudio de disfunción ventricular precoz en pacientes con Esclerodermia. Glaxosmithkline S.A. 2011-Ongoing.

Management centre: FIBHULP

Ríos Blanco JJ. Estudio de hipertensión pulmonar en la cohorte de pacientes con infección VIH del Hospital La Paz. Glaxosmithkline S.A. 2010-Ongoing.

Management centre: FIBHULP

Ríos Blanco JJ. PI-674 Estudio de la relación entre la rigidez arterial y la función endotelial en pacientes con hipertensión de bata blanca. Menarini Diagnósticos S.A. 2009-Ongoing.

Management centre: FIBHULP





ORGANIC DYSFUNCTION AND FAILURE IN THE AGGRESSION GROUP



Publications: 11
Impact Factor: 39.682
QI: 7

Abelardo García de Lorenzo y Mateos

Jefe de Servicio de Medicina Intensiva. HULP
Profesor Titular. Facultad de Medicina. UAM

Alexander Agrifoglio Rotaache

Facultativo Especialista de Área en Medicina Intensiva. HULP

José Manuel Añón Elizalde

Jefe de Sección en Medicina Intensiva. HULP

María Antonia Arce Mendiburu

Facultativo Especialista de Área en Medicina Intensiva. HULP

María José Asensio Martín

Facultativo Especialista de Área en Medicina Intensiva. HULP

Lucía Cachafeiro Fuciños

Facultativo Especialista de Área en Medicina Intensiva. HULP

Belén Civantos Martín

Facultativo Especialista de Área en Medicina Intensiva. HULP

María Belén Estebáñez Montiel

Facultativo Especialista de Área en Medicina Intensiva.

Coordinador de Trasplante. HULP

Juan Carlos Figueira Iglesias

Facultativo Especialista de Área en Medicina Intensiva. HULP

Eva Mercedes Flores Cabeza

Facultativo Especialista de Área en Medicina Intensiva. HULP

Ricardo García Hernández

Facultativo Especialista de Área en Medicina Intensiva. HULP

Eva Herrero de Lucas

Facultativo Especialista de Área en Medicina Intensiva. HULP

Jesús Javier Manzanares Gómez

Facultativo Especialista de Área en Medicina Intensiva. HULP

Eva Perales Ferrera

Facultativo Especialista de Área en Medicina Intensiva. HULP

Itziar Pozuelo Echegaray

Facultativo Especialista de Área en Medicina Intensiva. HULP

Santos Manuel Sánchez Sánchez

Jefe de Sección de Medicina Intensiva. HULP

Santiago Yus Teruel

Facultativo Especialista de Área en Medicina Intensiva. HULP

Strategic Objective

The global objective of the investigation team on Dysfunction and Organ Failure in Aggression is the optimization of the patient management in the really critical ill patients who can develop Organ Dysfunction or Organ Failure. Multiorgan Dysfunction & Multiorgan Failure Syndrome (MOF-MOD Syndrome) are correlated with bad prognostic and high mortality rates.

D-FMO Syndrome is correlated both with the disease severity and the therapeutic efforts. The therapeutic management of the patient must be early and directed to specific objectives.

Otherwise, the support measures must be directed to the specific situations (like sepsis, trauma ...) and to the Organs or Systems in Dysfunction or Failure (coagulation, haemodynamic, respiratory or renal...).

Finally, the detection of D-FMO syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers...) can bring a higher efficacy and better results.

Research Lines

- Biomarkers.
- Resuscitation outcome.
- Therapeutic support.

Research Activity

PUBLICATIONS

- Bauzano E, Estebáñez B, García-Morales I, Muñoz VF. Collaborative human-robot system for HALS suture procedures. *IEEE Syst J*. 2016;10(3):957-66. Article. IF: 3.882; D1
- Cuerda C, Álvarez J, Ramos P, Abanades JC, García-de-Lorenzo A, Gil P, de-la-Cruz JJ. Prevalence of malnutrition in subjects over 65 years of age in the Community of Madrid. *The DREAM + 65 Study*. *Nutr Hosp*. 2016;33(2):263-9. Article. IF: 0.747; Q4
- Frasson S, Gussoni G, Di Micco P, Barba R, Bertoletti L, Nunez MJ, Valero B, Samperiz AL, Rivas A, Monreal M (García de Lorenzo y Mateos A). Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. *J Thromb Thrombolys*. 2016;41(3):404-12. Article. IF: 2.142; Q3
- García-de-Lorenzo A, Luque S, Grau S, Agrifoglio A, Cachafeiro L, Herrero E, Asensio MJ, Sánchez SM, Roberts JA. Comparative population plasma and tissue pharmacokinetics of micafungin in critically ill patients with severe burn injuries and patients with complicated intra-abdominal infection. *Antimicrob Agents Ch*. 2016;60(10):5914-21. Article. IF: 4.302; Q1
- Garzotto F, Ostermann M, Martín-Langerwerf D, Sánchez-Sánchez M, Teng J, Robert R, Marinho A, Herrera-Gutiérrez ME, Mao HJ, Benavente D, Kipnis E, Lorenzin A, Marcelli D, Tetta C, Ronco C. The dose response multicentre investigation on fluid assessment (DoReMIFA) in critically ill patients. *Crit Care*. 2016;20:196. Article. IF: 5.358; Q1
- González-Ramos J, Noguera-Morel L, Tong HY, Ramírez E, Ruiz-Bravo E, Bellón T, Cabañas R, Cachafeiro L, Herranz-Pinto P. Two cases of overlap severe cutaneous adverse reactions to benzidazole treatment for asymptomatic Chagas disease in a non-endemic country. *Brit J Dermatol*. 2016;175(3):604-7. Article. IF: 4.706; D1
- Ortiz JE, Borrego AG, Gallego JLR, Sánchez-Palencia Y, Urbanczyk J, Torres T, Domingo L, Estebáñez B. Biomarkers and inorganic proxies in the paleoenvironmental reconstruction of mires: The importance of landscape in Las Conchas (Asturias, Northern Spain). *Org Geochem*. 2016;95:41-54. Article. IF: 3.081; Q1
- Planas M, Álvarez-Hernández J, León-Sanz M, Celaya-Pérez S, Araujo K, de Lorenzo AG. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCESA (R) study. *Support Care Cancer*. 2016;24(1):429-35. Article. IF: 2.698; Q1
- Sánchez-Recalde A, Moreno R, Flores BE, Jiménez-Valero S, Mateos AGDY, López-Sendon JL. Percutaneous transcatheter treatment for massive pulmonary embolism. *Rev Esp Cardiol*. 2016;69(3):340-42. Letter. IF: 4.485; Q2
- Sánchez-Sánchez M, García-de-Lorenzo A, Asensio MJ. First resuscitation of critical burn patients: progresses and problems. *Med Intensiva*. 2016;40(2):118-24. Article. IF: 1.231; Q4

- Villar J, Ambros A, Soler JA, Martínez D, Ferrando C, Solano R, Mosteiro F, Blanco J, Martín-Rodríguez C, Fernández MD, López J, Díaz-Domínguez FJ, Andaluz-Ojeda D, Merayo E, Pérez-Méndez L, Fernández RL, Kacmarek RM, (Civantos B). Age, Pao(2)/Fio(2), and plateau pressure score: A proposal for a simple outcome score in patients with the acute respiratory distress syndrome. *Crit Care Med*. 2016;44(7):1361-9. Article. IF: 7.05; Q1

CLINICAL TRIALS

Agrifoglio Rotaache A. Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con comparador, para evaluar la eficacia, la seguridad y la farmacocinética de ulimorelina (Ip101) administrada por vía intravenosa en pacientes con intolerancia a la alimentación enteral. Lyric Pharmaceuticals Incll.

HULP Code: 4624. Sponsored's Protocol Code: LP101-CL-201.

Signature Date: 17/5/2016

Añón Elizalde JM. Estudio comparativo, aleatorio, controlado, para evaluar la eficacia de la administración de dexametasona en el tratamiento de pacientes con el síndrome de distrés respiratorio agudo. Hospital Universitario de Gran Canaria.

HULP Code: 4680. Sponsored's Protocol Code: PII1-0143.

Signature Date: 4/10/2016

Fernández Dueñas E. Evaluación de la eficacia y seguridad de tapentadol solución oral en el tratamiento del dolor agudo posoperatorio que requiere tratamiento opioide en pacientes pediátricos con edades desde el nacimiento hasta menos de 18 años. Grunenthal Pharma S.A.

HULP Code: Anexo-II 4132. Sponsored's Protocol Code:

KF5503/65.

Signature Date: 12/5/2016

Figueira Iglesias JC. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de medi3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Astrazeneca Ab.

HULP Code: 4637. Sponsored's Protocol Code: D5470C00004.

Signature Date: 25/5/2016

PATENTS AND TRADEMARKS

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.





RESPIRATORY DISEASES GROUP



Publications: **29**

Impact Factor: **141.729**

Q1: **11**

Francisco José García Río

Jefe de Sección de Neumología (Contrato de Intensificación). HULP
Profesor Titular. Facultad de Medicina. UAMP

Cristina Aguado Cruz

Investigador Predoctoral. HULP

Sergio Alcolea Batres

Facultativo Especialista de Área en Neumología. HULP

Rodolfo Álvarez-Sala Walther

Jefe de Servicio de Neumología. HULP
Catedrático. Facultad de Medicina. UAM

Juan José Cabanillas Martín

Facultativo Especialista de Área en Neumología. HULP

Carlos Javier Carpio Segura

Facultativo Especialista de Área en Neumología. HULP

Raquel Casitas Mateo

Facultativo Especialista de Área en Neumología. HULP

Carolina Cubillos Zapata

Investigadora Posdoctoral (Contrato Sara Borrell). HULP

Raúl Galera Martínez

Facultativo Especialista de Área en Neumología. HULP

Luis Gómez Carrera

Facultativo Especialista de Área en Neumología. HULP

María Antonia Gómez Mendieta

Facultativo Especialista de Área en Neumología. HULP

Elisabet Martínez Cerón

Facultativo Especialista de Área en Neumología. HULP

José María Pino García

Facultativo Especialista de Área en Neumología. HULP

Concepción Prados Sánchez

Jefe de Sección de Neumología. HULP

David Romero Ribate

Facultativo Especialista de Área en Neumología. HULP

Ana Santiago Recuerda

Facultativo Especialista de Área en Neumología. HULP

Carlos Villasante Fernández-Montes

Jefe de Sección de Neumología. HULP

Strategic Objective

Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome (SAHS).

We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mechanisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders.

In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS. Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define the

methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

Research Lines

- Cardiovascular morbidity of sleep-disordered breathing.
- Pathogenesis of airflow limitation.
- Systematization of lung function testing.

Research Activity

DOCTORAL THESES

Díaz Agero P. Desarrollo de una técnica de terapia celular e ingeniería tisular con células troncales somáticas mesenquimales para el tratamiento de las fistulas traqueo-bronquiales postquirúrgicas y las de origen yatrogénico [dissertation]. Madrid: UAM: 2016(12/02/2016).

Director: Álvarez-Sala Walther R.

Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España [dissertation]. Madrid: UAM: 2016(03/05/2016).

Director: Álvarez-Sala Walther R.

Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral [dissertation]. Madrid: UAM: 2016(23/06/2016).

Directors: López-Collazo EM, García Río F.

Pandiella Dominique A. Aproximación cuantitativa a la Apnea del sueño (2006-2010) [dissertation]. Madrid: UAM: 2016(28/01/2016).

Director: García Río F.

Romero Ribate D. Valoración del Síndrome de Apneas-Hipopneas del sueño como factor de riesgo de la Enfermedad Tromboembólica [dissertation]. Madrid: UAM: 2016(14/09/2016).

Director: García Río F.

Ruano Encinar M. Efecto de la prescripción electrónica asistida en pacientes pediátricos hospitalizados: evaluación de errores de medicación [dissertation]. Madrid: UAM: 2016(03/11/2016).

Director: Álvarez-Sala Walther R.

Utrilla Contreras C. Valor de la Tomografía Computarizada Volumétrica en el estudio de la Enfermedad Pulmonar Obstructiva Crónica [dissertation]. Madrid: UAM: 2016(13/04/2016).

Director: García Río F.

PUBLICATIONS

- Alonso-Fernández A, Suquia AG, de la Peña M, Casitas R, Pierola J, Barcelo A, Soriano JB, Fernández-Capitán C, Martínez-Cerón E, Carrera M, García-Río F. OSA is a risk factor for recurrent VTE. *Chest*. 2016;150(6):1291-301. Article. IF: 6.044; Q1
- Caballero JD, del Campo R, Royuela A, Sole A, Maiz L, Oliveira C,

Quintana-Gallego E, de Gracia J, Cobo M, de la Pedrosa EGG, Oliver A, Cantón R, Sole A, Cortell I, Asensio O, García G, Martínez MT, Cols M, Salcedo A, Vázquez C, Baranda F, Girón R, Quintana E, Delgado I, de Miguel MA, García M, Oliva C, Prados MC, Barrio MI, Pastor MD, Oliveira C, de Gracia J, Álvarez A, Escribano A, Castillo S, Figuerola J, Tógores B, Oliver A, López C, Caballero JD, Tato M, Maiz L, Suarez L, Canton R. Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. *J Cyst Fibros*. 2016;15(3):357-65. Article. IF: 4.727; Q1

• Carpio C, Villasante C, Galera R, Romero D, de Cos A, Hernanz A, García-Río F. Systemic inflammation and higher perception of dyspnea mimicking asthma in obese subjects. *J Allergy Clin Immunol*. 2016;137(3):718-26. Article. IF: 13.081; D1

• Carrera LG, Walther RAS. Pulmonary fibrosis. *Med Clin-Barcelona*. 2016;146(3):115-6. Editorial Material. IF: 1.125; Q3

• Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, Arribas-Jiménez C, Hernández-Jiménez E, Toledano V, Villaescusa T, Moreno V, López-Collazo E. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma. *Oncoimmunology*. 2016;5(12):e1231290. Article. IF: 7.719; D1

• Chew CRM, Batres SA, Blanco JJR. Update in pulmonary arterial hypertension. *Rev Clin Esp*. 2016;216(8):436-44. Review. IF: 0.971; Q3

• de la Rosa D, Martínez-García MA, Oliveira C, Girón R, Maiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. *Chron Resp Dis*. 2016;13(4):361-71. Article. IF: 1.818; Q3

• Franssen FME, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, García-Río F, Kearney MT, Kwon N, Lundback B, Rabe KF, Raillard A, Muellerova H, Cockcroft JR. Lung function abnormalities in smokers with ischaemic heart disease. *Am J Resp Crit Care*. 2016;194(5):568-76. Article. IF: 13.204; D1

• García-Martínez D, Torres-Tamayo N, Torres-Sánchez I, García-Río F, Bastir M. Morphological and functional implications of sexual dimorphism in the human skeletal thorax. *Am J Phys Anthropol*. 2016;161(3):467-77. Article. IF: 2.552; Q2

• García-Sánchez A, Fernández-Navarro I, García-Río F. Central apneas and REM sleep behavior disorder as an initial presentation of multiple system atrophy. *J Clin Sleep Med*. 2016;12(2):267-70. Article. IF: 3.429; Q2

• Guzmán E, Taylor G, Hope J, Herbert R, Cubillos-Zapata C, Charleston B. Transduction of skin-migrating dendritic cells by human adenovirus 5 occurs via an actin-dependent phagocytic pathway. *J Gen Virol*. 2016;97:2703-18. Article. IF: 2.838; Q2

• López-Jiménez MJ, Masa JF, Corral J, Terán J, Ordaz E, Troncoso MF, González-Mangado N, González M, López-Martínez S, de Lucas P, Marín JM, Martí S, Díaz-Cambres T, Díaz-de-Aurari J, Chiner E, Aizpuru F, Egea C, Romero A, Benítez JM, Sánchez-Gómez J, Golpe R, Santiago-Recuerda A, Gómez S, Barbe F, Bengoa M. Mid- and long-term efficacy of non-invasive ventilation in obesity hypoventilation syndrome: The Pickwick's Study. *Arch Bronconeumol*. 2016;52(3):158-65. Article. IF: 2.979; Q2

• Martínez-Cerón E, Barquiel B, Bezos AM, Casitas R, Galera R, García-Benito C, Hernanz A, Alonso-Fernández A, García-Río F. Effect of continuous positive airway pressure on glycaemic control in patients with obstructive sleep apnea and type 2 diabetes A randomized clinical trial. *Am J Resp Crit Care*. 2016;194(4):476-85. Article. IF: 13.204; D1

• Martínez-Cerón E, Buño A, García-Río F. Analytical performance requirements for biomarker-based studies evaluating continuous positive airway pressure effects in obstructive sleep apnea reply. *Am J Resp Crit Care*. 2016;194(4):523-4. Letter. IF: 13.204; D1



- Martínez-Cerón E, Fernández-Navarro I, García-Río F. Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea. *Sleep Med Rev.* 2016;25:121-30. Review. IF: 8.958; D1
- Martínez-Cerón E, García A, Casitas R, Galera R, García-Río F. Cost-effectiveness analysis of 3 methacholine challenge tests: importance of simplified protocols. *J Invest Allerg Clin.* 2016;26(2):121-4. Editorial Material. IF: 3.094; Q2
- Masa JF, Corral J, Caballero C, Barrot E, Terán-Santos J, Alonso-Álvarez ML, Gómez-García T, González M, López-Martín S, de Lucas P, Marín JM, Martí S, Díaz-Cambres T, Chiner E, Egea C, Miranda E, Mokhlesi B, García-Ledesma E, Sánchez-Quiroga MA, Ordax E, González-Mangado N, Troncoso MF, Martínez-Martínez MA, Cantalejo O, Ojeda E, Carrizo SJ, Gallego B, Pallero M, Ramón MA, Díaz-de-Atauri J, Míoz-Méndez J, Senent C, Sancho-Chust JN, Ribas-Solis FJ, Romero A, Benítez JM, Sánchez-Gómez J, Golpe R, Santiago-Recuerda A, Gómez S, Bengoa M. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. *Thorax.* 2016;71(10):899-906. Article. IF: 8.272; D1
- Masa JF, Utrabo I, de Terreros JG, Aburto M, Esteban C, Prats E, Núñez B, Ortega-González A, Jara-Palomares L, Martín-Vicente MJ, Ferrero E, Binimelis A, Sala E, Serrano-Rebollo JC, Barrot E, Sánchez-Oro-Gómez R, Fernández-Álvarez R, Rodríguez-Jerez F, Sayas J, Benavides P, Catalá R, Rivas FJ, Egea CJ, Antón A, Penacoba P, Santiago-Recuerda A, Gómez-Mendieta MA, Méndez L, Cebrián JJ, Pina JA, Zamora E, Segrelles G. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units Precision medicine in intermediate care units. *BMC Pulm Med.* 2016;16:97. Article. IF: 2.435; Q3
- Miranda DG, Peces EMS, Babarro AA, Sánchez MCP, Cerdeira MV. HOLD study (Home care Obstructive Lung Disease): natural history of patients with advanced COPD. *BMC Palliat Care.* 2016;15:35. Article. IF: 1.602; Q3
- Miravittles M, Galdiz JB, Huerta A, Villacampa A, Carcedo D, García-Río F. Cost-effectiveness of combination therapy umecidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. *Int J Chron Obstruct Pulmon Dis.* 2016;11:123-32. Article. IF: 3.157; Q2
- Oliveira C, Sole A, Girón RM, Quintana-Gallego E, Mondéjar P, Baranda F, Álvarez A, Prados C, Rodríguez-González J, Herrero-Labarga I, Quitner A, Oliveira G. Depression and anxiety symptoms in Spanish adult patients with cystic fibrosis: associations with health-related quality of life. *Gen Hosp Psychiat.* 2016;40:39-46. Article. IF: 2.279; Q3
- Pomares X, Montón C, Bare M, Pont M, Estirado C, Gea J, Quintana JM, Vidal S, Santiago A. Emergency hospital care for exacerbation of COPD: Is inhaled maintenance therapy modified? *COPD.* 2016;13(1):11-8. Article. IF: 2.576; Q3
- Roche O, Déguiz ML, Tiana M, Galiana-Ribote C, Martínez-Alcázar D, Rey-Serra C, Ranz-Ribeiro B, Casitas R, Galera R, Fernández-Navarro I, Sánchez-Cuellar S, Bernard V, Ancochea J, Wasserman WW, García-Río F, Jiménez B, del Peso L. Identification of non-coding genetic variants in samples from hypoxic respiratory disease patients that affect the transcriptional response to hypoxia. *Nucleic Acids Res.* 2016;44(19):9315-30. Article. IF: 10.162; D1
- Ruano M, Villamañán E, Pérez E, Herrero A, Álvarez-Sala R. New technologies as a strategy to decrease medication errors: how do they affect adults and children differently? *World J Pediatr.* 2016;12(1):28-34. Review. IF: 1.164; Q3
- Ruiz-Pérez D, Largo C, García-Río F. Technical aspects and benefits of experimental mouse lung transplantation. *Arch Bronconeumol.* 2016;52(12):596-604. Review. IF: 2.979; Q2
- Soriano JB, García-Río F. Global lung function initiative equations:

The legacy starts. *Respiration.* 2016;92(3):131-3. Editorial Material. IF: 2.772; Q2

- Torres-Capelli M, Marsboom G, Li QOY, Tello D, Rodríguez FM, Alonso T, Sánchez-Madrid F, García-Río F, Ancochea J, Aragónés J. Role of Hif2 alpha oxygen sensing pathway in bronchial epithelial club cell proliferation. *Sci Rep-Uk.* 2016;6:25357. Article. IF: 4.259; Q1
- Villamañán E, González D, Armada E, Ruano M, Álvarez-Sala R, Herrero A. The patents game. Generic and biosimilar drugs. *Rev Calid Asist.* 2016;31(2):99-105. Article. Not Indexed
- Zamarrón-de Lucas E, García-Fernández E, Carpio C, Alcolea S, Martínez-Abad Y, Álvarez-Sala R. Massive cardiac lipomatosis, an autopsy finding in a patient with sudden death. *Med Clin-Barcelona.* 2016;146(12):541-3. Article. IF: 1.125; Q3

PUBLIC PROJECTS

García Río FJ. Contrato de Intensificación (INT15/00076). ISCIII. 2016-2017.

Management centre: FIBHULP

García Río FJ. Papel de las alteraciones de las dianas génicas de HIF y del Sistema Inmune Innato en el desarrollo del SAHS. Su implicación en cáncer y cardiopatía hisquémica (PI13/01512). ISCIII. 2014-2017.

Management centre: FIBHULP

Ruiz Pérez D. Predoctoral contract (FPU13/01638). MINECO. 2014-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

Álvarez-Sala Walther R. Actualización y renovación de la actividad investigadora en el Servicio de Neumología del Hospital Universitario La Paz. Chiesi España S.A. 2015-Ongoing.

Management centre: FIBHULP

Álvarez-Sala Walther R. Puesta al día en asma grave para Atención Primaria: de la investigación a la práctica clínica. Sandoz Farmaceutica S.A. 2016-Ongoing.

Management centre: FIBHULP

García Río FJ. Análisis de la actividad del Sistema Inmune Innato en pacientes con Síndrome de Apneas-Hipopneas del sueño grave. Roche Pharma S.A. 2014-Ongoing.

Management centre: FIBHULP

García Río FJ. Caracterización clínica de distintos fenotipos de exacerbación de EPOC. Evaluación de sus factores de riesgo, pronóstico y persistencia a medio plazo. Sociedad Madrileña de Neumología y Cirugía Torácica. 2016.

Management centre: Fundación NEUMOMADRID

García Río FJ. Contribución de las alteraciones de la percepción de la disnea al diagnóstico de asma ficticio en obesos. PI-795. Astrazeneca Farmaceutica Spain S.A. 2009-Ongoing.

Management centre: FIBHULP

García Río FJ. Regulación de la expresión génica por Hipoxia: identificación de polimorfismos que afectan a los sitios de unión del Factor Inducible por Hipoxia (HIF) en pacientes de EPOC y pacientes de SAHS. Sociedad Espa-

ñola de Neumología y Cirugía Torácica. 2014-2016.

Management centre: Fundación RESPIRA

García Río FJ. Valores de referencia para el consumo de oxígeno máximo, umbral de acidosis, reserva ventilatoria y reserva cardíaca en la población madrileña de ascendientes europeos. Sociedad Española de Neumología y cirugía torácica. 2014-2016.

Management centre: Fundación RESPIRA

Gómez Carrera L. Auditoría clínica sobre manejo de Fibrosis Pulmonar Idiopática (FPI) en el área sanitaria del Hospital La Paz. Boehringer Ingelheim España S.A. 2016-Ongoing.

Management centre: FIBHULP

Santiago Recuerda A. Efecto del tratamiento con ventilación mecánica no invasora y humidificación en las complicaciones infecciosas respiratorias. Menarini Diagnósticos S.A. 2014-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Álvarez-Sala Walther R. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de delafloxacino intravenoso con cambio a vía oral en sujetos adultos con neumonía bacteriana adquirida en la comunidad. Melinta Therapeutics Inc.

HULP Code: 4545. Sponsored's Protocol Code: ML-3341-306.

Signature Date: 14/06/2016

García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstructiva del sueño. Francisco José García Río .

HULP Code: PI-2386. Sponsored's Protocol Code: PI-2386.

Signature Date: 04/11/2016

Prados Sánchez C. Registro observacional europeo de pacientes con fibrosis quística (VOICE). Vertex Pharmaceuticals Incorporated. EPA-SP. 42548.

HULP Code: Contrato PI-2397. Sponsored's Protocol Code:

VX14-CFR-107.

Signature Date: 27/06/2016

Villasante Fernández-Montes C. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo de 52 semanas de duración para evaluar la eficacia y la seguridad de QAW039 añadido al tratamiento existente para el asma en pacientes con asma grave no controlada. Novartis Farmacéutica S.A.

HULP Code: Contrato 4507. Sponsored's Protocol Code:

CQAW039A2314.

Signature Date: 07/01/2016

Villasante Fernández-Montes C. Observacional, prospectivo, para evaluar la relación entre el grado de concordancia de las opiniones entre pacientes y médicos especialistas en el control sintomático y el riesgo futuro en pacientes con asma moderada. Mundipharma Pharmaceuticals S.L.

HULP Code: Contrato PI-1886. Sponsored's Protocol Code:

CONCORD-ASMA.

Signature Date: 29/01/2016





REGULATION OF GENE EXPRESSION AND BY HYPOXIA GROUP



Publications: 1
Impact Factor: 10.162
QI: 1

Luis del Peso Ovalle

Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. UAM

Benilde Jiménez Cuenca

Profesor Titular. Departamento de Bioquímica Facultad de Medicina. UAM

María Tiana Cerrolaza


Investigador Postdoctoral. UAMf

on endothelial cell proliferation and integration of this response in the induction of angiogenesis.

- Analysis of the functional effect of polymorphisms affecting HIF binding and investigation of their correlation with the different phenotypes in chronic respiratory diseases and cancer.

Research Activity

DOCTORAL THESES

Tiana Cerrolaza M. Mechanisms underlying gene repression in hypoxia [dissertation]. Madrid: UAM: 2016(01/12/2016). 

Director: del Peso Ovalle L. European Mention.

PUBLICATIONS

- Roche O, Deguiz ML, Tiana M, Galiana-Ribote C, Martínez-Alcázar D, Rey-Serra C, Ranz-Ribeiro B, Casitas R, Galera R, Fernández-Navarro I, Sánchez-Cuellar S, Bernard V, Ancochea J, Wasserman WW, García-Río F, Jiménez B, del Peso L. Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia. *Nucleic Acids Res.* 2016;44(19):9315-30. Article. IF: 10.162; DI

PUBLIC PROJECTS

del Peso Ovalle L. Estudio genómico, bioinformático y funcional del papel de la hipoxia en angiogénesis y el Síndrome de Von Hippel-Lindau (SAF2014-53819-R). MINECO. 2015-2017.

Management centre: UAM


Strategic Objective

The elucidation of the cellular and molecular responses to changes in oxygen tension constitutes an exciting research topic given the dependence of virtually all human tissues on appropriate oxygen supply and the involvement of hypoxia in high-incidence pathologies such as cardiopulmonary diseases and cancer. The Hypoxia Inducible transcription Factor (HIF) plays a pivotal role in this response by controlling the expression of most of the genes involved in the adaptation to hypoxia. Our research group aims to provide novel insight into transcriptional response to hypoxia and to exploit this knowledge to improve clinical management of pathologies in which hypoxia is a common feature. To this end we are currently involved in the following.

Research Lines

- Identification of network motifs within the gene regulatory network regulated by HIF and study of their role in the adaptation to hypoxia.
- Characterization of the effect of hypoxia/HIF

NEPHROLOGY GROUP



Publications: 26
Impact Factor: 375.556
QI: 22

Rafael Selgas Gutiérrez

Jefe de Servicio de Nefrología. HULP
Profesor Asociado. Facultad de Medicina. UAM

María Auxiliadora Bajo Rubio

Jefe de Sección de Nefrología. HULP
Profesora Asociado. Facultad de Medicina. UAM

María José Castro Notario

Enfermera. HULP

Olga Costero Fernández

Facultativo Especialista de Área en Nefrología. HULP

Gloria del Peso Gilsanz

Facultativo Especialista de Área en Nefrología. HULP

María José Fernández Reyes

Facultativo Especialista de Área en Nefrología. Hospital de Segovia

Helena García LLana

Psicóloga Investigadora. HULP

María Elena González García

Facultativo Especialista de Área en Nefrología. HULP

Guadalupe González Mateo

Investigadora Postdoctoral. HULP

Carlos Jiménez Martín

Jefe de Sección de Nefrología. HULP

María Ovidia López Oliva

Facultativo Especialista de Área en Nefrología. HULP

Virginia Martínez Cabeza

Técnico de Laboratorio. HULP

Teresa Olea Tejero

Facultativo Especialista de Área en Nefrología. HULP

Ramón Peces Serrano

Facultativo Especialista de Área en Nefrología. HULP

Begoña Rivas Becerra

Facultativo Especialista de Área en Nefrología. HULP

María Dolores Sánchez Niño

Investigadora Postdoctoral (Contrato Sara Borrell). HULP

Rafael Jesús Sánchez Villanueva

Facultativo Especialista de Área en Nefrología. HULP

Maximino Alberto Torre Carballada

Facultativo Especialista de Área en Nefrología. HULP

Strategic Objective

The strategic objective of this medical scientific group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time.

Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas.

Research Lines


The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.

A) Incipient nephropathies and kidney disease progression:

- Glomerular and tubular nephropathies. New diagnostic markers and interventions.
- Organisational Research (computerisation, organization of generational change in the department and network).



NEONATOLOGY GROUP



Publications: **18**
 Impact Factor: **61.438**
 QI: **11**

Adelina Pellicer Martínez

Jefe de Sección 5ª Neonatología, HULP
 Prof Asociado pediatría, UAM

Susana Ares Segura

Facultativo Especialista de Área en Neonatología. HULP

Juan Bernal Carrasco

Jefe de Departamento de Fisiopatología Endocrina y Sistema Nervioso. IIB "Alberto Sols"

María Carmen Bravo Laguna

Facultativo Especialista de Área en Neonatología. HULP

Antonio Buño Soto

Jefe de Servicio de Laboratorio de Urgencias. HULP

Fernando Cabañas González

Facultativo Especialista de Área en Neonatología. HULP
 Profesor Asociado. Departamento de Pediatría y Neonatología. UAM

María Jesús del Olmo Barros

Profesora Contratada. Departamento Interfacultativo de Música. UAM

María Dolores Elorza Fernández

Jefe de Sección 5ª Neonatología. HULP

Miriam Martínez Biarge

Facultativo Especialista de Área en Neonatología. Hospital Hammersmith, Londres

María Teresa Montes Bueno

Enfermera. HULP

María Natividad Pastrana Pérez

Enfermera. HULP

María Luisa Prieto Postigo

Auxiliar de Enfermería. HULP

Miguel Sáenz de Pipaón Marcos

Facultativo Especialista de Área en Neonatología. HULP
 Profesor Asociado. UAM

Belén Sáenz-Rico de Santiago

Profesor Contratado Doctor "Didáctica y Organización Escolar", UCM

Laura Sánchez García

Facultativo Especialista de Área en Neonatología. HULP

Eva Valverde Núñez

Facultativo Especialista de Área en Neonatología. HULP
 Profesora Asociada. UAM

Strategic Objective

Prevent structural damage to organs and systems in the high risk newborn.

Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.

Research Lines

- Developmental Neurobiology.
- Neonatal pulmonary and cardiovascular pathology.
- Thyroid in term and preterm neonates.
- Nutrition. Breast feeding. Microbiota.
- Perinatal and neonatal infectology. Immunology and vaccines.
- Neurodevelopmental. Follow-up.

Research Activity

PUBLICATIONS

- Aakre I, Strand TA, Bjoro T, Norheim I, Barikmo I, Ares S, Alcorta MD, Henjum S. Thyroid function among breastfed children with chronically excessive iodine intakes. *Nutrients*. 2016;8(7):398. Article. IF: 3.55; Q2
- Alarcón A, Martínez-Biarge M, Cabañas F, Quero J, García-Alix A. A Prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection. *Neonatology*. 2016;110(4):277-85. Article. IF: 2.598; Q1
- Alcaide MJ, Gómez-Rioja R, Louzao P, Fernández-Calle P, Oliver P, Iturzaeta JM, Fernández-Punero B, Buño A. Vitamin K interference in the measurement of plasma ammonia. *J Clin Pathol*. 2016;69(5):458-9. Letter. IF: 2.687; Q2
- dal-Re R, Omeñaça F, Gracia D. When the information provided to participants of a comparative effectiveness trial ends up in the court: The opening of Pandora's box? *Med Clin-Barcelona*. 2016;147(2):76-80. Article. IF: 1.125; Q3
- de la Calle M, Omeñaça F, Bartha JL. Varicella infection in pregnancy. *Med Clin-Barcelona*. 2016;146(1):40-1. Letter. IF: 1.125; Q3
- Estrin GL, Kyriakopoulou V, Makropoulos A, Ball G, Kuhendran L, Chew A, Hagberg B, Martínez-Biarge M, Allsop J, Fox M, Counsell SJ, Rutherford MA. Altered white matter and cortical structure in neonates with antenatally diagnosed isolated ventriculomegaly. *Neuroimage Clin*. 2016;11:139-48. Article. IF: 4.348; Q1
- García-Esquinas E, Guallar-Castillón P, Carnicero JA, Buño A, García-García FJ, Rodríguez-Mañas L, Rodríguez-Artalejo F. Serum uric acid concentrations and risk of frailty in older adults. *Exp Gerontol*. 2016;82:160-5. Article. IF: 3.34; Q1
- Kali GTJ, Martínez-Biarge M, Van Zyl J, Smith J, Rutherford M. Therapeutic hypothermia for neonatal hypoxic-ischaemic encephalopathy had favourable outcomes at a referral hospital in a middle-income country. *Acta Paediatr*. 2016;105(7):806-15. Article. IF: 2.043; Q2
- Martínez-Biarge M, Cheong JLY, Díez-Sebastián J, Mercuri E, Dubowitz LMS, Cowan FM. Risk factors for neonatal arterial ischemic stroke: The importance of the intrapartum period. *J Pediatr-Ur*. 2016;173:62-8. Article. IF: 3.874; D1
- Martínez-Biarge M, Groenendaal F, Kersbergen KJ, Benders MJNL, Foti F, Cowan FM, de Vries LS. MRI based preterm white matter injury classification: The importance of sequential imaging in determining severity of injury. *Plos One*. 2016;11(6):e0156245. Article. IF: 2.806; Q1
- Martínez-Cerón E, Buño A, García-Río F. Analytical performance requirements for biomarker-based studies evaluating continuous positive airway pressure effects in obstructive sleep apnea reply. *Am J Resp Crit Care*. 2016;194(4):523-4. Letter. IF: 13.204; D1
- Mazmanyán PA, Nikoghosyan KV, Kerobyan VV, Mellor KJ, Díez-Sebastián J, Martínez-Biarge M, Cowan FM. Preterm cranial ultrasound scanning is both feasible and effective in a middle-income country. *Acta Paediatr*. 2016;105(7):E291-9. Article. IF: 2.043; Q2
- Ng K, Stoll B, Chacko S, de Pipaón MS, Lauridsen C, Gray M, Squires EJ, Marini J, Zamora IJ, Olutoye OO, Burrin DG. Vitamin E in new-generation lipid emulsions protects against parenteral nutrition-associated liver disease in parenteral nutrition-fed preterm pigs. *JPEN-Parenter Enter*. 2016;40(5):656-71. Article. IF: 4.22; Q1
- Plomgaard AM, Hagmann C, Alderliesten T, Austin T, van Bel F, Claris O, Dempsey E, Franz A, Fumagalli M, Gluud C, Greisen G, Hyttel-Sorensen S, Lemmers P, Pellicer A, Pichler G, Benders M.

Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments. *Pediatr Res*. 2016;79(3):466-72. Article. IF: 2.882; Q1

- Plomgaard AM, van Oeveren W, Petersen TH, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Franz A, Fumagalli M, Gluud C, Hagmann C, Hyttel-Sorensen S, Lemmers P, Pellicer A, Pichler G, Winkel P, Greisen G. The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. *Pediatr Res*. 2016;79(4):528-35. Article. IF: 2.882; Q1
- Riera J, Cabañas F, Serrano JJ, Madero R, Pellicer A. New developments in cerebral blood flow autoregulation analysis in preterm infants: a mechanistic approach. *Pediatr Res*. 2016;79(3):460-5. Article. IF: 2.882; Q1
- Riera J, Hyttel-Sorensen S, Bravo MC, Cabañas F, López-Ortego P, Sánchez L, Ybarra M, Dempsey E, Greisen G, Austin T, Claris O, Fumagalli M, Gluud C, Lemmers P, Pichler G, Plomgaard AM, van Bel F, Wolf M, Pellicer A. The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings. *Arch Dis Child-Fetal*. 2016;101(4):F333-8. Article. IF: 3.786; D1
- Rosas R, Sanz MP, Fernández-Calle P, Alcaide MJ, Montes MT, Pastrana N, Segovia C, Omeñaça F, de Pipaón MS. Experimental study showed that adding fortifier and extra-hydrolysed proteins to preterm infant mothers' milk increased osmolality. *Acta Paediatr*. 2016;105(12):E555-60. Article. IF: 2.043; Q2

PUBLIC PROJECTS

Cabañas González F. Red de Salud Materno Infantil y del Desarrollo- SAMID (RD12/0026/0004). ISCIII. 2013-2014.

Management centre: FIBHULP

PRIVATE PROJECTS

Ares Segura S. Exceso de yodo: consecuencias en la fundación tiroidea y en el neurodesarrollo. Universidad de Akershus de Ciencias Aplicadas. 2013-Ongoing.

Management centre: FIBHULP

Bravo Laguna MC. Valoración cuantitativa de la repercusión hemodinámica del ductus arterioso persistente y su tratamiento en el recién nacido de bajo peso. Neonatcare S.L. 2008-Ongoing.

Management centre: FIBHULP

Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiográficamente guiado en el recién nacido prematuro con ibuprofeno con perfusión continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestinal. Fundación Mutua Madrileña. 2016-Ongoing.

Management centre: FIBHULP

Buño Soto A. Actualización y renovación de la actividad investigadora en el Servicio de Análisis Clínicos del Hospital Universitario La Paz. Radiometer Iberica S.L. 2012-Ongoing.

Management centre: FIBHULP

Buño Soto A. Method comparison evaluation between the radiometer procalitonin (PCT) assay on the AQT90 flex analyzer and the elecsys B.R.A.B.S. PCT on an automated roche immunoassay analyzer. Radiometer Medical A.P.S. 2015-Ongoing.

Management centre: FIBHULP



Buño Soto A. Recogida de muestras en deportistas de alto rendimiento para la evaluación de su variación biológica. FIBHULP. 2016-Ongoing.

Management centre: FIBHULP

Cabañas González F. Impacto de las técnicas de reproducción asistida en la salud del recién nacido. Varios. 2011-Ongoing.

Management centre: FIBHULP

del Olmo Barros MJ. Jornadas de investigación y atención directa en musicoterapia hospitalaria. Varios. 2015-Ongoing.

Management centre: FIBHULP

Omeñaca Terés F. Leche materna en niños prematuros: características nutricionales e infección por citomegalovirus. Infacare Pharmaceutical Corporation. 2010-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Pellicer Martínez A. Dobutamine for NEOnatal CIRCu-latory failure defined by novel biomarkers GA - 282533 (NEO-CIRC). EU. 2011-2016.

Management centre: FIBHULP

CLINICAL TRIALS

Omeñaca Terés F. Estudio en fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de un anticuerpo monoclonal humano, REGN2222, para la prevención de la infección por el VRS bajo atención médica en lactantes prematuros. Regeneron Pharmaceuticals Inc.

HULP Code: 4458. Sponsored's Protocol Code: R2222-RSV-1332.

Signature Date: 21/07/2016

Omeñaca Terés F. Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los estudios de tratamiento con retosibán. Glaxosmithkline Research And Development Limited.

HULP Code: Anexo-I 4322. Sponsored's Protocol Code: 200722.

Signature Date: 21/3/2016

Omeñaca Terés F. Inmunogenicidad y seguridad de una dosis de recuerdo de Infanrix Hexa® (217744) de GSK biologicals en niños sanos nacidos de madres vacunadas con Boostrix® en el embarazo o en el posparto inmediato. Glaxosmithkline S.A.

HULP Code: 4613. Sponsored's Protocol Code: 201334 BOOS-TRIX-049.

Signature Date: 13/5/2016

Omeñaca Terés F. Estudio en fase II, aleatorizado, enmascarado para el observador, controlado con placebo y con grupos secuenciales para determinar la inmunogenicidad y la seguridad de una vacuna. Novavax, Inc.

HULP Code: 4663. Sponsored's Protocol Code: RSV-M-301.

Signature Date: 19/10/2016

PATENTS AND TRADEMARKS

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.



AGING AND FRAGILITY IN THE ELDERLY GROUP



Publications: **17**

Impact Factor: **47.113**

QI: **3**

Juan Ignacio González Montalvo

Jefe de Servicio de Geriátria. HULP
Profesor Asociado. UAM

Juan Carlos Abánades Herranz

Médico. Centro de Salud Monóvar. Atención Primaria

María Teresa Alarcón Alarcón

Jefe de Sección de Geriátria. HULP

Juan Cárdenas Valladolid

Técnico de la Gerencia Adjunta de Planificación y Calidad de Atención Primaria. Atención Primaria

María Victoria Castell Alcalá

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Carmen de Burgos Lunar

Subdirectora General de Promoción, Prevención y Educación para la Salud. Dirección General de Salud Pública

Macarena Díaz de Bustamante de Ussía

Médico Interno Residente. HULP

Araceli Garrido Barral

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Paloma Gómez Campelo

Investigadora Postdoctoral. HULP

Pilar Gotor Pérez

Enfermera. Unidad de Valoración Geriátrica y Ortogeriatría. HULP

Rosa Julián Viñals

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Centro de Salud "Raúl de Castroviejo". Atención Primaria

Rocío Menéndez Colino

Facultativo Especialista de Área en Geriátria. Hospital de Cantoblanco - HULP

Ángel Otero Puime

Profesor Titular de Medicina Preventiva y Salud Pública. UAM
Médico Adjunto Medicina Preventiva. HULP

Rocío Queipo Matas

Investigadora Predoctoral. UAM

Raquel Ramírez Martín

Médico Interno Residente. HULP

Ana María Rosas Hernández

Investigadora Predoctoral. UAM

María del Pilar Sáez López

Facultativo Especialista de Área en Geriátria. Complejo Asistencial de Ávila

Miguel Ángel Salinero Fort

Médico. Subdirección General de Investigación Sanitaria, Consejería de Sanidad de Madrid

Mercedes Sánchez Martínez

Profesor Asociado. UAMf

Strategic Objective

- To promote and improve the quality of research in the field of Primary Health Care and Geriatrics in the area of influence of IdiPAZ.
- To continue the follow-up of the Cohorts of the Group: elderly people with population-based (Peñagrande Study), patients with frailty syndrome (FONDA) and patients with Type 2 Diabetes Mellitus (MADiabetes).
- Progress in the epidemiological study of frailty in the elderly.
- To consolidate clinical studies related to hip fracture and chronic diseases in the elderly, specially the Diabetes Mellitus.



Research Lines

- **Frailty syndrome in the elderly.** To promote the detection of frailty syndrome in elderly people above 75 years that consults at the Primary Health Care Center of the Hospital La Paz Setting and create a new cohort of those patients with functional impairment. Additionally, to develop and evaluate an intervention program with these patients, focused on the physical exercise, the geriatric evaluation, management of comorbidity, in the medication adjustment and in nutritional supplementation when necessary.
- **Hip fracture in the frail elderly.** To evaluate the implementation and evaluation of the FONDA intervention with frail elderly patients hospitalized at the La Paz Hospital based on: physical exercise program (active and passive), early normalization of plasma levels of VitD, nutritional supplementation in patients with hypoproteinemia, low or vitamin D deficiency, and control of the pain and anemia.
- **Follow-up of patients with Type 2 Diabetes Mellitus (MADIABETES Cohort, more than 3.500 patients) and prediabetes patients (SPREDIA Cohort, n=600) of Madrid,** to analyze clinical and psychosocial factors related to clinical outcomes (cardiovascular events, chronic kidney disease, retinopathy, and mortality), we are developing predictive models for main outcomes (chronic kidney disease, all-cause mortality and cardiovascular mortality).

Research Activity

PUBLICATIONS

- Alarcón T, González-Montalvo JI, Martín-Vega A, Gotor P. Improving persistence and adherence to osteoporosis treatment: a challenge to solve. *Osteoporosis Int.* 2016;27(3):1275-6. Letter. IF: 3.591; Q2
- de Hoyos-Alonso MC, Bonis J, Tapias-Merino E, Castell MV, Otero A. Estimated prevalence of dementia based on analysis of drug databases in the Region of Madrid (Spain). *Neurologia.* 2016;31(1):1-8. Article. IF: 2.103; Q3
- de Hoyos-Alonso MD, Bonis J, Bryant V, Alcalá MVC, Puime AO. Quality of registration of dementia diagnosis in primary care: The situation in Spain in 2002-2011. *Aten Prim.* 2016;48(1):33-41. Article. IF: 1.042; Q3
- Eiras A, Teixeira MA, González-Montalvo JI, Castell MV, Queipo R, Otero A. Consumption of drugs in over 65 in Porto (Portugal) and risk of potentially inappropriate medication prescribing. *Aten Prim.* 2016;48(2):110-20. Article. IF: 1.042; Q3
- González-Montalvo JI, Alarcón T, Gotor P, Queipo R, Velasco R, Hoyos R, Pardo A, Otero A. Prevalence of sarcopenia in acute hip fracture patients and its influence on short-term clinical outcome. *Geriatr Gerontol Int.* 2016;16(9):1021-7. Article. IF: 2.351; Q3
- Herbolzheimer F, Schaap LA, Edwards MH, Maggi S, Otero A, Timmermans EJ, Denking MD, van der Pas S, Dekker J, Cooper C, Dennison EM, van Schoor NM, Peter R. Physical activity patterns among older adults with and without knee osteoarthritis in six European countries. *Arthrit Care Res.* 2016;68(2):228-36. Article. IF: 3.319; Q2

- Jiménez-Trujillo I, González-Pascual M, Jiménez-García R, Hernández-Barrera V, Miguel-Yanes JMM, Méndez-Bailón M, de Miguel-Díez J, Salinero-Fort MA, Pérez-Farinos N, Carrasco-Garrido P, López-de-Andrés A. Type 2 diabetes mellitus and thoracic aortic aneurysm and dissection: an observational population-based study in Spain from 2001 to 2012. *Medicine.* 2016;95(18):e3618. Article. IF: 1.803; Q2
- Lahoz C, Mostaza JM, Salinero-Fort MA, García-Iglesias F, González-Alegre T, Estirado E, Laguna F, de Burgos-Lunar C, Sánchez-Arroyo V, Sabin C, López S, Cornejo-del-Río V, Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D, Montesano-Sánchez L. Peripheral atherosclerosis in patients with erectile dysfunction: A population-based study. *J Sex Med.* 2016;13(1):63-9. Article. IF: 2.978; Q2
- López-de-Andrés A, Hernández-Barrera V, López R, Martín-Junco P, Jiménez-Trujillo I, Álvaro-Meca A, Salinero-Fort MA, Jiménez-García R. Predictors of in-hospital mortality following major lower extremity amputations in type 2 diabetic patients using artificial neural networks. *BMC Med Res Methodol.* 2016;16:160. Article. IF: 3.295; Q1
- López-de-Andrés A, Jiménez-García R, Jiménez-Trujillo I, Hernández-Barrera V, de Miguel-Yanes JM, Méndez-Bailón M, Pérez-Farinos N, de Miguel-Díez J, Salinero-Fort MA, Carrasco-Garrido P. Incidence, surgical procedures, and outcomes of hip fracture among elderly type 2 diabetic and non-diabetic patients in Spain (2004-2013). *Osteoporosis Int.* 2016;27(2):605-16. Article. IF: 3.591; Q2
- Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abanades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, García-Iglesias F, González-Alegre T, Fernández-Puntero B, Montesano-Sánchez L, Vicent-López D, Cornejo-del Río V, Fernández-García PJ, Sánchez-Arroyo V, Sabin-Rodríguez C, López-López S, Patrón-Barandío P, Gómez-Campelo P. Performance of the Finnish diabetes risk score and a simplified Finnish diabetes risk score in a community-based, cross-sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. *Plos One.* 2016;11(7):e0158489. Article. IF: 2.806; Q1
- Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, Jiménez-García R, López-de-Andrés A, Gómez-Campelo P. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES cohort study: Association with chronic kidney disease. *J Diabetes Complicat.* 2016;30(2):227-36. Article. IF: 2.734; Q3
- Sánchez-Martínez M, Castell MV, González-Montalvo JI, de la Cruz JJ, Banegas JR, Otero A. Transitions in functional status of community dwelling older adults: Impact of physical performance, depression and cognition. *Eur Geriatr Med.* 2016;7(2):111-6. Article. IF: 1.336; Q4
- Siviero P, Zambón S, Limongi F, Castell MV, Cooper C, Deeg DJH, Denking MD, Dennison EM, Edwards MH, Gesmundo A, Otero A, Pedersen NL, Peter R, Queipo R, Timmermans EJ, van Schoor NM, Maggi S. How hand osteoarthritis, comorbidity, and pain interact to determine functional limitation in older people: Observations from the European Project on Osteoarthritis Study. *Arthritis Rheumatol.* 2016;68(11):2662-70. Article. IF: 6.918; D1
- van der Pas S, Schaap LA, Castell MV, Cooper C, Denking MD, Edwards MH, Herbolzheimer F, Maggi S, Sánchez-Martínez M, Pedersen NL, Peter R, Zambón S, Wiegersma SB, Dekker J, Dennison EM, Deeg DJH. Availability and use of neighborhood resources by older people with osteoarthritis: Results from the European Project on Osteoarthritis. *Health Place.* 2016;37:1-7. Article. IF: 2.541; Q2

- van Schoor NM, Zambón S, Castell MV, Cooper C, Denking MD, Dennison EM, Edwards MH, Herbolzheimer F, Maggi S, Sánchez-Martínez M, Pedersen NL, Peter R, Schaap LA, Rijnhart JJM, van der Pas S, Deeg DJH. Impact of clinical osteoarthritis of the hip, knee and hand on self-rated health in six European countries: the European Project on Osteoarthritis. *Qual Life Res.* 2016;25(6):1423-32. Article. IF: 2.344; Q2
- Zambón S, Siviero P, Denking MD, Limongi F, Castell MV, van der Pas S, Otero A, Edwards MH, Peter R, Pedersen NL, Sánchez-Martínez M, Dennison EM, Gesmundo A, Schaap LA, Deeg DJH, van Schoor NM, Maggi S. Role of osteoarthritis, comorbidity, and pain in determining functional limitations in older populations: European Project on Osteoarthritis. *Arthrit Care Res.* 2016;68(6):801-10. Article. IF: 3.319; Q2

PUBLIC PROJECTS

de Burgos Lunar C. Validación de los diagnósticos de fibrilación articular, infarto agudo de miocardio, ictus y exitus registrados en la Historia Clínica Informatizada de Atención Primaria (PI13/00632). ISCIII. 2014-2017.

Management centre: FIBHULP

Otero Puime A. Red de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF) (RD12/0043/0019). ISCIII. 2013-2017.

Management centre: FIBHULP

Salinero Fort MA. Análisis de Evolución temporal de las tasas y causas de mortalidad de una cohorte de diabetes mellitus tipo 2 y comparación con estadísticas oficiales (PI12/01806). ISCIII. 2013-2017.

Management centre: FIBAP

Salinero Fort MA. Estudio de cohortes sobre la morbilidad cardiovascular y mortalidad de sujetos con diabetes tipo 2 conocida y no conocida, prediabetes y normoglucemia (PI15/00259). ISCIII. 2016-2018.

Management centre: FIBAP

PRIVATE PROJECTS

González Montalbo JI. Proyecto de actualización bibliográfica básica de temas de investigación, documentación, actualización y transmisión bibliográfica en sesiones conjuntas de servicio. EISAI FARMACEUTICA SA. 2008-Ongoing.

Management centre: FIBHULP

González Montalbo JI. Estudio de la evolución a medio y largo plazo tras el tratamiento integral de los pacientes con fractura de cadera. evaluación de los factores predictivos del pronóstico funcional y vital (Estudio FONDA). FIBHULP. 2012-Ongoing.

Management centre: FIBHULP





MOLECULAR HEPATOLOGY GROUP



Publications: **7**
Impact Factor: **22.662**
Q1: **5**

Paloma Jara Vega

Emérito Asistencial. HULP

Sara Andueza Salazar

Técnico de Investigación. HULP

Carmen Camarena Grande

Médico Adjunto de Hepatología Pediátrica. HULP

Ángela de la Vega Bueno

Médico Adjunto de Hepatología Pediátrica. HULP

María Carmen Díaz Fernández

Jefe de Servicio de Hepatología Pediátrica. HULP

Esteban Frauca Remacha

Médico Adjunto de Hepatología Pediátrica. HULP

Loreto Hierro Llanillo

Jefe de Sección Hepatología Pediátrica. HULP

Gema Muñoz Bartolo

Médico Adjunto de Hepatología Pediátrica. HULP

María Ángeles Pajares Tarancón

Investigador Científico. CSIC

Luiz Stark Aroeira

Investigador Senior. HULP

David Vicent López

Investigador Senior (Contrato Miguel Servet - I2). HULP

Strategic Objective

Our research interest is focused on the study of the molecular mechanisms underlying the most severe paediatric liver disorders, namely cholestasis, which results from the impaired secretion of bile from the liver to the intestine. As such, it represents a clinical and biochemical syndrome that is produced by a wide variety of disease processes that affect the

liver. Individuals with cholestasis manifest jaundice, severe itching, malabsorption of fats and lipidsoluble vitamins and, in many cases, progressive liver damage. These clinical manifestations are due to the accumulation in blood and tissues of substances normally secreted in the bile, such as bilirubin, bile acids, and cholesterol and to the absence of bile from the intestine. When manifested in early infancy, cholestasis is often life threatening and usually requires liver transplantation. Extrahepatic biliary atresia (EHBA), Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) constitute the main paediatric cholestatic disorders. EHBA is an enigmatic disease of unknown aetiology, characterised by a precocious and accelerated obstruction of the biliary tree. Alagille syndrome is associated with mutations in the Jag1 gene and is characterised by a paucity or absence of intrahepatic bile ducts. PFIC encompasses a heterogeneous group of autosomal recessive diseases that exhibit similar clinical features. These diseases are caused by mutations in proteins located in the canalicular membrane of the hepatocyte and in proteins involved in bile secretion, such as the bile salt export pump (BSEP; ABCB1), the phospholipid transport protein MDR3 (ABCB4) and the aminophospholipid translocase FIC1 (ATP8B1). These cholestatic disorders constitute the most common indication for liver transplantation in childhood.

Research Lines

- Molecular basis of paediatric liver diseases.
- Liver Pathobiology.

Research Activity

PUBLICATIONS

- Bruguera M, Jara P, Berenguer M, Marino Z. Multidisciplinary units in tertiary referral hospitals to improve management of Wilson disease. *Gastroent Hepat-Barc.* 2016;39(9):571-3. Editorial Material. IF: 0.917; Q4
- Gordo-Gilart R, Andueza S, Hierro L, Jara P, Álvarez L. Functional rescue of trafficking-impaired ABCB4 mutants by chemical chaperones. *Plos One.* 2016;11(2):e0150098. Article. IF: 2.806; Q1
- Gordo-Gilart R, Hierro L, Andueza S, Muñoz-Bartolo G, López C, Díaz C, Jara P, Álvarez L. Heterozygous ABCB4 mutations in children with cholestatic liver disease. *Liver Int.* 2016;36(2):258-67. Article. IF: 4.116; Q1
- Martínez-Vega R, Murillo-Cuesta S, Partearroyo T, Varela-Moreiras G, Varela-Nieto I, Pajares MA. Long-term dietary folate deficiency accelerates progressive hearing loss on CBA/Ca mice. *Front Aging Neurosci.* 2016;8:209. Article. IF: 4.504; Q1
- Pérez C, Pérez-Zuniga FJ, Garrido F, Reytor E, Portillo F, Pajares MA. The oncogene PDRG1 is an interaction target of methionine adenosyltransferases. *Plos One.* 2016;11(8):e0161672. Article. IF: 2.806; Q1
- Sánchez-Gómez FJ, Díez-Dacal B, García-Martín E, Agúndez JAG, Pajares MA, Pérez-Sala D. Detoxifying enzymes at the crossroads of inflammation, oxidative stress, and drug hypersensitivity: Role of glutathione transferase PI-1 and aldose reductase. *Front Pharmacol.* 2016;7:237. Article. IF: 4.4; Q1
- Torre-Cisneros J, Aguado JM, Gastón JJ, Almenar L, Alonso A, Cantisan S, Carratala J, Cervera C, Cordero E, Farinas MC, Fernández-Ruiz M, Fortún J, Frauca E, Gavaldà J, Hernández D, Herrero I, Len O, López-Medrano F, Manito N, Marcos MA, Martín-Dávila P, Monforte V, Montejó M, Moreno A, Muñoz P, Navarro D, Pérez-Romero P, Rodríguez-Bernot A, Rumbao J, San Juan R, Vaquero JM, Vidal E. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REI-PI recommendations. *Transplant Rev-Orlan.* 2016;30(3):119-43. Article. IF: 3.113; Q2

PUBLIC PROJECTS

Hierro Llanillo L. Identificación de causas genéticas y epigenéticas en enfermedades colestásicas infantiles idiopáticas (PI15/O1127). ISCIII. 2016-2018.

Management centre: FIBHULP

Vicent López D. Miguel Servet Stabilisation Contracts (I2). ISCIII, CAM. 2008-Ongoing.

Management centre: FIBHULP

Vicente Capa C. Contrato de Técnico de Apoyo (PEJ15/BIO/TL-0238). CAM. 2016-2018.

Management centre: FIBHULP

PRIVATE PROJECTS

Díaz Fernández MC. Superando barreras... hacia una mejor calidad de vida: estado actual del trasplante pediátrico en el Hospital Infantil La Paz. Astellas Pharma S.A. 2014-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Identificación de nuevos genes responsables de enfermedades hepáticas infantiles. Fundación ACS. 2015-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Diagnóstico molecular de enfermedades

des hepáticas infantiles de carácter hereditario. Asociación Española del Síndrome de Sotos. 2012-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Desarrollo de métodos de diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación María Francisca de Roviralta. 2005-Ongoing.

Management centre: FIBHULP

Jara Vega P. Estudio epidemiológico, observacional sobre el riesgo de desarrollo de síndrome linfoproliferativo en pacientes pediátricos 3p-2007. Roche Pharma S.A. 2008-Ongoing.

Management centre: FIBHULP

Vicent López D. Caracterización clínica del nuevo factor de riesgo cardiovascular trimetilamina-n-óxido en pacientes diabéticos obesos. SENDIMAD. 2015-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Camarena Grande C. Estudio multicéntrico, aleatorizado, controlado por placebo de SBC-102 en pacientes con deficiencia de lipasa ácida lisosomal. Alexion Pharmaceutical Inc.

HULP Code: Anexo-II 3955. Sponsored's Protocol Code: LAL-CL02.

Signature Date: 22/06/2016

Camarena Grande C. Estudio abierto y multicéntrico de sebelipasa alfa en pacientes con déficit de lipasa ácida lisosomal. Alexion Pharmaceutical Inc.

HULP Code: Anexo-I 4130. Sponsored's Protocol Code: LAL-CL06.

Signature Date: 30/5/2016

Díaz Fernández MC. Estudio abierto y a largo plazo con un período de retirada farmacológico aleatorizado, controlado con placebo y doble ciego de LUM001, un inhibidor del transportador apical de ácidos biliares dependiente de sodio (ASBTI), en pacientes con Síndrome de Alagille. Lumena Pharmaceuticals Inc.

HULP Code: Anexo-II 4187. Sponsored's Protocol Code: LUM001-304.

Signature Date: 18/1/2016

Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV), con o sin dasabuvir (DSV) y con o sin ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la hepatitis C (VHC) genotipo 1 o 4 (Zircon). Abbvie Deutschland GmbH.

HULP Code: 4533. Sponsored's Protocol Code: M14-748.

Signature Date: 18/1/2016

Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV), con o sin dasabuvir (DSV) y con o sin ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la hepatitis C (VHC) genotipo 1 o 4 (Zircon). Abbvie Deutschland GmbH.

HULP Code: Anexo-I 4533. Sponsored's Protocol Code: M14-748.

Signature Date: 19/7/2016

Jara Vega P. Estudio abierto, no comparativo, a largo plazo, para evaluar la eficacia y la seguridad de un régimen de inmunosupresor basado en modigraf en pacientes pediátricos receptores de un aloinjerto de órgano sólido. Astellas Pharma Europe B.V.

HULP Code: Anexo-III 3252. Sponsored's Protocol Code: F506-CL-0404.

Signature Date: 10/2/2016



DIAGNOSIS AND TREATMENT OF ALLERGIC DISEASES GROUP



Publications: **38**
 Impact Factor: **130.932**
 QI: **8**

Santiago Eugenio Quirce Gancedo

Jefe de Servicio de Alergología. HULP

María Pilar Encarnación Barranco Sanz

Facultativo Especialista de Área en Alergología. HULP

María Teresa Boyano Martínez

Facultativo Especialista de Área en Alergología. HULP

María Teresa Caballero Molina

Facultativo Especialista de Área en Alergología. HULP

María Luisa Caballero Soto

Facultativo Especialista de Área en Inmunología. HULP

Francisco Javier Contreras Porta

Facultativo Especialista de Área en Alergología. HULP

Francisco Javier Domínguez Ortega

Facultativo Especialista de Área en Alergología. HULP

Ana María del Carmen Fiandor Román

Jefe de Sección de Alergología. HULP

Carmen Gómez Traseira

Facultativo Especialista de Área en Alergología. HULP

Juan Alberto Luna Porta

Facultativo Especialista de Área en Alergología. HULP

María Magdalena Lluch Bernal

Facultativo Especialista de Área en Alergología. HULP

María Flora Martín Muñoz

Facultativo Especialista de Área en Alergología. HULP

Santiago Olalde Sánchez

Facultativo Especialista de Área en Alergología. HULP

María Pedrosa Delgado

Facultativo Especialista de Área en Alergología. HULP

María Rosa Rodríguez Pérez

Investigadora Senior (Contrato Miguel Servet- Tipo 2). HULP

Margarita Tomás Pérez

Facultativo Especialista de Área en Alergología. HULP

Ana María Umpiérrez Rodríguez

Facultativo Especialista de Área en Alergología. HULP

Strategic Objective

These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angio-oedema and drug allergies).

The group's strategic research objectives include:

- The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile.
- The treatment of food allergies with oral desensitisation protocols.
- The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease.
- The study of the pathogenesis and treatment of eosinophilic diseases of the airways (eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis).
- The characterisation of various types of angioedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment.
- Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs.

Research Lines

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation.
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria.
- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation.
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis).
- Persistent and difficult to control asthma: Study on the influence of common and occupational allergens, comorbidities and new therapies.
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol.
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved.
- Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.

Research Activity

PUBLICATIONS

- Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Boysen HB, Caballero T. Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema. *Patient Prefer Adher*. 2016;10:1699-707. Article. IF: 1.798; Q2
- Belder MT, Michavila A, Bobolea I, Feito M, Bellón T, Quirce S. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS). *Allergol Immunopath*. 2016;44(1):83-95. Review. IF: 1.439; Q4
- Caballero ML, Lluch-Bernal M, Vila-Nadal G, Lluncor M, Quirce S. IgE-mediated anaphylaxis induced by macrogol 6000. *J Invest Allerg Clin*. 2016;26(6):398-400. Article. IF: 3.094; Q2
- Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. *J Invest Allerg Clin*. 2016;26(6):383-6. Article. IF: 3.094; Q2
- Canabal J, Caballero T, Caminoa M, Fiandor A, Quirce S, Cabanas R. Anaphylactic shock caused by a Hidden allergen in blood sausage. *J Invest Allerg Clin*. 2016;26(3):200-1. Editorial Material. IF: 3.094; Q2
- Carballeda-Sangiao N, Rodríguez-Mahillo AI, Careche M, Navas A, Caballero T, Domínguez-Ortega J, Jurado-Palomo J, González-Muñoz M. Ani s 11-like protein is a pepsin- and heat-resistant major allergen of anisakis spp and a valuable tool for anisakis allergy component-resolved diagnosis. *Int Arch Allergy Imm*. 2016;169(2):108-12. Article. IF: 2.72; Q3
- Contreras-Porta J, Ruiz-Baques A, Hortal EG, Torres FC, Pla MNA, Santisteban AZ, de la Maza ES. Evaluation of an educational programme with workshops for families of children with food allergies. *Allergol Immunopath*. 2016;44(2):113-9. Article. IF: 1.439; Q4
- Domínguez-Ortega J, Barranco P, Rodríguez-Pérez R, Quirce S. Biomarkers in occupational asthma. *Curr Allergy Asthm R*. 2016;16(9):63. Review. IF: 3.735; Q2

- Domínguez-Ortega J, Entrala A, Pola-Bibian B, González-Muñoz M, Fiandor A, Quirce S. Delayed allergic reaction to acetocoumarol with a positive lymphocyte transformation test. *J Invest Allerg Clin*. 2016;26(4):273-4. Editorial Material. IF: 3.094; Q2
- Domínguez-Ortega J, Phillips-Angles E, González-Muñoz M, Heredia R, Fiandor A, Quirce S. Allergy to several local anesthetics from the amide group. *J Allergy Clin Immunol Pract*. 2016;4(4):771-2. Letter. IF: 5.317; Q1
- Espinosa E, Soriano V, Malveyh J, Berrocal A, de Prado PM, Quindos M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puertolas T, Díaz-Beveridge R, de la Cruz-Merino L, Castro RL, López RL, Stevinson K, del Barrio P, Tornamira MV, Guillem V, Martín-Algarra S. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. *Melanoma Res*. 2016;26(3):278-83. Article. IF: 2.615; Q2
- García-Boyano M, Pedrosa M, Quirce S, Boyano-Martínez T. Household almond and peanut consumption is related to the development of sensitization in young children. *J Allergy Clin Immunol*. 2016;137(4):1248-51. Letter. IF: 13.081; D1
- García-Guereta L, García-Cerro E, Bret-Zurita M. Multidetector computed tomography for congenital anomalies of the aortic arch: vascular rings. *Rev Esp Cardiol*. 2016;69(7):681-93. Article. IF: 4.485; Q2
- González-Quevedo T, Larco JI, Marcos C, Guilarte M, Baeza ML, Cimbollek S, López-Serrano MC, Pinero-Saavedra M, Rubio M, Caballero T. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. *J Invest Allerg Clin*. 2016;26(3):161-7. Article. IF: 3.094; Q2
- Láinez N, García-Donas J, Esteban E, Puente J, Saez MI, Gallardo E, Pinto-Marín A, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Durán MA, Lázaro-Quintela M, del Alba AG, Méndez-Vidal MJ, Chirivella I, Alfonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnaiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Parra EF, Guzmán JCV, Martínez-Ortega E, González MB, Morán M, Suárez-Paniagua B, Lecumberri MJ, Castellano D. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. *BMC Cancer*. 2016;16:135. Article. IF: 3.288; Q2
- Longhurst HJ, Aberer W, Bouillet L, Caballero T, Maurer M, Fabien V, Zanichelli A. The icatibant outcome survey: treatment of laryngeal angioedema attacks. *Eur J Emerg Med*. 2016;23(3):224-7. Article. IF: 2.025; Q2
- Martín-Muñoz MF, Pineda F, Parrado GG, Guillén D, Rivero D, Belder T, Quirce S. Food allergy in breastfeeding babies. Hidden allergens in human milk. *Eur Ann Allergy Clin Immunol*. 2016;48(4):123-8. Article. Not Indexed
- Martín-Muñoz MF, Rivero D, Perales AD, Polanco I, Quirce S. Wheat allergy in celiac children. *Pediatr Allerg Imm-Uk*. 2016;27(1):102-5. Letter. IF: 3.775; D1
- Moral VP, Rodríguez CA, Gómez-Outes A, Ruiz FG, Vina AL, Belinchón FJP, Zamora JP, Jiménez JAQ, Gancedo SQ, Ortega JS, Villarrasa RS, Asens JRV. Obsolete anti-pneumococcal vaccination recommendations in the spanish guidelines for the management of asthma (GEMA 4.0): The authors reply. *Arch Bronconeumol*. 2016;52(8):449. Letter. IF: 2.979; Q2
- Moscato G, Pala G, Folletti I, Siracusa A, Quirce S. Occupational rhinitis affects occupational asthma severity. *J Occup Health*. 2016;58(3):310-3. Article. IF: 1.848; Q2
- Palao-Ocharan P, Domínguez-Ortega J, Barranco P, Díaz-Almiron M, Quirce S. Does the profile of sensitization to grass pollen allergens have clinical relevance? *J Invest Allerg Clin*. 2016;26(3):188-9. Editorial Material. IF: 3.094; Q2



- Pedrosa M, Phillips-Angles E, López-Lera A, López-Trascasa M, Caballero T. Complement study versus C1NH gene testing for the diagnosis of type I hereditary angioedema in children. *J Clin Immunol*. 2016;36(1):16-8. Letter. IF: 3.253; Q2
- Phillips-Angles E, González-Muñoz M, Domínguez-Ortega J, Cabañas R, Quirce S. Usefulness of basophil activation test in diagnosis of hypersensitivity to etoricoxib. *J Allergy Clin Immunol Pract*. 2016;4(2):350-1. Letter. IF: 5.317; Q1
- Plaza Moral V, Alonso Mostaza S, Álvarez Rodríguez C, Gómez-Outes A, Gómez Ruiz F, López Vina A, Molina París J, Pellegrini Belinchón FJ, Plaza Zamora J, Quintano Jiménez JA, Quirce Gancedo S, Sanz Ortega J, Soler Vilarrasa R, Villa Asensi JR. Spanish guideline on the management of asthma. *J Invest Allerg Clin*. 2016;26 Suppl 1(Suppl 1):1-92. Article. IF: 3.094; Q2
- Plaza V, del Río PR, Gómez F, Vina AL, Molina J, Quintano JA, Quirce S, Soler R, Villa JR, Nieto A. Identification of gaps in the clinical patient care of asthma in Spain. Results of the OPTIMA-GEMA survey. *An Sist Sanit Navar*. 2016;39(2):181-201. Article. IF: 0.625; Q4
- Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, de Llano LP, Gutiérrez-Pereyra F, Tarragona E, Palomino R, López-Vina A, (Quirce Gancedo S). Validation of the 'Test of the Adherence to Inhalers' (TAI) for asthma and COPD Patients. *J Aerosol Med Pulm D*. 2016;29(2):142-52. Article. IF: 2.528; Q3
- Prieto-García A, Marcos C, Caballero T. Classification of angioedema without wheals. *Ann Allerg Asthma Im*. 2016;116(2):177. Letter. IF: 3.728; Q2
- Prior N, Remor E, Pérez-Fernández E, Caminoa M, Gómez-Traceira C, Gaya F, Aabom A, Aberer W, Betschel S, Boccon-Gibod I, Bouillet L, Bygum A, Csuka D, Farkas H, Gomide M, Grumach A, Leibovich I, Malbran A, Moldovan D, Mihaly E, Obtulowicz K, Perpen C, Peveling-Oberhag A, Porebski G, Chavannes CR, Reshef A, Staubach P, Wiednig M, Caballero T. Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. *J Allergy Clin Immunol Pract*. 2016;4(3):464-73. Article. IF: 5.317; Q1
- Quirce S, Boyano-Martínez T, Díaz-Perales A. Clinical presentation, allergens, and management of wheat allergy. *Expert Rev Clin Immun*. 2016;12(5):563-72. Review. IF: 3.27; Q2
- Quirce S, Fiandor A. How should occupational anaphylaxis be investigated and managed? *Curr Opin Allergy Clin*. 2016;16(2):86-92. Review. IF: 3.463; Q2
- Quirce S, Vandenplas O, Campo P, Cruz MJ, de Blay F, Koschel D, Moscato G, Pala G, Raulf M, Sastre J, Siracusa A, Tarlo SM, Walusiak-Skorupa J, Cormier Y. Occupational hypersensitivity pneumonitis: an EAACI position paper. *Allergy*. 2016;71(6):765-79. Article. IF: 7.361; D1
- Raulf M, Buters JTM, Chapman M, Cecchi L, de Blay F, Doekes G, Eduard W, Heederik D, Jeebhay MF, Kespohl S, Krop E, Moscato G, Pala G, Quirce S, Sander I, Schlunssen V, Sigsgaard T, Walusiak-Skorupa J, Wiszniewska M, Wouters IM, Annesi-Maesano I. Monitoring of occupational and environmental aeroallergens - EAACI Position Paper. *Allergologie*. 2016;39(2):45-68. Article. IF: 0.311; Q4
- Sánchez R, Martínez J, Castro A, Pedrosa M, Quirce S, Rodríguez-Pérez R, Gasset M. The amyloid fold of Gad m 1 epitopes governs IgE binding. *Sci Rep-Uk*. 2016;6:32801. Article. IF: 4.259; Q1
- Sanchez-García S, Olaguibel JM, Quirce S, Ibáñez MD. Measurement of lung function and bronchial inflammation in children is underused by Spanish allergists. *J Invest Allerg Clin*. 2016;26(2):126-8. Editorial Material. IF: 3.094; Q2
- Torrijos EG, Gimeno PM, Iglesias AM, Rodríguez RG, Bonilla PG, El Kaddioui S, Díaz YCM, Gancedo SQ. Non-asthmatic eosinophilic bronchitis and idiopathic eosinophilic esophagitis. *J Invest Allerg Clin*. 2016;26(3):190-1. Editorial Material. IF: 3.094; Q2
- Xepapadaki P, Fiocchi A, Grabenhenrich L, Roberts G, Grimshaw KE, Fiandor A, Larco JI, Sigurdardottir S, Clausen M, Papadopoulos NG, Dahdah L, Mackie A, Sprickelman AB, Schoemaker AA, Dubakiene R, Butiene I, Kowalski ML, Zeman K, Gavrilis S, Keil T, Beyer K. Incidence and natural history of hen's egg allergy in the first 2 years of lifethe EuroPrevall birth cohort study. *Allergy*. 2016;71(3):350-7. Article. IF: 7.361; D1
- Yucesoy B, Kashon ML, Johnson VJ, Lummus ZL, Fluharty K, Gaurtrin D, Cartier A, Boulet LP, Sastre J, Quirce S, Tarlo SM, Cruz MJ, Muñoz X, Luster MI, Bernstein DI. Genetic variants in TNF alpha, TGFBI, PTGS1 and PTGS2 genes are associated with diisocyanate-induced asthma. *J Immunotoxicol*. 2016;13(1):119-26. Article. IF: 2.021; Q3
- Zanichelli A, Longhurst HJ, Maurer M, Bouillet L, Aberer W, Fabien V, Andresen I, Caballero T. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. *Ann Allerg Asthma Im*. 2016;117(4):394-8. Article. IF: 3.728; Q2

PUBLIC PROJECTS

Caballero Molina MT. Estudio de carga de Enfermedad del Angioedema hereditario en España (PI13/01758). ISCIII. 2014-2016.

Management centre: FIBHULP

Caballero Soto ML. Estudio de tumorigenesis asociada a Anisakis simple (PI12/00888). ISCIII. 2013-2017.

Management centre: FIBHULP

Rodríguez Pérez MR. Identificación de genes y de microRNAs implicados en la función de los linfocitos T y B como nuevos biomarcadores para el diagnóstico in vitro de la alergia a Anisakis (PI12/00581). ISCIII. 2013-2016.

Management centre: FIBHULP

Rodríguez Pérez MR. Miguel Servet Contracts Type II (MSII13/000022). ISCIII. 2014-Ongoing.

Management centre: FIBHULP

PRIVATE PROJECTS

Barranco Sanz MPE. Jornada de Investigación sobre asma de difícil control. Ediciones Mayo S.A. 2011-Ongoing.

Management centre: FIBHULP

Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life. *Hereditary Angio-Edema In*. 2009-Ongoing.

Management centre: FIBHULP

Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico "Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen de gramínea". *Inmunotek*. 2015-Ongoing.

Management centre: FIBHULP

Quirce Gancedo SE. Relación entre asma y obesidad en la población española mayor o igual a 18 años. Laboratorio Menarini S.A. 2009-Ongoing.

Management centre: FIBHULP

Rodríguez Pérez MR. Desarrollo de un programa formativo de formación en investigación en centros de trabajo. Colegio Valle del Miro. 2016-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Quirce Gancedo SE. Integrated approaches for food allergy and allergy risk management (iFAAM). EU. 2013-2017.

Management centre: FIBHULP

CLINICAL TRIALS

Barranco Sanz MPE. Carga del asma grave en España: estudio observacional multicéntrico. Glaxosmithkline S.A.
HULP Code: PI-2300. Sponsored's Protocol Code: 205738(HO-15-16438).

Signature Date: 9/6/2016

Caballero Molina MT. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, cruzado parcialmente, de dos períodos y tres secuencias para evaluar la eficacia y la seguridad de la administración subcutánea de 2000 u de un inhibidor de la esterasa c1 (humana) en líquido inyectable para la prevención de las crisis de angioedema en adolescentes y adultos con angioedema hereditario. Shire Viropharma, Inc.

HULP Code: Anexo-I 4539. Sponsored's Protocol Code: SHP-616-300.

Signature Date: 14/6/2016

Caballero Molina MT. Registro de pacientes de FIRA-ZYR-IO (Icatibant Outcome Survey). Shire Pharmaceuticals Iberica S.L.

HULP Code: Anexo-II 3080. Sponsored's Protocol Code: IOS.

Signature Date: 4/3/2016

Caballero Molina Mt. Estudio multicéntrico, abierto, no aleatorizado para evaluar la farmacocinética, tolerabilidad y seguridad de una única administración subcutánea de icatibant en niños y adolescentes con angioedema hereditario. Shire Human Genetic Therapies Inc.

HULP Code: Anexo-II 3507. Sponsored's Protocol Code: HGT-FIR-086.

Signature Date: 27/10/2016

Caballero Molina MT. Estudio (registro) postautorización de tipo observacional, multicéntrico, en varios países europeos de pacientes con angioedema hereditario (AEH) que reciben cinryze (inhibidor de la c1 [humano]) para el tratamiento o la prevención de las crisis de AEH. Viropharma SPRL.

HULP Code: Anexo-I 3744. Sponsored's Protocol Code: 0624-401.

Signature Date: 14/03/2016

Caballero Molina MT. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, cruzado parcialmente, de dos períodos y tres secuencias para evaluar la eficacia y la seguridad de la administración subcutánea de 2000 u de un inhibidor de la esterasa c1 (humana) en líquido inyectable para la prevención de las crisis de angioedema en adolescentes y adultos con angioedema hereditario. Shire Viropharma Inc.

HULP Code: 4539. Sponsored's Protocol Code: SHP-616-300.

Signature Date: 16/2/2016

Caballero Molina MT. Estudio aleatorizado, doble ciego, controlado con placebo, de diferentes dosis y de grupos paralelos, para evaluar la eficacia, seguridad, tolerabilidad, propiedades farmacocinéticas y farmacodinámicas de BCX7353 como tratamiento preventivo para reducir la frecuencia de ataques en sujetos con angioedema hereditario. Biocryst Pharmaceuticals Inc.

HULP Code: 4647. Sponsored's Protocol Code: BCX7353-203.

Signature Date: 5/9/2016

Domínguez Ortega FJ. Estudio fase IV, observacional, multinacional sobre el control de la enfermedad y los resultados notificados por los pacientes en tratamiento con inhaladores de combinación a dosis fija para asma persistente y EPOC en la práctica clínica habitual (SPRINT). Teva Pharmaceutical Industries Ltd.

HULP Code: Anexo-I PI-2002. Sponsored's Protocol Code: BFS-AS-40087.

Signature Date: 24/05/2016

Domínguez Ortega FJ. Estudio MARTE: estudio observacional sobre las características de los pacientes asmáticos en tratamiento de mantenimiento y rescate en España según práctica clínica habitual. Chiesi Farmaceutici S.P.A.

HULP Code: PI-2281. Sponsored's Protocol Code: CHI-FOR-2015-01.

Signature Date: 11/7/2016

Domínguez Ortega FJ. Estudio observacional para evaluar el uso de medicación de alivio en práctica clínica y su relación con el control del asma. Estudio MISTRAL. AstraZeneca Farmaceutica Spain, S.A.

HULP Code: PI-2405. Sponsored's Protocol Code: AST-ASM-2016-01 y D589BR00035.

Signature Date: 8/7/2016

PATENTS AND TRADEMARKS

Valenta R, Constantin C, Quirce Gancedo SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.



Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; CSIC, FIBHULP, assign. Food allergen extracts and methods of producing and using the same. I6382413.9; 2016 September 6.



GYNECOLOGIC ONCOLOGY GROUP



Publications: **14**
 Impact Factor: **42.043**
 Q1: **3**

Ignacio Zapardiel Gutiérrez

Subdirector Científico. IdiPAZ
 Facultativo Especialista de Área en Ginecología y Obstetricia.
 Unidad de Ginecología Oncológica. HULP
 Profesor Asociado Facultad de Medicina. UAM

Diana Alecsandru Danceanu

Médico Especialista en Inmunología. IVI Madrid

Covadonga Álvarez López

Facultativo Especialista de Área en Ginecología y Obstetricia.
 HULP

Ónica María Armijo Suárez

Facultativo Especialista de Área en Ginecología y Obstetricia.
 Unidad de Reproducción Asistida. HULP

María Cerrillo Martínez

Ginecóloga Especialista en Reproducción Humana. IVI Madrid

María Dolores Diestro Tejada

Facultativo Especialista de Área en Ginecología y Obstetricia.
 Unidad de Ginecología Oncológica. HULP

Juan Antonio García Velasco

Profesor Titular. Universidad Rey Juan Carlos

Cristina González Benítez

Facultativo Especialista de Área en Ginecología y Obstetricia.
 HULP

Alicia Hernández Gutiérrez

Facultativo Especialista de Área en Ginecología y Obstetricia.
 Unidad de Ginecología Oncológica. HULP
 Profesor Asociado Facultad de Medicina. UAM

María Herrera de la Muela

Facultativo Especialista de Área en Ginecología y Obstetricia.
 Unidad de Patología Mamaria. HULP

Ana López Carrasco

Facultativo Especialista de Área en Ginecología y Obstetricia.
 HULP

Israel Ortega Sánchez

Coordinador del Departamento Internacional. IVI Madrid

Margarita Sánchez-Pastor Ruiz

Facultativo Especialista de Área en Ginecología y Obstetricia.
 HULP

Profesor Asociado Facultad de Medicina. UAM

María Serrano Velasco

Facultativo Especialista de Área en Ginecología y Obstetricia.
 HULP

María Elisa Varela Sanz

Investigadora Postdoctoral. CNIO

Strategic Objective

The main objective of our group is to study all aspects related to gynaecologic malignancies. It includes from diagnosis to treatment and follow-up. For the next years we will focus our research on the malignancies affecting female uterus, including cervical and endometrial cancer as well as uterine sarcomas.

We will develop at least two stable and comprehensive specific research lines trying to pay attention to molecular aspects as well as clinical features of the Gynaecological cancers. But we will support the rest of aspects of the subspecialty.

Research Lines

- Evaluation, treatment and surgery of oncologic diseases in gynecology.
- Pelvic floor reconstructive surgery.

- Molecular disorders in preeclampsia, placenta and other obstetrical diseases.

Research Activity

PUBLICATIONS

- Arispe C, Pomares AI, de Santiago J, Zapardiel I. Evolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience. *Chinese J Cancer Res.* 2016;28(2):215-20. Article. IF: 3; Q2
- Brunel I, Iacoponi S, Hernández A, Diestro MD, de Santiago J, Zapardiel I. Intravascular leiomyomatosis: an exceptional entity. *Clin Exp Obstet Gyn.* 2016;43(3):443-5. Article. IF: 0.429; Q4
- Buda A, Papadia A, Zapardiel I, Vizza E, Ghezzi F, de Ponti E, Lissoni AA, Imboden S, Diestro MD, Verri D, Gasparri ML, Bussi B, Di Martino G, de la Noval BD, Mueller M, Crivellaro C. From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: A comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. *Ann Surg Oncol.* 2016;23(9):2959-65. Article. IF: 4.041; D1
- Enciso S, Díaz-Güemes I, Pérez-Medina T, Zapardiel I, de Santiago J, Uson J, Sánchez-Margallo FM. Validation of a structured intensive laparoscopic course for basic and advanced gynecologic skills training. *Int J Gynecol Obstet.* 2016;133(2):241-4. Article. IF: 2.174; Q2
- Iacoponi S, Rubio P, García E, Oehler MK, Díez J, Díaz-de la Noval B, Mora P, Gardella B, Gómez I, Kotsopoulos IC, Zalewski K, Zapardiel I. Prognostic factors of recurrence and survival in vulvar melanoma: Subgroup analysis of the VULvar CANcer Study. *Int J Gynecol Cancer.* 2016;26(7):1307-12. Article. IF: 2.369; Q2
- Iacoponi S, Zalewski K, Fruscio R, Díaz-de la Noval B, de Iaco P, Ceccaroni M, Barazi D, Chen F, Zapardiel I. Prognostic factors for recurrence and survival among patients with invasive vulvar Paget disease included in the VULCAN study. *Int J Gynecol Obstet.* 2016;133(1):76-9. Article. IF: 2.174; Q2
- López N, Grabowski JP, de Santiago J, Zapardiel I. Carcinoma of the recto-vaginal septum. *Comprehensive literature review.* *J Obstet Gynaecol.* 2016;36(4):450-4. Review. IF: 0.629; Q4
- Minig L, Otano L, Cruz P, Patrono MG, Botazzi C, Zapardiel I. Laparoscopic surgery for treating adnexal masses during the first trimester of pregnancy. *J Minim Access Surg.* 2016;12(1):22-5. Article. IF: 1.282; Q3
- Rodrigues MJ, Zapardiel I, Frelaut M, Brain E, Falandry C. A call for specific geriatric data on cervical cancers. *Future Oncol.* 2016;12(9):1101-4. Editorial Material. IF: 2.131; Q3
- Rychlik A, Marín S, de Santiago J, Zapardiel I. Utility of laparoscopic indocyanine green-guided sentinel node biopsy in open cervical cancer surgery. *Int J Gynecol Cancer.* 2016;26(7):1288-9. Article. IF: 2.369; Q2
- Zapardiel I, Cruz M, Diestro MD, Requena A, García-Velasco JA. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. *Hum Reprod Update.* 2016;22(3):281-305. Review. IF: 11.748; D1
- Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, Macuks R. Utility serum marker HE4 for the differential diagnosis between endometriosis and adnexal malignancy. *Int J Gynecol Cancer.* 2016;26(1):52-5. Article. IF: 2.369; Q2
- Zapardiel I, Moreno E, Pinera A, de Santiago J. Novel technique for the complete staging of endometrial cancer by single-port laparoscopy. *Gynecol Oncol.* 2016;140(2):369-71. Article. IF: 4.959; D1

- Zapardiel I. Treatment of ovarian tumours of low malignant potential (borderline ovarian tumours). *Int J Gynecol Cancer.* 2016;26:14. Article. IF: 2.369; Q2

PUBLIC PROJECTS

Antolín Alvarado E. Desarrollo de métodos predictivos basados en la integración de factores prenatales y postnatales para la detección de neurodesarrollo de cardiopatías congénitas (PII 3/02364). ISCIII. 2014-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

Herrera de la Muela MJ. Correlación de los hallazgos radiológicos y clínico-exploratorios con las características citológicas del fluido mamario obtenido mediante aspiración con el siste halo en una cohorte de mujeres snas portadoras de mutaciones deltereras en los genes BRCA. FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Herrera de la Muela MJ. Calidad de vida y satisfacción con la cirugía en mujeres con cáncer de mama con reconstrucción postmastectomía: estudio BRECAR (Breast Cancer Reconstruction Study). FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Ultraestadificación molecular ganglio centinela en cáncer de cérvix: MRNA e6/e7 HPV. FIBHULP. 2013-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. III Curso de investigación en laparoscopia avanzada en cadáveres. Karl Storz Endoscopia Ibética S.A. 2015-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Curso de investigación en laparoscopia ginecológica avanzada en cadáveres. Varios. 2013-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Evaluación del antígeno epididimal humano -HE4 - en el diagnóstico diferencial y seguimiento de la endometriosis superficial y profunda. Abbott Laboratories S.A. 2015-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Valor de la linfadenectomía en el cáncer de endometrio de riesgo intermedio (LICERI). FIBHCS. 2014-Ongoing.

Management centre: FIBHCS

CLINICAL TRIALS

Bartha Rasero JL. Ensayo clínico controlado, aleatorizado, doble ciego con prevastatina versus placebo para la prevención de preeclampsia. STATIN. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia.

HULP Code: Contrato 4716. Sponsored's Protocol Code:

FFIS/2015/01/ST.

Signature Date: 2/11/2016



de la Calle Fernández-Miranda M. Ensayo clínico uso precoz de progesterona para la prevención del parto pretérmino en la gestación gemelar. Estudio aleatorizado, doble ciego con placebo. Events. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia.

HULP Code: Contrato 4690. Sponsored's Protocol Code: FFIS/2015/02/EV.

Signature Date: 20/9/2016

de la Calle Fernández-Miranda M. Estudio de inmunogenicidad y seguridad de la vacuna DTPA de GSK biologicals, Boostrix® (263855), en mujeres embarazadas. Glaxosmithkline S.A.

HULP Code: Anexo-I 4397. Sponsored's Protocol Code: I16945.

Signature Date: 4/10/2016

Usandizaga Elio R. Edstudio sobre las condiciones de uso

de Caribán® y de otros antieméticos en el tratamiento de las náuseas y vómitos en el embarazo: estudio prospectivo observacional longitudinal. Laboratorios Inbisa S.A.

HULP Code: PI-2191. Sponsored's Protocol Code: LIN-DOX-2015-01.

Signature Date: 4/4/2016

PATENTS AND TRADEMARKS

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.



PATIENT BLOOD MANAGEMENT GROUP



Publications: **8**

Impact Factor: **14.836**

QI: **2**

Manuel Quintana Díaz

Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Urgencias en Análisis Clínicos. HULP
Profesor Asociado Facultad de Medicina. UAM

María José Alcaide Martín

Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. HULP

Rosa Capilla Pueyo

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP

Miriam Estebáñez Muñoz

Facultativo Especialista de Área en Medicina Interna. HULP

Sara Fabra Cadenas

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP

Pilar Fernández Calle

Facultativo Especialista de Área en Análisis Clínicos Coordinadora de Calidad de Análisis Clínicos. HULP

Sonia Galindo Gómez

Supervisora de Enfermería en Urgencias. HULP

José Antonio García Erce

Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca

Raquel Gómez Bravo

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP

Roswell Enrique González Rodiles Heredia

Médico Interno Residente en Medicina Familiar y Comunitaria. HULP

Manuel Jesús González Viñolis

Facultativo Especialista de Área en Neumología. HULP

Carmen Herrero Benito

Enfermera. HULP

Milagros Martí de Gracia

Facultativo Especialista de Área en Radiodiagnóstico. Jefe de Sección de Radiología de Urgencias. HULP

Ana María Martínez Virto

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. HULP

Marina Noguero Gutiérrez

Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP

Paloma Oliver Sáez

Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. HULP

María Inmaculada Pinilla Fernández

Facultativo Especialista de Área en Radiodiagnóstico. HULP

María Angélica Rivera Núñez

Facultativo Especialista de Área en Medicina Interna. HULP

Marcelino Sánchez Casado

Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud

María Torres de Sebastián

Médico Interno Residente en Urgencias. HULP

Strategic Objective

Stratifying risk in the critically ill patient:

- Stratify pulmonary thromboembolism risk.
- Try to diagnose the potentially ill polytraumatized patient at the emergency room.
- Early detection of sepsis at the emergency room.
- Enhance the use of the critically ill room at the emergency department.

Enhance the use of blood products:

- Critically ill patient coagulopathy.
- Early diagnosis of anemia at the emergency room.
- Intravenous iron usage



Research Lines

- Critical Bleeding.

Research Activity

DOCTORAL THESES

Cancelliere Fernández N. Evaluación de los modelos educativos, teórico y práctico, en residentes de primer año de especialidades médico-quirúrgicas [dissertation]. Madrid: UAM: 2016(19/9/2016).

Directors: Quintana Díaz M, Peña Sánchez JM.

Mateos Pañero B. Valoración del Euroscore y SAPS III como predictor de mortalidad hospitalaria en el postoperatorio de cirugía cardíaca [dissertation]. Madrid: UAM: 2016(1/12/2016).

Directors: Quintana Díaz M, Sánchez Casado M.

Rodríguez Fernández R. Evaluación de la eficacia de la funduplicatura Nissen laparoscópica mediante el uso de un cuestionario de calidad de vida y estudio esofagográfico baritado [dissertation]. Madrid: UAM: 2016(12/9/2016).

Directors: Quintana Díaz M, Martínez Cortijo S.

BOOKS AND BOOK CHAPTERS

García Erce JA, Quintana Díaz M. Interpretación de las alteraciones básicas de la coagulación: enfoque práctico. In: Manual de Formación Continuada 2015-2016: la efectividad en la Medicina del Laboratorio Clínico. Madrid: Asociación Española de Biopatología Médica (AEBM), 2016. p.48-71

Quintana Díaz M, Serrano Lázaro A. Uso de hemoderivados en el paciente crítico. In: Trauma en Medicina Intensiva. Madrid: Aula-Salud, 2016. p.1-12

Quintana-Díaz M, de Vega-Ríos E. Prevención secundaria con dabigatran del ICTUS cardioembólico en la fibrilación auricular no valvular. In: López Soto A, García Alegría J, Manzano L, Quintana-Díaz M, Vega-Ríos E, Altimir Losada S. Casos clínicos de la práctica a la teoría. Consenso de uso de Dabigatran. Proyecto ReThink. Madrid: EdikaMed S.L., 2016. p.37-43

Serrano Lázaro A, Quintana Díaz M. Fluidos, transfusión y soporte vasoactivo en el paciente traumático grave. In: Trauma en Medicina Intensiva. Madrid: Aula-Salud, 2016. p.1-8.

PUBLICATIONS

- Galán LAM, Egea-Guerrero JJ, Díaz MQ, Vilches-Arenas A. The effectiveness and safety of pharmacological prophylaxis against venous thromboembolism in patients with moderate to severe traumatic brain injury: A systematic review and meta-analysis. J Trauma. 2016;81(3):567-74. Review. IF: 3.403; Q1
- García-López S, Bocos JM, Gisbert JP, Bajador E, Chaparro M, Castano C, García-Erce JA, Gomollon F. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus-Italy. 2016;14(3):199-205. Article. IF: 1.607; Q4
- Muñoz R, Borobia AM, Quintana M, Martínez A, Ramírez E, Muñoz M, Frías J, Carcas AJ. Outcomes and costs of poisoned patients admitted to an adult emergency department of a spanish

tertiary hospital: Evaluation through a toxicovigilance program. Plos One. 2016;11(4):e0152876. Article. IF: 2.806; Q1

- Nanwani K, Saravia A, Suárez N, Martínez-Virto A, Quintana-Díaz M. A 70-year-old male with respiratory arrest secondary to angioedema. Med Intensiva. 2016;40(6):385-7. Letter. IF: 1.231; Q4
- Quintana-Díaz M, Erce JAG. Need for multidisciplinary massive transfusion protocol for non-trauma patient. Med Intensiva. 2016;40(9):525-6. Editorial Material. IF: 1.231; Q4
- Quintana-Díaz M, Fabra-Cadenas S, Gómez-Ramírez S, Martínez-Virto A, García-Erce JA, Muñoz M. A fast-track anaemia clinic in the emergency department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia. Blood Transfus-Italy. 2016;14(2):126-33. Article. IF: 1.607; Q4
- Revello R, Alcaide MJ, Dudzik D, Abehsera D, Bartha JL. Differential amniotic fluid cytokine profile in women with chorioamnionitis with and without funisitis. J Matern-Fetal Neo M. 2016;29(13):2161-5. Article. IF: 1.826; Q3
- Rodríguez-García J, Fernández-Santos R, García-Erce JA. Vaccination of patients with non-Hodgkin lymphoma under rituximab or other immunosuppressive drugs. Med Clin-Barcelona. 2016;146(1):43-4. Letter. IF: 1.125; Q3

PUBLIC PROJECTS

Martí de Gracia M. Mejora de la adecuación de la solicitud de pruebas de imagen con radiación ionizante (radiografía y TC) en los Servicios de Urgencias Hospitalarios. Proyectos MAPAC-imagen (PI13/01183). ISCIII. 2014-2016.

Management centre: FIBHULP

Quintana Díaz M. Proyecto de innovación docente: taller de trabajo en equipo (PID2016/17). UAM. 2016-2017.

Management centre: UAM

PRIVATE PROJECTS

Oliver Sáez P. Estudio de gasometría en el lugar de asistencia. Beneficio para el paciente. Asociación Española de Farmacéuticos Analistas. 2012-Ongoing.

Management centre: FIBHULP

Oliver Sáez P. Estudio comparativo multicéntrico sobre contaminación por microorganismos de las tiras reactivas de glucemia de uso hospitalario. Abbott Laboratories S.A. 2012-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Adecuación de las dosis de HBPM mediante la monitorización de los niveles de factor anti-Xa en pacientes que reciben tromboprolifaxis ampliada desde Urgencias. Laboratorios Farmacéuticos Rovi S.A. 2013-Ongoing.

Management centre: FIBHULP


Quintana Díaz M. Estudio de monitorización de heparinas de bajo peso molecular como profilaxis en un Servicio de Urgencias. Bayer Hispania S.L. 2011-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Identificación de factores de gravedad en el paciente con traumatismo potencialmente grave. FIBHULP. 2013-Ongoing.

Management centre: FIBHULP

ENDOCRINE DISEASES GROUP



Publications: 11

Impact Factor: 40.961

QI: 4

Lucrecia Herranz de la Morena

Jefe de Sección de Diabetes del Servicio de Endocrinología y Nutrición. HULP

Cristina Álvarez Escola

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Beatriz Barquiel Alcalá

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Isabel Calvo Viñuela

Enfermera de la Unidad de Obesidad, Endocrinología y Nutrición. HULP

Ana Isabel de Cos Blanco

Coordinadora de la Unidad Médico-Quirúrgica de Obesidad del Servicio de Endocrinología y Nutrición. HULP

Sonia del Río Prados

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Gumersindo Fernández Vázquez

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Ruth Gaspar Lafuente

Enfermera Educadora Endocrinología y Nutrición. Unidad de Diabetes. HULP

Noemí González Pérez de Villar

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Natalia Hillman Gadea

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Beatriz Lecumberri Santamaría

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Luis Felipe Pallardo Sánchez

Profesor Emérito. UYAM

Paola Andrea Parra Ramírez

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Lourdes Sáez de Ibarra y Vélez de Mendizábal

Enfermera Educadora Unidad de Diabetes, Endocrinología y Nutrición. HULP

Strategic Objective

The objective of this group is both basic and applied investigation, with its interest focused on translational investigation, comprising two specific areas within the speciality of Endocrinology and Nutrition. The first,



within metabolic pathology, includes diabetes and obesity. The second is focused on endocrine organ-specific pathology (thyroid, pituitary gland, neuro-endocrinology and rare endocrine disorders).

Research Lines

Metabolic pathology

- Diabetes and pregnancy.
- Diabetes related complications.
- Advanced technologies in diabetes.
- Epidemiological, clinical and comprehensive therapeutic approach to obesity.
- Adipose brown tissue metabolism.

Organ-specific pathology

- Molecular biology applied to the diagnosis and treatment of neuroendocrine disorders.
- Prognosis and treatment of differentiated thyroid cancer.
- Study of GnRH deficiency.
- GH secretion alterations and cardiometabolic pathology.
- Clinical-genetic characterizations of rare endocrine disorders and imprinting syndromes.

Research Activity

PUBLICATIONS

- Barquiel B, Herranz L, Hillman N, Burgos MA, Grande C, Tukiya KM, Bartha JL, Pallardo LF. HbA1c and gestational weight gain are factors that influence neonatal outcome in mothers with gestational diabetes. *J Womens Health*. 2016;25(6):579-85. Article. IF: 2.322; Q2
- Bernabéu I, Pico A, Venegas E, Aller J, Álvarez-Escola C, García-Arnés JA, Marazuela M, Jonsson P, Mir N, Vargas MG. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. *Pituitary*. 2016;19(2):127-37. Article. IF: 2.481; Q3
- Chico A, Herranz L, Corcoy R, Ramírez O, Goya MM, Bellart J, González-Romero S, Codina M, Sánchez P, Cortázar A, Acosta D, Picón MJ, Rubio JA, Megia A, Sancho MA, Balsells M, Sola E, Gonzalez NL, López-López J. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. *Eur J Obstet Gyn R B*. 2016;206:84-91. Article. IF: 1.666; Q3
- Herranz L, Sáez-de-Ibarra L, Hillman N, Gaspar R, Pallardo LF. Glycemic changes during menstrual cycles in women with type 1 diabetes. *Med Clin-Barcelona*. 2016;146(7):287-91. Article. IF: 1.125; Q3
- Luque RM, Ibáñez-Costa A, Sánchez-Tejada L, Rivero-Cortes E, Robledo M, Madrazo-Atutxa A, Mora M, Álvarez CV, Lucas-Mo-

rante T, Álvarez-Escola C, Fajardo C, Castaño L, Gaztambide S, Venegas-Moreno E, Soto-Moreno A, Gálvez MA, Salvador J, Valassi E, Webb SM, Pico A, Puig-Domingo M, Gilibert M, Bernabéu I, Marazuela M, Leal-Cerro A, Castano JP. The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research. *Endocrinol Nutr*. 2016;63(6):274-84. Article. IF: 1.106; Q4

- Martínez-Cerón E, Barquiel B, Bezos AM, Casitas R, Galera R, García-Benito C, Hernanz A, Alonso-Fernández A, García-Río F. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes A randomized clinical trial. *Am J Resp Crit Care*. 2016;194(4):476-85. Article. IF: 13.204; D1
- Mayor-Ibarguren A, Roldán-Puchalt MC, Gómez-Fernández C, Albizuri-Prado F, Álvarez-Escola C. Subacute cutaneous lupus erythematosus induced by mitotane. *JAMA Dermatol*. 2016;152(1):109-11. Letter. IF: 5.817; D1
- Mayor-Ibarguren A, Roldán-Puchalt MC, Sancho-Bueso T, Pérez-López C, Álvarez-Linera J, Frutos R, Álvarez-Escola C, Regojo-Zapata R, Beato-Merino MJ, Herranz-Pinto P, Lecumberri B. Kaposi sarcoma secondary to endogenous adrenocorticotropic hormone-dependent Cushing syndrome. *Brit J Dermatol*. 2016;174(6):1370-4. Article. IF: 4.706; D1
- Ramos-Levi AM, Bernabéu I, Álvarez-Escola C, Aller J, Lucas T, de Miguel P, Rodríguez-Canete L, Sampredo-Núñez MA, Halperin I, Puig-Domingo M, Marazuela M. Long-term treatment with pegvisomant for acromegaly: a 10-year experience. *Clin Endocrinol*. 2016;84(4):540-50. Article. IF: 3.327; Q2
- Ramos-Levi AM, Moreno JC, Álvarez-Escola C, Lacámara N, Montañez MC. Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves' disease. *Endocrinol Nutr*. 2016;63(3):139-41. Letter. IF: 1.106; Q4
- Thiele S, Mantovani G, Barlier A, Boldrin V, Bordogna P, de Sanctis L, Elli FM, Freson K, Garin I, Grybek V, Hanna P, Izzi B, Hiort O, Lecumberri B, Pereda A, Saraff V, Silve C, Turan S, Usardi A, Werner R, de Nancrales GP, Linglart A. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (IPPSD), a novel classification proposed by the EuroPHP network. *Eur J Endocrinol*. 2016;175(6):P1-17. Article. IF: 4.101; Q1

PRIVATE PROJECTS

de Cos Blanco AI. Tratamiento interdisciplinar de diabetes gestacional y obesidad. Banco de Castilla- La Mancha S.A. 2011-Ongoing.

Management centre: FIBHULP

Herranz de la Morena L. Actualización y proyección de la unidad funcional de la obesidad en la actividad clínica hospitalaria del Servicio de Endocrinología. Abbott Laboratories S.A. 2008-2017.

Management centre: FIBHULP

Herranz de la Morena L. Jornadas de formación en investigación sobre diabetes y obesidad. Astrazeneca Farmacéutica Spain S.A. 2013-Ongoing.

Management centre: FIBHULP

UROLOGY GROUP



Publications: 29

Impact Factor: 169.765

Q1: 12

Luis Martínez-Piñero Lorenzo

Jefe de Servicio de Urología. HULP

Alfredo Aguilera Bazán

Facultativo Especialista de Área en Urología. HULP

José María Alonso Dorrego

Facultativo Especialista de Área en Urología. HULP

Mario Álvarez Maestro

Facultativo Especialista de Área en Urología. HULP

Luisa María Botella Cubells

Investigador Senior. Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas- CSIC

José Ramón Cansino Alcaide

Facultativo Especialista de Área en Urología. HULP

Cristina de Castro Guerin

Facultativo Especialista de Área en Urología. HULP

Mercedes Ferrer Parra

Departamento de Fisiología, UAM.

Eugenia García Fernández

Facultativo Especialista de Área en Anatomía Patológica. HULP

Juan A. Gómez Rivas

Facultativo Especialista de Área en Urología. HULP

Estefanía Linares Espinós

Facultativo Especialista de Área en Urología. HULP

Pedro López Pereira

Jefe de Servicio de Urología Pediátrica. HULP

Nuria Malats Riera

Investigador Senior. Centro Nacional de Investigaciones Oncológicas. CNIO

José Antonio Moreno Valle

Facultativo Especialista de Área en Urología. HULP

María Justa García-Matres y Cortés

Facultativo Especialista de Área en Urología. HULP

José Ramón Pérez-Carral García

Facultativo Especialista de Área en Urología. HULP

Francisco Real

Investigador Senior. Centro Nacional de Investigaciones Oncológicas. CNIO

Emilio Ríos González

Médico Adjunto en Urología. Hosp. Univ. Infanta Sofía

Fermín Rodríguez de Bethencourt y Codes

Facultativo Especialista de Área en Urología. HULP

Ángel Tabernero Gómez

Facultativo Especialista de Área en Urología. HULP

M. Mar Valés Gómez

Investigador Senior. Centro Nacional de Biotecnología. CSIC

Strategic Objective

We aim to consolidate a strong research group into:

- Urologic Oncology
- Reconstructive surgery
- Endurologic and minimally invasive surgery
- Lithiasis
- Incontinence / Neuro-urology
- Andrology / Reproduction

Through basic and experimental research, clinical research, translational research and clinical trials.

The results of this projects should be translated into doctoral theses, publications in high impact journals and visibility factor, as to finally achieve patents and trademarks.



3.4 Large System Pathology Area

Research Lines

• Urological Oncology

The group's efforts will focus on the following fields of research:

BLADDER CANCER

- Immunological response in patients with bladder cancer treated with BCG.
- Urinary markers in diagnosis and prediction of response in patients with bladder cancer.
- New immunomodulatory treatments in bladder cancer.
- New imaging methods for the diagnosis of bladder cancer.
- Efficacy of combined chemo and immunotherapy hyperthermia in bladder cancer.

PROSTATE CANCER

- Castration-resistant prostate carcinoma, immune response, and evaluation of predictive markers of therapeutic response.
- Medical treatment of locally advanced and metastatic prostate cancer.
- Development of new surgical minimally invasive techniques for localized prostate cancer.

KIDNEY CANCER

- Development of new surgical minimally invasive techniques for localized kidney cancer.
- Research of new therapeutic lines in hereditary renal cancer.
- Medical treatment of locally advanced and metastatic renal carcinoma.

• Reconstructive surgery

- Development and improvement of new reconstructive surgery techniques for complex urethral strictures, genitourinary congenital malformations and genitourinary fistulas.
- Development of a Regenerative Medicine Unit and Tissue Bioengineering applied to reconstructive urologic surgery.

• Endurologic and minimally invasive surgery

- Development of new endourological surgery techniques for minimally invasive treatment of benign prostatic hyperplasia and urinary lithiasis.
- Development of a learning program in laparoscopy and other minimally invasive surgeries.

• Lithiasis

- Study of new inhibitors of crystallization of urine solutes as prevention of lithogenesis.
- Metabolic study of renal lithiasis.

• Incontinence and Neuro-urology

- Study and treatment of chronic pelvic pain.
- Development and improvement of new systems for the treatment of urinary incontinence.

• Andrology / Reproduction

- Study of new medical and surgical treatments for male infertility.
- Development of new medical and surgical treatments for erectile dysfunction.

Research Activity

DOCTORAL THESES

Linares Espinós EE. Valor predictivo del volumen-centro de los resultados de la cirugía de cáncer renal con extensión venosa. Impacto en el modelo asistencial [dissertation]. Madrid: UAM, 2016 (22/11/2016).

Director: Carballido Rodríguez J

BOOKS AND BOOK CHAPTERS

Cogorno L, Díez J, Sánchez J, Martínez-Piñero L. Urgencia miccional de novo tras cirugía de incontinencia urinaria de esfuerzo femenina. In: Archivos Clínicos de Urología. Monografía de vejiga hiperactiva. Coordinador: M. Unda. Editado por You & US, S.A., 2016, p. 37-43

Díez Rodríguez J, Sánchez Gómez J, Cogorno Wasylkowski L, Linares Quevedo A, Martínez-Piñero L. Tratamiento no farmacológico de las alteraciones urológicas en la enfermedad de Parkinson. Editores: Sociedad Española de Neurología y Federación Española de Parkinson, 2016. p. 30-41, 2016

Martínez-Piñero L, Rodríguez A, Medina R, Gómez-Veiga F. Manejo del paciente con recidiva bioquímica tras el tratamiento curativo. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 27-34

Medina R, Martínez-Piñero L, Rodríguez A, Gómez-Veiga F. Criterios diagnósticos para la individualización en el tratamiento del cáncer de próstata. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 16-26

Rodríguez A, Medina R, Martínez-Piñero L, Gómez-Veiga F. Biopsia, rebiopsia y evolución en el diagnóstico por imagen del cáncer de próstata. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 11-15

Rodríguez A, Medina R, Martínez-Piñero L, Gómez-Veiga F. Novedades en hormonoterapia y resistencia a castración. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y Curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 35-44

PUBLICATIONS

- Aguilera A, Alonso-Dorrego JM, Bañuelos B, Cisneros J, González P, Díez J. Oncological results in high grade prostate cancer treated surgically. Arch Esp Urol. 2016;69(4):162-71. Article. IF: 0.323; Q4
- Colombo JJ, Espinós EL, Tello JL, Cortés MDL, Merino JCA, Martínez-Piñero L. Perirrenal presentation of extranodal Rosai-Dorfman disease. Arch Esp Urol. 2016;69(7):446-7. Editorial Material. IF: 0.323; Q4
- de Maturana EL, Picornell A, Masson-Lecomte A, Kogevinas M, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Chanock S, Real FX, Goddard ME, Malats N. Prediction of non-muscle invasive bladder cancer outcomes

assessed by innovative multimarker prognostic models. BMC Cancer. 2016;16:351. Article. IF: 3.288; Q2

- de Maturana EL, Pineda S, Brand A, Van Steen K, Malats N. Toward the integration of Omics data in epidemiological studies: still a "long and winding road". Genet Epidemiol. 2016;40(7):558-69. Review. IF: 1.884; Q2
- Espinós EL, Sánchez-Salas R, Sivaraman A, Pérez-Reggeti JI, Barret E, Rozet F, Galiano M, Prapotnich D, Cathelineau X. Minimally invasive salvage prostatectomy after primary radiation or ablation treatment. Urology. 2016;94:111-6. Article. IF: 2.309; Q2
- Figueroa JD, Middlebrooks CD, Banday AR, Ye YQ, García-Closas M, Chatterjee N, Koutros S, Kiemeny LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Domínguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang ZM, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszewicz M, Castela JE, Calaza M, Martínez ME, Cordeiro P, Xu ZL, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-de-Mesquita HB, Ljungberg B, Clavel-Chapelón F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjonneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupert M, Comperat E, Turman C, de Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang LR, Gong YI, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Hosain GMM, Schwenn M, Kogevinas M, Tardon A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu XF, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016;25(6):1203-14. Article. IF: 5.34; Q2
- Frantzi M, van Kessel KE, Zwarthoff EC, Márquez M, Rava M, Malats N, Merseburger AS, Katafigioti I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtigthagen R, Brand K, Dakna M, Roubelakis MG, Theodorou D, Vlahou A, Mischak H, Anagnou NP. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin Cancer Res. 2016;22(16):4077-86. Article. IF: 9.619; D1
- Friesen MC, Wheeler DC, Vermeulen R, Locke SJ, Zaebst DD, Koutros S, Pronk A, Colt JS, Baris D, Karagas MR, Malats N, Schwenn M, Johnson A, Armentti KR, Rothman N, Stewart PA, Kogevinas M, Silverman DT. Combining decision rules from classification tree models and expert assessment to estimate occupational exposure to diesel exhaust for a case-control Study. Ann Occup Hyg. 2016;60(4):467-78. Article. IF: 1.71; Q3
- Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardeli V, Paskaralis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a large multicenter cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016;118(1):44-52. Article. IF: 4.338; Q1
- Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Márquez M, Segersten U, Aine M, Høglund M, Birkenkamp-Demtroder K, Fristrup N, Borre M, Hartmann A, Stohr

R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstrom PU, Malats N, Real FX, Zwarthoff EC, Orntoft TF, Dyrskjot L. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27-42. Article. IF: 27.407; D1

• Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti J I, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X. Localized prostate cancer focal therapy: "A la carte" Model. Arch Esp Urol. 2016;69(6):345-52. Article. IF: 0.323; Q4

• Lope V, García-Esquinas E, Ruiz-Domínguez JM, Llorca J, Jiménez-Moleón JJ, Ruiz-Cerdá JL, Alguacil J, Tardón A, Dierssen-Sotos T, Tabernero A, Mengual L, Kogevinas M, Aragónés N, Castano-Vinyals G, Pollán M, Pérez-Gómez B. Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. Cancer Epidemiol. 2016;43:49-55. Article. IF: 2.343; Q2

• Machiela MJ, Zhou WY, Karlins E, Sampson JN, Freedman ND, Yang Q, Hicks B, Dagnall C, Hautman C, Jacobs KB, Abnet CC, Aldrich MC, Amos C, Amundadotir LT, Arslan AA, Beane-Freeman LE, Berndt SI, Black A, Blot WJ, Bock CH, Bracci PM, Brinton LA, Bueno-de-Mesquita HB, Burdett L, Buring JE, Butler MA, Canzian F, Carreon T, Chaffee KG, Chang IS, Chatterjee N, Chen C, Chen C, Chen KX, Chung CC, Cook LS, Bou MC, Cullen M, Davis FG, De Vivo I, Ding T, Doherty J, Duell EJ, Epstein CG, Fan JH, Figueroa JD, Fraumeni JF, Friedenreich CM, Fuchs CS, Gallinger S, Gao YT, Gapstur SM, García-Closas M, Gaudet MM, Gaziano JM, Giles GG, Gillanders EM, Giovannucci EL, Goldin L, Goldstein AM, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Henriksson R, Holly EA, Hong YC, Hoover RN, Hsiung CA, Hu N, Hu W, Hunter DJ, Hutchinson A, Jenab M, Johansen C, Khaw KT, Kim HN, Kim YH, Kim YT, Klein AP, Klein R, Koh WP, Kolonel LN, Kooperberg C, Kraft P, Krogh V, Kurtz RC, LaCroix A, Lan Q, Landi MT, Le Marchand L, Li DH, Liang XL, Liao LM, Lin DX, Liu JJ, Lissowska J, Lu LG, Magliocco AM, Malats N, Matsuo K, McNeill LH, McWilliams RR, Melin BS, Mirabello L, Moore L, Olson SH, Orlov I, Park JY, Patino-García A, Peplonska B, Peters U, Petersen GM, Pooler L, Prescott J, Prokunina-Olsson L, Purdue MP, Qiao YL, Rajaraman P, Real FX, Riboli E, Risch HA, Rodriguez-Santiago B, Ruder AM, Savage SA, Schumacher F, Schwartz AG, Schwartz KL, Seow A, Setiawan VW, Severi G, Shen H, Sheng X, Shin MH, Shu XO, Silverman DT, Spitz MR, Stevens VL, Stolzenberg-Solomon R, Stram D, Tang ZZ, Taylor PR, Teras LR, Tobias GS, Van den Berg D, Viswanathan K, Wacholder S, Wang JC, Wang ZM, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolpin BM, Wong MP, Wu C, Wu TC, Wu XF, Wu YL, Wunder JS, Xia L, Yang HP, Yang PC, Yu K, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Ziegler RG, Pérez-Jurado LA, Caporaso NE, Rothman N, Tucker M, Dean MC, Yeager M, Chanock SJ. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun. 2016;7:118431. Article. IF: 12.124; D1

• Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Máster VA, Mckiernan JM, Libertino JA, Haferkamp A, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Máster VA, Mckiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JLP, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol. 2016;114(6):764-8. Article. IF: 2.993; Q1

• Masson-Lecomte A, de Maturana EL, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardón A, Llo-



3.4 Large System Pathology Area

- reta J, García-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N. Inflammatory-related genetic variants in non-muscle-invasive bladder cancer prognosis: A multimarker bayesian assessment. *Cancer Epidem Biomar*. 2016;25(7):1144-50. Article. IF: 4.142; Q1
- Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, Shuin T, Freedman ND, Kogevinas M, Malats N, Chanock SJ, García-Closas M, Silverman DT, Rothman N, Prokunina-Olsson L. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. *Nat Genet*. 2016;48(11):1330-8. Article. IF: 27.959; D1
 - Murcia-Pascual FJ, Gracia-Rodríguez R, Vázquez-Rueda F, Pereira PL, Esteban RMP. Testicular and paratesticular tumors in children. *Arch Esp Urol*. 2016;69(10):691-7. Article. IF: 0.323; Q4
 - Pérez-Reggeti JJ, Sánchez-Salas R, Sivaraman A, Espinós EL, de Gracia-Nieto AE, Barret E, Galiano M, Rozet F, Fregeville A, Renard-Penna R, Cathala N, Mombet A, Prapotnich D, Cathelineau X. High intensity focused ultrasound with Focal-One (R) device: Prostate-specific antigen impact and morbidity evaluation during the initial experience. *Actas Urol Esp*. 2016;40(10):608-14. Article. IF: 1.181; Q4
 - Rios E, Martínez-Pineiro L. Re: Primary endoscopic realignment of urethral disruption injuries—a double-edged sword? *Eur Urol*. 2016;69(3):536-7. Editorial Material. IF: 16.265; D1
 - Rivas JG, Gregorio SAY, Álvarez-Maestro M. Prostate capsule sparing radical cystectomy - a safe procedure for few REPLY. *Cent European J Urol*. 2016;69(1):34. Editorial Material. Not Indexed
 - Rivas JG, Gregorio SAY, Gómez AT, Álvarez-Maestro M, Sebastián JD, Ledo JC. Laparoscopic radical cystectomy with prostate capsule sparing. Initial experience. *Cent European J Urol*. 2016;69(1):25-31. Article. Not Indexed
 - Rivas JG, Gregorio SAY, Ledo JC, Gómez AT, Sebastián JD, Barthel JJD. The role of perioperative blood transfusion on postoperative outcomes and overall survival in patients after laparoscopic radical cystectomy. *J Cancer Res Ther*. 2016;12(1):146-9. Article. IF: 0.75; Q4
 - Rodríguez-Socarrás ME, Gómez-Rivas J, Álvarez-Maestro M, Tortolero L, Ribal MJ, Sanz MG, Roupert M. Spanish adaptation of the recommendations for the appropriate use of social networks in urology of the European Association of Urology. *Actas Urol Esp*. 2016;40(7):417-23. Review. IF: 1.181; Q4
 - Sánchez-Salas R, Linares Espinos E. Monográfico terapia focal en cáncer de próstata. *Arch Esp Urol*. 2016;69(6):257-9. Article. IF: 0.323; Q4
 - Shi JX, Park JH, Duan JB, Berndt ST, Moy W, Yu K, Song L, Wheeler W, Hua X, Silverman D, García-Closas M, Hsiung CA, Figueroa JD, Cortessis VK, Malats N, Karagas MR, Vineis P, Chang IS, Lin DX, Zhou BS, Seow A, Matsuo K, Hong YC, Caporaso NE, Wolpin B, Jacobs E, Petersen GM, Klein AP, Li DH, Risch H, Sanders AR, Hsu L, Schoen RE, Brenner H, Stolzenberg-Solomon R, Gejman P, Lan Q, Rothman N, Amundadottir LT, Landi MT, Levinson DF, Chanock SJ, Chatterjee N. Winner's curse correction and variable thresholding improve performance of polygenic risk modeling based on genome-wide association study summary-level data. *Plos Genet*. 2016;12(12):e1006493. Article. IF: 6.1; D1
 - Wasykowski LC, González ER, Lorenzo LMP. Diagnosis of urethral stenosis and follow-up after Urethroplasty. *Arch Esp Urol*. 2016;69(7):416-22. Article. IF: 0.323; Q4
 - Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serrera V, Larre S, di Stasi S, Colombo R, Babjuk M, Malmstrom PU, Malats N, Irani J, Baniel J, Cai T, Cha EGN, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099

- patients with T1G3 non muscle-invasive bladder cancer. *Urol Oncol-Semin Ori*. 2016;34(11):484.e19-e25. Article. IF: 3.767; Q1
- Zhang MF, Wang ZM, Obazee O, Jia JP, Childs EJ, Hoskins J, Figlioli G, Mucci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambriani A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PHM, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjonneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li DH, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget*. 2016;7(41):66328-43. Article. IF: 5.168; Q1
 - Zhou WY, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N, Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D, Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, García-Closas M, Real FX, Earl J, Marenne G, Rodríguez-Santiago B, Karagas M, Johnson A, Schwenn M, Wu XF, Gu J, Ye YQ, Hutchinson A, Tucker M, Pérez-Jurado LA, Dean M, Yeager M, Chanock SJ. Mosaic loss of chromosome Y is associated with common variation near TCL1A. *Nat Genet*. 2016;48(5):563. Article. IF: 27.959; D1

PUBLIC PROJECTS

García Fernández ME. Red de Biobancos (PT13/0010/0003). ISCIII-MICINN. 2014-2017.

Management centre: FIBHULP

PRIVATE PROJECTS

García Fernández ME. Facturación de Biobanco. CAM. 2014-2018.

Management centre: FIBHULP

López Pereira P. Curso CRM (Crisis Resource Management) en urología pediátrica. Varios Financiadores. 2016-2017.

Management centre: FIBHULP

López Pereira P. Utilización de constructos de mucosa urotelial autóloga obtenidos mediante ingeniería tisular para la realización uretroplastias reconstructivas en un modelo experimental de hipospadias proximal en conejos. Fundación para la Investigación en Urología. 2016-2018.

Management centre: FIBHULP

Martínez-Piñero Lorenzo L. Convenio de colaboración para el fomento de la formación. Covidien Spain S.L. (Tyco Healthcare Spain S.L.). 2006-Ongoing.

Management centre: FIBHULP

HEALTH CARE
NURSES RESEARCH
GROUP

Publications: 3

Impact Factor: 5.784

QI: 1

Jesús Castro Toro

Supervisor de Área Funcional. HULP

Laura Alonso Recio

Profesora Contratada. UNED

Verónica Álvarez Gonzalo

Fisioterapeuta. HULP

Elena Calderari Fernández

Enfermera en Centro de Especialidades José Marvá

Alicia Cerón Serrano

Enfermera asistencial. HULP

María Nélida Conejo Pérez

Enfermera en Servicio de Cuidados Intensivos Pediátricos. HULP

Víctor Manuel Cornejo del Río

Supervisor de Unidad Quirúrgica. Hospital Carlos III- HULP

María Ricardina Delgado Sandoval

Enfermera en Servicio de Consultas Externas. HULP

María Luisa Díaz Martínez

Profesora Contratada. UAM

María Durán Agüí

Enfermera en Servicio de Medicina Interna. HULP

Matilde Fernández y Fernández-Arroyo

Profesora en la Unidad Docente de Matronas. HULP

Salomé Herrero Cereceda

Enfermera Unidad Quirúrgica, Hospital Cantoblanco-HULP

Patricia Luna Castaño

Enfermera en Servicio de Cuidados Intensivos Pediátricos. HULP

Jesús Morente López

Enfermero en Unidad de Cuidados Críticos. HULP

Profesor colaborador. Universidad Pontificia de Comillas

Pedro Piqueras Rodríguez

Supervisor de Enfermería en Unidad de Cuidados Intensivos Pediátricos. HULP

María del Carmen Sellán Soto

Profesora Contratada. UAM

Gema Tapia Serrano

Enfermera de Cuidados Intensivos Pediátricos. HULP

Adrián Torres Hidalgo

Enfermero. Técnico de Salud en la Gerencia de Atención Especializada de la Comunidad de Madrid.

Strategic Objective

Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live.

This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful.

Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowledge and use of research results in clinical practice will contribute to improving the health of the population. Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes.

In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients.

Finally, it should be noted that using evidence in daily



practice can achieve health goals at a minimum cost. Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care.

At the same time, society is facing new economic, political, demographic, social and cultural challenges that require health services capable of meeting the growing health needs of the population.

It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.

Research Lines

- Vital Processes and complex care.
- Technological innovation and its application in health care.
- Management of care and results of professional practice.

Research Activity

BOOKS AND BOOK CHAPTERS

Canencia Cid MP, Elola Vicente P, Najera Santos MC, Abad Martín D, Rebollo Deliz MJ, Gil Martínez A, Fernández Acevedo MR, Castro Toro J. Implementación de la estrategia para la higiene de manos en la unidad de extracciones de un hospital de tercer nivel. Hospital Universitario La Paz. In: 27 Jornadas Nacionales de Enfermeras Gestoras. Burgos: ANDE, 2016.

Cornejo del Río V, Fernández y Fernández-Arroyo M, Gil Martínez A, Delgado Sandoval M, Calderari Fernández E, Cerón Serrano GA. Disfunción eréctil en pacientes diabéticos y prevención del Síndrome Cardiovascular. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.210-211

Fernández M. Actualización de conocimientos sobre Sexualidad Obstétrica/Ginecológica. In: León S. Actualización de conocimientos sobre sexualidad obstétrica/ginecológica. Una mirada especializada sobre el tema. Madrid: FUDEN, 2016. p.5-7

Fernández M. Una mirada especializada sobre el tema. In: Casado D, Sanz MJ. Embarazo y parto saludables. Conocimiento y recursos disponibles, y propuestas de mejora. Madrid: Polibe, 2016. p.1-40

Pedraza Anguera AM, Fernández y Fernández-Arroyo M, Gómez del Pulgar M, Reguera Carricondo A, de Castro Pedraza C, Adell Aguiló N, Tudela Valls C, de la Torre Luceño S. Valoración de la Autoestima en el programa de Salud i Escola. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.461-462

Piqueras-Rodríguez P, Arribas Estrada M, Carrión Navarro ME, Muños Pintor J. Seguridad del paciente como objetivo de la unidad. Implementación y valoración. In: 27 Jornadas Nacionales de Enfermeras Gestoras. Burgos: ANDE, 2016

Sellán MC, Díaz ML. Principios fundamentales de la bioética: dilemas éticos. In: Chillón Martínez R. Conceptos fundamentales para la práctica fisioterápica en atención primaria y atención especializada. Madrid: FUDEN, 2016

Tapia-Serrano G, Blázquez-García B, López-Sastre E, Piqueras-Rodríguez P. Cuestionario de satisfacción de padres de neonatos hospitalizados. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.149-152

PUBLICATIONS

- Anguita-Palacios MC, Talayero-San-Miguel M, Herrero-Cereceda S, Martín-Cadenas M, Pardo-Cuevas P, Gil-Martínez A. Fear and preoperative anxiety behaviour and pain intensity perceived after knee arthroscopy. *Enferm Clin.* 2016;26(4):227-33. Article. Not Indexed
- Lahoz C, Mostaza JM, Salinero-Fort MA, García-Iglesias F, González-Alegre T, Estirado E, Laguna F, de Burgos-Lunar C, Sánchez-Arroyo V, Sabin C, López S, Cornejo-del-Río V, Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D, Montesano-Sánchez L. Peripheral atherosclerosis in patients with erectile dysfunction: A population-based study. *J Sex Med.* 2016;13(1):63-9. Article. IF: 2.978; Q2
- Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abanades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, García-Iglesias F, González-Alegre T, Fernández-Puntero B, Montesano-Sánchez L, Vicent-López D, Cornejo-del Río V, Fernández-García PJ, Sánchez-Arroyo V, Sabin-Rodríguez C, López-López S, Patrón-Barandio P, Gómez-Campelo P. Performance of the Finnish diabetes risk score and a simplified Finnish diabetes risk score in a community-based, cross-sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. *Plos One.* 2016;11(7):e0158489. Article. IF: 2.806; Q1

PRIVATE PROJECTS

Castro Toro J. App para mejorar la adherencia al tratamiento en pacientes EPOC. Vivir con EPOC. Vodafone. 2016-Ongoing.

Management centre: Reto Salud Andalucía

MATERNAL AND FETAL MEDICINE GROUP*



José Luis Bartha Rasero

Jefe de Servicio de Obstetricia y Ginecología. HULP
Catedrático de Obstetricia y Ginecología. UAM

Eugenia Antolín Alvarado

Jefe de Sección de Obstetricia y Ginecología. HULP
Profesor asociado. UAM

Marta Cortés León

Médico Especialista en Ginecología y Obstetricia. HULP

María Amparo Gimeno Sanmartín

Médico Especialista en Ginecología y Obstetricia. HULP

María del Mar González Arlazón

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

María de la Cruz González Álvarez

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Beatriz Herrero Ruiz

Médico Adjunto de la Sección de Ecografía y Medicina Fetal. HULP

Sara López Magallón

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Francisco López Sánchez

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Fernando Magdaleno Dans

Jefe de Sección de Obstetricia y Ginecología
Profesor asociado. UAM

María Elena Martín Boado

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Nuria Martínez Sánchez

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Inmaculada Orensanz Fernández

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Roberto Rodríguez González

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Laura Sotillo Mallo

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Inmaculada Duyos Mateo

Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Strategic Objective

- To evaluate the involvement of placental energy metabolism in obstetric disorders
- To find new biomarkers in gestational diabetes mellitus and macrosomia
- To find new biomarkers of fetal and perinatal neurological damage establishing new prevention strategies
- To improve our understanding of the pathophysiology fetal heart damage in Anti-Ro positive women and to find new lines of treatment in these cases

Research Lines

- Diabetes mellitus, obesity and metabolic syndrome during pregnancy
- Energy metabolism during pregnancy
- Fetal neurodevelopment
- Inflammation, autoimmunity and pregnancy

* Group recently created: february 2017

EMERGENCY
AND CRITICAL
PATHOLOGY
GROUP***César Carballo Cardona**Facultativo Especialista de Área en Urgencias. HULP
Coordinador de Urgencias. HULP**María Teresa Ayuso Aragoneses**

Médico Adjunto en Urgencias. HULP

Gillermina Bejarano Redondo

Médico Adjunto en Urgencias. HULP

Labna Dani Ben Abdel lah

Facultativo Especialista de Área en Urgencias. HULP

Guadalupe Buitrago Weiland

Facultativo Especialista de Área en Urgencias. HULP

María Elena Calvín García

Facultativo Especialista de Área en Urgencias. HULP

Julio Cobo Mora

Jefe de la Unidad de Urgencias. HULP

Isabel Gallego Mínguez

Facultativo Especialista de Área en Urgencias. HULP

María de los Ángeles García Martín

Facultativo Especialista de Área especialista en Farmacia Hospitalaria. HULP

Olga González Peña

Facultativo Especialista de Área en Urgencias. HULP

Manuel Jesús González Viñolis

Facultativo Especialista de Área en Urgencias. HULP

María Milagros Jaén Cañadas

Facultativo Especialista de Área en Urgencias. HULP

Macarena Lerín Baratas

Facultativo Especialista de Área en Urgencias. HULP

Cristina López Paredes

Facultativo Especialista de Área en Urgencias. HULP

María Lorena López Corcuera

Facultativo Especialista de Área en Medicina Interna. HULP

Alejandro Martín Quirós

Unidad de Aislamiento de Alto Nivel. HULP

Carlos Martínez Caballero

Facultativo Especialista de Área en Urgencias. HULP

Rosa Mayayo Alvira

Médico Facultativo Especialista en Medicina Interna. HULP

Mikel Rico Briñas

Facultativo Especialista de Área en Urgencias. HULP

Paloma Isabel Romero Gallego-Acho

Facultativo Especialista de Área en Medicina Interna. HULP

María José Simón Merlo

Facultativo Especialista de Área en Radiología. HULP

Yaletung Chen

Facultativo Especialista de Área en Urgencias. HULP

José Manuel Valero Recio

Facultativo Especialista de Área en Urgencias. HULP

Strategic Objective

Our group will investigate new strategies to address very different pathologies that are presented in our emergency department, national referent in different fields of diagnosis and treatment. This heterogeneous group of specialists, will approach 6 main lines of research, which aim to contribute to the better definition of clinical, diagnostic and treatment strategies.

We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.

We develop a new and pioneering line of imaging-diagnostic, with the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise.

We will investigate the possibility of supporting us in new technologies that help the clinician in the decision making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level.

Finally, we will develop a line of toxicological research, focusing both on the early recognition of the intoxicated patient, as well as their adequate treatment, in collaboration with the clinical toxicology unit (CTU), with the aim of becoming a national reference center in the Management of the intoxicated patient, as well as in the development of protocols of attention to multiple victims of biological attack.

Research Lines

- Integral management of the treatment and follow-up of the diabetic patient.
- Emergency ultrasound.
- Care of infectious diseases in the emergency room
- Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes.
- Attention to cardiovascular pathology of emergencies.
- Attention to respiratory pathology.

* Group recently created: february 2017



3.5 Cancer and Human Molecular Genetics Area

Amparo Cano García

📄 Documents: **120** 📊 IF: **581.068**

📄 Originals: **102** 📊 IF: **522.905**

📊 DI: **20** 📊 QI: **58**

- INGEMM- Institute of Medical and Molecular Genetics Group
- Translational Oncology Group
- Experimental Therapies and Biomarkers in Cancer Group
- Oto-Neurosurgery Research Group
- Cancer Molecular Pathology and Therapeutic Targets Group
- Mechanisms of Tumour Progression Group
- Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Group
- Research and Diagnosis of Inherited Metabolic Diseases Group
- Regulation of Ciliary Structure and Function by Phosphoinositides Group

INGEMM- INSTITUTE OF MEDICAL AND MOLECULAR GENETICS GROUP



📄 Publications: **23**

📊 Impact Factor: **67.289**

📊 QI: **7**

Pablo Daniel Lapunzina Badía

Coordinador INGEMM. HULP

Cinthia Amiñoso Carbonero

Técnico de Laboratorio. HULP

Pedro Arias Lajara

Técnico de Laboratorio. HULP

Verónica Barca Tierno

Investigadora Predoctoral. HULP

Eva Barroso Ramos

Investigadora Postdoctoral. HULP

Alberta Belinchón Martínez

Investigadora Postdoctoral. HULP

Sara Benito Sanz

Investigadora Postdoctoral. HULP

Ángel Campos Barros

Investigador Senior (Contrato Miguel Servet- 12). Jefe de Laboratorio. HULP

Felipe de Frutos Pérez María

Técnico de Laboratorio. HULP

Ángela del Pozo Mate

Técnico Informático. HULP

Alicia Delicado Navarro

Genetista. HULP

María Ángeles Domínguez Díaz

Técnico de Laboratorio. HULP

Adela Escudero López

Investigadora Predoctoral. HULP

Begoña Ezquieta Zubizaray

Bioquímico Adjunto. HULP

Luis Fernández García-Moya

Biólogo. HULP

Blanca Nieves Fernández Martínez

Técnico de Laboratorio. HULP

María Victoria Fernández Montaña

Técnico de Laboratorio. HULP

Amparo García Cardenal

Técnico de Laboratorio. HULP

Fe Amalia García Santiago

Bióloga. HULP

Sixto García-Miñaur Rica

Genetista. HULP

Isabel Gómez Nieto

Técnico de Laboratorio. HULP

Héctor González-Pecellín

Técnico de Laboratorio. HULP

Karen Elise Heath

Investigadora Senior (Contrato Ramón y Cajal- 13). Jefe de Laboratorio. HULP

Teresa López Jiménez

Técnico de Laboratorio. HULP

Alicia Llorente Alonso

Técnico de Laboratorio. HULP

María Elena Mansilla Aparicio

Genetista. HULP

María Soledad Martín Rodríguez

Técnico de Laboratorio. HULP

Pilar Martínez González

Bióloga. HULP

Víctor Manuel Martínez González

Investigador Postdoctoral. HULP

Isabel Martínez María

Enfermera. HULP

María Cruz Martínez Martínez

Técnico de Laboratorio. HULP

Paloma Martínez Montero

Facultativo Especialista de Área en Análisis Bioquímicos. HULP



Jesús Molano Mateos
Jefe de Sección. HULP

María Ángeles Mori Álvarez
Bioquímico Adjunto. HULP

Julián Nevado Blanco
Biólogo. HULP

María Palomares Bralo
Bióloga. HULP

María Sol Pérez Coto
Técnico de Laboratorio. HULP

Teresa Ramos Álvarez
Enfermera. HULP

Sonia María Rodríguez Novoa
Facultativo Especialista de Área. Responsable del Laboratorio de Genética de las Enfermedades Metabólicas. HULP

Víctor Luis Ruiz Pérez
Investigador Postdoctoral. IIB "Alberto Sols"

Carmen Sánchez Gómez
Técnico de Laboratorio. HULP

Fernando Santos Simarro
Médico Adjunto de Pediatría. HULP

Juan Carlos Silla Castro
Bioinformático de Sistemas. HULP

Jesús Solera García
Facultativo Especialista de Área en Análisis Bioquímicos. HULP

Constanza Solís Villa
Farmacéutica Adjunta. HULP

María Luisa de Torres Perezhidalgo
Bióloga Adjunta. HULP

Strategic Objective

This is a clinical and basic research team that conducts several lines of research into early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects.

It is a heterogeneous group consisting of physicians, pharmacists, molecular biologists, bioinformaticians, technicians and administrative officers.

Research Lines

- Subtelomeric rearrangements in patients with idiopathic mental retardation.
- Genetic and functional analysis of the SHOX and SHOX2 genes in human growth.
- Overgrowth syndrom. Clinical and molecular analysis.
- Genetic aspects of harmonic short stature.
- Genetic aspects of monogenic diabetes mellitus.
- Genetics of the GH/rel axis in infantile onset obesity.
- SNPs arrays in pharmacogenetics of HIV patients.
- CGH arrays and genomic rearrangements in patients with congenital malformations, intellectual disability and tumours.
- Molecular genetics of hypertrophic cardiomyopathy.
- Functional analysis of CLCN1 mutations in congenital myotonia.

- Molecular study of endothelial dysfunction in diabetes and ageing.
- Molecular characterization of the 22q11.2 region by MLPA, microsatélites and FISH
- Pharmacogenetics and pharmacogenomics.
- Autosomal recessive osteogenesis imperfecta.
- Genomic tools for diagnosis: BAC, oligos and SNP arrays.
- Macrocephaly-capillary malformations and syndromes with macrocephaly.
- Next generation sequencing as a new tool in the diagnosis of genetic diseases.
- Dravet syndrome.

Research Activity

PUBLICATIONS

- Barraza-García J, Rivera-Pedroza CI, Belinchón A, Fernández-Cambor C, Valenciano-Fuente B, Lapunzina P, Heath KE. A novel SMARCAL1 missense mutation that affects splicing in a severely affected Schimke immunosseous dysplasia patient. *Eur J Med Genet.* 2016;59(8):363-6. Article. IF: 2.137; Q3
- Barraza-García J, Rivera-Pedroza CI, Salamanca L, Belinchón A, López-González V, Sentchordi-Montane L, del Pozo A, Santos-Simarro F, Campos-Barros A, Lapunzina P, Guillén-Navarro E, González-Casado I, García-Miñaur S, Heath KE. Two Novel POC1A Mutations in the primordial Dwarfism, SOFT syndrome: clinical homogeneity but also unreported malformations. *Am J Med Genet A.* 2016;170(1):210-6. Article. IF: 2.259; Q3
- Eggermann K, Bliet J, Brioude F, Algar E, Buiting K, Russo S, Tumer Z, Monk D, Moore G, Antoniadi T, Macdonald F, Netchine I, Lombardi P, Soellner L, Begemann M, Prawitt D, Maher ER, Mannens M, Riccio A, Weksberg R, Lapunzina P, Gronskov K, Mackay DJG, Eggermann T. EMQN best practice guidelines for the molecular genetic testing and reporting of chromosome 11p15 imprinting disorders: Silver-Russell and Beckwith-Wiedemann syndrome. *Eur J Hum Genet.* 2016;24(10):1377-87. Article. IF: 4.287; Q1
- Eggermann T, Brioude F, Russo S, Lombardi MP, Bliet J, Maher ER, Larizza L, Prawitt D, Netchine I, Gonzales M, Gronskov K, Tumer Z, Monk D, Mannens M, Chrzanowska K, Walasek MK, Begemann M, Soellner L, Eggermann K, Tenorio J, Nevado J, Moore GE, Mackay DJG, Temple K, Gillissen-Kaesbach G, Ogata T, Weksberg R, Algar E, Lapunzina P. Prenatal molecular testing for Beckwith-Wiedemann and Silver-Russell syndromes: a challenge for molecular analysis and genetic counseling. *Eur J Hum Genet.* 2016;24(6):784-93. Review. IF: 4.287; Q1
- Fergelot P, Van Belzen M, Van Gils J, Afenjar A, Armour CM, Arveiler B, Beets L, Burglen L, Busa T, Collet M, Deforges J, de Vries BBA, Garrido ED, Dorison N, Dupont J, Francannet C, García-Miñaur S, Vila EG, Gebre-Medhin S, Querol BG, Genevieve D, Gerard M, Gervasini CG, Goldenberg A, Josifova D, Lachlan K, Maas S, Maranda B, Moilanen JS, Nordgren A, Parent P, Rankin J, Reardon W, Rio M, Roume J, Shaw A, Smigiel R, Sojo A, Solomon B, Stembalska A, Stumpel C, Suarez F, Terhal P, Thomas S, Touraine R, Verloes A, Vincent-Delorme C, Wincent J, Peters DJM, Bartsch O, Larizza L, Lacombe D, Hennekam RC. Phenotype and genotype in 52 patients with rubinstein-taybi syndrome caused by EP300 mutations. *Am J Med Genet A.* 2016;170(12):3069-82. Article. IF: 2.259; Q3
- Grinspon RP, Nevado J, Álvarez MDM, del Rey G, Castera R, Venara M, Chiesa A, Podesta M, Lapunzina P, Rey RA. 46,XX ovotesticular DSD associated with a SOX3 gene duplication in a SRY-negative boy. *Clin Endocrinol.* 2016;85(4):673-5. Letter. IF: 3.327; Q2
- Haghighi A, Kavehmanesh Z, Haghighi A, Salehzadeh F, Santos-Simarro F, Van Maldergem L, Cimbalistiene L, Collins F, Chopra M, Al-Sinani S, Dastmalchian S, de Silva DC, Bakhti H, Garg A, Hilbert P. Congenital generalized lipodystrophy: identification of novel variants and expansion of clinical spectrum. *Clin Genet.* 2016;89(4):434-41. Article. IF: 3.326; Q2
- Macatangga M, de la Calle M, Torres ML, Bartha JL. Monozygotic monochorionic twins discordant for trisomy 21: A reason to evaluate both fetuses a case report. *J Reprod Med.* 2016;61(42828):167-70. Article. IF: 0.848; Q4
- Martínez-Payo C, García M, Mansilla E, de Azua Ballesteros M, Ruiz, Lapunzina P, Pérez Medina T. EP09.08: Sonographic findings in fetuses affected by microdeletion 17q21.31. *Ultrasound Obstet Gynecol.* 2016;48 Suppl 1:300. Article. IF: 4.71; D1
- Montane LS, Marín OR, Rivera-Pedroza CI, Vallespín E, del Pozo A, Heath KE. Early severe scoliosis in a patient with atypical progressive pseudoreumatoid dysplasia (PPD): identification of two WISP3 mutations, one previously unreported. *Am J Med Genet A.* 2016;170(6):1595-9. Article. IF: 2.259; Q3
- Navas P, Tenorio J, Quezada CA, Barrios E, Gordo G, Arias P, Meseguer ML, Santos-Lozano A, Doza JP, Lapunzina P, Subias PE. Molecular analysis of BMP2, TBX4, and KCNK3 and genotype-phenotype correlations in Spanish patients and families with idiopathic and hereditary pulmonary arterial hypertension. *Rev Esp Cardiol.* 2016;69(11):1011-9. Article. IF: 4.485; Q2
- Noguera-Morel L, Feito-Rodríguez M, Maldonado-Cid P, García-Miñaur S, Kamsteeg EJ, González-Sarmiento R, de Lucas-Laguna R, Hernández-Martín A, Torrelo A. Two cases of autosomal recessive congenital ichthyosis due to CYP4F2 mutations: expanding the genotype of self-healing collodion baby. *Pediatr Dermatol.* 2016;33(2):E48-51. Article. IF: 0.99; Q4
- Pampols T, Ramos FJ, Lapunzina P, Gozalo-Salellas I, Pérez-Jurado LA, Pujol A. A view on clinical genetics and genomics in Spain: of challenges and opportunities. *Mol Genet Genomic Med.* 2016;4(4):376-91. Article. Not Indexed
- Riancho-Zarrabeitia L, García-Unzueta M, Tenorio JA, Gómez-Gerique JA, Pérez-VLR, Heath KE, Lapunzina P, Riancho JA. Clinical, biochemical and genetic spectrum of low alkaline phosphatase levels in adults. *Eur J Intern Med.* 2016;29:40-5. Article. IF: 2.96; Q1
- Salas PC, Fernández L, Vela M, Bueno D, González B, Valentín J, Lapunzina P, Pérez-Martínez A. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. *Pediatr Hematol Oncol.* 2016;33(42954):415-22. Article. IF: 1.12; Q3
- Sánchez-Delgado M, Riccio A, Eggermann T, Maher ER, Lapunzina P, MacKay D, Monk D. Causes and consequences of multi-locus imprinting disturbances in humans. *Trends Genet.* 2016;32(7):444-55. Review. IF: 10.844; D1
- Sánchez-Soler MJ, Tenorio J, García-Miñaur S, Santos-Simarro F, Lapunzina P. Overgrowth syndromes and development of embryonic tumours: A review of cases in the last 5 years. *An Pediatr.* 2016;85(2):104-5. Letter. IF: 1.14; Q3
- Scheps KG, Francipane L, Nevado J, Basack N, Attie M, Bergonzi MF, Cerrone GE, Lapunzina P, Varela V. Cover Image, Volume 170A, Number 4, April 2016. *Am J Med Genet A.* 2016;170(4):i. Article. IF: 2.259; Q3
- Scheps KG, Francipane L, Nevado J, Basack N, Attie M, Bergonzi MF, Cerrone GE, Lapunzina P, Varela V. Multiple copy number variants in a pediatric patient with Hb H disease and intellectual disability. *Am J Med Genet A.* 2016;170(4):986-91. Article. IF: 2.259; Q3

- Suter AA, Itin P, Heinemann K, Ahmed M, Ashraf T, Fryssira H, Kini U, Lapunzina P, Miny P, Sommerlund M, Suri M, Vaeth S, Vasudevan P, Gallati S. Rothmund-Thomson syndrome: novel pathogenic mutations and frequencies of variants in the RECQL4 and USB1 (C16orf57) gene. *Mol Genet Genomic Med.* 2016;4(3):359-66. Article. Not Indexed
- Szafranski P, Gambin T, Dharmadhikari AV, Akdemir KC, Jhangiani SN, Schuette J, Godiwala N, Yatsenko SA, Sebastian J, Madan-Khetarpal S, Surti U, Abellar RG, Bateman DA, Wilson AL, Markham MH, Slamon J, Santos-Simarro F, Palomares M, Nevado J, Lapunzina P, Chung BHY, Wong WL, Chu YWY, Mok GTK, Ke-rem E, Reiter J, Ambalavanan N, Anderson SA, Kelly DR, Shieh J, Rosenthal TC, Scheible K, Steiner L, Iqbal MA, McKinnon ML, Hamilton SJ, Schlade-Bartusiak K, English D, Henderson G, Roeder ER, DeNapoli TS, Littlejohn RO, Wolff DJ, Wagner CL, Yeung A, Francis D, Fiorino EK, Edelman M, Fox J, Hayes DA, Janssens S, De Baere E, Menten B, Loccufier A, Vanwalleghem L, Moerman P, Sznajer Y, Lay AS, Kussmann JL, Chawla J, Payton DJ, Phillips GE, Brosens E, Tibboel D, de Klein A, Maystadt I, Fisher R, Sebire N, Male A, Chopra M, Pinner J, Malcolm G, Peters G, Arbuckle S, Lees M, Mead Z, Quarrell O, Sayers R, Owens M, Shaw-Smith C, Lioy J, McKay E, de Leeuw N, Feenstra I, Spruijt L, Elmslie F, Thiruchelvam T, Bacino CA, Langston C, Lupski JR, Sen P, Popek E, Stankiewicz P. Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins. *Hum Genet.* 2016;135(5):569-86. Article. IF: 4.637; Q1
- Tenorio J, Romanelli V, Martín-Trujillo A, Fernández GM, Segovia M, Perandones C, Jurado LAP, Esteller M, Fraga M, Arias P, Gordo G, Dapia I, Mena R, Palomares M, de Nanclares GP, Nevado J, García-Miñaur S, Santos-Simarro F, Martínez-Glez V, Vallespín E, Monk D, Lapunzina P. Clinical and molecular analysis of Beckwith-Wiedemann syndrome: Comparison between spontaneous conception and assisted reproduction techniques. *Am J Med Genet A.* 2016;170(10):2740-9. Article. IF: 2.259; Q3
- Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A, Yokozawa M, Suzumura H, Nakahara A, Nakano Y, Hokosaki T, Ohmori A, Sawada H, Migita O, Mima A, Lapunzina P, Santos-Simarro F, García-Miñaur S, Ogata T, Kawame H, Kurosawa K, Ohashi H, Inoue SI, Matsubara Y, Kure S, Aoki Y. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. *Hum Genet.* 2016;135(2):209-22. Article. IF: 4.637; Q1

PUBLIC PROJECTS

Barroso Ramos E. Identificación de nuevos genes responsables del Síndrome de Dravet y de espectros asociados de encefalopatías epilépticas febriles (PI14/01753). ISCIII. 2015-2017.

Management centre: FIBHULP

Campos Barros A. Aplicación de nuevas estrategias de análisis genómico a la identificación de los determinantes genéticos de la deficiencia idiopática de GH y deficiencia primaria de IGF-I en hipocrecimiento (PI12/00649). ISCIII. 2013-2016.

Management centre: FIBHULP

Campos Barros A. Miguel Servet stabilisation contracts (12). ISCIII/CAM. 2008-Ongoing.

Management centre: FIBHULP

Dapia García I. Contrato de garantía juvenil (PEJ15/BIO/AI-0222). CAM. 2016-2018.

Management centre: FIBHULP



Fernández Elvira M. Contrato de garantía juvenil (PEJ15/BIO/TL-0158). CAM. 2016-2018.

Management centre: FIBHULP

García Santiago FA. Desarrollo de la detección de aneuploidias fetales en sangre materna mediante secuenciación masiva (PI13/01964). ISCIII. 2014-2017.

Management centre: FIBHULP

Heath KE. Ramón y Cajal stabilisation contracts (I3). CAM. 2009-Ongoing.

Management centre: FIBHULP

Heath KE. Identificación y caracterización funcional de nuevos genes y loci genómicos implicados en displasias esqueléticas (SAF2015-66831-R). MINECO. 2016-2017.

Management centre: FIBHULP

Lapunzina Badía PD. Búsqueda de nuevos genes y nuevas patologías mediante la aplicación de secuenciación masiva en una cohorte de pacientes con síndromes de sobrecrecimiento bien caracterizados clínicamente (PI15/01481). ISCIII. 2016-2018.

Management centre: FIBHULP

Lobato Vidal N. Contrato de garantía juvenil (PEJ15/BIO/AI-0286). CAM. 2016-2018.

Management centre: FIBHULP

Palomares Bralo M. Secuenciación del exoma para el diagnóstico de niños con trastorno del desarrollo neurológico o discapacidad intelectual severa-moderada (PI13/02010). ISCIII. 2014-2017.

Management centre: FIBHULP

Rodríguez Novoa S. Diagnóstico genético de hipercolesterolemia familiar mediante next generation sequencing: estudio funcional de nuevas variantes. Transcriptómica y miRNAs y su impacto en el fenotipo (PI15/00122). ISCIII. 2016-2018.

Management centre: FIBHULP

Santos Simarro F. Clinical characterization and molecular genetic analysis of the baf complex related syndromes (PI14/01922). ISCIII. 2015-2017.

Management centre: FIBHULP

Vallespín García E. Aplicación de un protocolo diagnóstico basado en secuenciación masiva (Cardiomasseq) para malformaciones cardíacas congénitas en la rutina clínica (PI13/01450). ISCIII. 2014-2016.

Management centre: FIBHULP

PRIVATE PROJECTS

Campos Barros A. Análisis genético de la deficiencia idiopática de GH y deficiencia primaria de IGF-1 en talla baja. Ipsen Pharma SPS. 2012-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Estudios citogenéticos y moleculares en población con enfermedades de base genética en el Hospital La Paz. Agilent Technologies Spain S.L. 2007-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el Síndrome de Sotos: evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes

candidatos mediante secuenciación masiva de nueva generación en pacientes negativos para NSD1 PI-1543. Asociación Española del Síndrome de Sotos. 2013-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Análisis genético y genómico en pacientes afectados por la enfermedad de Gorham-Stout y por anomalías generales. Lymphatic Malformation Institute. 2012-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el Síndrome de Invdupdel(8p): evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. ASDID. 2015-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Análisis mutacional del gen SCNA1 en pacientes con diagnóstico clínico de Síndrome de Dravet. Abyntek Biopharma S.L. 2011.

Management centre: FIBHULP

Lapunzina Badía PD. Investigar y desarrollar un sistema diagnóstico rápido y eficaz de las patologías de origen genético. Construcción de un centro de excelencia de investigación en bioinformática que permita el desarrollo de la tecnología en proyectos de investigación que m. Dravet Syndrome Foundation (Delegación En España). 2012-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Investigar y desarrollar un sistema diagnóstico rápido y eficaz de las patologías de origen genético. Construcción de un centro de excelencia de investigación en bioinformática que permita el desarrollo de la tecnología en proyectos de investigación que mediante la implantación de sistemas de secuenciación de nueva generación que permita proporcionar diagnóstico avanzado a las patologías genéticas. CAM. 2013-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Análisis global de la hipofosfatasa: evaluación de la dosis genómica mediante MLPA y estudio del gen ALPL en pacientes con sospecha clínica. Alexion Pharma Spain S.L. 2014-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Organización jornadas de investigación: XXVII Congreso nacional de la Asociación Española de Genética humana. Tilesa Kenes Spain S.L. 2013-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Estudio genético-molecular de genes candidatos en pacientes con hipertensión pulmonar idiopática. Actelion Pharmaceuticals España. 2011-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Patrocinio Jornadas de DNA day. Varios. 2012-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Estudio clínico molecular en pacientes con Síndrome de Sobrecrecimiento (SSC). Estudio de los genes NSD1, NIZPI, HRAS, CDKN1C, GKP3, y de las regiones cromosómicas 5Q35, XQ26 y 11Q en pacientes con SSC. Effic Services para la Investigación S.L. 2005-Ongoing.

Management centre: FIBHULP

Lapunzina Badía PD. Determinación genómica de muestras del biomarcador del gen KRAS y NRAS. Amgen S.A. 2014-Ongoing.

Management centre: FIBHULP

Solera García J. Estudio de microRNAs en pacientes con glucogenosis tipo II (enfermedad de Pompe) como marcadores de diagnóstico, progresión de la enfermedad y respuesta al tratamiento. Fundación Genzyme. 2013-Ongoing.

Management centre: FIBHULP


PATENTS AND TRADEMARKS

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM Instituto de Genética Médica y Molecular del Hospital Universitario La Paz; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: MetaboArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.



Palomares M, Lapunzina P, Nevado J, Vallespín E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



Lapunzina P, Nevado J, Solera J, Vallespín E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.



Moreno JC, Moya CM, Vallespín E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.





TRANSLATIONAL ONCOLOGY GROUP



Publications: **29**
 Impact Factor: **214.391**
 QI: **13**

Jaime Feliú Batlle

Jaime Feliú Batlle

Jorge Barriuso Feijó

Facultativo Especialista de Área en Oncología. HULP

Borja Belandía Gómez

Científico Titular. IIB "Alberto Sols"

Beatriz Castelo Fernández

Facultativo Especialista de Área en Oncología. HULP

Paloma Cejas Guerrero

Investigadora Postdoctoral. HULP

Roberto Crespo Martín

Técnico Superior en Anatomía Patológica. HULP

Ana Belén Custodio Carretero

Facultativo Especialista de Área en Oncología. HULP

Esther Díaz López

Técnico de Laboratorio. HULP

Enrique Espinosa Arranz

Facultativo Especialista de Área en Oncología. HULP

Profesor Asociado. UAM

Juan Ángel Fresno Vara

Investigador Senior (Contrato Miguel Servet - 12). Jefe de Laboratorio. HULP

Ángelo Gámez Pozo

Investigador Postdoctoral (Contrato Técnico de Apoyo). HULP

Ismael Ghanem Cañete

Médico Adjunto en Oncología Médica. HULP

Juan Carlos Lacal Sanjuán

Profesor de Investigación. IIB "Alberto Sols"

Rocío López Vacas

Técnico de Laboratorio (Contrato Técnico de Apoyo). HULP

Virginia Martínez Marín

Facultativo Especialista de Área en Oncología. HULP

Víctor Moreno García

Facultativo Especialista de Área en Oncología. HULP

Juan Moreno Rubio

Investigador Postdoctoral. HULP

Ignacio Palmero Rodríguez

Científico Titular. IIB "Alberto Sols"

Álvaro Pinto Marín

Facultativo Especialista de Área en Oncología. HULP

Andrés Redondo Sánchez

Facultativo Especialista de Área en Oncología. HULP

Profesor Asociado. UAM

Nuria Rodríguez Salas

Facultativo Especialista de Área en Oncología. HULP

Pilar Zamora Auñón

Facultativo Especialista de Área en Oncología. HULP

Profesor Asociado. UAM

Strategic Objective

The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis.

Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in health-care takes too much time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.

The Translational Oncology group's objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians.

The main lines of study are based on tumours with the greatest incidence and impact on survival, such as lung, colorectal, breast and ovarian cancer, although other types of neoplasms have been incorporated such as gastric and renal cancer. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour.

Research Lines

- Identification of prognostic factors Clinical Genomic Proteomic.
- Identification of mechanisms of resistance to drugs.
- Efficacy and toxicity of antineoplastic therapies.
- Palliative care and supportive treatments.

Research Activity

DOCTORAL THESES

de Velasco Oria de Rueda G. Análisis de un perfil de microARNs como factor pronóstico en cáncer de mama con afectación axilar [dissertation]. Madrid: UCM 2016(14/04/2016).

Directors: Fresno Vara JA, Ciruelos Gil E, Paz-Ares L.

BOOKS AND BOOK CHAPTERS

Higuera O, Cruz P, Feliú J. Visión actual del cáncer. In: C. Gómez-Candela, S. Palma, S. Coral, P. Riobó, P. Robledo. Alimentación, Nutrición y Cáncer: prevención y tratamiento. Madrid: UNED, 2016.

PUBLICATIONS

- Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, Gil J, Moreno-Bueno G, Palmero I. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. *Oncogene*. 2016;35(27):3485-94. Article. IF: 7.519; D1
- Almagro E, González CS, Espinosa E. Prognostic factors of early breast cancer. *Med Clin-Barcelona*. 2016;146(4):167-71. Review. IF: 1.125; Q3
- Arance AM, Berrocal A, López-Martín JA, de la Cruz-Merino L, Soriano V, Algarra SM, Alonso L, Cerezuela P, la Orden B, Espinosa E. Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience. *Clin Transl Oncol*. 2016;18(11):1147-57. Article. IF: 2.353; Q3

- Bargiela-Iparraguirre J, Prado-Marchal L, Fernández-Fuente M, Gutiérrez-González A, Moreno-Rubio J, Muñoz-Fernández M, Sereno M, Sánchez-Prieto R, Perona R, Sánchez-Pérez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. *Sci Rep-Uk*. 2016;6:21519. Article. IF: 4.259; Q1
- Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JEL, García TG, Mancenido FA, Lacalle A, Cardona MF, Mangas M, Visa L, Buxo E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a National Cancer Registry. *J Natl Compr Canc Ne*. 2016;14(11):1379-88. Article. IF: 4.675; Q2
- Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CSW, Mendiola M, Burgos E, Feliú J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. *Nat Med*. 2016;22(6):685-91. Article. IF: 29.886; D1
- Espinosa E, Soriano V, Malvey J, Berrocal A, de Prado PM, Quindos M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puertolas T, Díaz-Beveridge R, de la Cruz-Merino L, Castro RL, López RL, Stevinson K, del Barrio P, Tornamira MV, Guillem V, Martín-Algarra S. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. *Melanoma Res*. 2016;26(3):278-83. Article. IF: 2.615; Q2
- Feliú J, de Corcuera ID, Manzano JL, Valladares-Ayerbes M, Alcaide J, García TG, Vera R, Sastre J. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. *Clin Transl Oncol*. 2017;19(4):498-507. Review. IF: 2.353; Q3
- Forner A, Reig M, Varela M, Burrel M, Feliú J, Briceno J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JL, Sangro B, Pardo F, Ayuso C, Bru C, Taberner J, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. *Med Clin-Barcelona*. 2016;146(11):511.e1-511.e22. Article. IF: 1.125; Q3
- García-Alfonso P, Feliú J, García-Carbonero R, Grávalos C, Guillén-Ponce C, Sastre J, García-Foncillas J. Isregorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? *Clin Transl Oncol*. 2016;18(11):1072-81. Review. IF: 2.353; Q3
- Gayarre J, Kamiński MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Cajal TRY, Hernández-Agudo E, Soto VH, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusido M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. *J Gynecol Oncol*. 2016;27(1):e7. Article. IF: 3.14; Q1
- González-Martín A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramenda JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JA, de la Haba J, López R, López-Vivanco G, Martínez-Janez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure A, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MA, Tusquets I, Zamora P, Martín M. Nab-paclitaxel in metastatic breast cancer: Defining the best patient profile. *Curr Cancer Drug Tar*. 2016;16(5):415-28. Article. IF: 2.992; Q3
- Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliú J. Management of pancreatic cancer in the elderly. *World J Gastroenterol*. 2016;22(2):764-75. Article. IF: 3.365; Q2



- Laimito KR, Gámez-Pozo A, Sepulveda J, Manso L, López-Vacas R, Pascual T, Vara JAF, Ciruelos E. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. *Ecantermedicals-cience*. 2016;10:632. Article. Not Indexed
 - Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. *Crit Rev Oncol Hemat*. 2016;105:65-72. Review. IF: 4.971; Q1
 - López-Gómez M, Casado E, Muñoz M, Alcalá S, Moreno-Rubio J, D'Errico G, Jiménez-Gordo AM, Salinas S, Sainz B. Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives. *Crit Rev Oncol Hemat*. 2016;107:54-71. Review. IF: 4.971; Q1
 - Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. *Clin Transl Oncol*. 2016;18(10):1044-50. Article. IF: 2.353; Q3
 - Martín-Broto J, Pousa AL, de las Penas R, del Muro XG, Gutiérrez A, Martínez-Trufero J, Cruz J, Álvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martín JA, Sala A, Meana JA, Ramos R, Martínez-Serra J, López-Guerrero JA, Sevilla I, Balana C, Vaz A, de Juan A, Alemany R, Poveda A. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A Spanish group for research on sarcoma study. *J Clin Oncol*. 2016;34(19):2294-302. Article. IF: 24.008; D1
 - Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, Velasco-Martín JP, Orozco RM, Luengo E, Martín RG, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. *P Natl Acad Sci Usa*. 2016;113(3):E328-37. Article. IF: 9.661; D1
 - Martínez-Jánez N, Chacón I, de Juan A, Cruz-Merino L, del Barco S, Fernández I, García-Tejido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 therapy beyond second-line for HER2-positive metastatic breast cancer: A short review and recommendations for several clinical scenarios from a Spanish expert panel. *Breast Care*. 2016;11(2):133-8. Article. IF: 1.553; Q3
 - Martín-Richard M, Beveridge RD, Arrazubi V, Alsina M, Guzmán MG, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). *Clin Transl Oncol*. 2016;18(12):1179-86. Article. IF: 2.353; Q3
 - Maurel J, López-Pousa A, Calabuig S, Bague S, del Muro XG, Sanjuan X, Rubio-Casadevall J, Cuatrecasas M, Martínez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Láinez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E. Phosphorylated-insulin growth factor 1 receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST): A GEIS 19 study. *Clin Sarcoma Res*. 2016;6:10. Article. Not Indexed
 - Mendiola M, Martínez-Marín V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto A, Miguel M, Díaz E, Gámez A, Fresno JA, de Molina AR, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. *Oncotarget*. 2016;7(17):24217-27. Article. IF: 5.168; Q1
 - Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balseg JR, Agarwal S, Matulonis UA. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *New Engl J Med*. 2016;375(22):2154-64. Article. IF: 72.406; D1
 - Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma HJ, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. *Gynecol Oncol*. 2016;143(1):27-34. Article. IF: 4.959; D1
 - Pinto A, Segura PP. Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM). *Eur J Cancer Prev*. 2016;25(2):137-41. Review. IF: 2.556; Q3
 - Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Láinez N, Martínez J, Redondo A, Romero I. SEOM clinical guideline in ovarian cancer (2016). *Clin Transl Oncol*. 2016;18(12):1206-12. Article. IF: 2.353; Q3
 - Shi JJ, Zhang YF, Zheng W, Michailidou K, Ghousaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao ZG, Guo XY, Benitez J, Beeghly-Fadiel A, Blot WJ, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Brueining T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dork T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guenel P, Haiman CA, Hamann U, Hartman M, Miao H, Hollestelle A, Hopper JL, Hsiung CN, Investigators K, Ito H, Jakubowska A, Johnson N, Torres D, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Li JM, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Matsuo K, McLean C, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Borresen-Dale AL, Olson JE, Orr N, van den Ouweland AMW, Peterlongo P, Putti TC, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Hou MF, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Toland AE, Tollenaar RAEM, Tomlinson I, Truong T, Tseng CC, Ven WQ, Winquist R, Wu AH, Yip CH, Zamora PM, Zheng Y, Floris G, Cheng CY, Hooning MJ, Martens JWM, Seynaeve C, Kristensen VN, Hall P, Pharoah PDP, Simard J, Chenevix-Trench G, Dunning AM, Antoniou AC, Easton DF, Cai QY, Long JR. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *Int J Cancer*. 2016;139(6):1303-17. Article. IF: 6.513; Q1
 - Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, de Miguel M, Martín-Hernández R, Reglero G, Feliú J, de Molina AR. 3' UTR Polymorphism in ACSL1 gene correlates with expression levels and poor clinical outcome in colon cancer patients. *Plos One*. 2016;11(10):e0168423. Article. IF: 2.806; Q1
 - Vera R, Dotor E, Feliú J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM clinical guideline for the treatment of pancreatic cancer (2016). *Clin Transl Oncol*. 2016;18(12):1172-8. Article. IF: 2.353; Q3
- recurrent ovarian cancer.** *New Engl J Med*. 2016;375(22):2154-64. Article. IF: 72.406; D1
- Management centre:** Fundación Instituto de Estudios de Ciencias

PUBLIC PROJECTS

Álvarez Castelao B. Análisis mutacional en cáncer epidermoide de cabeza y cuello. Implicaciones pronósticas y predictivas de respuesta en el ensayo clínico fase III TTCC (PI14/00071). ISCI. 2015-2017.

Management centre: Fundación Instituto de Estudios de Ciencias

Cejas Guerrero P. Nuevos mecanismos de regulación epigenética de la expresión implicados en la respuesta a los esquemas de quimioterapia en cáncer colorrectal (PI13/01818). ISCI. 2014-2017.

Management centre: FIBHULP

Espinosa Arranz E. Alimentos funcionales y estrategias nutricionales eficaces para la prevención y tratamiento de enfermedades crónicas (S2013/ABI-2728-ALIBIRD). CAM. 2014-2018.

Management centre: FIBHULP

Feliú Batlle J. Análisis de biomarcadores relacionados con la eficacia de las terapias dirigidas al cáncer colorectal (PI13/01659). ISCI. 2014-2017.

Management centre: FIBHULP

Fresno Vara JA. Caracterización molecular del cáncer de mama triple negativo (PI12/00444). ISCI. 2013-2017.

Management centre: FIBHULP

Fresno Vara JA. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente de cáncer de mama (PI15/01310). ISCI. 2016-2018.

Management centre: FIBHULP

Fresno Vara JA. Miguel Servet stabilisation contracts (I2). ISCI, CAM. 2012-Ongoing.

Management centre: FIBHULP

PRIVATE PROJECTS

Barriuso Feijó J. Estudio de biomarcadores predictores de resistencia a fármacos antiangiogénicos e inhibidores de mTOR en tumores neuroendocrinos gastro-enteropancreáticos. Fundación Eugenio Rodríguez Pascual. 2013-Ongoing.

Management centre: FIBHULP

Barriuso Feijó J. Puesta a punto de la técnica de PCR cuantitativa y determinación de grupos de genes que permitirán el desarrollo del conocimiento de los tumores neuroendocrinos pancreáticos. Pfizer S.L.U. 2012-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Promover la actividad investigadora en el Servicio de Oncología. Amgen S.A. 2010-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. 2ª Jornada de debates fármaco-económicos en Oncología e investigación. Astellas Pharma S.A. 2015-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Jornadas científicas sobre Investigación y actualización en Oncología. Astrazeneca Farmacéutica Spain S.A. 2016-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Implicaciones clínicas y terapéuticas de la expresión génica diferencial de las células madre tumorales procedentes de carcinomas de colon en estadios operables. Cephalon Pharma S.L.U. 2008-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Estudio de factores predictivos de toxicidad grave (grado 3-4) en anciano. CAM. 2012-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Utilidad de la determinación del DNA circulante para monitorizar la respuesta al tratamiento neoadyuvante en los pacientes con cáncer de recto localmente avanzado. Fundación Salud 2000. 2014-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Actualización en oncología y nuevos retos en investigación. Janssen-Cilag España S.A. 2014-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Sesiones de formación en oncología clínica e investigación. Lilly S.A. 2016-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Jornadas investigación traslacional en oncología. Pfizer S.L.U. 2016-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. 3ª Jornada de debates fármaco-económicos en oncología. Roche Farma S.A. 2015-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. MTA: procesamiento y tratamiento de muestras. Varios. 2016-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Proyecto desarrollo de consulta de Psicología en el Hospital Universitario La Paz. Varios. 2012-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Caracterización molecular del cáncer de mama mediante taqman low density arrays: aplicación al diagnóstico. FUAM. 2014-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Aplicación de ensayos funcionales con minigenes como estrategia para determinar la implicación de variantes de significado desconocido en el desarrollo de cáncer hereditario. FMMA. 2012-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Extracción y análisis de la expresión de miRNA en 160 biopsias de cáncer renal embebidas en parafina y su correlación con la evaluación clínica de los pacientes. Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre. 2010-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Extracción y análisis de la expresión miRNA en biopsias de cáncer de mama embebidas en parafina y su correlación con la evolución clínica de los pacientes. Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre. 2012-Ongoing.

Management centre: FIBHULP

Ghanem I. Alteraciones genómicas en carcinoma escamoso de ano. Secuenciación del exoma completo. Grupo Español Multidisciplinar de Cáncer de Aparato Digestivo. 2014-Ongoing.

Management centre: Grupo Español Multidisciplinar de Cáncer de Aparato Digestivo

Martínez Marín V. Estudio perfil mutacional e inmunohistoquímico en GIST: búsqueda de factores pronósticos y predictivos. Grupo Español de Investigación en Sarcomas. 2013-Ongoing.

Management centre: FIBHULP



Pinto Marín A. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente con cáncer: el caso del cáncer de prostata metastásico. FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Redondo Sánchez A. Caracterización de la acción de trabectedina y análogos, lurbinectedina y análogos y PM60184 en modelos celulares en dos y tres dimensiones de carcinoma de ovario. Pharmamar S.A. 2016-Ongoing.

Management centre: FIBHULP

Redondo Sánchez A. Análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Roche Farma S.A. 2014-Ongoing.

Management centre: FIBHULP

Redondo Sánchez A. Cáncer de mama y angiogénesis: estudio de perfiles de expresión génica en muestras para-finadas. Roche Farma S.A. 2009-Ongoing.

Management centre: FIBHULP

Zamora Auñón P. VI Curso de investigación en diagnóstico y tratamiento del cáncer de mama. Roche Farma S.A. 2014-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Castelo Fernández B. Rifto mki - pacientes asintomáticos con cáncer diferenciado de tiroides refractario al yodo radioactivo? Estudio observacional para evaluar la utilización de inhibidores de multiquinasa. Bayer Hispania S.L.

HULP Code: 4413. Sponsored's Protocol Code: BAY-SOR-2014-01.

Signature Date: 22/06/2016

Castelo Fernández B. Ensayo clínico abierto, randomizado, multicéntrico fase Ib/3 de talimogene laherparepvec en combinación con pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Amgen S.A.

HULP Code: 4538. Sponsored's Protocol Code: 20130232.

Signature Date: 11/04/2016

Castelo Fernández B. Ensayo clínico de fase Ib/3 multicéntrico, aleatorizado, de talimogene laherparepvec en combinación con pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Amgen S.A.

HULP Code: Anexo-I 4538. Sponsored's Protocol Code: 20130232.

Signature Date: 7/11/2016

Castelo Fernández B. Estudio de fase Ib-II, abierto y de un solo grupo de iph2201 preoperatorio en pacientes con carcinoma epidermoide de la cavidad bucal localmente avanzado y resecable. Medpace Germany GmbH.

HULP Code: 4548. Sponsored's Protocol Code: IPH2201.

Signature Date: 2/3/2016

Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase 2 de lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a I31i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. EISAI Europe Limited.

HULP Code: 4588. Sponsored's Protocol Code: E7080-G000-211.

Signature Date: 14/4/2016

Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase 2 de lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a I31i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. EISAI Europe Limited.

HULP Code: Anexo-I 4588. Sponsored's Protocol Code: E7080-G000-211.

Signature Date: 22/7/2016

Castelo Fernández B. Estudio de fase III, aleatorizado, abierto, global, multicéntrico de monoterapia con medi4736 y medi4736 en combinación con tremelimumab frente a terapia con tratamiento habitual en pacientes con carcinoma de células escamosas de cabeza y cuello recidivante o metastásico (CCECC). Astrazeneca Ab.

HULP Code: 4653. Sponsored's Protocol Code: D4193C00002.

Signature Date: 15/6/2016

Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de sandostatin lar con axitinib vs sandostatin lar con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (OMS 2010) de origen no pancreático. Grupo Español de Tumores Neuroendocrinos.

HULP Code: Anexo-2 3398. Sponsored's Protocol Code: AXI-IIG-02.

Signature Date: 15/2/2016

Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de sandostatin lar con axitinib vs sandostatin lar con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (OMS 2010) de origen no pancreático. Grupo Español de Tumores Neuroendocrinos.

HULP Code: Anexo-3 3398. Sponsored's Protocol Code: AXI-IIG-02.

Signature Date: 20/7/2016

Custodio Carretero AB. Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de pembrolizumab en monoterapia y en combinación con cisplatino + 5-fluorouracilo frente a placebo + cisplatino + 5-fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado. Merck Sharp & Dhome Corp.

HULP Code: 4689. Sponsored's Protocol Code: 3475-062.

Signature Date: 22/9/2016

Custodio Carretero AB. Ensayo en fase III, abierto y multicéntrico del avelumab (msb0010718c) como tratamiento de tercera línea del adenocarcinoma de la unión gastroesofágica o gástrico, metastásico, recurrente o irrecable. Merck Kgaa.

HULP Code: 4704. Sponsored's Protocol Code: EMRI00070-008.

Signature Date: 27/9/2016

Custodio Carretero AB. Evaluación de la respuesta radiológica de los tumores neuroendocrinos pancreáticos: comparación de los criterios choi y recist. Grupo Español de Tumores Neuroendocrinos.

HULP Code: PI-2406. Sponsored's Protocol Code: GET-SUN-2015-01.

Signature Date: 30/5/2016

Espinosa Arranz E. Ensayo clínico abierto, multicéntrico, no aleatorizado en fase II para evaluar la eficacia de nivolumab en combinación con ipilimumab en pacientes con melanoma uveal metastásico no tratados previamente. Grupo Español Multidisciplinar de Melanoma.

HULP Code: 4655. Sponsored's Protocol Code: GEM 1402.

Signature Date: 23/2/2016

Espinosa Arranz E. Estudio de extensión (transferencia) abierto de vemurafenib en pacientes con neoplasia maligna con la mutación brafv600 incluidos previamente en un protocolo anterior de vemurafenib. F.Hoffmann-La Roche Ltd.

HULP Code: Anexo-II 3871. Sponsored's Protocol Code: GO28399.

Signature Date: 01/3/2016

Espinosa Arranz E. Ensayo de fase Ib/3 multicéntrico de talimogene laherparepvec en combinación con pembrolizumab (mk-3475) para el tratamiento del melanoma en estadio IIIb a ivm1c no resecable (masterkey-265. Amgen, S.A.)

HULP Code: 4636. Sponsored's Protocol Code: 20110265.

Signature Date: 12/5/2016

Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de bruton, ibrutinib, en combinación con nab-paclitaxel y gemcitabina frente a placebo en combinación con nab-paclitaxel y gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Pharmacyclis Llc.

HULP Code: 4502. Sponsored's Protocol Code: PCYC-1137-CA.

Signature Date: 20/1/2016

Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de bruton, ibrutinib, en combinación con nab-paclitaxel y gemcitabina frente a placebo en combinación con nab-paclitaxel y gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Pharmacyclis Llc.

HULP Code: Anexo-I 4502. Sponsored's Protocol Code: PCYC-1137-CA.

Signature Date: 3/5/2016

Feliú Batlle J. Estudio de fase III aleatorizado y doble ciego para evaluar el uso de tas-102 más el mejor tratamiento sintomático frente a placebo más el mejor tratamiento sintomático en pacientes con cáncer gástrico metastásico resistente a los tratamientos de referencia. Taiho Oncology Usa Inc.

HULP Code: 4549. Sponsored's Protocol Code: TO-TAS-102-302.

Signature Date: 7/4/2016

Feliú Batlle J. Elección de terapias personalizadas en pacientes con carcinoma de páncreas metastásico de acuerdo al análisis genético del tumor y al modelo avatar. Fundación Centro Nacional de Investigaciones Oncológicas Carlos III.

HULP Code: 4607. Sponsored's Protocol Code: ERCAVATAR2015.

Signature Date: 12/5/2016

Feliú Batlle J. Estudio en fase Ib/2 del tratamiento combinado con ibrutinib en tumores gastrointestinales y ge-

nitourinarios avanzados seleccionados. Pharmacyclis Llc.

HULP Code: 4630. Sponsored's Protocol Code: PCYC-1128-CA.

Signature Date: 2/6/2016

Feliú Batlle J. Ensayo de fase III, multicéntrico y no enmascarado sobre el tratamiento de mantenimiento con avelumab (msb0010718c) frente a la continuación de la quimioterapia de primera línea en sujetos con un adenocarcinoma gástrico, o de la zona de unión gastroesofágica, irrecable, localmente avanzado o metastásico. Merck Kgaa.

HULP Code: 4643. Sponsored's Protocol Code: EMRI00070-007.

Signature Date: 20/9/2016

Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de gs-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Gilead Sciences Inc.

HULP Code: 4569. Sponsored's Protocol Code: GS-US-296-1080.

Signature Date: 15/3/2016

Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de GS-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Gilead Sciences Inc.

HULP Code: Anexo-I 4569. Sponsored's Protocol Code: GS-US-296-1080.

Signature Date: 30/8/2016

Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego, sobre el inhibidor jak1/2, ruxolitinib o placebo combinado con capecitabina en sujetos con adenocarcinoma de páncreas avanzado o metastásico que no respondieron o no toleran la quimioterapia en primera línea (estudio janus 1). Incyte Corporation.

HULP Code: Anexo-I 4186. Sponsored's Protocol Code: INCB 18424-362.

Signature Date: 27/7/2016

Martínez Marín V. Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de kit en pacientes con tumores del estroma gastrointestinal (gist) con respuesta prolongada a imatinib. Grupo Español de Investigación en Sarcomas.

HULP Code: PI-2367.

Signature Date: 01/6/2016

Martínez Marín V. Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (sstr) en el tumor de estroma gastrointestinal (gist) localizado (somagist. Grupo Español de Investigación en Sarcomas).

HULP Code: PI-2453. Sponsored's Protocol Code: GEIS 46.

Signature Date: 15/7/2016

Pinto Marín A. Estudio de fase III, aleatorizado, controlado, multicéntrico y abierto, para comparar el tivozanib clorhidrato frente al sorafenib en sujetos con carcinoma de células renales avanzado resistente al tratamiento. Aveo Pharmaceuticals.

HULP Code: 4570. Sponsored's Protocol Code: AV-951-15-303.

Signature Date: 2/6/2016



Pinto Marín A. Estudio de fase III, estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico. F.Hoffmann-La Roche Ltd.

HULP Code: 4699. Sponsored's Protocol Code: MO299833.

Signature Date: 5/10/2016

Pinto Marín A. Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre avelumab* (msb0010718c) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o metastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino. Pfizer, S.L.U.

HULP Code: 4659. Sponsored's Protocol Code: B9991001.

Signature Date: 4/7/2016

Pinto Marín A. Estudio exploratorio de fase II, abierto y con un solo grupo de tratamiento con afatinib oral en monoterapia tras el fracaso a platino en pacientes con carcinoma urotelial avanzado/metastásico con desregulación de los receptores erbb?. Boehringer Ingelheim España, S.A.

HULP Code: 4632. Sponsored's Protocol Code: 1200.261.

Signature Date: 15/7/2016

Pinto Marín A. Validación del consorcio de la base de datos internacional de cáncer renal metastásico (imdc) como clasificación pronóstica para terapias dirigidas (inhibidores de la itc/mtor) en segunda línea después del tratamiento con pazopanib primera línea (spazo-2). Grupo Grupo Sogug.

HULP Code: PI-2523. Sponsored's Protocol Code: SOGUG-2016-A-IEC.

Signature Date: 26/10/2016

Redondo Sánchez A. Estudio de fase II aleatorizado de mIn0128 (inhibidor doble de torc1/2), mIn0128 + mIn1117 (inhibidor de pi3k), paclitaxel semanal, o la combinación de paclitaxel semanal y mIn0128 en mujeres con cáncer de endometrio avanzado, recurrente o persistente. Millennium Pharmaceuticals, Inc.

HULP Code: 4614. Sponsored's Protocol Code: C31004.

Signature Date: 20/5/2016

Redondo Sánchez A. Estudio aleatorizado de fase III de lubinectedin (pm01183) frente a doxorubicina liposomal pegilada o topotecán en pacientes con cáncer de ovario resistente a platino (ensayo corail. Pharmamar, S.A.

HULP Code: Anexo-I 4400. Sponsored's Protocol Code: PMI183-C-004-14.

Signature Date: 13/7/2016

Redondo Sánchez A. Estudio de fase Ib (abierto) / fase 2 (aleatorizado, doble ciego) en el que se evalúan gemcitabina y docetaxel, con o sin olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Lilly, S.A.

HULP Code: 4543. Sponsored's Protocol Code: ISB-MC-JGDL.

Signature Date: 27/01/2016

Redondo Sánchez A. Estudio de fase Ib (abierto) / fase 2 (aleatorizado, doble ciego) en el que se evalúan gemcitabina y docetaxel, con o sin olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Lilly, S.A.

HULP Code: Anexo-I 4543. Sponsored's Protocol Code: ISB-MC-JGDL.

Signature Date: 29/2/2016

Redondo Sánchez A. Estudio de fase 3, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del tratamiento de mantenimiento con niraparib en pacientes con cáncer de ovario avanzado portador de deficiencia de la recombinación homóloga (hrd) que han respondido a la quimioterapia de primera línea con platino. Tesaro Inc.

HULP Code: 4642. Sponsored's Protocol Code: PR-30-5017-C.

Signature Date: 23/9/2016

Redondo Sánchez A. Estudio de fase III, abierto, multicéntrico, randomizado para evaluar la eficacia y seguridad de trastuzumab emtansine versus trastuzumab como tratamiento adyuvante en pacientes con cancer de mama primario her2-positivo con presencia patologica de tumor residual en la mama o nódulo linfático axilar tras tratamiento preoperatorio. F.Hoffmann-La Roche Ltd.

HULP Code: Anexo-I 3783. Sponsored's Protocol Code: BO27938.

Signature Date: 12/1/2016

Redondo Sánchez A. Estudio de fase III, multicéntrico, aleatorizado, abierto de avelumab (msb0010718c) en monoterapia o en combinación con doxorubicina liposomal pegilada frente a doxorubicina liposomal pegilada en monoterapia en pacientes con cáncer de ovario refractario/resistente a platino. Pfizer Inc.

HULP Code: 4652. Sponsored's Protocol Code: B9991009.

Signature Date: 23/6/2016

Redondo Sánchez A. Estudio en fase III, multicéntrico, aleatorizado y controlado con placebo de atezolizumab (anticuerpo anti-pd-1) combinado con nab-paclitaxel en comparación con placebo con nab-paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tratado previamente. Roche Farma, S.A.

HULP Code: 4581. Sponsored's Protocol Code: WO29522.

Signature Date: 20/4/2016

Redondo Sánchez A. Estudio fase II multicéntrico, abierto, de un solo brazo para evaluar la seguridad y eficacia de bevacizumab en combinación con carboplatino y paclitaxel en pacientes con cáncer de cérvix metastásico, recurrente o persistente. F.Hoffmann-La Roche Ltd.

HULP Code: Anexo-I 4422. Sponsored's Protocol Code: MO29594.

Signature Date: 15/4/2016

Rodríguez Salas N. Ensayo clínico multicéntrico randomizado, de tratamiento de mantenimiento basado en biomarcadores para primera línea de cáncer colorrectal metastásico (modul). Roche Farma, S.A.

HULP Code: 4532. Sponsored's Protocol Code: MO29112.

Signature Date: 4/1/2016

Rodríguez Salas N. Estudio abierto, aleatorizado, fase 2 que compara s95005 con bevacizumab frente a capecitabina con bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatas a terapia intensiva. Laboratorios Servier, S.L.

HULP Code: 4580. Sponsored's Protocol Code: CL2-95005-002.

Signature Date: 18/4/2016

Rodríguez Salas N. Estudio abierto, aleatorizado, fase 2 que compara s95005 con bevacizumab frente a capecita-

bina con bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatas a terapia intensiva. Laboratorios Servier, S.L.

HULP Code: Anexo-I 4580. Sponsored's Protocol Code: CL2-95005-002.

Signature Date: 23/9/2016

Rodríguez Salas N. Estudio fase II, prospectivo, multicéntrico, abierto, randomizado, controlado con fármaco activo, de 3 grupos paralelos, para comparar la eficacia y seguridad de masitinib en combinación con folfiri (irinotecán, 5-fluorouracil y ácido folínico) frente al masitinib solo, frente a mejores cuidados paliativos en pacientes con cáncer colorrectal metastásico en tercera o cuarta línea de tratamiento. Abscience.

HULP Code: Anexo-I 4426. Sponsored's Protocol Code: ABI2010.

Signature Date: 12/4/2016

Rodríguez Salas N. Tratamiento de inducción con folfox, con o sin aflibercept, seguido de quimio-radioterapia en carcinoma de recto localmente avanzado de alto riesgo. un ensayo abierto, fase II randomizado. Grupo Gemcad.

HULP Code: Anexo-I 4230. Sponsored's Protocol Code: GEM-CAD-1402.

Signature Date: 7/3/2016

Rubio Aparicio PM. Protocolo europeo de tratamiento para el neuroblastoma de riesgo bajo e intermedio". Instituto Investigación Sanitaria H La Fe.

HULP Code: Anexo-I 3353. Sponsored's Protocol Code: LINES.

Signature Date: 31/5/2016

Zamora Auñón P. Estudio aleatorizado, doble ciego, controlado con placebo, de lee011 en combinación con letrozol para el tratamiento de mujeres postmenopausicas con cancer de mama avanzado con receptor hormonal positivo, her2-negativo que no han recibido terapia previa para la enfermedad avanzada. Novartis Farmaceutica, S.A.

HULP Code: Anexo-I 4070. Sponsored's Protocol Code:

CLEE011A2301.

Signature Date: 4/3/2016

Zamora Auñón P. Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de palbociclib en combinación con fulvestrant o letrozol en pacientes con cáncer de mama metastásico her2 negativo, er+ (parsifal I. Medica Scientia Innovation Research).

HULP Code: Anexo-2 4390. Sponsored's Protocol Code: ME-DOPP067.

Signature Date: 4/5/2016

PATENTS AND TRADEMARKS

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with

colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.


Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada GJ, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentación, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887; 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360; 2015 September 23.





EXPERIMENTAL THERAPIES AND BIOMARKERS IN CANCER GROUP



Publications: **10**
 Impact Factor: **41.929**
 Q1: **6**

María Inmaculada Ibáñez de Cáceres

Investigadora Senior (Contrato Miguel Servet - Tipo 2). Jefe de Laboratorio. HULP

Javier de Castro Carpeño

Jefe de Sección de Oncología. HULP
 Profesor Asociado. UAM

Cristóbal Belda Iniesta

Facultativo Especialista de Área en Oncología. HULP

Jaime Carrillo García

Investigador Postdoctoral. IIB "Alberto Sols"

María Isabel Esteban Rodríguez

Facultativo Especialista de Área en Anatomía Patológica. HULP

María Galardi Castillo

Investigadora Predoctoral. UAM

Julia Jiménez Hernández

Investigadora Predoctoral. IIB "Alberto Sols"

Cristina Manguán García

Técnico de Laboratorio. IIB "Alberto Sols"

Olga Pernía Arias

Técnico de Laboratorio (Contrato PTA). HULP

Rosario Perona Abellón

Profesora de Investigación. IIB "Alberto Sols"

Verónica Pulido Sanz

Investigadora Predoctoral. HULP

Garcilaso Riesco Eizaguirre

Facultativo Especialista de Área en Endocrinología y Nutrición. HULP

Carlos Rodríguez Antolín

Bioinformático Contratado. HULP

Rocío Rosas Alonso

Farmacéutica Interna Residente. HULP

Isabel Sánchez Pérez

Profesora Contratada Doctor. UAM

Leandro Sastre Garzón

Investigador Científico. IIB "Alberto Sols"

Javier Andrés Soto

Investigador Predoctoral. UAM

Olga Vera Puente

Investigadora Predoctoral. HULP

Strategic Objective

Our research is focused on two distinct areas:

I-Genetic and epigenetic mechanisms involved in the resistance to chemotherapeutic drugs. Drug resistance is a crucial problem in clinical practice. We have used various strategies to approach this problem, such as identifying new targets involved in drug responses and studying their alterations in human samples. In addition, we have identified epigenetic changes in tumour suppressor genes associated with drug resistance and new gene inducers of chromosome instability associated with drug responses.

We have worked towards identifying the platinum-resistance epigenetic markers (genes and micro RNAs) for non-invasive cancer diagnosis in cancer. By using genomic, transcriptomic, epigenomics and expression reactivation techniques, we have identified various targets (genes and microRNAs) involved in the resistance to platinum-derived compounds in non-small cell lung cancer, ovarian and gastric cancer. Methylation of IGFBP-3 in NS-

CLC biopsies predicts resistance to cisplatin with 80% specificity. miR-7 epigenetic regulation predicts early recurrence in ovarian cancer patients. We also discovered a combination therapy based in sequential treatment of gastric cancer cells with taxol followed by cisplatin, which induces mitotic catastrophe and increases cell death. Another target, MKP1, is a dual-specific phosphatase expressed at high levels in biopsies from early-stage NSCLC and is also associated with tumour progression of this disease.

2- Strategies to reactivate telomerase activity in human cells with defects in telomerase and premature senescence.

We have identified a genetic suppressor element (GSE) termed 24-2 that, once expressed in human cells, is able to recover telomerase activity and promote survival to cisplatin. This GSE corresponds to an internal fragment of dyskerin, a protein that is part of the telomerase complex.

Expression of this GSE reactivates telomerase activity in cells with X-linked dyskeratosis congenita, a disease that is characterised by bone marrow failure and several other defects associated with a decrease in telomerase activity.

Research Lines

Translational research:

- Identification of predictive genetic and epigenetic biomarkers in the emergence of resistance in cancer and new therapeutic targets in NSCLC and ovarian cancer.
- Identification of novel non coding RNAs (miRNAs and lncRNAs) involved in chemoradiotherapy response in lung and ovarian cancer as well as in rare diseases as biomarkers for clinical use.
- Study of the mechanisms of resistance to chemotherapy in cancer: the role of tumour stem cells and exosomes in the response to chemotherapy in non-small cell lung cancer.
- Development of new strategies for the treatment of telomerase defective diseases.

Research Activity

PUBLICATIONS

- Bargiela-Iparraguirre J, Prado-Marchal L, Fernández-Fuente M, Gutiérrez-González A, Moreno-Rubio J, Muñoz-Fernández M, Sereno M, Sánchez-Prieto R, Perona R, Sánchez-Pérez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. *Sci Rep-Uk*. 2016;6:21519. Article. IF: 4.259; Q1
- Castellanos PC, D'Errico G, Miranda J, Carpeño JD. Adenoid cystic carcinoma of the lung. A case report. *Arch Bronconeumol*. 2016;52(1):50. Letter. IF: 2.979; Q2
- Cortés LQ, Castellanos PC, Carpeño JD. An example of difficulty in diagnosing and treating lung sarcoma. *Arch Bronconeumol*. 2016;52(6):331. Editorial Material. IF: 2.979; Q2
- García-Romero N, González-Tejedo C, Carrión-Navarro J, Esteban-Rubio S, Rackov G, Rodríguez-Fanjul V, Oliver-de la

Cruz J, Prat-Acín R, Peris-Celda M, Blesa D, Ramírez-Jiménez L, Sánchez-Gómez P, Perona R, Escobedo-Lucea C, Belda-Iniesta C, Ayuso-Sacido A. Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media. *Oncotarget*. 2016;7(40):65888-901. Article. IF: 5.168; Q1

- Isla D, Felip E, Vinolas N, Provencio M, Majem M, Artal A, Bover I, Lianes P, de las Penas R, Catot S, de Castro J, Blasco A, Terrasa J, González-Larriba JL, Juan O, Domine M, Bernabe R, Garrido P. Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07. *Anticancer Res*. 2016;36(12):6647-53. Article. IF: 1.937; Q3
- Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, Velasco-Martín JP, Orozco RM, Luengo E, Martín RG, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. *P Natl Acad Sci Usa*. 2016;113(3):E328-37. Article. IF: 9.661; D1
- Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gurpide J, Rojo F. c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer. *Mol Cancer Ther*. 2016;15(11):2780-90. Article. IF: 5.764; Q1
- Sag SO, Topak A, Gorukmez O, Türe M, Carrillo J, Sahinturk S, Gulten T, Perona R, Yakut T. Dyskeratosis congenita: A case report. *Genet Counsel*. 2016;27(2):263-7. Letter. IF: 0.236; Q4
- Smit E, Moro-Sibilot D, Carpeño JD, Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Girvan A, Visseren-Grul C, Schnabel PA. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. *Lung Cancer*. 2016;92:35-40. Article. IF: 4.294; Q1
- Soto J, Rodríguez-Antolín C, Vallespín E, Carpeño JD, Ibáñez de Cáceres I. The impact of next-generation sequencing on the DNA methylation-based translational cancer research. *Transl Res*. 2016;169:1-18. Review. IF: 4.652; Q1

PUBLIC PROJECTS

de Castro Carpeño J. Detección de alteraciones genéticas/genómicas en DNA tumoral de cáncer de pulmón de células no pequeñas en estadio I y evaluación de la utilidad del screening de DNA circulante tumoral en sangre periférica como estrategia de seguimiento del cáncer (PI12/01463). ISCIII. 2013-2017.

Management centre: FIBHULP

de Castro Carpeño J. Plataforma de Innovación (PT13/0006/0012). ISCIII. 2014-2017.

Management centre: FIBHULP

Ibáñez de Cáceres MI. Desarrollo y validación de dos prototipos de kit capaces de detectar un biomarcador que sirva a los oncólogos como herramienta objetiva para personalizar el tratamiento a pacientes con cáncer de pulmón no microcítico en estadios avanzados (RTC-2015-4362-1). MINECO. 2015-2017.

Management centre: FIBHULP

Ibáñez de Cáceres MI. Validación preclínica de biomarcadores epigenéticos de uso diagnóstico y predictivo en tumores sólidos tratados con derivados de platino. nuevos



retos clínicos asociados a la biopsia líquida (PI15/00186). ISCIII. 2016-2018.

Management centre: FIBHULP

Pernía Arias O. Contrato PTA (PTA2012-7141-I). 2013-2016.

Management centre: FIBHULP

Perona Abellón R. Estudio molecular integrado en CNMP. Búsqueda de marcadores moleculares pronósticos, heterogeneidad de células circulantes tumorales y sensibilidad extrema a tratamiento (PI14/01495). ISCIII. 2015-2017.

Management centre: CSIC-UAM

PRIVATE PROJECTS

de Castro Carpeño J. Determinación mediante inmunohistoquímica de la expresión de PDL-1 en carcinoma de célula no pequeña de pulmón. Varios. 2016-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. ELUXA 2: Estudio de fase III, abierto, aleatorizado y controlado con producto activo, multicéntrico e internacional, para evaluar la eficacia de B11482694 frente a un doblete de quimioterapia estándar que incluye platino en pacientes con cáncer de pulmón. Parexel International Limited. 2016-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Estudio de las diferencias de género en el impacto psicosocial y económico en pacientes con cáncer no microcítico de pulmón avanzado (IMPULSO). Investigación en Cáncer de Pulmón en Mujeres. 2015-Ongoing.

Management centre: ICAPEM

de Castro Carpeño J. Evaluación de la capacidad predictiva de un perfil proteómico en suero en la predicción de respuesta a un régimen de combinación estándar de primera línea en pacientes con carcinoma no microcítico de pulmón en estadios IIb no subsidiarios de radioterapia. Glaxosmithkline S.A. 2008-Ongoing

Management centre: FIBHULP

de Castro Carpeño J. Expresión de colinoquinasa (CHOK) y NF-KB en pacientes con carcinoma de colon y su relación con la respuesta a capecitabina en combinación con oxaliplatino. Roche Farma S.A. 2008-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Oncología translacional y la determinación de traslocaciones de ALK en muestras de tumores sólidos. Pfizer S.L.U. 2011-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Programa de e-learning de formación en cáncer de pulmón en mujeres. Investigación en Cáncer de Pulmón en Mujeres. 2015-Ongoing.

Management centre: ICAPEM

Ibáñez de Cáceres MI. Estudio comparativo de muestras de pacientes en parafina para medir el grado de metilación del gen IGFBP-3. Igen Biotech S.L. 2015-Ongoing.

Management centre: FIBHULP

Ibáñez de Cáceres MI. Evaluación del proyecto de investigación: Contribución del factor de transcripción runx2

en la progresión del cáncer de pulmón. Pontificia Universidad Javeriana. 2016-Ongoing.

Management centre: FIBHULP

Ibáñez de Cáceres MI. Identificación de marcadores epigenéticos para diagnóstico no invasivo en resistencia a platino y su implicación en el uso de terapias individualizadas. Ibáñez. 2013-Ongoing.

Management centre: FIBHULP

Ibáñez de Cáceres Mi. Identificación y uso de micrnas como marcadores epigenéticos de sensibilidad a cisplatino en cáncer de pulmón no microcítico: implicación en terapias individualizadas. Comunidad de Madrid. 2014-Ongoing

Management centre: FIBHULP

CLINICAL TRIALS

de Castro Carpeño J. Ensayo clínico aleatorizado, doble ciego, controlado con placebo, de fase 2, de alisertib (mln8237) en combinación con paclitaxel frente a placebo en combinación con paclitaxel como tratamiento de segunda línea para el cáncer de pulmón microcítico (CPM). Millennium Pharmaceuticals Inc.

HULP Code: Anexo-I 4136. Sponsored's Protocol Code: 4136 C14018.

Signature Date: 19/5/2016

de Castro Carpeño J. Ensayo en fase IIb, abierto, multicéntrico y aleatorizado, para investigar la eficacia y la seguridad de aldorubicina en comparación con topotecán en pacientes con cáncer de pulmón microcítico metastásico que o han sufrido una recidiva o no han respondido a quimioterapia previa. Cytrix Corporation.

HULP Code: Anexo-I 4304. Sponsored's Protocol Code: AL-DOXORUBICIN-P2-SCLC-01.

Signature Date: 25/4/2016

de Castro Carpeño J. Ensayo en fase III, aleatorizado, con el anticuerpo monoclonal anti-pd-1 pembrolizumab (mk-3475), en comparación con placebo para pacientes con cpnm en fase temprana después de resección y finalización del tratamiento complementario de referencia (PEARLS). Merck & Co. Inc.

HULP Code: 4558. Sponsored's Protocol Code: EORTC 1416-LCG.

Signature Date: 29/01/2016

de Castro Carpeño J. Ensayo internacional fase 3, aleatorizado, abierto y multicéntrico, con medi4736 en combinación con tremelimumab o medi4736 en monoterapia, frente a la quimioterapia habitual basada en platino, en el tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico (NSCLC) avanzado o metastásico (MYSTIC). Astrazeneca AB.

HULP Code: Anexo-I 4471. Sponsored's Protocol Code: D419AC00001.

Signature Date: 9/6/2016

de Castro Carpeño J. Estudio aleatorizado en fase II comparando vinorelbina oral como agente único administrada con dos esquemas diferentes en pacientes con cáncer de pulmón no microcítico avanzado no aptos para quimioterapia basada en platino. Randomized phase II study com-

paring single agent oral vinorelbine administered with two different schedules in patients with advanced non small cell lung cancer unfit for a platinum-based chemotherapy. Pierre Fabre Iberica, S.A.

HULP Code: 4433. Sponsored's Protocol Code: PM0259CA232J1.

Signature Date: 20/6/2016

de Castro Carpeño J. Estudio ceto, abierto, multicéntrico, global, en fase II con entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes NTRK1/2/3, ROS1 o ALK. Ignyta, Inc.

HULP Code: 4648. Sponsored's Protocol Code: RXDX-101-02.

Signature Date: 10/8/2016

de Castro Carpeño J. Estudio de extensión de un único brazo, abierto y multicéntrico en pacientes con tumores sólidos que reciben tratamiento con bevacizumab en cualquiera de los estudios esponsorizados por F. Hoffmann- La Roche y/o Genentech. F. Hoffmann-La Roche Ltd.

HULP Code: 4616. Sponsored's Protocol Code: MO25757.

Signature Date: 22/4/2016

de Castro Carpeño J. Estudio de fase 2 de MM-121 en combinación con docetaxel o pemetrexed en comparación con docetaxel o pemetrexed en monoterapia en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, positivo para heregulina. Merri-mack Pharmaceuticals.

HULP Code: Anexo-I 4436. Sponsored's Protocol Code: MM-121-01-01-09.

Signature Date: 18/2/2016

de Castro Carpeño J. Estudio de fase 2, multicéntrico, aleatorizado y abierto que compara el tratamiento de veliparib más carboplatino y paclitaxel frente al tratamiento quimioterápico habitual elegido por el investigador en pacientes fumadores o ex fumadores con cáncer de pulmón no microcítico (CPNM), no epidermoide, avanzado o metastásico que reciben quimioterapia citotóxica por primera vez. Abbvie Spain S.L.U.

HULP Code: Anexo-2 4329. Sponsored's Protocol Code: M14-359.

Signature Date: 9/3/2016

de Castro Carpeño J. Estudio de fase 2, multicéntrico, aleatorizado y abierto que compara el tratamiento de veliparib más carboplatino y paclitaxel frente al tratamiento quimioterápico habitual elegido por el investigador en pacientes fumadores o ex fumadores con cáncer de pulmón no microcítico (CPNM), no epidermoide, avanzado o metastásico que reciben quimioterapia citotóxica por primera vez. Abbvie Deutschland GmbH.

HULP Code: Anexo-3 4329. Sponsored's Protocol Code: M14-359.

Signature Date: 10/5/2016

de Castro Carpeño J. Estudio de fase 3, abierto y aleatorizado, de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR, en estadio IIIb/IV (Estudio solar). Astellas Pharma S.A.

HULP Code: 4535. Sponsored's Protocol Code: 8273-CL-0302.

Signature Date: 4/4/2016

de Castro Carpeño J. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y con control activo para evaluar la seguridad y la eficacia de la combinación de pro-netupitant/palonosetrón (260 mg/0,25 mg) por vía intravenosa para la prevención de náuseas y vómitos inducidos por quimioterapia en ciclos repetidos de quimioterapia en pacientes que reciben quimioterapia altamente emetogénica. Helsinn Healthcare S.A.

HULP Code: 4477. Sponsored's Protocol Code: NEPA-15-18.

Signature Date: 7/3/2016

de Castro Carpeño J. Estudio de fase I, multicéntrico, abierto, de interacción farmacológica para evaluar el efecto de ceritinib en la farmacocinética de warfarina y midazolam administrados como un coctel de dos fármacos en pacientes con tumores avanzados alk-positivo incluyendo cáncer de pulmón de células no pequeñas (NSCLC). Novartis Farmacéutica S.A.

HULP Code: 4553. Sponsored's Protocol Code: CLDK378A2103.

Signature Date: 27/01/2016

de Castro Carpeño J. Estudio de fase II, multicéntrico, de tres cohortes con el inhibidor oral de CMET, INC280, en pacientes adultos con cáncer de pulmón de células no pequeñas (NSCLC) avanzado y EGFR wild type (WT), que han recibido una o dos líneas previas de terapia sistémica para enfermedad avanzada/metastásica. Novartis Farmacéutica S.A.

HULP Code: 4554. Sponsored's Protocol Code: CINC280A2201.

Signature Date: 11/01/2016

de Castro Carpeño J. Estudio de fase III multicéntrico, abierto, randomizado, para investigar la eficacia y la seguridad de mpd13280a (anticuerpo anti-pd-1) comparado con docetaxel, en pacientes con cáncer de pulmón no microcítico, tras fracaso de quimioterapia basada en platino. F.Hoffmann-La Roche Ltd.

HULP Code: Anexo-I 4072. Sponsored's Protocol Code: GO28915.

Signature Date: 26/9/2016

de Castro Carpeño J. Estudio en fase III, abierto y aleatorizado para investigar la eficacia y seguridad de atezolizumab (anticuerpo anti-PD-1) en comparación con el tratamiento de soporte óptimo. F. Hoffmann-La Roche Ltd.

HULP Code: Anexo-I 4480. Sponsored's Protocol Code: GO29527.

Signature Date: 9/5/2016

de Castro Carpeño J. Estudio en fase III, aleatorizado y doble ciego de PF-06439535 más paclitaxel-carboplatino y bevacizumab más paclitaxel-carboplatino para el tratamiento de primera línea de pacientes con cáncer de pulmón no escamocelular no microcítico avanzado. Pfizer Inc.

HULP Code: 4512. Sponsored's Protocol Code: B7391003.

Signature Date: 18/01/2016

de Castro Carpeño J. Estudio fase III multinacional, aleatorizado, abierto de custirsén (tv-1011/ogx-011) en combinación con docetaxel frente a docetaxel como tratamiento de segunda línea en pacientes con cáncer de pulmón no microcítico avanzado o metastásico (estadio IV). Oncogenex Technologies Inc.

HULP Code: Anexo-3 3757. Sponsored's Protocol Code: TV1011-LC-303.

Signature Date: 25/3/2016



de Castro Carpeño J. Estudio fase III, aleatorizado, doble ciego y controlado con placebo de carboplatino más etopósido con o sin atezolizumab (anticuerpo anti-pd-11) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado. F.Hoffmann-La Roche Ltd.

HULP Code: 4615. Sponsored's Protocol Code: GO30081.

Signature Date: 22/4/2016

de Castro Carpeño J. Estudio fase III, aleatorizado, doble ciego y controlado con placebo de carboplatino más etopósido con o sin atezolizumab (anticuerpo anti-pd-11) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado. F.Hoffmann-La Roche Ltd.

HULP Code: Anexo-I 4615. Sponsored's Protocol Code: GO30081.

Signature Date: 2/8/2016

de Castro Carpeño J. Estudio observacional sobre el manejo de la disnea irruptiva en pacientes oncológicos. Evaluación en la práctica clínica. Kyowa Kirin Farmacéutica S.L.U.

HULP Code: Anexo-I PI-2025. Sponsored's Protocol Code: PI-2025.

Signature Date: 7/06/2016

de Castro Carpeño J. Seguridad y eficacia de lonquex® (lipegfilgrastim) en comparación con pegfilgrastim (neulasta®, amgen inc.) y placebo en pacientes con cáncer de pulmón no microcítico que reciben quimioterapia de primera línea. Merckle GMBH.

HULP Code: 4490. Sponsored's Protocol Code: XM22-ONC-40041.

Signature Date: 29/4/2016

PATENTS AND TRADEMARKS

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, CA2706467, JP2011504483; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E,

Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, US2015306037, JP2015529216; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradicio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, PCT/ES2014/070803, EP3061815, AU2014338820, CA2931429; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997; 2015 July 09. P201530997-PCT/ES2016/070516

OTO-NEUROSURGERY RESEARCH GROUP



Publications: **21**

Impact Factor: **59.742**

QI: **7**

Luis Lassaletta Atienza

Jefe de Sección de Otorrinolaringología. HULP

Carolina Alfonso Carrillo

Facultativo Especialista de Área en Otorrinolaringología. HULP

Miryam Calvino Fernández

Investigadora Postdoctoral. UAM

Alejandro Castro Calvo

Facultativo Especialista de Área en Otorrinolaringología. HULP

Isabel García López

Facultativo Especialista de Área en Otorrinolaringología. HULP

Javier Gavilán Bouzas

Jefe de Servicio de Otorrinolaringología. HULP

Catedrático. Departamento de Cirugía. Facultad de Medicina. UAM

Teresa González Otero

Facultativo Especialista de Área en Cirugía Maxilofacial. HULP

Silvia Murillo Cuesta

Investigadora Postdoctoral. IIB "Alberto Sols"

Carolina Peña Granero

Técnico de Laboratorio (Contrato PTA). HULP

Rosa María Pérez Mora

Facultativo Especialista de Área en Otorrinolaringología. HULP

Juan Antonio Rey Herranz

Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio.

HULP

Laura del Río Arroyo

Facultativo Especialista de Área en Otorrinolaringología. HULP

Lourdes Rodríguez de la Rosa

Técnico de Laboratorio. IIB "Alberto Sols"

Isabel Pilar Sánchez Cuadrado

Facultativo Especialista de Área en Otorrinolaringología. HULP

Miguel Torres Martín

Investigador Postdoctoral. HULP

María Isabel Varela Nieto

Profesor de Investigación. IIB "Alberto Sols"

Antonio Villalobo Polo

Profesor de Investigación. IIB "Alberto Sols"

Strategic Objective

The systematic use of magnetic resonance imaging (MRI) has dramatically increased the diagnosis of patients with vestibular schwannoma (VS). The majority of patients with VS complain of hypoacusis or tinnitus, and very few present more debilitating symptoms. Therefore, the approach with a patient with VS is complex because the treatment of the tumour is directed towards avoiding complications arising from its growth and not necessarily towards improving the patient's quality of life. Currently, there are no factors that allow us to predict the growth of vestibular schwannoma.

Recent advances in the field of oncogenetics have allowed us to better understand the development of VS.

The study of the correlation between clinical variables related to the biological behaviour of VS and its genetic and epigenetic disorders aims to find the factors that predict the behaviour of VS. This will help us identify patients who need active treatment of the tumour and avoid the morbidity associated with the treatment in those who do not need it.

The cochlear implant (CI) is currently the only solution for relieving the condition in patients with severe or profound hypoacusis who do not benefit from a



Tee AR, Teixeira-Clerc F, Telang S, Tencomnao T, Teng BB, Teng RJ, Terro F, Tettamanti G, Theiss AL, Theron AE, Thomas KJ, Thome MP, Thomes PG, Thorburn A, Thorner J, Thum T, Thumm M, Thurston TLM, Tian L, Till A, Ting JPY, Titorenko VI, Toker L, Toldo S, Tooze SA, Topisirovic I, Torgersen ML, Torosantucci L, Toriglia A, Torrisi MR, Tournier C, Towns R, Trajkovic V, Travassos LH, Triola G, Tripathi DN, Trisciuglio D, Troncoso R, Trougakos IP, Truttmann AC, Tsai KJ, Tschann MP, Tseng YH, Tsukuba T, Tsung A, Tsvetkov AS, Tu SP, Tuan HY, Tucci M, Tumbarello DA, Turk B, Turk V, Turner RFB, Tveita AA, Tyagi SC, Ubukata M, Uchiyama Y, Udelinow A, Ueno T, Umekawa M, Umemiya-Shirafuji R, Underwood BR, Ungermaier C, Ureshino RP, Ushioda R, Uversky VN, Uzcatégui NL, Vaccari T, Vaccaro MI, Vachova L, Vakifahmetoglu-Norberg H, Valdor R, Valente EM, Vallette F, Valverde AM, Van den Berghe G, Van Den Bosch L, van den Brink GR, van der Goot FG, van der Kleij IJ, van der Laan LJW, van Doorn WG, van Egmond M, van Golen KL, Van Kaer L, Campagne MV, Vandenaabee P, Vandenberghe W, Vanhorebeek I, Varela-Nieto I, Vasconcelos MH, Vasko R, Vavvas DG, Vega-Naredo I, Velasco G, Velentzas AD, Velentzas PD, Vellai T, Vellenga E, Vendelbo MH, Venkatachalam K, Ventura N, Ventura S, Veras PST, Verdier M, Vertessy BG, Viale A, Vidal M, Vieira HLA, Vierstra RD, Vigneswaran N, Vij N, Vila M, Villar M, Villar VH, Villarroya J, Vindis C, Viola G, Viscomi MT, Vitale G, Vogl DT, Voitsekhovskaja OV, von Haefen C, von Schwarzenberg K, Voth DE, Vouret-Craviari V, Vuori K, Vyas JM, Waeber C, Walker CL, Walker MJ, Walter J, Wan L, Wan XB, Wang B, Wang CH, Wang CY, Wang CS, Wang CR, Wang CH, Wang D, Wang F, Wang FX, Wang GH, Wang HJ, Wang HC, Wang HG, Wang HM, Wang HD, Wang J, Wang JJ, Wang M, Wang MQ, Wang PY, Wang P, Wang RC, Wang S, Wang TF, Wang X, Wang XJ, Wang XW, Wang X, Wang XJ, Wang Y, Wang Y, Wang Y, Wang YJ, Wang YP, Wang Y, Wang YT, Wang YQ, Wang ZN, Wappner P, Ward C, Ward DM, Warnes G, Watada H, Watanabe Y, Watase K, Weaver TE, Weekes CD, Wei JW, Weide T, Wehl CC, Weindl G, Weis SN, Wen LP, Wen X, Wen YF, Westermann B, Weyand CM, White AR, White E, Whitton JL, Whitworth AJ, Wiels J, Wild F, Wildenberg ME, Wileman T, Wilkinson DS, Wilkinson S, Willbold D, Williams C, Williams K, Williamson PR, Winklhofer KF, Witkin SS, Wohlgemuth SE, Wollert T, Wolvetang EJ, Wong E, Wong GV, Wong RW, Wong YKW, Woodcock EA, Wright KL, Wu CL, Wu DF, Wu GS, Wu J, Wu JF, Wu M, Wu M, Wu SZ, Wu WKK, Wu YH, Wu ZL, Xavier CPR, Xavier RJ, Xia GX, Xia T, Xia WL, Xia Y, Xiao HY, Xiao J, Xiao S, Xiao WH, Xie CM, Xie ZP, Xie ZL, Xilouri M, Xiong YY, Xu CS, Xu CF, Xu F, Xu HX, Xu HW, Xu J, Xu JZ, Xu JX, Xu L, Xu XL, Xu YQ, Xu Y, Xu ZX, Xu ZH, Xue Y, Yamada T, Yamamoto A, Yamana K, Yamashina S, Yamashiro S, Yan B, Yan B, Yan X, Yan Z, Yanagi Y, Yang DS, Yang JM, Yang L, Yang MH, Yang PM, Yang P, Yang Q, Yang WN, Yang WY, Yang XS, Yang Y, Yang Y, Yang ZF, Yang ZH, Yao MC, Yao PJ, Yao XF, Yao ZY, Yao ZY, Yasui LS, Ye MX, Yedvobnick B, Yeganeh B, Yeh ES, Yeyati PL, Yi F, Yi L, Yin XM, Yip CK, Yoo YM, Yoo YH, Yoon SY, Yoshida KI, Yoshimori T, Young KH, Yu HM, Yu JJ, Yu JT, Yu J, Yu L, Yu WH, Yu XF, Yu ZP, Yuan JY, Yuan ZM, Yue BYJT, Yue JB, Yue ZY, Zacks DN, Zacksenhaus E, Zaffaroni N, Zaglia T, Zakeri Z, Zecchini V, Zeng JS, Zeng M, Zeng Q, Zervos AS, Zhang DD, Zhang F, Zhang G, Zhang GC, Zhang H, Zhang H, Zhang H, Zhang HB, Zhang J, Zhang J, Zhang JW, Zhang JH, Zhang JP, Zhang L, Zhang L, Zhang L, Zhang L, Zhang MY, Zhang XN, Zhang XD, Zhang Y, Zhang Y, Zhang YJ, Zhang YM, Zhang YJ, Zhao M, Zhao WL, Zhao XN, Zhao YG, Zhao Y, Zhao YC, Zhao YX, Zhao ZD, Zhao ZZ, Zheng DX, Zheng XL, Zheng XX, Zhivotovsky B, Zhong Q, Zhou GZ, Zhou GF, Zhou HP, Zhou SF, Zhou XJ, Zhu HX, Zhu H, Zhu WG, Zhu WH, Zhu XF, Zhu YH, Zhuang SM, Zhuang XH, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016;12(1):1-222. Review. IF: 8.593; Q1

- Lassaletta L, Aristegui M, Medina M, Aránguez G, Pérez-Mora RM, Falcioni M, Gavilán J, Piazza P, Sanna M. Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2. *Eur Arch Oto-Rhino-L*. 2016;273(1):27-35. Article. IF: 1.66; Q2
- Lassaletta L, Calvino M, Zernotti M, Gavilán J. Postoperative pain in patients undergoing a transcutaneous active bone conduction implant (Bonebridge). *Eur Arch Oto-Rhino-L*. 2016;273(12):4103-10. Review. IF: 1.66; Q2
- Leal MF, Ribeiro HF, Rey JA, Pinto GR, Smith MC, Moreira-Nunes CA, Assumpcao PP, Lamarao LM, Calcagno DQ, Montenegro RC, Burbano RR. YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process. *Oncotarget*. 2016;7(51):85393-410. Article. IF: 5.168; Q1
- León-Soriano E, Alfonso C, Yébenes L, García-Polo J, Lassaletta L, Gavilán J. Bilateral synchronous ectopic ethmoid sinus olfactory neuroblastoma: A case report. *Am J Case Rep*. 2016;17:268-73. Article. Not Indexed
- Lorens A, Skarzynski H, Rivas A, Rivas JA, Zimmermann K, Parnes L, Lassaletta L, Gavilán J, Bodt MD, van de Heyning P, Martin J, Raine CH, Rajeswaran R, Kameswaran M, Manoj M, Pulibalingaling S. Patient management for cochlear implant recipients in audiology departments: A practice review. *Cochlear Implants Int*. 2016;17(3):123-8. Article. Not Indexed
- Martínez-Vega R, Murillo-Cuesta S, Partearroyo T, Varela-Moreiras G, Varela-Nieto I, Pajares MA. Long-term dietary folate deficiency accelerates progressive hearing loss on CBA/Ca mice. *Front Aging Neurosci*. 2016;8:209. Article. IF: 4.504; Q1
- Pardo-Maza A, Lassaletta L, González-Otero T, Roda JM, Moraleda S, Arbizu A, Gavilán J. Evolution of patients with immediate complete facial paralysis secondary to acoustic neuroma surgery. *Ann Oto Rhinol Laryn*. 2016;125(6):495-500. Article. IF: 1.384; Q2
- Pedrero-Escalas MF, Jiménez-Antolín J, Lassaletta L, Díaz-Saez G, Gavilán J. Hospital clinical trial: Homeopathy (Agraphis nutans 5CH, Thuya occidentalis 5CH, Kalium muriaticum 9CH and Arsenicum iodatum 9CH) as adjuvant, in children with otitis media with effusion. *Int J Pediatr Otorhi*. 2016;88:217-23. Article. IF: 1.159; Q3
- Polo R, Medina MD, Aristegui M, Lassaletta L, Gutiérrez A, Aránguez G, Prasad SC, Alonso A, Gavilán J, Sanna M. Subtotal petrosotomy for cochlear implantation: Lessons learned after 110 Cases. *Ann Oto Rhinol Laryn*. 2016;125(6):485-94. Article. IF: 1.384; Q2
- van de Heyning P, Arauz SL, Atlas M, Baumgartner WD, Caversaccio M, Chester-Browne R, Estienne P, Gavilán J, Godey B, Gstottner W, Han D, Hagen R, Kompis M, Kuzovkov V, Lassaletta L, Lefevre F, Li Y, Muller J, Parnes L, Kleine PA, Raine C, Rajan G, Rivas A, Rivas JA, Royle N, Sprinzl G, Stephan K, Walkowiak A, Yanov Y, Zimmermann K, Zorowka P, Skarzynski H. Electrically evoked compound action potentials are different depending on the site of cochlear stimulation. *Cochlear Implants Int*. 2016;17(6):251-62. Article. Not Indexed
- von Zglinicki T, Nieto IV, Brites D, Karagianni N, Ortolano S, Georgopoulos S, Cardoso AL, Novella S, Lepperdinger G, Trendelenburg AU, van Os R. Frailty in mouse ageing: A conceptual approach. *Mech Ageing Dev*. 2016;160:34-40. Article. IF: 3.087; Q2

PUBLIC PROJECTS

- Peña Granero C. Contrato PTA. MINECO. 2013-2016. Management centre: FIBHULP

Rey Herranz JA. Miguel Servet Stabilisation Contracts (12). ISCIII/CAM. 2006-Ongoing.

Management centre: FIBHULP

Varela Nieto I. Mecanismos de protección y neuropatogénesis en la pérdida auditiva. Factores de protección y reparación (SAF2014-53979). MINECO. 2015-2017.

Management centre: IIB Alberto Sols

Varela Nieto I. Nuevos tratamientos para la prevención y tratamiento de la hipoacusia. Estrategias de prevención. CDTI. 2015-2017.

Management centre: IIB Alberto Sols

Villalobo Polo A. Dominios de unión de calmodulina del eje *erbB2/c-src/grb7* como dianas terapéuticas en metástasis de cáncer de mama (SAF2014-52048). MINECO. 2015-2017.

Management centre: IIB Alberto Sols

Villalobo Polo A. The *cam-bd/cam-ld* of *erbB2* as therapeutic targets in breast cancer – el *cam-bd/cam-ld* de *erbB2* como dianas terapéuticas en cáncer de mama (COOPA20053). CSIC. 2015-2016.

Management centre: IIB Alberto Sols

PRIVATE PROJECTS

Lassaletta Atienza L. Influencia de las estrategias de codificación y el uso de sistemas de apoyo en la percepción y uso del teléfono en pacientes adultos con implante coclear. Med-El Elektromedizinische Geräte Gesellschaft M.B.H. 2011-Ongoing.

Management centre: FIBHULP

Prieto Nieto I. Determinación de la endoglina (CD105) como factor de diseminación y recurrencia en el cáncer colorrectal. Empresa Pública Hospital del Sureste. 2015-Ongoing.

Management centre: FIBHULP

Prieto Nieto I. Fuentes de medicina basada en eviden-

cias en investigación clínica: búsqueda y recuperación de la información. Laboratorios Farmacéuticos Rovi S.A. 2015-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Varela Nieto I. Development of a European Network for preclinical testing of interventions in mouse models of age and age-related diseases (mouseage) (BMI402). EU: COST ACTIONS. 2013-2018.

Management centre: IIB Alberto Sols

Varela Nieto I. Targear-targeting challenges of active ageing: innovative integrated strategies for the healing of age-related hearing loss (FP7-PEOPLE-2013-IAPP). EU: Marie Curie Industry-Academia Partnership and Pathway. 2013-2018.

Management centre: IIB Alberto Sols

PATENTS AND TRADEMARKS


Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediell Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. P200802895, PCT/ES2009/070433; 2008 October 14.

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geräte GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediell Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.



CANCER MOLECULAR PATHOLOGY AND THERAPEUTIC TARGETS GROUP



Publications: **23**

Impact Factor: **86.098**

QI: **9**

David Hardisson Hernández

Jefe de Servicio de Anatomía Patológica. HULP
Profesor Titular. Facultad de Medicina. UAM

Alberto Berjón García

Médico Adjunto Especialista de Área en Anatomía Patológica.
HULP

Emilio Burgos Lizáldez

Facultativo Especialista de Área en Anatomía Patológica. HULP

Javier de Santiago García

Jefe de Servicio de Ginecológica Oncológica. HULP
Profesor Asociado. Facultad de Medicina. UAM

Laura Guerra Pastroán

Médico Adjunto Especialista de Área en Anatomía Patológica.
HULP

Victoria María Heredia Soto

Investigador Predoctoral (Contrato FPU). HULP

Jorge Martín Pérez

Investigador Científico. IIB "Alberto Sols"

Marta Mendiola Sabio

Investigadora Postdoctoral. HULP

María Miguel Martín

Técnico de Laboratorio. HULP

Alberto Peláez García

Investigador Postdoctoral. HULP

Elia Pérez Fernández

Investigadora Predoctoral. HULP

José Juan Pozo Kreilinger

Facultativo Especialista de Área en Anatomía Patológica. HULP

José Ignacio Sánchez Méndez

Jefe de Sección en Ginecología y Obstetricia. HULP
Profesor Asociado. Facultad de Medicina. UAM

Laura Yébenes Gregorio

Médico Adjunto Especialista de Área en Anatomía Patológica.
HULP

Strategic Objective

The fundamental interest of our research group is centered in the study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.

Ovarian cancer Research Line

The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies. Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.

Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors. The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with value predictive and prognostic value for ovarian cancer patients.

Breast cancer Research Line

- C-Src is sobreexpressed and/or hyperactive in breast carcinoma biopsies and their implication in the tumorigenesis has been proved in murine models. Our studies on genetically modified human breast cancer cells and mice can establish the relevance of the function of scaffolding of SFKs in breast cancer. In addition, our work can lead to the development of new prognosis and therapeutic tools to improve the treatment of the breast cancer.
- Angiogenesis and cancer of breast. The angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of bevacizumab containing regimes.

Sarcomas Research Line

Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.

Neuroendocrine tumors Research Line

The neuroendocrine tumors (NET) include heterogeneous neoplasias, regarding morphologic and functionally features. They constitute a challenge for the medical management, mainly regarding diagnose and handling. Although we have improve the knowledge of molecular events related to their development in the last decade, we need to better known this tumors, in order to establish an early detection, that it improves the rates of survival.

In vitro 2- and 3D cell culture models for functional studies

The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development. that it improves the rates of survival.

Research Lines

- Ovarian cancer
- Breast cancer
- Sarcomas
- Neuroendocrine tumors

Research Activity

DOCTORAL THESES

Áncer Arellano AG. Estudio de la asociación de genotipos del virus del papiloma humano con Chlamydia trachomatis y otros gérmenes en pacientes con fallo reproductivo [dissertation]. Madrid: UAM: 2016(7/10/2016).

Directors: Hardisson Hernández D, Gallegos Ávila G

Heredia Soto V. Identificación de biomarcadores relacionados con la transición epitelio mesénquima y caracterización de modelos celulares tridimensionales in vitro en cáncer de ovario avanzado [dissertation]. Madrid: UAM: 2016(15/11/2016).

Directors: Hardisson Hernández D, Mendiola Sabio M

Paz Ramírez L. Utilidad del análisis molecular del ganglio centinela mediante técnica OSNA para la predicción intraoperatoria de afectación de ganglios no centinela en el cáncer de mama [dissertation]. Madrid: UAM: 2016(13/04/2016).

Directors: Hardisson Hernández D, Sánchez Méndez JI

BOOKS AND BOOK CHAPTERS

González-Peramato P, Regadera J, Hardisson D, Nistal M. Estructura del intersticio testicular. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.25-30

González-Peramato P, Serrano A, Hardisson D, Nistal M, Regadera J. Lesiones benignas de la próstata. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.179-91

González-Peramato P, Serrano A, Regadera A, Hardisson D. Cáncer de próstata. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.193-205

Hardisson D, González-Peramato P, Navarro S, Regadera J, Nistal M. Patología inflamatoria testicular. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.65-72

Hardisson D, Serrano A, Regadera J, González-Peramato P. Tumores de pene. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.233-9

Julve-Villalta E, Martínez-Piñeiro L, Hardisson D, González-Peramato P, Serrano A, Regadera A. Patología benigna del pene. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.221-31

Julve-Villalta E, Martínez-Piñeiro L, Regadera J, Hardisson D. Pene: anatomía, histología y vascularización de los cuerpos cavernosos y del cuerpo esponjoso. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.209-20

Palacios J, Hardisson D, Noguera R, Regadera J. Conductos eferentes. In: Regadera J, Noguera R, Hardisson R (Eds). Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.89-92



Palacios J, Regadera J, Hardisson D, Noguera R, Nistal M. Conducto del epidídimo. In: **Regadera J, Noguera R, Hardisson R (Eds).** Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.93-103

Regadera J, Hardisson D, González-Peramato P. Estructura de la albugínea y de la vaginal testicular. In: **Regadera J, Noguera R, Hardisson D (Eds).** Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.11-7

Regadera J, Noguera R, Hardisson D, González-Peramato P, Nistal M. Estructura general y anatomía vascular del testículo y de la vía espermática. In: **Regadera J, Noguera R, Hardisson D (Eds).** Atlas de Histología y del desarrollo del aparato genital masculino: introducción a la patología. Madrid: IMC, 2016. p.3-9

PUBLICATIONS

- Andrés AM, Santamaría M, Hernández-Oliveros F, Guerra L, López S, Stringa P, Vallejo MT, Largo C, Encinas JL, de las Heras MSG, López-Santamaría M, Tovar JA. Difficulties, guidelines and review of developing an acute rejection model after rat intestinal transplantation. *Transp Immunol.* 2016;36:32-41. Review. IF: 1.78; Q3
- Arispe C, Pomares AI, de Santiago J, Zapardiel I. Evolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience. *Chinese J Cancer Res.* 2016;28(2):215-20. Article. IF: 3; Q2.
- Brunel I, Iacoponi S, Hernández A, Diestro MD, de Santiago J, Zapardiel I. Intravasculer leiomyomatosis: an exceptional entity. *Clin Exp Obstet Gyn.* 2016;43(3):443-5. Article. IF: 0.429; Q4
- Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CSW, Mendiola M, Burgos E, Feliú J, Moreno-Rubio J, Guadalupe H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. *Nat Med.* 2016;22(6):685-91. Article. IF: 29.886; D1
- Díaz-Luján C, Triquell MF, Castillo C, Hardisson D, Kemmerling U, Fretes RE. Role of placental barrier integrity in infection by *Trypanosoma cruzi*. *Acta Trop.* 2016;164:360-8. Article. IF: 2.218; Q2
- Enciso S, Díaz-Guemes I, Pérez-Medina T, Zapardiel I, de Santiago J, Uson J, Sánchez-Margallo FM. Validation of a structured intensive laparoscopic course for basic and advanced gynecologic skills training. *Int J Gynecol Obstet.* 2016;133(2):241-4. Article. IF: 2.174; Q2
- Ferrer-Santacreu EM, Ortiz-Cruz EJ, Díaz-Almirón M, Kreilinger JJP. Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: clinical and radiological criteria-a follow-up. *J Oncol.* 2016;8262079. Article. Not Indexed
- Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin CC, Lu M, Hoog A, Pastrán LG, Lamarca A, Soto VH, Zedeneus J, Mendiola M, Lehtio J, Kjellman M. Proteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumors. *J Clin Endocr Metab.* 2016;101(10):3616-27. Article. IF: 5.455; Q1
- García-Palmero I, Torres S, Bartolomé RA, Peláez-García A, Larriba MJ, López-Lucendo M, Peña C, Escudero-Paniagua B, Muñoz A, Casal JJ. Twist1-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen alpha 1(VI). *Oncogene.* 2016;35(40):5224-36. Article. IF: 7.519; D1

- Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Cajal TRY, Hernández-Agudo E, Soto VH, Márquez-Rodas I, Echarrí MJ, Lacambra-Calvet C, Sáez R, Cusido M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. *J Gynecol Oncol.* 2016;27(1):e7. Article. IF: 3.14; Q1
- Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. *Crit Rev Oncol Hemat.* 2016;105:65-72. Review. IF: 4.971; Q1
- León-Soriano E, Alfonso C, Yébenes L, García-Polo J, Lassaletta L, Gavilán J. Bilateral synchronous ectopic ethmoid sinus olfactory neuroblastoma: A case report. *Am J Case Rep.* 2016;17:268-73. Article. Not Indexed
- López N, Grabowski JP, de Santiago J, Zapardiel I. Carcinoma of the recto-vaginal septum. *Comprehensive literature review.* *J Obstet Gynaecol.* 2016;36(4):450-4. Review. IF: 0.629; Q4
- López-Ruiz ME, Diestro MD, Yébenes L, Berjón A, de la Noval BD, Mendiola M, de Santiago J, Hardisson D. One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer. *Gynecol Oncol.* 2016;143(1):54-9. Article. IF: 4.959; D1
- Martín-Camean M, Delgado-Sánchez E, Pinera A, Diestro MD, de Santiago J, Zapardiel I. The role of surgery in advanced epithelial ovarian cancer. *Ecancermedalscience.* 2016;10:666. Article. Not Indexed
- Mendiola M, Martínez-Marín V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto A, Miguel M, Díaz E, Gámez A, Fresno JA, de Molina AR, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. *Oncotarget.* 2016;7(17):24217-27. Article. IF: 5.168; Q1.
- Moreno-Luna E, Alonso P, de Santiago J, Zapardiel I. Simple trachelectomy during pregnancy for cervical cancer. *Ecancermedalscience.* 2016;10:673. Article. Not Indexed
- Nogues L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, Ramos P, Mendiola M, Berjón A, Stamatakis K, Zhou XZ, Lu KP, Hardisson D, Mayor F, Penela P. G Protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a HDAC6-pin1 axis. *Ebiomedicine.* 2016;13:132-45. Article. Not Indexed
- Parroche P, Roblot G, Le Calvez-Kelm F, Tout I, Marotel M, Malfoy M, Durand G, McKay J, Ainouze M, Carreira C, Allatif O, Traverse-Glehen A, Mendiola M, Pozo-Kreilinger JJ, Caux C, Tommasino M, Goutagny N, Hasan UA. TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression. *Oncogenesis.* 2016;5:e244. Article. IF: 4.143; Q2
- Reigosa A, Hardisson D, Sanz F, Caleiras E, Saldívia F, Fernández A. Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution. *Invest Clin.* 2016;57(2):187-216. Article. IF: 0.493; Q4
- Rychlik A, Marin S, de Santiago J, Zapardiel I. Utility of Laparoscopic indocyanine green-guided sentinel node biopsy in open cervical cancer surgery. *Int J Gynecol Cancer.* 2016;26(7):1288-1289. Article. IF: 2.369; Q2
- Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, de Miguel M, Martín-Hernández R, Reglero G, Feliú J, de Molina AR. 3' UTR polymorphism in ACSL1 gene correlates with expression levels and poor clinical outcome in colon cancer patients. *Plos One.* 2016;11(12):e0168423. Article. IF: 2.806; Q1
- Zapardiel I, Moreno E, Pinera A, de Santiago J. Novel technique

for the complete staging of endometrial cancer by single-port laparoscopy. *Gynecol Oncol.* 2016;140(2):369-71. Article. IF: 4.959; D1

PRIVATE PROJECTS

Hardisson Hernández D, Diestro Tejada MD. Ultraestadificación Molecular Ganglio Centinela Carcinoma Endometrio: OSNA (ENDO-OSNA). Sysmex. 2016-Ongoing.

Management centre: FIBHULP

Hardisson Hernández D. Actualización y renovación de la actividad en el Servicio de Anatomía Patológica del Hospital Universitario La Paz. Dako Diagnosticos, S.A. 2011-Ongoing.

Management centre: FIBHULP

Hardisson Hernández D. Riesgo de recaída en pacientes con carcinoma de mama primario Her2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (MammaPrint® y EndoPredict®). Myriad Genetic España. 2015-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Caracterización molecular del carcinoma de ovario. empleo de modelos celulares en tres dimensiones para el estudio del papel central de hif1a en los fenómenos de hipoxia y transición epitelio mesénquima y su relación con la resistencia al tratamiento. Fundación Mutua Madrileña. 2013-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. FIBHULP. 2012-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Papel de rank1 en el sarcoma de ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing.

Management centre: FIBHULP


Mendiola Sabio M. Realización de técnicas de detección de expresión proteica. Construcción de matrices tisulares y tinciones con anticuerpos específicos. Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol. 2015-Ongoing.


Management centre: FIBHULP

PATENTS AND TRADEMARKS

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.



MECHANISMS
OF TUMOUR
PROGRESSION
GROUP

Publications: 17

Impact Factor: 86.1

Q1: 13

Amparo Cano García

Catedrática. Departamento de Bioquímica Facultad de Medicina. UAM

Antonio Barbachano Becerril

Investigador Postdoctoral. IIB "Alberto Sols"

Patricia Carrasco Ramírez

Investigadora Predoctoral. IIB "Alberto Sols"

Gemma Domínguez Muñoz

Profesora contratada. UAM

Asunción Fernández Barral

Investigadora Postdoctoral. IIB "Alberto Sols"

Gemma Ferrer Mayorga

Investigadora Predoctoral. IIB "Alberto Sols"

Alfredo Floristán Muruzábal

Investigador Predoctoral. IIB "Alberto Sols"

Pablo García Sanz

Investigador Postdoctoral. IIB "Alberto Sols"

Patricia González Santamaría

Investigadora Postdoctoral. UAM

Marta Hergueta Redondo

Investigadora Predoctoral. UAM

María Jesús Larriba Muñoz

Investigadora Postdoctoral. IIB "Alberto Sols"

Celia Jimena López Menéndez

Técnico Superior. IIB "Alberto Sols"

Alberto Martín Martín

Investigador Postdoctoral. IIB "Alberto Sols"

Ester Martín Villar

Investigadora Postdoctoral. IIB "Alberto Sols"

Saleta Morales Dolores

Técnico de Laboratorio. UAM

Gema Moreno Bueno

Profesora Titular. UAM

Alba Mota Jiménez

Investigadora Predoctoral. IIB "Alberto Sols"

Alberto Muñoz Terol

Profesor de Investigación. IIB "Alberto Sols"

Eva Pérez Cuevas

Investigadora Postdoctoral. IIB "Alberto Sols"

Francisco Portillo Pérez

Catedrático. Departamento de Bioquímica. UAM

Miguel Quintanilla Ávila

Profesor de Investigación. IIB "Alberto Sols"

Vanesa Santos Fernández

Técnico de Laboratorio. IIB "Alberto Sols"

José David Sarrio López

Investigador Postdoctoral. IIB "Alberto Sols"

Strategic Objective

Metastasis represents the most life-threatening event for cancer patients. Invasion of tumour cells from the primary tumour to adjacent tissues represents the first step in the metastatic cascade for most solid tumours.

The carcinoma invasion process involves the loss of Ecadherin mediated cell-cell contacts and cell polarity, degradation of the basement membrane, and acquisition of migratory properties. These changes are collectively known as the epithelial-mesenchymal transition (EMT). Presently, EMT is considered a manifestation of the epithelial plasticity of carcinomas. One of the most significant contributions in

the last decade has been the identification of mechanisms responsible for EMT induction.

Our previous studies, and those of other groups, led to the identification of several transcription factors from various families such as E-cadherin repressors and EMT inducers (EMT-TFs): Snail (Snail1, Snail2), bHLH (E47, E2-2, Twist) and Zeb (ZEB1/2). The EMT process is regulated by a plethora of signalling pathways at the transcriptional and posttranscriptional level, including TGF- β (one of the most potent EMT inducers), vitamin D (which antagonises Snail1 repression), phosphorylation events and lysyl oxidase-like 2 (LOXL2). EMT has been recently with stemness, opening new avenues for tumour initiation and metastatic dissemination.

The group is composed of several principal investigators leading specific research lines (see below) related to tumour progression and metastasis. The main objectives of the group are as follows:

1. Establish the role of various EMT-TFs in tumour progression and metastasis
2. Determine the role of LOXL2, LOXL3 and the microenvironment in epithelial plasticity and tumour progression
3. Determine the role of TGF β /endoglin and podoplanin in tumour progression
4. Determine the role of vitamin D in the regulation of EMT and stemness in colorectal tumours
5. Characterise stem cells and their niche in the epidermis and their influence on skin carcinogenesis

Research Lines

- Regulation of cell plasticity and tumour metastasis by EMT factors and lysyl oxidase LOXL2: Studies in mouse models of skin and breast tumorigenesis genetically modified for Loxl2, Snail and E47.
- LOXL3 involvement in melanomagenesis: Studies in melanoma cell lines and mouse models genetically modified for Loxl3.
- Genetic and molecular studies in breast and gynaecological cancers: Identification of novel predictive biomarkers.
- Characterization of novel resistance mechanisms in human cancer using high throughput techniques.
- Study of podoplanin role in epidermal homeostasis and skin cancer.
- Study of vitamin D effect on normal and cancer-associated fibroblasts and on normal and colon cancer patient-derived tumour organoids.
- Determine Δ Np73 role in tumour progression.
- Identify molecular alterations responsible for progression of precancerous colorectal lesions.

Research Activity**DOCTORAL THESES**

Carrasco Ramírez P. Podoplanina es un componente de vesículas extracelulares que reprograma el contenido

proteico de exosomas y modula la formación de vasos linfáticos [dissertation]. Madrid: UAM: 2016(1/04/2016).

Director: Quintanilla Ávila M

Ferrer Mayorga G. Efectos de la 1 α ,25-dihydroxyvitamin D3 en fibroblastos estromales de cáncer de colon [dissertation]. Madrid: UAM: 2016(25/11/2016).

Directors: Muñoz Terol A, Larriba Muñoz MJ

BOOKS AND BOOK CHAPTERS

Moreno-Bueno G. Alimentación, nutrición y cáncer: prevención y tratamiento. Chapter 6: Bases moleculares del cáncer. Madrid: UNED. 2016; p. 139-59.

PUBLICATIONS

- Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, Gil J, Moreno-Bueno G, Palmero I. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. *Oncogene*. 2016;35(27):3485-94. Article. IF: 7.519; D1
- Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Díez-Alarcía R, Juanes-García A, García-Taboada E, Hernández-Llorente R, Soriano J, Hamann S, Weners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Uriguen L, Gutkind JS, Guzmán M, Pérez-Gómez E, Sánchez C. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. *Oncotarget*. 2016;7(30):47565-75. Article. IF: 5.168; Q1
- Anta B, Pérez-Rodríguez A, Castro J, García-Domínguez CA, Ibiza S, Martínez N, Dura LM, Hernández S, Gragera T, Peña-Jiménez D, Yunta M, Zarich N, Crespo P, Serrador JM, Santos E, Muñoz A, Oliva JL, Rojas-Cabaneros JM. PGA(1)-induced apoptosis involves specific activation of H-Ras and N-Ras in cellular endomembranes. *Cell Death Dis*. 2016;7:e2311. Article. IF: 5.965; Q1
- Barbachano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Pau ECD, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Palmer HG, Rojas JM, Hernando E, Muñoz A. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. *Oncogene*. 2016;35(23):2991-3003. Article. IF: 7.519; D1
- Carrasco-Ramírez P, Greening DW, Andres G, Gopal SK, Martín-Villar E, Renart J, Simpson RJ, Quintanilla M. Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. *Oncotarget*. 2016;7(13):16070-89. Article. IF: 5.168; Q1
- Encabo-Berzosa MM, Gimeno M, Luján L, Sancho-Albero M, Gómez L, Sebastián V, Quintanilla M, Arruebo M, Santamaría J, Martín-Duque P. Selective delivery of photothermal nanoparticles to tumors using mesenchymal stem cells as Trojan horses. *Rsc Adv*. 2016;6(63):58723-32. Article. IF: 3.108; Q2
- Gahete MD, Rincon-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castano JP. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. *Oncotarget*. 2016;7(37):60110-22. Article. IF: 5.168; Q1
- García-Palmero I, Torres S, Bartolomé RA, Peláez-García A,



Larriba MJ, López-Lucendo M, Peña C, Escudero-Paniagua B, Muñoz A, Casal JI. Twist1-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen alpha 1(VI). *Oncogene*. 2016;35(40):5224-36. Article. IF: 7.519; D1

- Garranzo-Asensio M, Guzmán-Aránguez A, Poves C, Fernández-Acenero MJ, Torrente-Rodríguez RM, Montie VRV, Domínguez G, San Frutos L, Rodríguez N, Villalba M, Pingarrón JM, Campuzano S, Barderas R. Toward liquid biopsy: determination of the humoral immune response in cancer patients using haloTag fusion protein-modified electrochemical bioplatfoms. *Anal Chem*. 2016;88(24):12339-45. Article. IF: 6.32; D1
- Hellner K, Miranda F, Chedom DF, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Illiams R, Gaitskell K, Elorbany S, Xu RY, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miro M, Gatus S, Mota A, Moreno-Bueno G, Matías-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC, Kennedy SH, Hassan B, Lise S, García MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA. Pre-malignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. *Ebiomedicine*. 2016;10:137-49. Article. Not Indexed
- Hergueta-Redondo M, Sarrío D, Molina-Crespo A, Vicario R, Bernado-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez A, Castilla MA, González-Martín A, Pernas S, Cano A, Cortés J, Nuciforo PG, Peg V, Palacios J, Pujana MA, Arribas J, Moreno-Bueno G. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. *Oncotarget*. 2016;7(35):56295-08. Article. IF: 5.168; Q1
- Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KYM, Botthof J, Pérez-Gómez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. *Brit J Cancer*. 2016;115(2):212-22. Article. IF: 6.176; Q1
- Larriba MJ, de Herrerros AG, Muñoz A. Vitamin D and the epithelial to mesenchymal transition. *Stem Cells Int*. 2016: 6213872. Review. IF: 3.54; Q2
- Luengo-Gil G, Calvo MI, Martín-Villar E, Aguila S, Bohdan N, Antón AI, Espin S, de la Peña FA, Vicente V, Corral J, Quintanilla M, Martínez-Martínez L. Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. *Sci Rep-Uk*. 2016;6:27544. Article. IF: 4.259; Q1
- Núñez O, Román A, Johnson SR, Inoue Y, Hirose M, Casanova A, de Garibay GR, Herranz C, Bueno-Moreno G, Boni J, Mateo F, Petit A, Climent F, Soler T, Vidal A, Sánchez-Mut JV, Esteller M, López JI, García N, Guma A, Ortega R, Pla MJ, Campos M, Ansotegui E, Molina-Molina M, Valenzuela C, Ussetti P, Laporta R, Ancochea J, Xaubet A, Pollan M, Pujana MA. Study of breast cancer incidence in patients of lymphangioliomyomatosis. *Breast Cancer Res Tr*. 2016;156(1):195-201. Article. IF: 3.626; Q2
- Pérez C, Pérez-Zuniga FJ, Garrido F, Reytor E, Portillo F, Pajares MA. The oncogene PDRG1 is an interaction target of methionine adenosyltransferases. *Plos One*. 2016;11(8):e0161672. Article. IF: 2.806; Q1
- Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang XH, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, González-Suárez E, Esteller M, Moreno-Bueno G, Tjarnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MA. Cancer network activity associated with therapeutic response and synergism. *Genome Med*. 2016;8:88. Article. IF: 7.071; D1

PUBLIC PROJECTS

Cano García A. Contribution of LOXL2 and LOXL3y to tumour progression and metastasis (SAF2016-76504-R). MINECO. 2016-2019.

Management centre: UAM

Cano García A. Red Temática de Investigación Cooperativa en Cáncer-RTICC (RD12/0036/0007). ISCIII. 2013-2016.

Management centre: UAM

Domínguez Muñoz G. Implicación del deltanP73 en la diseminación tumoral: valor predictivo de recaída en pacientes con cáncer colorrectal estadio II (PI15/00246). ISCIII. 2016-2018.

Management centre: FIBHULP

Moreno Bueno G. Role of gasdermin B (GSDMB) in tumoral progression and clinical behaviour in HER2+ tumors (PI13/00132). ISCIII. 2014-2016.

Management centre: UAM

Muñoz Terol A. Cáncer de colon: efecto de la vitamina D sobre organoides normales y tumorales derivados de pacientes y sobre el microambiente tumoral (SAF2016-76377-R). 2016-2019.

Management centre: IIB "Alberto Sols"

Muñoz Terol A. Receptores Nucleares en Cáncer, Metabolismo e Inflamación" (NURCAMEIN) (Red de excelencia) (SAF2015-71878-REDT). MINECO. 2016-2017.

Management centre: IIB "Alberto Sols"

Muñoz Terol A. Red Temática de Investigación Cooperativa en Cáncer-RTICC. (RD12/0036/0021). 2013-2016.

Management centre: IIB "Alberto Sols"

Muñoz Terol A. Vitamina D y cáncer de colon: efectos sobre los fibroblastos estromales y células troncales e interrelación con las vías WNT de señalización (SAF2013-43468-R). MINECO. 2014-2016.

Management centre: IIB "Alberto Sols"

Quintanilla Ávila M. Función de las glicoproteínas de la superficie celular podoplanina y endogлина en la homeostasis de la piel y la carcinogénesis cutánea (SAF2013-46183-R). MINECO. 2014-2017.

Management centre: IIB "Alberto Sols"

PRIVATE PROJECTS

Cano García A. Understanding the role of Lysyl Oxidase-Like 2 in skin and breast cancer. Association for International Cancer Research. 2012-Ongoing.

Management Centre: UAM

Moreno Bueno G. Alteraciones moleculares relacionadas con la progresión tumoral en cáncer de endometrio. AECC. 2011-2016.

Management Centre: MD Anderson International Foundation

Moreno Bueno G. Genomic Approach for individualizing endometrial cancer diagnosis, prognosis and treatment. Fundació La Marató de TV3. 2014-2016.

Management Centre: Md Anderson International Foundation

INTERNATIONAL PROJECTS

Cano García A. Contribution of LOXL3 to melanomagenesis (VWCRI6-0295). Worldwide Cancer Research (formerly AICR), 2016-2018.

Management centre: 2016-2018

PATENTS AND TRADEMARKS


Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees. Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.


Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. EP14155510.2, PCT/EP2015/053387; 2014 February 18.





ANIMAL AND CELL MODELS FOR DETECTION AND CHARACTERIZATION OF LEUKEMIC STEM CELLS GROUP



Publications: **12**
Impact Factor: **74.737**
QI: **8**

Carmela Calés Bourdet

Profesora Titular Departamento de Bioquímica. UAM

Mónica Bravo Madrigal

Investigadora Predoctoral. UAM

Miguel Ramón Campanero García

Científico Titular. IIB "Alberto Sols"

Miguel Ángel Canales Albendea

Jefe de Sección de Hematología. HULP

Raquel de Paz Arias

Facultativo Especialista de Área en Hematología. HULP

Bárbara Fernández Morales

Investigadora Predoctoral. UAM

Dolores Hernández Maraver

Facultativo Especialista de Área en Hematología. HULP

Ana Kerguelen Fuentes

Facultativo Especialista de Área en Hematología. HULP

Yenny Montenegro Medina

Investigadora Postdoctoral. UAM

Marta Morado Arias

Técnico de Laboratorio. HULP

Gema Pérez Chacón

Investigadora Postdoctoral. IIB "Alberto Sols"

Juan Manuel Zapata Hernández

Científico Titular. IIB "Alberto Sols"

myelodysplastic or myeloproliferative syndromes, leukaemia and lymphoma. It is well known that alterations in transcriptional programs lead to transformed phenotypes, which are at the basis of the insidious acquisition of stem-like phenotypes of immature cells. Our group is interested in the role of transcriptional regulators, global regulators such as c-myc, c-myb, E2F and epigenetic controllers such as PcG factors in limiting the self-renewal capacity of common myeloid and lymphoid progenitors.

Our group has two main activities: basic research aimed to unravel the molecular mechanisms responsible for the acquisition of malignant haematological phenotypes (mouse models as well as ex vivo cell models to approach the questions outlined above); and research aimed to document clinical parameters and molecular markers that may be of use to a better understanding of the progression and outcome of haematological diseases, mainly myelodysplasia, lymphoma and multiple myeloma.

Research Lines

Role of epigenetic and transcriptional regulators in myelodysplasia: cellular and animal models

- Molecular and cellular basis of lymphoid neoplasias: non Hodgkin lymphomas and chronic lymphocytic leukaemia.
- Molecular markers of haematological malignancies.

Strategic Objective

Proper homeostasis of stem cells and pluripotent progenitor is pivotal to the development of haematopoietic proliferative disorders such as

Research Activity

PUBLICATIONS

- Álvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Barez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. *Brit J Haematol.* 2016;172(5):786-93. Article. IF: 5.67; Q1
- Álvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. *Haematol-Hematol J.* 2016;101(8):926-31. Article. IF: 7.702; D1
- Calés C, Pavón L, Starowicz K, Pérez C, Bravo M, Ikawa T, Koseki H, Vidal M. Role of polycomb RYBP in maintaining the B-1-to-B-2 B-cell lineage switch in adult hematopoiesis. *Mol Cell Biol.* 2016;36(6):900-12. Article. IF: 4.398; Q1
- Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjan JJ, Xiao ZJ, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, lanotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, te Boekhorst PAW, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease. *J Clin Oncol.* 2016;34(2):151-9. Article. IF: 24.008; D1
- Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. *Eur J Haematol.* 2016;96(3):285-90. Article. IF: 2.653; Q2
- González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. *Ann Hematol.* 2016;95(6):893-9. Article. IF: 3.083; Q2
- González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D. Long-term follow-up of a phase II trial of six cycles of dose-dense r-CHOP-14 for first-line treatment of diffuse large B-cell lymphoma in young and elderly patients. *Acta Haematol-Basel.* 2016;136(2):76-84. Article. IF: 1.205; Q4
- Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Álvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F. Long-term results of prednisone treatment for the anemia of myelofibrosis. *Leukemia Lymphoma.* 2016;57(1):120-4. Article. IF: 2.755; Q2
- Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A,

Caballero D. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase Ib study from GELTAMO group. *Brit J Haematol.* 2016;173(2):245-52. Article. IF: 5.67; Q1

- Pérez-Chacón G, Martínez-Laperche C, Rebolledo N, Somovilla-Crespo B, Muñoz-Calleja C, Buño I, Zapata JM. Indole-3-carbinol synergizes with and restores fludarabine sensitivity in chronic lymphocytic leukemia cells irrespective of p53 activity and treatment resistances. *Clin Cancer Res.* 2016;22(1):134-45. Article. IF: 9.619; D1
- Rebolledo N, Losada-Fernández I, Pérez-Chacón G, Castejón R, Rosado S, Morado M, Vallejo-Cremades MT, Martínez A, Vargas-Núñez JA, Pérez-Aciego P. Synergistic activity of deguelin and fludarabine in cells from chronic lymphocytic leukemia patients and in the New Zealand black murine model. *Plos One.* 2016;11(4):e0154159. Article. IF: 2.806; Q1
- Santacatterina F, Sánchez-Cenizo L, Formentini L, Mobasher MA, Casas E, Rueda CB, Martínez-Reyes I, de Arenas CN, García-Bermúdez J, Zapata JM, Sánchez-Arago M, Satrustegui J, Valverde AM, Cuezva JM. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. *Oncotarget.* 2016;7(1):490-508. Article. IF: 5.168; Q1

PUBLIC PROJECTS

Campanero García MR. Identificación y evaluación de nuevas dianas terapéuticas en cáncer (SAF2013-45258-P). MINECO. 2014-2016.

Management centre: UAM

PRIVATE PROJECTS

Canales Albendea MA. Programa para la investigación en neoplasias linfoides. ACERO. 2008-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Canales Albendea MA. Clínico estudio fase II de plitidepsin en pacientes con linfoma angioinmunoblástico de células T en recaída o refractario. Pharmamar S.A.

HULP Code: 4667. Sponsored's Protocol Code: APL-B-021-13.

Signature Date: 31/8/2016

Canales Albendea MA. Estudio abierto no aleatorizado de fase 2 en el que se estudia SAR3419 un anticuerpo anti-CD19 conjugado con maitansina administrado como monoterapia por infusión intravenosa a pacientes con linfoma b difuso de células grandes CD19+ recidivante o refractario al tratamiento. Sanofi Aventis S.A.

HULP Code: Anexo-2 3508. Sponsored's Protocol Code:

ARD10248.

Signature Date: 15/07/2016

Canales Albendea MA. Estudio de fase 3, aleatorizado, doble ciego, de grupos paralelos y controlado con fármaco activo para comparar la eficacia y la seguridad de ct-p10 y rituxan en pacientes con linfoma folicular con carga tumoral baja. Celltrion Inc.

HULP Code: Anexo-I 4511. Sponsored's Protocol Code: CT-P10

3.4.

Signature Date: 4/4/2016



Canales Albendea MA. Estudio fase IIb, comparativo, aleatorizado, de grupos paralelos, multicéntrico, para investigar la eficacia de rituximab subcutáneo (SC) versus rituximab intravenoso, ambos en combinación con chop (R.chop), en pacientes con linfoma difuso de células b grandes (LDCBG) CD20 positivo, no tratados previamente. F. Hoffmann-La Roche Ltd.

HULP Code: Anexo-1 3657. Sponsored's Protocol Code: MO28107.

Signature Date: 10/03/2016

Canales Albendea MA. Estudio fase III multicéntrico, abierto, aleatorizado de ofatumumab añadido a clorambucilo en sujetos con leucemia linfocítica crónica no tratados previamente. Novartis Farmaceutica S.A.

HULP Code: Anexo-2 2774. Sponsored's Protocol Code: OMB110911.

Signature Date: 17/05/2016

Canales Albendea MA. Estudio multicéntrico, fase III, abierto, aleatorizado, en pacientes con linfoma no-Hodgkin indolente avanzado, previamente no tratados para evaluar el beneficio de GAI01 (RO5072759) más quimioterapia en comparación con rituximab más quimioterapia seguida de terapia de mantenimiento con ga101 o rituximab en pacientes respondedores. F. Hoffmann-La Roche Ltd.

HULP Code: Anexo-2 3352. Sponsored's Protocol Code: BO21223.

Signature Date: 19/04/2016

Canales Albendea MA. Estudio observacional retrospectivo para describir el manejo de pacientes con linfoma de células del manto en recaída o refractario en la práctica clínica habitual (IMORS). Janssen-Cilag España S.A.

HULP Code: PI-2286. Sponsored's Protocol Code: JAN-IBR-2015-01.

Signature Date: 4/4/2016

de Paz Arias R. Estudio aleatorizado y sin enmascaramiento de ponatinib en comparación con nilotinib en pacientes con leucemia mielógena crónica en fase crónica resistentes a imatinib. Ariad Pharmaceutical Inc.

HULP Code: 4526. Sponsored's Protocol Code: AP24534-15-303.

Signature Date: 12/1/2016

de Paz Arias R. Estudio clínico de fase 2, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de pevonedistat más azacitidina frente a azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielógena aguda pobre en blastos. Millennium Pharmaceuticals Inc.

HULP Code: 4571. Sponsored's Protocol Code: Pevonedistat-2001.

Signature Date: 17/8/2016

de Paz Arias R. Estudio fase III, multicéntrico doble ciego, controlado con placebo en combinación con azacitidina en sujetos con síndromes mielodisplásicos (SMD) de riesgo intermedio-1, intermedio 2 o alto según el IPSS. Glaxosmithkline S.A.

HULP Code: Anexo-4 4134. Sponsored's Protocol Code: TRC112121.

Signature Date: 16/6/2016

de Paz Arias R. Estudio multicéntrico, de un único brazo, de remisión libre de tratamiento de nilotinib, en pacientes con leucemia mieloide crónica en fase crónica con bcr-abl1 positivo, que han alcanzado un estado de enfermedad residual mínima (ERM) duradera con tratamiento de primera línea con nilotinib. Novartis Farmaceutica S.A.

HULP Code: Anexo-1 3807. Sponsored's Protocol Code: CAM-N10712201.

Signature Date: 14/1/2016

Gómez Prieto P. Ensayo aleatorizado y doble ciego para evaluar la eficacia, la seguridad y la inmunogenicidad de ABP 798 en comparación con rituximab en sujetos con linfoma no Hodgkin (LNH) de células B CD20+. Amgen S.A.

HULP Code: Anexo-1 4216. Sponsored's Protocol Code: 20130109.

Signature Date: 12/4/2016

Morado Arias M. Protocolo de registro de la enfermedad de Gaucher. Genzyme Europe BV.

HULP Code: 4122. Sponsored's Protocol Code: GEN-GAU-2013-01. Signature Date: 27/5/2016

PATENTS AND TRADEMARKS

Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees. Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees. Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

RESEARCH AND DIAGNOSIS OF INHERITED METABOLIC DISEASES GROUP



Publications: 11

Impact Factor: 54.084

QI: 6

María Belén Pérez González

Profesora Titular. UAM
CBM "Severo Ochoa"

Patricia Alcaide Alonso
Investigadora Postdoctoral. CEDEM

Sandra Dolores Arduim Brasil
Investigadora Postdoctoral. CBM "Severo Ochoa"

Margarita Castro Reguera
Investigadora Predoctoral. CEDEM

Magdalena de Ugarte Pérez
Directora del CEDEM. CEDEM

María Jesús Ecay Crespo
Técnico de Laboratorio. CIBERER

Isaac Ferrer López
Técnico de Laboratorio. CEDEM

María Alejandra Gámez Abascal
Investigadora Senior (Contrato Ramón y Cajal). CBM "Severo Ochoa"

Fernando García Muñoz
Técnico de Laboratorio. CEDEM

Ana Jorge Finnigan
Investigadora Postdoctoral. CBM "Severo Ochoa"

Fátima Leal Pérez
Técnico de Laboratorio. CIBERER

Celia Medrano Rodríguez
Investigadora Predoctoral. CEDEM

María Begoña Merinero Cortés
Investigadora Senior. CEDEM

Rosa María Navarrete López de Soria
Técnico de Laboratorio. CIBERER

Celia María Lourdes Pérez-Cerdá Silvestre
Investigadora Senior. CEDEM

Isabel Reina Alba
Secretaría. CEDEM

Eva María Richard Rodríguez
Profesora Titular. UAM
CBM "Severo Ochoa"

María Pilar Rodríguez Pombo
Profesora Titular. UAM
CBM "Severo Ochoa"

María Lourdes Ruiz Desviat
Profesora Titular. UAM
CBM "Severo Ochoa"

Pedro Ruiz Sala
Investigador Postdoctoral. CEDEM

María Paloma Sanz Rebollo
Técnico de Laboratorio. CEDEM

Ana Isabel Vega Pajares
Investigadora Postdoctoral. CEDEM

Strategic Objective

- Development of genomic and metabolomic techniques aimed at improving the diagnosis of hereditary metabolic diseases.
- Study of mitochondrial dysfunction and oxidative stress as a modifier of the clinical phenotype and as a potential therapeutic target in organic acidurias.
- Development of animal and cellular models.
- Registry of patients with hereditary metabolic diseases.



Research Lines

- Improved diagnosis of congenital defects of glycosylation and mitochondrial defects through the application of genomic techniques (RNAseq and DNAseq of exoma and genome) and metabolomics.
- Identification of intronic mutations by the capture of the PAH and OTC gene. Functional validation in cellular splicing systems.
- Development of antisense therapy and pharmacological chaperones as therapeutic approaches transverse and applicable to numerous EMH.
- Study of oxidative stress and evaluation of common signatures of neuropathogenicity and cardiotoxicity in congenital defects of glycosylation, organic acidemias and mitochondrial diseases.
- Evaluation of drugs aimed at the recovery of mitochondrial function and biogenesis.
- Search for biomarkers as predictors of HMS severity and as systems for the evaluation of pharmacological therapies.
- Characterization of pathophysiology in a murine model of propionic acidemia.
- Identification of dysregulated miRNA in propionic acidemia and characterization of its association with pathology and its usefulness as biomarkers.
- Generation of iPSCs of patients with organic acidemia and congenital defects of glycosylation and differentiation to hepatocytes, neural progenitors or cardiomyocytes.

Research Activity

DOCTORAL THESES

Oyarzábal Sanz AL. Del gen a la patofisiología: nuevas enfermedades asociadas al catabolismo de los aminoácidos ramificados [dissertation]. Madrid: UAM: 2016(14/06/2016).

Director: Rodríguez Pombo P.

PUBLICATIONS

- Aldámiz-Echevarría L, Larena M, Bueno MA, Dalmau J, Vitoria I, Fernández-Marmiesse A, Andrade F, Blasco J, Alcalde C, Gil D, García MC, González-Lamuno D, Ruiz M, Ruiz MA, Peña-Quintana L, González D, Sánchez-Valverde F, Desviat LR, Pérez B, Couce ML. Molecular epidemiology, genotype-phenotype correlation and BH4 responsiveness in Spanish patients with phenylketonuria. *J Hum Genet.* 2016;61(8):731-44. Article. IF: 2.471; Q3
- Gallego-Villar L, Rivera-Barahona A, Cuevas-Martín C, Guenzel A, Pérez B, Barry MA, Murphy MP, Logan A, González-Quintana A, Martín MA, Medina S, Gil-Izquierdo A, Cuezva JM, Richard E, Desviat LR. In vivo evidence of mitochondrial dysfunction and altered redox homeostasis in a genetic mouse model of propionic acidemia: Implications for the pathophysiology of this disorder. *Free Radical Bio Med.* 2016;96:1-12. Article. IF: 5.606; Q1
- Jansen JC, Cirak S, van Scherpenzeel M, Timal S, Reunert J, Rust S, Pérez B, Vicogne D, Krawitz P, Wada Y, Ashikov A, Pérez-Cerdá C, Medrano C, Arnoldy A, Hoischen A, Huijben K, Steenbergen

G, Quelhas D, Diogo L, Rymen D, Jaeken J, Guffon N, Cheillan D, van den Heuvel LP, Maeda Y, Kaiser O, Schara U, Gerner P, van den Boogert MAW, Holleboom AG, Nassogne MC, Sokal E, Salomon J, van den Bogaart G, Drenth JPH, Huynen MA, Veltman JA, Wevers RA, Morava E, Matthijs G, Foulquier F, Marquardt T, Lefeber DJ. CCDC115 deficiency causes a disorder of golgi homeostasis with abnormal protein glycosylation. *Am J Hum Genet.* 2016;98(2):310-21. Article. IF: 9.025; D1

- Martínez-Pizarro A, Desviat LR, Ugarte M, Pérez B, Richard E. Endoplasmic reticulum stress and autophagy in homocystinuria patients with remethylation defects. *Plos One.* 2016;11(3):e0150357. Article. IF: 2.806; Q1
- Ortigoza-Escobar JD, Molero-Luis M, Arias A, Martí-Sánchez L, Rodríguez-Pombo P, Artuch R, Pérez-Dueñas B. Treatment of genetic defects of thiamine transport and metabolism. *Expert Rev Neurother.* 2016;16(7):755-63. Review. IF: 3.149; Q2
- Ortigoza-Escobar JD, Molero-Luis M, Arias A, Oyarzábal A, Darín N, Serrano M, García-Cazorla A, Tondo M, Hernández M, García-Villoria J, Casado M, Gort L, Mayr JA, Rodríguez-Pombo P, Ribes A, Artuch R, Pérez-Dueñas B. Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome. *Brain.* 2016;139(1):31-8. Article. IF: 10.292; D1
- Ortigoza-Escobar JD, Oyarzábal A, Montero R, Artuch R, Jou C, Jiménez C, Gort L, Briones P, Muchart J, López-Gallardo E, Emperador S, Pesini ER, Montoya J, Pérez B, Rodríguez-Pombo P, Pérez-Dueñas B. Ndufs4 related Leigh syndrome: A case report and review of the literature. *Mitochondrion.* 2016;28:73-8. Review. IF: 3.704; Q2
- Oyarzábal A, Bravo-Alonso I, Sánchez-Arago M, Rejas MT, Merinero B, García-Cazorla A, Artuch R, Ugarte M, Rodríguez-Pombo P. Mitochondrial response to the BCKDK-deficiency: Some clues to understand the positive dietary response in this form of autism. *Bba-Mol Basis Dis.* 2016;1862(4):592-600. Article. IF: 5.476; Q1
- Sala PR, Ruijter G, Acquaviva C, Chabli A, de Sain-van der Velden MGM, García-Villoria J, Heiner-Fokkema MR, Jeannesson-Thivisol E, Leckstrom K, Franzson L, Lynes G, Olesen J, Onkenhout W, Petrou P, Drousiotou A, Ribes A, Vianey-Saban C, Merinero B. Pilot experience with an external quality assurance scheme for acylcarnitines in plasma/serum. *JIMD Rep.* 2016;30:23-31. Article. Not Indexed
- Stojiljkovic M, Klaassen K, Djordjevic M, Sarajlija A, Brasil S, Kecman B, Grkovic S, Kostic J, Rodríguez-Pombo P, Desviat LR, Pavlovic S, Pérez B. Molecular and phenotypic characteristics of seven novel mutations causing branched-chain organic acidurias. *Clin Genet.* 2016;90(3):252. Article. IF: 3.326; Q2
- Vega AI, Medrano C, Navarrete R, Desviat LR, Merinero B, Rodríguez-Pombo P, Vitoria I, Ugarte M, Pérez-Cerdá C, Pérez B. Molecular diagnosis of glycogen storage disease and disorders with overlapping clinical symptoms by massive parallel sequencing. *Genet Med.* 2016;18(10):1037-43. Article. IF: 8.229; D1

PUBLIC PROJECTS

Pérez González MB. Acidemia metilmalónica: identificación de genes responsables, generación de modelos celulares de enfermedad e investigación en terapias (PI13/01239). ISCIII. 2014-2016.

Management centre: UAM

Pérez González MB. Desarrollo de una plataforma para el diagnóstico por secuenciación de nueva generación (ACCI2015). CIBERER. 2015-2016.

Management centre: UAM

Ruiz Desviat ML. In vivo and vitro studies of affected cellular pathways and genetic therapies in neurometabolic diseases (SAF2013-43005-R). MINECO. 2014-2016.

Management centre: UAM

PRIVATE PROJECTS

Pérez González MB. Bases moleculares de las enfermedades neurometabólicas y desarrollo de terapias específicas de mutación. Fundación Isabel Gemio. 2016-2020.

Management centre: Fundación Severo Ochoa

Pérez González MB. Tratamiento de CDG con reguladores de la proteostasis. Asociación Española para el estudio de CDG. 2016.

Management centre: Fundación Severo Ochoa

Ruiz Desviat ML. Análisis genómicos y transcriptómicos para identificar defectos de splicing y evaluación in vivo de la terapia antisentido. Fundación Ramón Areces. 2015-2019.

Management centre: Fundación Severo Ochoa

INTERNATIONAL PROJECTS

Pérez González MB. Strengthening the research potential of imge through reinforcement of biomedical science of rare diseases in Serbia – en route for innovation (serbor-disinn) (FP7-REGPOT). EU. 2013-2016.

Management centre: UAM

Pérez González MB. European Research Network directed towards improving diagnosis and treatment of inborn error of glycosylation (E-rare-3 JTC2015). EU. 2016-2018.


Management centre: UAM

Ruiz Desviat ML. Networking towards clinical application of antisense-mediated exon skipping. European Cooperation in Science and Technology (COST BM1207). EU. 2013-2017.

Management centre: UAM

PATENTS AND TRADEMARKS

B. Pérez, A. Gámez, P. Yuste, S. Brasil, M. Ugarte A. Martínez, J. Underhaug. Compounds for treating congenital disorders of Glycosylation. EP16382373.5 (EUROPA).





REGULATION OF CILIARY STRUCTURE AND FUNCTION BY PHOSPHOINOSITIDES GROUP*



Francesc García Gonzalo

Investigador Ramón y Cajal. UAM

Pablo Barbeito González

Investigador Postdoctoral. UAM

Raquel Martín Morales

Investigadora Predoctoral. UAM

Belén Sierra Rodero

Investigadora Predoctoral. UAM

Strategic Objective

Cilia are essential for our health and play important roles in some of our diseases. Our goal is to better understand how cilia work and how they can be manipulated to promote human health.

But what are cilia and why are they important for our health?

Cilia are cell membrane protrusions with an endoskeleton consisting of nine microtubule doublets. This basic architecture, shared by both cilia and flagella, is conserved from unicellular organisms to humans. There are two kinds of cilia: motile and immotile (a.k.a. primary). Motile cilia resemble oars, displacing extracellular fluids. This is how we expel mucus from our bronchi and how sperm swim. Instead, primary cilia behave like antennae, detecting optical, mechanical or chemical signals. Our vision, hearing and smell depend on immotile cilia. Primary cilia also

monitor urine flow in the kidney, act as sensors for hunger-controlling hormones in the brain, and control limb and nervous system patterning in the embryo, among many other functions.

Congenital ciliary defects cause ciliopathies, genetically and clinically diverse illnesses whose most common symptoms include mental retardation, retinal degeneration, kidney cysts, polydactyly, obesity, sterility, respiratory infections, and skeletal, heart and brain malformations. Many ciliopathies are rare syndromes (Meckel, Joubert, Bardet-Biedl, Kartagener, etc.), whereas others are more common and affect a single organ (polycystic kidney disease, retinitis pigmentosa).


Ciliopathies are not the only diseases cilia are involved in. Several cancer types, like medulloblastoma and basal cell carcinoma, arise from abnormal activation of Hedgehog signaling, a ciliary pathway

essential for embryonic development and adult stem cell function. On the other hand, increasing evidence suggests that cilia modulate the progression of other diseases, such as diabetes and Alzheimer's.

Given that ciliary function is critically dependent on their composition, our main strategy consists in understanding the molecular mechanisms underlying: (1) ciliary accumulation of the receptors and transducers that sensitize cilia to external stimuli, and (2) the changes in cilia composition whereby ciliary signals are relayed to the rest of the cell.

Research Lines

- Role of phosphoinositides in ciliary signal transduction.
- Regulation of cilia composition by phosphoinositides.
- Regulation of cilia composition by transition zone proteins.
- Factors affecting the ciliary localization of Hedgehog pathway proteins.
- Factors affecting the ciliary localization of polycystic kidney disease proteins.



* Group recently created: february 2017



3.6 Surgery, Transplant and Health Technologies Area

Leopoldo Martínez Martínez

Documents: **174** IF: **351.686**
 Originals: **141** IF: **281.096**
 DI: **11** QI: **35**

- Congenital Malformation Surgery Group
- Bone Pathophysiology and Biomaterials Group
- Cellular Engineering Group
- Clinical Pharmacology Group
- Osteoarticular Surgery Research — GICOA Group
- Reconstructive and Regenerative Research Group
- Transplant Group

CONGENITAL MALFORMATION SURGERY GROUP



Publications: **13**
 Impact Factor: **24.313**
 QI: **2**

Leopoldo Martínez Martínez

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

Rosa María Aras López

Investigadora Postdoctoral. UAM

Mercedes Díaz González

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

José Luis Encinas Hernández

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

Sara Sánchez Lago

Investigadora predoctoral. HULP

Ana Lourdes Luis Huertas

Investigadora postdoctoral. HULP

María Teresa Vallejo Cremades

Investigadora Postdoctoral (Contrato de Estabilización de Técnicos de Apoyo). Jefe de Laboratorio. HULP

embryo, prenatal chances for intervention on the malformations, and postnatal treatments including organ replacement.

Research Lines

- Congenital malformations.
- Small bowel transplantation and graft rejection.
- Fetal surgery.

Research Activity

PUBLICATIONS

- Andrés AM, Santamaría M, Hernández-Oliveros F, Guerra L, López S, Stringa P, Vallejo MT, Largo C, Encinas JL, de las Heras MSG, López-Santamaría M, Tovar JA. Difficulties, guidelines and review of developing an acute rejection model after rat intestinal transplantation. *Transpl Immunol.* 2016;36:32-41. Review. IF: 1.78; Q3
- Rebolledo N, Losada-Fernández I, Pérez-Chacón G, Castejón R, Rosado S, Morado M, Vallejo-Cremades MT, Martínez A, Vargas-Núñez JA, Pérez-Aciego P. Synergistic activity of deguelin and fludarabine in cells from chronic lymphocytic leukemia patients and in the New Zealand black murine model. *Plos One.* 2016;11(4):e0154159. Article. IF: 2.806; Q1
- Silva JT, San-Juan R, Fernández-Caamaño B, Prieto-Bozano G, Fernández-Ruiz M, Lumbreras C, Calvo-Pulido J, Jiménez-Romero C, Resino-Foz E, López-Medrano F, López-Santamaría M, Aguado JM. Infectious complications following small bowel transplantation. *Am J Transplant.* 2016;16(3):951-9. Article. IF: 6.165; D1

Strategic Objective

Paediatric surgery is an independent specialty that deals with all aspects of the surgical diseases of children. Its scope involves a wide range of clinical problems such as trauma, tumours and inflammatory diseases, and, more specifically, malformations. These conditions almost always have essentially unknown origins and are caused by unknown mechanisms. Surgery is required at various times in the life of patients with malformations, ranging from neonatal anatomical and functional reconstruction to replacement of dysfunctional organs later in life.

As a consequence, this line of research has an unusually broad spectrum as it encompasses the study of cellular and molecular mechanisms leading to malformations, the biology of the malformed foetus and



- García-Gómez S, Doforno RA, Martínez-Barricarte R, Torres JM, Cerdán AF, Dávila M, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Vallejo-Cremades MT, López-Collazo E, Arquero MF, Sánchez-Ramón S, Casanova JL, de Diego RP. Actin polymerisation after FC gamma R stimulation of human fibroblasts is BCL10 independent. *Clin Immunol*. 2016;163:120-2. Letter. IF: 3.99; Q2
- Chocarro G, Junco PT, Domínguez E, Amesty MV, Cerezo VN, Hernández F, Murcia J, Tovar JA, Santamaría ML. Portal cavernoma in the era of mesoportal shunt (Rex) and liver transplant in children. *Eur J Pediatr Surg*. 2016;26(1):7-12. Article. IF: 1.313; Q3
- Zani A, Eaton S, Puri P, Rintala R, Lukac M, Bagolan P, Kuebler JF, Friedmacher F, Hoellwarth ME, Wijnen R, Tovar JA, Pierro A. International survey on the management of congenital diaphragmatic hernia. *Eur J Pediatr Surg*. 2016;26(1):38-46. Article. IF: 1.313; Q3
- Chocarro G, Amesty MV, Encinas JL, Sánchez AV, Hernández F, Andrés AM, Gámez M, Tovar JA, Santamaría ML. Congenital portosystemic shunts: clinic heterogeneity requires an individual management of the patient. *Eur J Pediatr Surg*. 2016;26(1):74-80. Article. IF: 1.313; Q3
- Dore M, Junco PT, Andrés AM, Sánchez-Galán A, Amesty MV, Ramos E, Prieto G, Hernández F, Santamaría ML. Surgical rehabilitation techniques in children with poor prognosis short bowel syndrome. *Eur J Pediatr Surg*. 2016;26(1):112-6. Article. IF: 1.313; Q3
- Amesty MV, Chocarro G, Sánchez AV, Cerezo VN, de la Torre CA, Encinas JL, Arance MG, Hernández F, Santamaría ML. Mesohepatectomy for centrally located tumors in children. *Eur J Pediatr Surg*. 2016;26(1):128-32. Article. IF: 1.313; Q3
- Aras-López R, Tovar JA, Martínez L. Possible role of increased oxidative stress in pulmonary hypertension in experimental diaphragmatic hernia. *Pediatr Surg Int*. 2016;32(2):141-5. Article. IF: 1.181; Q3
- Antolín E, Rodríguez R, Encinas JL, Herrero B, Muner M, Pérez R, Ortíz L, Bartha JL. Patterns of fetal lung growth in fetuses with isolated left-sided congenital diaphragmatic hernia. *J Matern-Fetal Neo M*. 2016;29(15):2442-9. Article. IF: 1.826; Q3
- Dore Reyes M, Triana Junco P, Barrera Delfa S, Encinas J L, Romo Muñoz M, Vilanova Sánchez A, Chocarro Amatriain G, Hernández Oliveros F, Martínez Martínez L, López-Santamaría M. Primary versus secondary closure: ventilatory and nutritional differences in patients with gastrosquisis. *Cir Pediatr*. 2016;29(2):49-53. Article. Not Indexed
- Vilanova-Sánchez A, Sánchez Galán A, Andrés Moreno A M, Encinas Hernández J L, Núñez Cerezo V, Amesty Morello V, Chocarro Amatriain G, Martínez Martínez L, Martínez-Urrutia M J, López Santamaría M. Gynecological abnormalities in patients with rectovestibular fistula. *Cir Pediatr*. 2016;29(2):72-6. Article. Not Indexed

PUBLIC PROJECTS

Encinas Hernández JL. Estudio del potencial neuroprotector e inmunomodulador local de las células madre mesenquimales en la cirugía fetal del mielomeningocele de un modelo teratogénico (PI12/01040). ISCIII. 2013-2017.

Management centre: FIBHULP

Martínez Martínez L. Red de Salud Materno Infantil y del Desarrollo (Red SAMID) (RD12/0026/0011). ISCIII. 2013-2017.

Management centre: FIBHULP

Martínez Martínez L. Estudio comparativo del espectro de alcohol fetal según dos patrones de consumo humano y su prevención con antioxidantes (PI15/01179). ISCIII. 2016-2018.

Management centre: FIBHULP

Vallejo Cremades MT. Contratos de Estabilización de Técnicos de Apoyo. CAM, ISCIII. 2008-2016.

Management centre: FIBHULP

PRIVATE PROJECTS

Encinas Hernández JL. El estudio del potencial neuroprotector e inmunomodulador local del trasplante de células madre mesenquimales y sus implicaciones en la cirugía fetal de los defectos del tubo neural. Fundación Mutua Madrileña. 2012-Ongoing.

Management centre: FIBHULP

Martínez Martínez L. Proyecto de investigación en tecnologías terapéuticas avanzadas: dinamización del centro de simulación. Curso de suturas. Clientes Varios. 2015-Ongoing.

Management centre: FIBHULP

Vallejo Cremades MT. Servicios de investigación de la Plataforma de Apoyo de IdiPAZ, Laboratorio Inmunohistoquímica y Análisis de Imagen. 2012-Ongoing.

Management centre: FIBHULP

Vallejo Cremades MT. Formación en Investigación de actividades organizativas y de gestión de trabajo técnico en laboratorio. Opesa Centro de Formación. 2015-Ongoing.

Management centre: FIBHULP

Vallejo Cremades MT. Formación en Investigación en Anatomía Patológica. 2016-Ongoing.

Management centre: FIBHULP

BONE PATHOPHYSIOLOGY AND BIOMATERIALS GROUP



Publications: 6

Impact Factor: 11.069

QI: 1

Nuria Elda Vilaboa Díaz

Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP

Fátima Bensiamar Hadia

Técnico de Laboratorio. HULP - CIBER BBN

Alba Boré Medina

Técnico de Laboratorio. HULP - CIBER BBN

Clara Escudero Duch

Investigadora Predoctoral. HULP

Mabel Falguera Uceda

Investigadora Predoctoral. HULP

Eduardo García Cimbrello

Jefe de Servicio de Cirugía Ortopédica y Traumatológica A. HULP

Profesor Asociado. Departamento de Cirugía. Facultad de Medicina. UAM

Enrique Gil Garay

Jefe de Servicio de Cirugía Ortopédica y Traumatológica B. HULP

Profesor Titular. Departamento Cirugía. Facultad de Medicina. UAM

Francisco José Mancebo Pascual

Ayudante de Investigación. HULP

Carmen Martín Hervás

Facultativo Especialista de Área en Radiodiagnóstico. HULP

Profesora Asociada. Facultad de Medicina. UAM

Francisco Manuel Martín Saavedra

Investigador Postdoctoral. HULP - CIBER BBN

Laura Muñoz Moreno

Investigadora Postdoctoral. HULP - CIBER BBN

Laura Saldaña Quero

Investigadora Senior (Contrato Miguel Servet- Tipo I). Jefe de Laboratorio. HULP

Silvia Sánchez Casanova

Ayudante de Investigación. HULP

Gema Vallés Pérez

Investigadora Senior. Responsable de Cultivos Celulares y de los Laboratorios Comunes de IdiPAZ. HULP

Strategic Objective

The Bone Physiopathology and Biomaterials group includes basic and clinical researchers from IdiPAZ. The group has broad experience in clinical and basic research on biomaterials for orthopaedic implants and bone tissue engineering. The principal goal of the group is to improve the clinical outcome of orthopaedic surgery through research on implants and biomaterials used for manufacturing prosthetic devices. The group is also interested in bone tissue engineering applications, developing surgical procedures that make use of allotransplants, evaluating scaffolds manufactured by collaborative partners and developing novel gene therapy strategies aimed to heal bone defects. Specific areas of clinical research on implants include follow-up studies on various devices in use for osteoarticular surgery.

The main areas of interest in basic research on the biocompatibility of materials include: a) understanding the influence of the surface biomaterial properties on the behaviour of bone-related cells b) the study of cell reactions occurring in the vicinity of implanted materials caused by wear particles and c) the deliberate manipulation of cell responses after exposure to nanoparticles designed for gene delivery and optical hyperthermia applications.

The team is also interested in the development of effective protocols to enhance the therapeutic potential of MSCs for bone regeneration therapies as well as transcriptional targeting strategies to ensure tight control of the expression of therapeutic proteins and their potential application in inducing an orchestrated expression of growth factors involved in bone healing.



Research Lines

- Clinical research in implants for bone repair.
- Biocompatibility of new materials for potential use in implants for bone repair: cell and surface interactions, cell and particle interactions.
- Study of the connections between the immune and skeletal systems during bone tissue regeneration.
- Control of the expression of therapeutic genes using gene circuits.

Research Activity

DOCTORAL THESES

Fernández Fernández R. Resultados superiores del titanio frente al cromocobalto en cirugía primaria de cadera: resultados a largo plazo con el vástago Meridian[dissertation]. Madrid: UAM: 2016(21/04/2016).

Director: Gil Garay E.

Moreno García AC. Terapia celular con células troncales derivadas de tejido adiposo (ADSC) para mejorar el proceso de reparación de defectos óseos en un modelo animal[dissertation]. Madrid: UAM: 2016(04/07/2016).

Director: Gil Garay E.

PUBLICATIONS

- Bensiamar F, Olalde B, Cifuentes SC, Argarate N, Atorrasagasti G, González-Carrasco JL, García-Rey E, Vilaboa N, Saldaña L. Bioactivity of dexamethasone-releasing coatings on polymer/magnesium composites. *Biomed Mater*. 2016;11(5):55011. Article. IF: 2.469; Q2
- Cifuentes SC, Bensiamar F, Gallardo-Moreno AM, Osswald TA, González-Carrasco JL, Benavente R, González-Martín ML, García-Rey E, Vilaboa N, Saldaña L. Incorporation of Mg particles into PDLLA regulates mesenchymal stem cell and macrophage responses. *J Biomed Mater Res A*. 2016;104(4):866-78. Article. IF: 3.076; Q2
- Crespo L, Hierro-Oliva M, Barriuso S, Vadillo-Rodríguez V, Montealegre MA, Saldaña L, Gómez-Barrera E, González-Carrasco JL, González-Martín ML, Vilaboa N. On the interactions of human bone cells with Ti6Al4V thermally oxidized by means of laser shock processing. *Biomed Mater*. 2016;11(1):15009. Article. IF: 2.469; Q2
- García-Rey E, García-Cimbreló E. Abductor biomechanics clinically impact the total hip arthroplasty dislocation rate A prospective long-term study. *J Arthroplasty*. 2016;31(2):484-90. Article. IF: 3.055; Q1
- Calcerrada N, Fernández-Vega A, Valls-León C, García-Cimbreló E. Survey on the use and behaviour of metal-metal hip replacements in Spain. *Rev Esp Cir Ortop Traumatol*. 2016;60(1):20-8. Article. Not Indexed
- Martín-Saavedra F, Vilaboa N. Remote patterning of transgene expression using near infrared-responsive plasmonic hydrogels. *Methods Mol Biol*. 2016;1408:281-92. Article. Not Indexed

PUBLIC PROJECTS

Escudero Duch C. Contrato Predoctoral de Formación en Investigación (FI14/00447). ISCIII. 2015-2018.

Management centre: FIBHULP

Saldaña Quero L. Contrato Miguel Servet Tipo I (MSI1/00022). ISCIII. 2012-2016.

Management centre: FIBHULP

Saldaña Quero L. Precondicionamiento inflamatorio de células madre mesenquimales para su aplicación en terapias avanzadas de regeneración ósea mediante ingeniería de tejidos (PI15/00752). ISCIII. 2016-2018.

Management centre: FIBHULP

Saldaña Quero L. Respuesta celular a nuevos materiales compuestos bioreabsorbibles para osteosíntesis de PLLA con alta fracción de volumen de MG (MAT2012-37736-C05-05). MINECO. 2013-2016.

Management centre: FIBHULP

Sánchez Casanova S. Contrato Ayuda Investigación (PEJ15/BIO/AI-0250). CAM. 2016-2018.

Management centre: FIBHULP

Vilaboa Díaz NE. Biofunctionalization of titanium implant surfaces: protein conformation, osseointegration and antimicrobial activity (BIOSURFACES2016). CIBER-BBN. 2016-2017.

Management centre: CIBER-BBN

Vilaboa Díaz NE. Control espaciotemporal de la expresión de transgenes mediante irradiación con luz en el infrarrojo cercano (SAF2013-50364-EXP). MINECO. 2014-2017.

Management centre: FIBHULP

Vilaboa Díaz NE. Dynamic molecular bio-interfaces for controlled environments towards vascular morphogenesis (DYNAMIC-VASC-2). CIBER-BBN. 2016-2017.

Management centre: CIBER-BBN

Vilaboa Díaz NE. Hacia una terapia avanzada de regeneración ósea: intermediarios tisulares activables mediante energía infrarroja para la expresión controlada de factores osteogénicos y angiogénicos (PI15/01118). ISCIII. 2016-2018.

Management centre: FIBHULP

Vilaboa Díaz NE. Innovative biomedical tools for the early diagnosis and treatment of osteoporosis and osteoarthritis (OSTEOMIR). CIBER-BBN. 2016-2017.

Management centre: CIBER-BBN

Vilaboa Díaz NE. Materiales multifuncionales para los retos de la sociedad (S2013/MIT-2862). CAM. 2014-2018.

Management centre: FIBHULP

Vilaboa Díaz NE. Contrato Miguel Servet estabilización (I2). CAM, ISCIII. 2013.

Management centre: FIBHULP

Vilaboa Díaz NE. NIR-Responsive scaffolds for deliberate regulation of transgene expression in bone tissue engineering (HOT-SCAFF extended). CIBER-BBN. 2016-2017.

Management centre: CIBER-BBN

Vilaboa Díaz NE. Red de Investigación para el desarrollo de implantes de titanio funcionalizados (BIOIMPLANT) (MAT2014-52905-REDT). MINECO. 2014-2016.

Management centre: Universidad Politécnica de Valencia

PRIVATE PROJECTS

Vilaboa Díaz NE. Detección de activación de HSF parte II-parte XI. HSF Pharmaceuticals. 2004-Ongoing.

Management centre: FIBHULP

Vilaboa Díaz NE. Animal Model of Bone regeneration Induced by tissue intermediates responsive to near-infrared light (AMBIT). Roche Farma S.A. 2016-Ongoing.

Management centre: FIBHULP

PATENTS AND TRADEMARKS

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), assignees. Method to obtain a metallic-coated biomaterial. P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications. P201030950, PCT/ES2011/070440; 2010 June 21.

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Inhibitors of heat shock factor 1 and uses thereof. US 62/495,501; 2016 Sep 15.

nee. Ultrasound-triggerable agents for tissue engineering. PCT/US2013/044817, US2013/0330389; 2012 June 08.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), assignees. Chamber device for dynamic cell culture on biomaterials. P201330040, PCT/ES2013/070819; 2013 January 16.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernández V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles. P201330894, PCT/ES2014/070484; 2013 June 14.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER), assignees. Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Voellmy R, Vilaboa N, inventors; HSF Pharmaceuticals SA, assignee. Inhibitors of heat shock factor 1 and uses thereof. US 62/495,501; 2016 Sep 15.



CELLULAR
ENGINEERING
GROUP

Publications: **23**
 Impact Factor: **56.074**
 QI: **4**

María Paz de Miguel González

Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP

Verónica Aparicio Herranz

Ayudante de Investigación. HULP

María Pilar González-Peramato Gutiérrez

Facultativo Especialista de Área en Anatomía Patológica. HULP

Diana Martín Lorenzo

Licenciado contratado. HULP

Manuel Nistal Martín de Serrano

Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. UAM

Javier Francisco Regadera González

Catedrático. Departamento de Histología y Neurociencia. Facultad de Medicina. UAM

Diego Sainz de la Maza Redondo

Investigador Predoctoral. HULP

Strategic Objective

To ascertain the mechanisms responsible for converting a differentiated cell into a pluripotent cell and at the same time how these establish a relationship between cellular reprogramming and oncogenic transformation, in order to use divergent pathways governing these processes as clinical early diagnostic tools and therapeutic targets for clinical intervention.

To develop new cell therapy approaches in diverse organs transplants.

Research Lines

- Molecular mechanisms of cellular reprogramming in normal and neoplastic environments.
- New techniques and therapies in transplants.

Research Activity**BOOKS AND BOOK CHAPTERS**

de Miguel MP, González-Martín R, Nistal M. Development of the human fetal testis up to the second trimester: Medical Glory, 2016. p.235-252

Noguera R, Navarro S, Blázquez MJ, Cruz J, Pi-queras M, de Miguel MP, Regadera J. Desarrollo embrionario del testículo. In: **Regadera J, Noguera R, Hardisson D** (eds.). Atlas de histología y del desarrollo del aparato genital masculino: Introducción a la patología. Madrid: Editorial IMC, 2016. p.31-37

Regadera J, González-Peramato P, de Miguel MP, Santos-Álvarez I, Nistal M. Testículo infantil y puberal. In: **Regadera J, Noguera R, Hardisson D** (eds.). Atlas de histología y del desarrollo del aparato genital masculino: Introducción a la patología. Madrid: Editorial IMC, 2016. p.39-44

PUBLICATIONS

- Calatrava-Ferreras L, Gonzalo-Gobernado R, Reimers D, Herranz AS, Casarejos MJ, Jiménez-Escrig A, Regadera J, Velasco-Martín J, Vallejo-Muñoz M, Díaz-Gil JJ, Bazán E. Liver growth factor (LGF) upregulates frataxin protein expression and reduces oxidative stress in Friedreich's ataxia transgenic mice. *Int J Mol Sci.* 2016;17(12):2066. Article. IF: 3.226; Q2
- Martínez-Iglesias O, Olmeda D, Alonso-Merino E, Gómez-Rey S, González-López AM, Luengo E, Soengas MS, Palacios J, Regadera J, Aranda A. The nuclear corepressor 1 and the thyroid hormone receptor beta suppress breast tumor lymphangiogenesis. *Oncotarget.* 2016;7(48):79871-84. Article. IF: 5.168; Q1
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 22. Testicular involvement in systemic diseases. *Pediatr Devel Pathol.* 2016;19(6):431-51. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 23. Testicular pathology secondary to physical and chemical injury. *Pediatr Devel Pathol.* 2016;19(6):452-9. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspective in pediatric pathology, chapter 24. Testicular inflammatory processes in pediatric patients. *Pediatr Devel Pathol.* 2016;19(6):460-70. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 25. Testicular and paratesticular tumors in the pediatric age group. *Pediatr Devel Pathol.* 2016;19(6):471-92. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 19. Testicular torsion, testicular appendix torsion, and other forms of testicular infarction. *Pediatr Devel Pathol.* 2016;19(5):345-59. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 20. Adolescent varicocele. *Pediatr Devel Pathol.* 2016;19(5):360-70. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 21. Testicular pathology in heritable metabolic disease. *Pediatr Devel Pathol.* 2016;19(5):371-82. Article. IF: 1.089; Q4
- Amesty MA, Rodríguez AE, Hernández E, de Miguel MP, Alio JL. Tolerance of micronized mineral pigments for intrastromal keratopigmentation: A histopathology and immunopathology experimental study. *Cornea.* 2016;35(9):1199-205. Article. IF: 2.01; Q2
- Contreras-Jurado C, Alonso-Merino E, Saiz-Ladera C, Valino AJ, Regadera J, Alemany S, Aranda A. The thyroid hormone receptors inhibit hepatic interleukin-6 signaling during endotoxemia. *Sci Rep-Uk.* 2016;6:30990. Article. IF: 4.259; Q1
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 16. Klinefelter syndrome and other anomalies in X and Y chromosomes. Clinical and pathological entities. *Pediatr Devel Pathol.* 2016;19(4):259-77. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 17. Other hypergonadotropic hypogonadisms. *Pediatr Devel Pathol.* 2016;19(4):278-90. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 18. Hypogonadotropic hypogonadisms. Pediatric and pubertal presentations. *Pediatr*

Devel Pathol. 2016;19(4):291-309. Article. IF: 1.089; Q4

- Alonso-Merino E, Orozco RM, Ruiz-Llorente L, Martínez-Iglesias OA, Velasco-Martín JP, Montero-Pedrazuela A, Fanjul-Rodríguez L, Contreras-Jurado C, Regadera J, Aranda A. Thyroid hormones inhibit TGF-beta signaling and attenuate fibrotic responses. *P Natl Acad Sci USA.* 2016;113(24):E3451-60. Article. IF: 9.661; D1
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 13. Calcifications in the testis and paratesticular structures. *Pediatr Devel Pathol.* 2016;19(3):173-82. Editorial Material. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 14. Natural history of undescended testes. *Pediatr Devel Pathol.* 2016;19(3):183-201. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 15. Macrorchidism as the expression of several congenital and acquired pathologies. *Pediatr Devel Pathol.* 2016;19(3):202-18. Article. IF: 1.089; Q4
- Ramos-Levi AM, Bernabéu I, Álvarez-Escola C, Aller J, Lucas T, de Miguel P, Rodríguez-Canete L, Sampredo-Núñez MA, Halperin I, Puig-Domingo M, Marazuela M. Long-term treatment with pegvisomant for acromegaly: a 10-year experience. *Clin Endocrinol.* 2016;84(4):540-50. Article. IF: 3.327; Q2
- Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, Velasco-Martín JP, Orozco RM, Luengo E, Martín RG, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. *P Natl Acad Sci USA.* 2016;113(3):E328-37. Article. IF: 9.661; D1
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 11. Testicular pathology of hamartomatous origin. *Pediatr Devel Pathol.* 2016;19(1):1-11. Article. IF: 1.089; Q4
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M. Perspectives in pediatric pathology, chapter 12. Congenital epididymal anomalies. *Pediatr Devel Pathol.* 2016;19(1):12-23. Article. IF: 1.089; Q4
- Manku G, Hueso A, Brimo F, Chan P, González-Peramato P, Jabadó N, Gayden T, Bourgey M, Riazalhosseini Y, Culty M. Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas. *Andrology-US.* 2016;4(1):95-110. Article. IF: 2.427; Q2

PUBLIC PROJECTS

Aparicio Herranz V. Contrato de Garantía Juvenil (PEJ15/BIO/A1-A5). CAM. 2015-2016.

Management centre: FIBHULP

de Miguel Gonzalez MP. Miguel Servet Stabilisation Contracts (I2) (CP03/0007). CAM, ISCIII. 2010-2016.

Management centre: FIBHULP

Fuentes Julián S. Becas de Formación de personal universitario (AP2010-0659). MECED. 2012-2016.

Management centre: FIBHULP

PRIVATE PROJECTS

de Miguel González MP. Evaluación histopatológica de la biointegración de diversos pigmentos minerales micro-



nizados inyectados en el estroma corneal de 56 ojos de cerdo. Evaluación histopatológica de 11 corneas irradiadas con laser femtosegundo. Vissum Corporación Oftalmológica. 2011-Ongoing.

Management centre: FIBHULP

de Miguel González MP. La terapia celular en la superficie ocular: función y aplicaciones biosustitutivas de las células madre adultas mesenquimales para la regeneración corneal. Fundació La Marató TV3. 2012-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Mecanismos moleculares implicados en la reprogramación celular por medio de modificación metabólica. 2014-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Proveer del conocimiento técnico necesario para la implantación de láminas corneales decelularizadas y colonizadas o no con células madre mesenquimales derivadas de tejido adiposo para su uso en enfermedades corneales que involucren el estroma cor-

neal. Óptica General SARRL. 2015-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Bioengineered corneal tissue for endothelial transplantation. Roche Farma-FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Bio-Ingeniería de tejido corneal para trasplante endotelial: desarrollo de láminas ultrafinas de cornea decelularizada colonizadas por endotelio corneal humano expandido en cultivo. 2016-Ongoing.

Management centre: FIBHULP

PATENTS AND TRADEMARKS

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector. P201131222, PCT/ES2012/070543; 2011 July 18.

CLINICAL PHARMACOLOGY GROUP



Publications: **8**

Impact Factor: **24.025**

QI: **5**

Jesús Frías Iniesta

Jefe de Servicio de Farmacología Clínica. HULP
Catedrático. Facultad de Medicina. UAM

Alberto Borobia Pérez

Facultativo Especialista de Área en Farmacología Clínica. HULP

Antonio Javier Carcas Sansuán

Facultativo Especialista de Área en Farmacología Clínica. HULP
Profesor Titular. Facultad de Medicina. UAM

Alberto García Bartolomé

Investigador Postdoctoral. HULP

José Carlos Mantínez Ávila

Investigador Postdoctoral. HULP

Elena Ramírez García

Facultativo Especialista de Área en Farmacología Clínica. HULP

Hoi Yan Tong

Responsable de Farmacovigilancia. HULP

lity evidence on the efficacy of clinical trials, strategies of identification, evaluation and prevention of adverse reactions to medication (pharmacovigilance programmes) and evaluation of the suitability of their use and effectiveness (studies on the use of medication).

Research Lines

- Therapeutic drug monitoring (TDM) - Development of individualised therapeutic drug monitoring programmes and pharmacogenetics.
- Getting quality evidences for the establishment of drug efficacy, safety and adequate use of medicines in humans.

Research Activity

PUBLICATIONS


- Muñoz R, Borobia AM, Quintana M, Martínez A, Ramírez E, Muñoz M, Frías J, Carcas AJ. Outcomes and costs of poisoned patients admitted to an adult emergency department of a spanish tertiary hospital: Evaluation through a toxicovigilance program. Plos One. 2016;11(4):e0152876. Article. IF: 2.806; Q1
- Tong HY, Dávila-Fajardo CL, Borobia AM, Martínez-González LJ, Lubomirov R, León LMP, Banares MJB, Díaz-Villamarín X, Fernández-Capitán C, Barrera JC, Carcas AJ. A New pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed spanish population. Plos One. 2016;11(3):e0150456. Article. IF: 2.806; Q1
- González-Ramos J, Noguera-Morel L, Tong HY, Ramírez E, Ruiz-Bravo E, Bellón T, Cabañas R, Cachafeiro L, Herranz-Pinto P. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Brit J Dermatol. 2016;175(3):604-7. Article. IF: 4.706; D1

Strategic Objective

Clinical pharmacology, as a scientific and professional discipline, has the objective of achieving an effective, efficacious and efficient use of drugs, at both the individual and group level. This means that Clinical Pharmacology is a cross-sectional discipline that must establish collaborations with numerous other disciplines and health professionals.

In this context and in the field of clinical research, the interests of our group are focused on two fundamental aspects:

1. Customisation of drug treatments: research and development of techniques and methods that individualise the use of drugs, improve their efficacy and reduce their risks.
2. The improvement of treatment by obtaining high qua-





- Mulet JMA, Rodríguez VA, Pérez AMB, Rubio RV, Mazarro MDO, Galán CD. Multicenter, triple-blind randomized placebo controlled trial of adjuvant nitrous oxide 50% in oxygen 50%: efficacy for reducing pain and increasing satisfaction in patients treated for renal colic in the emergency department. *Emergencias*. 2016;28(5):305-12. Article. IF: 3.028; Q1
- Carcas-Sansuan AJ. Limited sampling strategies for once daily tacrolimus exposure monitoring. *Eur J Clin Pharmacol*. 2016;72(6):773-4. Letter. IF: 2.902; Q2
- Cendejas-Bueno E, Borobia AM, Gómez-López A, Escosa-García L, Río-García M, Plaza D, García-Rodríguez J, Carcas-Sansuán A. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible *Aspergillus fumigatus*: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. *Int J Antimicrob Ag*. 2016;47(5):410-1. Letter. IF: 4.307; Q1
- Bellón T, Ramírez E, Borobia AM, Lerma V, Moreno-Hidalgo MA, Laosa O, Aramburu JA, González-Herrada C, de Abajo FJ. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome. *Pharmacogenomics*. 2016;17(6):541-5. Article. IF: 2.35; Q3
- Medrano-Casique N, Tong HY, Borobia AM, Carcas AJ, Frías J, Ramírez E. Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. *Pediatr Hemat Oncol*. 2016;33(42954):441-56. Article. IF: 1.12; Q3

PUBLIC PROJECTS

Carcas Sansuán AJ. Optimización cinética-dinámica de la disoficación de amikacina en pacientes en hemodiálisis convencional: ensayo clínico aleatorizado de dos pautas de administración (PI13/01530). ISCIII. 2014-2017.

Managment centre: FIBHULP

Frías Iniesta J. Plataforma de apoyo de UCICEC (PT13/0002/0015). ISCIII. 2014-2017.

Managment centre: FIBHULP

Frías Iniesta J. Desarrollo de especialidades farmacéuticas genéricas antivirales para el tratamiento de Hepatitis B y VIH (RTC-2015-4250-1). MINECO. 2015-2018.

Managment centre: UAM

PRIVATE PROJECTS

Frías Iniesta J. Unidad Clínica de Investigación y Control de Ensayos Clínicos. FIBHULP. 2011-Ongoing.

Managment centre: FIBHULP

Ramírez García E. Estudio farmacoepidemiológico para evaluar los eventos tromboembólicos de las inmunoglobulinas inespecíficas. Características diferenciales de los eventos arteriales y venosos. FIBHULP. 2013-Ongoing.

Managment centre: FIBHULP

CLINICAL TRIALS

Borobia Pérez A. Ensayo clínico estudio en fase I, en abierto, de dosis única y no randomizado para evaluar la farmacocinética (FC) y la farmacodinámica (FD) de edoxabán en pacientes pediátricos. Daiichi-Sankyo Development Limited.

HULP Code: 4634. Sponsored's Protocol Code: DU176B-A-UI57.

Signature Date: 12/09/2016

PATENTS AND TRADEMARKS

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals. ESM 3.063.048; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Plus. ESM 3.063.052; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Clinical Pharmacology. ESM 3.063.053; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Medicine. ESM 3.063.049; 2013 February 12.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.



Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX. CM 13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

OSTEOARTICULAR SURGERY RESEARCH — GICOA GROUP



Publications: 32

Impact Factor: 63.684

QI: 4

Enrique Gómez Barrena

Jefe de Sección de Cirugía Ortopédica y Traumatología. HULP
Catedrático de Cirugía Ortopédica y Traumatología. Facultad de Medicina. UAM

Samuel Antuña Antuña

Jefe de Sección en Cirugía Ortopédica y Traumatología. HULP
Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. UAM

Raúl Barco Laakso

Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. HULP

Ana Cruz Pardos

Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. HULP

Marta Domínguez García-Simón

Enfermera Coordinadora de Ensayos Clínicos. UAM

Eduardo García Rey

Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. HULP
Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. UAM

Carlos Agustín Hernández Gil

Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. HULP

Norma Griseta Padilla Eguiluz

Investigadora Predoctoral. UAM

Carlos Emérito Rodríguez Merchán

Jefe de Sección de Cirugía Ortopédica y Traumatología. HULP

Juan Carlos Rubio Suárez

Jefe de Sección de Cirugía Ortopédica y Traumatología. HULP

and deepen our understanding of the prevention and solution of these failures. The medical, social, and economic relevance of orthopaedic implants, and their influence on quality of life, place this technology in the centre of translational research in orthopaedic surgery. Reconstruction based on biological strategies and biomaterials is rapidly evolving, and cutting-edge research on these topics may offer an advantage in clinical translational research. The group has for some time now developed sports medicine and ligament reconstruction, with various outcome approaches and the development of devices that may enhance surgical results. In this context, a multidisciplinary clinical and basic research group on orthopaedic surgery deepens our understanding of a wide variety of current research topics in the field and provides further progress towards clinical translation.

In order to contribute new advances in the field, our main clinical and experimental objectives are addressed by a joint research line that covers issues related to bone and joint reconstruction. These issues include the following:

- Failed hip and knee prostheses, including the material, biological, and clinical mechanisms of failure. This research may lead to proposals for materials and design modifications in orthopaedic implants and reconstructive devices and techniques. Functional recovery of the patient is the ultimate goal, considering various scenarios from an experimental and clinical point of view.

- Regenerative medicine approaches to bone and joint reconstruction, to generate preclinical and clinical proposals for bone and joint regeneration and repair, both in traumatic and non-traumatic bone and soft-tissue injuries.

Strategic Objective

Orthopaedic implant studies are required to assess the results of implants, detect the causes of failure,



Research Lines

- Clinical and basic research in Orthopaedics implants, and bone and joint reconstruction.

Research Activity

DOCTORAL THESES

Hernández Esteban P. Técnica anatómica frente a técnica transtibial en la reconstrucción del LCA de la rodilla en pacientes futbolistas de alta demanda funcional. [dissertation]. Madrid: UAM: 2016 (10/3/2016).

Director: Gómez Barrena E.

BOOKS AND BOOK CHAPTERS

Barco R, Antuña S. Avoiding complications in Elbow Surgery. In: Editors. Essentials Techniques in Elbow Surgery. London: Springer-Verlag, 2016. p.1-16

Antuña S, Hoffmann R, Barco R. Surgical Techniques for Cubital Tunnel Syndrome and Chronic Medial Instability. In: Editors. Essentials Techniques in Elbow Surgery. London: Springer-Verlag, 2016. p.25-40

Antuña S, Barco R. Elbow Stiffness: Open and Arthroscopic Capsulectomy. In: Editors. Essentials Techniques in Elbow Surgery. London: Springer-Verlag, 2016. p.87-102

Barco R, Antuña S. Performing Elbow Arthroscopy: How to Make It Safe. In: Editors. Essentials Techniques in Elbow Surgery. London: Springer-Verlag, 2016. p.143-154

García-Rey E, Gómez Barrena E, García Cimbrello E. Late Infections of the Knee Joint: Arthrodesis or Other Solutions. In: Authors. Periprosthetic Joint Infections: Springer International Publishing, 2016. p.283-291

PUBLICATIONS

- Bensiamar F, Olalde B, Cifuentes SC, Argarate N, Atorrasagasti G, González-Carrasco JL, García-Rey E, Vilaboa N, Saldaña L. Bioactivity of dexamethasone-releasing coatings on polymer/magnesium composites. *Biomed Mater.* 2016;11(5):55011. Article. IF: 2.469; Q2
- Brkljac M, Shah S, Hay C, Rodríguez-Merchán EC. Hindfoot fusion in haemophilic arthropathy: 6-year mean follow-up of 41 procedures performed in 28 adult patients. *Haemophilia.* 2016;22(2):E87-98. Article. IF: 3.569; Q2
- Calcerrada N, Fernández-Vega A, Valls-León C, García-Cimbrello E. Survey on the use and behaviour of metal-metal hip replacements in Spain. *Rev Esp Cir Ortop Traumatol.* 2016;60(1):20-8. Article. Not Indexed
- Capón-García D, López-Pardo A, Alves-Pérez MT. Causes for revision surgery in total hip replacement. A retrospective epidemiological analysis. *Rev Esp Cir Ortop Traumatol.* 2016;60(3):160-6. Article. Not Indexed
- Cifuentes SC, Bensiamar F, Gallardo-Moreno AM, Osswald TA, González-Carrasco JL, Benavente R, González-Martín ML, García-Rey E, Vilaboa N, Saldaña L. Incorporation of Mg particles into PDLLA regulates mesenchymal stem cell and macrophage responses. *J Biomed Mater Res A.* 2016;104(4):866-78. Article. IF: 3.076; Q2
- Crespo L, Hierro-Oliva M, Barriuso S, Vadillo-Rodríguez V, Mon-

telegre MA, Saldaña L, Gómez-Barrena E, González-Carrasco JL, González-Martín ML, Vilaboa N. On the interactions of human bone cells with Ti6Al4V thermally oxidized by means of laser shock processing. *Biomed Mater.* 2016;11(1):15009. Article. IF: 2.469; Q2

- Cruz-Pardos A, García-Rey E, Ortega-Chamarro JA, Durán-Manrique D, Gómez-Barrena E. Mid-term comparative outcomes of autologous bone-marrow concentration to treat osteonecrosis of the femoral head in standard practice. *Hip Int.* 2016;26(5):432-7. Article. IF: 1.055; Q3
- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Hernández-Moreno AL. Coexistence of factor VII deficiency and hereditary spastic paraplegia in two siblings. *Case Rep Hematol.* 2016;1351873. Article. Not Indexed
- de la Corte-Rodríguez H, Rodríguez-Merchán EC. The ICF (International Classification of Functioning, Disability and Health) developed by the WHO for measuring function in hemophilia. *Expert Rev Hematol.* 2016;9(7):661-8. Review. IF: 2.246; Q3
- García-Rey E, García-Cimbrello E. Abductor biomechanics clinically impact the total hip arthroplasty dislocation rate a prospective long-term study. *J Arthroplasty.* 2016;31(2):484-90. Article. IF: 3.055; Q1
- López-Franco M, López-Franco O, Murciano-Antón MA, Cañamero-Vaquero M, Fernández-Acenero MJ, Herrero-Beaumont G, Gómez-Barrena E. Meniscal degeneration in human knee osteoarthritis: in situ hybridization and immunohistochemistry study. *Arch Orthop Traum Su.* 2016;136(2):175-83. Article. IF: 1.942; Q2
- Molina-Manso D, del-Prado G, Gómez-Barrena E, Cordero-Ampuero J, Fernández-Roblas R, Esteban J. Effect of different agents with potential antibiofilm activity on antimicrobial susceptibility of biofilms formed by *Staphylococcus* spp. isolated from implant-related infections. *J Antibiot.* 2016;69(9):686-8. Article. IF: 2.237; Q2
- Ortega-Andréu M, Talavera G, Padilla-Eguiluz NG, Pérez-Chrzanoska H, Figueredo-Galve R, Rodríguez-Merchán CE, Gómez-Barrena E. Tranexamic acid in a multimodal blood loss prevention protocol to decrease blood loss in revision total knee arthroplasty: A cohort study. *Open Orthop J.* 2016;10:439-47. Article. Not Indexed
- Pérez-Jorge C, Gómez-Barrena E, Horcajada JP, Puig-Verdie L, Esteban J. Drug treatments for prosthetic joint infections in the era of multidrug resistance. *Expert Opin Pharmacol.* 2016;17(9):1233-46. Review. IF: 3.894; Q1
- Pérez-Robles T, Romero-Garrido JA, Rodríguez-Merchán EC, Herrero-Ambrosio A. Objective quantification of adherence to prophylaxis in haemophilia patients aged 12 to 25 years and its potential association with bleeding episodes. *Thromb Res.* 2016;143:22-7. Article. IF: 2.65; Q2
- Pérez-Tanoira R, Horwat D, Kinnari TJ, Pérez-Jorge C, Gómez-Barrena E, Migot S, Esteban J. Bacterial adhesion on biomedical surfaces covered by yttria stabilized zirconia. *J Mater Sci-Mater M.* 2016;27(1):6. Article. IF: 2.325; Q3
- Rodríguez-Merchán EC, de la Corte-Rodríguez H. Radiosynovectomy in haemophilic synovitis of elbows and ankles: Is the effectiveness of yttrium-90 and rhenium-186 different? *Thromb Res.* 2016;140:41-5. Article. IF: 2.65; Q2
- Rodríguez-Merchán EC, Gómez-Cardero P. Arthroscopic knee debridement can delay total knee replacement in painful moderate haemophilic arthropathy of the knee in adult patients. *Blood Coagul Fibrin.* 2016;27(6):645-7. Article. IF: 1.367; Q4
- Rodríguez-Merchán EC, Romero-Garrido JA, Gómez-Cardero P. Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A. *Haemophilia.* 2016;22(4):E318-20. Letter. IF: 3.569; Q2
- Rodríguez-Merchán EC, Valentino Leonard A. Orthopedic disor-

ders of the knee in hemophilia: A current concept review. *World J Orthop.* 2016;7(6):370-5. Review. Not Indexed

- Rodríguez-Merchán EC. Articular Bleeding in Hemophilia. *Cardiovasc Hematol Disord Drug Targets.* 2016;16(1):21-4. Review. Not Indexed
- Rodríguez-Merchán EC. Conservative treatment of acute knee osteoarthritis: A review of the Cochrane Library. *J Acute Dis.* 2016;5(3):190-3. Review. Not Indexed
- Rodríguez-Merchán EC. Intra-articular injections of mesenchymal stem cells (MSCs) as a treatment for hemophilic arthropathy. *Expert Rev Hematol.* 2016;9(8):737-41. Review. IF: 2.246; Q3
- Rodríguez-Merchán EC. Joint distraction in advanced haemophilic ankle arthropathy. *Haemophilia.* 2016;22(4):E301-4. Letter. IF: 3.569; Q2
- Rodríguez-Merchán EC. Knee bracing after anterior cruciate ligament reconstruction. *Orthopedics.* 2016;39(4):E602-9. Review. IF: 1.143; Q3
- Rodríguez-Merchán EC. Musculo-skeletal manifestations of haemophilia. *Blood Rev.* 2016;30(5):401-9. Review. IF: 6.342; Q1
- Rodríguez-Merchán EC. Pathophysiology of the disturbed angiogenesis in hemophilia. *Expert Rev Hematol.* 2016;9(10):933-8. Review. IF: 2.246; Q3
- Rodríguez-Merchán EC. Synovium and cartilage biomarkers in hemophilic arthropathy. *Expert Rev Hematol.* 2016;9(4):409-14. Review. IF: 2.246; Q3
- Rodríguez-Merchán EC. Patient dissatisfaction after total knee arthroplasty for hemophilic arthropathy and osteoarthritis (non-hemophilia patients). *Expert Rev Hematol.* 2016;9(1):59-68. Review. IF: 2.246; Q3
- Rodríguez-Merchán EC. Unicompartamental knee osteoarthritis (UKOA): Unicompartamental knee arthroplasty (UKA) or high tibial osteotomy (HTO)? *Arch Bone Jt Surg.* 2016;4(4):307-13. Review. Not Indexed
- Rodríguez-Merchán EC, Ortega-Andréu M, Padilla-Eguiluz NG, Gómez-Cardero P, Martínez-Lloreda A, Gómez-Barrena E. Low-volume formulation of intra-articular tranexamic acid, 25-ml tranexamic acid (2.5 g) plus 20-ml saline, is effective in decreasing blood transfusion rate in primary total knee replacement even without preoperative haemoglobin optimization. *Blood Coagul Fibrin.* 2016;27(6):660-6. Article. IF: 1.367; Q4
- Vila L, Donnay S, Arena J, Arrizabalaga JJ, Pineda J, García-Fuentes E, García-Rey C, Marín JL, Serra-Prat M, Velasco I, López-Guzmán A, Luengo LM, Villar A, Muñoz Z, Bandres O, Guerrero E, Muñoz

JA, Moll G, Vich F, Menéndez E, Riestra M, Torres Y, Beato-Vibora P, Aguirre M, Santiago P, Aranda J, Gutiérrez-Repiso C. Iodine status and thyroid function among Spanish schoolchildren aged 6-7 years: The Tirokid study. *Brit J Nutr.* 2016;115(9):1623-31. Article. IF: 3.706; Q1

PUBLIC PROJECTS

Gómez Barrena E. Estudio preclínico para evaluar células mesenquimales humanas de placenta que promuevan regeneración ósea y desarrollar un nuevo producto celular bajo condiciones GMP (SAF2012-40149-C02-01). MINECO. 2013-2016.

Management centre: FIBHULP

PRIVATE PROJECTS

Antuña Antuña S. Convenio para un proyecto de investigación. Sociedad Española de Cirugía Ortopédica y Traumatología. 2008-Ongoing.

Management centre: FIBHULP

Antuña Antuña S. Terapia celular con células troncales del tejido adiposo en roturas del manguito rotador. IACES Meetings. 2015-Ongoing.

Management centre: FIBHULP

Barco Laakso R. Terapia celular con células troncales derivadas del tejido adiposo (ASC) para mejorar el proceso de reparación en suturas tendinosas. Unión tendón-hueso (roturas del manguito rotador); Unión tendón-músculo (roturas del tendón de Aquiles). Sociedad Española de Cirugía Ortopédica y Traumatología. 2009-Ongoing.

Management centre: FIBHULP

Gómez Barrena E. Actualización y renovación de la actividad en el servicio de C.O.T. "A" del Hospital Universitario La Paz. Servicios Hospitalarios, S.L. 2012.

Management centre: FIBHULP

CLINICAL TRIALS

Gómez Barrena E. Estudio en fase IIIb multicéntrico, aleatorizado, doble ciego y controlado, para evaluar la eficacia y seguridad de rivaroxaban 10 mg frente a enoxaparina 4.000 ui para la profilaxis de TEV en cirugía ortopédica menor. Estudio Pronomos. Chu Saint Etienne.

HULP Code: 4550. Sponsored's Protocol Code: 1408143.


Signature Date: 01/06/2016


PATENTS AND TRADEMARKS


Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Permarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodized with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.



RECONSTRUCTIVE
AND
REGENERATIVE
RESEARCH GROUP

 Publications: **3**

 Impact Factor: **3.784**

 QI: **1**

Luis Landín Jarillo

Facultativo Especialista de Área en Cirugía Plástica. HULP

Sergio Álvarez García-Peñuela

Médico Interno Residente en Cirugía Plástica y Reparadora. HULP

Jorge Bonastre Juliá

Facultativo Especialista de Área en Cirugía Plástica. HULP

Elena Bravo Brañas

Facultativo Especialista de Área en Cirugía Plástica. HULP

César Casado Sánchez

Facultativo Especialista de Área en Cirugía Plástica. HULP

Marta García Redondo

Facultativo Especialista de Área en Cirugía Plástica. HULP

Álvaro González Miranda

Facultativo Especialista de Área en Cirugía Plástica. HULP

Carmen Iglesias Urraca

Facultativo Especialista de Área en Cirugía Plástica. HULP

José Ramón Martínez Méndez

Facultativo Especialista de Área en Cirugía Plástica. HULP

Strategic Objective

The objective of the Reconstructive and Regenerative Translational Research Group is to apply knowledge in basic science to improve health in a clinical context through research techniques, focusing on the treatment and functional improvement of patients presenting oncological, traumatic, and congenital or burns that limit autonomy of the patients.

Research Lines

- Research in Regenerative Medicine.
- Research in alterations of the healing processes.
- Research on burned.
- Research on congenital malformations.
- Research in post-oncological reconstruction.
- Research on posttraumatic reconstruction.
- Research in transplants.

Research Activity**PUBLICATIONS**

- Bonastre J, Landín L, Bolado P, Casado-Sánchez C, López-Collazo E, Díez J. Effect of cold preservation on chronic rejection in a rat hindlimb transplantation model. *Plast Reconstr Surg*. 2016;138(3):628-37. Article. IF: 3.784; QI
- Landín L, Bolado P, Gajete MA, González-Miranda A, Bonastre J. Algorithmic surgical enhancement of function after finger revascularisation. *Indian J Plast Surg*. 2016;49(2):239-44. Article. Not Indexed
- Sánchez-Sánchez M, García-de-Lorenzo A, Cachafeiro L, Herroero E, Asensio M J, Agrifoglio A, Flores E, Estebáñez B, Extremera P, Iglesias C, Martínez JR. Acute kidney injury in critically burned patients resuscitated with a protocol that includes low doses of Hydroxyethyl Starch. *Ann Burns Fire Disasters*. 2016;29(3):183-8. Article. Not Indexed

PRIVATE PROJECTS

Bonastre Juliá J. Inducción de tolerancia con galactomano en un modelo de trasplante de extremidad posterior en ratas. FIBHULP. 2016-Ongoing.

Management centre: FIBHULP

Casado Sánchez C. Formación en investigación en Cirugía Plástica. Mediwound Germany GmbH. 2016-Ongoing.


Management centre: FIBHULP

Landín Jarillo L. Efecto de la preservación en frío sobre el rechazo crónico en el modelo de trasplante de extremidad posterior en ratas. 2011-Ongoing.

Management centre: FIBHULP

Landín Jarillo L. Protocolo de inmunosupresión reducida tras condicionamiento con precursores hematopoyéticos en trasplante de tejido compuesto. Cortés. 2015-Ongoing.

Management centre: FIBHULP

TRANSPLANT
GROUP***Francisco Hernández Oliveros**

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

Virginia Amesty Morello

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

Ane Miren Andrés MorenoFacultativo Especialista de Área en Cirugía Pediátrica. HULP
Pediátrica Profesor Asociado. UAM**Carlos Andrés de la Torre Ramos**

Facultativo Especialista de Área en Cirugía Pediátrica. HULP

Jesús Carlos de Vicente Sánchez

Facultativo Especialista de Área en Anestesiología. HULP

María Isabel del Barrio Gómez de Agüero

Jefe de Sección de Neumología Pediátrica. HULP

Álvaro Gonzalez RocafortFacultativo Especialista de Área del Servicio de Cirugía
Cardiovascular Infantil. HULP**Manuel Molina Arias**

Médico Adjunto en Gastroenterología y Nutrición Infantil. HULP

María José Pascau González Garzón

Supervisora de la Unidad de Trasplante Pediátrico. HULP

Antonio Pérez FerrerFacultativo Especialista de Área en el servicio de Anestesiología
y Reanimación. HULP
Profesor Colaborador. UAM**Esther Ramos Boluda**Facultativo Especialista de Área en Servicio de Gastroenterología
y Nutrición Pediátrica. HULP**Fernando Reinoso Barbero**

Jefe de Servicio de Anestesia, Reanimación y Dolor Infantil. HULP

Strategic Objective


- To establish a reliable model of multivisceral transplantation in rodents.
- To establish the intestinal transplant model in mice, this objective is meant to take advantage of the immunological reactive panel available in mice, wider than this in rats.
- To establish an experimental model of organ perfusion aiming to perform studies in CCD donor organs and ischemia reperfusion phenomena.
- To develop safe and effective techniques of blood-saving in our practice.
- To establish guidelines for the transition from child to adult life in transplanted children.

Research Lines

- Experimental models in solid organ transplantation including cellular therapy.
- Clinical research in paediatric solid organ transplantation.
- Health related quality of life of transplanted patients.
- Graft optimization strategies.
- Blood-saving techniques in solid organ transplantation.
- Intestinal barrier failure in children undergoing transplantation (SOT/HSCP).
- Prothrombotic states in transplanted patients.
- Antibiotics optimization program in transplanted children.

* Group recently created: february 2017

4 ASSOCIATED CLINICIANS



Anesthesiology

Biostatistics

Neuropediatrics

**Nutrition and Functional Foods
Research (NUTRINVEST)**




**Orthopedic Surgery and
Traumatology**

Pediatric Nephrology



ANESTHESIOLOGY



 Publications: **32**
 Impact Factor: **39.643**
 Q1: **3**

Group Leader:

Fernando Gilsanz Rodríguez

Alfredo Abad Gurumeta
 Nicolas Brogly
 Enrique Canser Cuenca
 Emilia Guasch Arévalo
 Emilio Maseda Garrido
 Alejandro Suárez de la Rica
 Rafael Uña Orejón

Research Area

- Surgery, transplantation and health technology.

Research Activity

DOCTORAL THESES

Brogly N. Estudio comparativo de dos técnicas de localización del espacio epidural para la analgesia durante el trabajo de parto: pérdida de resistencia con aire o suero [dissertation]. Madrid: UAM: 2016(30/06/2016).

Directors: Gilsanz Rodríguez F, Guasch Arévalo E.

Valbuena Gómez I. Eficacia de los recuperadores de sangre postoperatorios. Factores de riesgo transfusional y de hemorragia en la artroplastia total de rodilla [dissertation]. Madrid: UAM: 2016(20/12/2016).

Directors: Gilsanz Rodríguez F, Guasch Arévalo E.

BOOKS AND BOOK CHAPTERS

Suárez de la Rica A, Gilsanz F, Maseda E. Procalcitonina en el paciente crítico con infección intraabdominal: Utilidad para guiar la duración del tratamiento antibiótico y como factor pronóstico. Madrid: Editorial Académica Española, 2016.

Martínez B, Canser E. Bloqueos y técnicas intervencionistas espinales y del sistema nervioso simpático. In: **Sánchez Corretger MD, Fernández CA, López CO.** Manual de Medicina del dolor. Fundamentos, evaluación y tratamiento. Madrid: Ed Panamericana, 2016. p. 251-8.

Martínez B, Canser E. Dolor y embarazo. In: **Sánchez Corretger MD, Fernández CA, López CO.** Manual de Medicina del dolor. Fundamentos, evaluación y tratamiento. Madrid: Ed Panamericana, 2016. p. 461-7.

Maseda Garrido E, Suárez de la Rica A. Terapia antimicrobiana y biomarcadores en la sepsis. In: **Fernández Quero L.** 50 Preguntas clave en sepsis. Barcelona: Permanyer, 2016. p. 13-20.

Herrera Hueso B, Maseda Garrido E, Suárez de la Rica A. Hemoperfusión con polimixina B en shock séptico secundario a diverticulitis sigmoidea perforada. In: **Suárez de la Rica A.** Casos Clínicos. Sepsis. Barcelona: Permanyer, 2016. p. 15-6.

PUBLICATIONS

- Abad Gurumeta A. The registration of clinical trials: Necessary and forced. Rev Esp Anesthesiol Reanim. 2016;63(6):311-2. Editorial Material. Not Indexed.

- Brogly N, Alsina E, de Celis I, Huercio I, Dominguez A, Gilsanz F. Perioperative temperature control: Survey on current practices. Rev Esp Anesthesiol Reanim. 2016;63(4):207-11. Article. Not Indexed.
- Brogly N, Schiraldi R, Puertas L, Maggi G, Yanci EA, Maldonado EHM, Arévalo EG, Rodríguez FG. Pulse contour analysis calibrated by Trans-pulmonar thermodilution (Picco Plus (R)) for the perioperative management of a caesarean section in a patient with severe cardiomyopathy. Rev Bras Anesthesiol. 2016;66(3):329-32. Article. IF: 0.903; Q4.
- Casans Frances R, Ripolles Melchor J, Abad-Gurumeta A, Longas Valien J, Calvo Vecino J M. The role of the anaesthesiologist in enhanced recovery programs. Rev Esp Anesthesiol Reanim. 2016;63(5):273-88. Article. Not Indexed.
- de La Rica AS, Gilsanz F, Maseda E. Epidemiologic trends of sepsis in western countries. Ann Transl Med. 2016;4(17): 325. Review. Not Indexed.
- Espinosa A, Ripolles-Melchor J, Casans-Frances R, Abad-Gurumeta A, Bergese SD, Zuleta-Alarcón A, López-Timoneda F, Calvo-Vecino JM. Perioperative use of clevidipine: A systematic review and meta-analysis. Plos One. 2016;11(3):e0150625. Review. IF: 2.806; Q1.
- Ferrer R, Zaragoza R, Rodríguez AH, Maseda E, Llinares P, Grau S, Álvarez-Lerma F, Quindos G, Salavert M, Huarte R. EPICO 3.0. Management of non-neutropenic patients in medical wards. Rev Iberoam Micol. 2016;33(4):216-23. Article. IF: 1.33; Q3.
- González-Pizarro P, García-Fernández J, Canfran S, Gilsanz F. Neonatal pneumothorax pressures surpass higher threshold in lung recruitment maneuvers: An in vivo interventional study. Resp Care. 2016;61(2):142-8. Article. IF: 1.733; Q4.
- Guasch E, Gilsanz F. Massive obstetric hemorrhage: Current approach to management. Med Intensiva. 2016;40(5):298-310. Review. IF: 1.231; Q4.
- Guasch E, Gilsanz F. Treatment of postpartum hemorrhage with blood products in a tertiary hospital: Outcomes and predictive factors associated with severe hemorrhage. Clin Appl Thromb-Hem. 2016;22(7):685-92. Article. IF: 2.096; Q3.
- Huercio I, Abad-Gurumeta A, Gilsanz F. Regional blocks for breast surgery: is it enough? Minerva Anesthesiol. 2016;82(3):369-70. Letter. IF: 2.623; Q2.
- International Surgical Outcomes Study group (Suárez de la Rica A, Maseda E, Villagrán F). Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Brit J Anaesth. 2016;117(5):601-9. Article. IF: 6.238; D1.
- López MM, Guasch E, Schiraldi R, Maggi G, Alonso E, Gilsanz F. Continuous spinal anaesthesia with minimally invasive haemodynamic monitoring for surgical hip repair in two patients with severe aortic stenosis. Braz J Anesthesiol. 2016;66(1):82-5. Article. IF: 0.903; Q4.
- Llau JV, Acosta FJ, Escolar G, Fernández-Mondéjar E, Guasch E, Marco P, Paniagua P, Páramo JA, Quintana M, Torrabadella P. Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document). Rev Esp Anesthesiol Reanim. 2016;63(1):e1-e22. Article. Not Indexed.
- Maseda E, Giménez MJ, Gilsanz F, Aguilar L. Basis for selecting optimum antibiotic regimens for secondary peritonitis. Expert Rev Anti-Infe. 2016;14(1):109-24. Review. IF: 3.139; Q2.
- Maseda E, Rodríguez AH, Aguilar G, Peman J, Zaragoza R, Ferrer R, Llinares P, Grau S. EPICO 3.0. Recommendations on invasive candidiasis in patients with complicated intra-abdominal infection and surgical patients with ICU extended stay. Rev Iberoam Micol. 2016;33(4):196-205. Article. IF: 1.33; Q3.
- Maseda E, Rodríguez-Manzanique M, Domínguez D, González-Serrano M, Mouriz L, Álvarez-Escudero J, Ojeda N, Sánchez-Zamora P, Granizo JJ, Giménez MJ. Intraabdominal candidiasis in surgical ICU patients treated with anidulafungin: A multicenter retrospective study. Rev Esp Quim. 2016;29(1):32-9. Article. IF: 0.75; Q4.
- Meier J, Filipescu D, Kozek-Langenecker S, Pitarch JL, Mallett S, Martus P, Matot I. (Gilsanz F) Intraoperative transfusion practices in Europe. Brit J Anaesth. 2016;116(2):255-U205. Article. IF: 6.238; D1.
- Montero A, Gilsanz F, Maseda E. Diagnostic and therapeutic approach of intra-abdominal candidiasis. Rev Esp Quim. 2016;29:52-55. Article. IF: 0.75; Q4.
- Pérez-Ferrer A, Gredilla-Díaz E, de Vicente-Sánchez J, Navarro-Suay R, Gilsanz-Rodríguez F. Characteristics and quality of intra-operative cell salvage in paediatric scoliosis surgery. Rev Esp Anesthesiol Reanim. 2016;63(2):78-83. Article. Not Indexed.
- Pérez-Ferrer A, Gredilla-Díaz E, de Vicente-Sánchez J, Sánchez Pérez-Grueso F, Gilsanz-Rodríguez F. Implementation of a patient blood management program in pediatric scoliosis surgery. Rev Esp Anesthesiol Reanim. 2016;63(2):69-77. Article. Not Indexed.
- Quecedo Gutiérrez L, Ruiz Abascal R, Calvo Vecino JM, Peral García A I, Matute González E, Muñoz Alameda L E, Guasch Arévalo E, Gilsanz Rodríguez F. Do not do recommendations of the Spanish Society of Anaesthesiology, Critical care and pain therapy. "Commitment to Quality by Scientific Societies" Project. Rev Esp Anesthesiol Reanim. 2016;63(9):519-27. Article. Not Indexed.
- Ripolles Melchor J, Casans Francés R, Espinosa A, Martínez Hurtado E, Navarro Pérez R, Abad Gurumeta A, Basora M, Calvo Vecino JM. Restrictive versus liberal transfusion strategy for red blood cell transfusion in critically ill patients and in patients with acute coronary syndrome: a systematic review, meta-analysis and trial sequential analysis. Minerva Anesthesiol. 2016;82(5):582-98. Review. IF: 2.623; Q2.
- Ripolles J, Espinosa A, Martínez-Hurtado E, Abad-Gurumeta A, Casans-Frances R, Fernández-Pérez C, López-Timoneda F, Calvo-Vecino JM. Intraoperative goal directed hemodynamic therapy in noncardiac surgery: a systematic review and meta-analysis. Rev Bras Anesthesiol. 2016;66(5):513-28. Review. IF: 0.903; Q4.
- Ripolles-Melchor J, Casans-Frances R, Abad-Gurumeta A, Suárez-de-la-Rica A, Ramírez-Rodríguez JM, López-Timoneda F, Calvo-Vecino JM. Spanish survey on enhanced recovery after surgery. Rev Esp Anesthesiol Reanim. 2016;63(7):376-83. Article. Not Indexed.
- Ripolles-Melchor J, Casans-Frances R, Espinosa A, Abad-Gurumeta A, Feldheiser A, López-Timoneda F, Calvo-Vecino JM. Goal directed hemodynamic therapy based in esophageal Doppler flow parameters: A systematic review, meta-analysis and trial sequential analysis. Rev Esp Anesthesiol Reanim. 2016;63(7):384-405. Article. Not Indexed.
- Ripolles-Melchor J, Espinosa A, Martínez-Hurtado E, Abad-Gurumeta A, Casans-Frances R, Fernández-Pérez C, López-Timoneda F, Calvo-Vecino JM. Perioperative goal-directed hemodynamic therapy in noncardiac surgery: a systematic review and meta-analysis. J Clin Anesth. 2016;28:105-15. Review. IF: 1.667; Q3.
- Salgado P, Gilsanz F, Maseda E. Resistant gram-negative bacteria. Therapeutic approach and risk factors. Rev Esp Quim. 2016;29:26-30. Article. IF: 0.75; Q4.



- Suárez-de-la-Rica A, Hernández-Gancedo C, López-Tofino A, Maseda E, Gilsanz F. Severe cefepime-induced status epilepticus treated with haemofiltration. *Rev Esp Anestesiol Reanim.* 2016;63(6):353-6. Article. Not Indexed.
- Uña Orejón R, Altiz Millán E, Aguar Fernández M, Ureta Tolsada M P. Catecholamine-secreting paraganglioma in a patient with Eisenmenger syndrome and a single ventricle. Nitric oxide administration and minimally invasive haemodynamic monitoring. *Rev Esp Anestesiol Reanim.* 2016;63(3):172-6. Article. Not Indexed.
- Uña Orejón R, del Huercio Martínez I, Casinello Ogea C, del Prado Ureta Tolsada M, Uña Orejón S. Intraoperative hydroxyethyl starch: A safe therapy or a poison? *Rev Esp Anestesiol Reanim.* 2016;63(10):588-3. Article. Not Indexed.
- Zaragoza R, Aguado JM, Ferrer R, Rodríguez AH, Maseda E, Llinares P, Grau S, Muñoz P, Fortún J, Bouzada M, del Pozo JC, Leon R. EPICO 3.0. Antifungal prophylaxis in solid organ

transplant recipients. *Rev Iberoam Micol.* 2016;33(4):187-95. Article. IF: 1.33; Q3.

PRIVATE PROJECTS

Gilsanz Rodríguez F. Donación Bristol Myers Dr. Gil. Bristol Myers Squibb S.L. 2005-Ongoing.

Management Centre: FIBHULP

Gilsanz Rodríguez F. Actividades de formación en investigación en anestesia inhalatoria. Baxter S.L. 2011-Ongoing.


Management Centre: FIBHULP

Maseda Garrido E. Eficacia y seguridad de micafungina en pacientes post-quirúrgicos. Estudio Mycrea. Astellas Pharma S.A. 2013-Ongoing.

Management Centre: FIBHULP




BIOSTATISTICS



 Publications: **17**

 Impact Factor: **34.13**

 QI: **6**

Group Leader:

Rosario Madero Jarabo

Mariana Díaz Almirón

Jesús Díez Sebastián

Research Area

- Surgery, transplantation and health technology.

Research Activity

BOOKS AND BOOK CHAPTERS

Herruzo Cabrera R, Díez Sebastián J, García Caballero J, del Rey Calero J. Infección hospitalaria: epidemiología y prevención. In: Piedrola. Medicina preventiva y salud pública. Barcelona: Elsevier, 2016. p. 717-28.

PUBLICATIONS

- Agudo MM, Colino RM, Ladrero MDC, Encinar MR, Sebastián JD, Bueno EV, Ambrosio AH, Montalvo JIG. Analysis of an electronic medication reconciliation and information at discharge programme for frail elderly patients. *Int J Clin Pharm-Net.* 2016; 38(4):996-1001. Article. IF: 1.555; Q4.
- Aguilera A, Alonso-Dorrego JM, Banuelos B, Cisneros J, González P, Díez J. Oncological results in high grade prostate cancer treated surgically. *Arch Esp Urol.* 2016; 69(4):162-71. Article. IF: 0.323; Q4.
- Bonastre J, Landín L, Bolado P, Casado-Sánchez C, López-Colla-

zo E, Díez J. Effect of cold preservation on chronic rejection in a rat hindlimb transplantation model. *Plast Reconstr Surg.* 2016; 138(3):628-37. Article. IF: 3.784; Q1.

- Calvino M, Gavilán J, Sánchez-Cuadrado I, Pérez-Mora RM, Muñoz E, Díez-Sebastián J, Lassaletta L. Using the HISQUI(29) to assess the sound quality levels of Spanish adults with unilateral cochlear implants and no contralateral hearing. *Eur Arch Oto-Rhino-L.* 2016; 273(9):2343-53. Article. IF: 1.66; Q2.
- Ferrer-Santacreu EM, Ortiz-Cruz EJ, Díaz-Almirón M, Kreilinger JJP. Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: Clinical and radiological criteria-a follow-up. *J Oncol.* 2016; 8262079. Article. Not indexed.
- González E, Díez JJ, Bajo MA, del Peso G, Grande C, Rodríguez O, Díaz-Almirón M, Iglesias P, Selgas R. Fibroblast growth factor 21 (FGF-21) in peritoneal dialysis patients: Natural history and metabolic implications. *Plos One.* 2016; 11(3):e0151698. Article. IF: 2.806; Q1.
- Iacoponi S, Rubio P, García E, Oehler MK, Díez J, Díaz-de la Noval B, Mora P, Gardella B, Gómez I, Kotsopoulos IC, Zaleski K, Zapardiel I. Prognostic factors of recurrence and survival in vulvar melanoma: Subgroup analysis of the VULvar CANcer Study. *Int J Gynecol Cancer.* 2016; 26(7):1307-12. Article. IF: 2.369; Q2.
- Jiménez C, López MO, Ros A, Aguilar A, Menéndez D, Rivas B, Santana MJ, Vaca MA, Escuin F, Madero R, Selgas R. The natural history of kidney graft cortical microcirculation determined by real-time contrast-enhanced sonography (RT-CES). *Plos One.* 2016; 11(3):e0150384. Article. IF: 2.806; Q1.
- Martínez-Biarge M, Cheong JLY, Díez-Sebastián J, Mercuri E, Dubowitz LMS, Cowan FM. Risk factors for neonatal arterial ischemic stroke: The importance of the intrapartum period. *J Pediatr-Us.* 2016; 173:62. Article. IF: 3.874; D1.
- Mazmanyan PA, Nikoghosyan KV, Kerobyan VV, Mellor KJ, Díez-Sebastián J, Martínez-Biarge M, Cowan FM. Preterm cranial



ultrasound scanning is both feasible and effective in a middle-income country. *Acta Paediatr.* 2016; 105(7):E291-9. Article. IF: 2.043; Q2.

- Palou-Redorta J, Solsona E, Angulo J, Fernández JM, Madero R, Unda M, Martínez-Piñero JA, Portillo J, Chantada V, Moyano JL. Retrospective study of various conservative treatment options with bacille Calmette-Guerin in bladder urothelial carcinoma T1G3: Maintenance therapy. *Actas Urol Esp.* 2016; 40(6):370-7. Article. IF: 1.181; Q4.
- Palao-Ocharan P, Domínguez-Ortega J, Barranco P, Díaz-Almirón M, Quirce S. Does the profile of sensitization to grass pollen allergens have clinical relevance? *J Invest Allerg Clin.* 2016; 26(3):188-9. Editorial Material. IF: 3.094; Q2.
- Pérez RS, Lois JR, López LP, Peinado AA, Rocafort AG, González RP, Bronte LD, Zurita MB, Silva LGG, Sebastián JD, Blanco FV. Vascular rings and tracheoesophageal compression: 15 years of surgical experience. *Cir Cardiovasc.* 2016; 23(3):119-24. Article. Not indexed.
- Riera J, Cabañas F, Serrano JJ, Madero R, Pellicer A. New developments in cerebral blood flow autoregulation analysis in preterm infants: a mechanistic approach. *Pediatr Res.* 2016; 79(3):460-5. Article. IF: 2.882; Q1

- Rivas JG, Gregorio SAY, Ledo JC, Gómez AT, Sebastián JD, Barthel JJD. The role of perioperative blood transfusion on postoperative outcomes and overall survival in patients after laparoscopic radical cystectomy. *J Cancer Res Ther.* 2016; 12(1):146-9. Article. IF: 0.75; Q4.
- Rivas JG, Gregorio SAY, Gómez AT, Álvarez-Maestro M, Sebastián JD, Ledo JC. Laparoscopic radical cystectomy with prostate capsule sparing. Initial experience. *Cent European J Urol.* 2016; 69(1):25-31. Article. Not indexed.
- Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feito M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. *AIDS.* 2016; 30(1):75-82. Article. IF: 5.003; Q1.


PRIVATE PROJECTS

Madero Jarabo R. Grupos emergentes. FIBHULP. 2007 -Ongoing.

Management Centre: FIBHULP




NEUROPEDIATRY



 Publications: **7**

 Impact Factor: **17.79**

 QI: **2**

Group Leader:

Ramón Velázquez Fragua

Pilar Tirado Requero

María del Mar García Romero

Research Area

- Neurosciences.

Research Activity

PUBLICATIONS

- Fiz-Pérez L, Velázquez-Fragua R, García-Guixot S, García-Romero M, Martínez-Bermejo A. Dissection of vertebral arteries as the cause of acute cerebrovascular event in children. *Rev Neurología.* 2016; 62(8):382-3. Letter. IF: 0.743; Q4
- Lupo V, García-García F, Sancho P, Tello C, García-Romero M, Villarreal L, Alberti A, Sivera R, Dopazo J, Pascual-Pascual SI, Márquez-Infante C, Casasnovas C, Sevilla T, Espinos C. Assessment of targeted next-generation sequencing as a tool for the diagnosis of charcot-marie-tooth disease and hereditary motor neuropathy. *J Mol Diagn.* 2016; 18(2):225-34. Article. IF: 4.526; Q1
- Pascual-Pascual SI, Nascimento A, Fernández-Llamazares CM,

Medrano-López C, Villalobos-Pinto E, Martínez-Moreno M, Ley M, Manrique-Rodríguez S, Blasco-Alonso J. Clinical guidelines for infantile-onset pompe disease. *Rev Neurología.* 2016; 63(6):269-79. Article. IF: 0.743; Q4

- Pérez-Villena A, Soto-Insuga V, Castano-de la Mota C, Martín-del Valle F, Pons-Rodríguez M, Losada-del Pozo R, Moreno-Acero N, Alarcón-Martínez H, Rodrigo-Moreno M, Miravet-Fuster E, Monfort-Belenguer L, Polo-Antúnez A, Martínez-Bermejo A, Merino-Andréu M. The importance of sleep problems in children with headache and other neurodevelopmental disorders in neuropaediatric services. *Rev Neurología.* 2016; 62(2):61-7. Article. IF: 0.743; Q4
- Pesántez-Ríos, G, Martínez-Bermejo, A, Pesántez-Cuesta, G. Neuropsychological alterations are frequent in rolandic epilepsy and its atypical developments. *Rev Neurología.* 2016; 63(3):125-9. Review. IF: 0.743; Q4
- Sevilla T, Lupo V, Martínez-Rubio D, Sancho P, Sivera R, Chumillas MJ, García-Romero M, Pascual-Pascual SI, Muelas N, Dopazo J, Vilchez JJ, Palau F, Espinos C. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. *Brain.* 2016; 139:62-72. Article. IF: 10.292; D1
- Tapias G, García-Romero M, Crespo C, Cuesta M, Forne C, Pascual-Pascual SI. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study. *Farm Hosp.* 2016; 40(5):412-26. Article. Not Indexed.



NUTRITION AND FUNCTIONAL FOODS RESEARCH (NUTRINVEST)



Publications: **7**
Impact Factor: **15.804**
QI: **2**

Group Leader:

Carmen Gómez-Candela

Laura María Bermejo López

Bricia López Plaza

Samara Palma Milla

Emilia Carmen Arrebola Vivas

María Natalia García Vázquez

Arturo Lisbona Catalán

Marina Morato Martínez

Marlhyh Raquel Valero Pérez

Research Area

- Surgery, transplantation and health technology.

Research Activity

BOOKS AND BOOK CHAPTERS

Alarcón Quinte N, Santamaría Jaramillo B, Palma Milla S, Valero Pérez M, López Plaza B, Gómez Candela C. Alimentación y nutrición en las diferentes etapas de la vida. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 377-401.

Campos del Portillo R, Palma Milla S, Gómez Candela C. Evaluación y soporte nutricional en el cáncer hematológico y trasplante de progenitores hematopoyéticos. In: **Gómez Candela C, Palma Milla S, Calvo**

Bruzos SC, Riobó Serván P, Robledo Sáenz PJ. Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 517-45.

Campos del Portillo R, Palma Milla S, Morato Martínez M, Rico Hernández MA, Gómez Candela C. Suplementación oral y nutrición enteral. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 333-57.

Campos del Portillo R, Riobó Serván P, Alarcón Quinte N, Robledo Sáenz PJ, Palma Milla S, Gómez Candela C. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 211-48.

García Vázquez N, Palma Milla S, Gómez Candela C. Nutrición Parenteral. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 359-82.

Gómez Candela C, Mora Mendoza A, Rico Hernández MA, Pulido Vega M, Expósito García M, Valero Pérez M, Palma Milla S. Nutrición artificial domiciliar y ambulatoria en el paciente con cáncer. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 383-412.

Gómez Candela C, Roldán Puchalt MC, Santamaría B, Zamora P, Palma Milla S. Desarrollo de estrategias

de intervención nutricional: objetivos del tratamiento nutricional y algoritmos de intervención. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 413-33.

Iglesias Rosado C, Riobó Serván P, Gómez Candela C. Hidratación en la salud y el la enfermedad. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 77-92.

Valero Pérez M, Alarcón Quinte N, Palma Milla S, Santamaría Jaramillo B, López Plaza B, Gómez Candela C. Las grasas y sus alimentos fuente. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 191-203.

López Plaza B, Bermejo López LM, Morato Martínez L, Palma Milla S, Gómez Candela C. Necesidad de nuevos alimentos funcionales. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 317-36.

López Plaza B, Bermejo López LM, Palma Milla S, Gómez Candela C. Epidemiología nutricional y estrategias para la prevención del cáncer. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 181-209.

López Plaza B, Morato Martínez M, Bermejo López LM, Santamaría Jaramillo B, Gómez Candela C. Instrumentos para la elaboración de dietas. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 299-316.

López Plaza B, Palma Milla S, Bermejo López LM, Morato Martínez M, Santamaría Jaramillo B, Gómez Candela C. Diseño y planificación de dietas saludables. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 259-76.

López Plaza B, Santamaría Jaramillo B, Bermejo López LM, Palma Milla S, Gómez Candela C. Pautas a seguir para elaborar una dieta. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 277-98.

Santamaría Jaramillo B, Valero Pérez M, Alarcón Quinte N, Palma Milla S, López Plaza B, Gómez Candela C. Los otros nutrientes: vitaminas, minerales y oligoelementos. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 219-39.

Meneses González D, Palma Milla S, López Plaza B, Gómez Candela C. Los hidratos de carbono y sus alimentos fuente. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 205-18.

Morato Martínez M, Palma Milla S, Alarcón Quinte N,

Valero Pérez M, López Plaza B, Gómez Candela C. Macronutrientes I. Las proteínas y sus alimentos fuente. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 171-89.

Palma Milla S, Castelo Fernández B, Gómez Candela C. Evaluación y soporte nutricional en el tumor de cabeza y cuello. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 457-75.

Palma Milla S, Ghanem Cañete I, Castelo Fernández B, Gómez Candela C. Evaluación del soporte nutricional en los tumores del aparato digestivo. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 477-99.

Palma Milla S, Meneses González D, Morato Martínez M, Valero Pérez M, López Plaza B, Gómez Candela C. Grupos de población con riesgo de desnutrición. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 403-16.

Riobó Serván P, Palma Milla S, Gómez Candela C. Fisiopatología de los trastornos nutricionales en cáncer: caquexia tumoral. Tratamiento nutricional y farmacológico. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 285-306.

Riobó Serván P, Palma Milla S, Gómez Candela C. Malnutrición en el paciente con cáncer. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 269-84.

Robledo Sáenz PJ, Morato Martínez M, Palma Milla S, Gómez Candela C. Dietoterapia básica y adaptada. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 307-32.

Robledo Sáenz PJ, Santamaría B, Valero Pérez M, Palma Milla S, Gómez Candela C. Evaluación y soporte nutricional en el cáncer de pulmón y otros tumores masculinos. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 547-63.

Robledo Sáenz PJ, Santamaría Jaramillo B, Zamora Auñón P, Gómez Candela C. Efectos nutricionales de los tratamientos antineoplásicos: cirugía, quimioterapia, radioterapia, inmunoterapia y otras terapias biológicas. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.** Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED; 2016. p. 249-67.

Santamaría Jaramillo B, Riobó Serván P, Palma Milla S, Gómez Candela C. Evaluación del soporte nutricional en el cáncer ginecológico y de mama. In: **Gómez Candela C, Palma Milla S, Calvo Bruzos SC, Riobó Serván P, Robledo Sáenz PJ.**



Alimentación, nutrición y cáncer. Prevención y tratamiento. Madrid: Eds. Publicaciones UNED, 2016. p. 501-17.

PUBLICATIONS

- Aranceta-Bartrina J, Gil A, Marcos A, Pérez-Rodrigo C, Serra-Majem L, Varela-Moreiras G, Drewnowski A, Palou A, Anadón A, Murray B, Gómez-Candela C, Maffei C, Ramón D, Benton D, Corella D, Alonso-Aperte E, Martínez de Victoria E, O'Neal E, Pfeffer F, Braun H, Lukaski H, Polanco I, Bernal J, González-Alonso J, Ordvas JM, del Coso J, Kenney L, Sardinha LB, Díaz-Rubio M, González-Gross M, Kapsokefalou M, Sawka MN, Millard-Stafford M, Palacios N, Watson P, Riobo P, Urrialde R, Mora-Rodríguez R, Maughan RJ, Ortega RM, Gellert R, Oliver S, Trangmar S, Partearroyo T. Conclusions of the II International and IV Spanish Hydration Congress. Toledo, Spain, 2nd-4th December, 2015. *Nutr Hosp.* 2016; 33(Suppl 3):308. Article. IF: 0.747; Q4
- Gómez-Candela C, Fernández LP, París AS, Peláez RB, Martín PM, Almeida JMG, Palmero AM. Analysis of elderly patients with diabetes participating in VIDA study on admission. *Nutr Hosp.* 2016; 33(1):31-6. Article. IF: 0.747, Q4
- Martín A, Ruiz E, Sanz A, García JM, Gómez-Candela C, Burgos R, Matía P, Ramalle-Gomera E. Accuracy of different mini nutritional assessment reduced forms to evaluate the nutritional status of elderly hospitalised diabetic patients. *J Nutr Health Aging.* 2016; 20(4):370-5. Article. IF: 2.772; Q2
- Palma-Milla S, López-Plaza B, Santamaría B, de Arriba-Sánchez A, Bermejo LM, Gómez-Candela C. New, immunomodulatory, oral nutrition formula for use prior to surgery in patients with head and neck cancer: An exploratory study. *JPEN-Parenter Enter.* 2016; 6676839. Article. IF: 4.22; Q1
- Sanz-Paris A, Gómez-Candela C, Martín-Palmero A, García-Almeida JM, Burgos-Peláez R, Matía-Martín P, Arbones-Mainar JM. Application of the new ESPEN definition of malnutrition in geriatric diabetic patients during hospitalization: A multicentric study. *Clin Nutr.* 2016; 35(6):1564-7. Article. IF: 4.548; Q1
- Szendrei B, González-Lamuno D, Amigo T, Wang G, Pitsiladis Y, Benito PJ, Gómez-Candela C, Calderón FJ, Cupeiro R. Influence of ADRB2 Gln27Glu and ADRB3 Trp64Arg polymorphisms on body weight and body composition changes after a controlled weight-loss intervention. *Appl Physiol Nutr Me.* 2016; 41(3):307-14. Article. IF: 2.023; Q2
- Wanden-Berghe Lozano C, Campos Martín C, Cuerda Compes C, Gómez Candela C, Burgos Peláez R, Moreno Villares JM, Pereira Cunill JL, Pérez de la Cruz A, Virgili Casas N, Martínez Faedo C, Álvarez Hernández J, Garde Orbaiz C, Penacho Lázaro MA, Sánchez Martos EA, Sanz Paris A, Gonzalo Marín M, Zugasti Murillo A, Matia Martín P, Martín Folgueras T, Carabana Pérez F, Díaz Guardiola P, Tejera Pérez C, de Luis Román D, Luengo Pérez LM, Santacruz Carmona N, Apezetxea Celaya A, Ponce González MA, Urgeles Planella JR, Laborda González L, Martínez Olmos MA, Sánchez-Vilar Burdiel O, Joaquín Ortiz C, Martínez Costa C, Suárez Llanos JP, Calleja Fernández A, Leyes García P, Gil Martínez MC, Mauri Roca S, García Zafra MV, Carrera Santaliestra MJ, Grupo. Nutrición Parenteral Domiciliaria en España durante 2015, informe del Grupo de Nutrición Artificial Domiciliaria y Ambulatoria NADYA. *Nutr Hosp.* 2016; 33(6):1487-90. Article. IF: 0.747, Q4

PUBLIC PROJECTS

Gómez Candela C. Investigación y desarrollo clínico de una nueva molécula para el control de peso y prevención de la obesidad (FAT-BINDER DAMM) (RTC-2016-5317-1). MINECO. 2016-2018.

Management centre: FIBHULP

Gómez Candela C. Alimentos funcionales y estrategias nutricionales eficaces para la prevención y tratamiento de enfermedades crónicas (S2013/ABI-2728-ALIBIRD). MINECO. 2014-2018.

Management centre: FIBHULP

PRIVATE PROJECTS

Coronado Poggio M. Pruebas de investigación pet del "estudio multicéntrico abierto de fase 2 del anticuerpo monoclonal anti-CCR4 KW-0761 (mogamulizumab) en pacientes con linfoma de célula T periférico (LCTP) previamente tratado". Kyowa Hakko Kirin Pharma Inc. 2012-Ongoing.

Management centre: FIBHULP

Gómez Candela C. Plan de sustentación científica de la eficacia de probióticos en homeostasis inmune. 2010-Ongoing.

Management centre: FIBHULP

Gómez Candela C. Perspectivas de la actividad investigadora de la Unidad de Nutrición Clínica y Dietética. Abbott Laboratories S.A. 2008-Ongoing.

Management centre: FIBHULP

Gómez Candela C. Desarrollo de nuevas metodologías y tecnologías emergentes de evidenciación de la eficacia de alimentos con propiedades de salud para la reducción de riesgos de patologías crónicas en la edad media de vida (HENUFOOD). Ibermática S.A. 2011-Ongoing.

Management centre: FIBHULP

Gómez Candela C. Perspectivas de la unidad investigadora de la Unidad de Nutrición Clínica y Dietética. Nestlé Healthcare Nutrition S.A. 2009-Ongoing.

Management centre: FIBHULP

Gómez Candela C. Evaluación de las propiedades antioxidantes de alimentos funcionales enriquecidos en polifenoles (hidroxitirosol derivado del aceite de oliva y punicalagina derivada de la granada) y valoración de sus efectos en la prevención de factores de riesgo asociados al síndrome metabólico en un estudio de intervención en población sana. CAM. 2010-Ongoing.

Management centre: FIBHULP

CLINICAL TRIALS

Gómez Candela C. Estudio fase III, aleatorizado, abierto, con evaluador enmascarado y comparador activo para evaluar la no inferioridad en la eficacia y seguridad de liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III.

HULP code: 4530. Sponsored's protocol code: AN-EPI3331. Sponsored by: Linical France Sarl.


Signed date: 02/02/2016

Gómez Candela C. Estudio abierto para evaluar la eficacia y seguridad de Liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III.

HULP code: 4686. Sponsored's protocol code: AN-EPI3334. Sponsored by: Amgen S.A.

Signed date: 23/09/2016

ORTHOPEDIC SURGERY AND TRAUMATOLOGY



Publications: 7

Impact Factor: 3.562

QI: -

Group Leader:

Francisco Javier Sánchez Pérez-Grueso

Mercedes Agüera Gavaldá
María Dolores Alonso Valdazo
Gregorio Arroyo Salcedo
Irene Barrientos Ruiz
Manuel Blanco del Moral
Juan Cabello Blanco
Juan de la Cerda Sanchez
Jorge de las Heras Sotos,
Pablo Díaz Freire
David Durán Manrique
Rafael Echevarría de Rada
Carlos Encinas Ullan
Ricardo Fernández Fernández
Nicomedes Fernández-Baillo Gallego de la Sacristana
Agustín Garabito Cociña
Cristina García Córdoba
José Antonio García-Ramos García
Primitivo Gómez Cardero
Gaspar González Morán
Aitor Ibarzábal Gil
Carlos Kalbakdjij Sánchez
José Manuel Martínez Díez
Ángel Martínez Lloreda
Jesús María Martínez Miranda
José Luis Mauleon Álvarez de Linera
Inmaculada Moracia Ochagavía

Luis Moraleda Novo
José Ortega Chamarro
Eduardo Ortiz Cruz
Javier Pallares Sanmartín
Manuel Peleteiro Pensado
Javier Pizones Arce
José Quintans Rodríguez
Juan Carlos Rubio Suárez
Juan Sebastián Ruiz Pérez
José Luis Salazar Iriarte
María Salcedo Montejo
José Miguel Sánchez Márquez
Alfonso Vaquero Picado
Patricia Villanueva Blaya
José Ignacio Viñuales García

Research Area

- Surgery, transplantation and health technology.

Research Activity

DOCTORAL THESES

Fernández Fernández R. Resultados superiores del titanio frente al cromocobalto en cirugía primaria de cadera: resultados a largo plazo con el vástago Meridian [dis-



sertation]. Madrid: Universidad Autónoma de Madrid: 2016(21/04/2016).

Director: Gil Garay E.

BOOKS AND BOOK CHAPTERS

Antuna S, Barco R. Essential Techniques in Elbow Surgery. Suiza: Springer International Publishing, 2016.

Kabalkdij-Sanchez C, Gómez-Barrena E. Intra-articular corticosteroids and hyaluronic acid in the knee joint. In: Joint preservation in the adult knee. In: Rodríguez-Merchán EC, Liddle AD. Joint Preservation in the Adult Knee. Suiza: Springer International Publishing, 2016. p. 23-28.

Peleteiro-Pensado M, Barrientos-Ruiz I, Ortiz-Cruz EJ. Bone Tumors Around the Knee. In: Rodríguez-Merchán EC, Liddle AD. Joint Preservation in the Adult Knee. Suiza: Springer International Publishing, 2016. p. 153-73.

PUBLICATIONS

- Cruz-Pardos A, García-Rey E, Ortega-Chamarro JA, Durán-Manrique D, Gómez-Barrena E. Mid-term comparative outcomes of autologous bone-marrow concentration to treat osteonecrosis of the femoral head in standard practice. Hip Int. 2016;26(5):432-7. Article. IF: 1.055; Q3.
- Ferrer-Santacreu EM, Ortiz-Cruz EJ, Díaz-Almirón M, Kreilinger JJP. Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: Clinical and radiological criteria-a follow-up. J Oncol. 2016; 8262079. Article. Not Indexed.
- Ortega-Andréu M, Talavera G, Padilla-Eguiluz NG, Pérez-Chrzanoska H, Figueredo-Galve R, Rodríguez-Merchán EC, Gómez-Barrena E. Tranexamic acid in a multimodal blood loss prevention protocol to decrease blood loss in revision total knee arthroplasty: A cohort study. Open Orthop J. 2016;10:439-47. Article. Not Indexed.

- Pizones J, Martín-Buitrago MP, Sánchez Pérez-Grueso FJ, Pellise F, Alanay A, Obeid I, Kleinstuck F, Acaroglu ER. Untreated thoracic curve in adult idiopathic scoliosis: What are patients' concerns? Spine Deform. 2016;4(6):439-45. Article. Not Indexed.
- Pizones J, Sánchez-Mariscal F, Zuñiga L, Izquierdo E. The effect of sublaminar wires on the rib hump deformity during scoliosis correction manoeuvres. Eur J Orthop Surg Tr. 2016;26(7):771-7. Article. Not Indexed.
- Quesada U, Cabello J, González Morán G, Calvo C. Neuro-pathic physeal injury: Differential diagnosis with osteomyelitis. An Pediatr. 2016; 30292. Article. IF: 1.14; Q3.
- Rodríguez-Merchán EC, Ortega-Andréu M, Padilla-Eguiluz NG, Gómez-Cordero P, Martínez-Lloreda A, Gómez-Barrena E. Low-volume formulation of intra-articular tranexamic acid, 25-ml tranexamic acid (2.5 g) plus 20-ml saline, is effective in decreasing blood transfusion rate in primary total knee replacement even without preoperative haemoglobin optimization. Blood Coagul Fibrin. 2016;27(6):660-6. Article. IF: 1.367; Q4.

PRIVATE PROJECTS

Barrientos Ruiz I. Ensayo clínico fase IV, aleatorizado, doble ciego, controlado con placebo, para evaluar el impacto de la reducción de transfusiones sanguíneas tras la administración de dos pautas de ácido tranexámico en pacientes intervenidos por sarcomas óseos o de partes blandas. SECOT. 2016-Ongoing.

Management centre: FIBHULP



PEDIATRIC NEFROLOGY



Publications: **2**

Impact Factor: **9.627**

QI: **2**

Group Leader:

Laura Espinosa Román

Ángel Alonso Melgar

Marta Melgosa Hijosa

Carlota Fernández Cambor

Alejandro Zarauza Santoveña

Juan Bravo Feitó

Research Area

- Large System Pathology.

Research Activity

PUBLICATIONS

- Hogan J, Couchoud C, Bonthuis M, Groothoff JW, Jager KJ, Schaefer F, Van Stralen KJ (Alonso Melgar A). Gender disparities in access to pediatric renal transplantation in Europe: Data from the ESPN/ERA-EDTA Registry. Am J Transplant. 2016;16(7):2097-105. Article. IF: 6.165; D1
- Pereira PL, Urrutia MJM, Román LE. Renal transplant and reconstructive surgery. Eur Urol Suppl. 2016;15(9):402-7. Article. IF: 3.462; Q1.



IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

**Hospital Universitario
La Paz** Hospital Carlos III
Hospital Cantoblanco


UNIVERSIDAD AUTÓNOMA
DE MADRID



Unión Europea

Fondo Europeo
de Desarrollo Regional
"Una manera de hacer Europa"

